FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Marchetti, P Bugliani, M Lupi, R Marselli, L Masini, M Boggi, U Filipponi, F Weir, GC Eizirik, DL Cnop, M AF Marchetti, P. Bugliani, M. Lupi, R. Marselli, L. Masini, M. Boggi, U. Filipponi, F. Weir, G. C. Eizirik, D. L. Cnop, M. TI The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients SO DIABETOLOGIA LA English DT Article DE endoplasmic reticulum; beta cell; BiP; C/EBP homologous protein; CHOP; immunoglobulin heavy chain binding protein; unfolded protein response; X-box binding protein 1; XBP-1 ID LASER-CAPTURE MICRODISSECTION; FREE FATTY-ACIDS; ER STRESS; GENE-EXPRESSION; QUALITY-CONTROL; APOPTOSIS; ISLETS; DYSFUNCTION; MECHANISMS; GLUCOSE AB Aims/hypothesis Pancreatic beta cells have highly developed endoplasmic reticulum (ER) due to their role in insulin secretion. Since ER stress has been associated with beta cell dysfunction, we studied several features of beta cell ER in human type 2 diabetes. Methods Pancreatic samples and/ or isolated islets from non- diabetic controls (ND) and type 2 diabetes patients were evaluated for insulin secretion, apoptosis (electron microscopy and ELISA), morphometric ER assessment (electron microscopy), and expression of ER stress markers in beta cell prepared by laser capture microdissection and in isolated islets. Results Insulin release was lower and beta cell apoptosis higher in type 2 diabetes than ND islets. ER density volume was significantly increased in type 2 diabetes beta cells. Expression of alpha- mannosidase (also known as mannosidase, alpha, class 1A, member 1) and UDP-glucose glycoprotein glucosyl transferase like 2 (UGCGL2), assessed by microarray and/ or real-time reverse transcriptase polymerase chain reaction (RT-PCR), differed between ND and type 2 diabetes beta cells. Expression of immunoglobulin heavy chain binding protein (BiP, also known as heat shock 70 kDa protein 5 [glucose- regulated protein, 78 kDa] [HSPA5]), X-box binding protein 1 (XBP- 1, also known as XBP1) and C/EBP homologous protein (CHOP, also known as damage- inducible transcript 3 [DDIT3]) was not higher in type 2 diabetes beta cell or isolated islets cultured at 5.5 mmol/l glucose (microarray and real- time RT-PCR) than in ND samples. When islets were cultured for 24 h at 11.1 mmol/l glucose, there was induction of BiP and XBP- 1 in type 2 diabetes islets but not in ND islets. Conclusions/interpretation Beta cell in type 2 diabetes showed modest signs of ER stress when studied in pancreatic samples or isolated islets maintained at physiological glucose concentration. However, exposure to increased glucose levels induced ER stress markers in type 2 diabetes islet cells, which therefore may be more susceptible to ER stress induced by metabolic perturbations. C1 Univ Pisa, Osped Cisanello, Metabol Unit, Dept Endocrinol & Metab, I-56100 Pisa, Italy. Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. Univ Pisa, Dept Oncol Transplants & Adv Technol, Pisa, Italy. Univ Libre Bruxelles, Fac Med, Expt Med Lab, Brussels, Belgium. Univ Libre Bruxelles, Erasmus Hosp, Div Endocrinol, Brussels, Belgium. RP Marchetti, P (reprint author), Univ Pisa, Osped Cisanello, Metabol Unit, Dept Endocrinol & Metab, Via Paradisa 2, I-56100 Pisa, Italy. EM marchant@immr.med.unipi.it RI Marchetti, Piero/J-7439-2013; OI Marchetti, Piero/0000-0003-4907-0635; Cnop, Miriam/0000-0002-5112-1692 NR 50 TC 204 Z9 213 U1 0 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD DEC PY 2007 VL 50 IS 12 BP 2486 EP 2494 DI 10.1007/s00125-007-0816-8 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 228HQ UT WOS:000250721400011 PM 17906960 ER PT J AU Horn, DL Fishman, JA Steinbach, WJ Anaissie, EJ Marr, KA Olyaei, AJ Pfaller, MA Weiss, MA Webster, KM Neofytos, D AF Horn, David L. Fishman, Jay A. Steinbach, William J. Anaissie, Elias J. Marr, Kieren A. Olyaei, Ali J. Pfaller, Michael A. Weiss, Mark A. Webster, Karen M. Neofytos, Dionissios TI Presentation of the PATH Alliance (R) registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article; Proceedings Paper CT 17th Focus on Fungal Infections Conference CY MAR 07-09, 2007 CL San Diego, CA DE registry; database; web-based electronic case report form (e-CRF) ID ASPERGILLOSIS; CANCER; VORICONAZOLE; CANDIDIASIS; DIAGNOSIS; DESIGN; ADULTS AB Randomized clinical trials for patients with invasive fungal infections (IFIs) are often limited or precluded, necessitating alternate sources of information. The Prospective Antifungal Therapy Alliance (PATH Alliance (R)) is a registry that collects data on patients with IFIs at medical centers in North America. Patients with a diagnosis of proven or probable 1171 are enrolled and followed prospectively for 12 weeks. Using a Web-based electronic data capture and reporting system, the registry collects anonymous data to address end points in epidemiology, diagnosis, treatment, and outcome of IFIs. As of October 2006, 1892 IFIs were observed in 1710 patients enrolled at 22 sites. The most commonly encountered IFIs were caused by Candida spp. (73.0%), presenting predominantly as candidemia, followed by Aspergillus spp. (14.8%). A small number of IFIs with uncommon and emerging moulds were observed. Culture remains the main diagnostic tool for most IFIs (91.8%). Antifungal agent choice depended on the fungal species isolated, with fluconazole being the most frequently administered agent (58.2%). The overall crude 12-week mortality, excluding the patients lost-to follow-up, was 43.9%. PATH Alliance (R) is a network of medical institutions gathering significant information about IFIs in North America. Significant trends and treatment practices conceming yeasts and moulds were observed. As enrollment continues, additional data will be analyzed and published, which will provide valuable information concerning the epidemiology, therapy, and outcomes of IFIs. (c) 2007 Elsevier Inc. All rights reserved. C1 [Horn, David L.; Neofytos, Dionissios] Thomas Jefferson Univ, Div Infect Dis, Philadelphia, PA 19107 USA. [Fishman, Jay A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA. [Steinbach, William J.] Duke Univ, Med Ctr, Div Pediat Infect Dis, Durham, NC 27710 USA. [Anaissie, Elias J.] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA. [Marr, Kieren A.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Olyaei, Ali J.] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97201 USA. [Pfaller, Michael A.] Univ Iowa Hlth Care, Iowa City, IA 52242 USA. [Weiss, Mark A.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. [Webster, Karen M.] Axiom Real Time Metr, Oakville, ON L6J 7WS, Canada. RP Horn, DL (reprint author), Thomas Jefferson Univ, Div Infect Dis, Philadelphia, PA 19107 USA. EM david.horn@jefferson.edu NR 19 TC 48 Z9 51 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD DEC PY 2007 VL 59 IS 4 BP 407 EP 414 DI 10.1016/j.diagmicrobio.2007.06.008 PG 8 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 243PK UT WOS:000251809600009 PM 17888614 ER PT J AU Hittelman, A Sridharan, S Roy, R Fridlyand, J Loda, M Collins, C Paris, PL AF Hittelman, Adam Sridharan, Shivaranjani Roy, Ritu Fridlyand, Jane Loda, Massimo Collins, Colin Paris, Pamela L. TI Evaluation of whole genome amplification Protocols for array and oligonucleotide CGH SO DIAGNOSTIC MOLECULAR PATHOLOGY LA English DT Article DE whole genome amplification; aCGH; oCGH ID HIGH-RESOLUTION ANALYSIS; PROSTATE-CANCER; DISPLACEMENT AMPLIFICATION; GENETIC ALTERATIONS; FRESH-FROZEN; DNA; HYBRIDIZATION; TUMORS; CELL; MICROARRAYS AB Genome-based technologies such as genomic arrays and next generation sequencing are poised to make significant contributions to clinical oncology. However, translation of these technologies to the clinic will require that they produce high-quality reproducible data from small archived tumor specimens and biopsies. Herein, we report on a systematic and comprehensive microarray analysis comparing multiple whole genome amplification methods using a variety of difficult clinical specimens, including formalin-fixed and paraffin-embedded tissues. Quantitative analysis and clustering suggest that Sigma's whole genome amplification protocol performed best on all specimens and, moreover, worked well with a formalin-fixed, paraffin-embedded biopsy. C1 Univ Calif San Francisco, Dept Urol, San Francisco, CA USA. Univ Calif San Francisco, Ctr Comprehens Canc, Biostat Ctr Bioinformat & Mol Biostat, San Francisco, CA USA. Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. RP Collins, C (reprint author), Univ Calif San Francisco, Box 0808, San Francisco, CA 94143 USA. EM collins@cc.ucsf.edu NR 31 TC 6 Z9 6 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1052-9551 J9 DIAGN MOL PATHOL JI Diagn. Mol. Pathol. PD DEC PY 2007 VL 16 IS 4 BP 198 EP 206 PG 9 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Pathology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Pathology GA 235ZU UT WOS:000251273600002 PM 18043282 ER PT J AU Krouse, RS Grant, M Wendel, CS Mohler, MJ Rawl, SM Baldwin, CM Coons, SJ McCorkle, R Ko, CY Schmidt, CM AF Krouse, Robert S. Grant, Marcia Wendel, Christopher S. Mohler, M. Jane Rawl, Susan M. Baldwin, Carol M. Coons, Stephen Joel McCorkle, Ruth Ko, Clifford Y. Schmidt, C. Max TI A mixed-methods evaluation of health-related quality of life for male veterans with and without intestinal stomas SO DISEASES OF THE COLON & RECTUM LA English DT Article DE Ostomy; focus groups; quality of life; stomas ID PSYCHOSOCIAL MORBIDITY; RECTAL-CANCER; SURGERY; COLOSTOMY; DYSFUNCTION; ADJUSTMENT AB PURPOSE: Intestinal stomas have a major impact on Cases' lives. It is essential to better understand the areas in which interventions may help to minimize the negative consequences. METHODS: This was a case-control survey study using validated instruments (City of Hope Quality of Life-Ostomy and Short Form 36 for Veterans). Cases were accrued from Veterans Affairs Medical Centers in Tucson, Indianapolis, and Los Angeles. Eligibility included a major intra-abdominal surgical procedure that led to an ostomy (cases), or a similar procedure that did not mandate a stoma (controls). Analysis included quantitative and qualitative responses. RESULTS: The response rate was 48 percent (511/1063). Cases and controls had relatively similar demographic characteristics. Because of low numbers of female respondents (13 cases and 11 controls), only results for males are reported. Based on both the City of Hope Quality of Life-Ostomy and Short Form 36 for Veterans, cases reported significantly poorer scores on scales/domains reflecting psychologic and social functioning and well being. Additionally, cases reported poorer scores on Short Form 36 for Veterans scales reflecting physical functioning and significantly lower scores on multiple Life-Ostomy compared with controls. Two-thirds of cases replied to an open-ended question on their "greatest challenge" related to their ostomy, which led to further clarification of major issues. CONCLUSIONS: Multiple health-related quality of life problems were reported by male veterans with intestinal stomas. The greatest differences between cases and controls were observed in the social and psychologic domains/scales. Findings from this study provide a greater understanding of the challenges faced by ostomates and will inform the development and evaluation of urgently needed intervention strategies. C1 [Krouse, Robert S.; Wendel, Christopher S.; Mohler, M. Jane] Univ Arizona, Coll Med, So Arizona VA Hlth Care Syst, Tucson, AZ 85723 USA. [Grant, Marcia] City Hope Natl Med Ctr, Dept Nursing Res & Educ, Duarte, CA 91010 USA. [Mohler, M. Jane] Univ Arizona, Coll Publ Hlth, Tucson, AZ USA. [Rawl, Susan M.] Indiana Univ, Sch Nursing, Ctr Nursing Res, Indianapolis, IN 46204 USA. [Baldwin, Carol M.] Arizona State Univ, Coll Nursing, Phoenix, AZ USA. [Mohler, M. Jane; Coons, Stephen Joel] Univ Arizona, Coll Pharm, Div Social & Adm Sci, Tucson, AZ 85721 USA. [McCorkle, Ruth] Yale Univ, Sch Nursing, New Haven, CT 06536 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Ctr Hlth Sci, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Schmidt, C. Max] Indiana Univ, Sch Med, Dept Surg, Richard L Roudebush VA Med Ctr, Indianapolis, IN 46204 USA. RP Krouse, RS (reprint author), Univ Arizona, Coll Med, So Arizona VA Hlth Care Syst, 2-112,3601 S 6th Ave, Tucson, AZ 85723 USA. EM robert.krouse@va.gov OI Baldwin, Carol/0000-0002-0732-2307; Rawl, Susan/0000-0003-2052-2853 NR 44 TC 26 Z9 26 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0012-3706 J9 DIS COLON RECTUM JI Dis. Colon Rectum PD DEC PY 2007 VL 50 IS 12 BP 2054 EP 2066 DI 10.1007/s10350-007-9004-7 PG 13 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 241FG UT WOS:000251641700007 PM 17701071 ER PT J AU Winhusen, T Somoza, E Sarid-Segald, O Goldsmith, RJ Harrer, JM Coleman, FS Kahn, R Osman, S Mezinskis, J Li, SH Lewis, D Afshar, M Ciraulo, DA Horn, P Montgomery, MA Elkashef, A AF Winhusen, Theresa Somoza, Eugene Sarid-Segald, Ofra Goldsmith, R. Jeffrey Harrer, Judy M. Coleman, Florence S. Kahn, Roberta Osman, Sabuhi Mezinskis, Juris Li, Shou-Hua Lewis, Daniel Afshar, Maryam Ciraulo, Domenic A. Horn, Paul Montgomery, Margaret A. Elkashef, Ahmed TI A double-blind, placebo-controlled trial of reserpine for the treatment of cocaine dependence SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE cocaine dependence; reserpine; clinical trial; double-blind ID METHAMPHETAMINE; DRUGS; DEPRESSION; ADDICTION; DOPAMINE AB Background: Cocaine's increase of dopamine is strongly associated with its reinforcing properties and, thus, agents that reduce dopamine have received much attention as candidate cocaine-dependence treatments. The potential efficacy of reserpine, a dopamine depletor, for treating cocaine dependence is suggested by both pre-clinical research and a small clinical trial. Method: One hundred and nineteen participants who met DSM-IV criteria for cocaine dependence were enrolled into this 12-week, double-blind, placebo-controlled outpatient trial. Participants received either reserpine (0.5 mg/day) or matching placebo. All participants received 1 h of manualized individual cognitive behavioral therapy on a weekly basis. Outcome measures included cocaine use as determined by self-report confirmed with urine benzoylecgonine results, cocaine craving, addiction severity index scores, and clinical global impression scores. Safety measures included adverse events, EKGs, vital signs, laboratory tests, and the Hamilton Depression Inventory. Results: Seventy-nine participants (i.e., 66%) completed the 12-week trial. The safety results suggest that reserpine was safe and well tolerated by the participants. The efficacy measures indicated no significant differences between reserpine and placebo. Conclusion: These results do not support the efficacy of reserpine as a cocaine-dependence treatment. (c) 2007 Elsevier Ireland Ltd. All rights reserved. C1 Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA. CinARC, Cincinnati, OH 45220 USA. Vet Affairs Med Ctr VISN 10, Cincinnati, OH 45220 USA. Boston Univ, Sch Med, VA Boston Hlth Care Syst, MDRU,Dept Psychiat, Boston, MA 02118 USA. Dayton VA Med Ctr, Dayton, OH USA. Natl Inst Drug Abuse, Div Treatment Res & Dev, Bethesda, MD 20892 USA. Univ Cincinnati, Dept Math, Cincinnati, OH 45221 USA. RP Winhusen, T (reprint author), Univ Cincinnati, 3210 Jefferson Ave, Cincinnati, OH 45220 USA. EM winhusen@mdru.uc.edu OI Ciraulo, Domenic/0000-0001-7706-8765; Winhusen, Theresa/0000-0002-3364-0739 FU NIDA NIH HHS [N01-DA-9-8095] NR 24 TC 15 Z9 15 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD DEC 1 PY 2007 VL 91 IS 2-3 BP 205 EP 212 DI 10.1016/j.drugalcdep.2007.05.021 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 228RN UT WOS:000250747500013 PM 17628352 ER PT J AU Luo, ZJ Li, JL Qin, YF Ma, Y Liang, XH Xian, J Lu, DC Wei, MY Yang, JY Yang, MQ He, ZH AF Luo, Zuojie Li, Jianling Qin, Yinfen Ma, Yan Liang, Xinghuan Xian, Jing Lu, Decheng Wei, Minyi Yang, Jack Y. Yang, Mary Qu He, Zhiheng TI Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas SO ENDOCRINE PATHOLOGY LA English DT Article DE pheochromocytoma; hTERT mRNA; hTERT; Ki-67; p27(kip1) ID CELL-CYCLE REGULATORS; MALIGNANT PHEOCHROMOCYTOMA; PROGNOSTIC-SIGNIFICANCE; REVERSE-TRANSCRIPTASE; P27(KIP1) EXPRESSION; INHIBITOR P27(KIP1); BREAST-CANCER; BENIGN; TUMORS; KI-67 AB In pheochromocytomas, it is very difficult to predict malignant potential by conventional histology or immunohistochemical and molecular markers. We investigated the expression of human telomerase catalytic component (hTERT) mRNA, hTERT protein, Ki-67 antigen, and p27(kip1) in pheochromocytomas (27 benign, 7 suspected malignant, and 7 malignant), and evaluated the possibility of expressions of these proteins, and hTERT mRNA serve as diagnostic markers for predicting the biological behavior of these tumors. All tumors showed the classical histology and typical immunohistochemical pattern. By in situ hybridization, hTERT mRNA was expressed in 5/7 malignant tumors (defined as the presence of metastasis and/or extensive local invasion) as compared with 3/27 benign tumors. We examined the hTERT by immunohistochemistry to confirm the mRNA. hTERT mRNA expression was correlated with hTERT protein expression. All benign tumors exhibited no immunopositivity or <1% of cells stained for Ki-67 antigen. Six out of seven malignant tumors have shown either hTERT mRNA expression or Ki-67 immunoreactivity. While no statistical difference in p27(kip1) expressions was observed among benign, malignant, and suspected malignant tumors, there was a statistical difference between the normal adrenal medulla samples and tumors (p < 0.001). Thus, hTERT mRNA detection by in situ hybridization, hTERT expression, and Ki-67 antigen expression are all useful tools for differentiating malignant from benign pheochromocytomas. C1 Guangxi Med Univ, Dept Endocrinol, Nanning 530021, Peoples R China. First Affiliated Hosp, Nanning 530021, Peoples R China. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. Natl Human Genome Res Inst, US Dept Hlth & Human Serv, Rockville, MD 20850 USA. Harvard Univ, Joslin Diabet Ctr, Div Res, Sch Med, Boston, MA 02215 USA. RP Luo, ZJ (reprint author), Guangxi Med Univ, Dept Endocrinol, 6 Shuangyong Rd, Nanning 530021, Peoples R China. EM zluo888@yahoo.com.cn NR 31 TC 1 Z9 1 U1 0 U2 8 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1046-3976 J9 ENDOCR PATHOL JI Endocr. Pathol. PD WIN PY 2007 VL 17 IS 4 BP 387 EP 398 PG 12 WC Endocrinology & Metabolism; Pathology SC Endocrinology & Metabolism; Pathology GA 160FN UT WOS:000245926400010 ER PT J AU Gourcerol, G Wang, L Wang, YH Million, M Tache, Y AF Gourcerol, G. Wang, L. Wang, Y. H. Million, M. Tache, Y. TI Urocortins and cholecystokinin-8 act synergistically to increase satiation in lean but not obese mice: Involvement of corticotropin-releasing factor receptor-2 pathway SO ENDOCRINOLOGY LA English DT Article ID SUPPRESSES FOOD-INTAKE; CRF RECEPTORS; HORMONE RECEPTOR-2; BODY-WEIGHT; FEEDING MICROSTRUCTURE; FUNCTIONAL DYSPEPSIA; ENERGY-BALANCE; IN-VITRO; CCK; RATS AB Interactions between gastrointestinal signals are a part of integrated systems regulating food intake (FI). We investigated whether cholecystokinin (CCK)-8 and urocortin systems potentiate each other to inhibit FI and gastric emptying (GE) in fasted mice. Urocortin 1 and urocortin 2 (1 mu g/kg) were injected ip alone or with CCK ( 3 mu g/kg) in lean, diet-induced obese ( DIO) or corticotropin-releasing factor receptor-2 (CRF(2))-deficient mice. Gastric vagal afferent activity was recorded from a rat stomach-vagus in vitro preparation. When injected separately, urocortin 1, urocortin 2, or CCK did not modify the 4-h cumulative FI in lean mice. However, CCK plus urocortin 1 or CCK plus urocortin 2 decreased significantly the 4-h FI by 39 and 27%, respectively, compared with the vehicle + vehicle group in lean mice but not in DIO mice. Likewise, CCK-urocortin-1 delayed GE in lean but not DIO mice, whereas either peptide injected alone at the same dose had no effect. CCK-urocortin 2 suppression of FI was observed in wild-type but not CRF2-deficient mice. Gastric vagal afferent activity was increased by intragastric artery injection of urocortin 2 after CCK at a subthreshold dose, and the response was reversed by devazepide. These data establish a peripheral synergistic interaction between CCK and urocortin 1 or urocortin 2 to suppress FI and GE through CRF2 receptor in lean mice that may involve CCK modulation of gastric vagal afferent responsiveness to urocortin 2. Such synergy is lost in DIO mice, suggesting a resistance to the satiety signaling that may contribute to maintain obesity. C1 VA Greater Los Angeles Healthcare Syst, Ctr Neurovisceral Sci & Womens Hlth, Dept Med, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Neurovisceral Sci & Womens Hlth, Dept Med, CURE Bldg 115,Room 203,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU NIDDK NIH HHS [DK 41301, R01 DK 33061] NR 69 TC 18 Z9 19 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD DEC PY 2007 VL 148 IS 12 BP 6115 EP 6123 DI 10.1210/en.2007-0678 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 231RP UT WOS:000250967000056 PM 17932219 ER PT J AU Chin, PS Berg, AT Spencer, SS Sperling, MR Haut, SR Langfitt, JT Bazil, CW Walczak, TS Pacia, SV Vickrey, BG AF Chin, Peter S. Berg, Anne T. Spencer, Susan S. Sperling, Michael R. Haut, Sheryl R. Langfitt, John T. Bazil, Carl W. Walczak, Thaddeus S. Pacia, Steven V. Vickrey, Barbara G. TI Employment outcomes following resective epilepsy surgery SO EPILEPSIA LA English DT Article DE epilepsy surgery; employment ID REFRACTORY EPILEPSY; SEIZURE SURGERY; ADJUSTMENT AB Purpose: Analyze determinates of employment changes from before to 2 years after surgery in refractory focal epilepsy patients. Methods: Preoperative employment was prospectively assessed in 375 adults with refractory epilepsy. Two-year postsurgical employment status was obtained for 299; factors potentially associated with employment status change among subgroups unemployed and employed at baseline were analyzed. Results: Presurgical employment status was full-time (n = 148, 39.5%), part-time (n = 26, 6.9%), disabled and unemployed (n = 100, 26.7%), unemployed n = 44, 11.7%), and other (n = 57, 15.2%). Those with and without 2-year follow-up did not differ on baseline characteristics (all p > 0.10). Two years after surgery, 42.8% were employed full-time and 12.4%, part-time. Among those unemployed before surgery, better seizure outcome was associated with gaining employment at 2 years (p = 0.03). Conclusions: Net employment gains were modest 2 years after surgery and higher with better seizure outcomes, reinforcing the need for optimizing surgical candidate selection, long-term follow-up studies, and postsurgical vocational rehabilitation. C1 [Vickrey, Barbara G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Pacia, Steven V.] NYU Med Ctr, Comprehens Epilepsy Ctr, New York, NY 10016 USA. [Walczak, Thaddeus S.] MINCEP Epilepsy Care, Minneapolis, MN USA. [Bazil, Carl W.] Columbia Univ, Neurol Inst, Comprehens Epilepsy Ctr, New York, NY USA. [Langfitt, John T.] Univ Rochester, Dept Neurol, Rochester, NY USA. [Langfitt, John T.] Univ Rochester, Dept Psychiat, Rochester, NY USA. [Haut, Sheryl R.] Montefiore Med Ctr, Albert Einstein Coll Med, Comprehens Epilepsy Management Ctr, Bronx, NY 10467 USA. [Haut, Sheryl R.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA. [Sperling, Michael R.] Thomas Jefferson Univ, Dept Neurol, Jefferson Comprehens Epilepsy Ctr, Philadelphia, PA 19107 USA. [Spencer, Susan S.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA. [Spencer, Susan S.] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA. [Berg, Anne T.] No Illinois Univ, Dept Biol, De Kalb, IL 60115 USA. [Chin, Peter S.] Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA USA. [Chin, Peter S.] Univ Calif Los Angeles, Dept Med, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90024 USA. [Chin, Peter S.] Univ Calif Los Angeles, Dept Neurol, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90024 USA. RP Vickrey, BG (reprint author), Univ Calif Los Angeles, Dept Neurol, C109 RNRC,Box 951769, Los Angeles, CA 90095 USA. EM bvickrey@ucla.edu RI shengkun, yu/B-8440-2012 FU PHS HHS [R01 32375-06] NR 14 TC 24 Z9 26 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD DEC PY 2007 VL 48 IS 12 BP 2253 EP 2257 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 239XU UT WOS:000251552400006 PM 17645537 ER PT J AU Besio, WG Koka, K Cole, AJ AF Besio, Walter G. Koka, Kanthaiah Cole, Andrew J. TI Effects of noninvasive transcutaneous electrical stimulation via concentric ring electrodes on pilocarpine-induced status epilepticus in rats SO EPILEPSIA LA English DT Article DE status epilepticus; transcutaneous electrical stimulation; concentric ring electrodes; pilocarpine-induced seizures ID TRANSCRANIAL MAGNETIC STIMULATION; HIPPOCAMPAL SLICES; BRAIN-STIMULATION; SEIZURES; EPILEPSY; NUCLEUS; SUPPRESSION; DIAZEPAM; FIELDS AB Purpose: The aim of this pilot study was to investigate the antiepileptic effects of a novel noninvasive stimulation technique, transcutaneous electrical stimulation (TcES) via scalp concentric ring electrodes, on pilocarpine-induced status epilepticus ( SE) in rats. Methods: Five minutes after the onset of SE, TcES was administered to the experimental rat via bipolar concentric ring electrode at the CZ location. Symmetrical, biphasic, charge-balanced, constant current, isolated pulses were applied via a custom-made stimulator. TcES parameters ranged from 200-750 Hz, 200 or 300 mu s pulse duration, and 50 or 60 mA, applied for 1 min, started with the least intense parameter set and progressively increased. Results: TcES attenuated electrographic seizure activity and halted the progression of behavioral seizures. Interruption of seizure activity outlasted the period of stimulation and appeared to be long-lasting. TcES treatment significantly extended the life and enhanced the survival of rats after SE. Conclusions: Noninvasive TcES, applied 5min after SE onset via novel concentric ring electrodes on the scalp, reduced, or abolished electrographic and behavioral seizure activity in pilocarpine-induced SE in rats. These findings suggest that TcES may have a role in the treatment of SE. C1 [Besio, Walter G.] Louisiana Tech Univ, Dept Biomed Engn, Ruston, LA 71272 USA. [Koka, Kanthaiah] Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO USA. [Cole, Andrew J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Epilepsy Serv, Boston, MA USA. RP Besio, WG (reprint author), Louisiana Tech Univ, Dept Biomed Engn, 711 S Vienna St,POB 10157, Ruston, LA 71272 USA. EM walterb@latech.edu NR 25 TC 25 Z9 25 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD DEC PY 2007 VL 48 IS 12 BP 2273 EP 2279 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 239XU UT WOS:000251552400009 PM 17651415 ER PT J AU Muzykewicz, DA Newberry, P Danforth, N Halpern, EF Thiele, EA AF Muzykewicz, David A. Newberry, Peter Danforth, Nicole Halpern, Elkan F. Thiele, Elizabeth A. TI Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex SO EPILEPSY & BEHAVIOR LA English DT Article DE tuberous sclerosis complex; mood disorder; anxiety disorder; attention-deficit hyperactivity disorder; aggressive/disruptive behavior disorder; epilepsy ID DEVELOPMENTAL DISORDERS; ANTIEPILEPTIC DRUGS; EPILEPSY; CHILDREN; TSC1; BEHAVIOR; ADULTS; IDENTIFICATION; RISPERIDONE; SEIZURES AB Psychiatric symptoms were retrospectively assessed in a clinic population of 241 children and adults with tuberous sclerosis complex (TSC). Sixty-six (27%) patients had a history of mood disorder symptoms, 66 (27%) had a history of anxiety disorder symptoms, 73 (30%) had a history of attention-deficit hyperactivity disorder (ADHD) symptoms, and 68 (28%) had a history of aggressive/disruptive behavior disorder symptoms. Significant relationships were found between these symptoms and patient age, gender, genetic mutation, seizure history, surgical history, cognitive impairment, features of autism or pervasive developmental disorder, and neurological manifestations of TSC. In 43 patients seen by at least one of two affiliated psychiatrists, the most common formal diagnoses were anxiety disorders (28%), mood disorders (26%), adjustment disorders (21%), ADHD (21%), and mental disorders not otherwise specified due to general medical condition (42%). Citalopram demonstrated efficacy in treating anxiety and depression, and risperidone, in treating problematic behaviors. (C) 2007 Elsevier Inc. All rights reserved. C1 [Muzykewicz, David A.; Thiele, Elizabeth A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Newberry, Peter; Danforth, Nicole] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Halpern, Elkan F.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. RP Thiele, EA (reprint author), Carol & James Herscot Ctr Tuberous Sclerosis Comp, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM ethiele@partners.org NR 42 TC 52 Z9 52 U1 0 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 EI 1525-5069 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD DEC PY 2007 VL 11 IS 4 BP 506 EP 513 DI 10.1016/j.yebeh.2007.07.010 PG 8 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 243GM UT WOS:000251783500004 PM 17936687 ER PT J AU Pramuka, M Hendrickson, R Zinski, A Van Cott, AC AF Pramuka, Michael Hendrickson, Rick Zinski, Anne Van Cott, Anne C. TI A psychosocial self-management program for epilepsy: A randomized pilot study in adults SO EPILEPSY & BEHAVIOR LA English DT Article DE self-management; quality of life; QOLIE-89; randomized; clinical trial; intervention; psychosocial; treatment ID EFFICACY; PEOPLE; EMPOWERMENT; DEPRESSION; THERAPY; TRIALS; CHARGE; LIFE AB Objective. The goal of the work described here was to develop and pilot a theoretically based self-management intervention in adults with epilepsy. Methods. A randomized, controlled trial examined intervention effectiveness of a 6-week psychosocial intervention designed to improve self-efficacy and quality of life for 61 adults with diagnosed epilepsy. Measures included the Quality of Life in Epilepsy-89 inventory (QOLIE-89), the Washington Psychosocial Seizure Inventory (WPSI), a locus of control scale (LOC), and the Epilepsy Self-Efficacy Scale-2000 (ESES). Group differences were examined between groups using analysis of covariance. Results. There was a significant improvement in the QOLIE-89 Role Limitations-Emotional score in the treatment group at followup, but no significant differences in overall quality of life. Strong and significant correlations were observed between outcome measures. Conclusion. Although the intervention had little effect on improving overall quality of life, we observed promising trends in postintervention group comparisons linking self-efficacy and other psychosocial factors with quality of life. Intervention material can be modified for stage-based behavior change and retested in another study. (C) 2007 Elsevier Inc. All rights reserved. C1 [Pramuka, Michael; Hendrickson, Rick; Van Cott, Anne C.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Zinski, Anne] Univ Alabama, Birmingham, AL 35487 USA. [Van Cott, Anne C.] Vet Affairs Pittsburg Hlthcare Syst, Pittsburgh, PA USA. RP Pramuka, M (reprint author), Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, 5044 Forbes Tower-Atwood, Pittsburgh, PA 15260 USA. EM mpramuka@pitt.edu FU PHS HHS [U48/CCU320171] NR 42 TC 26 Z9 28 U1 2 U2 10 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD DEC PY 2007 VL 11 IS 4 BP 533 EP 545 DI 10.1016/j.yebeh.2007.06.013 PG 13 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 243GM UT WOS:000251783500008 PM 17904909 ER PT J AU Boelen, PA Prigerson, HG AF Boelen, Paul A. Prigerson, Holly G. TI The influence of symptoms of prolonged grief disorder, depression, and anxiety on quality of life among bereaved adults SO EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE LA English DT Article DE anxiety; death and dying; depression; grief; quality-of-life ID COMPLICATED GRIEF; TRAUMATIC GRIEF; DIAGNOSTIC-CRITERIA; SUICIDAL IDEATION; DISTINCT; REPLICATION; INVENTORY; RISK AB Objective Research has shown that symptoms of Prolonged Grief Disorder (PGD, formerly called Complicated Grief) are distinct from those of depression and anxiety, and have incremental validity in that they predict impairments in functioning, independent of depression and anxiety. This study sought to replicate these findings using a prospective design, a heterogeneous sample of mourners, and the most recent criteria to define PGD. Method Data from 346 mourners who were bereaved between 6 months and 2 years and who were recruited from professional and lay mental health care workers and the Internet, were used in a confirmatory factor analysis to determine the distinctiveness of symptoms of PGD, depression, and anxiety. Regression analyses estimated the effects of symptoms of PGD, depression, and anxiety on quality of life and mental health 6 months (T2) and 15 months (T3) after baseline, in a subgroup of 96 mourners assessed at follow-up. Results PGD, depression, and anxiety represented three distinct factors. When we controlled the influence of relevant background variables but not the shared variance between the factors, all three factors predicted quality of life and mental health outcomes at T2 and T3. When we controlled the shared variance between factors, the PGD factor at T1 predicted unique variance in four outcomes at T2 (mental health, suicidal ideation, PGD severity, and depression severity) and two outcomes at T3 (mental health and PGD severity), the depression factor in one outcome at T2 (depression severity) but none at T3, and the anxiety factor in six outcomes at T2 (mental health, energy, general health perception, sleeping problems, depression severity, and anxiety severity) and one at T3 (anxiety severity). Conclusions We found PGD (defined according to the newest criteria) to be distinct from depression and anxiety and to be predictive of reduced quality of life and mental health. The concept of PGD is needed to detect mourners at risk for health impairments, who would go undetected with an exclusive focus on depression or anxiety. C1 [Boelen, Paul A.] Univ Utrecht, Dept Clin & Hlth Psychol, NL-3508 TC Utrecht, Netherlands. [Prigerson, Holly G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat,Ctr Psychooncol & Palliat Care Res, Boston, MA 02115 USA. [Prigerson, Holly G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Palliat Care, Boston, MA 02115 USA. RP Boelen, PA (reprint author), Univ Utrecht, Dept Clin & Hlth Psychol, POB 80140, NL-3508 TC Utrecht, Netherlands. EM P.Boelen@fss.uu.nl FU NCI NIH HHS [CA106370, R01 CA106370]; NIMH NIH HHS [MH63892] NR 35 TC 88 Z9 90 U1 3 U2 19 PU DR DIETRICH STEINKOPFF VERLAG PI DARMSTADT PA PO BOX 10 04 62, D-64204 DARMSTADT, GERMANY SN 0940-1334 J9 EUR ARCH PSY CLIN N JI Eur. Arch. Psych. Clin. Neurosci. PD DEC PY 2007 VL 257 IS 8 BP 444 EP 452 DI 10.1007/s00406-007-0744-0 PG 9 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 246XL UT WOS:000252041600003 PM 17629728 ER PT J AU Van Kimmenade, RRJ Pinto, Y Januzzi, JL AF Van Kimmenade, Roland R. J. Pinto, Yigal Januzzi, James L., Jr. TI When renal and cardiac insuficiencies intersect: is there a role for natriuretic peptide testing in the 'cardio-renal syndrome'? SO EUROPEAN HEART JOURNAL LA English DT Editorial Material ID HEART-FAILURE; CHALLENGE C1 Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Van Kimmenade, Roland R. J.; Pinto, Yigal] Univ Hosp, Dept Cardiol, Maastricht, Netherlands. RP Januzzi, JL (reprint author), Massachusetts Gen Hosp, Div Cardiol, Yawkey 5800,55 Fruit St, Boston, MA 02114 USA. EM jjanuzzi@partners.org RI Kimmenade, R.R.J./L-4432-2015 NR 11 TC 7 Z9 9 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD DEC PY 2007 VL 28 IS 24 BP 2960 EP 2961 DI 10.1093/eurheartj/ehl399 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 241UF UT WOS:000251680600004 PM 17984131 ER PT J AU Horn, D Neofytos, D Fishman, J Steinbach, W Anaisie, E Marr, KA Pfaller, M Olyaei, A AF Horn, D. Neofytos, D. Fishman, J. Steinbach, W. Anaisie, E. Marr, K. A. Pfaller, M. Olyaei, A. TI Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 44th Annual Meeting of the Infectious-Diseases-Society-of-America CY OCT 12-15, 2006 CL Toronto, CANADA SP Infect Dis Soc Amer ID BLOOD-STREAM INFECTIONS; ATTRIBUTABLE MORTALITY; AMPHOTERICIN-B; UNITED-STATES; CANDIDIASIS; HOSPITALS AB Candidemia is an increasing complication of the care of complex patients. Adherence to Infectious Diseases Society of America (IDSA) guidelines for the treatment of candidemia was investigated to assess the impact of compliance on outcomes of therapy. Data on the epidemiology, diagnosis, and treatment of patients with invasive fungal infections (IFIs) was extracted from the PATH Alliance registry, a prospective, multicenter, observational database of invasive fungal infections. Patients with proven candidemia were evaluated for adherence to the IDSA guidelines in terms of choice, dosage, and duration of antifungal therapy. Removal of central venous catheters and time to treatment initiation were assessed. Four-week survival data were compared. Of the 418 patients with candidemia who were included in the study, 361 patients with the necessary data sets were identified, of whom 262 (72.6%) were treated within the IDSA guidelines for the treatment of candidemia (IDSA group); the remaining 99 (27.4%) patients received treatment different from the guidelines (non-IDSA group). Kaplan-Meier (KM) survival analysis for patients in the IDSA and non-IDSA group showed mortality rates of 21.9 and 13.6%, respectively; the difference between the two groups was not statistically significant (P=0.093). Following the exclusion of patients requiring mechanical ventilation or acute cardiac support, the modified survival KM curves were similar between the two groups. Significantly more patients in the IDSA group required mechanical ventilation and tunneled central catheters, had a concomitant IFI, and received caspofungin. The duration of treatment and inappropriate dosing did not appear to have had a significant impact on survival. Most of the deviations from IDSA guidelines were due to the inappropriate duration and dosing of therapy. No significant difference in mortality was noted between the IDSA and non-IDSA groups. The basis of these differences merit further study. C1 Thomas Jefferson Univ Hosp, Div Infect Dis, Philadelphia, PA 19107 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA. Duke Univ, Med Ctr, Div Pediat Infect Dis, Durham, NC 27710 USA. Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Div Support Care, Little Rock, AR 72205 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98119 USA. Univ Iowa Hlth Care, Dept Pathol, Iowa City, IA 52242 USA. Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. RP Horn, D (reprint author), Thomas Jefferson Univ Hosp, Div Infect Dis, 211 S 9th St,Suite 210, Philadelphia, PA 19107 USA. EM david.horn@jefferson.edu NR 15 TC 11 Z9 12 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0934-9723 J9 EUR J CLIN MICROBIOL JI Eur. J. Clin. Microbiol. Infect. Dis. PD DEC PY 2007 VL 26 IS 12 BP 907 EP 914 DI 10.1007/s10096-007-0383-4 PG 8 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 229EK UT WOS:000250785600008 PM 17899230 ER PT J AU Shi, FX Corrales, CE Liberman, MC Edge, ASB AF Shi, Fuxin Corrales, Carleton Eduardo Liberman, M. Charles Edge, Albert S. B. TI BMP4 induction of sensory neurons from human embryonic stem cells and reinnervation of sensory epithelium SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE differentiation; neural progenitors; neurosphere; pluripotency; stem cell specification ID BONE MORPHOGENETIC PROTEINS; NEURAL PROGENITOR CELLS; SPIRAL GANGLION NEURONS; OTIC PLACODE INDUCTION; DIFFERENTIAL EXPRESSION; DOPAMINERGIC-NEURONS; PARKINSONS-DISEASE; FATE SPECIFICATION; COCHLEAR IMPLANTS; AUDITORY NEURONS AB In mammals, hair cells and auditory neurons lack the capacity to regenerate, and damage to either cell type can result in hearing loss. Replacement cells for regeneration could potentially be made by directed differentiation of human embryonic stem (hES) cells. To generate sensory neurons from hES cells, neural progenitors were first made by suspension culture of hES cells in a defined medium. The cells were positive for nestin, a neural progenitor marker, and Pax2, a marker for cranial placodes, and were negative for alpha-fetoprotein, an endoderm marker. The precursor cells could be expanded in vitro in fibroblast growth factor (FGF)-2. Neurons and glial cells were found after differentiation of the neural progenitors by removal of FGF-2, but evaluation of neuronal markers indicated insignificant production of sensory neurons. Addition of bone morphogenetic protein 4 (BMP4) to neural progenitors upon removal of FGF-2, however, induced significant numbers of neurons that were positive for markers associated with cranial placodes and neural crest, the sources of sensory neurons in the embryo. Neuronal processes from hES cell-derived neurons made contacts with hair cells in denervated ex vivo sensory epithelia and expressed synaptic markers, suggesting the formation of synapses. In a gerbil model with a denervated cochlea, the ES cell-derived neurons engrafted in the auditory nerve trunk and sent out neurites that grew toward the auditory sensory epithelium. These data indicate that hES cells can be induced to form sensory neurons that have the potential to treat neural degeneration associated with sensorineural hearing loss. C1 Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Tillotson Unit Cell Biol, Boston, MA 02114 USA. Harvard Univ, MIT, Div Hlth Sci & Technol, Program Speech & Hearing Biosci & Technol, Cambridge, MA 02139 USA. RP Edge, ASB (reprint author), Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. EM albert_edge@meei.harvard.edu FU NIDCD NIH HHS [P30 DC05209, R01 DC007174, P30 DC005209] NR 49 TC 60 Z9 62 U1 1 U2 9 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD DEC PY 2007 VL 26 IS 11 BP 3016 EP 3023 DI 10.1111/j.1460-9568.2007.05909.x PG 8 WC Neurosciences SC Neurosciences & Neurology GA 232NK UT WOS:000251026200003 PM 18005071 ER PT J AU Mandal, RV Mark, EJ Kradin, RL AF Mandal, Rajni V. Mark, Eugene J. Kradin, Richard L. TI Megakaryocytes and platelet homeostasis in diffuse alveolar damage SO EXPERIMENTAL AND MOLECULAR PATHOLOGY LA English DT Article DE adult respiratory distress syndrome; diffuse alveolar damage; megakaryocytes; platelets ID RESPIRATORY-DISTRESS-SYNDROME; FAILURE AB Platelet homeostasis reflects a balance between the production of platelets via cytoplasmic fragmentation of megakaryocytes in the pulmonary microvasculature and their catabolism. Increased numbers of megakaryocytes are entrapped in the injured lung, potentially affecting circulating platelet counts. We enumerated pulmonary megakaryocytes and blood platelets in patients with diffuse alveolar damage (DAD) in order to determine their association with clinical outcome. Lung biopsies were examined from 21 patients with histologically documented DAD in its proliferative phase and secondary to a variety of causes. Blood platelet counts were determined within 24 h prior to lung biopsy, and CD61+ pulmonary megakaryocytes were localized in in situ immunohistochemical stains. The overall mortality in this series was 67%. Patients with DAD attributable to drug toxicity (DAD-D) had higher mortality (80%) and greater number of intrapulmonary CD61+ megakaryocytes than those with DAD due to other causes (23 +/- 7, 10 +/- 2, p < 0.05). Patients with blood platelet counts =350 th/cm(3) showed increased survival (p < 0.05). The findings support the hypothesis that abnormal platelet homeostasis is associated with increased mortality in acute lung injury and indicate that thrombocytosis in ARDS is associated with improved survival. The mechanisms of altered platelet homeostasis in DAD merit further investigation. (c) 2007 Elsevier Inc. All rights reserved. C1 [Mandal, Rajni V.; Mark, Eugene J.; Kradin, Richard L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Kradin, Richard L.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA. RP Kradin, RL (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. EM rkradin@partners.org NR 21 TC 8 Z9 11 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4800 J9 EXP MOL PATHOL JI Exp. Mol. Pathol. PD DEC PY 2007 VL 83 IS 3 BP 327 EP 331 DI 10.1016/j.yexmp.2007.08.005 PG 5 WC Pathology SC Pathology GA 246WF UT WOS:000252037800005 PM 17961550 ER PT J AU Morales, SA Mareninov, S Prasad, P Wadehra, M Braun, J Gordon, LK AF Morales, Shawn A. Mareninov, Sergey Prasad, Pradeep Wadehra, Madhuri Braun, Jonathan Gordon, Lynn K. TI Collagen gel contraction by ARPE-19 cells is mediated by a FAK-Src dependent pathway SO EXPERIMENTAL EYE RESEARCH LA English DT Article DE proliferative vitreoretinopathy; retinal pigment epithelium; focal adhesion kinase; integrin; collagen gel contraction ID PIGMENT EPITHELIAL-CELLS; FOCAL ADHESION KINASE; GROWTH-FACTOR; PROLIFERATIVE VITREORETINOPATHY; INTEGRIN RECEPTOR; IN-VITRO; FIBROBLASTS; PROTEIN; INHIBITION; EXPRESSION AB Proliferative vitreoretinopathy (PVR) may result in part from de-differentiation of retinal pigment epithelium (RPE) in an aberrant wound-healing strategy. An in vitro model of PVR, collaggen gel contraction by RPE, likely requires integrin engagement and activation as an important initial step. The purpose of this study was to identify the important associated integrins and signal transduction pathway. The retinal pigment epithelial cell line ARPE-19 was used in these studies. Cell surface integrin expression was assessed using flow cytometry. An in vitro contraction assay was performed and the percent contraction quantified at specific time intervals using image capture (Gel Doc) and NIH Image software. Cells were pretreated with either small molecule inhibitors of signal transduction pathways or monoclonal antibodies with specificity for specific integrin isoforms. Transient transfections with a FAK siRNA were used to decrease FAK expression. ARPE-19 cells express alpha 1, alpha 2, and alpha 3 integrin, isoforms involved in collagen ligation. Cell surface integrin blockade using anti-integrin alpha 2 (P = 0.02), alpha 3 (P = 0.01), or a combination of alpha 1, alpha 2, and alpha 3 (P = 0.001) antibodies significantly reduced collagen gel contraction. Inhibition of the FAK-Src complex, but not MEK or PI3K, significantly decreased contraction (P = 0.0001). FAK siRNA transient transfection significantly reduced FAK protein expression by 71% (P = 0.02) and concordantly decreased gel contraction (P = 0.0001). RPE-mediated collagen gel contraction is a multi-step process. Integrin ligation and FAK-Src activation is necessary for collagen gel contraction produced by the ARPE-19 cell line. Validation of these observations in primary RPE cells may suggest new targets for therapeutic intervention in PVR. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Morales, Shawn A.; Wadehra, Madhuri; Braun, Jonathan] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Morales, Shawn A.; Mareninov, Sergey; Prasad, Pradeep; Gordon, Lynn K.] Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Gordon, Lynn K.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Surg, Los Angeles, CA 90099 USA. RP Gordon, LK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM lgordon@ucla.edu FU NIAID NIH HHS [AI 52031]; NICHD NIH HHS [HD 48540] NR 31 TC 23 Z9 25 U1 0 U2 2 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0014-4835 J9 EXP EYE RES JI Exp. Eye Res. PD DEC PY 2007 VL 85 IS 6 BP 790 EP 798 DI 10.1016/j.exer.2007.08.014 PG 9 WC Ophthalmology SC Ophthalmology GA 246VZ UT WOS:000252037100007 PM 17915217 ER PT J AU Gerstner, ER Duda, DG di Tomaso, E Sorensen, G Jain, RK Batchelor, TT AF Gerstner, Elizabeth R. Duda, Dan G. di Tomaso, Emmanuelle Sorensen, Greg Jain, Rakesh K. Batchelor, Tracy T. TI Antiangiogenic agents for the treatment of glioblastoma SO EXPERT OPINION ON INVESTIGATIONAL DRUGS LA English DT Review DE antiangiogenesis; glioma; vascular normalization; vasogenic edema ID ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; PHASE-II TRIAL; MATRIX-METALLOPROTEINASE INHIBITORS; NEWLY-DIAGNOSED GLIOBLASTOMA; RECURRENT MALIGNANT GLIOMA; BRAIN-TUMOR CONSORTIUM; HIGH-GRADE GLIOMAS; FACTOR-RECEPTOR; IN-VIVO AB Glioblastomas are highly vascularized and, therefore, antiangiogenic agents are increasingly being explored as therapeutic options. This review summarizes the present data on antiangiogenic agents in glioblastoma treatment. The angiogenic pathway in gliomas and the proposed mechanisms of antiangiogenic agents are reviewed briefly, and details of the drugs in clinical trial are provided. In addition to their effects on blood vessels, these agents also have potent anti-edema effects that may have therapeutic benefit. The review concludes with a discussion of the role of biomarkers and neuroimaging in the assessment of tumor response. Although preliminary studies of these drugs in glioblastoma have been promising, larger prospective trials that include survival as an end point will be required to determine the ultimate utility of this class of agents. it seems likely that a combination of antiangiogenesis agents with other cytotoxic therapies will be required to achieve maximal efficacy. C1 [Batchelor, Tracy T.] Massachusetts Gen Hosp, Stephen E & Catherine Papas Ctr Neuro Oncol, Boston, MA 02114 USA. [Gerstner, Elizabeth R.; Batchelor, Tracy T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Gerstner, Elizabeth R.; Batchelor, Tracy T.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA USA. [Duda, Dan G.; Sorensen, Greg; Jain, Rakesh K.; Batchelor, Tracy T.] Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA. [Sorensen, Greg] Harvard Univ, Sch Med, Dept Radiol, Boston, MA USA. RP Batchelor, TT (reprint author), Massachusetts Gen Hosp, Stephen E & Catherine Papas Ctr Neuro Oncol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA. EM tbatchelor@partners.org NR 86 TC 21 Z9 21 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1354-3784 J9 EXPERT OPIN INV DRUG JI Expert Opin. Investig. Drugs PD DEC PY 2007 VL 16 IS 12 BP 1895 EP 1908 DI 10.1517/13543784.16.12.1895 PG 14 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 246IK UT WOS:000252000500003 PM 18041999 ER PT J AU Marneros, AG She, H Zambarakji, H Hashizume, H Connolly, EJ Kim, I Gragoudas, ES Miller, JW Olsen, BR AF Marneros, Alexander G. She, Haicheng Zambarakji, Hadi Hashizume, Hiroya Connolly, Edward J. Kim, Ivana Gragoudas, Evangelos S. Miller, Joan W. Olsen, Bjorn R. TI Endogenous endostatin inhibits choroidal neovascularization SO FASEB JOURNAL LA English DT Article DE angiogenesis; collagen XVIII; Bruch's membrane; age-related macular degeneration ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; COLLAGEN-XVIII; MACULAR DEGENERATION; TUMOR-GROWTH; FACTOR VEGF; BASEMENT-MEMBRANE; FACTOR EXPRESSION; KNOBLOCH-SYNDROME; AGE AB Endostatin, a fragment of the basement membrane component collagen XVIII, exhibits antiangiogenic properties in vitro and in vivo when high doses are administered. It is not known whether endogenous endostatin at physiological levels has a protective role as an inhibitor of pathological angiogenesis, such as choroidal neovascularization ( CNV) in age- related macular degeneration. Using a laser injury model, we induced CNV in mice lacking collagen XVIII/ endostatin and in control mice. CNV lesions in mutant mice were similar to 3-fold larger than in control mice and showed increased vascular leakage. These differences were independent of age- related changes at the choroid-retina interface. Ultrastructural analysis of the choroidal vasculature in mutant mice excluded morphological vascular abnormalities as a cause for the larger CNV lesions. When recombinant endostatin was administered to collagen XVIII/ endostatin- deficient mice, CNV lesions were similar to those seen in control mice. In control mice treated with recombinant endostatin, CNV lesions were almost undetectable. These findings demonstrate that endogenous endostatin is an inhibitor of induced angiogenesis and that administration of endostatin potently inhibits CNV growth and vascular leakage. Endostatin may have a regulatory role in the pathogenesis of CNV and could be used therapeutically to inhibit growth and leakage of CNV lesions. C1 Harvard Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA. Harvard Med Sch, Dept Cell Biol, Boston, MA USA. Harvard Med Sch, Massachusetts Eye & Ear Infirm, Angiogenesis Lab & Retina Serv, Boston, MA USA. Niigata Univ, Postgrad Sch Med & Dental Sci, Div Microscop Anatomy & Bioimaging, Niigata, Japan. RP Marneros, AG (reprint author), Harvard Sch Dent Med, Dept Dev Biol, 188 Longwood Ave, Boston, MA 02115 USA. EM alexander_marneros@yahoo.com FU NEI NIH HHS [P30EY14104]; NIAMS NIH HHS [AR36820] NR 40 TC 37 Z9 37 U1 0 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD DEC PY 2007 VL 21 IS 14 BP 3809 EP 3818 DI 10.1096/fj.07-8422com PG 10 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 236DP UT WOS:000251283500005 PM 17526870 ER PT J AU Crimi, E Ignarro, LJ Napoli, C AF Crimi, E. Ignarro, L. J. Napoli, C. TI Microcirculation and oxidative stress SO FREE RADICAL RESEARCH LA English DT Review DE microcirculation; oxidative stress; endothelial dysfunction; antioxidants ID C-REACTIVE PROTEIN; ENDOTHELIUM-DEPENDENT VASODILATION; NITRIC-OXIDE SYNTHASE; SPONTANEOUSLY HYPERTENSIVE-RATS; FACTOR-KAPPA-B; HYPOXIC PULMONARY VASOCONSTRICTION; SENSITIVE POTASSIUM CHANNELS; SIGNAL-TRANSDUCTION PATHWAY; POMEGRANATE FRUIT EXTRACT; ACUTE CORONARY SYNDROMES AB The microcirculation is a complex and integrated system, transporting oxygen and nutrients to the cells. The key component of this system is the endothelium, contributing to the local balance between pro and anti-inflammatory mediators, hemostatic balance, as well as vascular permeability and cell proliferation. A constant shear stress maintains vascular endothelium homeostasis while perturbed shear stress leads to changes in secretion of vasodilator and vasoconstrictor agents. Increased oxidative stress is a major pathogenetic mechanism of endothelial dysfunction by decreasing NO bioavailability, promoting inflammation and participating in activation of intracellular signals cascade, so influencing ion channels activation, signal transduction pathways, cytoskeleton remodelling, intercellular communication and ultimately gene expression. Targeting the microvascular inflammation and oxidative stress is a fascinating approach for novel therapies in order to decrease morbidity and mortality of chronic and acute diseases. C1 [Crimi, E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. [Ignarro, L. J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA. [Napoli, C.] Univ Naples 2, Sch Med 1, Clin Pathol & Excellence Res Ctr Cardiiovasc Dis, Dept Gen Pathol, Naples, Italy. [Napoli, C.] IRCCS Multimedia, Milan, Italy. [Napoli, C.] Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA. [Napoli, C.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA. RP Crimi, E (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. EM ecrimi@partners.org OI Napoli, Claudio/0000-0002-5455-555X NR 172 TC 63 Z9 69 U1 1 U2 6 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1071-5762 J9 FREE RADICAL RES JI Free Radic. Res. PD DEC PY 2007 VL 41 IS 12 BP 1364 EP 1375 DI 10.1080/10715760701732830 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 255OV UT WOS:000252668200007 PM 18075839 ER PT J AU Strobel, O Dor, Y Alsina, J Stirman, A Lauwers, G Trainor, A Castillo, CF Warshaw, AL Thayer, SP AF Strobel, Oliver Dor, Yuval Alsina, Janivette Stirman, Amy Lauwers, Gregory Trainor, Amanda Castillo, Carlos Fernandez-del Warshaw, Andrew L. Thayer, Sarah P. TI Basic-liver, pancreas, and biliary tract SO GASTROENTEROLOGY LA English DT Article ID TO-DUCTAL METAPLASIA; ACINAR-CELL; TUBULAR COMPLEXES; INTRAEPITHELIAL NEOPLASIA; MALIGNANT-TRANSFORMATION; EXOCRINE PANCREAS; TRANSGENIC MICE; BETA-CELL; CANCER; ORIGIN AB Background & Aims: Chronic injury results in regeneration of normal pancreatic tissue and formation of a metaplasia of ductal phenotype. Metaplastic ductal lesions are seen in pancreatitis as well as in specimens of pancreatic cancer and are thought to represent a condition with increased risk of neoplasia. Acinar-to-ductal transdifferentiation is thought to be the source of this metaplasia. This has been suggested for flat duct-like lesions called tubular complexes and for lesions exhibiting a mucinous metaplasia. However, available studies are based on interpretation of static data rather than on direct evidence. Transdifferentiation from acinar to ductal cells has never been confirmed in the adult pancreas. Methods: Here, we use Cre-loxP-based genetic lineage tracing in vivo to investigate whether transdifferentiation of acinar cells contributes to regeneration and metaplasia in pancreatitis. Resuits: The results show that transdifferentiation does not play a role in regeneration of normal tissue. Acinar cells are regenerated by preexisting acinar cells and not from other cell types. Three different types of metaplastic ductal lesions are observed and analyzed. Whereas the majority of metaplastic lesions are not of acinar origin, acinar-to-ductal transdifferentiation is identified in a minority of mucinous metaplastic lesions. Conclusions: Here, we provide direct evidence that acinar-to-ductal transdifferentiation occurs in the adult pancreas in vivo. However, it accounts for only a minority of metaplastic lesions. C1 Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Heidelberg, Dept Gen Surg, Heidelberg, Germany. Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Thayer, SP (reprint author), Massachusetts Gen Hosp, Dept Surg, WACC 460, Boston, MA 02114 USA. EM sthayer@partners.org RI Dor, Yuval/C-2405-2011 FU NIDDK NIH HHS [DK071329, K08 DK071329, K08 DK071329-04] NR 31 TC 123 Z9 124 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD DEC PY 2007 VL 133 IS 6 BP 1999 EP 2009 DI 10.1053/j.gastro.2007.09.009 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 239RM UT WOS:000251535400031 PM 18054571 ER PT J AU Lauwers, GY Srivastava, A AF Lauwers, Gregory Y. Srivastava, Arnitabh TI Gastric preneoplastic lesions and epithelial dysplasia SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA LA English DT Review ID FAMILIAL ADENOMATOUS POLYPOSIS; HELICOBACTER-PYLORI INFECTION; FUNDIC GLAND POLYPS; UPPER GASTROINTESTINAL POLYPS; CPG ISLAND METHYLATION; COLI GARDNERS-SYNDROME; INTESTINAL METAPLASIA; FOLLOW-UP; MICROSATELLITE INSTABILITY; NONINVASIVE NEOPLASIA AB The incidence of gastric cancer is declining; however, it remains the second most common cause of cancer-related deaths worldwide. This article describes gastric preneoplastic lesions and epithelial dysplasia. The possible role of Helicobader pylori infection is emphasized. C1 [Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Gastrointestinal Pathol Serv, Boston, MA 02114 USA. [Srivastava, Arnitabh] Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03755 USA. RP Lauwers, GY (reprint author), Massachusetts Gen Hosp, Dept Pathol, Gastrointestinal Pathol Serv, 55 Fruit Str,Warren 2, Boston, MA 02114 USA. EM glauwers@partners.org RI Srivastava, Amitabh/A-9386-2009; OI Srivastava, Amitabh/0000-0001-5165-8142 NR 136 TC 22 Z9 22 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8553 J9 GASTROENTEROL CLIN N JI Gastroenterol. Clin. North Am. PD DEC PY 2007 VL 36 IS 4 BP 813 EP + DI 10.1016/j.gtc.2007.08.008 PG 18 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 241TS UT WOS:000251679300004 PM 17996792 ER PT J AU Kankel, MW Hurlbut, GD Upadhyay, G Yajnik, V Yedvobnick, B Artavanis-Tsakonas, S AF Kankel, Mark W. Hurlbut, Gregory D. Upadhyay, Geeta Yajnik, Vijay Yedvobnick, Barry Artavanis-Tsakonas, Spyros TI Investigating the genetic circuitry of mastermind in drosophila, a notch signal effector SO GENETICS LA English DT Article ID NUCLEAR-PROTEIN; CAENORHABDITIS-ELEGANS; WING DEVELOPMENT; BINDING-PROTEIN; EYE DEVELOPMENT; LIN-12 ACTIVITY; MELANOGASTER; PATHWAY; COMPLEX; TRANSCRIPTION AB Notch signaling regulates multiple developmental processes and is implicated in various human diseases. Through use of the Notch transcriptional co-activator mastermind, we conducted a screen for Notch signal modifiers rising the Exelixis collection of insertional mutations, which affects similar to 50% of the Drosophila genome, recovering 160 genes never before associated with Notch, extending the previous roster of genes that interact functionally with the Notch pathway and mastermind. As the molecular identify for most recovered genes is known, gene ontology (GO) analysis vas applied, grouping genes according to functional classifications. We identify novel Notch-associated GO categories, uncover nodes of integration between Notch and other signaling pathways, and unveil groups of modifiers that: suggest the existence of Notch-independent mastermind functions, including a conserved ability to regulate Wnt signaling. C1 [Kankel, Mark W.; Hurlbut, Gregory D.; Artavanis-Tsakonas, Spyros] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. [Hurlbut, Gregory D.] Univ Paris 11, Fac Sci Orsay, F-75248 Paris, France. [Upadhyay, Geeta; Yajnik, Vijay] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Yedvobnick, Barry] Emory Univ, Dept Biol, Atlanta, GA 30322 USA. [Artavanis-Tsakonas, Spyros] Coll France, F-75231 Paris 05, France. RP Artavanis-Tsakonas, S (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave,LHRRB-418, Boston, MA 02115 USA. EM artavanis@hms.harvard.edu FU NCI NIH HHS [CA098402, R01 CA098402]; NINDS NIH HHS [R37 NS026084, NS26084, R01 NS026084] NR 61 TC 42 Z9 42 U1 0 U2 0 PU GENETICS PI BALTIMORE PA 428 EAST PRESTON ST, BALTIMORE, MD 21202 USA SN 0016-6731 J9 GENETICS JI Genetics PD DEC PY 2007 VL 177 IS 4 BP 2493 EP 2505 DI 10.1534/genetics.107.080994 PG 13 WC Genetics & Heredity SC Genetics & Heredity GA 245QF UT WOS:000251949800043 PM 18073442 ER PT J AU Levy, DE Youatt, EJ Shields, AE AF Levy, Douglas E. Youatt, Emily J. Shields, Alexandra E. TI Primary care physicians' concerns about offering a genetic test to tailor smoking cessation treatment SO GENETICS IN MEDICINE LA English DT Article DE smoking; smoking cessation; addiction; primary care; legal protections ID DOPAMINE-RECEPTOR GENE; TRYPTOPHAN-HYDROXYLASE GENE; RANDOMIZED CONTROLLED-TRIAL; NICOTINE DEPENDENCE; BREAST-CANCER; CIGARETTE-SMOKING; SELF-REPORT; COLORECTAL-CANCER; RISK-FACTORS; CHART AUDIT AB Purpose: We assessed the importance assigned by primary care physicians to eight factors influencing whether they would order a genetic test to individually tailor smoking cessation treatment. Methods: A random sample of United States primary care physicians was surveyed about how important each of eight factors were in the decision to order the test. Broadly, these factors included the ability of the test to improve treatment, the patient's reaction to test results, concern about misuse of test results, and the ability of the physician's office to manage informed consent for the test. Results: Physicians indicated the most important factor they would consider in ordering a genetic test to tailor smoking cessation treatment was the ability to improve cessation outcomes. However, when told the genotype identified by the test was associated with stigma-inducing mental health conditions, physicians emphasized the importance of possible racial, insurance, and employment discrimination in their decisions. Conclusions: Primary care physicians are eager. to improve smoking cessation treatment, but the collateral information generated by genetic testing to tailor treatment may be an impediment unless proper antidiscrimination measures are in place. C1 [Levy, Douglas E.; Youatt, Emily J.; Shields, Alexandra E.] Massachusetts Gen Hosp, Inst Hlth Policy, Harvard MGH Ctr Genom Vulnerable Populat & Hlth D, Boston, MA 02114 USA. [Levy, Douglas E.; Shields, Alexandra E.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Levy, DE (reprint author), Inst Hlth Policy, Harvard MGH Ctr Genom Vulnerable Populat & Hlth D, 50 Staniford St,Suite 901, Boston, MA 02114 USA. EM douglas_levy2@hms.harvard.edu FU NHGRI NIH HHS [P20 HG003400] NR 72 TC 14 Z9 14 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD DEC PY 2007 VL 9 IS 12 BP 842 EP 849 DI 10.1097/GIM.0b013e31815bf953 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 245DU UT WOS:000251915900007 PM 18091434 ER PT J AU Zhang, Z Yu, Y Xu, F Berchuck, A van Haaften-Day, C Havrilesky, LJ de Bruijn, HWA van der Zee, AGJ Woolas, RP Jacobs, IJ Skates, S Chan, DW Bast, RC AF Zhang, Zhen Yu, Yinhua Xu, Fengji Berchuck, Andrew van Haaften-Day, Carolien Havrilesky, Laura J. de Bruijn, Henk W. A. van der Zee, Ate G. J. Woolas, Robert P. Jacobs, Ian J. Skates, Steven Chan, Daniel W. Bast, Robert C., Jr. TI Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer SO GYNECOLOGIC ONCOLOGY LA English DT Article DE ovarian cancer; tumor marker; early detection; multivariate model; artificial neural network ID ARTIFICIAL NEURAL-NETWORK; COLONY-STIMULATING FACTOR; BENIGN PELVIC MASSES; TRANSVAGINAL ULTRASONOGRAPHY; CA-125 LEVELS; CA 125; CARCINOMA; ELEVATION; DIAGNOSIS; RISK AB Objective. Currently available tumor markers for ovarian cancer are still inadequate in both sensitivity and specificity to be used for population-based screening. Artificial neural network (ANN) as a modeling tool has demonstrated its ability to assimilate information from multiple sources and to detect subtle and complex patterns. In this paper, an ANN model was evaluated for its performance in detecting early stage epithelial ovarian cancer using multiple serum markers. Methods. Serum specimens collected at four institutions in the US, the Netherlands and the United Kingdom were analyzed for CA 125II, CA 724, CA 15-3 and macrophage colony stimulating factor (M-CSF). The four tumor marker values were then used as inputs to an ANN derived using a training set from 100 apparently healthy women, 45 women with benign conditions arising from the ovary and 55 invasive epithelial ovarian cancer patients (including 27 stage I/II cases). A separate validation set from 27 apparently healthy women, 56 women with benign conditions and 35 women with various types of malignant pelvic masses was used to monitor the ANN's performance during training. An independent test data set from 98 apparently healthy women and 52 early stage epithelial ovarian cancer patients (38 stage I and 4 stage II invasive cases and 10 stage I borderline ovarian tumor cases) was used to evaluate the ANN. Results. ROC analysis confirmed the overall superiority of the ANN-derived composite index over CA 125II alone (p=0.0333). At a fixed specificity of 98%, the sensitivities for ANN and CA 125II alone were 71% (37/52) and 46% (24/52) (p=0.047), respectively, for detecting early stage epithelial ovarian cancer, and 71% (30/42) and 43% (18/42) (p=0.040), respectively, for detecting invasive early stage epithelial ovarian cancer. Conclusions. The combined use of multiple tumor markers through an ANN improves the overall accuracy to discern healthy women from patients with early stage ovarian cancer. Analysis of multiple markers with an ANN may be a better choice than the use of CA 125II alone in a two-step approach for population screening in which a secondary test such as ultrasound is used to keep the overall specificity at an acceptable level. (C) 2007 Elsevier Inc. All rights reserved. C1 [Zhang, Zhen; Chan, Daniel W.] Johns Hopkins Med Inst, Dept Pathol, Dept Biomarker Discovery, Baltimore, MD 21231 USA. [Yu, Yinhua; Xu, Fengji; Bast, Robert C., Jr.] Anderson Canc Ctr, Houston, TX 77030 USA. [Berchuck, Andrew; Havrilesky, Laura J.] Duke Univ, Med Ctr, Durham, NC 27710 USA. [van Haaften-Day, Carolien; de Bruijn, Henk W. A.] Royal Hosp Women, Sydney, NSW, Australia. [van der Zee, Ate G. J.] Univ Groningen, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands. [Woolas, Robert P.] St Marys Hosp, Portsmouth, Hants, England. [Jacobs, Ian J.] Queen Marys Sch Med, Barts & London, London, England. [Skates, Steven] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA USA. RP Zhang, Z (reprint author), Johns Hopkins Med Inst, Dept Pathol, Dept Biomarker Discovery, 1550 Orleans St, Baltimore, MD 21231 USA. EM zzhang7@jhmi.edu RI Bast, Robert/E-6585-2011; Jacobs, Ian/F-1743-2013 OI Bast, Robert/0000-0003-4621-8462; Jacobs, Ian/0000-0002-8112-4624 FU NCI NIH HHS [P50 CA083639, 1P50 CA83639, P50 CA083639-07, R43 CA080459-01, U24 CA115102, U24 CA115102-03] NR 24 TC 56 Z9 59 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD DEC PY 2007 VL 107 IS 3 BP 526 EP 531 DI 10.1016/j.ygyno.2007.08.009 PG 6 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 241BP UT WOS:000251632200025 PM 17920110 ER PT J AU Maghami, EG Talbot, SG Patel, SG Singh, B Polluri, A Bridger, PG Cantu, G Cheesman, AD De Sa, G Donald, P dos Santos, LRM Fliss, D Gullane, P Janecka, I Kamata, SE Kowalski, LP Kraus, DH Levine, PA Pradhan, S Schramm, V Snyderman, C Wei, WI Shah, JP AF Maghami, Ellie G. Talbot, Simon G. Patel, Snehal G. Singh, Bhuvanesh Polluri, Ashok Bridger, Patrick G. Cantu, Giulio Cheesman, Anthony D. De Sa, Geraldo Donald, Paul dos Santos, Luiz R. M. Fliss, Dan Gullane, Patrick Janecka, Ivo Kamata, Shin-Estu Kowalski, Luiz P. Kraus, Dennis H. Levine, Paul A. Pradhan, Sultan Schramm, Victor Snyderman, Carl Wei, William I. Shah, Jatin P. TI Craniofacial surgery for nonmelanoma skin malignancy: Report of an international collaborative study SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Review DE skull base neoplasm; skull base/craniofacial surgery; skin cancer; head and neck; basal cell carcinoma; squamous cell carcinoma; treatment outcome; international collaboration ID SQUAMOUS-CELL CARCINOMA; SKULL BASE; PROGNOSTIC FACTORS; SURVIVAL ANALYSIS; TUMORS; RESECTION; CANCER; EXTENSION; SINUS AB Background. This study examined the efficacy of craniofacial surgery (CFS) in treating locally advanced nonmelanoma skin cancer (NMSC). Methods. One hundred twenty patients who underwent CFS for NMSC were identified from 17 participating institutions, Patient, tumor, and treatment information was analyzed for prognostic impact on survival. Results. Surgical margins were negative in 74%, close in 3%, and involved in 23% of patients. Complications occurred in 35% of patients, half of which were local wound problems. Operative mortality was 4%. Median follow-up interval after CFS was 27 months. The 5-year overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) rates were 64%, 75%, and 60%, respectively. Squamous cell histology, brain invasion, and positive resection margins independently predicted worse OS, DSS, and RFS. Conclusion, CFS is an effective treatment for patients with NMSC invading the skull base. Histology, extent of disease, and resection margins are the most significant predictors of outcome. (c) 2007 Wiley Periodicals, Inc. C1 Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA. Prince Wales Hosp, Dept Otolaryngol Head & Neck Surg, Randwick, NSW 2031, Australia. Inst Nazl Tumori, Milan, Italy. Royal Natl Throat Nose & Ear Hosp, Inst Laryngol & Otol, London WC1X 8DA, England. Hosp Canc 1, Inst Nacl Canc, Dept Head & Neck Surg, Rio De Janeiro, Brazil. Univ Calif Davis, Dept Otolaryngol Head & Neck Surg, Sacramento, CA 95817 USA. Hosp Clin Sao Paulo, Dept Head & Neck Surg, Sao Paulo, Brazil. Tel Aviv Sourasky Med Ctr, Dept Otolaryngol Head & Neck Surg, Tel Aviv, Israel. Toronto Gen Hosp, Dept Otolaryngol Head & Neck Surg, Toronto, ON, Canada. Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. Canc Inst Hosp, Div Head & Neck, Tokyo, Japan. Hosp Canc AC Camargo, Dept Otorhinolaryngol Head & Neck Surg, Sao Paulo, Brazil. Univ Virginia, Dept Otolaryngol Head & Neck Surg, Charlottesville, VA USA. Tata Mem Hosp, Head & Neck Serv, Bombay 400012, Maharashtra, India. Presbyterian St Lukes Med Ctr, Ctr Craniofacial Skull Base Surg, Denver, CO USA. Univ Pittsburgh, Inst Eye & Ear, Pittsburgh, PA 15213 USA. Univ Hong Kong, Med Ctr, Dept Surg, Hong Kong, Hong Kong, Peoples R China. RP Shah, JP (reprint author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA. EM shahj@mskcc.org RI Kowalski, Luiz/D-1701-2012; Francisco, Suely/D-9065-2014; OI Kowalski, Luiz/0000-0001-5865-9308; wei, william/0000-0002-6281-7126; Kowalski, Luiz Paulo/0000-0002-0481-156X; Shah, Jatin/0000-0002-6444-6592 NR 18 TC 4 Z9 4 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1043-3074 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD DEC PY 2007 VL 29 IS 12 BP 1136 EP 1143 DI 10.1002/hed-20656 PG 8 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 239TD UT WOS:000251539700010 PM 17764086 ER PT J AU Anderson, KC AF Anderson, Kenneth C. TI Multiple myeloma - Preface SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Editorial Material C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. RP Anderson, KC (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM kenneth_anderson@dfci.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD DEC PY 2007 VL 21 IS 6 BP XIII EP XIV DI 10.1016/j.hoc.2007.08.012 PG 2 WC Oncology; Hematology SC Oncology; Hematology GA 239RB UT WOS:000251534300001 PM 17996584 ER PT J AU Tonon, G AF Tonon, Giovanni TI Molecular pathogenesis of multiple myeloma SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Review ID GROWTH-FACTOR RECEPTOR-3; IN-SITU HYBRIDIZATION; ADVERSE PROGNOSTIC-FACTOR; COMPARATIVE GENOMIC HYBRIDIZATION; STEM-CELL TRANSPLANTATION; TUMOR-SUPPRESSOR GENES; HIGH-DOSE THERAPY; C-MYC ONCOGENE; UNDETERMINED SIGNIFICANCE; MONOCLONAL GAMMOPATHY AB Several genetic mechanisms underlying the pathogenesis of multiple myeloma have been elucidated in the past decade. In particular, the presence of two distinct karyotypic patterns, that identify two patient groups and drive different pathogenetic and prognostic paths in the development of myeloma, have been identified, and the role of reciprocal chromosomal translocations and cyclin dysregulation have been identified. Despite this progress, several questions of critical importance remain to be addressed for the understanding of the pathogenesis of multiple myeloma. For example, little is known about the role of die primary events, including cyclin D overexpression and multiple myeloma set domain activity in the early pathogenesis of the disease. The additional lesions that promote the evolution of monoclonal gammopathy of undetermined significance to multiple myeloma (MM) and, within MM, the progression toward a more aggressive and proliferative disease is only starting to emerge. The heterotypic relationship between the stroma and the MM plasma cells also has not been fully explored. The understanding of the biology of MM cancer stem cells and of the pathways driving their maintenance, proliferation, and differentiation is still in its infancy. Recent and ongoing high-resolution genomic studies are leading the way toward a more refined and conclusive understanding of this disease. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Tonon, G (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Mayer Bldg,Rm 417,44 Binney St, Boston, MA 02115 USA. EM giovanni_tonon@dfci.harvard.edu NR 153 TC 20 Z9 20 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD DEC PY 2007 VL 21 IS 6 BP 985 EP + DI 10.1016/j.hoc.2007.08.004 PG 23 WC Oncology; Hematology SC Oncology; Hematology GA 239RB UT WOS:000251534300002 PM 17996585 ER PT J AU Mitsiades, CS McMillin, DW Klippel, S Hideshima, T Chauhan, D Richardson, PG Munshi, NC Anderson, KC AF Mitsiades, Constantine S. McMillin, Douglas W. Klippel, Steffen Hideshima, Teru Chauhan, Dharminder Richardson, Paul G. Munshi, Nilchil C. Anderson, Kenneth C. TI The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Review ID GROWTH-FACTOR-I; HUMAN MULTIPLE-MYELOMA; MEDIATED DRUG-RESISTANCE; NF-KAPPA-B; TYROSINE KINASE INHIBITOR; COLONY-STIMULATING FACTOR; THALIDOMIDE PLUS DEXAMETHASONE; FARNESYL TRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITION; INFLAMMATORY PROTEIN 1-ALPHA AB Multiple myeloma (MM) is viewed as a prototypic disease state for the study of how neoplastic cells interact with their local bone marrow (BM) microenvironment. This interaction reflects not only the osteotropic clinical behavior of MM and the clinical impact of the lytic bone lesions caused by its tumor cells but also underlines the broadly accepted notion that nonneoplastic cells of the BM can attenuate the activity of cytotoxic chemotherapy and glucocorticoids. This article summarizes the recent progress in characterization, at the molecular and cellular levels, of how the BM milieu interacts with MM cells and modifies their biologic behavior. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. RP Mitsiades, CS (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM constantine_mitsiades@dfci.harvard.edu NR 227 TC 69 Z9 72 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD DEC PY 2007 VL 21 IS 6 BP 1007 EP + DI 10.1016/j.hoc.2007.08.007 PG 30 WC Oncology; Hematology SC Oncology; Hematology GA 239RB UT WOS:000251534300003 PM 17996586 ER PT J AU Mitsiades, CS Anderson, KC Carrasco, DR AF Mitsiades, Constantine S. Anderson, Kenneth C. Carrasco, Daniel R. TI Mouse models of human myeloma SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Review ID HUMAN MULTIPLE-MYELOMA; IN-VIVO MODEL; 5T33 MURINE MYELOMA; BONE-MARROW MICROENVIRONMENT; HUMAN INTERLEUKIN-6 RECEPTOR; SCID-HU MOUSE; BCL-X-L; C57BL/KALWRIJ MOUSE; PLASMA-CELLS; ENDOTHELIAL-CELLS AB Multiple myeloma (MM) remains incurable despite high-dose chemotherapy with stem cell support. There is need, therefore, for continuous efforts directed toward the development of novel rational-based therapeutics for MM, which requires a detailed knowledge of the mutations driving this malignancy. In improving the success rate of effective drug development, it is equally imperative that biologic systems be developed to better validate these target genes. Here we review the recent developments in the generation of mouse models of MM and their impact as preclinical models for designing and assessing target-based therapeutic approaches. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. RP Mitsiades, CS (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM constantine_mitsiades@dfci.harvard.edu NR 114 TC 16 Z9 17 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD DEC PY 2007 VL 21 IS 6 BP 1051 EP + DI 10.1016/j.hoc.2007.08.003 PG 20 WC Oncology; Hematology SC Oncology; Hematology GA 239RB UT WOS:000251534300005 PM 17996588 ER PT J AU Hideshima, T Anderson, KC AF Hideshima, Teru Anderson, Kenneth C. TI Preclinical studies of novel targeted therapies SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Review ID MULTIPLE-MYELOMA CELLS; HISTONE DEACETYLASE INHIBITOR; ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; TYROSINE KINASE INHIBITOR; SOLUBLE INTERLEUKIN-6 RECEPTOR; BONE-MARROW MICROENVIRONMENT; UNFOLDED PROTEIN RESPONSE; OVERCOMES DRUG-RESISTANCE; SMALL-MOLECULE INHIBITOR AB The bone mar-row (BM) milieu confers drug resistance in multiple myeloma (MM) cells to conventional therapies. Novel biologically based therapies are therefore needed. Preclinical studies have identified and validated molecular targeted therapeutics in MM. In particular, recognition of the biologic significance of the BM microenvironment in MM pathogenesis and as a potential target for novel therapeutics has already derived several promising approaches. Thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade) are directed not only at MM cells but also at the BM milieu and have moved rapidly from the bench to the bedside and United States Food and Drug Administration approval to treat MM. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. RP Hideshima, T (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM teru_hideshima@dfci.harvard.edu FU NCI NIH HHS [P01 CA078378-08, R01 CA050947-16, R01 CA050947-15, P01 CA078378-03, P01 CA078378-04, P50 CA100707-010001, P50 CA100707, R01 CA050947-13, R01 CA050947-14, P01 CA078378-06A1, P01 CA078378, P01 CA078378-09, R01 CA050947-12, P01 CA078378-05, P01 CA078378-06A10007, P01 CA078378-10, R01 CA050947, P01 CA078378-07] NR 150 TC 13 Z9 16 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD DEC PY 2007 VL 21 IS 6 BP 1071 EP + DI 10.1016/j.hoc.2007.08.013 PG 23 WC Oncology; Hematology SC Oncology; Hematology GA 239RB UT WOS:000251534300006 PM 17996589 ER PT J AU Kastritis, E Mitsiades, CS Dimopoulos, MA Richardson, PG AF Kastritis, Efstathios Mitsiades, Constantine S. Dimopoulos, Meletios A. Richardson, Paul G. TI Management of relapsed and relapsed refractory myeloma SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Review ID RELAPSED/REFRACTORY MULTIPLE-MYELOMA; PEGYLATED LIPOSOMAL DOXORUBICIN; STEM-CELL TRANSPLANTATION; HIGH-DOSE DEXAMETHASONE; THALIDOMIDE PLUS DEXAMETHASONE; PROTEASOME INHIBITOR PS-341; BONE-MARROW-TRANSPLANTATION; COOPERATIVE-ONCOLOGY-GROUP; IMPAIRED RENAL-FUNCTION; TERM-FOLLOW-UP AB Studies of bortezomib, thalidomide, and lenalidomide have shown promising clinical activity in relapsed/refractory multiple myeloma (MM). Bortezomib alone and in combination with other agents is associated with high response rates, consistently high rates of complete response, and a predictable and manageable profile of adverse events. Thalidomide-based regimens have also shown substantial clinical activity. The accumulating experience from ongoing trials of bortezomib/lenalidomide/dexamethasone combinations in patients who have relapsed/refractory or newly diagnosed MM will provide critical information that will determine the possible role of this combination as the basic backbone for combination regimens for management of advanced MM. C1 Univ Athens, Sch Med, Dept Clin Therapeut, Athens 14561, Greece. Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. RP Dimopoulos, MA (reprint author), Univ Athens, Sch Med, Dept Clin Therapeut, 227 Kifissias Ave, Athens 14561, Greece. EM mdimop@med.uoa.gr OI Kastritis, Efstathios/0000-0001-8191-5832 NR 167 TC 7 Z9 9 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD DEC PY 2007 VL 21 IS 6 BP 1175 EP + DI 10.1016/j.hoc.2007.08.014 PG 42 WC Oncology; Hematology SC Oncology; Hematology GA 239RB UT WOS:000251534300011 PM 17996594 ER PT J AU Prabhala, RH Munshi, NC AF Prabhala, Rao H. Munshi, Nikhil C. TI Immune therapies SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article ID MULTIPLE-MYELOMA PATIENTS; REGULATORY T-CELLS; HIGH-DOSE CHEMOTHERAPY; COLONY-STIMULATING FACTOR; DENDRITIC CELLS; IDIOTYPE VACCINATION; CD8-T-CELL MEMORY; CD4-T-CELL HELP; TARGET GENES; DIFFERENTIATION AB Immune cells with specific functions and abilities are vital to cancer treatment prevention. Although there have been many accomplishments made in the areas of immunotherapy and immunobiology of myeloma, there are still many obstacles in the way of conceptualizing the interrelationships between immune cells and tumor cells. To provide better understanding of these concepts and to move toward improved therapies for myeloma, cell-based therapeutic approaches should be developed. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Multiple Myeloma Med Ctr,Dept Med Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. Vet Adm Boston Healthcare Syst, W Roxbury, MA 02132 USA. RP Munshi, NC (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Multiple Myeloma Med Ctr,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM nikhil_munshi@dfci.harvard.edu FU NCI NIH HHS [P01 CA078378, P50 CA100707, P01 CA078378-09] NR 83 TC 4 Z9 4 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD DEC PY 2007 VL 21 IS 6 BP 1217 EP + DI 10.1016/j.hoc.2007.08.011 PG 16 WC Oncology; Hematology SC Oncology; Hematology GA 239RB UT WOS:000251534300012 PM 17996595 ER PT J AU Kanwal, F Hoang, T Spiegel, BMR Eisen, S Dominitz, JA Gifford, A Goetz, M Asch, SM AF Kanwal, Fasiha Hoang, Tuyen Spiegel, Brennan M. R. Eisen, Seth Dominitz, Jason A. Gifford, Allen Goetz, Mathew Asch, Steven M. TI Predictors of treatment in patients with chronic hepatitis C infection - Role of patient versus nonpatient factors SO HEPATOLOGY LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; UNITED-STATES; VIRUS-INFECTION; GEOGRAPHIC-VARIATION; ANTIVIRAL THERAPY; EXPLAINED VARIATION; US VETERANS; HEALTH-CARE; MANAGEMENT; ASSOCIATION AB Treatment with interferon and ribavirin is effective in patients with chronic infection with hepatitis C vim (HCV). Previous data indicate that treatment rates arc suboptimal. We sought to identify patient and providcr-lcvel predictors of treatment receipt in HCV by conducting a retrospective cohort study of 5701 HCV patients in a large regional Veteran's Administration (VA) healthcare network. We also determined the degree of variation in treatment rates attributable to patient, provider, and facility factors. Three thousand seven hundred forty-three patients (65%) were seen by a specialist and 894 (15.7%) received treatment. Treatment rates varied from 6% to 29% across the 5 facilities included in the analysis. Patients were less likely to receive treatment if they were older [RR, 0.55; 95% CI, 0.45, 0.67), single (RR, 0.77; 95%CI, 0.67, 0.88), had hepatic dysfimction MR, 0.73; 95%CI, 0.66,0.89), had normal alanine aminotransferase (ALT) (RR, 0.73; 95%CI, 0.59, 0.89), had HCV genotype 1 (RR, 0.78; 95%CI, 0.71, 0.86), were African American with genotype 1 (RR, 0.78; 95% CI, 0.71, 0.86), or were anemic (RR, 0.70; CI, 0.60, 0.89). In addition, patients evaluated by less experienced providers were 77% less likely to receive treatment than those evaluated by more experienced providers. The patient, provider, and facility factors explained 23%, 25%, and 7% of variation in treatment rates, respectively. Conclusion: These data suggest that although patient characteristics arc important predictors of treatment in HCV, a significant proportion of variation in treatment rates is explained by provider factors. These potentially modifiable provider-level factors may serve as high-yield targets for future quality improvement initiatives in HCV. C1 St Johns Mercy Med Ctr, St Louis, MO 63141 USA. St Louis Univ, Div Gastroenterol, St Louis, MO USA. Univ Calif Los Angeles, Ctr Outcomes Res & Educ, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Internal Med, Los Angeles, CA USA. Washington Univ, Sch Med, Dept Internal Med, St Louis, MO USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA 98195 USA. Boston Univ, Dept Internal Med, Boston, MA 02215 USA. RP Kanwal, F (reprint author), St Johns Mercy Med Ctr, 915 N Grand,111 JC-G1, St Louis, MO 63141 USA. EM fasiha.kanwal@va.gov NR 36 TC 75 Z9 76 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD DEC PY 2007 VL 46 IS 6 BP 1741 EP 1749 DI 10.1002/hep.21927 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 238TY UT WOS:000251471700012 PM 18046707 ER PT J AU Fagenholz, PJ Gutman, JA Murray, AF Noble, VE Camargo, CA Harris, NS AF Fagenholz, Peter J. Gutman, Jonathan A. Murray, Alice F. Noble, Vicki E. Camargo, Carlos A., Jr. Harris, N. Stuart TI Evidence for increased intracranial pressure in high altitude pulmonary edema SO HIGH ALTITUDE MEDICINE & BIOLOGY LA English DT Article; Proceedings Paper CT 15th International Hypoxia Symposium CY FEB 27-MAR 04, 2007 CL Lake Louise, CANADA DE pulmonary edema; HAPE; optic nerve sheath; intracranial pressure ID OPTIC-NERVE SHEATH; CEREBROSPINAL-FLUID PRESSURE; ULTRASOUND; EMERGENCY; ULTRASONOGRAPHY; DIAMETER AB Fagenholz, Peter J., Jonathan A. Gutman, Alice F. Murray, Vicki E. Noble, Carlos A. Camargo, Jr., and N. Stuart Harris. Evidence for increased intracranial pressure in high altitude pulmonary edema. High Alt. Med. Biol. 8:331-336, 2007.-We sought to determine if optic nerve sheath diameter (ONSD), a surrogate measure of ICP, is increased in high altitude pulmonary edema (HAPE). Five HAPE patients (one with a codiagnosis of high altitude cerebral edema [HACE]) treated at the Himalayan Rescue Association clinic in Pheriche, Nepal (4240 m), underwent optic nerve sheath ultrasonography (ONSU) at admission to determine ONSD. Results were compared to ONSD in 32 control subjects at the same altitude without evidence of altitude illness. Four of the five HAPE patients underwent repeat ONSU at discharge. All exams were read by two blinded observers. The mean ONSD for HAPE patients on presentation was 5.7 +/- 0.44 mm and for controls was 4.7 +/- 0.56 mm (p = 0.003). Excluding the patient with a coexistent clinical diagnosis of HACE, mean ONSD at presentation for the other four HAPE patients was 5.7 +/- 0.50 mm and was significantly different from controls (p = 0.007). In the four HAPE patients with repeat exams, ONSD decreased by 17% +/- 15% (95% CI 4-30%) between admission and discharge. We conclude that HAPE is associated with increased ONSD, a surrogate measure of increased ICP. C1 [Fagenholz, Peter J.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Gutman, Jonathan A.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Hematol Oncol, Seattle, WA 98195 USA. [Murray, Alice F.] New Royal Infirm Edinburgh, Emergency Dept, Edinburgh, Midlothian, Scotland. [Noble, Vicki E.; Camargo, Carlos A., Jr.; Harris, N. Stuart] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Fagenholz, PJ (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St, Boston, MA 02114 USA. EM pfagenholz@partners.org NR 25 TC 6 Z9 6 U1 0 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1527-0297 J9 HIGH ALT MED BIOL JI High Alt. Med. Biol. PD WIN PY 2007 VL 8 IS 4 BP 331 EP 336 DI 10.1089/ham.2007.1019 PG 6 WC Biophysics; Public, Environmental & Occupational Health; Sport Sciences SC Biophysics; Public, Environmental & Occupational Health; Sport Sciences GA 245TU UT WOS:000251962500008 PM 18081509 ER PT J AU Fagenholz, PJ Gutman, JA Murray, AF Noble, VE Wu, A Zeimer, G Harris, NS AF Fagenholz, Peter J. Gutman, Jonathan A. Murray, Alice F. Noble, Vicki E. Wu, Anette Zeimer, Gerhard Harris, N. Stuart TI Arterial thrombosis at high altitude resulting in loss of limb SO HIGH ALTITUDE MEDICINE & BIOLOGY LA English DT Article; Proceedings Paper CT 15th International Hypoxia Symposium CY FEB 27-MAR 04, 2007 CL Lake Louise, CANADA DE altitude sickness; altitude; thrombosis; thromboembolism; blood coagulation; mountaineering; ischemia ID MOLECULAR-WEIGHT HEPARINS; OCCLUSIVE DISEASE; PULMONARY-EDEMA; RT-PA; COAGULATION; FIBRINOLYSIS; ISCHEMIA; EMBOLISM; THERAPY AB Fagenholz, Peter J., Jonathan A. Gutman, Alice F. Murray, Vicki E. Noble, Anette Wu, Gerhard Zeimer, and N. Stuart Harris. Arterial thrombosis at high altitude resulting in loss of limb. High Alt. Med. Biol. 8:340-347, 2007.-Vascular thrombosis is an uncommon but recognized peril of high altitude travel. Traditionally, this has been associated with prolonged exposure to extreme altitudes where dehydration, hemoconcentration, cold, use of constrictive clothing, and enforced stasis due to severe weather have been named as contributing factors. It is widely hypothesized that hypoxia itself alters the coagulation cascade to create a prothrombotic milieu, though evidence thus far is limited and frequently conflicting. Case reports have described venous thrombosis, pulmonary embolism, cerebrovascular accidents, transient ischemic attacks, and thromboses of the portal circulation at altitude. We report a unique case of aortic thrombosis presenting with critical lower extremity ischemia in a previously healthy individual after a brief exposure to altitudes up to 4620 m. None of the frequently invoked risk factors of dehydration, cold, enforced use of constrictive clothing, weather-imposed inactivity, or extreme altitude were present, and no medical predisposition to thrombosis was identified, suggesting hypoxia as the most likely prothrombotic stimulus. We discuss the treatment of this problem and the application of Doppler ultrasonography in a wilderness setting. C1 [Fagenholz, Peter J.; Wu, Anette] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02140 USA. [Gutman, Jonathan A.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Hematol Oncol, Seattle, WA 98195 USA. [Murray, Alice F.] New Royal Infirm Edinburgh, Emergency Dept, Edinburgh, Midlothian, Scotland. [Noble, Vicki E.; Harris, N. Stuart] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Zeimer, Gerhard] Univ Tubingen Hosp, Dept Thorac Cardiac & Vasc Surg, Tubingen, Germany. RP Fagenholz, PJ (reprint author), Massachusetts Gen Hosp, Dept Surg, GRB 425,55 Fruit St, Boston, MA 02140 USA. EM pfagenholz@partners.org NR 34 TC 7 Z9 7 U1 0 U2 11 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1527-0297 J9 HIGH ALT MED BIOL JI High Alt. Med. Biol. PD WIN PY 2007 VL 8 IS 4 BP 340 EP 347 DI 10.1089/ham.2007.1028 PG 8 WC Biophysics; Public, Environmental & Occupational Health; Sport Sciences SC Biophysics; Public, Environmental & Occupational Health; Sport Sciences GA 245TU UT WOS:000251962500010 PM 18081511 ER PT J AU Ciesielski, KT Hamalainen, MS Geller, DA Wilhelm, S Goldsmith, TE Ahlfors, SP AF Ciesielski, Kristina T. Hamalainen, Matti S. Geller, Daniel A. Wilhelm, Sabine Goldsmith, Timothy E. Ahlfors, Seppo P. TI Dissociation between MEG alpha modulation and performance accuracy on visual working memory task in obsessive compulsive disorder SO HUMAN BRAIN MAPPING LA English DT Review DE limited resources inhibitory control; visual-spatial working memory task; event-related alpha modulation; event-related desynchrordzation (ERD); event-related synchronization (ERS); temporal-spectral evolution technique (TSE); magnetoencephalography; obsessive-compulsive disorder (OCD) ID DORSOLATERAL PREFRONTAL CORTEX; GLUCOSE METABOLIC RATES; EEG ALPHA; ELECTROPHYSIOLOGICAL CORRELATE; SELECTIVE ATTENTION; SYNCHRONIZATION ERS; SYMPTOM PROVOCATION; UNIPOLAR DEPRESSION; CORTICAL ACTIVITY; CHILDHOOD-ONSET AB Oscillatory brain activity in the alpha band (8-13 Hz) is modulated by cognitive events. Such modulation is reflected in a decrease of alpha (event-related desynchronization; ERD) with high cognitive load, or an increase (event-related synchronization) with low cognitive demand or with active inhibition of distractors. We used magnetoencephalography to investigate the pattern of prefrontal and parieto-occipital alpha modulation related to two variants of visual working memory task (delayed matching-to-sample) with and without a distractor. We tested nonmedicated, nondepressed patients suffering obsessive-compulsive disorder (OCD), and pair-matched healthy controls. The level of event-related alpha as a function of time was estimated using the temporal-spectral evolution technique. The results in OCD patients indicated: (1) a lower level of prestimulus (reference) alpha when compared to controls, (2) a task-phase specific reduction in event-related alpha ERD in particular for delayed matching-to-sample task with distractor, (3) no significant correlations between the pattern of modulation in prefrontal and parietal-occipital alpha oscillatory activity. Despite showing an abnormally low alpha modulation, the OCD patients' performance accuracy was normal. The results suggest a relationship of alpha oscillations and the underlying thalamocortical network to etiology of OCD and an involvement of a compensatory mechanism related to effortful inhibition of extrinsic and intrinsic interference. C1 Massachusetts Gen Hosp, MIT, HMS Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02129 USA. Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA. RP Ciesielski, KT (reprint author), Massachusetts Gen Hosp, MIT, HMS Athinoula A Martinos Ctr Biomed Imaging, 149 13th St, Boston, MA 02129 USA. EM ktc@nmr.mgh.harvard.edu RI Hamalainen, Matti/C-8507-2013; Ahlfors, Seppo/P-3644-2016 FU NCRR NIH HHS [P41RR14075] NR 120 TC 16 Z9 16 U1 13 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1065-9471 EI 1097-0193 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD DEC PY 2007 VL 28 IS 12 BP 1401 EP 1414 DI 10.1002/hbm.20365 PG 14 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 237PC UT WOS:000251386600013 PM 17370341 ER PT J AU Kobayashi, N Karisola, P Pena-Cruz, V Dorfman, DM Jinushi, M Umetsu, SE Butte, MJ Nagumo, H Chernova, I Zhu, BG Sharpe, AH Ito, S Dranoff, G Kaplan, GG Casasnovas, JM Umetsu, DT Dekruyff, RH Freeman, GJ AF Kobayashi, Norimoto Karisola, Piia Pena-Cruz, Victor Dorfman, David M. Jinushi, Masahisa Umetsu, Sarah E. Butte, Manish J. Nagumo, Haruo Chernova, Irene Zhu, Baogong Sharpe, Arlene H. Ito, Susumu Dranoff, Glenn Kaplan, Gerardo G. Casasnovas, Jose M. Umetsu, Dale T. Dekruyff, Rosemarie H. Freeman, Gordon J. TI TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells SO IMMUNITY LA English DT Article ID MACROPHAGE RECOGNITION; MOLECULE-1 KIM-1; KIDNEY INJURY; GENE FAMILY; T-CELLS; CLEARANCE; RECEPTOR; PHAGOCYTOSIS; ACTIVATION; SURFACE AB The T cell immunoglobulin mucin (TIM) proteins regulate T cell activation and tolerance. Here we showed that TIM-4 is expressed on human and mouse macrophages and dendritic cells, and both TIM-4 and TIM-1 specifically bound phosphatidylserine (PS) on the surface of apoptotic cells but not any other phospholipid tested. TIM-4(+) peritoneal macrophages, TIM-1(+) kidney cells, and TIM-4- or TIM-1-transfected cells efficiently phagocytosed apoptotic cells, and phagocytosis could be blocked by TIM-4 or TIM-1 monoclonal antibodies. Mutations in the unique cavity of TIM-4 eliminated PS binding and phagocytosis. TIM-4 mAbs that blocked PS binding and phagocytosis mapped to epitopes in this binding cavity. These results show that TIM-4 and TIM-1 are immunologically restricted members of the group of receptors whose recognition of PS is critical for the efficient clearance of apoptotic cells and prevention of autoimmunity. C1 [Kobayashi, Norimoto; Pena-Cruz, Victor; Jinushi, Masahisa; Nagumo, Haruo; Chernova, Irene; Zhu, Baogong; Dranoff, Glenn; Freeman, Gordon J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Kobayashi, Norimoto; Pena-Cruz, Victor; Jinushi, Masahisa; Nagumo, Haruo; Chernova, Irene; Zhu, Baogong; Dranoff, Glenn; Freeman, Gordon J.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Karisola, Piia; Umetsu, Dale T.; Dekruyff, Rosemarie H.] Harvard Univ, Sch Med, Childrens Hosp, Div Immunol, Boston, MA 02115 USA. [Dorfman, David M.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Umetsu, Sarah E.] Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA. [Butte, Manish J.; Sharpe, Arlene H.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Ito, Susumu] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA. [Kaplan, Gerardo G.] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA. [Casasnovas, Jose M.] CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain. RP Freeman, GJ (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM gordon_freeman@dfci.harvard.edu RI Jinushi, Masahisa/A-4311-2012; Casasnovas, Jose/L-6299-2014; OI Casasnovas, Jose/0000-0002-2873-6410; Butte, Manish/0000-0002-4490-5595 FU NIAID NIH HHS [P01 AI054456-019001, P01 AI054456, P01 AI054456-010002]; NINDS NIH HHS [R01 NS045937, R01 NS045937-01, R01 NS045937-02, R01 NS045937-03, R01 NS045937-04, R01 NS045937-05] NR 40 TC 264 Z9 280 U1 1 U2 14 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1074-7613 J9 IMMUNITY JI Immunity PD DEC PY 2007 VL 27 IS 6 BP 927 EP 940 DI 10.1016/j.immuni.2007.11.011 PG 14 WC Immunology SC Immunology GA 245AS UT WOS:000251907300012 PM 18082433 ER PT J AU Santiago, C Ballesteros, A Martinez-Munoz, L Mellado, M Kaplan, GG Freeman, GJ Casasnovas, JM AF Santiago, Cesar Ballesteros, Angela Martinez-Munoz, Laura Mellado, Mario Kaplan, Gerardo G. Freeman, Gordon J. Casasnovas, Jose M. TI Structures of T cell immunoglobulin mucin protein 4 show a metal-ion-dependent ligand binding site where phosphatidylserine binds SO IMMUNITY LA English DT Article ID HEPATITIS-A-VIRUS; TIM GENE FAMILY; PERIPHERAL TOLERANCE; IMMUNE-RESPONSES; RECEPTOR; RECOGNITION; MECHANISM; IDENTIFICATION; ACTIVATION; REVEALS AB The T cell immunoglobulin and mucin domain (TIM) proteins are important regulators of T cell responses. Crystal structures of the murine TIM-4 identified a metal-ion-dependent ligand binding site (MILIBS) in the immunoglobulin (Ig) domain of the TIM family. The characteristic CC' loop of the TIM domain and the hydrophobic FG loop shaped a narrow cavity where acidic compounds penetrate and coordinate to a metal ion bound to conserved residues in the TIM proteins. The structure of phosphatidylserine bound to the Ig domain showed that the hydrophilic head penetrates into the MILIBS and coordinates with the metal ion, whereas the aromatic residues on the tip of the FG loop interacted with the fatty acid chains and could insert into the lipid bilayer. Our results also revealed an important role of the MILIBS in the trafficking of TIM-1 to the cell surface. C1 [Santiago, Cesar; Ballesteros, Angela; Martinez-Munoz, Laura; Mellado, Mario; Casasnovas, Jose M.] CSIC, Ctr Nacl Biotecnol, Madrid 28049, Spain. [Kaplan, Gerardo G.] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA. [Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Dept Med, Boston, MA 02115 USA. RP Casasnovas, JM (reprint author), CSIC, Ctr Nacl Biotecnol, Campus Univ Autonoma, Madrid 28049, Spain. EM jcasasnovas@cnb.uam.es RI Casasnovas, Jose/L-6299-2014; Mellado, Mario/M-9893-2014; Santiago, Cesar/K-4240-2014 OI Casasnovas, Jose/0000-0002-2873-6410; Mellado, Mario/0000-0001-6325-1630; Santiago, Cesar/0000-0002-5149-1722 FU NIAID NIH HHS [AI054456, P01 AI054456, P01 AI054456-01] NR 36 TC 106 Z9 114 U1 0 U2 8 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1074-7613 J9 IMMUNITY JI Immunity PD DEC PY 2007 VL 27 IS 6 BP 941 EP 951 DI 10.1016/j.immuni.2007.11.008 PG 11 WC Immunology SC Immunology GA 245AS UT WOS:000251907300013 PM 18083575 ER PT J AU Linkin, DR Fishman, NO Landis, JR Barton, TD Gluckman, S Kostman, J Metlay, JP AF Linkin, Darren R. Fishman, Neil O. Landis, J. Richard Barton, Todd D. Gluckman, Steven Kostman, Jay Metlay, Joshua P. TI Effect of communication errors during calls to an antimicrobial stewardship program SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID MANAGEMENT PROGRAM; OUTCOMES; RESISTANCE; HOSPITALS; INFECTION; PHYSICIAN; COSTS AB OBJECTIVE. To determine how inaccurate communication of patient data by clinicians in telephone calls to the prior-approval antimicrobial stewardship program (ASP) staff affects the incidence of inappropriate antimicrobial recommendations made by ASP practitioners. DESIGN. A retrospective cohort design was used. The accuracy of the patient data communicated was evaluated against patients' medical records to identify predetermined, clinically significant inaccuracies. Inappropriate antimicrobial recommendations were defined having been made if an expert panel unanimously rated the actual recommendations as inappropriate after reviewing vignettes derived from inpatients' medical records. SETTING. The setting was an academic medical center with a prior-approval ASP. PATIENTS. All inpatient subjects of ASP prior-approval calls were eligible for inclusion. RESULTS. Of 200 ASP telephone calls, the panel agreed about whether or not antimicrobial recommendations were inappropriate for 163 calls (82%); these 163 calls were then used as the basis for further analyses. After controlling for confounders, inaccurate communication was found to be associated with inappropriate antimicrobial recommendations (odds ratio [OR], of 2.2; P=.03). In secondary analyses of specific data types, only inaccuracies in microbiological data were associated with the study outcome ( OR, 7.5; P= .002). The most common reason panelists gave for rating a recommendation as inappropriate was that antimicrobial therapy was not indicated. CONCLUSIONS. Inaccurate communication of patient data, particularly microbiological data, during prior-approval calls is associated with an increased risk of inappropriate antimicrobial recommendations from the ASP. Clinicians and ASP practitioners should work to confirm that critical data has been communicated accurately prior to use of that data in prescribing decisions. C1 Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. RP Linkin, DR (reprint author), 809 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM linkin@mail.med.upenn.edu RI Landis, J. Richard/A-9330-2010; OI Landis, J Richard/0000-0001-8099-0988 FU AHRQ HHS [U18 HS010399, F32-HS-023982, U18-HS10399]; NIAID NIH HHS [K23 AI060887, K23 AI060887-05, K23-AI-060887, L30 AI057268-01] NR 22 TC 14 Z9 15 U1 1 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD DEC PY 2007 VL 28 IS 12 BP 1374 EP 1381 DI 10.1086/523861 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 226VG UT WOS:000250616000011 PM 17994518 ER PT J AU Norman, DC Wong, MB Yoshikawa, TT AF Norman, Dean C. Wong, Megan Bernadette Yoshikawa, Thomas T. TI Fever of unknown origin in older persons SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; ELDERLY-PATIENTS; PROSPECTIVE MULTICENTER; INFECTIVE ENDOCARDITIS; BACTERIAL-MENINGITIS; CLINICAL-FEATURES; AGE; ADULTS; BACTEREMIA; TUBERCULOSIS AB Infectious diseases in general in the aged are associated with higher morbidity and mortality rates. Decremental biologic changes with age affect host defenses and responses to infection, and the frequent presence of comorbidities also may adversely impact host defenses, especially in frail older persons. Infections may present differently in older persons than in younger populations, making early diagnosis difficult. Within this context, the article explores the importance of how fever of unknown origin (FUO) in the old differs significantly from FUO in younger adults because the etiology is different. Moreover, it is important to aggressively determine the etiology of FUO in this older population because it is often treatable. C1 [Norman, Dean C.; Yoshikawa, Thomas T.] Univ Calif Los Angeles, Los Angeles David Geffen Sch Med, Los Angeles, CA USA. [Norman, Dean C.; Wong, Megan Bernadette; Yoshikawa, Thomas T.] VA Greater Los Angeles Healthcare Syst 11, Los Angeles, CA 90073 USA. RP Norman, DC (reprint author), W Los Angeles Hlth Care Ctr, US Dept Vet Affairs, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM dean.norman@va.gov NR 47 TC 9 Z9 11 U1 2 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0891-5520 J9 INFECT DIS CLIN N AM JI Infect. Dis. Clin. North Am. PD DEC PY 2007 VL 21 IS 4 BP 937 EP + DI 10.1016/j.ide.2007.09.003 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 246QM UT WOS:000252022000005 PM 18061083 ER PT J AU Smith, RM AF Smith, R. M. TI Immunity, trauma and the elderly SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED LA English DT Article DE elderly; immune reaction; cytokine; monocyte; susceptibility to infection; IL10; zinc ID TISSUE TRAUMA; BONE-FRACTURE; ZINC STATUS; RESPONSES; AGE; ACTIVATION; HEMORRHAGE; INJURY; YOUNG AB It is believed that an uncontrolled or poorly coordinated immune reaction can be stimulated by major trauma and be responsible for the development of the multiple organ dysfunction syndrome (MODS). The elderly have a reduced ability to mount an effective immune reaction with deficiencies involving both humoral and cellular aspects of immunity that involve poor function of both the stimulatory and immuno-suppressive sides of the immune process. However, there is currently no hard evidence that the excess mortality after major trauma in the elderly is associated with an impaired or excessive immune response. It is possible that their poor resistance to infection is important and immune modulated but the dominant factor in the excess mortality in the elderly population is probably associated with their tack of physiological reserve to respond to a major physiological challenge. (C) 2007 Elsevier Ltd. All rights reserved. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Orthopaed Trauma Serv, Boston, MA 02114 USA. RP Smith, RM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Orthopaed Trauma Serv, YAW 3600-3c,55 Fruit St, Boston, MA 02114 USA. EM msmith23@partners.org NR 22 TC 15 Z9 17 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-1383 J9 INJURY JI Injury-Int. J. Care Inj. PD DEC PY 2007 VL 38 IS 12 BP 1401 EP 1404 DI 10.1016/j.injury.2007.09.013 PG 4 WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery GA 254XD UT WOS:000252620400009 PM 18045600 ER PT J AU Nagurney, JT Huang, C Kulkarni, RG Sane, S Davis, MA Anderson, PD Gaufberg, SV Ciottone, GR Motola, I Chang, Y Setnik, G AF Nagurney, J. T. Huang, C. Kulkarni, R. G. Sane, S. Davis, M. A. Anderson, P. D. Gaufberg, S. V. Ciottone, G. R. Motola, I. Chang, Y. Setnik, G. TI An attempt to measure the spread of emergency medicine internationally SO INTERNAL AND EMERGENCY MEDICINE LA English DT Article DE World health; Emergency medicine; Epidemiology; International health problems AB Objective: To determine the feasibility of using the internet to track the spread of emergency medicine internationally. Methods: Overview: This was an attempt to perform a descriptive cross-sectional study employing a web-based survey. Subjects: Potential respondents were identified from multiple sources. Observations: The primary outcome was the response to 16 questions about EM care and the setting in which it was delivered for acute cardiac, paediatric, obstetrical illnesses and trauma. The questions were divided into six general areas and elicited for urban, semi-urban and rural settings. A series of four e-mails soliciting completion of the survey were sent to potential respondents. Analysis: Simple descriptive statistics. Results: We identified 358 potential respondents with valid e-mail addresses over a period of three years. Overall, 145 (41%) responded and 117 (33% 95% CI 28-38%) of them were complete and interpretable. There was one response from 54 and two responses from 29 countries, representing an overall response rate by country surveyed of 65% (95% CI 57-73%), but of all existing countries of only 43% (95% CI 36-50%). Based on sparse data, it appears that in urban areas, 47% (obstetrics) to 65% (paediatric) of acutely sick or injured patients are taken to an ED-equivalent. For rural areas, this range was 19% (obstetrical) to 40% (trauma). CT scans are available in 78% of urban ED-equivalents but 12% of rural ones. Haematocrits are available in 72% of rural settings. In 60% of responding nations, some type of EM training was available, and in 42% physicians went abroad to study EM. Conclusions: A survey of international EM is challenging to achieve because of difficulty in both identifying and in contacting potential respondents. Based on sparse data, population density (urban, rural) appears to be related to both the location to which acutely ill patients are taken for their care and to the level of technology available. The specialty of EM is now recognised internationally and education in EM is common. C1 [Nagurney, J. T.; Sane, S.; Chang, Y.] Massachusetts Gen Hosp, Dept Emergency Med, Clin 115, Boston, MA 02115 USA. [Nagurney, J. T.; Kulkarni, R. G.; Sane, S.; Davis, M. A.; Anderson, P. D.; Gaufberg, S. V.; Ciottone, G. R.; Motola, I.; Chang, Y.; Setnik, G.] Harvard Univ, Sch Med, Boston, MA USA. [Huang, C.] Tufts Med Sch, Boston, MA USA. [Kulkarni, R. G.; Motola, I.] Harvard Affiliated Emergency Med Residency, Boston, MA USA. [Davis, M. A.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Anderson, P. D.; Ciottone, G. R.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Gaufberg, S. V.] Cambridge Hosp, Cambridge, MA 02139 USA. [Setnik, G.] Mt Auburn Hosp, Cambridge, MA USA. RP Nagurney, JT (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Clin 115, 55 Fruit St, Boston, MA 02115 USA. EM nagurney.john@mgh.harvard.edu NR 30 TC 4 Z9 4 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1828-0447 J9 INTERN EMERG MED JI Intern. Emerg. Med. PD DEC PY 2007 VL 2 IS 4 BP 302 EP 310 DI 10.1007/s11739-007-0083-1 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA V93ZC UT WOS:000206352000010 PM 18060470 ER PT J AU Tseng, CL Helmer, D Rajan, M Tiwari, A Miller, D Crystal, S Safford, M Greenberg, J Pogach, L AF Tseng, Chin-Lin Helmer, Drew Rajan, Mangala Tiwari, Anjali Miller, Donald Crystal, Stephen Safford, Monika Greenberg, Jeffrey Pogach, Leonard TI Evaluation of regional variation in total, major, and minor amputation rates in a national health-care system SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE LA English DT Article DE amputation; diabetes mellitus; Medicare; quality of health care; veterans ID FOOT ULCER; VETERANS; QUALITY; INDICATORS; PREVALENCE; VALIDATION; IMPACT; RISK; CITY AB Background. Health-care systems need actionable information on amputation rates in order to improve foot-care delivery. Objective. To evaluate regional variation in total, major, and minor amputation rates using individual-level data. Methods. This was a retrospective cohort study of Veterans Health Administration users with diabetes who were Medicare enrolled between fiscal years 1998 and 2000 (10/1/1997-9/30/2000). The outcome was outlier status, based upon observed-to-expected ratios, for total, major, and minor amputations of 22 regional networks in fiscal year 2000. Results. 331,806 patients incurred a total of 4,037 (12.2 per 1000; range 9.3-16.7 across networks) amputations in fiscal year 2000: 2,271 major amputations (6.8 per 1000; 4.7-9.1) and 1,766 minor amputations (5.3 per 1000; 3.9-7.6). All network outliers based upon the total amputation observed-to-expected ratio were also outliers based on major amputation observed-to-expected ratio. However, two of the five non-outliers based on total amputations were outliers based on major amputations. Simultaneous evaluation of major and minor amputation observed-to-expected ratios demonstrated four patterns of dual outlier status among networks: two networks had lower than expected minor and major amputation rates; two had higher than expected minor and major amputation rates; one network was lower than expected by major but higher by minor amputation rate; one was higher than expected by major but lower by minor amputation rate. Conclusions. Simultaneous evaluation of major and minor amputation rates identifies different patterns of regional outlier status compared to total or major amputation rates alone. This strategy may facilitate targeted evaluations of health-care processes and structures. C1 [Tseng, Chin-Lin; Helmer, Drew; Rajan, Mangala; Tiwari, Anjali; Pogach, Leonard] Ctr Healthcare Knowledge Management, New Jersey Healthcare Syst, Dept Vet Affairs, E Orange, NJ 07018 USA. [Tseng, Chin-Lin; Helmer, Drew; Tiwari, Anjali; Pogach, Leonard] Univ Med & Dent New Jersey, New Jersey Med Coll, Newark, NJ USA. [Miller, Donald] Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Miller, Donald] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Crystal, Stephen] Rutgers State Univ, New Brunswick, NJ 08903 USA. [Safford, Monika] Deep S Ctr Effectiveness, Birmingham VA Med Ctr, Birmingham, AL USA. [Safford, Monika] Univ Alabama, Birmingham, AL USA. [Greenberg, Jeffrey] NYU, Sch Med, New York, NY USA. RP Tseng, CL (reprint author), Ctr Healthcare Knowledge Management, New Jersey Healthcare Syst, Dept Vet Affairs, 385 Tremont Ave,129, E Orange, NJ 07018 USA. EM chin-lin.tseng@va.gov NR 30 TC 13 Z9 13 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1353-4505 J9 INT J QUAL HEALTH C JI Int. J. Qual. Health Care PD DEC PY 2007 VL 19 IS 6 BP 368 EP 376 DI 10.1093/intqhc/mzm044 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 245UH UT WOS:000251963800006 PM 17947387 ER PT J AU Gee, MS Upadhyay, R Bergquist, H Weissleder, R Josephson, L Mahmood, U AF Gee, Michael S. Upadhyay, Rabi Bergquist, Henry Weissleder, Ralph Josephson, Lee Mahmood, Umar TI Multiparameter noninvasive assessment of treatment susceptibility, drug target inhibition and tumor response guides cancer treatment SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE breast cancer; trastuzumab; molecular imaging; antibody therapy; HER2/neu; apoptosis ID ERBB2-OVEREXPRESSING BREAST-CANCER; CELLS IN-VITRO; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; HERCEPTIN; VIVO; EXPRESSION; HER2; RESPONSIVENESS; SURVEILLANCE AB New cancer therapies are increasingly molecular- pathway specific. The evaluation of these novel therapies would be greatly facilitated by the development of noninvasive methods to assess multiple tumor cellular and molecular parameters. Using fluorescent probes specific for HER2/neu (AF750-trastuzumab) and apoptosis (Cy5.5-Annexin), we demonstrate a multichannel near infrared molecular imaging approach that yields accurate and early assessment of treatment susceptibility, drug target inhibition and tumor response during HER2-targeted therapy of orthotopic human mammary carcinomas in mice with trastuzumab (Herceptin). This combined approach detects both partial treatment response (tumor growth inhibition without regression) as well as therapeutic resistance before alterations in tumor growth are apparent. Partially responsive tumors exhibit increased Annexin signal when trastuzumab is combined with a cytotoxic agent (paclitaxel), which predicts subsequent tumor regression and suggests that imaging can guide therapy optimization. This multiparametric imaging approach has great potential in the clinical setting for determining patient eligibility, adequate drug dosing and early biological response of molecularly-targeted cancer therapies. (C) 2007 Wiley-Liss, Inc. C1 Massachusetts Gen Hosp, Ctr Mol Imaging Res, Boston, MA 02114 USA. RP Mahmood, U (reprint author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Simches 8226,185 Cambridge St, Boston, MA 02114 USA. EM mahmood@helix.mgh.harvard.edu FU NCI NIH HHS [P50-CA86355, R24-CA92782]; NIBIB NIH HHS [R01-EB001872, R01-EB004472] NR 35 TC 12 Z9 13 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD DEC 1 PY 2007 VL 121 IS 11 BP 2492 EP 2500 DI 10.1002/ijc.22995 PG 9 WC Oncology SC Oncology GA 226AN UT WOS:000250559600018 PM 17683072 ER PT J AU Meyer, MA Levine, WC Egan, MT Cohen, BJ Spitz, G Garcia, P Chueh, H Sandberg, WS AF Meyer, Mark A. Levine, Wilton C. Egan, Marie T. Cohen, Brett J. Spitz, Gabriel Garcia, Patricia Chueh, Henry Sandberg, Warren S. TI A computerized perioperative data integration and display system SO INTERNATIONAL JOURNAL OF COMPUTER ASSISTED RADIOLOGY AND SURGERY LA English DT Article DE Data integration; Operating room; Status display; OR black box recorder; Surgery team AB Object The operating room is rich in digital data that must be rapidly gathered and integrated by caregivers, potentially distracting them from direct patient care. We hypothesized that current desktop computers could integrate enough electronically accessible perioperative data to present a unified, contextually appropriate snapshot of the patient to the operating room team without requiring any user intervention. Materials and methods We implemented a system that integrates data from surgical and anesthesia devices and information systems, as well as an active radiofrequency identification location tracking system, to create a comprehensive, unified, time-synchronized database of all digital data produced by these systems. Next, a human factors engineering approach was used to identify selected data to show on a large format display during surgery. Results A prototype system has been in daily use in a clinical operating room since August 2005. The system functions automatically without any user input, as the display system self-configures based on cues from the primary data. The system is vendor agnostic with respect to input data sources and display options. Conclusion Automatic integration and display of teamsynchronizing data from medical devices and hospital information systems is now possible using software that runs on a personal computer. C1 [Meyer, Mark A.; Chueh, Henry] Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. [Levine, Wilton C.; Sandberg, Warren S.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. [Egan, Marie T.] Massachusetts Gen Hosp, Dept Nursing, Boston, MA 02114 USA. [Cohen, Brett J.] LiveData Inc, Cambridge, MA USA. [Spitz, Gabriel] Aptima Inc, Woburn, MA USA. [Garcia, Patricia] Harvard Univ, Sch Med, Boston, MA USA. RP Sandberg, WS (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, 55 Fruit St,Clin 309, Boston, MA 02114 USA. EM wsandberg@partners.org OI Sandberg, Warren/0000-0002-9246-777X FU Telemedicine and Advanced Technology Research Center, U.S. Army Medical Research and Materiel Command [DAMD17-W81XWH-04-C-0015]; Center for Integration of Medicine and Innovative Technology (CIMIT, Cambridge, MA) Career Development Award; Massachusetts General Hospital Department of Anesthesia and Critical Care (Boston, Massachusetts) FX This work is supported by the Telemedicine and Advanced Technology Research Center, U.S. Army Medical Research and Materiel Command under Contract No. DAMD17-W81XWH-04-C-0015 (SBIR) to LiveData, Inc. The views, opinions and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation. Further support was provided by a Center for Integration of Medicine and Innovative Technology (CIMIT, Cambridge, MA) Career Development Award to W.S. Additional departmental support was provided by the Massachusetts General Hospital Department of Anesthesia and Critical Care (Boston, Massachusetts). NR 23 TC 7 Z9 7 U1 0 U2 1 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1861-6410 EI 1861-6429 J9 INT J COMPUT ASS RAD JI Int. J. Comput. Assist. Radiol. Surg. PD DEC PY 2007 VL 2 IS 3-4 BP 191 EP 202 DI 10.1007/s11548-007-0126-0 PG 12 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging; Surgery SC Engineering; Radiology, Nuclear Medicine & Medical Imaging; Surgery GA V32ZT UT WOS:000208989800006 ER PT J AU Kasckow, J Montross, L Golshan, S Mohamed, S Patterson, T Sollanzano, E Zisook, S AF Kasckow, J. Montross, L. Golshan, S. Mohamed, S. Patterson, T. Sollanzano, E. Zisook, S. TI Suicidality in middle aged and older patients with schizophrenia and depressive symptoms: relationship to functioning and Quality of Life SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE suicidality; schizophrenia; geriatric middle aged; depression; functioning; Quality of Life ID RISK-FACTORS; SCHIZOAFFECTIVE PATIENTS; COMPLETED SUICIDE; RATING-SCALE; OUTPATIENTS/; RELIABILITY; ASSOCIATION; VALIDITY AB Background Suicidality is a health concern inpatients with schizophrenia. We examined the hypotheses: (1) Middle aged and older patients with schizophrenia, depressive symptoms and suicidality would exhibit worse quality of life and worse everyday functioning, social skills and medication management relative to those without suicidality; (2) higher levels of suicidality would be significantly associated with worse functioning, worse quality of life and older age. Methods We examined 146 outpatients with schizophrenia and depression. Patients were at least 40 years old and were diagnosed with schizophrenia or schizoaffective disorder and had two or more depressive symptoms based on DSM-IV criteria for major depression. We assessed suicidality with the Intersept Suicide Scale (ISS) and functioning with the UCSD Performance-based Skills Assessment (UPSA), Social Skills Performance Assessment (SSPA), and Medication Management Ability Assessment (MMAA). Quality of life was assessed with the Heinrichs Quality of Life Scale (QLS). Results The mean age of patients was 52.4 + 6.9 years. Subjects with suicidality (ISS scores > 0) had lower QLS scores compared to those without suicidality. However, there were no differences in UPSA, SSPA nor MMAA scores between the two groups. In addition, based on Spearman's rho correlational analysis, there were significant associations of QLS scores with ISS scores (r = -0.236) and with MMAA "total errors" scores (r = 0. 174). Logistic regression demonstrated that only QLS scores predicted suicidality. Conclusion Thirty-six percent of our sample had at least mild degrees of suicidality. Lower quality of life appears to bean important predictor of suicidality. Copyright (c) 2007 John Wiley & Sons, Ltd. C1 [Kasckow, J.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA 15206 USA. [Kasckow, J.] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA. [Montross, L.; Golshan, S.; Patterson, T.; Sollanzano, E.; Zisook, S.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Montross, L.; Golshan, S.; Patterson, T.; Sollanzano, E.; Zisook, S.] VA San Diego Healthcare Syst, San Diego, CA USA. [Mohamed, S.] Cent Texas Vet Hlth Care Syst, Temple, TX USA. RP Kasckow, J (reprint author), VA Pittsburgh Hlth Care Syst, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM kasckowjw@upmc.edu FU NIMH NIH HHS [R01 MH063798-06, R01 MH063931, R01 MH063931-05, 1R01 MH6398-01, R01 MH063798] NR 22 TC 12 Z9 13 U1 3 U2 5 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD DEC PY 2007 VL 22 IS 12 BP 1223 EP 1228 DI 10.1002/gps.1817 PG 6 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 241JG UT WOS:000251652100006 PM 17506025 ER PT J AU Katdare, M Efimova, EV Labay, E Khodarev, NN Darga, TE Garofalo, M Nakamura, S Kufe, DW Posner, MC Weichselbaum, RR AF Katdare, Mukta Efimova, Elena V. Labay, Edwardine Khodarev, Nikolai N. Darga, Thomas E. Garofalo, Michael Nakamura, Satoaki Kufe, Donald W. Posner, Mitchell C. Weichselbaum, Ralph R. TI Diverse TNF alpha-induced death pathways are enhanced by inhibition of NF-kappa B SO INTERNATIONAL JOURNAL OF ONCOLOGY LA English DT Article DE TNF alpha; NF-kappa B; necrosis; senescence; apoptosis ID TUMOR-NECROSIS-FACTOR; ISOLATED LIMB PERFUSION; SOFT-TISSUE SARCOMA; INDUCED CELL-DEATH; CHEMOTHERAPEUTIC DRUGS; CANCER-THERAPY; JNK ACTIVATION; PHASE-I; APOPTOSIS; RECEPTOR AB TNF alpha was initially described as inducing necrotic death in tumors in vivo, and more recently as a cytokine that mediates cytoprotection and inflammation. The anti-tumor effects of TNF alpha are poorly characterized because TNFainduced death of human tumor cells has largely been studied in the presence of agents that block transcription or protein synthesis. Also, most reports in model cell systems describe apoptosis within relatively early time points as the principal mode of cell death induced by TNF alpha. We investigated the cytotoxic effects of 10 ng/ml TNF alpha on human tumor cells of different histological types without concomitant exposure to these inhibitors. Eleven of 21 human tumor cell lines underwent TNF alpha-induced cell death which ranged from 41% to complete loss of viability. Only one cell line demonstrated caspase-dependent apoptosis within 24 h. Nine cell lines underwent death between 48 h and 21 days. Seven of these lines underwent caspase-3 independent death consistent with necrosis. One tumor line exhibited characteristics of senescence following TNFa exposure. Nine of 9 cell lines activated NF-kappa B following TNFa exposure by 24 h. In all cell lines studied, with the exception of the epidermoid carcinoma cell line that underwent early apoptosis, expression of one or more NF-kappa B target genes was demonstrated at 24-96 h. C1 Univ Chicago Hosp, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA. Univ Chicago Hosp, Dept Surg, Sect Gen Surg, Chicago, IL 60637 USA. Univ Maryland, Dept Radiat Oncol, Baltimore, MD 21201 USA. Osaka Univ, Grad Sch Med, Dept Radiat Oncol, Osaka, Japan. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Weichselbaum, RR (reprint author), Univ Chicago Hosp, Dept Radiat & Cellular Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA. OI Darga, Thomas/0000-0002-8968-6701 FU NCI NIH HHS [CA111423] NR 49 TC 8 Z9 8 U1 0 U2 2 PU PROFESSOR D A SPANDIDOS PI ATHENS PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE SN 1019-6439 J9 INT J ONCOL JI Int. J. Oncol. PD DEC PY 2007 VL 31 IS 6 BP 1519 EP 1528 PG 10 WC Oncology SC Oncology GA 236ZG UT WOS:000251341700028 PM 17982679 ER PT J AU Papadaki, M Doukas, A Farinelli, WA Kaban, L Troulis, M AF Papadaki, M. Doukas, A. Farinelli, William A. Kaban, L. Troulis, M. TI Vertical ramus osteotomy with Er : YAG laser: a feasibility study SO INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article DE Er : YAG laser; vertical ramus osteotomy; energy/pulse; endoscopy; surgical time ID MAXILLOFACIAL SURGERY; CONTINUOUS-WAVE; CARBON-DIOXIDE; 3RD MOLARS; MU-M; BONE; ABLATION; ERBIUM; TISSUE; DEPTH AB The general advantages of laser surgery, such as decreased bleeding and dry surgical field, reduced postoperative pain and less oedema, have led to a continuous interest in laser applications for bone cutting. The ability to cut bone with a laser beam would also be of great technical benefit in minimally invasive maxillofacial surgery (endoscopic). The Erbium:yttrium aluminum garnet (Er:YAG) laser has been demonstrated to result in minimal thermal damage of bone, precise cutting, rapid osseous healing and osteoinduction. The purpose of this study was to assess the feasibility of using Er:YAG laser to perform vertical ramus osteotomy, and to determine the most efficient energy per pulse for its completion. Two fresh pig mandibles, one pig cadaver head and one human mandible were used. A different energy per pulse (0.5, 1, 1.5 and 2 J/pulse) was used for each osteotomy on the pig mandibles (n = 4). Vertical ramus osteotomy was feasible with all energy settings but time decreased considerably from 28 to 5.33 min as the energy per pulse increased. The human and the pig cadaver head mandibles were osteotomized bilaterally with 2000 mJ/pulse that was the most efficient in terms of time. Bone cuts were smooth with no carbonization in all cases. C1 [Papadaki, M.; Kaban, L.; Troulis, M.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. [Papadaki, M.; Kaban, L.; Troulis, M.] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. [Doukas, A.; Farinelli, William A.] Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed, Boston, MA 02114 USA. [Doukas, A.; Farinelli, William A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Papadaki, M (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Warren 1201, Boston, MA 02114 USA. EM mpapadaki@partners.org NR 30 TC 20 Z9 22 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0901-5027 J9 INT J ORAL MAX SURG JI Int. J. Oral Maxillofac. Surg. PD DEC PY 2007 VL 36 IS 12 BP 1193 EP 1197 DI 10.1016/j.ijom.2007.05.019 PG 5 WC Dentistry, Oral Surgery & Medicine; Surgery SC Dentistry, Oral Surgery & Medicine; Surgery GA 241VD UT WOS:000251683000010 PM 18036780 ER PT J AU Culshaw, S Han, XZ La Rosa, K Eastcott, JW Smith, DJ Taubman, MA AF Culshaw, Shauna Han, Xiaozhe La Rosa, Karen Eastcott, Jean W. Smith, Daniel J. Taubman, Martin A. TI Assessment of human immune response to mutans streptococcal glucosyltransferase peptides selected by MHC class II binding probability SO INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS LA English DT Article DE peptide; vaccine; MHC binding prediction ID MAJOR HISTOCOMPATIBILITY COMPLEX; DENTAL-CARIES; GLUCAN-BINDING; IMMUNOLOGICAL CHARACTERISTICS; LOCAL IMMUNIZATION; IMMUNOGENICITY; ANTIBODY; DOMAIN; RATS; ENDOCARDITIS AB Dental decay is a major public health challenge, causing substantial social and economic burdens. In animals, vaccination against mutans streptococci, the causative organism, interferes with dental caries. The mutans streptococcal glucosyltransferase (GTF) has been effectively used as a protein antigen in experimental dental caries vaccines. Compared to whole proteins, peptide subunits can focus immune responses on protective epitopes, and not on potentially harmful cross reactive antigens. In the past we selected peptide subunits of GTF for vaccine discovery based on putative functional significance and conservation of GTF primary structure. To focus on the immunogenicity of peptides, we estimated the probability of MHC class II binding. Twenty 20-mer linear GTF peptides were synthesized on this basis and their immunoreactivity explored. Significant human peripheral blood mononuclear cell (PBMC; n = 12) proliferation was observed in response to amino acids (AA) 502-521 (peptide 7), located in the catalytic domain of GTF. Human serum (n = 36) antibody reactivity was observed to AA 438-457 (peptide 5), AA 502-521 (peptide 7), and AA 1376-1395 (peptide 16). Whole saliva mutans streptococcal levels were used as markers of mutans infection, and dental examinations to determine existing and historic caries (DMFS score) were performed. DMFS scores correlated with mutans streptococcal counts, but not with immune responses. We have identified peptides with projected avid MHC-binding activity that reacted with human PBMC and serum antibody, implying that these peptides are immunogenic and may be of significance in a subunit dental caries vaccine. C1 Forsyth Inst, Dept Immunol, Boston, MA 02115 USA. RP Taubman, MA (reprint author), Forsyth Inst, Dept Immunol, 140 Fenway, Boston, MA 02115 USA. EM mtaubman@forsyth.org NR 36 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1573-3149 EI 1573-3904 J9 INT J PEPT RES THER JI Int. J. Pept. Res. Ther. PD DEC PY 2007 VL 13 IS 4 BP 525 EP 531 DI 10.1007/s10989-007-9110-3 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 228HV UT WOS:000250721900007 ER PT J AU Wo, J Taghian, A AF Wo, Jennifer Taghian, Alphonse TI Radiotherapy in setting of collagen vascular disease SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Review DE collagen vascular disease; radiotherapy; acute toxicity; late toxicity ID TOTAL LYMPHOID IRRADIATION; INTRACTABLE RHEUMATOID-ARTHRITIS; EARLY BREAST-CANCER; SYSTEMIC-SCLEROSIS SCLERODERMA; RADIATION-INDUCED FIBROSIS; LATE COMPLICATIONS; NASOPHARYNGEAL CARCINOMA; CONSERVATION THERAPY; CONSERVING THERAPY; D-PENICILLAMINE C1 [Wo, Jennifer; Taghian, Alphonse] Harvard Univ, Dept Radiat Oncol, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Taghian, A (reprint author), Harvard Univ, Dept Radiat Oncol, Sch Med, Massachusetts Gen Hosp, 100 Blossom St,Cox Bldg 302, Boston, MA 02114 USA. EM ataghian@partners.org NR 45 TC 9 Z9 9 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD DEC 1 PY 2007 VL 69 IS 5 BP 1347 EP 1353 DI 10.1016/j.ijrobp.2007.07.2357 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 240BD UT WOS:000251561100001 PM 18035210 ER PT J AU Chambers, MS Jones, CU Biel, MA Weber, RS Hodge, KM Chen, Y Holland, JM Ship, JA Vitti, R Armstrong, I Garden, AS Haddad, R AF Chambers, Mark S. Jones, Christopher Uwe Biel, Merrill A. Weber, Randal S. Hodge, Kenneth M. Chen, Y. Holland, John M. Ship, Jonathan A. Vitti, Robert Armstrong, Ingrid Garden, Adam S. Haddad, Robert TI Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article; Proceedings Paper CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol DE cevimeline; xerostomia; radiation; head-and-neck tumor; pilocarpine ID MUSCARINIC ACETYLCHOLINE-RECEPTORS; RADIATION-INDUCED XEROSTOMIA; QUALITY-OF-LIFE; NECK-CANCER; SJOGRENS-SYNDROME; ORAL PILOCARPINE; DOUBLE-BLIND; SALIVARY-GLANDS; HEAD; RADIOTHERAPY AB Purpose: To assess the safety of long-term cevimeline treatment of radiation-induced xerostomia in patients with head-and-neck cancer; and to assess the efficacy of cevimeline in these patients. Methods and Materials: A total of 255 adults with head-and-neck cancer who had received more than 40 Gy of radiation 4 months or more before entry and had clinically significant salivary gland dysfunction received cevimeline hydrochloride 45 mg t.i.d. orally for 52 weeks. Adverse events (AEs), their severity, and their relationship to the study medication were assessed by each investigator. The efficacy assessment was based on subjects' global evaluation of oral dryness on a scale of 0 (none) to 3 (severe). Results: Overall, 175 subjects (68.6%) experienced expected treatment-related AEs, most mild to moderate. The most frequent was increased sweating (47.5%), followed by dyspepsia (9.4%), nausea (8.2%), and diarrhea (6.3%). Fifteen subjects (5.9%) experienced Grade 3 treatment-related AEs, of which the most frequent was increased sweating. Eighteen subjects (7.1 %) reported at least one serious AE, and 45 subjects (17.6 %) discontinued study medication because of an AE. The global efficacy evaluation at the last study visit showed that cevimeline improved dry mouth in most subjects (59.2 %). Significant improvement was seen at each study visit in the mean change from baseline of the numeric global evaluation score (p < 0.0001). Conclusions: Cevimeline 45 mg t.i.d. was generally well tolerated over a period of 52 weeks in subjects with xerostomia secondary to radiotherapy for cancer in the head-and-neck region. (c) 2007 Elsevier Inc. C1 [Chambers, Mark S.; Weber, Randal S.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA. [Garden, Adam S.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA. [Jones, Christopher Uwe] Radiol Associates Sacramento, Sacramento, CA USA. [Biel, Merrill A.] Ear Nose & Throat Specially Care Minnesota, Minneapolis, MN USA. [Hodge, Kenneth M.] Commonwealth Ear Nose & Throat, Louisville, KY USA. [Chen, Y.] Univ Rochester, Ctr Canc, Dept Radiat Oncol, Rochester, NY 14642 USA. [Holland, John M.] Oregon Hlth & Sci Univ, Dept Radiat Oncol, Portland, OR 97201 USA. [Ship, Jonathan A.] NYU, Coll Dent, Bluestone Ctr Clin Res, New York, NY USA. [Vitti, Robert; Armstrong, Ingrid] Daiichi Pharmaceut Corp, Montvale, NJ USA. [Haddad, Robert] Harvard Univ, Dana Farber Canc Ctr, Boston, MA 02115 USA. RP Chambers, MS (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA. EM mchamber@mdanderson.org NR 35 TC 16 Z9 19 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD DEC 1 PY 2007 VL 69 IS 5 BP 1369 EP 1376 DI 10.1016/j.ijrobp.2007.05.024 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 240BD UT WOS:000251561100004 PM 17855005 ER PT J AU Sher, DJ Wolfgang, JA Niemierko, A Choi, NC AF Sher, David J. Wolfgang, John A. Niemierko, Andrzej Choi, Noah C. TI Quantification of mediastinal and hilar lymph node movement using four-dimensional computed tomography scan: Implications for radiation treatment planning SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article; Proceedings Paper CT 47th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 16-20, 2005 CL Denver, CO SP Amer Soc Therapeut Radiol & Oncol DE treatment planning; organ motion; four-dimensional treatment planning; computed tomography; lung cancer ID CELL LUNG-CANCER; TARGET VOLUMES; TUMOR; MOTION; RADIOTHERAPY; SURVIVAL; MARGINS; THORAX; IMPACT; STAGE AB Purpose: To quantitatively describe mediastinal and hilar lymph node movement in patients with lymph node-positive lung cancer. Methods and Materials: Twenty-four patients with lung cancer who underwent four-dimensional computed tomography scanning at Massachusetts General Hospital were included in the study. The maximum extent of superior motion of the superior border was measured, as well as the maximum inferior movement of the inferior border. The average of these two values is defined as the peak-to-peak movement. This process was repeated for mediolateral (ML) and anterior-posterior (AP) movement. Linear regression was used to determine lymph node characteristics associated with peak-to-peak movement. Various uniform expansions were investigated to determine the expansion margins necessary to ensure complete internal target volume (ITV) coverage. Results: The mean peak-to-peak displacements of paratracheal lymph nodes were 4 mm (craniocaudal [CC]), 2 mm (ML), and 2 mm (AP). For subcarinal lymph nodes, the mean peak-to-peak movements were 6 mm (CC), 4 mm (ML), and 2 mm (AP). The mean peak-to-peak displacements of hilar lymph nodes were 7 mm (CC), 1 mm (ML), and 4 mm (AP). On multivariate analysis, lymph node station and lymph node size were significantly related to peak-to-peak movement. Expansions of 8 mm for paratracheal nodes and 13 mm for subcarinal and hilar nodes would have been necessary to cover the ITV of 95% of these nodal masses. Conclusions: Subcarinal and hilar lymph nodes may move substantially throughout the respiratory cycle. In the absence of patient-specific information on nodal motion, expansions of at least 8 mm, 13 mm, and 13 mm should be considered to cover the ITV of paratracheal, subcarinal, and hilar lymph nodes, respectively. (c) 2007 Elsevier Inc. C1 [Sher, David J.; Wolfgang, John A.; Niemierko, Andrzej; Choi, Noah C.] Harvard Univ, Dept Radiat Oncol, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Choi, NC (reprint author), Harvard Univ, Dept Radiat Oncol, Sch Med, Massachusetts Gen Hosp, 100 Blossom St,Cox 3, Boston, MA 02114 USA. EM nchoi@partners.org NR 15 TC 12 Z9 17 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD DEC 1 PY 2007 VL 69 IS 5 BP 1402 EP 1408 DI 10.1016/j.ijrobp.2007.05.022 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 240BD UT WOS:000251561100009 PM 17920783 ER PT J AU Allen, AM Schofield, D Hacker, F Court, LE Czerminska, M AF Allen, Aaron M. Schofield, Deborah Hacker, Fred Court, Laurence E. Czerminska, Maria TI Restricted field imrt dramatically enhances IMRT planning for mesothelioma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE intensity-modulated radiotherapy; IMRT; mesothelioma; optimization ID MALIGNANT PLEURAL MESOTHELIOMA; INTENSITY-MODULATED RADIOTHERAPY; CELL LUNG-CANCER; VOLUME HISTOGRAM ANALYSIS; RADIATION-THERAPY; EXTRAPLEURAL PNEUMONECTOMY; PHASE-I; PNEUMONITIS; OPTIMIZATION; CHEMOTHERAPY AB Purpose: To improve the target coverage and normal tissue sparing of intensity-modulated radiotherapy (IMRT) for mesothelioma after extrapleural pneumonectomy. Methods and Materials: Thirteen plans from patients previously treated with IMRT for mesothelioma were re-planned using a restricted field technique. This technique was novel in two ways. It limited the entrance beams to 200 around the target and three to four beams per case had their field apertures restricted down to the level of the heart or liver to further limit the contralateral lung dose. New constraints were added that included a mean lung dose of < 9.5 Gy and volume receiving >= 5 Gy of < 55%. Results: In all cases, the planning target volume coverage was excellent, with an average of 97% coverage of the planning target volume by the target dose. No change was seen in the target coverage with the new technique. The heart, kidneys, and esophagus were all kept under tolerance in all cases. The average mean lung dose, volume receiving >= 20 Gy, and volume receiving >= 5 Gy with the new technique was 6.6 Gy, 3.0%, and 50.8%, respectively, compared with 13.8 Gy, 15%, and 90% with the previous technique (p < 0.0001 for all three comparisons). The maximal value for any case in the cohort was 8.0 Gy, 7.3%, and 57.5% for the mean lung dose, volume receiving >= 20 Gy, and volume receiving >= 5 Gy, respectively. Conclusion: Restricted field IMRT provides an improved method to deliver IMRT to a complex target after extrapleural pneumonectomy. An upcoming Phase I trial will provide validation of these results. (c) 2007 Elsevier Inc. C1 [Allen, Aaron M.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Allen, Aaron M.; Schofield, Deborah; Hacker, Fred; Court, Laurence E.; Czerminska, Maria] Brigham & Womens Hosp, Harvard Med Sch, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. RP Allen, AM (reprint author), Dana Farber Canc Inst, Dept Radiat Oncol, 44 Binney St, Boston, MA 02115 USA. EM aallen@lroc.harvard.edu OI Hacker, Fred/0000-0001-7535-7598 NR 22 TC 28 Z9 28 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD DEC 1 PY 2007 VL 69 IS 5 BP 1587 EP 1592 DI 10.1016/j.ijrobp.2007.06.075 PG 6 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 240BD UT WOS:000251561100034 PM 17892915 ER PT J AU Craft, D Halabi, T Shih, HA Bortfeld, T AF Craft, David Halabi, Tarek Shih, Helen A. Bortfeld, Thomas TI An approach for practical multiobjective IMRT treatment planning SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE multiobjective; inverse planning; optimization; IMRT; linear programming; EUD; multicriteria; Pareto ID INTENSITY-MODULATED RADIOTHERAPY; FLUENCE MAP OPTIMIZATION; RADIATION-THERAPY; NORMAL TISSUE; TOLERANCE; NUMBER AB Purpose: To introduce and demonstrate a practical multiobjective treatment planning procedure for intensity-modulated radiation therapy (IMRT) planning. Methods and Materials: The creation of a database of Pareto optimal treatment plans proceeds in two steps. The first step solves an optimization problem that finds a single treatment plan which is close to a set of clinical aspirations. This plan provides an example of what is feasible, and is then used to determine mutually satisfiable hard constraints for the subsequent generation of the plan database. All optimizations are done using linear programming. Results: The two-step procedure is applied to a brain, a prostate, and a lung case. The plan databases created allow for the selection of a final treatment plan based on the observed tradeoffs between the various organs involved. Conclusions: The proposed method reduces the human iteration time common in IMRT treatment planning. Additionally, the database of plans, when properly viewed, allows the decision maker to make an informed final plan selection. (c) 2007 Elsevier Inc. C1 [Craft, David; Halabi, Tarek; Shih, Helen A.; Bortfeld, Thomas] Massachusetts Gen Hosp, Harvard Med Sch, Dept Radiat Oncol, Boston, MA 02114 USA. RP Craft, D (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Dept Radiat Oncol, 0 Grove St, Boston, MA 02114 USA. EM dcraft@partners.org FU NCI NIH HHS [1 R01 CA103904-01A1] NR 20 TC 50 Z9 54 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD DEC 1 PY 2007 VL 69 IS 5 BP 1600 EP 1607 DI 10.1016/j.ijrobp.2007.08.019 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 240BD UT WOS:000251561100036 PM 17920782 ER PT J AU Drummond, MF Wilson, DA Kanavos, P Ubel, P Rovira, J AF Drummond, Michael F. Wilson, David A. Kanavos, Panos Ubel, Peter Rovira, Joan TI Assessing the economic challenges posed by orphan drugs SO INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE LA English DT Article; Proceedings Paper CT Roundtable Meeting on Use of Health Economics for Orphan Drugs CY DEC 16, 2005 CL London Sch Econ & Polit Sci, London, ENGLAND SP Genzyme HO London Sch Econ & Polit Sci DE cost-effectiveness analysis; equity; health policy ID REIMBURSEMENT; CARE AB Historically, patients with rare diseases have been underserved by commercial drug development. In several jurisdictions, specific legislation has been enacted to encourage the development of drugs for rare diseases (orphan drugs), which would otherwise not be commercially viable. However, because of the small market, these drugs are often very expensive. Under the standard methods of health technology assessment (HTA) incorporating economic evaluation, orphan drugs do not usually prove to be cost-effective and this, coupled with their high cost, means that funding and patient access may be limited. However, these restrictions may not be in line with societal preferences. Therefore, this study discusses whether the standard methods of HTA are adequate for assisting decisions on patient access to and funding of orphan drugs and outlines a research agenda to help understand the societal value of orphan drugs and issues surrounding their development, funding, and use. C1 Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England. Massachusetts Gen Hosp, Inst Hlth Profess, Boston, MA 02129 USA. Genzyme Corp, Dept Hlth Econ, Cambridge, MA 02142 USA. London Sch Econ, LSE Hlth & Social Care, London WC2A 2AE, England. Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. Univ Barcelona, Dept Econ Theory, Fac Econ & Managerial Sci, Barcelona, Spain. SOIKOS, SOIKOS Consultancy Firm, Barcelona 08013, Spain. RP Drummond, MF (reprint author), Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England. EM md18@york.ac.uk; dwilson@genzyme.com; p.g.kanavos@lse.ac.uk; paubel@umich.edu; jrovira@soikos.com NR 21 TC 99 Z9 101 U1 4 U2 15 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0266-4623 J9 INT J TECHNOL ASSESS JI Int. J. Technol. Assess. Health Care PD WIN PY 2007 VL 23 IS 1 BP 36 EP 42 PG 7 WC Health Care Sciences & Services; Public, Environmental & Occupational Health; Medical Informatics SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Medical Informatics GA 144WC UT WOS:000244826100006 PM 17234015 ER PT J AU Burman, W Weis, S Vernon, A Khan, A Benator, D Jones, B Silva, C King, B LaHart, C Mangura, B Weiner, M El-Sadr, W AF Burman, W. Weis, S. Vernon, A. Khan, A. Benator, D. Jones, B. Silva, C. King, B. LaHart, C. Mangura, B. Weiner, M. El-Sadr, W. TI Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; HIV; antiretroviral therapy; immune reconstitution ID ACTIVE ANTIRETROVIRAL THERAPY; INFLAMMATORY SYNDROME; INFECTED PATIENTS; RISK-FACTORS; MYCOBACTERIAL INFECTIONS; HIV-1-INFECTED ADULTS; PARADOXICAL REACTIONS; INITIATION; HAART; ERA AB SETTING: Patients were enrolled in a prospective trial of rifabutin-based tuberculosis (TB) treatment for human immunodeficiency virus related TB. Antiretroviral therapy (ART) was encouraged, but not required. OBJECTIVE: To evaluate the frequency, risk factors and duration of immune reconstitution events. DESIGN: Patients were prospectively evaluated for immune reconstitution events, and all adverse event reports were reviewed to identify possible unrecognized events. RESULTS: Of 169 patients, 25 (15%) developed immune, reconstitution events related to TB. All 25 were among the 137 patients who received ART during TB treatment, so the frequency in this subgroup was 18% (25/137). Risk factors for an immune reconstitution event in multivariate analysis were Black race, the presence of extra-pulmonary TB and a shorter interval from initiation of TB treatment to initiation of ART. The most common clinical manifestations were fever (64%), new or worsening adenopathy (52%) and worsening pulmonary infiltrates (40%). Twelve patients (48%) were hospitalized for a median of 7 days, six underwent surgery and 11 had needle aspiration. The median duration of events was 60 days (range 11-442). CONCLUSION: Immune reconstitution events we're common among patients receiving ART during TB treatment, produced substantial morbidity and had a median duration of 2 months. C1 [Burman, W.; Mangura, B.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. [Weis, S.; King, B.; Weiner, M.] Univ N Texas Hlth Sci Ctr, Tarrant Cty Hlth Dept, Ft Worth, TX USA. [Vernon, A.; Khan, A.; El-Sadr, W.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Benator, D.] George Washington Univ, Med Ctr, Vet Affairs Med Ctr, Washington, DC USA. [Jones, B.; Silva, C.] Univ So Calif, Med Ctr, Los Angeles, CA USA. [LaHart, C.] Baylor Coll Med, Houston, TX 77030 USA. [Mangura, B.] Univ Med & Dent New Jersey, Sch Med, Natl Tuberculosis Ctr, Newark, NJ 07103 USA. [Weiner, M.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [El-Sadr, W.] Columbia Univ, Coll Phys & Surg, Harlem Hosp Ctr, New York, NY USA. RP Burman, W (reprint author), 605 Bannock St, Denver, CO 80204 USA. EM bburman@dhha.org NR 32 TC 81 Z9 83 U1 0 U2 1 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD DEC PY 2007 VL 11 IS 12 BP 1282 EP 1289 PG 8 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 240YH UT WOS:000251623600004 PM 18229435 ER PT J AU Szekely, CA Breitner, JCS Zandi, PP AF Szekely, C. A. Breitner, J. C. S. Zandi, P. P. TI Prevention of Alzheimer's disease SO INTERNATIONAL REVIEW OF PSYCHIATRY LA English DT Review ID MILD COGNITIVE IMPAIRMENT; RANDOMIZED CONTROLLED-TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PLACEBO-CONTROLLED TRIAL; NATURAL CHOLINESTERASE INHIBITOR; ANTIHYPERTENSIVE-MEDICATION-USE; ESTROGEN REPLACEMENT THERAPY; DIETARY MODIFICATION TRIAL; TOTAL HOMOCYSTEINE LEVELS; BETA IMMUNIZATION AN1792 AB The already considerable public health burden of Alzheimer's disease will likely worsen as populations around the world age. As a result, there is considerable motivation to develop effective strategies for preventing the disease. A wide variety of such strategies are under investigation and include pharmaceuticals, nutriceuticals, diet, physical activity and cognitive activity. We review here the most promising candidates and the epidemiologic evidence for their efficacy. Although none of these have yet to be definitively shown to prevent Alzheimer's disease, further research should help to clarify what role they may play in reducing the burden of this disease. C1 [Breitner, J. C. S.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Breitner, J. C. S.] Univ Washington, Seattle, WA 98195 USA. [Breitner, J. C. S.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Zandi, PP (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Hampton House Suite 850,624 N Broadway, Baltimore, MD 21205 USA. EM pzandi@jhsph.edu RI Szekely, Christine/C-1342-2009 NR 175 TC 16 Z9 16 U1 4 U2 13 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0261 J9 INT REV PSYCHIATR JI Int. Rev. Psych. PD DEC PY 2007 VL 19 IS 6 BP 693 EP 706 DI 10.1080/09540260701797944 PG 14 WC Psychiatry SC Psychiatry GA 253RL UT WOS:000252535200009 PM 18092245 ER PT J AU Pulliam, SJ Ferzandi, TR Hota, LS Elkadry, EA Rosenblatt, PL AF Pulliam, Samantha J. Ferzandi, Tanaz R. Hota, Lekha S. Elkadry, Eman A. Rosenblatt, Peter L. TI Use of synthetic mesh in pelvic reconstructive surgery: a survey of attitudes and practice patterns of urogynecologists SO INTERNATIONAL UROGYNECOLOGY JOURNAL LA English DT Article; Proceedings Paper CT 27th Annual Meeting of the American-Urogynecologic-Society CY OCT 19-21, 2006 CL Palm Springs, CA SP Amer Urogynecol Soc DE urogynecology; pelvic reconstructive surgery; mesh survey; surgery ID URINARY-INCONTINENCE; PROLAPSE; REPAIR AB This study surveyed attitudes and practice patterns of urogynecologists regarding the use of synthetic mesh in pelvic reconstructive surgery. A web-based survey was administered to members of the American Urogynecologic Society. The survey evaluated the use of the mesh for sacrocolpopexy, suburethral sling, and vaginal pelvic reconstructive surgery. The survey had a 30.5% response rate. One hundred one (39%) respondents were women, and 158 (61%) were men. One hundred forty-seven (56.8%) participated in fellowship training. Two hundred forty-seven (99.5%) currently perform procedures using synthetic mesh, including 93% who perform sacrocolpopexy and 93% who perform suburethral slings. In a logistic regression model including gender, fellowship training, and practice setting, male surgeons and those who had not undergone fellowship training were more likely to use the mesh than those who were fellowship trained. Respondents use the mesh most commonly when performing sacrocolpopexies and suburethral slings. The use of the mesh for anterior and posterior colporrhaphy is less common. C1 Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol, Div Urogynecol, Boston, MA 02114 USA. Mt Auburn Hosp, Div Urogynecol, Cambridge, MA 02138 USA. RP Pulliam, SJ (reprint author), Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol, Div Urogynecol, 55 Fruit St,YAW 4, Boston, MA 02114 USA. EM spulliam@partners.org NR 11 TC 10 Z9 10 U1 0 U2 2 PU SPRINGER LONDON LTD PI ARTINGTON PA ASHBOURNE HOUSE, THE GUILDWAY, OLD PORTSMOUTH ROAD, ARTINGTON GU3 1LP, GUILDFORD, ENGLAND SN 0937-3462 J9 INT UROGYNECOL J JI Int. Urogynecol. J. PD DEC PY 2007 VL 18 IS 12 BP 1405 EP 1408 DI 10.1007/s00192-007-0360-6 PG 4 WC Obstetrics & Gynecology; Urology & Nephrology SC Obstetrics & Gynecology; Urology & Nephrology GA 227BC UT WOS:000250631200007 PM 17457509 ER PT J AU Geraldes, P Yamagata, M Rook, SL Sassa, Y Ma, RC Clermont, A Gao, B Aiello, LP Feener, EP King, GL AF Geraldes, Pedro Yamagata, Michiko Rook, Susan L. Sassa, Yukio Ma, Ronald C. Clermont, Allen Gao, Benbo Aiello, Lloyd Paul Feener, Edward P. King, George L. TI Glypican 4, a membrane binding protein for bactericidal/permeability-increasing protein signaling pathways in retinal pigment epithelial cells SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID HEPARAN-SULFATE PROTEOGLYCANS; GROWTH-FACTORS; PERICYTE LOSS; PERMEABILITY; EXPRESSION; BPI; ANGIOGENESIS; CAPILLARIES; RECEPTORS; INDUCTION AB PURPOSE. Originally identified as a lipopolysaccharide binding protein with Gram-negative bactericidal activity in the leukocytes, bactericidal/permeability-increasing protein (BPI) has been shown to induce various effects in retinal cells in vivo and in vitro. METHODS. The authors recently reported that BPI can induce ERK1/2 and Akt activity and that it increases DNA synthesis in the bovine retinal pigment epithelial (RPE) and pericyte cells. The authors have extended the characterization of BPI interaction with membrane proteins from bovine RPE. Crude membrane pools from RPE were isolated, solubilized, and bound to rBPI(21) affinity column. Bound proteins were separated by SDS-PAGE and stained with Coomassie blue, which showed an intense band at 36 kDa consistently displaced by rBPI(21). RESULTS. Tandem mass spectrometry of the 36-kDa band suggested that cell surface protein glypican 4 (GPC4) serves as a putative BPI-binding protein. Heparitinase, phosphatidylinositol-specific phospholipase C, and anti - GPC4 antibody suppressed BPI-induced ERK and Akt phosphorylation in bovine RPE. Moreover, heparitinase also inhibited BPI actions on VEGF and PDGF-B mRNA expression induced by H2O2. CONCLUSIONS. These new findings suggest that GPC4 is a specific binding protein for BPI on RPE to mediate the activation of ERK1/2, Akt, and the mRNA expressions of PDGF-B and VEGF. C1 Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. Harvard Med Sch, Dept Med, Boston, MA USA. Harvard Med Sch, Dept Ophthalmol, Boston, MA USA. RP King, GL (reprint author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA. EM george.king@joslin.harvard.edu RI Sassa, Yukio/H-6339-2012; Ma, Ronald/C-2788-2009 OI Ma, Ronald/0000-0002-1227-803X FU NIDDK NIH HHS [P30 DK036836, P30 DK36836] NR 31 TC 5 Z9 6 U1 0 U2 3 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD DEC PY 2007 VL 48 IS 12 BP 5750 EP 5755 DI 10.1167/iovs.07-0470 PG 6 WC Ophthalmology SC Ophthalmology GA 238MB UT WOS:000251450800051 PM 18055828 ER PT J AU Sahani, DV Soulez, G Chen, KM Lepanto, L Xu, JR Nelson, RC Grazioli, L Vanzulli, A Heiken, JP AF Sahani, Dushyant V. Soulez, Gilles Chen, Ke-Min Lepanto, Luigi Xu, Jian-Rong Nelson, Rendon C. Grazioli, Luigi Vanzulli, Angelo Heiken, Jay P. CA Investigators of the IMPACT Study TI A comparison of the efficacy and safety of lopamidol-370 and lodixanol-320 in patients undergoing multidetector-row computed tomography SO INVESTIGATIVE RADIOLOGY LA English DT Article DE computed tomography (CT); contrast media; heart rate; liver enhancement ID NONINVASIVE CORONARY-ANGIOGRAPHY; CONTRAST-INDUCED NEPHROPATHY; CHRONIC KIDNEY-DISEASE; IODINE CONCENTRATION; HEART-RATE; HEPATOCELLULAR-CARCINOMA; CT ANGIOGRAPHY; IMAGE QUALITY; ENHANCEMENT; MEDIA AB Objectives: To prospectively compare the effects on heart rate (HR) and contrast enhancement efficacy of iopamidol-370 and iodixanol-320 in contrast-enhanced, multidetector-row computed tomography (CE-MDCT). Methods: IMPACT is a multicenter, double-blind study involving 166 patients undergoing CE-MDCT of the liver (n = 121) or peripheral arteries (n = 45) randomized to receive equi-iodine doses (40 gI) of iopamidol-370 or iodixanol-320 intravenous at 4 mL/s. CE-MDCT was performed using 16-MDCT scanners according to predefined imaging protocols. HR was measured with the patient in the supine position before and continuously for 5 minutes after contrast medium administration. Mean and peak increases in HR and the proportion of subjects with predefined HR increases (>5 to <10, 10 to <15, 15 to <20, >20 bpm) were compared in the 2 populations. Liver images were assessed by 2 independent, blinded readers for contrast enhancement [Hounsfield unit (HU)], using predefined regions-of-interest during the arterial and portal-venous phase of enhancement. Results: Effects on HR: Eighty-four subjects received iopamidol-370 whereas 82 received iodixanol-320. Mean age, gender distribution, weight, total iodine dose, dose/body weight, concomitant medications and use of beta-blockers were comparable in the 2 groups. Mean baseline HR was similar in the 2 groups (iopamidol-370: 72.3 +/- 12.5 bpm; iodixanol-320: 74.5 +/- 11.9 bpm). Mean changes from baseline to peak postdose were similar in the 2 groups (8.0 +/- 9.3 bpm after iopamidol-370 and 8.4 +/- 14.7 after iodixanol-320, P = 0.72). The proportion of subjects in each group having increases of <5, >5 to <10, 10 to <15, 15 to <20, or >20 bpm was comparable (P = 0.87). Two subjects experienced postcontrast tachycardia (HR increase >70 bpm, peak HR of 146 and 164 bpm), both in the iodixanol-320 group (2.4%). Contrast Enhancement: Of the 121 patients undergoing liver CT, 60 received iopamidol-370 whereas 61 received iodixanol-320. Mean age, gender distribution, weight, total iodine dose, and dose/body weight were comparable in the 2 groups. Iopamidol-370 provided significantly higher HU values in abdominal aorta during the arterial phase of enhancement for both readers [R1: 301.3 +/- 80.2 vs. 273.6 +/- 65.9 HU, 95% confidence interval (6.1 - 56.8), P = 0.02; R2: 302.0 +/- 73.6 vs. 275.1 +/- 62.9 HU, 95% confidence interval (2.3 - 51.3), P = 0.03]. No significant difference was observed between the 2 contrast medium during the portal venous phase of enhancement. Conclusions: When the same injection rate and iodine dose is used, the effects on HR of bolus intravenous injections of iopamidol-370 and iodixanol-320 were similar. Iopamidol-370 provides significantly greater enhancement during the arterial phase and similar enhancement during the portal venous phase compared with iodixanol-320. C1 Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. Univ Montreal, Ctr Hosp, Dept Radiol, Montreal, PQ, Canada. Rui Jin Hosp, Dept Radiol, Shanghai, Peoples R China. Ren Ji Hosp, Dept Radiol, Shanghai, Peoples R China. Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA. Univ Brescia Hosp, Serv Radiol, Brescia, Italy. Osped Niguarda Ca Granda, Dept Radiol, Milan, Italy. Washington Univ, Med Ctr, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA. RP Sahani, DV (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. EM dsahani@partners.org NR 22 TC 16 Z9 17 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0020-9996 J9 INVEST RADIOL JI Invest. Radiol. PD DEC PY 2007 VL 42 IS 12 BP 856 EP 861 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 233VG UT WOS:000251117800009 PM 18007158 ER PT J AU Thomas, LS Manning, A Holmes, CB Naidoo, S van der Linde, F Gray, GE Martinson, NA AF Thomas, Leena S. Manning, Arthur Holmes, Charles B. Naidoo, Shan van der Linde, Frans Gray, Glenda E. Martinson, Neil A. TI Comparative costs of inpatient care for HIV-Infected and uninfected children and adults in Soweto, South Africa SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE antiretrovirals; HIV; hospitalization; LOS; opportunistic infections; pediatric AB Background: HIV/AIDS creates a massive burden of care for health systems. A better understanding of the impact of HIV infection on health care utilization and costs may enable better use of limited resources. Methods: We compared public sector inpatient costs of HIV-infected versus uninfected adults and children at a large hospital in Soweto, South Africa. Daily hotel costs estimated from hospital financial data and total patient visits were combined with utilization, abstracted from patients' charts, and costed using government price lists to estimate total inpatient costs. Results: A total of 1185 eligible records were included over a 6-week period in 2005. Eight hundred twelve were from HIV-infected patients, and of these, 77 were on antiretroviral (ARV) therapy The mean length of stay (LOS) and mean drug and intravenous fluid utilization of HIV-infected adults not on ARVs was greater than those of uninfected adults, resulting in a $200 higher total average admission cost. Patients on ARVs had longer LOS and incurred a total average admission cost of $750 more than HIV-infected adults not on ARVs. Conclusions: inpatient costs were greater for this selected group of HIV-infected adults, and even higher for the small proportion of individuals receiving ARVs. Budget allocations should incorporate case mix by HIV and ARV status as a key determinant of hospital expenditure. C1 MBBCh, Perinatal HIV Res Unit, ZA-1864 Diepkloof, South Africa. Univ Witwatersrand, Sch Publ Hlth, Gauteng Dept Hlth, Johannesburg, South Africa. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa. Johns Hopkins Univ, Ctr Tuberculosis Res, Baltimore, MD USA. RP Martinson, NA (reprint author), MBBCh, Perinatal HIV Res Unit, C-O,PO Box 114, ZA-1864 Diepkloof, South Africa. EM neill.martinson@gmail.com FU NIAID NIH HHS [R01 AI058736, R0 AI058736-01A] NR 23 TC 10 Z9 10 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD DEC 1 PY 2007 VL 46 IS 4 BP 410 EP 416 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 231ZH UT WOS:000250987200006 PM 17786130 ER PT J AU Wolf, LL Ricketts, P Freedberg, KA Williams-Roberts, H Hirschhorn, LR Allen-Ferdinand, K Rodriguez, WR Divi, N Wong, MT Losina, E AF Wolf, Lindsey L. Ricketts, Paul Freedberg, Kenneth A. Williams-Roberts, Hazel Hirschhorn, Lisa R. Allen-Ferdinand, Kathleen Rodriguez, William R. Divi, Nomita Wong, Michael T. Losina, Elena TI The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE antiretroviral therapy; Caribbean; cost-effectiveness; Organization of Eastern Caribbean States ID UNITED-STATES; COTE-DIVOIRE; INCOME COUNTRIES; INFECTED ADULTS; SOUTH-AFRICA; TRIAL; SETTINGS; SURVIVAL; REGIMENS; EFFICACY AB Background: Antiretroviral therapy (ART) recently became available in the Organization of Eastern Caribbean States (OECS). Survival benefits and budgetary implications associated with universal access to ART have not been examined in the Caribbean. Methods: Using a state-transition simulation model of HIV with regional data, we projected survival, cost, and cost-effectiveness of treating an HIV-infected cohort. We examined I or 2 ART regimens and cotrimoxazole. In sensitivity analysis, we varied HIV natural history and ART efficacy, cost, and switching criteria. Results: Without treatment, mean survival was 2.30 years (mean baseline CD4 count = 288 cells/mu L). One ART regimen with cotrimoxazole when the CD4 count was <350 cells/mu L provided an additional 5.86 years of survival benefit compared with no treatment; the incremental cost-effectiveness ratio was $690 per year of life saved (YLS). A second regimen added 1.04 years of survival benefit; the incremental cost-effectiveness ratio was $10,960 per YLS compared with I regimen. Results were highly dependent on second-line ART costs. Per-person lifetime costs decreased from $17,020 to $9290 if second-line ART costs decreased to those available internationally, yielding approximately $8 million total savings. Conclusions: In the OECS, ART is cost-effective by international standards. Reducing second-line ART costs increases cost-effective-ness and affordability. Current funding supports implementing universal access regionally over the next year, but additional funding is required to sustain lifetime care for currently infected persons. C1 Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Div Gen Med, Partners AIDS Res Ctr, Boston, MA USA. Minist Hlth, Roseau, Dominica. Harvard Med Sch, Ctr AIDS Res, Div AIDS, Boston, MA USA. Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. Harvard Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA. RP Wolf, LL (reprint author), Massachusetts Gen Hosp, Div Gen Med, 50 Standford St,9th Flr, Boston, MA 02114 USA. EM llwolf@partners.org FU NIAID NIH HHS [R37 AI42006, K24 AI062476, K25 AI050436, K25 AI050436-05, K25 AI50436, R37 AI042006, R37 AI042006-10A1, P30 AI060354-03, P30 AI060354, K24 AI062476-04] NR 46 TC 12 Z9 13 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD DEC 1 PY 2007 VL 46 IS 4 BP 463 EP 471 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 231ZH UT WOS:000250987200013 PM 18077836 ER PT J AU Backus, BC Guinan, JJ AF Backus, Bradford C. Guinan, John J., Jr. TI Measurement of the distribution of medial olivocochlear acoustic reflex strengths across normal-hearing individuals via otoacoustic emissions SO JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY LA English DT Article DE human; stimulus-frequency otoacoustic emission; normative data; auditory efferent reflex ID CONTRALATERAL SUPPRESSION; FINE-STRUCTURE; HUMANS; BUNDLE; NOISE; STIMULATION; TONES; OAES AB A clinical test for the strength of the medial olivocochlear reflex (MOCR) might be valuable as a predictor of individuals at risk for acoustic trauma or for explaining why some people have trouble understanding speech in noise. A first step in developing a clinical test for MOCR strength is to determine the range and variation of MOCR strength in a research setting. A measure of MOCR strength near I kHz was made across a normal-hearing population (N=25) by monitoring stimulusfrequency otoacoustic emissions (SFOAEs) while activating the MOCR with 60 dB SPL wideband contralateral noise. Statistically significant MOCR effects were measured in all 25 subjects; but not all SFOAE frequencies tested produced significant effects within the time allotted. To get a metric of MOCR strength, MOCR-induced changes in SFOAEs were normalized by the SFOAE amplitude obtained by two-tone suppression. We found this "normalized MOCR effect" varied across frequency and time within the same subject, sometimes with significant differences between measurements made as little as 40 Hz apart or as little as a few minutes apart. Averaging several single-frequency measures spanning 200 Hz in each subject reduced the frequency- and time-dependent variations enough to produce correlated measures indicative of the true MOCR strength near I kHz for each subject. The distribution of MOCR strengths, in terms of SFOAE suppression near 1 kHz, across our normal-hearing subject pool was reasonably approximated by a normal distribution with mean suppression of approximately 35% and standard deviation of approximately 12%. The range of MOCR strengths spanned a factor of 4, suggesting that whatever function the MOCR plays in hearing (e.g., enhancing signal detection in noise, reducing acoustic trauma), different people will have corresponding differences in their abilities to perform that function. C1 UCL, Ear Inst, London WC1X 8EE, England. Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. Massachusetts Eye & Ear Infirm, Eaton Peabody Lab Auditory Physiol, Dept Otolaryngol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Backus, BC (reprint author), UCL, Ear Inst, 332 Grays Inn Rd, London WC1X 8EE, England. EM bradford.c.backus@alum.dartmouth.org FU NIDCD NIH HHS [P30 DC005209, R01 DC005977] NR 30 TC 35 Z9 36 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1525-3961 J9 JARO-J ASSOC RES OTO JI JARO PD DEC PY 2007 VL 8 IS 4 BP 484 EP 496 DI 10.1007/s10162-007-0100-0 PG 13 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 232MP UT WOS:000251024100007 PM 17932717 ER PT J AU Woody, GE Kane, V Lewis, K Thompson, R AF Woody, George E. Kane, Vince Lewis, Kimberly Thompson, Richard TI Premature deaths after discharge from methadone maintenance: A replication SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE methadone maintenance; mortality; treatment discharge ID RANDOMIZED CONTROLLED-TRIAL; DRUG-USE; OPIOID DEPENDENCE; HEROIN-ADDICTION; MORTALITY; IMPACT; REINFORCEMENT; ABSTINENCE; ABUSE; USERS AB Objective: Examine rate and causes of death among patients discharged from methadone maintenance, relate them to reasons for discharge, and discuss treatment implications. Method: Naturalistic study of deaths and causes of death among 636 opioid-dependent veterans treated with methadone maintenance between January 1, 2000 and August 31, 2002. Results: Among 456 patients who remained on methadone, 31 (6.8%) died (overdose, 1 accident, 13 liver problems, 16 other medical). Among 180 discharged patients, 34 (18.8%) died. Reasons for discharge and causes of death were: continuing drug use IN 52), 11 deaths (4 overdoses, 4 liver problems, 3 other medical); other disciplinary problems (N = 31), 8 deaths (2 suicides, 2 overdoses, 3 other medical, 1 unknown); other reasons (N = 97), 15 deaths (2 suicides, 1 overdose, 1 accident, 7 liver problems, 3 other medical, 1 unknown). Deaths were significantly less (P < 0.05) among patients who remained on methadone than in each category of those discharged. Follow-up interviews of 99 of 146 discharged patients showed problems in drug use, medical, employment, and psychiatric areas, and that only 21% were in treatment. Conclusions: These findings are consistent with a previous study from the same program, and also from other studies, showing that participating in methadone maintenance reduces mortality. Considered in light of the increased mortality among patients discharged for continuing drug use or behavioral problems, these data suggest that premature mortality can be reduced by keeping patients in treatment and/or taking steps to ensure that discharged patients are promptly enrolled in another program. C1 [Woody, George E.; Kane, Vince; Lewis, Kimberly; Thompson, Richard] Dept Vet Affairs Med Ctr, Res Educ & Clin Ctr MIRECC, VISN Mental Illness 4, Philadelphia, PA 19104 USA. [Woody, George E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Woody, George E.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA. [Thompson, Richard] Univ Illinois, Dept Psychol, Chicago, IL 60612 USA. RP Woody, GE (reprint author), Treatment Res Inst, 600 Publ Ledger Bldg,150 S Independence Mall W, Philadelphia, PA USA. EM woody@tresearch.org RI Thompson, Richard/G-5408-2011 OI Thompson, Richard/0000-0003-0127-513X NR 41 TC 21 Z9 21 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-0620 J9 J ADDICT MED JI J. Addict. Med. PD DEC PY 2007 VL 1 IS 4 BP 180 EP 185 DI 10.1097/ADM.0b013e318155980e PG 6 WC Substance Abuse SC Substance Abuse GA 305GM UT WOS:000256166000002 PM 21768955 ER PT J AU Scott, JE ElKhal, A Freyschmidt, EJ MacArthur, DH McDonald, D Howell, MD Leung, DYM Laouar, A Manjunath, N Bianchi, T Boes, M Oettgen, HC Geha, RS AF Scott, Jordan E. ElKhal, Abdallah Freyschmidt, Eva-Jasmin MacArthur, Daniel H. McDonald, Douglas Howell, Michael D. Leung, Donald Y. M. Laouar, Amale Manjunath, N. Bianchi, Teresa Boes, Marianne Oettgen, Hans C. Geha, Raif S. TI Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE eczema vaccinatum; allergy; vaccinia virus; smallpox vaccination; viral response; T(H)1/T(H)2 cells ID INTERFERON-GAMMA; ATOPIC-DERMATITIS; SMALLPOX VACCINATION; EPICUTANEOUS SENSITIZATION; ECZEMA VACCINATUM; SKIN INFLAMMATION; DENDRITIC CELLS; MICE LACKING; T-CELLS; INFECTION AB Background: Patients with atopic dermatitis (AD) exposed to the vaccinia virus (VV) smallpox vaccine have an increased risk of developing eczema vaccinatum. Objective: To investigate the effects of local allergic skin inflammation on vaccinia immunity. Methods: BALB/c mice were epicutaneously sensitized with ovalbumin (OVA) to induce allergic skin inflammation or with saline control, then inoculated with an attenuated VV strain by skin scarification or intraperitoneally. After 8 days, serum IgG anti-VV and cytokine secretion by splenocytes were measured. Results: Mice inoculated with VV at sites of epicutaneous sensitization with OVA, but not control mice inoculated at saline exposed sites, developed satellite pox lesions and had impaired secretion of T(H)1 cytokines in response to VV, decreased VV specific serum IgG(2a), increased VV specific serum IgG(1), and impaired upregulation of IFN-alpha, but not the cathelicidin-related antimicrobial peptide, at the infection site. The VV immune response of OVA-sensitized mice inoculated with VV at distant skin sites or intraperitoneally was normal. Conclusion: Local immune dysregulation at sites of allergic skin inflammation underlies the impaired T(H)1 immune response to VV introduced at these sites and the increased susceptibility to develop satellite pox lesions, a characteristic of eczema vaccinatum in patients with AD. Clinical implications: In a mouse model of AD, inoculation of VV at inflamed skin sites is associated with increased numbers of satellite pox lesions and an abnormal immune response to the virus. This may contribute to the susceptibility of patients with AD to virus dissemination after smallpox vaccination. C1 [Scott, Jordan E.; ElKhal, Abdallah; Freyschmidt, Eva-Jasmin; MacArthur, Daniel H.; McDonald, Douglas; Oettgen, Hans C.; Geha, Raif S.] Childrens Hosp, Div Allergy & Immunol, Dept Pediat, Boston, MA 02115 USA. [Laouar, Amale; Manjunath, N.] Harvard Univ, Sch Med, Ctr Blood Res, Inst Biomed Res, Boston, MA 02115 USA. [Howell, Michael D.; Leung, Donald Y. M.] Natl Jewish Ned & Res Ctr, Denver, CO USA. [Bianchi, Teresa; Boes, Marianne] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA. [Bianchi, Teresa; Boes, Marianne] Harvard Univ, Sch Med, Dept Pediat & Dermatol, Boston, MA USA. RP Geha, RS (reprint author), Childrens Hosp, Div Immunol, Karp 10th Floor,1 Blackfan St, Boston, MA 02115 USA. EM raif.geha@childrens.harvard.edu FU NIAMS NIH HHS [R01 AR052810]; PHS HHS [HHSN266200400030C] NR 33 TC 23 Z9 24 U1 2 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD DEC PY 2007 VL 120 IS 6 BP 1382 EP 1388 DI 10.1016/j.jaci.2007.08.004 PG 7 WC Allergy; Immunology SC Allergy; Immunology GA 241JX UT WOS:000251653800021 PM 17889291 ER PT J AU Kong, J Gollub, R Huang, T Polich, G Napadow, V Hui, K Vangel, M Rosen, B Kaptchuk, TJ AF Kong, Jian Gollub, Randy Huang, Tao Polich, Ginger Napadow, Vitaly Hui, Kathleen Vangel, Mark Rosen, Bruce Kaptchuk, Ted J. TI Acupuncture de qi, from qualitative history to quantitative measurement SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Article ID PLACEBO NEEDLE; RANDOMIZED-TRIAL; DE-QI; OSTEOARTHRITIS; STIMULATION; SENSATION; KNEE; FMRI AB De qi is an important traditional acupuncture term used to describe the connection between acupuncture needles and the energy pathways of the body. The concept is discussed in the earliest Chinese medical texts, but details of de qi phenomenon, which may include the acupuncturist's and/or the patient's experiences, were only fully described in the recent hundred years. In this paper, we will trace de qi historically as an evolving concept, and review the literature assessing acupuncture needle sensations, and the relationship between acupuncture-induced de qi and therapeutic effect. Thereafter, we will introduce the MGH Acupuncture Sensation Scale ( MASS), a rubric designed to measure sensations evoked by acupuncture stimulation as perceived by the patient alone, and discuss some alternative statistical methods for analyzing the results of this questionnaire. We believe widespread use of this scale, or others like it, and investigations of the correlations between de qi and therapeutic effect will lead to greater precision in acupuncture research and enhance our understanding of acupuncture treatment. C1 [Kong, Jian; Gollub, Randy; Polich, Ginger] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. [Huang, Tao] Chinese Acad Tradit Chinese Med, Inst Acupuncture, Beijing, Peoples R China. [Napadow, Vitaly; Hui, Kathleen; Vangel, Mark; Rosen, Bruce] Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Kaptchuk, Ted J.] Harvard Univ, Sch Med, Osher Inst, Boston, MA 02115 USA. RP Kong, J (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. OI Gollub, Randy L./0000-0002-9434-4044 FU NCCIH NIH HHS [R21AT00949, K01-AT002166, K24-AT004095, P01-AT002048, P01-AT003883]; NCRR NIH HHS [M01-RR14075] NR 39 TC 143 Z9 161 U1 5 U2 30 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD DEC PY 2007 VL 13 IS 10 BP 1059 EP 1070 DI 10.1089/acm.2007.0524 PG 12 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 249RK UT WOS:000252247200005 PM 18166116 ER PT J AU Pumbwe, L Skilbeck, CA Wexler, HM AF Pumbwe, Lilian Skilbeck, Christopher A. Wexler, Hannah M. TI Induction of multiple antibiotic resistance in Bacteroides fragilis by benzene and benzene-derived active compounds of commonly used analgesics, antiseptics and cleaning agents SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE cross-resistance; detergents; disinfectants; gene derepression ID ESCHERICHIA-COLI; EFFLUX PUMP; SALICYLATE INDUCTION; MAR OPERON; DISINFECTANTS; MUTANTS; STRAINS; CHLORIDE AB Objectives: To determine the potential of active compounds (ACs) present in commonly used analgesics/antiseptics and cleaning agents (detergents and disinfectants) to induce multiple antibiotic resistance (MAR) in Bacteroides fragilis. Methods: B. fragilis ATCC 25285 untreated or pretreated with sublethal concentrations of ACs (n = 25) was grown for 12 h. Susceptibility of cells pre-treated with various ACs to antibiotics and expression of resistance nodulation division family (bmeB) efflux pumps and putative marA-like global activators (PGAs) were measured. Results: Twelve aromatic ACs containing benzene or its activated derivatives (salicylate, acetaminophen, gingerol, benzoate, phenol, chlorhexidine gluconate, capsaicin, juglone, cinnamaldehyde, benzene, ibuprofen and Triton X-100) induced MAR, which was reduced by carbonyl cyanide m-chlorophenylhydrazone. There was a positive correlation between the predicted degree of benzene activation and the level of induction. Deactivated benzene or non-aromatic ACs were either poor inducers or non-inducers. Efflux pumps bmeB1, 3, 4, 7 and two PGAs bfrA1 and bfrA2 were overexpressed. Expression of bfrA1 or bfrA2 in Escherichia coli caused a > 2-fold increase in the MAR and overexpression of acrB, suggesting that they were putative marA orthologues. Conclusions: These data demonstrate (i) the presence of an MarA-like system(s) in B. fragilis and (ii) the propensity of benzene or its activated derivatives present in pharmaceutical products to induce MAR. C1 Univ Calif Los Angeles, Dept Med, Wadsworth Anaerobe Lab, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA USA. RP Pumbwe, L (reprint author), Univ Calif Los Angeles, Dept Med, Wadsworth Anaerobe Lab, Bldg 304,Room E3-226,GLAVAHCS 691-151J, Los Angeles, CA 90073 USA. EM lilskil@ucla.edu NR 32 TC 11 Z9 12 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD DEC PY 2007 VL 60 IS 6 BP 1288 EP 1297 DI 10.1093/jac/dkm363 PG 10 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 234XV UT WOS:000251198800014 PM 17884830 ER PT J AU Sah, AP Ready, JE AF Sah, Alexander P. Ready, John E. TI Use of Oxidized Zirconium Hemiarthroplasty in Hip Fractures SO JOURNAL OF ARTHROPLASTY LA English DT Article DE zirconium; hemiarthroplasty; spectrum analysis AB Oxidized zirconium may have improved wear characteristics against polyethylene, but its performance against native cartilage is unknown. Between 1996 and 1998, 52 patients received an oxidized zirconium hemiarthroplasty for the treatment of a hip fracture. Twelve patients (23%) died within I year of surgery, and 24 (46%) were surviving at 5 years. In 38 patients with minimum 2-years follow-up, clinical evaluation after surgery averaged 4.5 years with Harris hip scores averaging 78 (range, 55-92). Three patients radiographically showed acetabular protrusion or significant wear, with 2 undergoing revision surgery. An explanted prosthesis demonstrated no appreciable damage by spectrum analysis. Because of the high mortality rate after hip fracture, the clinical benefits of oxidized zirconium hemiarthroplasty in this population, if existent, are difficult to appreciate and Currently show no benefits over standard prostheses. C1 [Sah, Alexander P.] Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA 02114 USA. [Ready, John E.] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA. RP Sah, AP (reprint author), Massachusetts Gen Hosp, Dept Orthopaed, 55 Fruit St,GRB 624, Boston, MA 02114 USA. NR 43 TC 5 Z9 5 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 J9 J ARTHROPLASTY JI J. Arthroplast. PD DEC PY 2007 VL 22 IS 8 BP 1174 EP 1180 DI 10.1016/j.arth.2006.10.018 PG 7 WC Orthopedics SC Orthopedics GA V83JY UT WOS:000205636600015 PM 18078887 ER PT J AU Vagin, O Sachs, G Tokhtaeva, E AF Vagin, Olga Sachs, George Tokhtaeva, Elmira TI The roles of the Na,K-ATPase beta 1 subunit in pump sorting and epithelial integrity SO JOURNAL OF BIOENERGETICS AND BIOMEMBRANES LA English DT Article DE Na; K-ATPase beta subunit; N-glycosylation; Adherens junctions; tight junctions; cell adhesion; epithelial integrity ID CELL-ADHESION; E-CADHERIN; N-GLYCANS; JUNCTIONS; POLARITY; ANKYRIN; SIGNALS; COMPLEX; FODRIN AB In epithelial MDCK cells, the Na,K-ATPase is co-localized with adherens junctions in all stages of monolayer formation starting from initiation of cell-cell contact. The Na,K-ATPase and adherens junction proteins stay partially co-localized even after internalization due to disruption of intercellular contacts by Ca2+ deprivation. Similar to adherens junction proteins, the Na,K-ATPase is resistant to extraction with non-ionic detergent, suggesting pump association with the cytoskeleton. In contrast, the heterodimer formed by expressed unglycosylated Na,K-ATPase beta(1) subunit and the endogenous alpha(1) subunit is easily dissociated from the adherens junctions and cytoskeleton by detergent extraction. The MDCK cells in which half of the endogenous beta(1) subunits in the lateral membrane are substituted by unglycosylated beta(1) subunits display a slower rate of cell-to-cell contact formation and decreased ability to both spread over the surface and migrate. The lack of N-glycans in the Na,K-ATPase beta(1) subunit results in an impairment of mature cell-cell junctions as detected by an increase in the paracellular permeability of the MDCK cell monolayers and by a decrease in resistance of adherens junction proteins to extraction by a non-ionic detergent. Therefore the N-glycans of the Na,K-ATPase beta(1) subunit are important for retention of the pump at the sites of cell-cell contact. Moreover, they are important for the integrity and stability of cell-cell junctions in mature epithelia. In addition, N-glycans contribute to the formation of cell-cell contacts between surface-attached dispersed cells by mediating lamellipodia formation and stabilizing the newly formed adherens junctions. C1 [Vagin, Olga; Sachs, George; Tokhtaeva, Elmira] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Vagin, Olga; Sachs, George; Tokhtaeva, Elmira] Vet Adm Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. RP Vagin, O (reprint author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. EM olgav@ucla.edu FU NIDDK NIH HHS [DK077149, DK58333, R01 DK077149-02, R01 DK077149, R01 DK077149-01A1]; PHS HHS [D53642] NR 19 TC 15 Z9 16 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0145-479X J9 J BIOENERG BIOMEMBR JI J. Bioenerg. Biomembr. PD DEC PY 2007 VL 39 IS 5-6 BP 367 EP 372 DI 10.1007/s10863-007-9103-0 PG 6 WC Biophysics; Cell Biology SC Biophysics; Cell Biology GA 252TC UT WOS:000252468500003 PM 18000747 ER PT J AU Li, G Papannagari, R Nha, KW DeFrate, LE Gill, TJ Rubash, HE AF Li, Guoan Papannagari, Ramprasad Nha, Kyung Wook DeFrate, Louis E. Gill, Thomas J. Rubash, Harry E. TI The coupled motion of the femur and patella during in vivo weightbearing knee flexion SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME LA English DT Article DE kinematics; tibiofemoral joint; patellofernoral joint; coupled knee kinematics; knee joint motion ID ANTERIOR CRUCIATE LIGAMENT; SIMULATED MUSCLE LOADS; PATELLOFEMORAL CONTACT PRESSURES; JOINT KINEMATICS; NATURAL-HISTORY; DEFICIENT KNEE; TRACKING; RECONSTRUCTION; WALKING AB The movement of the knee joint consists of a coupled motion between the tibiofemoral and patellofemoral articulations. This study measured the six degrees-of-freedom kinematics of the tibia, femur, and patella using dual-orthogonal fluoroscopy and magnetic resonance imaging. Ten normal knees,from ten living subjects were investigated during weightbearing flexion from full extension to maximum flexion. The femoral and the patellar motions were measured relative to the tibia. The femur externally rotated by 12.9 deg and the patella tilted laterally by 16.3 deg during the full range of knee flexion. Knee flexion was strongly correlated with patellar flexion (R-2=0.91), posterior femoral translation was strongly correlated to the posterior patellar translation (R-2 =0.87), and internal-external rotation of the femur was correlated to patellar tilt (R-2=0.73) and medial-lateral patellar translation (R-2=0.63). These data quantitatively indicate a kinematic coupling between the tibia, femur, and patella, and provide base line information. on normal knee joint kinematics throughout the full/ range of weightbearing flexion. The data also suggest that the kinematic coupling of tibia, femur, and patella should be considered when. investigating patellar pathologies and when developing surgical techniques to treat knee joint diseases. C1 [Li, Guoan; Papannagari, Ramprasad; DeFrate, Louis E.; Gill, Thomas J.; Rubash, Harry E.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Bioengn Lab, Boston, MA 02114 USA. [Nha, Kyung Wook] Inje Univ, Dept Orthopaed Surg, Goyang 4411706, South Korea. [Nha, Kyung Wook] Ilsan Paik Hosp, Goyang 4411706, South Korea. [Li, Guoan; Papannagari, Ramprasad; DeFrate, Louis E.; Gill, Thomas J.; Rubash, Harry E.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Li, G (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Bioengn Lab, Boston, MA 02114 USA. EM glil@partners.org FU NIAMS NIH HHS [R01-AR052408] NR 39 TC 27 Z9 29 U1 0 U2 2 PU ASME-AMER SOC MECHANICAL ENG PI NEW YORK PA THREE PARK AVE, NEW YORK, NY 10016-5990 USA SN 0148-0731 J9 J BIOMECH ENG-T ASME JI J. Biomech. Eng.-Trans. ASME PD DEC PY 2007 VL 129 IS 6 BP 937 EP 943 DI 10.1115/1.2803267 PG 7 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 251LD UT WOS:000252374000019 PM 18067400 ER PT J AU Bhattacharyya, T Chang, D Meigs, JB Estok, DM Malchau, H AF Bhattacharyya, Timothy Chang, Denis Meigs, James B. Estok, Daniel M., II Malchau, Henrik TI Mortality after periprosthetic fracture of the femur SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID FEMORAL FRACTURES; KNEE ARTHROPLASTY; HIP-ARTHROPLASTY; CLASSIFICATION; COMPLICATIONS; DEMOGRAPHICS; REPLACEMENT; DATABASES; PLATES AB Background: Management of periprosthetic femoral fractures is often complex, and few studies have documented its associated mortality. Methods: We retrospectively identified from our trauma and surgical registries 106 patients who underwent surgery for a periprosthetic femoral fracture. We then identified a contemporaneous age and sex-matched control cohort of 309 patients who had a hip fracture (femoral neck or intertrochanteric) and 311 patients who underwent primary hip or knee replacement. Mortality at one year was identified with use of the Social Security database. Results: Twelve (11%) of 106 patients died within one year following surgical treatment of a periprosthetic fracture. During the same follow-up period, fifty-one (16.5%) of 309 patients died following surgery for a hip fracture and nine (2.9%) of 311 patients died following primary joint replacement. The mortality rate after a periprosthetic femoral fracture was significantly higher (p < 0.0001) compared with that for matched patients who had undergone primary joint replacement, and it was similar to the mortality rate after a hip fracture. For periprosthetic fractures, a delay of greater than two days from admission to the time of surgery was associated with an increased mortality rate at one year (p < 0.0007). Forty-nine patients underwent revision arthroplasty for the treatment of a Vancouver type-B periprosthetic fracture, and six (12%) died. In contrast, twenty-four patients with a Vancouver type-B periprosthetic fracture were treated with open reduction and internal fixation and eight (33%) died. The difference was significant (p < 0.03). Conclusions: The mortality rate within one year following surgical treatment of periprosthetic femoral fractures is high and is similar to that after treatment for hip fractures. Because revision arthroplasty for the treatment of type-B periprosthetic fractures was associated with a one-year mortality rate that was significantly less than that after surgical treatment with open reduction and internal fixation, in instances when either treatment option is feasible, revision arthroplasty may be the preferred option. C1 Massachusetts Gen Hosp, Orthopaed Trauma Serv, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA USA. RP Bhattacharyya, T (reprint author), Massachusetts Gen Hosp, Orthopaed Trauma Serv, Boston, MA 02114 USA. NR 26 TC 84 Z9 88 U1 0 U2 9 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD DEC PY 2007 VL 89A IS 12 BP 2658 EP 2662 DI 10.2106/JBJS.F01538 PG 5 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 237UM UT WOS:000251401900011 PM 18056498 ER PT J AU Nguyen, LC deBros, FM Alston, TA AF Nguyen, Liem C. deBros, Frederic M. Alston, Theodore A. TI ST-Segment changes - Diagnosis: Accelerated junctional rhythm with retrograde P Waves SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Article DE arrhythmia; electrocardiogram; electrophysiology ID BLOCK C1 [Nguyen, Liem C.; deBros, Frederic M.; Alston, Theodore A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. RP Alston, TA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, 55 Fruit St, Boston, MA 02114 USA. EM talston@partners.org NR 5 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-0770 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD DEC PY 2007 VL 21 IS 6 BP 908 EP 909 DI 10.1053/j.jvca.2007.04.016 PG 2 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA 245BL UT WOS:000251909300029 PM 18068080 ER PT J AU Qiao, M Pardee, AB AF Qiao, Meng Pardee, Arthur B. TI Biomarkers, regerons, and pathways to lethal cancer SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE regerons; cancer; biomarkers ID GENE-EXPRESSION SIGNATURE; SERUM TUMOR-MARKERS; BREAST-CANCER; PROSTATE-CANCER; LUNG-CANCER; CELL-PROLIFERATION; COLORECTAL-CANCER; STEM-CELLS; MICRORNA; BLOOD AB Cancer is a disease of "outlaw" cells that become mutated in regulatory mechanisms. They have lost normal self controls and relationships to the whole organism. Cancers can progress by several pathways, from a normal cell to malignant cancer, from bad to worse. Questions about advisability of treatment for some cancers arise from the possibility that they are arrested during progression and so never become lethal. Techniques could be developed to determine the degree of progression and possibility for successful treatment. This article is intended to suggest a way of looking at cancer. It is not a review so references to research articles are infrequent. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. RP Pardee, AB (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM arthur_pardee@dfci.harvard.edu NR 70 TC 1 Z9 1 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD DEC 1 PY 2007 VL 102 IS 5 BP 1076 EP 1086 DI 10.1002/jcb.21534 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 239DF UT WOS:000251498100002 PM 17957698 ER PT J AU You, ZR Yang, JS Takahashi, K Yager, PH Kim, HH Qin, T Stahl, GL Alan, R Ezekowitz, B Carroll, MC Whalen, MJ AF You, Zerong Yang, Jinsheng Takahashi, Kazue Yager, Phoebe H. Kim, Hyung-Hwan Qin, Tao Stahl, Gregory L. Alan, R. Ezekowitz, B. Carroll, Michael C. Whalen, Michael J. TI Reduced tissue damage and improved recovery of motor function after traumatic brain injury in mice deficient in complement component C4 SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE complement; mice; behavior; traumatic brain injury; inflammation; genetics ID CLOSED-HEAD INJURY; CENTRAL-NERVOUS-SYSTEM; STREPTOCOCCAL INFECTION; CEREBROSPINAL-FLUID; REPERFUSION INJURY; FACTOR-B; RATS; RECEPTORS; C3; ACTIVATION AB Complement component C4 mediates C3-dependent tissue damage after systemic ischemia reperfusion injury. Activation of C3 also contributes to the pathogenesis of experimental and human traumatic brain injury (TBI); however, few data exist regarding the specific pathways (classic, alternative, and lectin) involved. Using complement knockout mice and a controlled cortical impact (CCI) model, we tested the hypothesis that the classic pathway mediates secondary damage after TBI. After CCI, C4c and C3d immunostaining were detected in cortical vascular endothelial cells in wild-type (WT) mice; however, C4c and C3d immunostaining were also detected in C1q(-/-) mice, and C3d immunostaining was detected in C4(-/-) mice. After CCI, WT and C1q(-/-) mice had similar motor deficits, Morris water maze performance, and brain lesion size. Naive C4(-/-) and WT mice did not differ in baseline motor performance, but C4(-/-) mice had reduced postinjury motor deficits (days 1 to 7, P < 0.05) and decreased brain tissue damage (days 14 and 35, P < 0.05) versus WT. Reconstitution of C4(-/-) mice with human C4 (hC4) reversed their protection against postinjury motor deficits (P < 0.05 versus vehicle), but administration of hC4 did not impair postinjury motor performance (versus vehicle) in WT mice. The protective effects of C4(-/-) were functionally distinct from the classic pathway and terminal complement, as C1q(-/-) and C3(-/-) mice had postinjury tissue damage and motor dysfunction similar to WT. Thus, C4 contributes to motor deficits and brain tissue damage after CCI by mechanism(s) fundamentally different from those involved in experimental systemic ischemia-reperfusion injury. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Boston, MA USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Vasc Med Res Unit, Boston, MA USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med,Ctr Expt T, Boston, MA USA. Harvard Univ, Sch Med, CBR Inst Biomed Res Inc, Boston, MA USA. RP Whalen, MJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02129 USA. EM mwhalen@partners.org FU NHLBI NIH HHS [HL52886, HL56086]; NIAID NIH HHS [AI42788-04]; NINDS NIH HHS [P30NS045776, R01NS47447] NR 37 TC 25 Z9 25 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD DEC PY 2007 VL 27 IS 12 BP 1954 EP 1964 DI 10.1038/sj.jcbfm.9600497 PG 11 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 231OB UT WOS:000250957800007 PM 17457366 ER PT J AU Brown, TE Spencer, TJ Anderson, CS Silverberg, A Youcha, SH AF Brown, Thomas E. Spencer, Thomas J. Anderson, Colleen S. Silverberg, Arthur Youcha, Sharon H. TI Improved executive function with triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation, in adults with ADHD SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 47th Annual Meeting of the New-Clinical-Drug-Evaluation-Unit CY JUN 11-14, 2007 CL Boca Raton, FL SP Natl Inst Ment Hlth, New Clin Drug, Evaluat Unit C1 [Brown, Thomas E.] Yale Univ, Sch Med, Hamden, CT USA. [Spencer, Thomas J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Spencer, Thomas J.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Anderson, Colleen S.; Silverberg, Arthur; Youcha, Sharon H.] Shire Dev Inc, Wayne, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1044-5463 J9 J CHILD ADOL PSYCHOP JI J. Child Adolesc. Psychopharmacol. PD DEC PY 2007 VL 17 IS 6 BP 877 EP 878 PG 2 WC Pediatrics; Pharmacology & Pharmacy; Psychiatry SC Pediatrics; Pharmacology & Pharmacy; Psychiatry GA 256QU UT WOS:000252745500022 ER PT J AU Quinones, MP Ahmadi, S Ahuja, SS Torres, V Nery, FG Olvera, R Hatch, JP Pliszka, S Soares, JC AF Quinones, Marlon P. Ahmadi, Sara Ahuja, Seema S. Torres, Victor Nery, Fabiano G. Olvera, Rene Hatch, John P. Pliszka, Steve Soares, Jair C. TI Differential involvement of inflammatory markers in adult and pediatric bipolar disorder SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 47th Annual Meeting of the New-Clinical-Drug-Evaluation-Unit CY JUN 11-14, 2007 CL Boca Raton, FL SP New Clin Drug Evaluat Unit, NIMH C1 [Quinones, Marlon P.; Soares, Jair C.] Univ N Carolina, CERT BD, Chapel Hill, NC 27515 USA. [Quinones, Marlon P.; Soares, Jair C.] Univ N Carolina, Chapel Hill, NC USA. [Ahmadi, Sara; Ahuja, Seema S.; Torres, Victor; Olvera, Rene; Hatch, John P.; Pliszka, Steve] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX USA. [Ahuja, Seema S.] Vet Adm Ctr Res AIDS & HIV 1 Infect, San Antonio, TX USA. [Ahuja, Seema S.; Nery, Fabiano G.; Olvera, Rene; Pliszka, Steve] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Nery, Fabiano G.] Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1044-5463 J9 J CHILD ADOL PSYCHOP JI J. Child Adolesc. Psychopharmacol. PD DEC PY 2007 VL 17 IS 6 BP 882 EP 883 PG 2 WC Pediatrics; Pharmacology & Pharmacy; Psychiatry SC Pediatrics; Pharmacology & Pharmacy; Psychiatry GA 256QU UT WOS:000252745500032 ER PT J AU Tohen, M Kryzhanovskaya, L Carlson, G DelBello, M Wozniak, J Kowatch, R Wagner, K Findling, R Lin, D Robertson-Plouch, C Xu, W Dittman, R Biederman, J AF Tohen, Mauricio Kryzhanovskaya, Ludmila Carlson, Gabrielle DelBello, Melissa Wozniak, Janet Kowatch, Robert Wagner, Karen Findling, Robert Lin, Daniel Robertson-Plouch, Carol Xu, Wen Dittman, Ralf Biederman, Joe TI Olanzapine in the treatment of adolescents with bipolar mania; 26-week open-label extension SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 47th Annual Meeting of the New-Clinical-Drug-Evaluation-Unit CY JUN 11-14, 2007 CL Boca Raton, FL SP Natl Inst Ment Hlth, New Clin Drug, Evaluat Unit C1 [Tohen, Mauricio; Kryzhanovskaya, Ludmila; Lin, Daniel; Robertson-Plouch, Carol; Xu, Wen] Lilly Res Labs, Indianapolis, IN USA. [Carlson, Gabrielle] SUNY Stony Brook, Sch Med, New York, NY USA. [Kowatch, Robert] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA. [Wozniak, Janet; Biederman, Joe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA. [Wagner, Karen] Univ Texas Galveston, Med Branch, Galveston, TX 77555 USA. [Findling, Robert] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Dittman, Ralf] Lilly Deutschland Med Dept, Bad Homburg, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1044-5463 J9 J CHILD ADOL PSYCHOP JI J. Child Adolesc. Psychopharmacol. PD DEC PY 2007 VL 17 IS 6 BP 882 EP 882 PG 1 WC Pediatrics; Pharmacology & Pharmacy; Psychiatry SC Pediatrics; Pharmacology & Pharmacy; Psychiatry GA 256QU UT WOS:000252745500031 ER PT J AU Brown, T Kelsey, D Holdnack, J Saylor, K Adler, L Spencer, T Paczkowski, M Schuh, K Trzepacz, P AF Brown, Thomas Kelsey, Douglas Holdnack, James Saylor, Keith Adler, Lenard Spencer, Thomas Paczkowski, Martin Schuh, Kory Trzepacz, Paula TI Atomoxetine alleviates executive function impairments in adults with ADHD SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 47th Annual Meeting of the New-Clinical-Drug-Evaluation-Unit CY JUN 11-14, 2007 CL Boca Raton, FL SP Natl Inst Ment Hlth, New Clin Drug, Evaluat Unit C1 [Brown, Thomas] Yale Univ, Sch Med, Hamden, CT USA. [Kelsey, Douglas; Paczkowski, Martin; Schuh, Kory; Trzepacz, Paula] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Holdnack, James] Harcourt Assessment, Bear, DE USA. [Saylor, Keith] Neurosci Inc, Herndon, VA USA. [Adler, Lenard] NYU, Sch Med, New York, NY USA. [Spencer, Thomas] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1044-5463 J9 J CHILD ADOL PSYCHOP JI J. Child Adolesc. Psychopharmacol. PD DEC PY 2007 VL 17 IS 6 BP 886 EP 886 PG 1 WC Pediatrics; Pharmacology & Pharmacy; Psychiatry SC Pediatrics; Pharmacology & Pharmacy; Psychiatry GA 256QU UT WOS:000252745500040 ER PT J AU Wilens, TE Adler, LA Weiss, MD Ramsey, JL Moore, RJ Renard, D Levine, LR AF Wilens, Timothy E. Adler, Lenard A. Weiss, Margaret D. Ramsey, Janet L. Moore, Rodney J. Renard, Didier Levine, Louise R. TI Atomoxetine treatment of adults with ADHD and comorbid alcohol abuse SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 47th Annual Meeting of the New-Clinical-Drug-Evaluation-Unit CY JUN 11-14, 2007 CL Boca Raton, FL SP Natl Inst Ment Hlth, New Clin Drug, Evaluat Unit C1 [Wilens, Timothy E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Adler, Lenard A.] NYU, Sch Med, New York, NY USA. [Ramsey, Janet L.; Moore, Rodney J.; Levine, Louise R.] Lilly Res Labs, Indianapolis, IN USA. [Renard, Didier] Lilly Res Labs, Brussels, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1044-5463 J9 J CHILD ADOL PSYCHOP JI J. Child Adolesc. Psychopharmacol. PD DEC PY 2007 VL 17 IS 6 BP 887 EP 887 PG 1 WC Pediatrics; Pharmacology & Pharmacy; Psychiatry SC Pediatrics; Pharmacology & Pharmacy; Psychiatry GA 256QU UT WOS:000252745500041 ER PT J AU Lyczkowski, DA Conant, KD Pulsifer, MB Jarrett, DY Grant, PE Kwiatkowski, DJ Thiele, EA AF Lyczkowski, David A. Conant, Kerry D. Pulsifer, Margaret B. Jarrett, Delma Y. Grant, P. Ellen Kwiatkowski, David J. Thiele, Elizabeth A. TI Intrafamilial phenotypic variability in tuberous sclerosis complex SO JOURNAL OF CHILD NEUROLOGY LA English DT Article DE tuberous sclerosis complex; phenotypic variation; monozygotic twins ID MUTATIONAL ANALYSIS; ATTENTION DEFICITS; TSC2; TWINS; EPILEPSY; PATHOGENESIS; DISCORDANT; DIAGNOSIS; SEVERITY; SEIZURES AB Clinical manifestations were retrospectively assessed in 5 families with tuberous sclerosis complex, including I pair of monozygotic twins. Interfamilial variation in tuber count was significantly larger than intrafamilial variation. Severity of epilepsy and cognitive profiles varied both between and within families, particularly between the monozygotic twins, and IQ was inversely related to tuber count. Cutaneous, renal, and cardiac findings did not appear to cluster within families. Although the monozygotic twins displayed similar physical manifestations of tuberous sclerosis complex (renal and cardiac hamartomas), they differed markedly in neurocognitive profiles. Phenotypic variation within these families may be explained largely as a function of the randomness of second-hit events that cause hamartomas in tuberous sclerosis complex or by as-yet-unidentified genetic modifiers. Familial variation in tuberous sclerosis complex phenotype has important implications for genetic counseling. C1 [Lyczkowski, David A.; Conant, Kerry D.; Thiele, Elizabeth A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Pulsifer, Margaret B.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Jarrett, Delma Y.; Grant, P. Ellen] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Kwiatkowski, David J.] Brigham & Womens Hosp, Genet Lab, Div Translat Med, Boston, MA 02115 USA. RP Thiele, EA (reprint author), Carol & James Herscot Ctr, Tuberous Sclerosis Complex,175 Cambridge St,Suite, Boston, MA 02114 USA. EM ethiele@partners.org NR 52 TC 18 Z9 19 U1 1 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0883-0738 J9 J CHILD NEUROL JI J. Child Neurol. PD DEC PY 2007 VL 22 IS 12 BP 1348 EP 1355 DI 10.1177/0883073807307093 PG 8 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 240MJ UT WOS:000251591400004 PM 18174550 ER PT J AU Misra, M Cord, J Prabhakaran, R Miller, KK Klibanski, A AF Misra, Madhusmita Cord, Jennalee Prabhakaran, Rajani Miller, Karen K. Klibanski, Anne TI Growth hormone suppression after an oral glucose load in children SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID GH CONCENTRATIONS; NORMAL STATURE; SECRETION; GIRLS; PULSATILE; PUBERTY; GENDER; WOMEN; MATURATION; CONSENSUS AB Background: GH nonsuppression after oral glucose is diagnostic for GH excess, but normative data are lacking in children. Adult data cannot be extrapolated to children given the pubertal increase in GH concentration. In addition, because GH levels are higher in pubertal girls than boys, nadir GH may differ across gender. Objective: Our objective was to determine whether nadir GH during an oral glucose tolerance test ( OGTT) is gender and pubertal stage specific. We hypothesized that nadir GH would be higher in girls, and at the pubertal stage known to correspond with peak height velocity ( Tanner 2-3 in girls and Tanner 3-4 in boys) and maximal GH concentrations. Subjects/Methods: A 2-h OGTT using 2.35 g/kg oral glucose ( maximum 100 g) was performed in 64 girls and 43 boys, 9-17 yr ( 10th-90th percentiles for body mass index). Girls were grouped as group 1 ( Tanner 1), group 2 ( Tanner 2-3), and group 3 ( Tanner 4-5), and boys as group 1 ( Tanner 1-2), group 2 ( Tanner 3-4), and group 3 ( Tanner 5). Results: Nadir GH was higher in girls than boys, and in group 2 girls and boys than the other two groups. The upper limit for nadir GH was highest in group 2 girls ( 1.57 ng/ml), and lower for the other two groups of girls ( 0.64 ng/ml), and for boys ( 0.50 ng/ml). All but one girl, and all boys suppressed to less than 1.0 ng/ml. There were 16 girls and five boys who had a nadir GH of more than 0.3 ng/ml. Conclusion: GH suppression after oral glucose is gender and pubertal stage specific. C1 Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp Children, Pediat Endocrine Unit, Boston, MA 02114 USA. RP Misra, M (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, 55 Fruit St, Boston, MA 02114 USA. EM mmisra@partners.org FU NCRR NIH HHS [K23 RR018851, M01-RR-01066]; NIDDK NIH HHS [DK 062249, P30 DK040561, P30 DK040561-12] NR 27 TC 9 Z9 9 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD DEC PY 2007 VL 92 IS 12 BP 4623 EP 4629 DI 10.1210/jc.2007-1244 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 237TQ UT WOS:000251399700021 PM 17878248 ER PT J AU Goldfine, AB Mun, EC Devine, E Bernier, R Baz-Hecht, M Jones, DB Schneider, BE Holst, JJ Patti, ME AF Goldfine, A. B. Mun, E. C. Devine, E. Bernier, R. Baz-Hecht, M. Jones, D. B. Schneider, B. E. Holst, J. J. Patti, M. E. TI Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID GLUCAGON-LIKE PEPTIDE-1; TYPE-2 DIABETIC-PATIENTS; SEVERE DUMPING SYNDROME; HYPERINSULINEMIC HYPOGLYCEMIA; REACTIVE HYPOGLYCEMIA; MORBID-OBESITY; PLASMA-CONCENTRATIONS; ISLET HYPERPLASIA; BARIATRIC SURGERY; BODY-WEIGHT AB Context and Objective: Hyperinsulinemic hypoglycemia is newly recognized as a rare but important complication after Roux-en-Y gastric bypass ( GB). The etiology of the syndrome and metabolic characteristics remain incompletely understood. Recent studies suggest that levels of incretin hormones are increased after GB and may promote excessive beta-cell function and/or growth. Patients and Methods: We performed a cross-sectional analysis of metabolic variables, in both the fasting state and after a liquid mixed-meal challenge, in four subject groups: 1) with clinically significant hypoglycemia [neuroglycopenia (NG)] after GB surgery, 2) with no symptoms of hypoglycemia at similar duration after GB surgery, 3) without GB similar to preoperative body mass index of the surgical cohorts, and 4) without GB similar to current body mass index of the surgical cohorts. Results: Insulin and C-peptide after the liquid mixed meal were both higher relative to the glucose level achieved in persons after GB with NG compared with asymptomatic individuals. Glucagon, glucagonlike peptide 1, and glucose-dependent insulinotropic peptide levels were higher in both post-GB surgical groups compared with both overweight and morbidly obese persons, and glucagon-like peptide 1 was markedly higher in the group with NG. Insulin resistance, assessed by homeostasis model assessment of insulin resistance, the composite insulin sensitivity index, or adiponectin, was similar in both post-GB groups. Dumping score was also higher in both GB groups but did not discriminate between asymptomatic and symptomatic patients. Notably, the frequency of asymptomatic hypogly-cemia after a liquid mixed meal was high in post-GB patients. Conclusion: A robust insulin secretory response was associated with postprandial hypoglycemia in patients after GB presenting with NG. Increased incretin levels may contribute to the increased insulin secretory response. C1 Joslin Diabet Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen, Denmark. RP Goldfine, AB (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM allison.goldfine@joslin.harvard.edu OI Holst, Jens Juul/0000-0001-6853-3805 FU NCRR NIH HHS [M01 RR001032]; NIDDK NIH HHS [DK060837, DK062948, DK36836, DK70648, K23-DK02795] NR 47 TC 157 Z9 159 U1 0 U2 3 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD DEC PY 2007 VL 92 IS 12 BP 4678 EP 4685 DI 10.1210/jc.2007-0918 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 237TQ UT WOS:000251399700029 PM 17895322 ER PT J AU Mitsiades, CS Hayden, P Kotoula, V McMillin, DW McMullan, C Negri, J Delmore, JE Poulaki, V Mitsiades, N AF Mitsiades, Constantine S. Hayden, Patrick Kotoula, Vassiliki McMillin, Douglas W. McMullan, Ciaran Negri, Joseph Delmore, Jake E. Poulaki, Vassiliki Mitsiades, Nicholas TI Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID APOPTOSIS-INDUCING LIGAND; SMALL-MOLECULE INHIBITORS; FAMILY-MEMBERS; LUNG-CANCER; TUMOR-CELLS; DEATH; ADDICTION; PEPTIDES; BCL-X(L); GENE AB Context: The Bcl-2 family of proteins regulates apoptosis in various models and may represent a promising therapeutic target in human malignancies. Objective/Methods: We evaluated the sensitivity of thyroid carcinoma cell lines ( two papillary, one follicular, two anaplastic, three medullary) in vitro to BH3I-1 and BH3I-2 ', two cell-permeable inhibitors of the Bcl-2 homology (BH)-3 domain-mediated interaction between proapoptotic and antiapoptotic Bcl-2 family members. The thyroid carcinoma cell line FRO was stably transfected with cDNA for Bcl-2 or constitutively active Akt and evaluated for sensitivity to BH3-domain inhibition. Results: BH3-domain inhibition disrupted the mitochondrial membrane potential in thyroid carcinoma cells, induced caspase-dependent apoptosis, and potently sensitized them to sublethal concentrations of doxorubicin and the proteasome inhibitor bortezomib (Velcade). Overexpression of constitutively active Akt suppressed BH3I-1- induced cell death. Bcl-2-overexpressing FRO cells were more resistant to conventional chemotherapeutic agents ( such as doxorubicin) but significantly more sensitive to BH3I-1 than control cells and were found to overexpress caspase-9, caspase-8, Bmf, Bok, and Bik transcripts and express less A1, BRaf, and FLIP transcripts. Conclusions: Bcl-2 expression protects thyroid carcinomas against chemotherapy-induced apoptosis. Nevertheless, overexpression of Bcl-2 may result in "oncogene addiction" of the cancer cell, which can be exploited by using BH3-domain inhibitors alone or in combination with other agents, including conventional chemotherapeutics (such as doxorubicin) or novel targeted therapies ( such as the proteasome inhibitor bortezomib), for the treatment of aggressive thyroid cancer, including the medullary and anaplastic types. C1 Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02114 USA. Aristotle Univ Thessaloniki, Sch Med, Dept Pathol, Thessaloniki 54006, Greece. RP Mitsiades, CS (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Mayer Bldg,Rm M555,Binney St, Boston, MA 02115 USA. EM constantine_mitsiades@dfci.harvard.edu NR 40 TC 16 Z9 17 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD DEC PY 2007 VL 92 IS 12 BP 4845 EP 4852 DI 10.1210/jc.2007-0942 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 237TQ UT WOS:000251399700054 PM 17848408 ER PT J AU Blinderman, CD AF Blinderman, Craig D. TI Jewish law and end-of-life decision making: A case report SO JOURNAL OF CLINICAL ETHICS LA English DT Editorial Material ID ADVANCED DEMENTIA; FUTILITY; AUTONOMY; PATIENT C1 Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA. RP Blinderman, CD (reprint author), Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA. EM cblinderman@partners.org NR 25 TC 2 Z9 2 U1 0 U2 1 PU UNIV PUBLISHING GROUP PI HAGERSTOWN PA 138 W WASHINGTON ST, STE 403-405, HAGERSTOWN, MD 21740 USA SN 1046-7890 J9 J CLIN ETHIC JI J. Clin. Ethics PD WIN PY 2007 VL 18 IS 4 BP 384 EP 390 PG 7 WC Ethics; Social Sciences, Biomedical SC Social Sciences - Other Topics; Biomedical Social Sciences GA 257UG UT WOS:000252823600013 PM 18321000 ER PT J AU Demetri, GD AF Demetri, George D. TI Structural reengineering of imatinib to decrease cardiac risk in cancer therapy SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Editorial Material ID GASTROINTESTINAL STROMAL TUMORS; CARDIOTOXICITY; MESYLATE; TARGETS AB Imatinib, a selective, small-molecule tyrosine kinase inhibitor, has fife-saving clinical activity in certain cancers, but questions have been raised about the potential for cardiac toxicity through inhibition of its target, ABL kinase. In this issue of the JCI, Fernandez et al. describe a novel method by which the ABL-inhibitory activity of imatinib was deleted by modifying its chemical structure (see the related article beginning on page 4044). The anticancer activity of the reengineered agent, called WBZ_4, was instead preserved against gastrointestinal stromal tumors in both in vitro and in vivo models via inhibition of KIT tyrosine kinase, and the desired safety was demonstrated with less cardiotoxicity of V.7BZ_4 compared with imatinib via the inhibition of JNK. The study shows that structural reengineering of a kinaseinhibitory drug to improve tolerability while preserving efficacy is feasible. C1 Dana Farber Canc Inst, Ludwig Ctr Canc Res, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Ludwig Inst Canc Res, New York, NY USA. RP Demetri, GD (reprint author), Dana Farber Canc Inst, Ludwig Ctr Canc Res, Dana 1212,44 Binney St, Boston, MA 02115 USA. EM gdemetri@partners.org NR 15 TC 23 Z9 24 U1 0 U2 0 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD DEC PY 2007 VL 117 IS 12 BP 3650 EP 3653 DI 10.1172/JCI34252 PG 4 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 237SL UT WOS:000251396600011 PM 18060025 ER PT J AU Scadden, DT AF Scadden, David T. TI The weight of cell identity SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Editorial Material ID CIRCULATING PROGENITOR CELLS; HEMATOPOIETIC STEM-CELLS; B-CELLS; HEPATOCYTES AB Recent studies involving molecular modification of adult somatic cells have pointed to a remarkable plasticity in cell identity. In this issue of the JCI, Koh and colleagues assessed whether bone marrow-derived cells could alter their fate under circumstances conducive to adipocyte generation in vivo (see the related article beginning on page 3684). These cells remained true to their roots, indicating how difficult it will be to exploit cell plasticity for therapeutic purposes. C1 Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. RP Scadden, DT (reprint author), Massachusetts Gen Hosp, Ctr Regenerat Med, 185 Cambridge St,CPZN-4265A, Boston, MA 02114 USA. EM scadden.david@mgh.harvard.edu NR 16 TC 6 Z9 6 U1 0 U2 0 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD DEC PY 2007 VL 117 IS 12 BP 3653 EP 3655 DI 10.1172/JCI34181 PG 3 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 237SL UT WOS:000251396600012 PM 18060026 ER PT J AU Gupta, K MacIntyre, A Vanasse, G Dembry, LM AF Gupta, Kalpana MacIntyre, Ann Vanasse, Gary Dembry, Louise-Marie TI Trends in prescribing beta-lactam antibiotics for treatment of community-associated methicillin-resistant Staphylococcus aureus infections SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID VALENTINE LEUKOCIDIN GENES; FIELD GEL-ELECTROPHORESIS; SOFT-TISSUE INFECTIONS; USA-300 CLONE; EMERGENCE; SKIN; EPIDEMIOLOGY; PNEUMONIA; OUTCOMES; ADULTS AB Rates of prescribing of beta-lactam antibiotics as initial empirical therapy for patients with skin and soft tissue infections (SSTIs) caused by molecularly and epidemiologically characterized community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) isolates were assessed over a 3-year period. A prospectively developed database was used to calculate the prevalence of CA-MRSA SSTIs from 2004 to 2006. Molecular characterization of the MRSA isolate and medical record review for assessment of initial antimicrobial therapy were performed on a subset of patients. Among 2,636 patients with S. aureus SSTIs, the prevalence of CA-MRSA was 9% in 2004, 16% in 2005, and 21% in 2006 (P < 0.0001, chi-square test for trend). Seventy-five percent of CA-MRSA isolates tested were of the USA 300 or 400 clone type. Ninety-two percent of CA-MRSA isolates tested were positive for Panton-Valentine leukocidin, of which 90% carried staphylococcal chromosomal cassette mec type IV. The rate of use of a beta-lactam antibiotic as initial empirical therapy for patients with CA-MRSA SSTIs was 86%, 77%, and 60% in 2004, 2005, and 2006, respectively (P = 0.04, chi-square test for trend). Thirty percent of beta-lactam-treated patients had a documented risk factor for CA-MRSA infection. The use of a beta-lactam antibiotic as initial empirical therapy for CA-MRSA SSTIs has decreased significantly over the past 3 years. However, even as the prevalence of CA-MRSA SSTIs approaches 25%, the majority of patients are still receiving inactive antimicrobial therapy. Further evaluation of the outcomes associated with discordant therapy for CA-MRSA SSTIs is needed. C1 [Gupta, Kalpana] VA Connecticut Hlth Care Syst, Dept Med, West Haven, CT USA. [Gupta, Kalpana; MacIntyre, Ann; Dembry, Louise-Marie] Yale Univ, Sch Med, Dept Med, Infect Dis Sect, New Haven, CT 06520 USA. [Vanasse, Gary] Yale Univ, Sch Med, Dept Med, Sect Hematol, New Haven, CT 06520 USA. [MacIntyre, Ann; Dembry, Louise-Marie] Yale New Haven Med Ctr, Qual Improvement Support Serv Dept, New Haven, CT USA. RP Gupta, K (reprint author), VA Boston Hlth Care Syst, 150 S Huntington Ave,151 MAV, Boston, MA 02130 USA. EM Kalpana.gupta@va.gov NR 29 TC 12 Z9 12 U1 1 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 2007 VL 45 IS 12 BP 3930 EP 3934 DI 10.1128/JCM.01510-07 PG 5 WC Microbiology SC Microbiology GA 241AT UT WOS:000251630000010 PM 17942648 ER PT J AU Swenson, JM Brasso, WB Ferraro, MJ Hardy, DJ Knapp, CC McDougal, LK Reller, LB Sader, HS Shortridge, D Skov, R Weinstein, MP Zimmer, BL Patel, JB AF Swenson, Jana M. Brasso, William B. Ferraro, Mary Jane Hardy, Dwight J. Knapp, Cynthia C. McDougal, Linda K. Reller, L. Barth Sader, Helio S. Shortridge, Dee Skov, Robert Weinstein, Melvin P. Zimmer, Barbara L. Patel, Jean B. TI Detection of inducible clindamycin resistance in staphylococci by broth microdilution using erythromycin-clindamycin combination wells SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID INDUCTION AB A study conducted by 11 laboratories investigated the ability of four combinations of erythromycin (ERY) and clindamycin (CC) (ERY and CC at 4 and 0.5, 6 and 1, 8 and 1.5, and 0.5 and 2 mu g/ml) in a single well of a broth microdilution panel to predict the presence of inducible CC resistance. Each laboratory tested approximately 30 Staphylococcus aureus isolates and 20 coagulase-negative staphylococcus (CoNS) isolates in a panel using cation-adjusted Mueller-Hinton broth from three different manufacturers. Only the strains resistant to ERY and those susceptible or intermediate to CC were included in the analysis (S. aureus, n = 333; CoNS, n = 97). Results of the D-zone test were used as the gold standard. After an 18-h incubation, the combination of 4 mu g/ml ERY and 0.5 mu g/ml CC performed the best, with 98 to 100% sensitivity and 100% specificity for both organism groups. After a 24-h incubation, the ERY-CC combinations of 4 and 0.5, 6 and 1, and 8 and 1.5 mu g/ml correlated well with the D-zone test. C1 [Swenson, Jana M.; McDougal, Linda K.; Patel, Jean B.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Antimicrobial Resistance Team, Atlanta, GA 30333 USA. [Brasso, William B.] BD Diagnost Syst, Sparks, MD 21152 USA. [Ferraro, Mary Jane] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hardy, Dwight J.] Univ Rochester, Med Ctr Hosp, Rochester, NY 14642 USA. [Knapp, Cynthia C.] Trek Diagnost Syst, Cleveland, OH 44131 USA. [Reller, L. Barth] Duke Univ Hosp, Durham, NC 27710 USA. [Sader, Helio S.] JMI Labs, Iowa City, IA 52317 USA. [Shortridge, Dee] BioMerieux Inc, Hazelwood, MO 63042 USA. [Skov, Robert] Statens Serum Inst, DK-2300 Copenhagen, Denmark. [Weinstein, Melvin P.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA. [Zimmer, Barbara L.] Dade Behring MicroScan Inc, West Sacramento, CA 95691 USA. RP Swenson, JM (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Antimicrobial Resistance Team, Mailstop G08,1600 Clifton Rd, Atlanta, GA 30333 USA. EM jms1@cdc.gov NR 8 TC 7 Z9 11 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 2007 VL 45 IS 12 BP 3954 EP 3957 DI 10.1128/JCM.01501-07 PG 4 WC Microbiology SC Microbiology GA 241AT UT WOS:000251630000014 PM 17942655 ER PT J AU Fox, JG Boutin, SR Handt, LK Taylor, NS Xu, SL Rickman, B Marini, RP Dewhirst, FE Paster, BJ Motzel, S Klein, HJ AF Fox, James G. Boutin, Samuel R. Handt, Laurence K. Taylor, Nancy S. Xu, Shilu Rickman, Barry Marini, Robert P. Dewhirst, Floyd E. Paster, Bruce J. Motzel, Sherri Klein, Hilton J. TI Isolation and characterization of a novel helicobacter species, "Helicobacter macacae," from rhesus monkeys with and without chronic idiopathic colitis SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID PHYLOGENY; DISEASES; CHILDREN; PYLORI; 16S AB Chronic idiopathic colitis is a common clinical entity in young captive rhesus monkeys. Eight isolates, cultured from five monkeys in colony 1 with endemic diarrhea and three from colony 2 without diarrhea, were grown under microaerobic conditions on selective agar and were classified by full 16S rRNA sequence, biochemical, and phenotypic analysis as a novel helicobacter, "Helicobacter macacae" (proposed name). All eight strains of H. macacae had 99.5% identical 16S rRNA sequences. C1 [Fox, James G.; Boutin, Samuel R.; Taylor, Nancy S.; Xu, Shilu; Rickman, Barry; Marini, Robert P.] MIT, Div Comparat Med, Cambridge, MA 02139 USA. [Dewhirst, Floyd E.; Paster, Bruce J.] Forsyth Inst, Dept Mol Genet, Boston, MA USA. [Handt, Laurence K.; Motzel, Sherri; Klein, Hilton J.] Merck & Co Inc, Merck Res Lab, West Point, PA USA. RP Fox, JG (reprint author), MIT, Div Comparat Med, 77 Massachusetts Ave,Bldg 16,Rm 825C, Cambridge, MA 02139 USA. EM jgfox@mit.edu FU NCI NIH HHS [R01 CA067529, R01 CA67529]; NCRR NIH HHS [T32 RR007036, T32 RR07036]; NIEHS NIH HHS [P30 ES02109, P30 ES002109] NR 14 TC 20 Z9 20 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 2007 VL 45 IS 12 BP 4061 EP 4063 DI 10.1128/JCM.01100-07 PG 3 WC Microbiology SC Microbiology GA 241AT UT WOS:000251630000034 PM 17928421 ER PT J AU Kawai, M Hrachovy, RA Franklin, PJ Foreman, PJ AF Kawai, Makoto Hrachovy, Richard A. Franklin, Peggy J. Foreman, Perry J. TI Video-EEG monitoring in a geriatric veteran population SO JOURNAL OF CLINICAL NEUROPHYSIOLOGY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Clinical-Neurophysiology-Society CY NOV 01-05, 2006 CL Chicago, IL DE video-EEG monitoring; veteran; epilepsy; elderly; nonepileptic ID NONEPILEPTIC SEIZURES; EPILEPSY AB Video-EEG monitoring is a standard too] to evaluate possible seizures. However, there are limited data available for the elderly population, and no data are available for the elderly veteran population. The records of 71 veterans ages 60 and older who underwent video-EEG monitoring at the Michael E. DeBakey Veterans Affairs Medical Center from 1999 to 2006 were reviewed. The average age was 68 years, and 94% were male. Typical events occurred in 34 of 71 patients (48%). Twelve patients (35%) had epileptic seizures; most were temporal lobe seizures (75%). The remaining 22 patients (65%) had a nonepileptic event. Of these, 10 (45%) had psychogenic nonepileptic seizures and 12 (55%) had other physiologic nonepileptic events. AEDs were previously prescribed in 14 of the 22 nonepileptic patients (64%). In our study, most events were nonepileptic, partly reflecting the unique nature of the VA population. There was a slightly higher number of physiologic nonepileptic events; however, psychogenic seizures are also frequently seen. Most of the patients with nonepileptic events were previously treated with AEDs. Most of the epileptic events captured were temporal lobe seizures. Video-EEG monitoring in the elderly is useful in the characterization of paroxysmal events. C1 [Kawai, Makoto; Hrachovy, Richard A.; Franklin, Peggy J.; Foreman, Perry J.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Kawai, Makoto; Hrachovy, Richard A.; Foreman, Perry J.] Baylor Coll Med, Dept Neurol, Peter Kellaway Sect Neurophysiol, Houston, TX 77030 USA. RP Kawai, M (reprint author), Toyota Mem Hosp, Heiwa Cho 1-1, Toyota, Aichi 4515813, Japan. EM makoto_kawai_ab@mail.toyota.co.jp NR 14 TC 5 Z9 5 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0736-0258 J9 J CLIN NEUROPHYSIOL JI J. Clin. Neurophysiol. PD DEC PY 2007 VL 24 IS 6 BP 429 EP 432 DI 10.1097/WNP.0b013e31815ba0c8 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 242SI UT WOS:000251745600002 PM 18090522 ER PT J AU Hochster, HS Luo, WX Popa, EC Lyman, BT Mulcahy, M Beatty, PA Benson, AB AF Hochster, Howard S. Luo, Weixiu Popa, Elizabeta C. Lyman, Bruce T. Mulcahy, Mary Beatty, Peter A. Benson, Al Bowen TI Phase II study of uracil-tegafur with leucovorin in elderly (>= 75 years old) patients with colorectal cancer: ECOG 1299 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 41st Annual Meeting of the American-Society-of-Clinical-Oncology CY MAY 13-17, 2005 CL Orlando, FL SP Amer Soc Clin Oncol ID ORAL LEUCOVORIN; POOLED ANALYSIS; 5-FLUOROURACIL-BASED CHEMOTHERAPY; 1ST-LINE TREATMENT; CLINICAL-TRIALS; FLUOROURACIL; PHARMACOKINETICS; CAPECITABINE; EFFICACY; INFUSION AB Purpose To evaluate the tolerability and effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients with advanced colorectal cancer. Patients and Methods Patients >= 75 years of age with previously untreated colorectal cancer were eligible for this phase II, single-arm, open-label, multicenter cooperative group clinical trial. UFT 100 mg/m(2) plus LV 30 mg orally every 8 hours for 28 days every 35 days was administered until progression. Results Fifty-eight patients were enrolled between June 2000 and July 2001, and 55 were treated. The median age of treated patients was 81 years (range, 75 to 90 years), 26 patients were (47%) women, and 80% had good performance status (0 to 1). The observed overall response rate was 22% (95% CI, 11.8% to 35.0%). The estimated median overall survival time was 13.0 months (95% CI, 9.6 to 17.4 months), and median progression-free survival time was 4.6 months (95% CI, 2.6 to 6.7 months). Among the 56 treated patients (including one ineligible patient), 31 (55%) experienced grade 3 to 4 toxicities, most commonly diarrhea (25%) and GI toxicity (36%), with patients older than 85 years of age at highest risk. Conclusion The results of this trial support the efficacy of oral UFT/LV in elderly patients with colorectal cancer. The regimen is tolerated moderately well overall, particularly as compared with other fluoropyrimidine regimens, although there is increased GI toxicity in the most elderly. These results suggest that studies using newer oral fluoropyrimidine analogs should be investigated in this patient population. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Northwestern Univ, Chicago, IL 60611 USA. Meriter Hosp, Madison, WI USA. RP Hochster, HS (reprint author), NYU, Inst Canc, 160 E 34th St, New York, NY 10016 USA. EM howard.hochster@med.nyu.edu FU NCI NIH HHS [CA23318]; PHS HHS [11083, 66636, 16087, 17145, 21076, 21115] NR 22 TC 19 Z9 23 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2007 VL 25 IS 34 BP 5397 EP 5402 DI 10.1200/JCO.2006.10.4521 PG 6 WC Oncology SC Oncology GA 272UL UT WOS:000253885700011 PM 18048821 ER PT J AU Papakostas, GI Montgomery, SA Thase, ME Katz, JR Krishen, A Tucker, VL AF Papakostas, George I. Montgomery, Stuart A. Thase, Michael E. Katz, Judith R. Krishen, Alok Tucker, Vivian L. TI Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: A pooled survival analysis of 7 double-blind, randomized clinical trials SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID SUSTAINED-RELEASE; ANTIDEPRESSANT EFFICACY; VENLAFAXINE-XR; FLUOXETINE; PAROXETINE; SERTRALINE; ESCITALOPRAM; OUTPATIENTS; REBOXETINE; TIANEPTINE AB Objective: Several controlled studies, as well as a meta-analysis, suggest that the efficacy of bupropion, a norepinephrine-dopamine reuptake inhibitor, is comparable to that of the selective serotonin reuptake inhibitors (SSRIs). The current analysis was undertaken to determine if these antidepressants differ in rapidity of clinical effect. Method: Individual patient data were obtained from 7 double-blind, randomized studies of 8 weeks' duration that compared bupropion (N=836) and SSRIs (sertraline, paroxetine, fluoxetine, and escitalopram; N=836). Time to first response and first remission were compared between treatment groups with the use of Cox proportional hazards regression models, stratified by trial number, with depression severity at baseline as a covariate. A secondary analysis compared outcomes in the 2 bupropion versus escitalopram studies. Random-effects metaanalyses were then conducted to confirm the survival-analysis findings. Results: There was no statistically significant difference between bupropion and the SSRIs in time to first response (hazard ratio [HR]=0.955; p=.43) and first remission (HR=1.00; p=.97). Similarly, there was no statistically significant difference between bupropion and escitalopram in time to first response (HR=0.897; p=.29), and first remission (HR=0.999; p=.99). These results were confirmed with the use of randomeffects meta-analyses (p >.05, all 4 analyses). Conclusion: There does not appear to be any statistically detectable difference in the rapidity of antidepressant effect between bupropion and the SSRIs overall or escitalopram specifically. C1 [Papakostas, George I.; Katz, Judith R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Montgomery, Stuart A.] Imperial Coll Sch Med, London, England. [Thase, Michael E.] Univ Penn, Philadelphia, PA 19104 USA. [Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Krishen, Alok; Tucker, Vivian L.] GlaxoSmithKline Inc, Durham, NC USA. RP Papakostas, GI (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 15 Parkman St,WACC 812, Boston, MA 02114 USA. EM gpapakostas@partners.org RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 FU NIMH NIH HHS [K23 MH069629] NR 32 TC 13 Z9 13 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD DEC PY 2007 VL 68 IS 12 BP 1907 EP 1912 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 246ZC UT WOS:000252045900011 PM 18162022 ER PT J AU Davis, LL Frazier, EC Gaynes, BN Trivedi, MH Wisniewski, SR Fava, M Barkin, J Kashner, M Shelton, RC Alpert, JE Rush, AJ AF Davis, Lori L. Frazier, Elizabeth C. Gaynes, Bradley N. Trivedi, Madhukar H. Wisniewski, Stephen R. Fava, Maurizio Barkin, Jennifer Kashner, Michael Shelton, Richard C. Alpert, Jonathan E. Rush, A. John TI Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID SEQUENCED TREATMENT ALTERNATIVES; INTERACTIVE VOICE RESPONSE; SPECTRUM DISEASE; MAJOR DEPRESSION; CLINICAL-FEATURES; LINKAGE ANALYSIS; ALCOHOLISM; SCALE; SYMPTOMATOLOGY; QUESTIONNAIRE AB Objective: This report compares the baseline demographic and clinical characteristics of outpatients with nonpsychotic major depressive disorder (MDD) and a family history of substance use disorder (SUD) versus those with MDD and no family history of SUD. Method: Using data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, we grouped participants with MDD (DSM-IV criteria) according to presence or absence of family history of SUD based on participant report. Between-group comparisons were made of demographic and clinical characteristics, depressive symptoms, and psychiatric comorbidities. Patients were enrolled from July 2001 until August 2004. Results: Of 4010 participants, 46% had a positive family history of SUD. Those with a positive family history were less likely to be Hispanic (p=.0029) and more likely to be female (p=.0013). They were less educated (p=.0120), less likely to be married (p <.01), and more likely to be divorced (p <.01). They also reported an earlier age at onset of MDD, greater length of illness, and more major depressive episodes (all p <.001). They had an increased likelihood of recurrent MDD, more prior suicide attempts, and more concurrent psychiatric comorbidities, including posttraumatic stress disorder, SUD, and generalized anxiety disorder (all p <.0001). Conclusion: Depressed patients with a family history of SUD had a more severe previous course of depression, were more likely to have attempted suicide, and had a greater burden of psychiatric comorbid conditions than patients without such a family history. These findings represent important clinical features to be considered in the evaluation and treatment planning of patients with MDD. C1 [Davis, Lori L.] VA Med Ctr 151, Dept Vet Affairs, Tuscaloosa, AL 35404 USA. [Davis, Lori L.] Univ Alabama, Sch Med, Dept Psychiat, Birmingham, AL USA. [Frazier, Elizabeth C.] Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA. [Gaynes, Bradley N.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. [Trivedi, Madhukar H.; Kashner, Michael; Rush, A. John] Univ Texas Dallas, SW Med Ctr, Dept Psychiat, Dallas, TX USA. [Wisniewski, Stephen R.; Barkin, Jennifer] Univ Pittsburgh, Epidemiol Data Ctr, Pittsburgh, PA USA. [Fava, Maurizio; Alpert, Jonathan E.] Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, Boston, MA 02114 USA. [Shelton, Richard C.] Vanderbilt Univ, Dept Psychol, Nashville, TN 37240 USA. RP Davis, LL (reprint author), VA Med Ctr 151, Dept Vet Affairs, 3701 Loop Rd E, Tuscaloosa, AL 35404 USA. EM lori.davis@va.gov OI Wisniewski, Stephen/0000-0002-3877-9860; Alpert, Jonathan/0000-0002-4332-908X; Gaynes, Bradley/0000-0002-8283-5030; Rush, Augustus/0000-0003-2004-2382 FU NIMH NIH HHS [N01MH90003] NR 31 TC 8 Z9 8 U1 0 U2 4 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD DEC PY 2007 VL 68 IS 12 BP 1931 EP 1938 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 246ZC UT WOS:000252045900014 PM 18162025 ER PT J AU Joffe, H Petrillo, LF Viguera, AC Gottshcall, H Soares, CN Hall, JE Cohen, LS AF Joffe, Hadine Petrillo, Laura F. Viguera, Adele C. Gottshcall, Hannah Soares, Claudio N. Hall, Janet E. Cohen, Lee S. TI Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: A preliminary report SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 158th Annual Scientific Meeting of the American-Psychiatric-Association CY MAY 21-26, 2005 CL Atlanta, GA SP Amer Psychiat Assoc ID DYSPHORIC DISORDER; MENSTRUAL-CYCLE; FREE INTERVAL; SYMPTOMS; DROSPIRENONE; MOOD; EXACERBATION; IMPROVEMENT; ESTROGEN AB Objective: Despite the efficacy of antidepressants, depression can break through premenstrually. Oral contraceptive pills (OCPs) stabilize reproductive hormones and treat premenstrual dysphoric disorder. Management of depression that breaks through premenstrually has not been studied. Method: Women taking antidepressants with successfully treated depression, except during the late luteal phase (Montgomery-Asberg Depression Rating Scale [MADRS] score >= 15) and high late-luteal phase (Daily Rating of Severity of Problems scores) were randomly assigned to open-label ethinyl estradiol (EE) 30 mu g/day plus drospirenone 3 mg/day (EE/DRSP) for 21 days and double-blinded treatment with EE 30 mu g/day or placebo for days 22 through 28 of 2 cycles. Participants were recruited from community and psychiatry outpatient clinics and enrolled into this study in 2004 - 2005. Results: Of 25 subjects who received EE/DRSP (N=12 with EE and N=13 with placebo), 21 completed treatment. For study completers, premenstrual MADRS (p=.0019) and Daily Rating of Severity of Problems scores (p=.0001) improved significantly in both groups. Outcome did not differ between groups. Conclusion: This study provides preliminary evidence that addition of EE/DRSP (EE) to antidepressants may treat premenstrual breakthrough of depression. Stabilizing hormone levels with EE/DRSP may provide an important therapeutic option for women taking antidepressants whose symptoms break through premenstrually. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Perinatal & Repord Psychiat Program, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrine Unit, Boston, MA 02114 USA. RP Joffe, H (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Perinatal & Repord Psychiat Program, 185 Cambridge St,2nd Floor, Boston, MA 02114 USA. EM hjoffe@partners.org NR 30 TC 13 Z9 14 U1 2 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD DEC PY 2007 VL 68 IS 12 BP 1954 EP 1962 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 246ZC UT WOS:000252045900018 PM 18162029 ER PT J AU Goff, DC Keefe, R Citrome, L Davy, K Krystal, JH Large, C Thompson, TR Volavka, J Webster, EL AF Goff, Donald C. Keefe, Richard Citrome, Leslie Davy, Katherine Krystal, John H. Large, Charles Thompson, Thomas R. Volavka, Jan Webster, Elizabeth L. TI Lamotrigine as add-on therapy in schizophrenia - Results of 2 placebo-controlled trials SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Article ID TREATMENT-RESISTANT SCHIZOPHRENIA; GLUTAMATE-RECEPTOR AGONIST; RATING-SCALE; DOUBLE-BLIND; KETAMINE; ANTAGONIST; CLOZAPINE; ATTENUATION; DYSFUNCTION; INHIBITION AB Objective: Lamotrigine previously was found to attenuate ketamine-induced behavioral changes and, in 2 placebo-controlled trials, to improve psychosis when added to antipsychotic medication. We sought to evaluate the potential role of lamotrigine augmentation in schizophrenia patients resistant to atypical antipsychotic medication. Methods: Two multicenter, randomized, double-blind, 12-week, parallel-group trials were conducted to compare flexibly dosed lamotrigine (100-400 mg/d) with placebo as add-on treatment in schizophrenia patients with stable, residual psychotic symptoms. The primary end point was changed in Positive and Negative Syndrome Scale total score at week 12. Results: Two hundred seventeen patients were enrolled in study 1 and 212 in study 2; completion rates in the intent-to-treat samples were 71% and 74%, respectively, and did not differ between treatment groups. Overall, mean Positive and Negative Syndrome Scale total scores improved in both studies and did not differ between treatment groups. In study 1, the Scale for Assessment of Negative Symptoms total score and Clinical Global Impression improved more with placebo than with lamotrigine; in study 2, the cognitive composite score improved more with lamotrigine than with placebo. Conclusions: Results from these 2 studies do not support the use of lamotrigine as an adjunct to atypical antipsychotics in patients with refractory psychosis. It is unclear why positive results from previous lamotrigine trials were not replicated. The positive effect of lamotrigine on cognition in one trial, while of uncertain significance, may rnerit further study. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Duke Univ, Med Ctr, Durham, NC USA. Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA. GlaxoSmithKline Inc, Harlow, Essex, England. GlaxoSmithKline Inc, Verona, Italy. GlaxoSmithKline Inc, Res Triangle Pk, NC USA. RP Goff, DC (reprint author), 25 Staniford St, Boston, MA 02114 USA. EM goff@psych.mgh.harvard.edu RI Citrome, Leslie/G-6428-2012; OI Citrome, Leslie/0000-0002-6098-9266 NR 34 TC 68 Z9 69 U1 3 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD DEC PY 2007 VL 27 IS 6 BP 582 EP 589 DI 10.1097/jcp.0b013e31815abf34 PG 8 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 234RO UT WOS:000251181600005 PM 18004124 ER PT J AU Thase, ME Pritchett, YL Ossanna, MJ Swindle, RW Xu, J Detke, MJ AF Thase, Michael E. Pritchett, Yili Lu Ossanna, Melissa J. Swindle, Ralph W. Xu, Jimmy Detke, Michael J. TI Efficacy of duloxetine and selective serotonin reuptake inhibitors - Comparisons as assessed by remission rates in patients with major depressive disorder SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Article; Proceedings Paper CT 42nd Meeting of the American-College-of-Neuropsychopharmacology CY DEC 07-11, 2003 CL San Juan, PR SP Amer Coll Neuropsychopharmacol ID PAROXETINE-CONTROLLED TRIAL; CLINICAL-TRIALS; PLACEBO; VENLAFAXINE; ANTIDEPRESSANTS; FOOD AB It has been proposed that serotonin and norepinephrine reuptake inhibitors (SNRIs) may result in higher remission rates of major depressive disorder than therapy with selective serotonin reuptake inhibitors (SSRIs). To test this hypothesis, a meta-analysis of individual patient data (N = 1833) was performed for the complete set of 6 phase II/III studies that compared duloxetine (fixed doses; range, 40-120 mg/d) with 2 SSRIs (paroxetine or fluoxetine; 20 mg/d) in outpatients with major depressive disorder. Remission was defined as an end point score of less than or equal to 7 on the 17-item Hamilton Rating Scale for Depression (HAMD(17)); alternate outcome criteria were also examined, as were remission rates among the 1044 patients with moderate-to-severe depression (HAMD17 total score greater than or equal to 19). The HAMD(17) remission rates were 40.3% (351/871), 38.3% (162/423), and 28.4% (144/507) for duloxetine, the 2 SSRIs, and placebo, respectively. Both active treatments were superior to placebo; the difference between duloxetine and SSRIs was not statistically significant. Similar findings were observed for alternate outcomes. Duloxetine therapy was significantly more effective than therapy with the 2 SSRIs for patients with more severe depression, with remission rates of 35.9% (183/510) versus 28.6% (70/245) (P = 0.046). A secondary analysis of dose-response relationships indicated that this advantage was not attributable to the studies using higher doses of duloxetine. Thus, whereas duloxetine and the 2 SSRIs were comparably efficacious overall, therapy with the serotonin and norepinephrine reuptake inhibitor resulted in a significantly higher remission rate among patients with moderate-to-severe depression. C1 Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA. Univ Pittsburgh, Ctr Med, Dept Psychiat, Pittsburgh, PA USA. Abbott Labs, Abbott Pk, IL 60064 USA. Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46204 USA. McLean Hosp, Dept Psychiat, Belmont, MA 02178 USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA USA. Eli Lilly & Co, Indianapolis, IN 46285 USA. RP Thase, ME (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3535 Market St,Room 689, Philadelphia, PA 19104 USA. EM thase@mail.med.upenn.edu NR 23 TC 71 Z9 80 U1 6 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD DEC PY 2007 VL 27 IS 6 BP 672 EP 676 DI 10.1097/jcp.0b013e31815a4412 PG 5 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 234RO UT WOS:000251181600016 PM 18004135 ER PT J AU Sugiyama, A Sugiura, M Piris, A Tomita, Y Mihm, MC AF Sugiyama, Akiko Sugiura, Mitsuhiro Piris, Adriano Tomita, Yasushi Mihm, Martin C. TI Apocrine cystadenoma and apocrine hidrocystoma: examination of 21 cases with emphasis on nomenclature according to proliferative features SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Article ID EXPRESSION AB Background: Apocrine cystadenoma (AC) and apocrine hidrocystoma (AH) have been used interchangeably in the literature to designate cystic lesions of apocrine glands. Methods: We reviewed 21 cases with biopsies of apocrine cystic lesions diagnosed as AH or AC stained by hematoxylin and eosin. The following histological characteristics were recorded: (a) number of cysts, (b) predominant architectural growth pattern of cyst wall, (c) tumor circumscription, (d) nuclear atypia, (e) mitotic activity, counted per 1 mm(2) and (f) Ki-67 staining pattern. Results: Our findings clearly show that there is a non-proliferative group and a proliferative group among the lesions. In the non-proliferative group, one may see some structures that resemble papillary projections but lack a fibrous core. In the proliferative group, we found true papillae, and this change was associated with atypia, mitotic activity and increased Ki-67 staining. Conclusions: Apocrine cystic lesions with true papillary projections should be referred to as AC rather than AH, to emphasize the proliferative adenomatous growth and depicted by their frequency of cytological atypia and high mitotic activity. Furthermore, we suggest complete excision of AC that are proliferative tumors. C1 Nagoya Univ, Grad Sch Med, Dept Dermatol, Nagoya, Aichi, Japan. Massachusetts Gen Hosp, Dept Pathol, Dermapathol Unit, Boston, MA 02114 USA. RP Sugiyama, A (reprint author), Nagoya Univ, Grad Sch Med, Dept Dermatol, Showa Ku, 65 Tsurumai-cho, Nagoya, Aichi 4668550, Japan. EM aksugiura@hotmail.com NR 16 TC 12 Z9 15 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD DEC PY 2007 VL 34 IS 12 BP 912 EP 917 DI 10.1111/j.1600-0560.2007.00757.x PG 6 WC Dermatology; Pathology SC Dermatology; Pathology GA 230ZR UT WOS:000250915900004 PM 18001413 ER PT J AU Gilbert, RJ Napadow, VJ Gaige, TA Wedeen, VJ AF Gilbert, Richard J. Napadow, Vitaly J. Gaige, Terry A. Wedeen, Van J. TI Anatomical basis of lingual hydrostatic deformation SO JOURNAL OF EXPERIMENTAL BIOLOGY LA English DT Review DE magnetic resonance imaging; myoarchitecture; tissue mechanics ID DIFFUSION-WEIGHTED MRI; HUMAN TONGUE; RESTRICTED DIFFUSION; BOVINE TONGUE; MODEL; MOVEMENT; MORPHOLOGY; MUSCLE; DEGLUTITION; MUSCULATURE AB The mammalian tongue is believed to fall into a class of organs known as muscular hydrostats, organs for which muscle contraction both generates and provides the skeletal support for motion. We propose that the myoarchitecture of the tongue, consisting of intricate arrays of muscular fibers, forms the structural basis for hydrostatic deformation. Owing to the fact that maximal diffusion of the ubiquitous water molecule occurs orthogonal to the short axis of most fiber-type cells, diffusion-weighted magnetic resonance imaging (MRI) measurements can be used to derive information regarding 3-D fiber orientation in situ. Image data obtained in this manner suggest that the tongue consists of a complex juxtaposition of muscle fibers oriented in orthogonal arrays, which provide the basis for multidirectional contraction and isovolemic deformation. From a mechanical perspective, the lingual tissue may be considered as set of continuous coupled units of compression and expansion from which 3-D strain maps may be derived. Such functional data demonstrate that during physiological movements, such as protrusion, bending and swallowing, hydrostatic deformation occurs via synergistic contractions of orthogonally aligned intrinsic and extrinsic fibers. Lingual deformation can thus be represented in terms of models demonstrating that synergistic contraction of fibers at orthogonal or near-orthogonal directions to each other is a necessary condition for volume-conserving deformation. Evidence is provided in support of the supposition that hydrostatic deformation is based on the contraction of orthogonally aligned intramural fibers functioning as a mechanical continuum. C1 MIT, Dept Mech Engn, Cambridge, MA 02139 USA. Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Cambridge, MA 02139 USA. RP Gilbert, RJ (reprint author), MIT, Dept Mech Engn, Cambridge, MA 02139 USA. EM rgilbert@mit.edu FU NIDCD NIH HHS [R01-DC05604]; NIMH NIH HHS [R01-MH64044] NR 54 TC 37 Z9 38 U1 0 U2 7 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0022-0949 J9 J EXP BIOL JI J. Exp. Biol. PD DEC 1 PY 2007 VL 210 IS 23 BP 4069 EP 4082 DI 10.1242/jeb.007096 PG 14 WC Biology SC Life Sciences & Biomedicine - Other Topics GA 233RP UT WOS:000251108300010 PM 18025008 ER PT J AU Gottlieb, K AF Gottlieb, Klaus TI Doppler-endosonography with the GF-UE 160 electronic radial echoendoscope - Current use and future potential SO JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES LA English DT Article DE color Doppler ultrasonography; endoscopic ultrasonography; review ID PORTAL VENOUS SYSTEM; BUDD-CHIARI-SYNDROME; OF-THE-ART; ENDOSCOPIC ULTRASOUND; CT ANGIOGRAPHY; HEPATIC-ARTERY; BLOOD-FLOW; DIAGNOSIS; EUS; COLOR AB This tutorial survey with images examines current and possible future applications of the recently introduced 360-degree Doppler capable echoendoscopes. The better gray-scale resolution together with flow, spectral and color Doppler can improve endosonography (EUS) investigations in the mediastinum, abdomen and pelvis. There is no or very little EUS literature covering such important fields as Budd-Chiari syndrome, anatomic variations of the celiac trunk and hepatic artery, mesenteric artery flow determinations in the evaluation of mesenteric ischemia and arterial compression syndromes (celiac, superior mesenteric artery and hepatic artery). Additional other areas of possible future research are suggested. C1 [Gottlieb, Klaus] Deaconess Med Ctr, Spokane, WA USA. RP Gottlieb, K (reprint author), 1314 S Grand Blvd 2141, Spokane, WA 99202 USA. EM klausg@u.washington.edu OI Gottlieb, Klaus/0000-0002-3747-2541 FU Deaconess and Valley Healthcare Foundation FX The author thanks the Deaconess and Valley Healthcare Foundation for their generous support of the Deaconess Endoscopic Ultrasound and Endobronchial Ultrasound Program. NR 47 TC 2 Z9 2 U1 0 U2 1 PU MEDICAL UNIV PRESS PI CLUJ-NAPOCA PA 3RD MEDICAL CLINIC, STR CROITORILOR NO 19-21, CLUJ-NAPOCA, 400162, ROMANIA SN 1841-8724 J9 J GASTROINTEST LIVER JI J. Gastrointest. Liver Dis. PD DEC PY 2007 VL 16 IS 4 BP 455 EP 461 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 343UK UT WOS:000258880500020 PM 18193133 ER PT J AU Safford, MM Allison, JJ Kiefe, CI AF Safford, Monika M. Allison, Jeroan J. Kiefe, Catarina I. TI Patient complexity: More than comorbidity. The Vector Model of Complexity SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT AcademyHealth Annual Research Meeting CY JUN 03-05, 2007 CL Orlando, FL SP AcademyHealth DE patient complexity; evidence-based care; Vector Model of Complexity ID ACUTE MYOCARDIAL-INFARCTION; CHRONIC DISEASE; CHRONIC ILLNESS; HEART-FAILURE; MEDICAL-CARE; HEALTH; GUIDELINES; OLDER; HYPERTENSION; MORBIDITY AB BACKGROUND: The conceptualization of patient complexity is just beginning in clinical medicine. OBJECTIVES: This study aims (1) to propose a conceptual approach to complex patients; (2) to demonstrate how this approach promotes achieving congruence between patient and provider, a critical step in the development of maximally effective treatment plans; and (3) to examine availability of evidence to guide trade-off decisions and assess healthcare quality for complex patients. METHODS/RESULTS: The Vector Model of Complexity portrays interactions between biological, socioeconomic, cultural, environmental and behavioral forces as health determinants. These forces are not easily discerned but exert profound influences on processes and outcomes of care for chronic medical conditions. Achieving congruence between patient, physician, and healthcare system is essential for effective, patient-centered care; requires assessment of all axes of the Vector Model; and, frequently, requires trade-off decisions to develop a tailored treatment plan. Most evidence-based guidelines rarely provide guidance for trade-off decisions. Quality measures often exclude complex patients and are not designed explicitly to assess their overall healthcare. CONCLUSIONS/RECOMMENDATIONS: We urgently need to expand the evidence base to inform the care of complex patients of all kinds, especially for the clinical trade-off decisions that are central to tailoring care. We offer long- and short-term strategies to begin to incorporate complexity into quality measurement and performance profiling, guided by the Vector Model. Interdisciplinary research should lay the foundation for a deeper understanding of the multiple sources of patient complexity and their interactions, and how provision of healthcare should be harmonized with complexity to optimize health. C1 Univ Alabama, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. RP Safford, MM (reprint author), Univ Alabama, 1717 11th Ave S,MT643, Birmingham, AL 35294 USA. EM msafford@uab.edu OI Allison, Jeroan/0000-0003-4472-2112 FU NHLBI NIH HHS [R01 HL080477]; NIDDK NIH HHS [R18 DK065001, R18DK65001-01AZ] NR 57 TC 78 Z9 79 U1 2 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2007 VL 22 SU 3 BP 382 EP 390 DI 10.1007/s116O6-007-0307-0 PG 9 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 239UM UT WOS:000251543500004 PM 18026806 ER PT J AU Vogeli, C Shields, AE Lee, TA Gibson, TB Marder, WD Weiss, KB Blumenthal, D AF Vogeli, Christine Shields, Alexandra E. Lee, Todd A. Gibson, Teresa B. Marder, William D. Weiss, Kevin B. Blumenthal, David TI Multiple chronic conditions: Prevalence, health consequences, and implications for quality, care management, and costs SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE chronic disease; comorbidity; prevalence; quality of health care ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; ADVERSE DRUG EVENTS; METABOLIC SYNDROME; MEDICARE BENEFICIARIES; CHRONIC ILLNESS; DISEASE MANAGEMENT; DEPRESSION CARE; HEART-FAILURE; OF-CARE AB Persons with multiple chronic conditions are a large and growing segment of the US population. However, little is known about how chronic conditions cluster, and the ramifications of having specific combinations of chronic conditions. Clinical guidelines and disease management programs focus on single conditions, and clinical research often excludes persons with multiple chronic conditions. Understanding how conditions in combination impact the burden of disease and the costs and quality of care received is critical to improving care for the 1 in 5 Americans with multiple chronic conditions. This Medline review of publications examining somatic chronic conditions co-occurring with 1 or more additional specific chronic illness between January 2000 and March 2007 summarizes the state of our understanding of the prevalence and health challenges of multiple chronic conditions and the implications for quality, care management, and costs. C1 Massachusetts Gen Hosp, Dept Med, Inst Hlth Policy, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Thomson Healthcare, Ann Arbor, MI USA. Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA. Edward Hines Jr VA Hosp, Ctr Complex Chron Care, Hines, IL 60141 USA. RP Vogeli, C (reprint author), Massachusetts Gen Hosp, Dept Med, Inst Hlth Policy, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM cvogeli@partners.org OI Marder, William/0000-0002-7198-6933 NR 56 TC 307 Z9 309 U1 6 U2 29 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2007 VL 22 SU 3 BP 391 EP 395 DI 10.1007/s11606-007-0322-1 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 239UM UT WOS:000251543500005 PM 18026807 ER PT J AU Lee, TA Shields, AE Vogeli, C Gibson, TB Woong-Sohn, M Marder, WD Blumenthal, D Weiss, KB AF Lee, Todd A. Shields, Alexandra E. Vogeli, Christine Gibson, Teresa B. Woong-Sohn, Min Marder, William D. Blumenthal, David Weiss, Kevin B. TI Mortality rate in veterans with multiple chronic conditions SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE chronic conditions; coexistant conditions; mortality; veterans ID COMORBIDITY MEASURES; PREVALENCE; DISEASES; CANCER; HEALTH; IMPACT; CARE; ASCERTAINMENT; SURVIVAL; INDEX AB BACKGROUND: Among patients with multiple chronic conditions, there is increasing appreciation of the complex interrelatedness of diseases. Previous studies have focused on the prevalence and economic burden associated with multiple chronic conditions, much less is known about the mortality rate associated with specific combinations of multiple diseases. OBJECTIVE: Measure the mortality rate in combinations of 11 chronic conditions. DESIGN. Cohort study of veteran health care users. PARTICIPANTS: Veterans between 55 and 64 years that used Veterans Health Administration health care services between October 1999 and September 2000. MEASUREMENTS: Patients were identified as having one or more of the following: COPD, diabetes, hypertension, rheumatoid arthritis, osteoarthritis, asthma, depression, ischemic heart disease, dementia, stroke, and cancer. Mutually exclusive combinations of disease based on these conditions were created, and 5-year mortality rates were determined. RESULTS: There were 741,847 persons included. The number in each group by a count of conditions was: none = 217,944 (29.34%): 1=221,111 (29.8%); 2=175,228 (23.6%); 3=86,447 (11.7%); and 4+=41,117 (5.5%). The 5-year mortality rate by the number of conditions was: none=4.1%; 1=6.0%; 2=7.8%; 3=11.2%; 4+=16.7%. Among combinations with the same number of conditions, there was significant variability in mortality rates. CONCLUSIONS: Patients with multiple chronic conditions have higher mortality rates. Because there was significant variation in mortality across clusters with the same number of conditions, when studying patients with multiple coexisting illnesses, it is important to understand not only that several conditions may be present but that specific conditions can differentially impact the risk of mortality. C1 Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA. Northwestern Univ, Feinberg Sch Med, Inst Heathcare Studies, Chicago, IL USA. Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med, Chicago, IL USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. Thompson MedStat Inc, Ann Arbor, MI USA. RP Lee, TA (reprint author), Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, POB 5000,151-H, Hines, IL 60141 USA. EM todd.lee@va.gov OI Marder, William/0000-0002-7198-6933 NR 20 TC 58 Z9 58 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2007 VL 22 SU 3 BP 403 EP 407 DI 10.1007/s11606-007-0277-2 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 239UM UT WOS:000251543500007 PM 18026809 ER PT J AU Young, AS Chaney, E Shoai, R Bonner, L Cohen, AN Doebbeling, B Dorr, D Goldstein, MK Kerr, E Nichol, P Perrin, R AF Young, Alexander S. Chaney, Edmund Shoai, Rebecca Bonner, Laura Cohen, Amy N. Doebbeling, Brad Dorr, David Goldstein, Mary K. Kerr, Eve Nichol, Paul Perrin, Ruth TI Information technology to support improved care for chronic illness SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT State of the Art Conference on Managing Complexity in Chronic Care CY SEP 13-15, 2006 CL Arlington, VA SP Dept Vet Affairs Res & Dev DE chronic disease; informatics; clinical information systems; quality improvement; decision making ID CLINICAL DECISION-SUPPORT; QUALITY-OF-CARE; HEALTH-CARE; GUIDELINE IMPLEMENTATION; UNITED-STATES; SYSTEMS; SCHIZOPHRENIA; STRATEGIES; LESSONS; RECORDS AB BACKGROUND: In populations with chronic illness, outcomes improve with the use of care models that integrate clinical information, evidence-based treatments, and proactive management of care. Health information technology is believed to be critical for efficient implementation of these chronic care models. Health care organizations have implemented information technologies, such as electronic medical records, to varying degrees. However, considerable uncertainty remains regarding the relative impact of specific informatics technologies on chronic illness care. OBJECTIVE: To summarize knowledge and increase expert consensus regarding informatics components that support improvement in chronic illness care. Design: A systematic review of the literature was performed. "Use case" models were then developed, based on the literature review, and guidance from clinicians and national quality improvement projects. A national expert panel process was conducted to increase consensus regarding information system components that can be used to improve chronic illness care. RESULTS: The expert panel agreed that informatics should be patient-centered, focused on improving outcomes, and provide support for illness self-management. They concurred that outcomes should be routinely assessed, provided to clinicians during the clinical encounter, and used for population-based care management. It was recommended that interactive, sequential, disorder-specific treatment pathways be implemented to quickly provide clinicians with patient clinical status, treatment history, and decision support. CONCLUSIONS: Specific informatics strategies have the potential to improve care for chronic illness. Software to implement these strategies should be developed, and rigorously evaluated within the context of organizational efforts to improve care. C1 VA Desert Pacific Mental Illness Res Educ & Clin, W Los Angeles VA Healthcare Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA USA. VA VISN Hlth Serv Res & Dev Ctr, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. Indianapolis VA, Indianapolis, IN USA. Indiana Univ, Sch Med, Indianapolis, IN USA. Portland VA, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. GRECC, VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. Stanford Univ, Stanford, CA 94305 USA. Ann Arbor VA, Ann Arbor, MI USA. Univ Michigan, Ann Arbor, MI 48109 USA. VA Informat Resource Ctr, Hines, IL USA. RP Young, AS (reprint author), VA Desert Pacific Mental Illness Res Educ & Clin, W Los Angeles VA Healthcare Ctr, Los Angeles, CA 90073 USA. EM ayoung@ucla.edu RI Doebbeling, Bradley/C-6620-2009; Young, Alexander/A-1523-2009 OI Young, Alexander/0000-0002-9367-9213 FU NIMH NIH HHS [P30 MH068639] NR 39 TC 21 Z9 22 U1 2 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2007 VL 22 SU 3 BP 425 EP 430 DI 10.1007/s116O6-007-0303-4 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 239UM UT WOS:000251543500010 PM 18026812 ER PT J AU Safford, MM Shewchuk, R Qu, HY Williams, JH Estrada, CA Ovalle, F Allison, JJ AF Safford, Monika M. Shewchuk, Richard Qu, Haiyan Williams, Jessica H. Estrada, Carlos A. Ovalle, Fernando Allison, Jeroan J. TI Reasons for not intensifying medications: Differentiating "Clinical inertia" from appropriate care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE clinical inertia; primary care; conceptual model ID BLOOD-PRESSURE; HYPERTENSION; PERFORMANCE; MANAGEMENT; PAY AB BACKGROUND "Clinical inertia" has been defined as inaction by physicians caring for patients with uncontrolled risk factors such as blood pressure. Some have proposed that it accounts for up to 80% of cardiovascular events, potentially an important quality problem. However, reasons for so-called clinical inertia are poorly understood. OBJECTIVE To derive an empiric conceptual model of clinical inertia as a subset of all clinical inactions from the physician perspective. METHODS We used Nominal Group panels of practicing physicians to identify reasons why they do not intensify medications when seeing an established patient with uncontrolled blood pressure. MEASUREMENTS AND MAIN RESULTS We stopped at 2 groups (N=6 and 7, respectively) because of the high degree of agreement on reasons for not intensifying, indicating saturation. A third group of clinicians (N=9) independently sorted the reasons generated by the Nominal Groups. Using multidimensional scaling and hierarchical cluster analysis, we translated the sorting results into a cognitive map that represents an empirically derived model of clinical inaction from the physician's perspective. The model shows that much inaction may in fact be clinically appropriate care. CONCLUSIONS/RECOMMENDATIONS Many reasons offered by physicians for not intensifying medications suggest that low rates of intensification do not necessarily reflect poor quality of care. The empirically derived model of clinical inaction can be used as a guide to construct performance measures for monitoring clinical inertia that better focus on true quality problems. C1 Univ Alabama, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. RP Safford, MM (reprint author), Univ Alabama, Birmingham, AL 35294 USA. EM msafford@uab.edu OI Allison, Jeroan/0000-0003-4472-2112 FU NIDDK NIH HHS [R18 DK065001, R18DK65001-01A2] NR 23 TC 60 Z9 61 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2007 VL 22 IS 12 BP 1648 EP 1655 DI 10.1007/s11606-007-0433-8 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 232IC UT WOS:000251011100003 PM 17957346 ER PT J AU Washington, DL Shacter, HE Saha, S Cooper, LA Long, JA AF Washington, Donna L. Shacter, Hannah E. Saha, Somnath Cooper, Lisa A. Long, Judith A. TI Update in health disparities SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE ethnic groups; continental population groups ID BREAST-CANCER; RACIAL/ETHNIC GROUP; CARE; AMERICANS; TRIAL C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. Philadelphia VA Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. Vet Affairs Med Ctr, Gen Internal Med Sect, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA. Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD USA. Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA. Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. RP Washington, DL (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM donna.washington@va.gov NR 14 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2007 VL 22 IS 12 BP 1756 EP 1761 DI 10.1007/s11606-007-0442-7 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 232IC UT WOS:000251011100019 ER PT J AU Pugh, JA AF Pugh, Jacqueline A. TI Priority setting for patients with multiple comorbidities: Diabetes may not end up number one SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78285 USA. RP Pugh, JA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78285 USA. EM pugh@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X NR 2 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2007 VL 22 IS 12 BP 1783 EP 1784 DI 10.1007/s11606-007-0434-7 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 232IC UT WOS:000251011100025 PM 17985189 ER PT J AU Ilyas, AM Nourissat, G Jupiter, JB AF Ilyas, Asif M. Nourissat, Geoffroy Jupiter, Jesse B. TI Segmental neurofibromatosis of the hand and upper extremity: A case report SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE nerve tumor; neurilemoma; neurofibroma; neurofibromatosis; schwannoma; schwannomatosis; segmental ID ULNAR NERVE; TYPE-1 NF1; NEURILEMOMAS; SCHWANNOMATOSIS; GENE AB A case of segmental neurofibromatosis of the upper extremity is presented. Multiple neurofibromas involving different peripheral nerves limited to a single body part or limb is a rare form of neurofibromatosis. The clinical, genetic, and histologic findings of segmental neurofibromatosis are described. The criteria for segmental neurofibromatosis are reviewed, and the differentiation of neurofibromatosis types 1 and 2 and schwannomatosis is also briefly reviewed. C1 [Ilyas, Asif M.; Nourissat, Geoffroy; Jupiter, Jesse B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Hand & Upper Extrem Serv, Boston, MA 02114 USA. [Ilyas, Asif M.; Nourissat, Geoffroy; Jupiter, Jesse B.] SOS Main, Serv Chirurg Orthoped & Traumatol, Unite Membre Super, Paris, France. RP Ilyas, AM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Hand & Upper Extrem Serv, 55 Fruit St Yawkey 2100, Boston, MA 02114 USA. EM aimd2001@yahoo.com NR 27 TC 4 Z9 5 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 EI 1531-6564 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD DEC PY 2007 VL 32A IS 10 BP 1538 EP 1542 DI 10.1016/j.jhsa.2007.07.012 PG 5 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 245OR UT WOS:000251945400008 PM 18070641 ER PT J AU Lindenhovius, ALC Jupiter, JB AF Lindenhovius, Anneluuk L. C. Jupiter, Jesse B. TI The posttraumatic stiff elbow: A review of the literature SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Review DE contracture; elbow; release; stiffness ID HETEROTOPIC BONE-FORMATION; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONTINUOUS PASSIVE MOTION; REVERSED DYNAMIC SLINGS; TOTAL HIP-REPLACEMENT; RADIAL HEAD; SURGICAL-TREATMENT; ARTHROSCOPIC TREATMENT; FLEXION CONTRACTURES; OPERATIVE RELEASE AB Loss of motion is a common complication of elbow trauma. Restoration of joint motion in the posttraumatic stiff elbow can be a difficult, time-consuming, and costly challenge. in this review of the literature, the biologic response to trauma and the possible etiologic events that may lead to fibrosis of the capsules and heterotopic ossification will be discussed, as well as nonsurgical and surgical management of stiffness and expected outcomes of treatment. C1 [Lindenhovius, Anneluuk L. C.; Jupiter, Jesse B.] Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA. [Lindenhovius, Anneluuk L. C.; Jupiter, Jesse B.] Harvard Univ, Sch Med, Boston, MA USA. RP Jupiter, JB (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand & Upper Extrem Serv, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM jjupiter1@partners.org NR 205 TC 46 Z9 56 U1 0 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD DEC PY 2007 VL 32A IS 10 BP 1605 EP 1623 DI 10.1016/j.jhsa.2007.09.015 PG 19 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 245OR UT WOS:000251945400020 PM 18070653 ER PT J AU Mudgal, CS Mudgal, S AF Mudgal, C. S. Mudgal, Sharmila TI Closed traumatic rupture of the extensor digitorum communis and extensor indicis proprius at the musculo-tendinous junction SO JOURNAL OF HAND SURGERY-EUROPEAN VOLUME LA English DT Article DE closed traumatic rupture; digital; extensors ID POLLICIS LONGUS TENDON; RHEUMATOID-ARTHRITIS; FRACTURE AB This report describes a closed rupture of the entire extensor digitorum communis and extensor indicis proprius. C1 [Mudgal, C. S.] Harvard Univ, Massachusetts Gen Hosp, Orthopaed Hand Serv, Sch Med, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge Hlth Alliance, Div Occupat Med, Cambridge, MA 02138 USA. RP Mudgal, CS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Orthopaed Hand Serv, Sch Med, Yawkey Ctr,Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM emudgal@partners.org NR 11 TC 2 Z9 2 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1753-1934 J9 J HAND SURG-EUR VOL JI J. Hand Surg.-Eur. Vol. PD DEC PY 2007 VL 32E IS 6 BP 675 EP 676 DI 10.1016/j.jhse.2007.07.008 PG 2 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 246NG UT WOS:000252013100011 PM 17993430 ER PT J AU Chen, XS Yin, YP Tucker, JD Gao, X Cheng, F Wang, TF Wang, HC Huang, PY Cohen, MS AF Chen, Xiang-Sheng Yin, Yue-Ping Tucker, Joseph D. Gao, Xing Cheng, Feng Wang, Tian-Fu Wang, Hong-Chun Huang, Pei-Yong Cohen, Myron S. TI Detection of acute and established HIV infections in sexually transmitted disease clinics in Guangxi, China: Implications for screening and prevention of HIV infection SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID FEMALE SEX WORKERS; TO-URBAN MIGRANTS; RISK-FACTORS; YUNNAN PROVINCE; DRUG-USERS; TRANSMISSION; SYPHILIS; EPIDEMIC; SPREAD; POPULATION AB Background. Human immunodeficiency virus (HIV) has spread throughout China and to some degree has penetrated the general heterosexual population in some regions. Methods. A cross-sectional survey of 11,461 sexually transmitted disease (STD) clinic attendees in 8 cities in Guangxi, China, was conducted for syphilis and for acute and established HIV infections. Results. The prevalence of acute and established HIV infections was 1.2% among the participants. Five acute (preseroconversion) HIV infections were detected. Multivariate analysis showed that HIV infection was independently related to unmarried status (odds ratio [OR], 1.73 [95% confidence interval {CI}, 1.00-2.99), less education (OR for less than primary school, 4.21 [90% CI, 1.21-14.58]), residence in city A (OR, 11.48 [95% CI, 2.05-64.31]) or city B (OR, 7.93 [95% CI, 1.75-35.91]), working in the entertainment industry (OR, 3.98 [95% CI, 1.14-13.88]), injection drug use (OR, 25.09 [95% CI, 10.43-60.39]), no condom use during most recent sexual intercourse (OR, 4.97 [95% CI, 1.38-17.88]), and syphilitic infection (OR, 1.91 [95% CI, 1.03-3.56]). Conclusions. HIV prevalence in STD clinics is significantly greater than that in the general population, and subjects were identified who would be missed by conventional surveillance. China's nationwide system of public STD clinics, which reach down to the township level, should be used for HIV control programs. C1 Natl Ctr STD Control, Nanjing 210042, Peoples R China. Tsing Hua Univ, Dept Social Med, Beijing, Peoples R China. Guangxi AutonomousReg Inst Dermatol, Nanning, Peoples R China. Massachusetts Gen Hosp, Div Infect Dis, Boston, MA USA. Univ N Carolina, Inst Global Hlth & Infect Dis, Chapel Hill, NC USA. RP Chen, XS (reprint author), Natl Ctr STD Control, 12 Jiangwangmiao St, Nanjing 210042, Peoples R China. EM chenxs@vip.163.com FU FIC NIH HHS [D43 TW01039] NR 50 TC 24 Z9 24 U1 2 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 1 PY 2007 VL 196 IS 11 BP 1654 EP 1661 DI 10.1086/522008 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 231RE UT WOS:000250965900012 PM 18008249 ER PT J AU Dong, K Thabethe, Z Hurtado, R Sibaya, T Dlwati, H Walker, B Wilson, D AF Dong, Krista Thabethe, Zinhle Hurtado, Rocio Sibaya, Thobe Dlwati, Hlubi Walker, Bruce Wilson, Doug TI Challenges to the success of HIV and tuberculosis care and treatment in the public health sector in South Africa SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Conference on Realities of Antiretroviral Therapy Rollout - Challenges to Successful Programmatic Implementation CY OCT, 2006 CL Durban, SOUTH AFRICA AB The escalating human immunodeficiency virus (HIV) and tuberculosis (TB) epidemics have had a significant impact on public health services in resource-limited settings. The province of KwaZulu-Natal in South Africa is estimated to have one of the greatest TB/HIV coinfection burdens on the African continent, coupled with historically low TB treatment success rates. In May 2004, the South African government began providing antiretroviral therapy (ART) for HIV-infected individuals within the public sector. As in many counties, this HIV treatment program was established in parallel with an existing TB treatment service. In 2005, the Integration of TB in Education and Care for HIV/AIDS (iTEACH) Program was launched in KwaZulu-Natal at Edendale Hospital. The goal of iTEACH was to identify barriers to effective treatment and develop support interventions to enable rapid expansion of access to ART and improve ART and TB treatment outcomes within the district served by this facility. In the present article, we discuss challenges to the delivery of TB and HIV care by these separate treatment programs, as well as opportunities to improve both TB treatment and ART outcomes through lessons learned during ART scale-up in the context of the HIV and TB coepidemics. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Infect Dis, Boston, MA USA. Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA USA. Howard Hughes Med Inst, Chevy Chase, MD USA. Edendale Hosp, Integrat TB Educ & Care HIV AIDS Program, Pietermaritzburg, South Africa. Univ KwaZulu Natal, Nelson R Mandela Sch Med, Durban, South Africa. RP Dong, K (reprint author), Edendale Hosp, iTEACH Program, Dept Med, Private Bag X509, ZA-3216 Pietermaritzburg, KwaZulu Natal, South Africa. EM woodil.iteach@gmail.com NR 5 TC 18 Z9 18 U1 1 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 1 PY 2007 VL 196 SU 3 BP S491 EP S496 DI 10.1086/521111 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 237TA UT WOS:000251398100008 PM 18181699 ER PT J AU Hirschhorn, LR Ojikutu, B Rodriguez, W AF Hirschhorn, Lisa R. Ojikutu, Bisola Rodriguez, William TI Research for change: Using implementation research to strengthen HIV care and treatment scale-up in resource-limited settings SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID TO-CHILD TRANSMISSION; ANTIRETROVIRAL TREATMENT; PUBLIC-HEALTH; SOUTH-AFRICA; PROGRAM; QUALITY; THERAPY; NEVIRAPINE; INFECTION; TRIAL AB The expansion of human immunodeficiency virus (HIV) care and treatment in Africa and other resource-limited settings has begun to mitigate the impact of the acquired immunodeficiency syndrome pandemic. As this expansion has occurred, critical research has been conducted that has helped to define best practices and establish guidelines in HIV care. However, despite this research, a tremendous gap exists between the actual delivery of care and those strategies with proven efficacy in the clinical research setting: the program-implementation gap. The field of implementation research has the potential to fill this knowledge gap and to address the barriers to the effective replication of evidence-based interventions in local settings. This article reviews the current understanding of the field of implementation research and discusses its association with other areas of health services research, clinical research, and quality management work. Opportunities for conducting implementation research are proposed, and future steps to develop the field are outlined. C1 Harvard Univ, Sch Med, Off Int Programs, Div Aids, Boston, MA 02215 USA. JSI Res & Training, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Clinton Fdn HIV AIDS Initiat, Quincy, MA USA. RP Hirschhorn, LR (reprint author), Harvard Univ, Sch Med, Off Int Programs, Div Aids, Landmark Ctr 2 E,401 Pk Dr, Boston, MA 02215 USA. EM LRH3@HMS.Harvard.edu NR 50 TC 17 Z9 17 U1 2 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 1 PY 2007 VL 196 SU 3 BP S516 EP S522 DI 10.1086/521120 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 237TA UT WOS:000251398100013 PM 18181704 ER PT J AU Kiviat, AD Geary, MC Sunpath, H Moosa, MYS Wilson, D Narasimhan, P Gandhi, RT AF Kiviat, Aurora D. Geary, Meghan C. Sunpath, Henry Moosa, Mahorned-Yunus S. Wilson, Douglas Narasimhan, Padmanesan Gandhi, Raiesh T. TI HIV online provider education (HOPE): The internet as a tool for training in HIV medicine SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID TELEMEDICINE; TECHNOLOGY; AFRICA AB Human immunodeficiency virus (HIV) treatment programs in resource-limited areas are expanding rapidly. Providing training and education to health care providers in these programs is a major challenge. We have employed Internet-based conferencing technology to conduct interactive case-based training conferences with health care professionals in Africa, Asia, and the Caribbean. This online program may be a model for other efforts to provide education to health care providers treating HIV-infected patients in the developing world. C1 Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA. Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA. Harvard Univ, Ctr AIDS Res, Boston, MA 02115 USA. Harvard Univ, Sch Med, Div Aids, Boston, MA USA. McCord Hosp, Dept Med, Durban, South Africa. Univ KwaZulu Natal, Dept Infect Dis, Durban, South Africa. Univ KwaZulu Natal, Pietermaritzburg Hosp Complex, Dept Med, Pietermaritzburg, South Africa. YR Gaitonde Ctr AIDS Res & Educ, Madras, Tamil Nadu, India. RP Gandhi, RT (reprint author), Massachusetts Gen Hosp, Infect Dis Unit, GRJ 504,55 Fruit St, Boston, MA 02114 USA. EM rgandhi@partners.org RI Narasimhan, Padmanesan/B-8033-2008; OI Narasimhan, Padmanesan/0000-0002-2020-0865 NR 8 TC 8 Z9 8 U1 2 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 1 PY 2007 VL 196 SU 3 BP S512 EP S515 DI 10.1086/521117 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 237TA UT WOS:000251398100012 PM 18181703 ER PT J AU Murphy, RA Sunpath, H Kuritzkes, DR Venter, F Gandlhi, RT AF Murphy, Richard A. Sunpath, Henry Kuritzkes, Daniel R. Venter, Francois Gandlhi, Raiesh T. TI Antiretroviral therapy-associated toxicities in the resource-poor world: The challenge of a limited formulary SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; REVERSE-TRANSCRIPTASE INHIBITORS; LACTIC-ACIDOSIS; HYPERSENSITIVITY REACTIONS; HIV-1-INFECTED PATIENTS; PERIPHERAL NEUROPATHY; HEPATITIS-C; MITOCHONDRIAL TOXICITY; LOPINAVIR-RITONAVIR AB Toxicities related to antiretroviral therapy make long-term adherence to therapy difficult for patients and present challenges to providers, especially those in the resource-poor world who work with a limited formulary. In resource-poor settings, where limited drug options are the rule, when and how to change therapy are especially difficult problems. Drugs such as stavudine and didanosine are associated with serious metabolic complications, such as lactic acidosis, pancreatitis, and peripheral neuropathy. Antiretroviral agents associated with fewer metabolic effects, such as tenofovir and abacavir, remain widely unavailable. Because the current formulary restrictions appear to be unlikely to change quickly, providers in resource-poor countries must be familiar with the common adverse events-including metabolic complications, hypersensitivity reactions, anemia, and liver enzyme abnormalities-and must understand how to manage them with what is locally available. Most importantly, to avoid drug toxicities, a larger formulary is needed in resource-poor settings, and this must be a high priority for policy makers and health care professionals involved in treating human immunodeficiency virus infection globally. C1 Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02214 USA. Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02214 USA. Brigham & Womens Hosp, Sect Retroviral Therapeut, Boston, MA 02115 USA. Harvard Univ, Sch Med, Div Aids, Boston, MA USA. Harvard Univ, AIDS Res Ctr, Boston, MA 02115 USA. Univ Witwatersrand, Johannesburg, South Africa. McCord Hosp, Durban, South Africa. RP Murphy, RA (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Gray Bldg,5th Fl,55 Fruit St, Boston, MA 02214 USA. EM rmurphy6@partners.org NR 55 TC 30 Z9 32 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 1 PY 2007 VL 196 SU 3 BP S449 EP S456 DI 10.1086/521112 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 237TA UT WOS:000251398100002 PM 18181693 ER PT J AU Ojikutu, B Jack, C Ramjee, G AF Ojikutu, Bisola Jack, Chris Ramjee, Gita TI Provision of antiretroviral therapy in South Africa: Unique challenges and remaining obstacles SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID TRADITIONAL HEALERS; TUBERCULOSIS; HEALTH; PREVALENCE; HIV/AIDS; IMPACT; AIDS; CARE AB From 2003 to 2006, the number of human immunodeficiency virus-infected people in sub-Saharan Africa able to access antiretroviral therapy (ART) has increased from 100,000 to >1 million. The World Health Organization estimates that >3.5 million patients are still in need. The challenges to more expeditious provision of ART in Africa are many. This article is an analysis of the barriers to ART scale-up that are unique to South Africa. With 5.3 million people infected and I million needing ART, this country carries nearly one-quarter of the treatment burden of the continent. Although South Africa is undeniably a middle-income nation, inequities born of apartheid, lack of political commitment, poverty, and cultural barriers have significantly slowed efforts to provide universal access to ART to South African citizens. C1 Harvard Univ, Sch Med, Div Aids, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. MRC, Durban, South Africa. Keep Child Alive, Durban, South Africa. RP Ojikutu, B (reprint author), Harvard Univ, Sch Med, Div Aids, 401 Pk Dr,2nd Fl E, Boston, MA 02215 USA. EM bojikutu@partners.org NR 41 TC 16 Z9 16 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 1 PY 2007 VL 196 SU 3 BP S523 EP S527 DI 10.1086/521119 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 237TA UT WOS:000251398100014 PM 18181705 ER PT J AU Ojikutu, B AF Ojikutu, Bisola TI The realities of antiretroviral therapy rollout: Overcoming challenges to successful programmatic implementation SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article AB In 2006, 2 million human immunodeficiency virus (HIV)-infected people living in low- to middle-income countries were receiving antiretroviral therapy (ART). Although this is an improvement over previous years, significant operational challenges have inhibited progress toward universal access to HIV care and treatment. Despite these challenges, the intense efforts focused on addressing the HIV epidemic present an opportunity for overall health systems improvement in developing nations. In October 2006, Harvard University's Centers for AIDS Research, the Nelson Mandela School of Medicine, the Department of Health of KwaZulu-Natal, and the Medical Research Council of South Africa held a conference entitled "The Realities of Antiretroviral Therapy Rollout: Challenges to Successful Programmatic Implementation" in Durban, South Africa. The goal of the meeting was to bring together international and local leadership,, I including policy makers, health care workers, and funders, to propose an agenda that would address the challenges to more expeditious provision of HIV care and treatment in resource-limited settings. C1 Harvard Univ, Sch Med, Div Aids, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Ojikutu, B (reprint author), Harvard Univ, Sch Med, Div Aids, 401 Pk Dr,2nd Fl E, Boston, MA 02215 USA. EM bojikutu@partners.org NR 18 TC 6 Z9 7 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 1 PY 2007 VL 196 SU 3 BP S445 EP S448 DI 10.1086/521123 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 237TA UT WOS:000251398100001 PM 18181692 ER PT J AU Lo, AS Gorak-Stolinska, P Bachy, V Ibrahim, MA Kemeny, DM Maher, J AF Lo, Agnes S. Gorak-Stolinska, Patricia Bachy, Veronique Ibrahim, Mohammad A. Kemeny, David M. Maher, John TI Modulation of dendritic cell differentiation by colony-stimulating factor-1: role of phosphatidylinositol 3 '-kinase and delayed caspase activation SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE macrophage; monocyte; apoptosis ID MACROPHAGE DIFFERENTIATION; TUMOR-CELLS; MONOCYTES; RECEPTOR; BLOOD; PREVENTS; SURVIVAL; KINASE; CSF-1; INTERLEUKIN-6 AB Monocytes acquire a dendritic cell (DC) phenotype when cultured with GM-CSF and IL-4. By contrast, CSF-1 is a potent inducer of monocyte-to-macrophage differentiation. Increasing evidence indicates that DC development is impaired in conditions characterized by CSF-1 overproduction, including pregnancy, trauma, and diverse malignancies. To study this, we have exposed newly established monocyte-derived DC cultures to conditions of CSF-1 excess. As a consequence, differentiation is skewed toward a unique intermediate phenotype, which we have termed DC-M. Such cells exhibit macrophage-like morphology with impaired allostimulatory capacity, altered cytokine production, and a distinctive cell surface immuno-phenotype. In light of the emerging role of caspase activation during macrophage differentiation, the activity of caspases 3, 8, and 9 was examined in DC and DC-M cultures. It is striking that DC-M cultures exhibit a delayed and progressive increase in activation of all three caspases, associated with depolarization of mitochondrial membrane potential. Furthermore, when DC-M cultures were supplemented with an inhibitor of caspase 8 or caspase 9, impairment of DC differentiation by CSF-1 was counteracted. To investigate upstream regulators of caspase activation in DC-M cultures, experiments were performed using inhibitors of proximal CSF-1 receptor signaling. These studies demonstrated that the PI-3K inhibitors, wortmannin and LY294002, antagonize the ability of CSF-1 to inhibit DC differentiation and to promote caspase activation. Together, these data identify a novel, PI-3K-dependent pathway by which CSF-1 directs delayed caspase activation in monocytes and thereby modulates DC differentiation. C1 Kings Coll NHS Fdn Trust, Dept Allergy & Clin Immunol, London, England. Kings Coll London, Div Canc Studies, Breast Canc Biol Grp, London WC2R 2LS, England. RP Lo, AS (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Jimmy Fund Bldg, Room 707,44 Binney St, Boston, MA 02115 USA. EM agnes_lo@dfci.harvard.edu RI Ibrahim, Mohammad/G-1387-2011 OI Ibrahim, Mohammad/0000-0002-0116-597X NR 42 TC 11 Z9 12 U1 0 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD DEC 1 PY 2007 VL 82 IS 6 BP 1446 EP 1454 DI 10.1189/jlb.0307142 PG 9 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 235OI UT WOS:000251243800012 PM 17855501 ER PT J AU Moschella, PC Rao, VU McDermott, PJ Kuppuswamy, D AF Moschella, Phillip C. Rao, Vijay U. McDermott, Paul J. Kuppuswamy, Dhandapani TI Regulation of mTOR and S6K1 activation by the nPKC isoforms, PKC epsilon and PKC epsilon in adult cardiac muscle cells SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Article DE cardiomyocytes; PKC; mTOR; S6K1; endothelin-1; phenylephrine; hypertrophy ID PROTEIN-KINASE-C; MAMMALIAN TARGET; SIGNALING PATHWAYS; RAPAMYCIN MTOR; GROWTH CONTROL; P70S6 KINASE; CYCLIC-AMP; IN-VIVO; PHOSPHORYLATION; HYPERTROPHY AB Activation of both mTOR and its downstream target, S6K1 (p70 S6 kinase) have been implicated to affect cardiac hypertrophy. Our earlier work, in a feline model of 1-48 It pressure overload, demonstrated that mTOR/S6K1 activation occurred primarily through a PKC/c-Raf pathway. To further delineate the role of specific PKC isoforms on rnTOR/S6K1 activation, we utilized primary cultures of adult feline cardiomyocytes in vitro and stimulated with endothelin-1 (ET-1), phenylephrine (PE), TPA, or insulin. All agonist treatments resulted in S2248 phosphorylation of mTOR and T389 and S421/T424 phosphorylation of S6K1, however only ET-1 and TPA-stimulated mTOR/S6K1 activation was abolished with infection of a dominant negative adenoviral c-Raf (DN-Raf) construct. Expression of DN-PKC epsilon blocked ET-1-stimulated mTOR S2448 and S6K1 S421/T424 and T389 phosphorylation but had no effect on insulin-stimulated S6KI phosphorylation. Expression of DN-PKC delta or pretreatment of cardiomyocytes with rottlerin, a PKC delta specific inhibitor, blocked both ET-I and insulin stimulated mTOR S2448 and S6KI T389 phosphorylation. However, treatment with Go6976, a specific classical PKC (cPKC) inhibitor did not affect mTOR/S6K1 activation. These data indicate that: (i) PKC, is required for ET-1-stimulated T421/S424 phosphorylation of S6K1, (ii) both PKC epsilon and PKC epsilon are required for ET-1-stimulated mTOR S2448 and S6K1 T389 phosphorylation, (iii) PKC epsilon, is also required for insulin-stimulated mTOR S2448 and S6K1 T389 phosphorylation. Together, these data delineate both distinct and combinatorial roles of specific PKC isoforms on mTOR and S6K1 activation in adult cardiac myocytes following hypertrophic stimulation, (c) 2007 Elsevier Inc. All rights reserved. C1 [Moschella, Phillip C.; Rao, Vijay U.; McDermott, Paul J.; Kuppuswamy, Dhandapani] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Columbia, SC 29208 USA. [McDermott, Paul J.; Kuppuswamy, Dhandapani] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Kuppuswamy, D (reprint author), Gazes Cardiac Res Inst, 114 Doughty St, Charleston, SC 29425 USA. EM kuppusd@musc.edu FU NHLBI NIH HHS [P01 HL048788-140001, P01 HL048788-120007, P01 HL048788-120001, HL 48788, P01 HL048788-140007, P01 HL048788-149006, P01 HL048788-129006, T32 HL007260, T32 HL 07260, P01 HL048788-159006, P01 HL048788-150007, P01 HL048788-150001, P01 HL048788-139006, P01 HL048788-130007, P01 HL048788-130001, P01 HL048788-119006, P01 HL048788-110007, P01 HL048788-110001, P01 HL048788] NR 50 TC 35 Z9 38 U1 0 U2 2 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD DEC PY 2007 VL 43 IS 6 BP 754 EP 766 DI 10.1016/j.yjmcc.2007.09.015 PG 13 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA 245IR UT WOS:000251928800013 PM 17976640 ER PT J AU Scheffer, D Sage, C Plazas, PV Huang, MQ Wedemeyer, C Zhang, DS Chen, ZY Elgoyhen, AB Corey, DP Pingault, V AF Scheffer, Deborah Sage, Cyrille Plazas, Paola V. Huang, Mingqian Wedemeyer, Carolina Zhang, Duan-Sun Chen, Zheng-Yi Elgoyhen, A. Belen Corey, David P. Pingault, Veronique TI The alpha 1 subunit of nicotinic acetylcholine receptors in the inner ear: transcriptional regulation by ATOH1 and co-expression with the gamma subunit in hair cells SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE ATOH1 protein; basic-helix-loop-helix transcription factors; cholinergic receptors; inner ear; hair cells AB Acetylcholine is a key neurotransmitter of the inner ear efferent system. In this study, we identify two novel nAChR subunits in the inner ear: alpha 1 and gamma, encoded by Chrna1 and Chrng, respectively. In situ hybridization shows that the messages of these two subunits are present in vestibular and cochlear hair cells during early development. Chrna1 and Chrng expression begin at embryonic stage E13.5 in the vestibular system and E17.5 in the organ of Corti. Chrna1 message continues through P7, whereas Chrng is undetectable at post- natal stage P6. The alpha 1 and gamma subunits are known as muscle-type nAChR subunits and are surprisingly expressed in hair cells which are sensory-neural cells. We also show that ATOH1/MATH1, a transcription factor essential for hair cell development, directly activates CHRNA1 transcription. Electrophoretic mobility-shift assays and supershift assays showed that ATOH1/E47 heterodimers selectively bind on two E boxes located in the proximal promoter of CHRNA1. Thus, Chrna1 could be the first transcriptional target of ATOH1 in the inner ear. Co-expression in Xenopus oocytes of the alpha 1 subunit does not change the electrophysiological properties of the alpha 9 alpha 10 receptor. We suggest that hair cells transiently express alpha 1 gamma-containing nAChRs in addition to alpha 9 alpha 10, and that these may have a role during development of the inner ear innervation. C1 [Scheffer, Deborah; Sage, Cyrille; Pingault, Veronique] Hop Henri Mondor, INSERM, U841, Dept Genet,Equipe Avenir, F-94010 Creteil, France. [Plazas, Paola V.; Wedemeyer, Carolina; Elgoyhen, A. Belen] Univ Buenos Aires, Fac Med, CONICET, Inst Invest Ingn Genet & Biol Mol, RA-1053 Buenos Aires, DF, Argentina. [Plazas, Paola V.; Wedemeyer, Carolina; Elgoyhen, A. Belen] Univ Buenos Aires, Fac Med, Tercera Catedra Farmacol, RA-1053 Buenos Aires, DF, Argentina. [Huang, Mingqian; Chen, Zheng-Yi] Massachusetts Gen Hosp, Neurol Serv, Boston, MA 02114 USA. [Zhang, Duan-Sun; Corey, David P.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA. [Zhang, Duan-Sun; Corey, David P.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA. RP Pingault, V (reprint author), Hop Henri Mondor, INSERM, U841, Dept Genet,Equipe Avenir, F-94010 Creteil, France. EM pingault@creteil.inserm.fr OI Scheffer, Deborah/0000-0002-6066-5907; Corey, David/0000-0003-4497-6016 FU NIH/NIDCD [DC04546]; Howard Hughes Medical Institute; ANPCyT; UBA (Argentina); INSERM/Ile de France; Fondation pour la Recherche Medicale FX We want to thank M. E Gomez-Casati for her graphics help for the electrophysiology data, R. Palmer for technical assistance (U2OS cells), Dr J. Boulter for providing the mouse alpha 1, delta, delta, and beta 1 cDNA clones, Dr Jane E. Johnson for the monoclonal rabbit anti-ATOH1 antibody and Dr H. Y Zoghbi for the Atoh1-/- mice. This work was supported by the Avenir project at INSERM, a grant from the NIH/NIDCD to DPC, a grant from the NIH/NIDCD (DC04546) to ZYC, an International Research Scholar Grant from the Howard Hughes Medical Institute and a Research Grant from ANPCyT and UBA (Argentina) to ABE. DS is a recipient of a INSERM/Ile de France and Fondation pour la Recherche Medicale fellowship. DPC is an Investigator, ABE is an International Research Scholar and VP was an Associate of the Howard Hughes Medical Institute. NR 66 TC 15 Z9 15 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD DEC PY 2007 VL 103 IS 6 BP 2651 EP 2664 DI 10.1111/j.1471-4159.2007.04980.x PG 14 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA V04MN UT WOS:000207062600011 PM 17961150 ER PT J AU Stevens, CF Williams, JH AF Stevens, Charles F. Williams, James H. TI Discharge of the readily releasable pool with action potentials at hippocampal synapses SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article ID TERM SYNAPTIC DEPRESSION; PRESYNAPTIC CALCIUM CURRENT; TRANSMITTER RELEASE; ASYNCHRONOUS RELEASE; VESICLE POOLS; NEURONS; CALYX; SIZE; MICROCULTURES; NONSATURATION AB Discharge of the readily releasable pool with action potentials at hippocampal synapses. J Neurophysiol 98: 3221-3229, 2007. First published October 17, 2007; doi:10.1152/jn.00857.2007. A readily releasable pool (RRP) of synaptic vesicles has been identified at hippocampal synapses with application of hypertonic solution. RRP size correlates with important properties of synaptic function such as release probability. However, a discrepancy in RRP size has been reported depending on the method used to evoke synaptic release. This study was undertaken to determine quantitative relationships between the RRP defined with hypertonic solution and that released with trains of action potentials. We find that asynchronous release at cell culture synapses contributes significantly to the discharge of the RRP with trains of action potentials and that RRP size is the same when elicited by either nerve stimuli or hypertonic challenge. C1 [Stevens, Charles F.; Williams, James H.] Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA. [Williams, James H.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. RP Stevens, CF (reprint author), Salk Inst Biol Studies, Mol Neurobiol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA. EM cfs@salk.edu FU NIGMS NIH HHS [T32 GM007592, T32 GM07198-32, T32 GM007592-22, T32 GM007198, T32 GM07592] NR 43 TC 53 Z9 55 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD DEC PY 2007 VL 98 IS 6 BP 3221 EP 3229 DI 10.1152/jn.00857.2007 PG 9 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 243DS UT WOS:000251775700010 PM 17942621 ER PT J AU Lok, J Wang, H Murata, Y Zhu, HH Qin, T Whalen, MJ Lo, EH AF Lok, Josephine Wang, Hui Murata, Yoshihiro Zhu, Hai Hao Qin, Tao Whalen, Michael J. Lo, Eng H. TI Effect of neuregulin-1 on histopathological and functional outcome after controlled cortical impact in mice SO JOURNAL OF NEUROTRAUMA LA English DT Article DE controlled cortical impact; neuregulin; neuroprotection; probe; spatial memory; traumatic brain injury ID TRAUMATIC BRAIN-INJURY; COGNITIVE DYSFUNCTION; CEREBRAL-ISCHEMIA; TISSUE-DAMAGE; RATS; DEATH; RECOVERY; SURVIVAL; DEFICITS; STROKE AB Neuregulin-1 is a pleiotropic endogenous growth factor that is neuroprotective in experimental models of cerebral ischemia. We tested the hypothesis that pretreatment with neuregulin-1 would be similarly protective after traumatic brain injury in mice. Mice were administered neuregulin-1 or equal amounts of vehicle intravenously immediately before controlled cortical impact. Injured mice were subjected to motor and cognitive testing, and brain tissue loss was quantitated at 4 weeks. Compared to vehicle, pretreatment with neuregulin-1 had no effect on brain tissue loss, motor function, or acquisition of a spatial learning task. However, neuregulin-1 treated mice showed improved retention of spatial memory versus vehicle-treated mice in subsequent probe trials (p < 0.05). These proof-of-principle data suggest that neuregulin-1 may improve some functional outcomes after brain trauma. Further studies are therefore warranted to more carefully explore molecular mechanisms, dose-responses, and relationships between morphological outcome and long-term recovery. C1 [Lok, Josephine; Murata, Yoshihiro; Zhu, Hai Hao; Lo, Eng H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol & Neurol,Neuroprotect Res Lab, Boston, MA USA. [Lok, Josephine; Whalen, Michael J.] Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Boston, MA 02114 USA. [Wang, Hui] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Bone Marrow Transplantat Sect, Boston, MA USA. [Qin, Tao] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurosci, Boston, MA USA. RP Lok, J (reprint author), Neuroprotect Res Lab, MGH E 149-2401, Charlestown, MA 02129 USA. EM jlok1@partners.org FU NINDS NIH HHS [R01-NS48422, R01-NS47447, R01-NS37074, R01-NS53560, P01-NS55104] NR 23 TC 8 Z9 8 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD DEC PY 2007 VL 24 IS 12 BP 1817 EP 1822 DI 10.1089/neu.2007.0372 PG 6 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 245BR UT WOS:000251910000004 PM 18159993 ER PT J AU El Fakhri, G Santos, PA Badawi, RD Holdsworth, CH Van den Abbeele, AD Kijewski, MF AF El Fakhri, Georges Santos, Paula A. Badawi, Ramsey D. Holdsworth, Clay H. Van den Abbeele, Annick D. Kijewski, Marie Foley TI Impact of acquisition geometry, image processing, and patient size on lesion detection in whole-body F-18-FDG PET SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE whole-body F-18-FDG PET; 2D/3D acquisition; lesion detection; numeric observer ID EMISSION COMPUTED-TOMOGRAPHY; HUMAN-OBSERVER; TUMOR-DETECTION; FDG-PET; PERFORMANCE; NOISE; QUANTITATION; ONCOLOGY; SCANNER; MODEL AB The aim of this work was to develop a rigorous evaluation methodology to assess performance of different acquisition and processing methods for variable patient sizes in the context of lesion detection in whole-body F-18-FDG PET. Methods: Fifty-nine bed positions were acquired in 32 patients in 2-dimensional (2D) and 3-dimensional (3D) modes 1-4 h after F-18-FDG injection (740 MBq) using a EGO PET scanner. Three spheres (1.0-, 1.3-, and 1.6-cm diameter) containing Ge-68 were also imaged separately in air, at locations corresponding to possible lesion sites in 2D and 3D (590 targets per condition). Each bed position was acquired for 7 min in 2D and 6 min in 3D and corrected for randoms using delayed window randoms subtraction (DWS) or randoms variance reduction (RVR). Sphere sinograms were attenuated using the 2D or 3D attenuation map derived from the transmission scan of the patient, after scaling 2D and 3D sinograms with identical factors to ensure marginal detectability. Resulting 2D sinograms were reconstructed with filtered backprojection (FBP) and ordered-subsets expectation maximization (OSEM) without any scatter or attenuation correction (FBP-NATS and OSEM-NATS) or corrected for scatter and attenuation and reconstructed using FBP (FBP-ATT) or attenuation-weighted OSEM (AWOSEM). 3D sinograms were processed identically after Fourier rebinning. Next, reconstructed volumes were compared on the basis of performance of a 3-channel Hotelling observer (CHO-SNR [SNR is signal-to-noise ratio]) in detecting the presence of a sphere of unknown size on an anatomic background while modeling observer noise. The noise equivalent count (NEC) rate was computed in 2D and 3D for 3 different phantoms sizes (40, 60, and 95 kg) and compared with lesion detection SNR. Results: 3D imaging yielded better lesion detectability than 2D (P < 0.025, 2-tailed paired t test) in patients of normal size (body mass index [BMI] <= 31). However, 2D imaging yielded better lesion cletectability than 3D in large patients (BMI > 31), as 3D performance deteriorated in large patients (P < 0.05). 2D and 3D yielded similar results for different lesion sizes. CHO-SNR were 40% greater for AWOSEM, FBP-ATT, and FBPNAT than for OSEM (P < 0.05), and AWOSEM yielded significantly better lesion cletectability than did FBP. In all patients, RVR yielded a systematic improvement in CHO-SNR over DWS in both 2D and 3D. root NEC was characterized by a behavior similar to that of SNRCHO for the 3 different phantom sizes considered in this study. C1 [El Fakhri, Georges; Santos, Paula A.; Kijewski, Marie Foley] Harvard Univ, Brigham & Womens Hosp, Dept Radiol, Div Nucl Med, Boston, MA 02115 USA. [Santos, Paula A.] Univ Lisbon, Fac Sci, Biophys & Biomed Engn Inst, P-1699 Lisbon, Portugal. [Santos, Paula A.] Univ Calif Davis, Med Ctr, Dept Radiol, Sacramento, CA 95817 USA. [Van den Abbeele, Annick D.] Dana Faber Canc Inst, Dept Radiol, Boston, MA USA. RP El Fakhri, G (reprint author), Harvard Univ, Brigham & Womens Hosp, Dept Radiol, Div Nucl Med, 75 Francis St, Boston, MA 02115 USA. EM elfakhri@bwh.harvard.edu FU NIBIB NIH HHS [R01-EB001989, R01 EB000802, R01-EB000802, R01-EB005876] NR 22 TC 25 Z9 25 U1 0 U2 6 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD DEC PY 2007 VL 48 IS 12 BP 1951 EP 1960 DI 10.2967/jnumed.108.007369 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 258UN UT WOS:000252895100012 PM 18006613 ER PT J AU Billings, JA AF Billings, J. Andrew TI A palliative care career - J. Andrew Billings, MD SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Biographical-Item C1 Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA. RP Billings, JA (reprint author), Massachusetts Gen Hosp, Palliat Care Serv, 55 Fruit St,Founders 600, Boston, MA 02114 USA. EM jbillings@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD DEC PY 2007 VL 10 IS 6 BP 1258 EP 1261 DI 10.1089/jpm.2007.9844 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 248MK UT WOS:000252157200012 PM 18095803 ER PT J AU Hammel, JF Sullivan, AM Block, SD Twycross, R AF Hammel, James F. Sullivan, Amy M. Block, Susan D. Twycross, Robert TI End-of-life and palliative care education for final-year medical students: A comparison of Britain and the United States SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID FACULTY-DEVELOPMENT PROGRAM; SUSTAINING TREATMENT; HIDDEN CURRICULUM; DEATH; DECISIONS; SCHOOLS; BEREAVEMENT; LIMIT AB Purpose: (1) To assess British medical students' experiences and education in palliative care. (2) To compare experiences and education in palliative care between medical students in Britain and the United States. Method: Using a self-administered questionnaire adapted from an earlier U. S. study, British students were surveyed on the quantity and quality of palliative care education, training in specific end-of-life topics, preparation to provide end-of-life care, exposure to palliative care role models, attitudes, and culture. Results: Four hundred forty-five final-year students from four British medical schools (response rate 97% in sampled schools, or 12% of British final-year students in 2003) were compared to 1455 students from 62 U.S. schools (overall response rate 62%, or 9% of U.S. final-year students in 2001). Compared to U.S. students, British medical students reported more training in palliative care, more positive clinical encounters in palliative care, greater educational training in specific end-of-life topics, greater preparedness for caring for patients at the end of life, a culture within medicine more favorable toward palliative care, and attitudes more consistent with support for palliative care (all at statistically significant levels of p < 0.0001). Conclusions: Palliative care education, from the perspective of medical students, appears to be more effective in Britain than in the United States. Our findings suggest three changes with the potential to improve U. S. palliative care education of medical students: increasing required coursework in palliative care, increasing the number of palliative medicine role models, and creating robust academic palliative medicine departments to lead and support these advances. C1 [Hammel, James F.] Mt Sinai Med Ctr, Dept Psychiat, New York, NY 10029 USA. [Hammel, James F.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. [Hammel, James F.] Univ Oxford, Green Coll, Oxford, England. [Sullivan, Amy M.; Block, Susan D.] Dana Farber Canc Inst, Div Psychosoc Oncol & Palliat Care, Boston, MA 02115 USA. [Sullivan, Amy M.; Block, Susan D.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Sullivan, Amy M.; Block, Susan D.] Harvard Univ, Sch Med, Ctr Palliat Hlth Care, Cambridge, MA 02138 USA. [Twycross, Robert] Univ Oxford, Oxford OX1 2JD, England. RP Hammel, JF (reprint author), Mt Sinai Med Ctr, Dept Psychiat, 1 Gusteve Levy Pl, New York, NY 10029 USA. EM hammel@post.harvard.edu NR 39 TC 21 Z9 21 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD DEC PY 2007 VL 10 IS 6 BP 1356 EP 1366 DI 10.1089/jpm.2007.0059 PG 11 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 248MK UT WOS:000252157200024 PM 18095815 ER PT J AU Takeuchi, T Ham, M Mizumori, M Guth, PH Engel, E Kaunitz, JD Akiba, Y AF Takeuchi, T. Ham, M. Mizumori, M. Guth, P. H. Engel, E. Kaunitz, J. D. Akiba, Y. TI Solute diffusion through stripped mouse duodenum SO JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY LA English DT Article DE upper villous cells; fluorescence; CO2; ion transport inhibitor; chemical diffusion; serosal perfusate; duodenum; diffusion barrier carboxyfluorescein; dimethylamiloride; carbon dioxide; zomporide ID MUCOSAL BICARBONATE SECRETION; RAT SMALL-INTESTINE; HYDROGEN EXCHANGER ISOFORM-1; NECTURUS ANTRAL MUCOSA; INTRACELLULAR PH; IN-VIVO; HCO3-SECRETION; USSING CHAMBER; ION-TRANSPORT; CARBONIC-ANHYDRASES AB We measured villous cell intracellular pH (pH(i)) and solute diffusion between the bathing media and the epithelial cells in stripped, chambered mouse duodenum. Apical perfusion of a high CO2 solution rapidly acidified the upper villous cells with recovery after its removal. Apical zoniporide (ZP) enhanced CO2-induced acidification. Serosal ZP, dimethylamiloride (DMA) or stilbene anion transport inhibitors failed to alter CO2-induced acidification, whereas serosal high CO2 buffer acidified the upper villous cells. Serosal 5-hydroxytryptamine rapidly acidified the upper villous cells. All serosally-perfused fluorescent compounds stained the crypt area, but not the villi or villous cells. In contrast, intravenous carboxyfluorescein quickly diffused into the interstitial space of the entire mucosa, and mucosally perfused fluorescent compound rapidly penetrated the epithelial cell layer. In muscle-stripped duodenum mounted in a small-aperture perfusion chamber, serosal solutes can readily diffuse only to the crypt cell region, whereas access to the villous epithelial cells is diffusion-limited. In contrast, rapid villous cell responses to serosally applied solutes are best explained by neural reflexes. Limited viability of the villous cells and impaired structural stability of the villi further limit long-term, villous cell functional studies of mucosal preparations mounted in small aperture diffusion chambers. C1 [Guth, P. H.; Kaunitz, J. D.] Univ Calif Los Angeles, Greater Los Angles Vet Affairs Healthcare Syst, Los Angeles, CA 90024 USA. [Takeuchi, T.; Mizumori, M.; Kaunitz, J. D.; Akiba, Y.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Ham, M.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. [Engel, E.] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90024 USA. [Akiba, Y.] Brentwood Biomed Res Inst, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu NR 53 TC 4 Z9 4 U1 0 U2 4 PU POLISH PHYSIOLOGICAL SOC PI GRZEGORZECKA PA JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31-531 KRAKOW, 16 GRZEGORZECKA, POLAND SN 0867-5910 J9 J PHYSIOL PHARMACOL JI J. Physiol. Pharmacol. PD DEC PY 2007 VL 58 IS 4 BP 767 EP 791 PG 25 WC Physiology SC Physiology GA 245ZB UT WOS:000251976200013 PM 18195487 ER PT J AU Fueki, K Kimoto, K Ogawa, T Garrett, NR AF Fueki, Kenji Kimoto, Katsuhiko Ogawa, Takahiro Garrett, Neal R. TI Effect of implant-supported or retained dentures on masticatory performance: A systematic review SO JOURNAL OF PROSTHETIC DENTISTRY LA English DT Review ID REMOVABLE PARTIAL DENTURES; COOPERATIVE DENTAL IMPLANT; WEARING FIXED PROSTHESIS; 2 TREATMENT MODALITIES; BLADE-VENT IMPLANTS; OSSEOINTEGRATED IMPLANTS; PATIENT SATISFACTION; ORAL FUNCTION; MANDIBULAR OVERDENTURES; CONVENTIONAL DENTURES AB Statement of problem. While subjective patient-based measures have been recognized as critical outcomes for prosthodontic treatment, there continues to be a need to validate for patients what changes in masticatory function can be expected with the provision of new implant-supported or retained dentures. Purpose. The purpose of this review was to evaluate the critical factors impacting change in masticatory performance following the provision of new implant-supported or retained dentures. Material and methods. Information retrieval followed a systematic approach using PubMed and the Cochrane Library. English articles published from 1966 to June 2007, in which the masticatory performance of subjects with implant-supported or retained dentures was assessed by objective methods and compared to performance with conventional dentures, were included. Ratings of the evidence provided in each article followed United States Agency for Healthcare Research and Quality recommendations. Results. From 281 articles identified, 18 peer-reviewed articles met prespecified criteria for inclusion. Specific outcomes of significance identified by these articles rated as level II are: (1) fixed implant-supported partial dentures do not provide significant improvement in masticatory performance compared to conventional removable partial dentures for Kennedy Class I and II partially edentulous mandibles; (2) the combination of a mandibular implant-supported or retained overdenture (IOD) and maxillary conventional complete denture (CD) provides significant improvement in masticatory performance compared to CDs in both the mandible and maxilla for a limited population having persistent functional problems with an existing mandibular CD due to severely resorbed mandible; and (3) the type of implant and attachment system for mandibular IODs has a limited impact. Specific outcomes of significance identified by articles rated as having a moderate level of evidence (level III) are: (1) mandibular fixed implant-supported complete dentures provide significant improvement in masticatory performance compared to mandibular CDs in subjects dissatisfied with their CDs; and (2) implant-supported mandibular resection dentures have an advantage over conventional dentures in masticatory performance on the defect side of the mouth. C1 [Fueki, Kenji] Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo 1138549, Japan. [Kimoto, Katsuhiko] Kanagawa Dent Coll, Dept Oral & Maxillofacial Rehabil, Yokosuka, Kanagawa 238, Japan. [Ogawa, Takahiro] Univ Calif Los Angeles, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Sch Dent, Los Angeles, CA USA. [Garrett, Neal R.] Vet Adm Greater Los Angeles Healthhcare Syst, Dent Res Lab, Los Angeles, CA USA. [Ogawa, Takahiro; Garrett, Neal R.] Univ Calif Los Angeles, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Div Adv Prosthodont Biomat, Los Angeles, CA 90024 USA. [Ogawa, Takahiro; Garrett, Neal R.] Univ Calif Los Angeles, Hosp Dent, Jane & Jerry Weintraub Ctr Reconstruct, Los Angeles, CA 90024 USA. RP Fueki, K (reprint author), Tokyo Med & Dent Univ, Bunkyo Ku, 1-5-45 Yuhima, Tokyo 1138549, Japan. EM kunfu.rpro@tmd.ac.jp RI Fueki, Kenji/A-9909-2008 OI Fueki, Kenji/0000-0002-5885-2447 FU NCRR NIH HHS [C06 RR-14529-01] NR 40 TC 60 Z9 68 U1 2 U2 25 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3913 J9 J PROSTHET DENT JI J. Prosthet. Dent. PD DEC PY 2007 VL 98 IS 6 BP 470 EP 477 DI 10.1016/S0022-3913(07)60147-4 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 248OS UT WOS:000252164100007 PM 18061741 ER PT J AU Zhang, XY Tan, YL Zhou, DF Cao, LY Wu, GY Xu, Q Shen, Y Halle, CN Kosten, TA Kosten, TR AF Zhang, Xiang Yang Tan, Yun Long Zhou, Dong Feng Cao, Lian Yuan Wu, Gui Ying Xu, Qi Shen, Yan Halle, Colin N. Kosten, Therese A. Kosten, Thomas R. TI Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE schizophrenia; antipsychotic; weight gain; BDNF; serum; sex difference ID NEUROTROPHIC FACTOR; MESSENGER-RNA; ATYPICAL ANTIPSYCHOTICS; TARDIVE-DYSKINESIA; DECREASED LEVELS; RAT HIPPOCAMPUS; BRAIN; MICE; EXPRESSION; OBESITY AB Several lines of evidence suggest that central brain-derived neurotrophic factor (BDNF) modulates food intake, metabolism, and increases in body weight. Reports have also shown that serum BDNF is altered in schizophrenic patients treated with antipsychotics. This study aimed to determine if there was a relationship between BDNF and antipsychotic-induced weight gain in patients with chronic schizophrenia. Serum BDNF was measured in 124 schizophrenia patients chronically treated with clozapine (n = 57), risperidone (n = 23) or typical antipsychotics (n = 44) and 50 healthy control subjects. To further assess group differences in serum BDNF, additional analyses were performed in a subset of patients and controls individually matched for body mass index (BMI). BDNF levels were lower in patients with schizophrenia than normal controls. However, this difference was not present when controlling for current BMI. In the individually BMI-matched sample, no differences in serum BDNF levels were observed in schizophrenic patients compared to BMI-matched healthy controls. BDNF levels negatively correlated with BMI gain in female but not in male patients when gender was considered. Antipsychotic class exerted differential effects over BDNF levels and BMI gain. Our findings suggest that decreased BDNF levels may be associated with weight gain in female schizophrenic patients on long-term antipsychotic treatment. (c) 2006 Published by Elsevier Ltd. C1 Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Peking Univ, Inst Metal Hlth, Beijing 100083, Peoples R China. Beijing Hui Long Guan Hosp, Ctr Biol Psychiat, Beijing 100096, Peoples R China. Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China. Peking Union Med, Beijing 100005, Peoples R China. RP Zhang, XY (reprint author), Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Bldg 109,Rm 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu OI Haile, Colin/0000-0001-8293-7291 FU NIDA NIH HHS [K05-DA0454, P50-DA18827] NR 52 TC 44 Z9 47 U1 2 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD DEC PY 2007 VL 41 IS 12 BP 997 EP 1004 DI 10.1016/j.jpsychires.2006.08.007 PG 8 WC Psychiatry SC Psychiatry GA 215TZ UT WOS:000249833200003 PM 17095017 ER PT J AU Dickerson, BC AF Dickerson, Bradford C. TI The brain and behavior: An introduction to behavioral neuroanatomy SO JOURNAL OF PSYCHOSOMATIC RESEARCH LA English DT Book Review C1 [Dickerson, Bradford C.] Massachusetts Gen Hosp, Memory Disorders Unit, Harvard Med Sch, Boston, MA 02114 USA. RP Dickerson, BC (reprint author), Massachusetts Gen Hosp, Memory Disorders Unit, Harvard Med Sch, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3999 EI 1879-1360 J9 J PSYCHOSOM RES JI J. Psychosomat. Res. PD DEC PY 2007 VL 63 IS 6 BP 683 EP 683 DI 10.1016/j.jpsychores.2007.01.005 PG 1 WC Psychiatry SC Psychiatry GA 240XY UT WOS:000251622700016 ER PT J AU Bunton, K Kent, RD Duffy, JR Rosenbek, JC Kent, JF AF Bunton, Kate Kent, Raymond D. Duffy, Joseph R. Rosenbek, John C. Kent, Jane F. TI Listener agreement for auditory-perceptual ratings of dysarthria SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH LA English DT Article DE auditory-perceptual ratings; dysarthria; listener agreement ID VOICE QUALITY; SPEAKING TASK; SPEECH; RELIABILITY; SAMPLES AB Purpose: Darley, Aronson, and Brown (1969a, 1969b) detailed methods and results of auditory-perceptual assessment for speakers with dysarthrias of varying etiology. They reported adequate listener reliability for use of the rating system as a tool for differential diagnosis, but several more recent studies have raised concerns about listener reliability using this approach. Method: In the present study, the authors examined intrarater and interrater agreement for perceptual ratings of 47 speakers with various dysarthria types by 2 listener groups (inexperienced and experienced). The entire set of perceptual features proposed by Darley et al. was rated based on a 40-s conversational speech sample. Results: No differences in levels of agreement were found between the listener groups. Agreement was within 1 scale value or better for 67% of the pairwise comparisons. Levels of agreement were lower when the average rating fell in the mid-range of the scale compared with samples that had an average rating near either of the scale endpoints; agreement was above chance level. No significant differences in agreement were found between the perceptual features. Discussion: The levels of listener agreement that were found indicate that auditory-perceptual ratings show promise during clinical assessment for identifying salient features of dysarthria for speakers with various etiologies. C1 [Bunton, Kate; Kent, Raymond D.] Waisman Ctr Mental Retardat & Human Dev, Madison, WI USA. [Duffy, Joseph R.] Mayo Clin, Rochester, NY USA. [Rosenbek, John C.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Bunton, K (reprint author), Univ Arizona, Dept Speech Language & Hearing Sci, POB 210071, Tucson, AZ 85721 USA. EM bunton@u.arizona.edu FU NIDCD NIH HHS [R01 DC00319, R03 DC005902] NR 31 TC 32 Z9 32 U1 0 U2 6 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1092-4388 J9 J SPEECH LANG HEAR R JI J. Speech Lang. Hear. Res. PD DEC 1 PY 2007 VL 50 IS 6 BP 1481 EP 1495 DI 10.1044/1092-4388(2007/102) PG 15 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA 267HG UT WOS:000253499500006 PM 18055769 ER PT J AU Johnson, TS O'Neill, AC Motarjem, PM Amann, C Nguyen, T Randolph, MA Winograd, JM Kochevar, IE Redmond, RW AF Johnson, T. Shane O'Neill, Anne C. Motarjem, Pejman M. Amann, Christopher Nguyen, Tuan Randolph, Mark A. Winograd, Jonathan M. Kochevar, Irene E. Redmond, Robert W. TI Photochemical tissue bonding: A promising technique for peripheral nerve repair SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE tissue bonding; rose bengal; sciatic nerve; nerve repair; photochemistry tissue adhesive ID RAT SCIATIC-NERVE; PROTEIN BAND TECHNIQUE; CARBON-DIOXIDE LASER; FIBRIN GLUE; MICROEPINEURIAL ANASTOMOSES; CORNEAL INCISIONS; SUTURE TECHNIQUES; FACIAL-NERVE; REGENERATION; KERATODESMOS AB Background. Photochemical tissue bonding (PTB) is a novel tissue repair technique that uses visible light and a photosensitizing dye to crosslink proteins on tissue surfaces. This technique has been successfully demonstrated in a number of tissue repair models. An ideal nerve repair technique would be atraumatic and avoid placement of foreign bodies at the repair site. The epineurium is suited to photochemical repair as it is thin, translucent and has a relatively high collagen content. This study was designed to determine if PTB could be successfully applied in a peripheral nerve repair model. Material and methods. Forty Sprague Dawley rats underwent transection of the sciatic nerve. Animals were then randomized to four treatment groups; epineurial suture repair, epineurial cuff with PTB, epineurial cuff alone, and no repair. Functional recovery was assessed at 10 day intervals using walking track analysis and sciatic function index calculations. At 90 days postoperatively animals were sacrificed and sciatic nerves harvested for histology and histomorphometry. Results. Functional recovery in the suture repair and epineural cuff with PTB groups were not significantly different (-70.6 \ 17.8 versus -76.9 \ 10.3, P = 0.64) at 90 days postrepair. Histology showed good axonal regeneration with all repair techniques. Histomorphometric analysis found no significant difference between the repair groups. Conclusions. This study illustrates that peripheral nerves can be successfully repaired using a photochemical tissue bonding technique with results similar to those achieved with the current gold standard. With further development and refinement PTB may prove a useful tool in peripheral nerve repair. (c) 2007 Elsevier Inc. All rights reserved. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Plast Surg Res Lab, Boston, MA 02114 USA. RP Redmond, RW (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, W-224, Boston, MA 02114 USA. EM redmond@helix.mgh.harvard.edu NR 22 TC 25 Z9 30 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD DEC PY 2007 VL 143 IS 2 BP 224 EP 229 DI 10.1016/j.jss.2007.01.028 PG 6 WC Surgery SC Surgery GA 236CS UT WOS:000251281200006 PM 17543988 ER PT J AU Zhang, W Liu, M Wu, YC Zhu, PC Yin, CJ Zhang, W Gu, M AF Zhang, Wei Liu, Min Wu, Yichao Zhu, Pengcheng Yin, Changjun Zhang, Wei Gu, Min TI Protective effects of atorvastatin on chronic allograft nephropathy in rats SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE kidney transplantation; chronic allograft nephropathy; atorvastatin; fibrosis ID CYCLOSPORINE-INDUCED NEPHROPATHY; COA REDUCTASE INHIBITORS; GROWTH-FACTOR-BETA; INTERSTITIAL INFLAMMATION; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; PROTEIN-KINASE; PRAVASTATIN; EXPRESSION; STATINS AB Objective. Chronic allograft nephropathy (CAN) is the leading cause of late kidney allograft loss. Recent studies have suggested that atorvastatin (ATO) may interact with the acute inflammatory process in the renal interstitium and suppress the proliferation of mesangial cells. We hypothesized that ATO could also inhibit the chronic inflammatory process and prevent the progression of CAN. Materials and methods. Fisher (F344) kidneys were orthotopically transplanted into Lewis rat recipients. Lewis-to-Lewis rat kidney transplantation was served as the syngeneic control (Syn group). Allograft recipients were randomized and treated with cyclosporine A alone (Allo group) or in combination with ATO (15 or 30 mg/kg/d intrgastric, respectively, the low dose treatment group/high dose treatment group [LT/HT] groups). Renal function and the urine protein excretion were analyzed. Animals were sacrificed 20 weeks posttransplantation for histological and immunohistochemical studies, as well as analysis of mRNA levels of cytokines and chemokines. Results. Renal function progressively deteriorated and substantial proteinuria developed in the Allo group compared with the Syn group. ATO-treated rats had significantly higher creatinine clearance rate and less amount of proteinuria. Histological examination revealed obvious features of CAN in the Allo group, whereas LT/HT groups demonstrated minimal glomerulosclerosis, interstitial fibrosis, intimal thickening, and tubular atrophy. The numbers of infiltrating mononuclear cells (ED1+, CD8+, and CD68+) decreased markedly, and the intragraft expression of transforming growth factor beta 1 (TGF-beta 1) and collagen III were also significantly attenuated in the LT/HT groups, as compared with the Allo group. The mRNA levels of proinflammatory cytokines (interieukin-2, interferon-gamma, interleukin-10), chemokines (RANTES, MCP-1), and profibrotic genes (TGF-beta 1, collagen 111) were significantly down-regulated in ATO-treated rats. Conclusion. Atorvastatin showed excellent favorable effects on blocking renal inflammation and fibrosis, and thus, efficiently inhibited the development and progression of CAN, which might improve the long-term survival rate of renal allografts. (c) 2007 Elsevier Inc. All rights reserved. C1 Nanjing Med Univ, Affiliated Hosp 1, Div Urol & Kidney Transplantat, Nanjing 210029, Jiangsu, Peoples R China. Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA. RP Zhang, W (reprint author), Nanjing Med Univ, Affiliated Hosp 1, Div Urol & Kidney Transplantat, Nanjing 210029, Jiangsu, Peoples R China. EM zhangwei@medmail.com.cn OI Liu, Min/0000-0002-8117-4808 NR 42 TC 16 Z9 17 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD DEC PY 2007 VL 143 IS 2 BP 428 EP 436 DI 10.1016/j.jss.2006.12.557 PG 9 WC Surgery SC Surgery GA 236CS UT WOS:000251281200035 PM 17628598 ER PT J AU Sisto, R Moleti, A Shera, CA AF Sisto, Renata Moleti, Arturo Shera, Christopher A. TI Cochlear reflectivity in transmission-line models and otoacoustic emission characteristic time delays SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article ID COHERENT REFLECTION; BASILAR-MEMBRANE; LATENCY AB In transmission-line models of cochlear mechanics, predictions about otoacoustic-emission delays depend on the place- or wave-fixed nature of the emission generation mechanism. In this work, transient evoked otoacoustic emissions (TEOAEs), recorded at different stimulus levels in 10 young subjects, were analyzed using wavelet-based time-frequency analysis to determine the latency of each frequency component of the response. The,same wave forms were Fourier analyzed to evaluate the phase-gradient delay as a function of frequency. Interpreting the relation between these two characteristic delays using cochlear models shows that most of the TEOAE response can be attributed to place-fixed reflection mechanisms. The causality principle explains observed correlations between fluctuations of the TEOAE amplitude and phase-gradient delay. (c) 2007 Acoustical Society of America. C1 [Sisto, Renata] ISPESL, Dipartimento Igiene Lavoro, I-00040 Rome, Italy. [Moleti, Arturo] Univ Roma Tor Vergata, Dipartimento Fis, I-00133 Rome, Italy. [Shera, Christopher A.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab Auditory Physiol, Boston, MA 02114 USA. [Shera, Christopher A.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Sisto, R (reprint author), ISPESL, Dipartimento Igiene Lavoro, Via Fontana Candida 1, I-00040 Rome, Italy. EM r.sisto@dil.ispesl.it; arturo.moleti@roma2.infn.it; shera@epl.meei.harvard.edu RI Moleti, Arturo/P-6812-2016; OI Moleti, Arturo/0000-0002-2465-8849; Renata, Sisto/0000-0002-5086-7003 FU NIDCD NIH HHS [R01 DC003687] NR 23 TC 24 Z9 24 U1 0 U2 1 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD DEC PY 2007 VL 122 IS 6 BP 3554 EP 3561 DI 10.1121/1.2799498 PG 8 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA 241IS UT WOS:000251650700037 PM 18247763 ER PT J AU Kalluri, R Shera, CA AF Kalluri, Radha Shera, Christopher A. TI Comparing stimulus-frequency otoacoustic emissions measured by compression, suppression, and spectral smoothing SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article ID NONLINEAR MECHANICS; AMPLITUDE; COCHLEA; DPOAE; PHASE; OAES AB Stimulus-frequency otoacoustic emissions (SFOAEs) have been measured in several different ways, including (1) nonlinear compression, (2) two-tone suppression, and (3) spectral smoothing. Each of the three methods exploits a different cochlear phenomenon or signal-processing technique to extract the emission. The compression method makes use of the compressive growth of emission amplitude relative to the linear growth of the stimulus. The emission is defined as the complex difference between ear-canal pressure measured at one intensity and the rescaled pressure measured at a higher intensity for which the emission is presumed negligible. The suppression method defines the SFOAE as the complex difference between the ear-canal pressure measured with and without a suppressor tone at a nearby frequency. The suppressor tone is presumed to substantially reduce or eliminate the emission. The spectral smoothing method involves convolving the complex ear-canal pressure spectrum with a smoothing function. The analysis exploits the differing latencies of stimulus and emission and is equivalent to windowing in the corresponding latency domain. Although the three methods are generally assumed to yield identical emissions, no equivalence has. ever been established. This paper compares human SFOAEs measured with the three methods using procedures that control for temporal drifts, contamination of the calibration by evoked emissions, and other potential confounds. At low stimulus intensities, SFOAEs measured using all three methods are nearly identical. At higher intensities, limitations of the procedures contribute to small differences, although the general spectral shape and phase of the three SFOAEs remain similar. The near equivalence of SFOAEs measured by compression, suppression, and spectral smoothing indicates that SFOAE characteristics are not mere artifacts of measurement methodology. (c) 2007 Acoustical Society of America. C1 [Kalluri, Radha; Shera, Christopher A.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab Auditory Physiol, Boston, MA 02114 USA. [Kalluri, Radha; Shera, Christopher A.] MIT, Harvard Mit Div Hlth Sci & Technol, Speech & Hearing Biosci & Technol Program, Cambridge, MA 02138 USA. [Shera, Christopher A.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Kalluri, R (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab Auditory Physiol, 243 Charles St, Boston, MA 02114 USA. EM shera@epl.meei.harvard.edu FU NIDCD NIH HHS [R01 DC03687, R01 DC003687] NR 40 TC 36 Z9 38 U1 0 U2 5 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD DEC PY 2007 VL 122 IS 6 BP 3562 EP 3575 DI 10.1121/1.2793604 PG 14 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA 241IS UT WOS:000251650700038 PM 18247764 ER PT J AU Lauer, AM Dooling, RJ Leek, MR Poling, K AF Lauer, Amanda M. Dooling, Robert J. Leek, Marjorie R. Poling, Kirsten TI Detection and discrimination of simple and complex sounds by hearing-impaired Belgian Waterslager canaries SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article ID PARAKEET MELOPSITTACUS-UNDULATUS; STARLING STURNUS-VULGARIS; AUDITORY INTENSITY DISCRIMINATION; TEMPORAL INTEGRATION; SERINUS-CANARIUS; FREQUENCY DISCRIMINATION; DURATION DISCRIMINATION; HARMONIC COMPLEXES; DIFFERENCE LIMENS; ADULT CHICKENS AB Belgian Waterslager canaries (BWC) are bred to produce a distinctive low-pitched song with energy restricted to a lower range of frequencies than in other types of canaries. Previous studies have shown a high frequency hearing loss primarily above 2000 Hz that is related to hair cell abnormalities in BWC, but little is known about auditory perception in these birds. Here, frequency, duration, and intensity discrimination, temporal integration, gap detection, and discrimination of temporally reversed harmonic cornplexes in BWC were measured and compared to normal-hearing non-BWC. BWC had excellent frequency discrimination ability at 1000 Hz, but showed poor frequency discrimination compared to non-BWC at frequencies in the region of hearing loss. Duration and intensity discrimination were not adversely affected in BWC. Temporal integration was reduced in BWC, except at 2000 Hz. Gap detection and discrimination of temporally reversed stimuli were somewhat better in BWC than in non-BWC. Those tests that relied primarily on temporal processing were less affected by the cochlear damage in BWC than tests that probably relied more on audibility and spectral analysis. Thus, despite significant high frequency hearing loss and extensive damage along the basilar papilla, BWC retain relatively good hearing abilities under many conditions. (c) 2007 Acoustical Society of America. C1 [Lauer, Amanda M.; Dooling, Robert J.; Poling, Kirsten] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. [Leek, Marjorie R.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97207 USA. RP Lauer, AM (reprint author), Johns Hopkins Univ, 521 Traylor Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA. EM alauer2@jhmi.edu OI Lauer, Amanda/0000-0003-4184-7374 FU NIDCD NIH HHS [DC-00626, DC-005450, DC-01372, DC-04664, F31 DC005450, P30 DC004664, R01 DC001372] NR 68 TC 6 Z9 7 U1 1 U2 9 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 EI 1520-8524 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD DEC PY 2007 VL 122 IS 6 BP 3615 EP 3627 DI 10.1121/1.2799482 PG 13 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA 241IS UT WOS:000251650700043 PM 18247769 ER PT J AU Potter, M Bullitt, E AF Potter, Mona Bullitt, Ethel TI The case against homework: How homework is hurting our children and what we can do about it SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Book Review C1 Massachusetts Gen Hosp, McLean Hosp, Boston, MA 02114 USA. RP Potter, M (reprint author), Massachusetts Gen Hosp, McLean Hosp, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 4 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD DEC PY 2007 VL 46 IS 12 BP 1677 EP 1678 DI 10.1097/01.chi.0000270795.20196.49 PG 2 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 234DV UT WOS:000251141800018 ER PT J AU Potter, M Bullitt, E AF Potter, Mona Bullitt, Ethel TI The homework myth: Why our kids get too much of a bad thing SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Book Review C1 Massachusetts Gen Hosp, McLean Hosp, Boston, MA 02114 USA. RP Potter, M (reprint author), Massachusetts Gen Hosp, McLean Hosp, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 4 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD DEC PY 2007 VL 46 IS 12 BP 1677 EP 1678 DI 10.1097/01.chi.0000270795.20196.49 PG 2 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 234DV UT WOS:000251141800017 ER PT J AU Gordon, CM Anderson, EJ Herlyn, K Hubbard, JL Pizzo, A Gelbard, R Lapey, A Merkel, PA AF Gordon, Catherine M. Anderson, Ellen J. Herlyn, Karen Hubbard, Jane L. Pizzo, Angela Gelbard, Rondi Lapey, Allen Merkel, Peter A. TI Nutrient status of adults with cystic fibrosis SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Article ID VITAMIN-D; BODY-COMPOSITION; NUTRITIONAL ASSESSMENT; CLINICAL STATUS; BONE HEALTH; CHILDREN; OSTEOPOROSIS; ADOLESCENTS; MANAGEMENT; OSTEOPENIA AB Nutrition is thought to influence disease status in patients with cystic fibrosis (CF). This cross-sectional study sought to evaluate nutrient intake and anthropometric data from 64 adult outpatients with cystic fibrosis. Nutrient intake from food and supplements was compared with the Dietary Reference Intakes for 16 nutrients and outcomes influenced by nutritional status. Attention was given to vitamin D and calcium given potential skeletal implications due to cystic fibrosis. Measurements included weight, height, body composition, pulmonary function, and serum metabolic parameters. Participants were interviewed about dietary intake, supplement use, pulmonary function, sunlight exposure, and pain. The participants' mean body mass index ( standard deviation) was 21.8+/-4.9 and pulmonary function tests were normal. Seventy-eight percent used pancreatic enzyme replacement for malabsorption. Vitamin D deficiency [25-hydroxyvitamin D (250HD)<37.5 nmol/L] was common: 25 (39%) were deficient despite adequate vitamin D intake. Lipid profiles were normal in the majority, even though total and saturated fat consumption represented 33.0% and 16.8% of energy intake, respectively. Reported protein intake represented 16.9% of total energy intake (range 10%-25%). For several nutrients, including vitamin D and calcium, intake from food and supplements in many participants exceeded recommended Tolerable Upper Intake Levels. Among adults with cystic fibrosis, vitamin D deficiency was common despite reported adequate intake, and lipid profiles were normal despite a relatively high fat intake. Mean protein consumption was adequate, but the range of intake was concerning, as both inadequate or excessive intake may have deleterious skeletal effects. These findings call into question the applicability of established nutrient thresholds for patients with cystic fibrosis. C1 [Gordon, Catherine M.] Childrens Hosp, Div Adolescent Med, Boston, MA 02115 USA. [Gordon, Catherine M.] Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA. [Anderson, Ellen J.; Hubbard, Jane L.] Massachusetts Gen Hosp, Mallinckrodt Gen Clin Res Ctr, Boston, MA 02114 USA. [Herlyn, Karen; Pizzo, Angela; Merkel, Peter A.] Massachusetts Gen Hosp, Rheumatol Unit, Boston, MA 02114 USA. [Pizzo, Angela; Gelbard, Rondi; Merkel, Peter A.] Boston Univ, Sch Med, Rheumatol Sect, Boston, MA 02118 USA. [Lapey, Allen] Massachusetts Gen Hosp, Cyst Fibrosis Res Ctr, Boston, MA 02114 USA. [Lapey, Allen] Massachusetts Gen Hosp, Div Pediat Pulmonol, Boston, MA 02114 USA. [Merkel, Peter A.] Boston Univ, Sch Med, Clin Epidemiol Unit, Boston, MA 02118 USA. RP Gordon, CM (reprint author), Childrens Hosp, Div Adolescent Med, 300 Longwood Ave, Boston, MA 02115 USA. EM catherine.gordon@childrens.harvard.edu FU NCRR NIH HHS [M01 RR002172, M01 RR 01066, M01 RR001066, M01 RR2172]; NIAMS NIH HHS [K24 AR002224, K24 AR02224]; NIDDK NIH HHS [P30 DK040561, P30 DK040561-12] NR 42 TC 22 Z9 23 U1 0 U2 5 PU AMER DIETETIC ASSOC PI CHICAGO PA 216 W JACKSON BLVD #800, CHICAGO, IL 60606-6995 USA SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD DEC PY 2007 VL 107 IS 12 BP 2114 EP 2119 DI 10.1016/j.jada.2007.09.005 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 239ZY UT WOS:000251558000014 PM 18060897 ER PT J AU Yosefy, C Levine, RA Picard, MH Vaturi, M Handschumacher, MD Isselbacher, EM AF Yosefy, Chaim Levine, Robert A. Picard, Michael H. Vaturi, Mordehay Handschumacher, Mark D. Isselbacher, Eric M. TI Pseudodyskinesis of the inferior left ventricular wall: Recognizing an echocardiographic mimic of myocardial infarction SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY LA English DT Article ID TWO-DIMENSIONAL ECHOCARDIOGRAPHY; CORONARY-ARTERY DISEASE; SEPTAL MOTION; NATURAL-HISTORY; CARDIAC-SURGERY; DIAPHRAGM; ISCHEMIA; SHAPE; MECHANISM; EXPANSION AB Introduction: Dyskinesis is diagnosed by outward systolic bulging, but a similar inferior wall (IW) motion is sometimes observed in patients without infarction. Such diastolic flattening of the IW is followed by systolic rounding and outward bulging, consistent with extrinsic diastolic compression that is overcome by systolic contraction. Hypothesis: Pseudodyskinesis (PD) (paradoxical IW motion) is associated with preserved systolic wall thickening and does not reflect ischemic dysfunction. Methods. We compared 100 consecutive patients having a pattern of PD on transthoracic echocardiography with control groups of 50 patients with documented inferior myocardial infarction and 50 healthy individuals. Percent systolic thickening of the inferior, anterior, septal, and lateral left ventricular (LV) walls was measured in a midventricular short-axis view, and LV cross-sectional shape was evaluated by the ratio of two perpendicular diameters. Diaphragmatic position was evaluated on chest radiograph. Results: Systolic IW thickening was not significantly different in PD from that of normal (58.2 +/- 6.2% vs 53.0 +/- 4.6%) and of non-IW in the same patients (50.4 +/- 6.8%). The LV was circular (diameter ratio= 1.0) in systole and diastole in healthy individuals; in PD, it was noncircular in diastole consistent with IW compression (P <.01), and circular in systole; in inferior myocardial infarction, it was circular in diastole and noncircular in systole (P <.01) consistent with decreased IW contraction. The left hemidiaphragm was more elevated in PD (78% vs 8.5%, P <.01). Conclusions: In PD, the IW thickens normally to produce a circular LV cavity in systole. This motion, consistent with extrinsic compression, is important to distinguish from inferior myocardial infarction. C1 [Yosefy, Chaim; Levine, Robert A.; Picard, Michael H.; Vaturi, Mordehay; Handschumacher, Mark D.; Isselbacher, Eric M.] Harvard Univ, Cardiac Ultrasound Lab, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Isselbacher, EM (reprint author), Harvard Univ, Cardiac Ultrasound Lab, Massachusetts Gen Hosp, Sch Med, 55 Fruit St,YAW 5800, Boston, MA 02114 USA. EM eisselbacher@partners.org OI Picard, Michael/0000-0002-9264-3243 NR 32 TC 3 Z9 4 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0894-7317 J9 J AM SOC ECHOCARDIOG JI J. Am. Soc. Echocardiogr. PD DEC PY 2007 VL 20 IS 12 BP 1374 EP 1379 DI 10.1016/j.echo.2007.05.003 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 248JL UT WOS:000252149500009 PM 17764898 ER PT J AU Schwartzman, A AF Schwartzman, Armin TI Statistical analysis of diffusion tensors in diffusion-weighted magnetic resonance imaging data - Comment SO JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION LA English DT Editorial Material C1 [Schwartzman, Armin] Dana Farber Canc Inst, Harvard Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Schwartzman, A (reprint author), Dana Farber Canc Inst, Harvard Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. EM armins@hsph.harvard.edu OI Schwartzman, Armin/0000-0001-5335-1611 NR 5 TC 1 Z9 1 U1 0 U2 0 PU AMER STATISTICAL ASSOC PI ALEXANDRIA PA 1429 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0162-1459 J9 J AM STAT ASSOC JI J. Am. Stat. Assoc. PD DEC PY 2007 VL 102 IS 480 BP 1102 EP 1105 DI 10.1198/016214507000001193 PG 4 WC Statistics & Probability SC Mathematics GA 243WY UT WOS:000251829200002 ER PT J AU Zwaginga, JJ Sakarjassen, KS King, MR Diacovo, TG Grabowski, EF Nash, G Hoylaerts, M Heemskerk, JWM AF Zwaginga, J. J. Sakarjassen, K. S. King, M. R. Diacovo, T. G. Grabowski, E. F. Nash, G. Hoylaerts, M. Heemskerk, J. W. M. CA The Biorheology Subcommittee TI Can blood flow assays help to identify clinically relevant differences in von Willebrand factor functionality in von Willebrand disease types 1-3? SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Article ID VONWILLEBRAND DISEASE; PLATELET-ADHESION; DIAGNOSIS AB Department of Experimental Immunohaematology, Sanquin Research, Amsterdam and Immunohaematology Bloodtransfusion, University Hospital Leiden, Leiden, the Netherlands; double dagger KellSa s. a. s., Biella, Italy; double dagger Department of Biomedical Engineering, University of Rochester, Rochester, New York, NY; Departments of Pediatrics and Pathology, Columbia University Medical Center, New York, NY; Cardiovascular Thrombosis Laboratory, Massachusetts General Hospital-Harvard Medical School, Boston, MA, USA; **Centre for Cardiovascular Sciences and MRC Centre for Immune Regulation, University of Birmingham, Birmingham, UK; double dagger double dagger Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium; and double dagger double dagger Department of Biochemistry, CARIM, University of Maastricht, Maastricht, the Netherlands C1 Leiden Univ Hosp, Dept Expt Immunohaematol, Sanquin Res, Amsterdam & Immunohaematol Bloodtransfus, Leiden, Netherlands. KellSa, Biella, Italy. Univ Rochester, Dept Biomed Engn, Rochester, NY 14627 USA. Columbia Univ, Ctr Med, Dept Pediat, New York, NY USA. Columbia Univ, Ctr Med, Dept Pathol, New York, NY USA. Massachusetts Gen Hosp, Harvard Med Sch, Cardiovasc Thrombosis Lab, Boston, MA USA. Univ Birmingham, MRC Ctr Immune Regulat, Ctr Cardiovasc Sci, Birmingham, W Midlands, England. Univ Leuven, Ctr Mol & Vasc Biol, Louvain, Belgium. Univ Maastricht, CARIM, Dept Biochem, Maastricht, Netherlands. RP Zwaginga, JJ (reprint author), Leiden Univ Hosp, PO Box 9600, NL-2300 RC Leiden, Netherlands. EM j.j.zwaginga@lumc.nl RI King, Michael/A-1138-2007; Nash, Gerard/E-4182-2010 OI Nash, Gerard/0000-0002-5935-2831 NR 9 TC 15 Z9 15 U1 1 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1538-7933 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD DEC PY 2007 VL 5 IS 12 BP 2547 EP 2549 DI 10.1111/j.1538-7836.2007.02807.x PG 3 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 234ZP UT WOS:000251203600031 PM 17944987 ER PT J AU Jakupcak, M Conybeare, D Phelps, L Hunt, S Holmes, HA Felker, B Klevens, M McFall, ME AF Jakupcak, Matthew Conybeare, Daniel Phelps, Lori Hunt, Stephen Holmes, Hollie A. Felker, Bradford Klevens, Michele McFall, Miles E. TI Anger, hostility, and aggression among Iraq and Afghanistan war veterans reporting PTSD and subthreshold PTSD SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; VIETNAM COMBAT VETERANS; TRAUMA-RELATED SYMPTOMS; OPERATION DESERT-STORM; PRIMARY-CARE; COMPENSATION-SEEKING; FOLLOW-UP; VICTIMS; PREVALENCE; PREDICTORS AB Iraq and Afghanistan War veterans were grouped by level of posttraumatic stress disorder (PTSD) symptomatology and compared on self-report measures of trait anger, hostility, and aggression. Veterans who screened positive for PTSD reported significantly greater anger and hostility than those in the subthreshold-PTSD and non-PTSD groups. Veterans in the subthreshold-PTSD group reported significantly greater anger and hostility than those in the non-PTSD group. The PTSD and subthreshold-PTSD groups did not differ with respect to aggression, though both groups were significantly more likely to have endorsed aggression than the non-PTSD group. These findings suggest that providers should screen for anger and aggression among Iraq and Afghanistan War veterans who exhibit symptoms of PTSD and incorporate relevant anger treatments into early intervention strategies. C1 [Jakupcak, Matthew; Conybeare, Daniel; Phelps, Lori; Hunt, Stephen; Holmes, Hollie A.; Felker, Bradford; Klevens, Michele; McFall, Miles E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Conybeare, Daniel; Phelps, Lori; Holmes, Hollie A.; Klevens, Michele; McFall, Miles E.] Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. RP Jakupcak, M (reprint author), Seattle VA Med Ctr, Deployment Hlth Clin, 1660 S Columbian Way, Seattle, WA 98108 USA. EM matthew.jakupcak@va.gov NR 61 TC 179 Z9 181 U1 2 U2 16 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD DEC PY 2007 VL 20 IS 6 BP 945 EP 954 DI 10.1002/jts.20258 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 245RG UT WOS:000251952900003 PM 18157891 ER PT J AU Richie, JP AF Richie, Jerome P. TI Editorial comment SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Urol, Boston, MA 02115 USA. RP Richie, JP (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Urol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD DEC PY 2007 VL 178 IS 6 BP 2307 EP 2307 DI 10.1016/j.juro.2007.08.204 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 230AO UT WOS:000250847900017 ER PT J AU Garzotto, M AF Garzotto, Mark TI Untitled - Editorial comments SO JOURNAL OF UROLOGY LA English DT Editorial Material ID PROSTATE-CANCER; PREDICTORS C1 Oregon Hlth & Sci Univ, Dept Urol, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Radiat Med, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. RP Garzotto, M (reprint author), Oregon Hlth & Sci Univ, Dept Urol, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD DEC PY 2007 VL 178 IS 6 BP 2365 EP 2365 DI 10.1016/j.juro.2007.08.202 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 230AO UT WOS:000250847900033 ER PT J AU Sartor, O AF Sartor, Oliver TI Editorial comment SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. RP Sartor, O (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, 44 Binney St, Boston, MA 02115 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD DEC PY 2007 VL 178 IS 6 BP 2377 EP 2377 DI 10.1016/j.juro.2007.08.114 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 230AO UT WOS:000250847900039 ER PT J AU Ross, RW AF Ross, Robert W. TI Untitled - Editorial comments SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. RP Ross, RW (reprint author), Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD DEC PY 2007 VL 178 IS 6 BP 2384 EP 2384 DI 10.1016/j.juro.2007.08.197 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 230AO UT WOS:000250847900042 ER PT J AU Brown, DB Gould, JE Gervais, DA Goldberg, SN Murthy, R Millward, SF Rilling, WS Geschwind, JFS Salem, R Vedantham, S Cardella, JF Soulen, MC AF Brown, Daniel B. Gould, Jennifer E. Gervais, Debra A. Goldberg, S. Nahum Murthy, Ravi Millward, Steven F. Rilling, William S. Geschwind, Jean-Francois S. Salem, Riad Vedantham, Suresh Cardella, John F. Soulen, Michael C. TI Transcatheter therapy for hepatic malignancy: Standardization of terminology and reporting criteria SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID UNRESECTABLE HEPATOCELLULAR-CARCINOMA; RANDOMIZED CONTROLLED TRIAL; ARTERIAL CHEMOEMBOLIZATION; OILY CHEMOEMBOLIZATION; Y-90 MICROSPHERES; LIPIODOL-CHEMOEMBOLIZATION; GALLBLADDER INFARCTION; PARTICLE EMBOLIZATION; TUMOR RESPONSE; LIVER-TUMORS AB The field of interventional oncology includes tumor ablation as well as the use of transcatheter therapies such as embolization, chemoembolization, and radioembolization. Terminology and reporting standards for tumor ablation have been developed. The development of standardization of terminology and reporting criteria for transcatheter therapies should provide a similar framework to facilitate the clearest communication among investigators and provide the greatest flexibility in comparing established and emerging technologies. An appropriate vehicle for reporting the various aspects of catheter directed therapy is outlined, including classification of therapies and procedure terms, appropriate descriptors of imaging guidance, and terminology to define imaging and pathologic findings. Methods for standardizing the reporting of outcomes toxicities, complications, and other important aspects that require attention when reporting clinical results are addressed. It is the intention of the group that adherence to the recommendations will facilitate achievement of the group's main objective: improved precision and communication for reporting the various aspects of transcatheter management of hepatic malignancy that will translate to more accurate comparison of technologies and results and, ultimately, to improved patient outcomes. C1 [Brown, Daniel B.; Gould, Jennifer E.; Vedantham, Suresh] Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, St Louis, MO 63110 USA. [Gervais, Debra A.] Massachusetts Gen Hosp, Dept Radiol, Gastrointestinal Genitourinary Div, Boston, MA 02114 USA. [Goldberg, S. Nahum] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA. [Murthy, Ravi] Univ Texas MD Anderson Canc Ctr, Div Diagnost Imaging, Houston, TX USA. [Millward, Steven F.] Peterborough Reg Hlth Ctr, Dept Diagnost Imaging, Omemee, ON, Canada. [Rilling, William S.] Med Coll Wisconsin, Dept Vasc & Intervent Radiol, Milwaukee, WI 53226 USA. [Geschwind, Jean-Francois S.] Johns Hopkins Univ Hosp, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA. [Salem, Riad] NW Mem Hosp, Div Intervent Radiol, Chicago, IL 60611 USA. [Cardella, John F.] Tufts Univ, Sch Med, Dept Radiol, Springfield, MA 01199 USA. [Soulen, Michael C.] Univ Penn, Med Ctr, Dept Radiol, Sect Intervent Radiol, Philadelphia, PA 19104 USA. RP Brown, DB (reprint author), Thomas Jefferson Univ Hosp, Div Cardiovasc & Intervent Radiol, Suite 4200 Gibbon Bldg,111 S 11th St, Philadelphia, PA 19107 USA. EM dbbjeffir@yahoo.com NR 63 TC 49 Z9 50 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD DEC PY 2007 VL 18 IS 12 BP 1469 EP 1478 DI 10.1016/j.jvir.2007.08.027 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 241KF UT WOS:000251654600001 PM 18057279 ER PT J AU Hirsch, JA Bendok, BR Paulsen, RD Cognard, C Campos, J Cronqvist, M AF Hirsch, Joshua A. Bendok, Bernard R. Paulsen, Richard D. Cognard, Christophe Campos, Jorge Cronqvist, Mats TI Midterm clinical experience with a complex-shaped detachable platinum coil system for the treatment of cerebral aneurysms: Trufill DCS Orbit detachable coil system registry interim results SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID RUPTURED INTRACRANIAL ANEURYSMS; ENDOVASCULAR TREATMENT; UNRUPTURED ANEURYSMS; TRIAL ISAT; FOLLOW-UP; PACKING; OCCLUSION; EMBOLIZATION; THICKNESS; VOLUME AB PURPOSE: To report an interim analysis of the registry data and evaluate the performance of Trufill DCS Orbit coils in terms of the stability of initial aneurysmal occlusion. MATERIALS AND METHODS: From May 1, 2004, to February 1, 2006, 291 patients with ruptured or unruptured aneurysms were enrolled in a multiple-center global registry from 37 centers in the United States, Europe, and Latin America to be treated via endovascular embolization with Trufill DCS Orbit detachable platinum coils. Acute and long-term anatomic and clinical data were collected and evaluated. RESULTS: Initially, complete obliteration was reported in 187 of 300 treated aneurysms (62.3%) for which data were available; one treated aneurysm had no initial occlusion data. At follow-up (<= 1 year), 99 aneurysms were assessed. For 56 aneurysms with initial complete obliteration, 49 (87.5%) remained stable. The overall grade of occlusion of 99 aneurysms remained stable or improved in 81 cases (81.8%). Recanalization was seen in 16.2% of aneurysms (15 cases of coil compaction and one case of aneurysm growth); two aneurysms (2.0%) had coil migration. Five aneurysms (5.1%) underwent repeat treatment. CONCLUSIONS: The use of Trufill DCS Orbit coils for the endovascular occlusion of aneurysms allowed a favorable rate of initial complete obliteration, high packing density, and aneurysmal stability at follow-up as long as 1 year. Longer-term follow-up is needed to determine the long-term stability of aneurysmal occlusion. C1 [Hirsch, Joshua A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02214 USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02214 USA. [Bendok, Bernard R.] Northwestern Univ, Dept Neurosurg, Chicago, IL 60611 USA. [Bendok, Bernard R.] Northwestern Univ, Dept Radiol, Chicago, IL 60611 USA. [Paulsen, Richard D.] Jewish Med Ctr, Dept Radiol, Louisville, KY USA. [Cognard, Christophe] Univ Toulouse, Hop Purpan, Dept Neuroradiol, Toulouse, France. [Campos, Jorge] Hosp Santa Maria, Dept Neuroradiol, Lisbon, Portugal. [Cronqvist, Mats] Univ Lund Hosp, Dept Neuroradiol, S-22185 Lund, Sweden. RP Hirsch, JA (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02214 USA. EM jahirsch@partners.org OI cognard, christophe/0000-0003-4287-2627 NR 28 TC 7 Z9 11 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD DEC PY 2007 VL 18 IS 12 BP 1487 EP 1494 DI 10.1016/j.jvir.2007.07.020 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 241KF UT WOS:000251654600004 PM 18057282 ER PT J AU Rowan, PJ Dunn, NJ El-Serag, HB Kunik, ME AF Rowan, P. J. Dunn, N. J. El-Serag, H. B. Kunik, M. E. TI Views of hepatitis C virus patients delayed from treatment for psychiatric reasons SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE chronic hepatitis; communication; decision making; qualitative research ID ANTIVIRAL THERAPY; VETERANS; ALCOHOL; DEPRESSION; INFECTION AB For patients with chronic hepatitis C virus, certain psychiatric disorders are contraindications for antiviral therapy with interferon-alpha (IFN). Although these conditions delay a significant portion of patients from beginning therapy, no one has yet portrayed the views of these patients. A qualitative analysis, drawing upon semi-structured interviews, was developed to generate hypotheses regarding patient views of the treatment disposition process, and to generate strategies for increasing the portion of treatment-eligible patients. Two focus groups were conducted: one for patients delayed from treatment due to current or recent depression, and one for patients delayed due to current or recent alcohol use. A grounded theory analysis of the interview data were conducted. Patients were generally satisfied with the decision-making process, based largely on education from, and trust in, physicians. Upon learning their diagnosis, patients reported making healthy behaviour changes regarding alcohol, diet, exercise and herbal remedies. Some patients reported that requiring a period of alcohol abstinence was excessive, as they believed that they could discontinue alcohol use immediately, if so instructed by a physician. Patients seemed to over-interpret the likelihood of suicide during interferon-alpha (IFN) therapy. Current or recent psychiatric morbidity delays many patients from beginning interferon therapy. Nonetheless, this may be an optimal time for physicians to encourage healthy behaviours including abstinence from alcohol. Also, physicians may need to extensively assess the use of herbal remedies by patients. To help patients make judgments about beginning therapy, physicians should focus upon risk communication regarding the likelihood of suicide on therapy with interferon. C1 Univ Texas Houston, Sch Publ Hlth, Div Management Policy & Community Hlth, Houston, TX 77030 USA. Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Gastroenterol Sect, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Sect Hlth Serv Res, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Rowan, PJ (reprint author), Univ Texas Houston, Sch Publ Hlth, Div Management Policy & Community Hlth, 1200 Herman Pressler, Houston, TX 77030 USA. EM paul.j.rowan@uth.tmc.edu NR 23 TC 12 Z9 12 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD DEC PY 2007 VL 14 IS 12 BP 883 EP 889 DI 10.1111/j.1365-2893.2007.00884.x PG 7 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 237LH UT WOS:000251374700009 PM 18070292 ER PT J AU Butt, AA Khan, UA McGinnis, KA Skanderson, M Kwoh, CK AF Butt, A. A. Khan, U. A. McGinnis, K. A. Skanderson, M. Kwoh, C. Kent TI Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE comorbidities; drug abuse; HCV; psychiatric illness; substance abuse; veterans ID CHRONIC HEPATITIS-C; INTERFERON-ALPHA-2B PLUS RIBAVIRIN; UNITED-STATES VETERANS; VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; DIABETES-MELLITUS; INITIAL TREATMENT; RANDOMIZED-TRIAL; HIV; PREVALENCE AB Comorbidities may affect the decision to treat chronic hepatitis C virus (HCV) infection. We undertook this study to determine the prevalence of these conditions in the HCV-infected persons compared with HCV-uninfected controls. Demographic and comorbidity data were retrieved for HCV-infected and -uninfected subjects from the VA National Patient Care Database using ICD-9 codes. Logistic regression was used to determine the odds of comorbid conditions in the HCV-infected subjects. HCV-uninfected controls were identified matched on age, race/ethnicity and sex. We identified 126 926 HCV-infected subjects and 126 926 controls. The HCV-infected subjects had a higher prevalence of diabetes, anaemia, hypertension, chronic obstructive pulmonary disease (COPD)/asthma, cirrhosis, hepatitis B and cancer, but had a lower prevalence of coronary artery disease and stroke. The prevalence of all psychiatric comorbidities and substance abuse was higher in the HCV-infected subjects. In the HCV-infected persons, the odds of being diagnosed with congestive heart failure, diabetes, anaemia, hypertension, COPD/asthma, cirrhosis, hepatitis B and cancer were higher, but lower for coronary artery disease and stroke. After adjusting for alcohol and drug abuse and dependence, the odds of psychiatric illness were not higher in the HCV-infected persons. The prevalence and patterns of comorbidities in HCV-infected veterans are different from those in HCV-uninfected controls. The association between HCV and psychiatric diagnoses is at least partly attributable to alcohol and drug abuse and dependence. These factors should be taken into account when evaluating patients for treatment and designing new intervention strategies. C1 Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. Albany Med Ctr, Albany, NY USA. RP Butt, AA (reprint author), Univ Pittsburgh, Med Ctr, 3601 5th Ave,Suite 3A,Falk Med Bldg, Pittsburgh, PA 15213 USA. EM butta@dom.pitt.edu FU NIDA NIH HHS [K23 DA016175-01A1] NR 38 TC 60 Z9 60 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD DEC PY 2007 VL 14 IS 12 BP 890 EP 896 DI 10.1111/j.1365-2893.2007.00885.x PG 7 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 237LH UT WOS:000251374700010 PM 18070293 ER PT J AU Thobakgale, CF Ramduth, D Reddy, S Mkhwanazi, N de Pierres, C Moodley, E Mphatswe, W Blanckenberg, N Cengimbo, A Prendergast, A Tudor-Williams, G Dong, K Jeena, P Kindra, G Bobat, R Coovadia, H Kiepiela, P Walker, BD Goulder, PJR AF Thobakgale, Christina F. Ramduth, Dhanwanthie Reddy, Sharon Mkhwanazi, Nompumelelo de Pierres, Chantal Moodley, Eshia Mphatswe, Wendy Blanckenberg, Natasha Cengimbo, Ayanda Prendergast, Andrew Tudor-Williams, Gareth Dong, Krista Jeena, Prakash Kindra, Gupreet Bobat, Raziya Coovadia, Hoosen Kiepiela, Photini Walker, Bruce D. Goulder, Philip J. R. TI Human immunodeficiency virus-specific CD8(+) T-Cell activity is detectable from birth in the majority of in utero-infected infants SO JOURNAL OF VIROLOGY LA English DT Article ID PRIMARY HIV-1 INFECTION; TYPE-1 INFECTION; VIRAL LOAD; HIV-1-INFECTED INFANTS; LYMPHOCYTE RESPONSES; DISEASE PROGRESSION; CHILD TRANSMISSION; RANDOMIZED-TRIAL; 1ST YEAR; ESCAPE AB Human immunodeficiency virus (HIV)-infected infants in sub-Saharan Africa typically progress to AIDS or death by 2 years of life in the absence of antiretroviral therapy. This rapid progression to HIV disease has been related to immaturity of the adaptive immune response in infants. We screened 740 infants born to HIV-infected mothers and tracked development and specificity of HIV-specific CD8(+) T-cell responses in 63 HIV-infected infants identified using gamma interferon enzyme-linked immunospot assays and intracellular cytokine staining. Forty-four in utero-infected and 19 intrapartum -infected infants were compared to 45 chronically infected children >2 years of age. Seventy percent (14 of 20) in utero-infected infants tested within the first week of life demonstrated HIV-specific CD8(+) T-cell responses. Gag, Pol, and Nef were the principally targeted regions in chronic pediatric infection. However, Env dominated the overall response in one-third (12/36) of the acutely infected infants, compared to only 2/45 (4%) of chronically infected children (P = 0.00083). Gag-specific CD4(+) T-cell responses were minimal to undetectable in the first 6 months of pediatric infection. These data indicate that failure to control HIV replication in in utero-infected infants is not due to an inability to induce responses but instead suggest secondary failure of adaptive immunity in containing this infection. Moreover, the detection of virus-specific CD8(+) T-cell responses in the first days of life in most in utero-infected infants is encouraging for HIV vaccine interventions in infants. C1 Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, Durban, South Africa. Dept Paediat, Nuffield Dept Med, Oxford OX1 3SY, England. Univ London Imperial Coll Sci & Technol, Dept Paediat, London, England. Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02129 USA. Howard Hughes Med Inst, Chevy Chase, MD USA. RP Thobakgale, CF (reprint author), Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, Durban, South Africa. EM Thobakgalec@ukzn.ac.za FU Medical Research Council [G0500384]; Wellcome Trust NR 39 TC 39 Z9 39 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD DEC PY 2007 VL 81 IS 23 BP 12775 EP 12784 DI 10.1128/JVI.00624-07 PG 10 WC Virology SC Virology GA 236VC UT WOS:000251330500007 PM 17881456 ER PT J AU Mehle, A Wilson, H Zhang, C Brazier, AJ McPike, M Pery, E Gabuzda, D AF Mehle, Andrew Wilson, Heather Zhang, Chengsheng Brazier, Andrew Jay McPike, Mark Pery, Erez Gabuzda, Dana TI Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 vif and inhibitors of Vif-APOBEC3G binding SO JOURNAL OF VIROLOGY LA English DT Article ID VIRION INFECTIVITY FACTOR; EDITING ENZYME APOBEC3G; E3 UBIQUITIN LIGASE; HIV-1 VIF; ANTIVIRAL ACTIVITY; REVERSE TRANSCRIPTION; CYTIDINE DEAMINATION; STRESS GRANULES; SOCS-BOX; PROTEIN AB The APOBEC3 cytidine deaminases are potent antiviral factors that restrict replication of human immunodeficiency virus type 1 (HIV-1). HIV-1 Vif binds APOBEC3G and APOBEC3F and targets these proteins for ubiquitination by forming an E3 ubiquitin ligase with cullin 5 and elongins B and C. The N-terminal region of Vif is required for APOBEC3G binding, but the binding site(s) is unknown. To identify the APOBEC3G binding site in Vif, we established a scalable binding assay in a format compatible with development of high-throughput screens. In vitro binding assays using recombinant proteins identified Vif peptides and monoclonal antibodies that inhibit Vif-APOBEC3G binding and suggested involvement of Vif residues 33 to 83 in APOBEC3G binding. Cell-based binding assays confirmed these results and demonstrated that residues 40 to 71 in the N terminus of Vif contain a nonlinear binding site for APOBEC3G. Mutation of the highly conserved residues His42/43 but not other charged residues in this region inhibited Vif-APOBEC3G binding, Vif-mediated degradation of APOBEC3G, and viral infectivity. In contrast, mutation of these residues had no significant effect on Vif binding and degradation of APOBEC3F, suggesting a differential requirement for His42/43 in Vif binding to APOBEC3G and APOBEC3F. These results identify a nonlinear APOBEC3 binding site in the N terminus of Vif and demonstrate that peptides or antibodies directed against this region can inhibit Vif-APOBEC3G binding, validating the Vif-APOREC3 interface as a potential drug target. C1 Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Gabuzda, D (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, JF816,44 Binney St, Boston, MA 02115 USA. EM dana_gabuzda@dfci.harvard.edu FU NIAID NIH HHS [R21 AI067032-02, R01 AI062555-03, R01 AI062555-01, R01 AI062555, AI67032, AI62555, R01 AI062555-02, R01 AI062555-04, R21 AI067032, R21 AI067032-01] NR 41 TC 76 Z9 76 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD DEC PY 2007 VL 81 IS 23 BP 13235 EP 13241 DI 10.1128/JVI.00204-07 PG 7 WC Virology SC Virology GA 236VC UT WOS:000251330500054 PM 17898068 ER PT J AU Choi, AI Rodriguez, RA Bacchetti, P Bertenthal, D Volberding, PA O'Hare, AM AF Choi, A. I. Rodriguez, R. A. Bacchetti, P. Bertenthal, D. Volberding, P. A. O'Hare, A. M. TI The impact of HIV on chronic kidney disease outcomes SO KIDNEY INTERNATIONAL LA English DT Article DE AIDS; HIV nephropathy; epidemiology and outcomes ID HUMAN-IMMUNODEFICIENCY-VIRUS; GLOMERULAR-FILTRATION-RATE; STAGE RENAL-DISEASE; ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; SERUM CREATININE; VETERAN POPULATION; DIETARY-PROTEIN; MORTALITY RISK; UNITED-STATES AB Chronic kidney disease (CKD) is a known complication of the human immunodeficiency virus (HIV) but outcomes among HIV-infected patients with kidney disease are unknown. We studied a national sample of 202 927 patients with CKD (stage 3 or higher) for death, end-stage renal disease (ESRD) and the mean annual rate of decline in estimated glomerular filtration rate (eGFR) over a median period of 3.8 years. Within this sample, 0.3% of the patients were diagnosed with HIV, 43.5% were diabetic, whereas the remainder had neither disease. In this national CKD cohort, HIV-infected black patients were at higher risk of death, a similar risk for ESRD and loss of eGFR than black patients with diabetes. HIV-infected white patients experienced higher rates of death but a lower risk of ESRD than their counterparts with diabetes. Our results highlight a need to study mortality and mechanisms of ESRD in the HIV infected population. C1 San Francisco Gen Hosp, Renal Ctr, San Francisco, CA 94110 USA. Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94143 USA. Univ Washington, Dept Med, VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, VA Res Enhancement Award Program, San Francisco, CA USA. RP Choi, AI (reprint author), San Francisco Gen Hosp, Renal Ctr, 1001 Potrero Ave,Bldg 100,Rm 342,Box 1341, San Francisco, CA 94110 USA. EM andy.choi@ucsf.edu FU NIA NIH HHS [K23-AG28980-01]; NIAID NIH HHS [P30-AI27763]; NIDDK NIH HHS [T32-DK07219] NR 55 TC 42 Z9 42 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD DEC PY 2007 VL 72 IS 11 BP 1380 EP 1387 DI 10.1038/sj.ki.5002541 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 231NR UT WOS:000250955900018 PM 17805235 ER PT J AU Patel, TV Goes, N AF Patel, T. V. Goes, N. TI Page kidney SO KIDNEY INTERNATIONAL LA English DT Editorial Material C1 Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dept Med, Renal Unit, Boston, MA 02114 USA. RP Patel, TV (reprint author), Brigham & Womens Hosp, Dept Med, Div Renal, MRB-4,75 Francis St, Boston, MA 02115 USA. EM tvpatel@partners.org NR 0 TC 3 Z9 3 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD DEC PY 2007 VL 72 IS 12 BP 1562 EP 1562 DI 10.1038/sj.ki.5002580 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 235WX UT WOS:000251266100021 PM 18046425 ER PT J AU Foschi, F Fontana, CR Ruggiero, K Riahi, R Vera, A Doukas, AG Pagonis, TC Kent, R Stashenko, PP Soukos, NS AF Foschi, Federico Fontana, Carla R. Ruggiero, Karriann Riahi, Reza Vera, Antonio Doukas, Apostolos G. Pagonis, Tom C. Kent, Ralph Stashenko, Philip P. Soukos, Nikolaos S. TI Photodynamic inactivation of Enterococcus faecalis in dental root canals in vitro SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE methylene blue; scanning electron microscopy; diode laser ID MULTICELL TUMOR SPHEROIDS; ND-YAG LASER; DENTINAL TUBULES; APICAL PERIODONTITIS; ENDODONTIC TREATMENT; FLUENCE RATE; SODIUM-HYPOCHLORITE; CANDIDA-ALBICANS; OZONATED WATER; THERAPY AB Background and Objectives: We previously reported the use of a flexible fiber optic that uniformly distributed light in the root canal space for targeting bacteria after their sensitization with methylene blue (MB). In the present study, we investigated the photodynamic effects of MB on Enterococcus faecalis species in experimentally infected root canals of extracted teeth after their sensitization with a concentration of MB that exhibits reduced dark toxicity. Study Design/Materials and Methods: In a model of root canal infection, 64 root canal specimens were prepared from extracted, single-rooted teeth and inoculated with E. faecalis (ATCC 29212). Three days later root canal infection was confirmed by scanning electron microscopy. The root canal systems were then incubated with 6.25 mu g/ml MB for 5 minutes followed by exposure to light at 665 nm (60 J/cm(2)) that was delivered from a diode laser via a fiber optic with a diameter of 500 mu m. Following photodynamic therapy (PDT) the canal content was sampled by flushing the root canals, serially diluted and cultured on blood agar. Survival fractions were calculated by counting colony-forming units. High-performance liquid chromatography (HPLC) was employed to determine the porphyrins content of E. faecalis. Results: Scanning electron microscopy confirmed the presence of bacteria in the root canal system. PDT achieved 77.5% reduction of E. faecalis viability. MB alone and light alone reduced bacterial viability by 19.5% and 40.5%, respectively. HPLC did not reveal any porphyrin patterns expressed by E. faecalis. Conclusion: The results of this study support the need to determine the optimum MB concentration and light parameters to maximize bacterial killing in root canals. C1 [Foschi, Federico; Fontana, Carla R.; Ruggiero, Karriann; Soukos, Nikolaos S.] Forsyth Inst, Appl Mol Photomed Lab, Boston, MA 02115 USA. [Riahi, Reza; Vera, Antonio; Pagonis, Tom C.] Harvard Univ, Sch Dent Med, Div Endodont, Boston, MA 02115 USA. [Doukas, Apostolos G.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Kent, Ralph] Forsyth Inst, Dept Biostat, Boston, MA 02115 USA. [Stashenko, Philip P.] Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA. RP Soukos, NS (reprint author), Forsyth Inst, Appl Mol Photomed Lab, 140 Fenway, Boston, MA 02115 USA. EM nsoukos@forsyth.org RI Foschi, Federico /E-7531-2012; Fontana, Carla/C-2033-2012; OI Fontana, Carla/0000-0002-9135-3690; Foschi, Federico/0000-0001-6901-0280 FU NIDCR NIH HHS [R01 DE 16922] NR 46 TC 54 Z9 63 U1 0 U2 10 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD DEC PY 2007 VL 39 IS 10 BP 782 EP 787 DI 10.1002/lsm.20579 PG 6 WC Dermatology; Surgery SC Dermatology; Surgery GA 246EP UT WOS:000251990600005 PM 18081066 ER PT J AU Neri, P Tassone, P Shammas, M Yasui, H Schipani, E Batchu, RB Blotta, S Prabhala, R Catley, L Hamasaki, M Hideshima, T Chauhan, D Jacob, GS Picker, D Venuta, S Anderson, KC Munshi, NC AF Neri, P. Tassone, P. Shammas, M. Yasui, H. Schipani, E. Batchu, R. B. Blotta, S. Prabhala, R. Catley, L. Hamasaki, M. Hideshima, T. Chauhan, D. Jacob, G. S. Picker, D. Venuta, S. Anderson, K. C. Munshi, N. C. TI Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma SO LEUKEMIA LA English DT Article DE atiprimod; multiple myeloma; SCID-hu model; experimental treatment; gene expression profile; bone effects ID HUMAN MULTIPLE-MYELOMA; TARGETING ANTIARTHRITIC COMPOUND; BONE-DISEASE; RANK LIGAND; MODEL; CELL; RAT; SK-AND-F-105685; MARROW; DEXAMETHASONE AB Atiprimod (Atip) is a novel oral agent with anti-inflammatory properties. Although its in vitro activity and effects on signaling in multiple myeloma (MM) have been previously reported, here we investigated its molecular and in vivo effects in MM. Gene expression analysis of MM cells identified downregulation of genes involved in adhesion, cell-signaling, cell cycle and bone morphogenetic protein (BMP) pathways and upregulation of genes implicated in apoptosis and bone development, following Atip treatment. The pathway analysis identified integrin, TGF-beta and FGF signaling as well as Wnt/beta-catenin, IGF1 and cell-cycle regulation networks as being most modulated by Atip treatment. We further evaluated its in vivo activity in three mouse models. The subcutaneous model confirmed its in vivo activity and established its dose; the SCID-hu model using INA-6 cells, confirmed its ability to overcome the protective effects of BM milieu; and the SCID-hu model using primary MM cells reconfirmed its activity in a model closest to human disease. Finally, we observed reduced number of osteoclasts and modulation of genes related to BMP pathways. Taken together, these data demonstrate the in vitro and in vivo antitumor activity of Atip, delineate potential molecular targets triggered by this agent, and provide a preclinical rational for its clinical evaluation in MM. C1 Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Adult Oncol, Boston, MA USA. Harvard Med Sch, Boston VA Healthcare Syst, Dept Med, Boston, MA USA. Magna Graecia Univ Catanzaro, Ctr Canc, Dept Expt & Clin Med, Catanzaro, Italy. Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. Callisto Pharmaceut Inc, New York, NY USA. RP Munshi, NC (reprint author), Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA. EM nikhil_munshi@dfci.harvard.edu FU PHS HHS [P01-78378, P50-100707, R01-50947] NR 38 TC 15 Z9 15 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD DEC PY 2007 VL 21 IS 12 BP 2519 EP 2526 DI 10.1038/sj.leu.2404912 PG 8 WC Oncology; Hematology SC Oncology; Hematology GA 234CY UT WOS:000251139500017 PM 17882285 ER PT J AU Otazo, R Tsai, SY Lin, FH Posse, S AF Otazo, Ricardo Tsai, Shang-Yueh Lin, Fa-Hsuan Posse, Stefan TI Accelerated Short-TE 3D proton echo-planar spectroscopic Imaging using 2D-SENSE with a 32-channel array coil SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE echo-planar spectroscopic imaging; parallel imaging; SENSE; regularization; large array coil ID TO-NOISE RATIO; HUMAN BRAIN; CHEMICAL-SHIFT; CEREBRAL GRAY; WHITE-MATTER; NMR; RECONSTRUCTION; SENSE; MRI; TESLA AB MR spectroscopic imaging (MRSI) with whole brain coverage in clinically feasible acquisition times still remains a major challenge. A combination of MRSI with parallel imaging has shown promise to reduce the long encoding times and 2D acceleration with a large array coil is expected to provide high acceleration capability. In this work a very high-speed method for 3D-MRSI based on the combination of proton echo planar spectroscopic imaging (PEPSI) with regularized 2D-SENSE reconstruction is developed. Regularization was performed by constraining the singular value decomposition of the encoding matrix to reduce the effect of low-value and overlapped coil sensitivities. The effects of spectral heterogeneity and discontinuities in coil sensitivity across the spectroscopic voxels were minimized by unaliasing the point spread function. As a result the contamination from extracranial lipids was reduced 1.6-fold on average compared to standard SENSE. We show that the acquisition of short-TE (15 ms) 3D-PEPSI at 3 T with a 32 x 32 x 8 spatial matrix using a 32-channel array coil can be accelerated 8-fold (R = 4 X 2) along y-z to achieve a minimum acquisition time of 1 min. Maps of the concentrations of N-acetyl-aspartate, creatine, choline, and glutamate were obtained with moderate reduction in spatial-spectra quality. The short acquisition time makes the method suitable for volumetric metabolite mapping in clinical studies. C1 Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA. Natl Taiwan Univ, Dept Elect Engn, Taipei 10764, Taiwan. MGH HMS MIT Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA USA. Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. Natl Taiwan Univ, Inst Biomed Engn, Taipei 10764, Taiwan. Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM 87131 USA. Univ New Mexico, Dept Phys & Astron, Albuquerque, NM 87131 USA. RP Otazo, R (reprint author), Univ New Mexico, Dept Elect & Comp Engn, MSC01 1100 ECE Bldg, Albuquerque, NM 87131 USA. EM otazo@ece.unm.edu RI Lin, Fa-Hsuan/G-6988-2012; Tsai, Shang-Yueh/O-2226-2013; OI Lin, Fa-Hsuan/0000-0002-9539-1731; Tsai, Shang-Yueh/0000-0002-6310-4750; Otazo, Ricardo/0000-0002-3782-4930 FU NCRR NIH HHS [P41 RR14075]; NIBIB NIH HHS [R01 EB000790-04]; NICHD NIH HHS [R01 HD040712]; NINDS NIH HHS [R01 NS037462] NR 40 TC 23 Z9 23 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0740-3194 J9 MAGN RESON MED JI Magn. Reson. Med. PD DEC PY 2007 VL 58 IS 6 BP 1107 EP 1116 DI 10.1002/mrm.21426 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 237BE UT WOS:000251346800005 PM 17968995 ER PT J AU Sun, PZ Farrar, CT Sorensen, AG AF Sun, Phillip Zhe Farrar, Christian T. Sorensen, A. Gregory TI Correction for artifacts induced by B-0 and B-1 field inhomogeneities in pH-Sensitive chemical exchange saturation transfer (CEST) Imaging SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE amide proton transfer (APT); chemical exchange; chemical exchange saturation transfer (CEST); field inhomogeneity; magnetization transfer (MT) ID TRANSFER RATIO MEASUREMENTS; MAGNETIZATION-TRANSFER; QUANTITATIVE DESCRIPTION; CONTRAST AGENTS; PARACEST AGENTS; ROTATING-FRAME; RESONANCE; MRI; RELAXATION; WATER AB Chemical exchange saturation transfer (CEST) imaging provides an indirect detection mechanism that allows quantification of certain labile groups unobservable using conventional MRI. Recently, amide proton transfer (APT) imaging, a variant form of CEST imaging, has been shown capable of detecting lactic acidosis during acute ischemia, providing information complementary to that of perfusion and diffusion MRI. However, CEST contrast is usually small, and therefore, it is important to optimize experimental conditions for reliable and quantitative CEST imaging. In particular, CEST imaging is sensitive to So and Ell field, while on the other hand; field inhomogeneities persist despite recent advances in magnet technologies, especially for in vivo imaging at high fields. Consequently, correction algorithms that can compensate for field inhomogeneity-induced measurement errors in CEST imaging might be very useful. In this study, the dependence of CEST contrast on field distribution was solved and a correction algorithm was developed to compensate for field inhomogeneity-induced CEST imaging artifacts. In addition, the proposed algorithm was verified with both numerical simulation and experimental measurements, and showed nearly complete correction of CEST imaging measurement errors caused by moderate field inhomogeneity. C1 Harvard Univ, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Sch Med,Dept Radiol, Charlestown, MA 02129 USA. RP Sun, PZ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Sch Med,Dept Radiol, Charlestown, MA 02129 USA. EM pzhesun@nmr.mgh.harvard.edu FU NCRR NIH HHS [P41RR14075]; NIA NIH HHS [K25 AG029415-01A1, K25 AG029415-05, K25 AG029415-04, K25 AG029415, K25 AG029415-02, K25 AG029415-03]; NINDS NIH HHS [5R01NS038477-08] NR 33 TC 76 Z9 78 U1 1 U2 9 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0740-3194 J9 MAGN RESON MED JI Magn. Reson. Med. PD DEC PY 2007 VL 58 IS 6 BP 1207 EP 1215 DI 10.1002/mrm.21398 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 237BE UT WOS:000251346800015 PM 17969015 ER PT J AU Munshi, NC AF Munshi, Nikhil C. TI Monoclonal gammopathy of undetermined significance: Genetic vs environmental etiologies SO MAYO CLINIC PROCEEDINGS LA English DT Editorial Material ID HELICOBACTER-PYLORI INFECTION; ADULT-POPULATION; UNITED-STATES; PREVALENCE; COMPONENTS; PROTEINS; MYELOMA; SERUM C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,VA Boston Healthcare Syst, Boston, MA 02215 USA. RP Munshi, NC (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,VA Boston Healthcare Syst, 44 Binney St, Boston, MA 02215 USA. EM nikhil_munshi@dfci.harvard.edu NR 23 TC 11 Z9 11 U1 0 U2 0 PU MAYO CLINIC PROCEEDINGS PI ROCHESTER PA 660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA SN 0025-6196 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD DEC PY 2007 VL 82 IS 12 BP 1457 EP 1459 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 237OI UT WOS:000251384300002 PM 18053450 ER PT J AU Parchman, ML Zeber, JE Romero, RR Pugh, JA AF Parchman, Michael L. Zeber, John E. Romero, Raquel R. Pugh, Jacqueline A. TI Risk of coronary artery disease in type 2 diabetes and the delivery of care consistent with the chronic care model in primary care settings - A STARNet study SO MEDICAL CARE LA English DT Article; Proceedings Paper CT Conference of the Practice-Based-Research-Networks CY 2005 CL Washington, DC SP Practice Based Res Networks DE primary care; type 2 diabetes; chronic disease; myocardial infarction; organization of care ID CHRONIC ILLNESS CARE; QUALITY IMPROVEMENT; HEART-DISEASE; OF-CARE; IMPLEMENTATION; CHALLENGES; ADULTS AB Background: Modifiable risks for coronary heart disease (CHD) in type 2 diabetes include glucose, blood pressure, lipid control, and smoking. The chronic care model (CCM) provides an organizational framework for improving these outcomes. Objective: To examine the relationship between CHD risk attributable to modifiable risk factors among patients with type 2 diabetes and whether care delivered in primary care settings is consistent with the CCM. Subjects/Methods: Approximately 30 patients in each of 20 primary care clinics. CHD risk factors were assessed by patient survey and chart abstraction. Absolute 10-year CHD risk was calculated using the UK Prospective Diabetes Study risk engine. Attributable risk was calculated by setting all 4 modifiable risk factors to guideline indicated values, recalculating the risk, and subtracting it from the absolute risk. In each clinic, the consistency of care with the CCM was evaluated using the Assessment of Chronic Illness Care (ACIC) survey. Results: Only 15.4% had guideline-recommended control of Alc, blood pressure, and lipids. The absolute 10-year risk CHD was 16.2% (SD 16.6). One-third of this risk, 5.0% (SD 7.4), was attributable to poor risk factor control. After controlling for patient and clinic characteristics, the ACIC score was inversely associated with attributable risk: a I point increase in the ACIC score was associated with a 16% (95% CI, 5-26%) relative decrease in attributable risk. Discussion: The degree to which care delivered in a primary care clinic conforms to the CCM is an important predictor of the 10-year risk of CHD among patients with type 2 diabetes. C1 S Texas Vet Hlth Care Syst, VERDICT Ctr 11C6, Audie L Murphys Div, Vet Affairs HSR&D, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Parchman, ML (reprint author), S Texas Vet Hlth Care Syst, VERDICT Ctr 11C6, Audie L Murphys Div, Vet Affairs HSR&D, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM parchman@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X; Parchman, Michael/0000-0001-7129-2889 FU AHRQ HHS [K08 HS013008-02] NR 28 TC 34 Z9 34 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD DEC PY 2007 VL 45 IS 12 BP 1129 EP 1134 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 239ST UT WOS:000251538700003 PM 18007162 ER PT J AU Rucker, B Almeida, ME Libermann, TA Zerbini, LF Wink, MR Sarkis, JJF AF Ruecker, Barbara Almeida, Manoela E. Libermann, Towia A. Zerbini, Luiz F. Wink, Marcia R. Sarkis, Joao Jose Freitas TI Biochemical characterization of ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP, EC 3.1.4.1) from rat heart left ventricle SO MOLECULAR AND CELLULAR BIOCHEMISTRY LA English DT Article DE E-NPPs; left ventricle; cardiac synaptosomes ID 5'-NUCLEOTIDE PHOSPHODIESTERASE; FUNCTIONAL-CHARACTERIZATION; DIPHOSPHOHYDROLASE ACTIVITY; EXTRACELLULAR METABOLISM; ATP-DIPHOSPHOHYDROLASE; MOLECULAR-CLONING; PYROPHOSPHATASE; EXPRESSION; CELLS; HYDROLYSIS AB In the present study we investigate the biochemical properties of the members of NPP family in synaptosomes prepared from rat heart left ventricles. Using p-nitrophenyl-5'-thymidine monophosphate (p-Nph-5'-TMP) as substrate for E-NPPs in rat cardiac synaptosomes, we observed an alkaline pH dependence, divalent cation dependence and the K (M) value corresponded to 91.42 +/- 13.97 mu M and the maximal velocity (V (max) ) value calculated was 63.79 +/- 3.59 nmol p-nitrophenol released/min/mg of protein (mean +/- SD, n = 4). Levamisole (1 mM), was ineffective as inhibitor of p-Nph-5'-TMP hydrolysis in pH 8.9 (optimum pH for the enzyme characterized). Suramin (0.25 mM) strongly reduced the hydrolysis of p-Nph-5'-TMP by about 46%. Sodium azide (10 and 20 mM) and gadolinium chloride (0.3 and 0.5 mM), E-NTPases inhibitors, had no effects on p-Nph-5'-TMP hydrolysis. RT-PCR analysis of left ventricle demonstrated the expression of NPP2 and NPP3 enzymes, but excluded the presence of NPP1 member. By quantitative real-time PCR we identified the NPP3 as the enzyme with the highest expression in rat left ventricle. The demonstration of the presence of the E-NPP family in cardiac system, suggest that these enzymes could contribute with the fine-tuning control of the nucleotide levels at the nerve terminal endings of left ventricles that are involved in several cardiac pathologies. C1 Univ Fed Rio Grande do Sul, Inst Ciencia Basicas Saude, Dept Bioquim, BR-90035 Porto Alegre, RS, Brazil. Harvard Med Sch, BIDMC Genom Ctr, Boston, MA USA. Fundacao Faculdade, Fed Ciencias Med Porto Alegre, Dept Ciencias Fisiol, Porto Alegre, RS, Brazil. RP Sarkis, JJF (reprint author), Univ Fed Rio Grande do Sul, Inst Ciencia Basicas Saude, Dept Bioquim, Rua Ramiro Barcelos,2600 Predio ANEXO, BR-90035 Porto Alegre, RS, Brazil. EM jjsarkis@plug-in.com.br RI Libermann, Towia/F-9866-2010; Zerbini, Luiz /B-7720-2015; OI Libermann, Towia/0000-0002-4006-8179 NR 51 TC 16 Z9 17 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0300-8177 J9 MOL CELL BIOCHEM JI Mol. Cell. Biochem. PD DEC PY 2007 VL 306 IS 1-2 BP 247 EP 254 DI 10.1007/s11010-007-9576-5 PG 8 WC Cell Biology SC Cell Biology GA 222NT UT WOS:000250304900028 PM 17786543 ER PT J AU Schuller, U Zhao, Q Godinho, SA Heine, VM Medema, RH Pellman, D Rowitch, DH AF Schueller, Ulrich Zhao, Qing Godinho, Susana A. Heine, Vivi M. Medema, Rene H. Pellman, David Rowitch, David H. TI Forkhead transcription factor FoxM1 regulates mitotic entry and prevents spindle defects in cerebellar granule neuron precursors SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID SONIC HEDGEHOG; NERVOUS-SYSTEM; CELL-CYCLE; N-MYC; GENE-EXPRESSION; PURKINJE-CELLS; HISTONE H3; PROLIFERATION; MITOSIS; MOUSE AB The forkhead transcription factor FoxM1 has been reported to regulate, variously, proliferation and/or spindle formation during the G(2)/M transition of the cell cycle. Here we define specific functions of FoxM1 during brain development by the investigation of FoxM1 loss-of-function mutations in the context of Sonic hedgehog (Shh)-induced neuroproliferation in cerebellar granule neuron precursors (CGNP). We show that FoxM1 is expressed in the cerebellar anlagen as well as in postnatal proliferating CGNP and that it is upregulated in response to activated Shh signaling. To determine the requirements for FoxM1 function, we used transgenic mice carrying conventional null alleles or conditionally targeted alleles in conjunction with specific Cre recombinase expression in CGNP or early neural precursors driven by Math 1 or Nestin enhancers. Although the overall cerebellar morphology was grossly normal, we observed that the entry into mitosis was postponed both in vivo and in Shh-treated CGNP cultures. Cell cycle analysis and immunohistochemistry with antibodies against phosphorylated histone H3 indicated a significant delay in the G2/M transition. Consistent with this, FoxM1-deficient CGNP showed decreased levels of the cyclin B1 and Cdc25b proteins. Furthermore, the loss of FoxM1 resulted in spindle defects and centrosome amplification. These findings indicate that the functions of FoxM1 in Shh-induced neuroproliferation are restricted to the regulation of the G(2)/M, transition in CGNP, most probably through transcriptional effects on target genes such as those coding for B-type cyclins. C1 Univ Calif San Francisco, Inst Regenerat Med, Dept Pediat, San Francisco, CA 94143 USA. Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA. Univ Med Ctr, Dept Med Oncol, Utrecht, Netherlands. Univ Munich, Ctr Neuropathol, Munich, Germany. RP Rowitch, DH (reprint author), Univ Calif San Francisco, Inst Regenerat Med, Dept Pediat, 533 Parnassus Ave,U503, San Francisco, CA 94143 USA. EM rowitchd@peds.ucsf.edu RI Heine, Vivi/F-1741-2011; OI Medema, Rene/0000-0002-6754-0381 FU NINDS NIH HHS [NS 047527, R01 NS047527] NR 45 TC 57 Z9 57 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD DEC PY 2007 VL 27 IS 23 BP 8259 EP 8270 DI 10.1128/MCB.00707-07 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 239OH UT WOS:000251527100019 PM 17893320 ER PT J AU Sun, YL Xu, Y Roy, K Price, BD AF Sun, Yingli Xu, Ye Roy, Kanaklata Price, Brendan D. TI DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID DOUBLE-STRAND BREAKS; PROTEIN-KINASE; HISTONE ACETYLTRANSFERASE; MRE11-RAD50-NBS1 COMPLEX; 3-DIMENSIONAL STRUCTURE; ATAXIA-TELANGIECTASIA; C-TERMINUS; IN-VITRO; DOMAIN; AUTOPHOSPHORYLATION AB The ATM protein kinase is essential for cells to repair and survive genotoxic events. The activation of ATM's kinase activity involves acetylation of ATM by the Tip60 histone acetyltransferase. In this study, systematic mutagenesis of lysine residues was used to identify regulatory ATM acetylation sites. The results identify a single acetylation site at lysine 3016, which is located in the highly conserved C-terminal FATC domain adjacent to the kinase domain. Antibodies specific for acetyl-lysine 3016 demonstrate rapid (within 5 min) in vivo acetylation of ATM following exposure to bleomycin. Furthermore, lysine 3016 of ATM is a substrate in vitro for the Tip60 histone acetyltransferase. Mutation of lysine 3016 does not affect unstimulated ATM kinase activity but does abolish upregulation of ATM's kinase activity by DNA damage, inhibits the conversion of inactive ATM dimers to active ATM monomers, and prevents the ATM-dependent phosphorylation of the p53 and chk2 proteins. These results are consistent with a model in which acetylation of lysine 3016 in the FATC domain of ATM activates the kinase activity of ATM. The acetylation of ATM on lysine 3016 by Tip60 is therefore a key step linking the detection of DNA damage and the activation of ATM kinase activity. C1 Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Canc Inst,Div Genom Stabil & DNA Repa, Boston, MA 02115 USA. RP Price, BD (reprint author), Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Canc Inst,Div Genom Stabil & DNA Repa, JF516,44 Binney St, Boston, MA 02115 USA. EM brendan_price@dfci.harvard.edu FU NCI NIH HHS [CA64585, T32 CA009078, R01 CA064585, CA93602, R01 CA093602, T32 CA09078]; PHS HHS [U19A1067751] NR 42 TC 149 Z9 158 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD DEC PY 2007 VL 27 IS 24 BP 8502 EP 8509 DI 10.1128/MCB.01382-07 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 239OJ UT WOS:000251527300008 PM 17923702 ER PT J AU Dillon, RL Brown, ST Ling, C Shioda, T Muller, WJ AF Dillon, Rachelle L. Brown, Stephen T. Ling, Chen Shioda, Toshishiro Muller, William J. TI An EGR2/CITED1 transcription factor complex and the 14-3-3 sigma tumor suppressor are involved in regulating ErbB2 expression in a transgenic-Mouse model of human breast cancer SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID RECEPTOR TYROSINE KINASE; HUMAN MAMMARY-CARCINOMA; CELL-LINES; GENE-EXPRESSION; SEGMENTAL EXPRESSION; NEU-ONCOGENE; HINDBRAIN SEGMENTATION; SIGNALING PATHWAY; MUSCLE-SPINDLE; PROTO-ONCOGENE AB Amplification and elevated expression of the ErbB2 receptor tyrosine kinase occurs in 20% of human breast cancers and is associated with a poor prognosis. We have previously demonstrated that mammary tissue-specific expression of activated ErbB2 under the control of its endogenous promoter results in mammary tumor formation. Tumor development was associated with amplification and overexpression of ErbB2 at both the transcript and protein levels. Here we demonstrate that the EGR2/Krox20 transcription factor and its coactivator CITED1 are coordinately upregulated during ErbB2 tumor induction. We have identified an EGR2 binding site in the erbB2 promoter and demonstrated by chromatin immunoprecipitation assays that EGR2 and CITED1 associate specifically with this region of the promoter. EGR2 and CITED1 were shown to associate, and expression from an erbB2 promoter-reporter construct was stimulated by EGR2 and was further enhanced by CITED1 coexpression. Furthermore, expression of the 14-3-3 sigma tumor suppressor led to downregulation of ErbB2 protein levels and relocalization of EGR2 from the nucleus to the cytoplasm. Taken together, these observations suggest that, in addition to an increased gene copy number and upregulation of EGR2 and CITED1, an elevated erbB2 transcript level involves the loss of 14-3-3 sigma, which sequesters a key transcriptional regulator of the erbB2 promoter. C1 McGill Univ, Mol Oncol Grp, McGill Univ Hlth Ctr, Montreal, PQ, Canada. McGill Univ, Dept Biochem, Montreal, PQ, Canada. McGill Univ, Dept Med, Montreal, PQ, Canada. McMaster Univ, Dept Biol, Hamilton, ON, Canada. Massachusetts Gen Hosp, Canc Res Ctr, Dept Tumor Biol, Charlestown, MA USA. RP Muller, WJ (reprint author), Royal Victoria Hosp, Mol Oncol Grp, Room H5-63A,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada. EM william.muller@mcgill.ca FU NCI NIH HHS [U01 CA105490] NR 53 TC 24 Z9 26 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD DEC PY 2007 VL 27 IS 24 BP 8648 EP 8657 DI 10.1128/MCB.00866-07 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 239OJ UT WOS:000251527300020 PM 17938205 ER PT J AU Tenno, M Ohtsubo, K Hagen, FK Ditto, D Zarbock, A Schaerli, P von Andrian, UH Ley, K Le, D Tabak, LA Marth, JD AF Tenno, Mari Ohtsubo, Kazuaki Hagen, Fred K. Ditto, David Zarbock, Alexander Schaerli, Patrick von Andrian, Ulrich H. Ley, Klaus Le, Dzung Tabak, Lawrence A. Marth, Jamey D. TI Initiation of protein O glycosylation by the polypeptide GalNAcT-1 in vascular biology and humoral immunity SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID FAMILIAL TUMORAL CALCINOSIS; UDP-N-ACETYLGALACTOSAMINE; CORE-2 BRANCHING BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE; SELECTIN-DEFICIENT MICE; LINKED GLYCOSYLATION; BOVINE COLOSTRUM; CDNA CLONING; B-LYMPHOCYTE; EXPRESSION; BIOSYNTHESIS AB Core-type protein O glycosylation is initiated by pollypeptide N-acetylgalactosamine (GalNAc) transferase (ppGalNAcT) activity and produces the covalent linkage of serine and threonine residues of proteins. More than a dozen ppGalNAcTs operate within multicellular organisms, and they differ with respect to expression patterns and substrate selectivity. These distinctive features imply that each ppGalNAcT may differentially modulate regulatory processes in animal development, physiology, and perhaps disease. We found that ppGalNAcT-1 plays key roles in cell and glycoprotein selective functions that modulate the hematopoietic system. Loss of ppGalNAcT-1 activity in the mouse results in a bleeding disorder which tracks with reduced plasma levels of blood coagulation factors V, VII, VIII, IX, X, and XII. ppGalNAcT-1 further supports leukocyte trafficking and residency in normal homeostatic physiology as well as during inflammatory responses, in part by providing a scaffold for the synthesis of sellectin ligands expressed by neutrophils and endothellial cells of peripheral lymph nodes. Animals lacking ppGalNAcT4 are also markedly impaired in immunoglobulin G production, coincident with increased germinal center B-cell apoptosis and reduced levels of plasma B cells. These findings reveal that the initiation of protein 0 glycosylation by ppGalNAcT-1 provides a distinctive repertoire of advantageous functions that support vascular responses and humoral immunity. C1 Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA. Univ Calif San Diego, Dept Cell & Mol Med, La Jolla, CA 92093 USA. Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY USA. Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA. Univ Munster, Dept Anesthesiol & Crit Care Med, Munster, Germany. Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA USA. Univ Virginia, Dept Biomed Engn, Charlottesville, VA USA. NIDDKD, Sect Biol Chem, Natl Inst Hlth, Dept Hlth & Human Serv, Bethesda, MD USA. RP Marth, JD (reprint author), Univ Calif San Diego, Howard Hughes Med Inst, 9500 Gilman Dr,MC0625, La Jolla, CA 92093 USA. EM jmarth@ucsd.edu RI von Andrian, Ulrich/A-5775-2008 FU NIDDK NIH HHS [DK48247, R01 DK048247] NR 68 TC 59 Z9 61 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD DEC PY 2007 VL 27 IS 24 BP 8783 EP 8796 DI 10.1128/MCB.01204-07 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 239OJ UT WOS:000251527300031 PM 17923703 ER PT J AU Lombard, DB Alt, FW Cheng, HL Bunkenborg, J Streeper, RS Mostoslavsky, R Kim, J Yancopoulos, G Valenzuela, D Murphy, A Yang, Y Chen, Y Hirschey, MD Bronson, RT Haigis, M Guarente, LP Farese, RV Weissman, S Verdin, E Schwer, B AF Lombard, David B. Alt, Frederick W. Cheng, Hwei-Ling Bunkenborg, Jakob Streeper, Ryan S. Mostoslavsky, Raul Kim, Jennifer Yancopoulos, George Valenzuela, David Murphy, Andrew Yang, Yinhua Chen, Yaohui Hirschey, Matthew D. Bronson, Roderick T. Haigis, Marcia Guarente, Leonard P. Farese, Robert V., Jr. Weissman, Sherman Verdin, Eric Schwer, Bjoern TI Mammalian sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID CALORIE RESTRICTION; GLUTAMATE DEHYDROGENASE; DEPENDENT DEACETYLASE; SIR2-LIKE PROTEINS; MICE LACKING; AMINO GROUPS; GENE; SIRTUINS; THERMOGENESIS; PROTEOME AB Homologs of the Saccharomyces cerevisiae Sir2 protein, sirtuins, promote longevity in many organisms. Studies of the sirtuin SIRT3 have so far been limited to cell culture systems. Here, we investigate the localization and function of SIRT3 in vivo. We show that endogenous mouse SIRT3 is a soluble mitochondrial protein. To address the function and relevance of SIRT3 in the regulation of energy metabolism, we generated and phenotypically characterized SIRT3 knockout mice. SIRT3-deficient animals exhibit striking mitochondrial protein hyperacetylation, suggesting that SIRT3 is a major mitochondrial deacetylase. In contrast, no mitochondrial hyperacetylation was detectable in mice lacking the two other mitochondrial sirtuins, SIRT4 and SIRT5. Surprisingly, despite this biochemical phenotype, SIRT3-deficient mice are metabolically unremarkable under basal conditions and show normal adaptive thermogenesis, a process previously suggested to involve SIRT3. Overall, our results extend the recent finding of lysine acetylation of mitochondrial proteins and demonstrate that SIRT3 has evolved to control reversible lysine acetylation in this organelle. C1 Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Immune Dis Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Odense Univ, Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark. Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA. Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA. Yale Univ, Sch Med, Dept Genet, New Haven, CT 06519 USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. MIT, Dept Biol, Cambridge, MA 02139 USA. Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med & Biochem, San Francisco, CA 94143 USA. Univ Calif San Francisco, Cardiovasc Res Inst, Dept Biophys, San Francisco, CA 94143 USA. Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA. Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA. RP Alt, FW (reprint author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Immune Dis Inst, Boston, MA 02115 USA. EM alt@enders.tch.harvard.edu; everdin@gladstone.ucsf.edu OI Verdin, Eric/0000-0003-3703-3183; Murphy, Andrew/0000-0003-4152-4081; Hirschey, Matthew/0000-0003-4541-5376 FU NCRR NIH HHS [1C06RR18928, C06 RR018928] NR 36 TC 500 Z9 517 U1 2 U2 41 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD DEC PY 2007 VL 27 IS 24 BP 8807 EP 8814 DI 10.1128/MCB.01636-07 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 239OJ UT WOS:000251527300033 PM 17923681 ER PT J AU Zhu, AX Sahani, DV Di Tomaso, E Duda, D Sindhwani, V Yoon, SS Blaszkowsky, LS Clark, JW Ryan, DP Jain, RK AF Zhu, Andrew X. Sahani, Dushyant V. Di Tomaso, Emmanuelle Duda, Dan Sindhwani, Vivek Yoon, Sam S. Blaszkowsky, Lawrence S. Clark, Jeffrey W. Ryan, David P. Jain, Rakesh K. TI Efficacy, safety, and changes in angiogenic markers following sunitinib monotherapy in patients with advanced hepatocellular carcinoma: Experience from a phase II study SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Zhu, Andrew X.; Sahani, Dushyant V.; Di Tomaso, Emmanuelle; Duda, Dan; Sindhwani, Vivek; Yoon, Sam S.; Blaszkowsky, Lawrence S.; Clark, Jeffrey W.; Jain, Rakesh K.] Massachusetts Gen Hosp, Ctr Canc, Harvard Med Sch, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3332S EP 3333S PN 2 PG 2 WC Oncology SC Oncology GA 245WH UT WOS:000251969000008 ER PT J AU Penson, RT Berlin, ST Krasner, CN Roche, M Tyburski, KA Belden, SE Daniels, GH Garg, RK Ivy, P Matulonis, UA AF Penson, Richard T. Berlin, Suzanne T. Krasner, Carolyn N. Roche, Maria Tyburski, Karin A. Belden, Sarah E. Daniels, Gilbert H. Garg, Rajesh K. Ivy, Percy Matulonis, Ursula A. TI Thyroid toxicity with the VEGF/PDGF receptor TKI AZD-2171 (Recentin (TM)) in a phase II study of recurrent mullerian tumors SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Penson, Richard T.; Krasner, Carolyn N.; Roche, Maria; Belden, Sarah E.; Daniels, Gilbert H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Berlin, Suzanne T.; Tyburski, Karin A.; Matulonis, Ursula A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Garg, Rajesh K.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Ivy, Percy] Natl Canc Inst, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3339S EP 3339S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000029 ER PT J AU Zhang, X Zhang, L Yang, H Huang, X Otu, H Libermann, TA DeWolf, WC Khosravi-Far, R Olumi, AF AF Zhang, Xiaoping Zhang, Liang Yang, Hongmei Huang, Xu Otu, Hasan Libermann, Towia A. DeWolf, William C. Khosravi-Far, Roya Olumi, Aria F. TI c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Zhang, Xiaoping; Olumi, Aria F.] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA USA. [Zhang, Liang; Yang, Hongmei; Huang, Xu; Otu, Hasan; Libermann, Towia A.; DeWolf, William C.; Khosravi-Far, Roya] Harvard Med Sch, BIDMC, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3350S EP 3350S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000059 ER PT J AU McGuire, W Matulonis, U Hirte, H Husain, A Chiang, A Aghajanian, C Hawtin, R Goldberg, Z AF McGuire, William Matulonis, Ursula Hirte, Hal Husain, Amreen Chiang, Anne Aghajanian, Carol Hawtin, Rachel Goldberg, Zelanna TI SNS-595 demonstrates initial clinical activity in a phase 2 trial in platinum resistant epithelial ovarian cancer SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [McGuire, William] Harry & Jeanette Weinberg Canc Ctr, Baltimore, MD USA. [Matulonis, Ursula] Dana Farber Canc Inst, Boston, MA USA. [Hirte, Hal] Juravinski Canc Ctr, Hamilton, ON, Canada. [Husain, Amreen] Stanford Univ, Stanford, CA USA. [Chiang, Anne; Aghajanian, Carol] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Hawtin, Rachel; Goldberg, Zelanna] Sunesis Pharmaceut, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3387S EP 3388S PN 2 PG 2 WC Oncology SC Oncology GA 245WH UT WOS:000251969000168 ER PT J AU Srivastava, N Kuan, CT Marasco, W Bigner, DD AF Srivastava, Nidhi Kuan, Chein-Tsun Marasco, Wayne Bigner, Darell D. TI Development of a recombinant single-chain variable fragment (scFv) antibody against MRP3 (multi drug resistance protein) for immunotargetting of GBM (glioblastoma multiforme). SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Srivastava, Nidhi; Kuan, Chein-Tsun; Bigner, Darell D.] Univ Durham, Ctr Med, Durham, NC USA. [Marasco, Wayne] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3450S EP 3450S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000357 ER PT J AU Sequist, LV Janne, PA Walker, J Sweeney, J Grayzel, D Lynch, TJ AF Sequist, Lecia V. Janne, Pasi A. Walker, John Sweeney, Jennifer Grayzel, David Lynch, Thomas J. TI Phase I/II trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage 11113 or stage IV non-small cell lung cancer stratified by EGFR mutation status. SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Sequist, Lecia V.; Lynch, Thomas J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Janne, Pasi A.] Dana Farber Canc Inst, Boston, MA USA. [Walker, John; Sweeney, Jennifer; Grayzel, David] Infinity Pharmaceut Inc, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3457S EP 3457S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000380 ER PT J AU Hong, D Kurzrock, R Supko, JG Lawrence, D Wheeler, J Eder, JP Ng, C Mier, J Konopleva, M Konoplev, S Ekmekcioglu, S Andreeff, M Grimm, EA Kufe, D Meyer, CJ Shapiro, GI Dezube, BJ AF Hong, David Kurzrock, Razelle Supko, Jeffrey G. Lawrence, Donald Wheeler, Jennifer Eder, Joseph P. Ng, Chaan Mier, James Konopleva, Marina Konoplev, Sergej Ekmekcioglu, Suhenclan Andreeff, Michael Grimm, Elizabeth A. Kufe, Donald Meyer, Colin J. Shapiro, Geoffrey I. Dezube, Bruce J. TI Phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies. SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Hong, David; Kurzrock, Razelle; Wheeler, Jennifer; Ng, Chaan; Konopleva, Marina; Konoplev, Sergej; Ekmekcioglu, Suhenclan; Andreeff, Michael; Grimm, Elizabeth A.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Supko, Jeffrey G.; Lawrence, Donald] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Eder, Joseph P.; Kufe, Donald; Shapiro, Geoffrey I.] Dana Farber Canc Inst, Boston, MA USA. [Mier, James; Dezube, Bruce J.] Beth Israel Deaconess Med Ctr, Boston, MA USA. [Meyer, Colin J.] Reata Pharmaceut Inc, Irving, TX USA. RI Ekmekcioglu, Suhendan/A-9686-2009 NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3458S EP 3459S PN 2 PG 2 WC Oncology SC Oncology GA 245WH UT WOS:000251969000383 ER PT J AU Wittner, BS Sgroi, DC Ryan, PD Bruinsma, TJ Glas, AM Male, A Dahiya, S Habin, K Bernards, R Haber, DA van 'Tveer, LJ Ramaswamy, S AF Wittner, Ben S. Sgroi, Dennis C. Ryan, Paula D. Bruinsma, Tako J. Glas, Annuska M. Male, Anitha Dahiya, Sonika Habin, Karleen Bernards, Rene Haber, Daniel A. van 'tVeer, Laura J. Ramaswamy, Sridhar TI Analysis of the 70-gene breast cancer prognosis signature in a general hospital population SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Wittner, Ben S.; Sgroi, Dennis C.; Ryan, Paula D.; Male, Anitha; Habin, Karleen; Haber, Daniel A.; Ramaswamy, Sridhar] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Bruinsma, Tako J.; Glas, Annuska M.] Agendia BV, Amsterdam, Netherlands. [Bernards, Rene; van 'tVeer, Laura J.] Netherlands Canc Inst, Amsterdam, Netherlands. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3489S EP 3489S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000470 ER PT J AU Camidge, DR Britten, CD Schellens, JHM Guo, F Milham, R Eckhardt, SG Wong, SG Boss, DS Lucca, J Jannes, PA AF Camidge, D. R. Britten, C. D. Schellens, J. H. M. Guo, F. Milham, R. Eckhardt, S. G. Wong, S. G. Boss, D. S. Lucca, J. Jannes, P. A. TI First-in-human study of PF-00299804, a small molecule irreversible panHER inhibitor in patients with advanced cancer: Update on safety and pharmacokinetics and initial report on pharmacodynamic responses and clinical benefit SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Camidge, D. R.; Eckhardt, S. G.] Univ Colorado, Denver, CO USA. [Britten, C. D.; Wong, S. G.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Schellens, J. H. M.; Boss, D. S.] Netherlands Canc Inst, Amsterdam, Netherlands. [Guo, F.; Milham, R.] Pfizer Global Res & Dev, New London, CT USA. [Lucca, J.; Jannes, P. A.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3505S EP 3505S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000523 ER PT J AU Shapiro, GI Heath, E Malburg, L DeZube, B Miles, D Keer, HN Xu, AX Laeder, T LoRusso, P AF Shapiro, Geoffrey I. Heath, Elizabeth Malburg, Lisa DeZube, Bruce Miles, Dale Keer, Harold N. Xu, Andrew X. Laeder, Theresa LoRusso, Patricia TI A Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor, administered daily to patients (pts) with advanced malignancies SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Shapiro, Geoffrey I.] Dana Farber Canc Inst, Boston, MA USA. [Heath, Elizabeth; Malburg, Lisa; Laeder, Theresa; LoRusso, Patricia] Karmanos Canc Inst, Detroit, MI USA. [DeZube, Bruce] Beth Israel Hosp, Boston, MA USA. [Miles, Dale; Keer, Harold N.] Exelixis Inc, San Francisco, CA USA. [Xu, Andrew X.] Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3510S EP 3511S PN 2 PG 2 WC Oncology SC Oncology GA 245WH UT WOS:000251969000540 ER PT J AU Ross, RW Srinivasan, R Vaishampayan, U Bukowski, R Rosenberg, J Eisenberg, P Logan, T Srinivas, S Stein, M Mueller, T Keer, HN AF Ross, Robert W. Srinivasan, Ramaprasad Vaishampayan, Ulka Bukowski, Ronald Rosenberg, Jonathan Eisenberg, Peter Logan, Theodore Srinivas, Sandhya Stein, Mark Mueller, Thomas Keer, Harold N. TI A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC) SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Ross, Robert W.] Dana Farber Canc Inst, Boston, MA USA. [Srinivasan, Ramaprasad] Natl Canc Inst, Urol Oncol Branch, Bethesda, MD USA. [Vaishampayan, Ulka] Karmanos Canc Ctr, Detroit, MI USA. [Bukowski, Ronald] Cleveland Clin, Cleveland, OH USA. [Rosenberg, Jonathan] Univ Calif San Francisco, San Francisco, CA USA. [Eisenberg, Peter] California Canc Ctr, Greenbrae, CA USA. [Logan, Theodore] Indiana Univ, Ctr Canc, Indianapolis, IN USA. [Srinivas, Sandhya] Stanford Univ, Ctr Canc, Stanford, CA 94305 USA. [Stein, Mark] Inst Canc Res, New Brunswick, NJ USA. [Mueller, Thomas; Keer, Harold N.] Exelixis Inc, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3511S EP 3511S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000541 ER PT J AU Matulonis, U Berlin, S Krasner, C Tyburski, K Lee, J Roche, M Ivy, P Penson, R AF Matulonis, Ursula Berlin, Suzanne Krasner, Carolyn Tyburski, Karin Lee, Julie Roche, Maria Ivy, Percy Penson, Richard TI Phase II study of cediranib (RECENTIN (TM), AZD2171) in recurrent epithelial ovarian cancer SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Matulonis, Ursula; Berlin, Suzanne; Tyburski, Karin; Lee, Julie] Dana Farber Canc Inst, Boston, MA USA. [Krasner, Carolyn; Roche, Maria; Penson, Richard] Massachusetts Gen Hosp, Boston, MA USA. [Ivy, Percy] Natl Canc Inst, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3515S EP 3515S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000554 ER PT J AU Lazaro, JB Dejmek, J Iglehart, JD AF Lazaro, Jean-Bernard Dejmek, Janna Iglehart, James Dirk TI The DNA-dependent protein kinase (DNA-PK) complex recruits the facilitator of chromatin transcription (FACT) complex and induces the exit of FACT from the nucleolus in response to cisplatin treatment SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Lazaro, Jean-Bernard; Dejmek, Janna; Iglehart, James Dirk] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3548S EP 3548S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000655 ER PT J AU Amler, L Makhija, S Januario, T Lin, CY Derynck, M Birkner, M Matulonis, U Strauss, A Sliwkowski, M Paton, V AF Amler, L. Makhija, S. Januario, T. Lin, C-Y Derynck, M. Birkner, M. Matulonis, U. Strauss, A. Sliwkowski, M. Paton, V. TI Downregulation of HER3: A potential surrogate for activation of HER2 through heterodimerization may predict clinical benefit in ovarian cancer from pertuzumab, a HER dimerization inhibiting antibody SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Amler, L.; Januario, T.; Lin, C-Y; Derynck, M.; Birkner, M.; Sliwkowski, M.; Paton, V.] Genentech Inc, San Francisco, CA USA. [Makhija, S.] Univ Alabama, Birmingham, AL USA. [Matulonis, U.] Dana Farber Canc Inst, Boston, MA USA. [Strauss, A.] Roche Diagnostics GmbH, Penzberg, Germany. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3572S EP 3572S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000722 ER PT J AU Zurita, AJ Wu, HK Kulke, M Tye, L Bello, CL DePrimo, SE Mckee, KS Heymach, JV AF Zurita, Amado J. Wu, Hua-Kang Kulke, Matthew Tye, Lesley Bello, Carlo L. DePrimo, Samuel E. McKee, Kathryn S. Heymach, John V. TI Sunitinib affects specific subpopulations of peripheral blood monocytic cells in patients with unresectable Neuroendocrine Tumor (NET): An 8-color flow cytometry analysis SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Zurita, Amado J.; Wu, Hua-Kang; Tye, Lesley; McKee, Kathryn S.; Heymach, John V.] MD Anderson Canc Ctr, Houston, TX USA. [Kulke, Matthew] Dana Farber Canc Inst, Boston, MA USA. [Bello, Carlo L.; DePrimo, Samuel E.] Pfizer Global Res & Dev, La Jolla, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3580S EP 3580S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000743 ER PT J AU Houk, BE Bello, C Cohen, DP Demetri, GD Casali, PG Shirao, K AF Houk, Brett E. Bello, Carlo Cohen, Darrel P. Demetri, George D. Casali, Paolo G. Shirao, Kuniaki TI Efficacy of sunitinib in patients with gastrointestinal stromal tumor (GIST): An exposure-response based meta-analysis SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Houk, Brett E.; Bello, Carlo; Cohen, Darrel P.] Pfizer Global Res & Dev, La Jolla, CA USA. [Demetri, George D.] Dana Farber Canc Inst, Ludwigs Ctr, Boston, MA USA. [Casali, Paolo G.] Ist Nazl Tumori, Milan, Italy. [Shirao, Kuniaki] Natl Canc Ctr, Tokyo, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3589S EP 3589S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000770 ER PT J AU Shapiro, GI Edelman, G Calvo, E Aggarwal, SK Laird, AD AF Shapiro, Geoffrey I. Edelman, Gerald Calvo, Emiliano Aggarwal, Sanjay K. Laird, A. Douglas TI Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Shapiro, Geoffrey I.] Dana Farber Canc Inst, Boston, MA USA. [Edelman, Gerald] Mary Crowley Canc Res Ctrs, Dallas, TX USA. [Calvo, Emiliano] Vall Hebron Univ Hosp, Barcelona, Spain. [Aggarwal, Sanjay K.; Laird, A. Douglas] Exelixis Inc, San Francisco, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3594S EP 3594S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000785 ER PT J AU Finkler, NJ Dizon, D Micha, J Braly, P Lassen, U Sngelholm, SA Glasspool, R Crowley, E Li, SX Buhl-Jensen, P Penson, R AF Finkler, Neil J. Dizon, Don Micha, John Braly, Patricia Lassen, Ulrik Sngelholm, S. A. Glasspool, Rosalind Crowley, Elizabeth Li, Shu-Xia Buhl-Jensen, Peter Penson, Richard TI Phase II multicenter trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) for patients (pts) with relapsed ovarian cancer SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Finkler, Neil J.] Florida Hosp, Inst Canc, Orlando, FL USA. [Dizon, Don] Women & Infants Hosp Rhode Isl, Providence, RI USA. [Micha, John] Gynecol Oncol Assoc, Newport Beach, CA USA. [Braly, Patricia] Hematol Oncol Specialist, LLC, Metairie, LA USA. [Lassen, Ulrik; Sngelholm, S. A.] Univ Hosp, Rigshosp, Copenhagen, Denmark. [Glasspool, Rosalind] Beatason W Scotland Canc Ctr, Glasgow, Lanark, Scotland. [Crowley, Elizabeth; Li, Shu-Xia] CuraGen Corp, Branford, CT USA. [Buhl-Jensen, Peter] TopoTarget A S, Copenhagen, Denmark. [Penson, Richard] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3599S EP 3599S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000802 ER PT J AU Rao, S Majumder, PK O'Neil, J Reilly, J Liberator, C Tammam, J Efferson, C Ware, C Sarnecki, C Kohl, NE Richon, V Carroll, P Draetta, G Look, AT Bergstrom, D Strack, PR Winter, CG AF Rao, Sudhir Majumder, Pradip K. O'Neil, Jennifer Reilly, John Liberator, Cole Tammam, Jennifer Efferson, Clay Ware, Christopher Sarnecki, Charlyn Kohl, Nancy E. Richon, Victoria Carroll, Pamela Draetta, Giulio Look, A. Thomas Bergstrom, Donald Strack, Peter R. Winter, Christopher G. TI Targeting Notch in cancer with gamma-secretase inhibitors SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Rao, Sudhir; Majumder, Pradip K.; Reilly, John; Liberator, Cole; Tammam, Jennifer; Efferson, Clay; Ware, Christopher; Sarnecki, Charlyn; Kohl, Nancy E.; Richon, Victoria; Carroll, Pamela; Draetta, Giulio; Bergstrom, Donald; Strack, Peter R.; Winter, Christopher G.] Merck Res Labs, Boston, MA USA. [O'Neil, Jennifer; Look, A. Thomas] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3603S EP 3603S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000814 ER PT J AU Kennedy, R D'Andrea, AD AF Kennedy, Richard D'Andrea, Alan D. TI Targeting Fanconi anemia/BRCA pathway defects in cancer therapeutics SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Kennedy, Richard; D'Andrea, Alan D.] Dana Farber Canc Inst, Boston, MA USA. RI Kennedy, Richard/J-3489-2012 OI Kennedy, Richard/0000-0003-4737-6163 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3631S EP 3631S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000895 ER PT J AU Garraway, L AF Garraway, Levi TI From genomic diversity to tumor dependency in human cancer SO MOLECULAR CANCER THERAPEUTICS LA English DT Meeting Abstract C1 [Garraway, Levi] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2007 VL 6 IS 12 BP 3634S EP 3634S PN 2 PG 1 WC Oncology SC Oncology GA 245WH UT WOS:000251969000901 ER PT J AU Marasco, WA Sui, J AF Marasco, Wayne A. Sui, Jianhua TI The growth and potential of human antiviral monoclonal antibody therapeutics SO NATURE BIOTECHNOLOGY LA English DT Review ID WEST-NILE-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; ACUTE RESPIRATORY SYNDROME; HEPATITIS-C VIRUS; VARICELLA-ZOSTER-VIRUS; MEMORY B-CELLS; ARGENTINE HEMORRHAGIC-FEVER; PROXIMAL EXTERNAL REGION; REGULATORY T-CELLS; NEUTRALIZING ANTIBODIES AB Monoclonal antibodies (mAbs) have long provided powerful research tools for virologists to understand the mechanisms of virus entry into host cells and of antiviral immunity. Even so, commercial development of human (or humanized) mAbs for the prophylaxis, preemptive and acute treatment of viral infections has been slow. This is surprising, as new antibody discovery tools have increased the speed and precision with which potent neutralizing human antiviral mAbs can be identified. As longstanding barriers to antiviral mAb development, such as antigenic variability of circulating viral strains and the ability of viruses to undergo neutralization escape, are being overcome, deeper insight into the mechanisms of mAb action and engineering of effector functions are also improving the efficacy of antiviral mAbs. These successes, in both industrial and academic laboratories, coupled with ongoing changes in the biomedical and regulatory environments, herald an era when the commercial development of human antiviral mAb therapies will likely surge. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. RP Marasco, WA (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA. EM wayne_marasco@dfci.harvard.edu; jianhua_sui@dfci.harvard.edu OI SUI, JIANHUA/0000-0002-1272-9662 NR 159 TC 15 Z9 15 U1 7 U2 24 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1087-0156 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD DEC PY 2007 VL 25 IS 12 DI 10.1038/nbt1363 PG 14 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA 238OT UT WOS:000251457800032 ER PT J AU Ahmad, R Raina, D Trivedi, V Ren, J Rajabi, H Kharbanda, S Kufe, D AF Ahmad, Rehan Raina, Deepak Trivedi, Vishal Ren, Jian Rajabi, Hasan Kharbanda, Surender Kufe, Donald TI MUC1 oncoprotein activates the I kappa B kinase beta complex and constitutive NF-kappa B signalling SO NATURE CELL BIOLOGY LA English DT Article ID TUMOR-NECROSIS-FACTOR; MAMMARY EPITHELIAL-CELLS; FACTOR-ALPHA; TNF; CANCER; IKK; MORPHOGENESIS; RECEPTOR-1; PATHWAY; GROWTH AB Nuclear factor-kappa B ( NF-kappa B) is constitutively activated in diverse human malignancies by mechanisms that are not understood(1,2). The MUC1 oncoprotein is aberrantly overexpressed by most human carcinomas and, similarly to NF-kappa B, blocks apoptosis and induces transformation(3-6). This study demonstrates that overexpression of MUC1 in human carcinoma cells is associated with constitutive activation of NF-kappa B p65. We show that MUC1 interacts with the high-molecular-weight I kappa B kinase (IKK) complex in vivo and that the MUC1 cytoplasmic domain binds directly to IKK beta and IKK gamma. Interaction of MUC1 with both IKK beta and IKK gamma is necessary for IKK beta activation, resulting in phosphorylation and degradation of I kappa B alpha. Studies in non-malignant epithelial cells show that MUC1 is recruited to the TNF-R1 complex and interacts with IKK eta-IKK gamma in response to TNF alpha stimulation. TNF alpha-induced recruitment of MUC1 is dependent on TRADD and TRAF2, but not the death-domain kinase RIP1. In addition, MUC1-mediated activation of IKK beta is dependent on TAK1 and TAB2. These findings indicate that MUC1 is important for physiological activation of IKK beta and that overexpression of MUC1, as found in human cancers, confers sustained induction of the IKK beta-NF kappa B p65 pathway. C1 Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA. RP Kufe, D (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA. EM donald_kufe@dfci.harvard.edu FU NCI NIH HHS [CA100707, CA42802, CA97098, P50 CA100707, R01 CA042802, R01 CA097098] NR 35 TC 103 Z9 104 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1465-7392 J9 NAT CELL BIOL JI Nat. Cell Biol. PD DEC PY 2007 VL 9 IS 12 BP 1419 EP U146 DI 10.1038/ncb1661 PG 19 WC Cell Biology SC Cell Biology GA 236QA UT WOS:000251317300015 PM 18037881 ER PT J AU Finn, AV Gold, HK AF Finn, A. V. Gold, H. K. TI Total erythrocyte membrane cholesterol: a marker of plaque instability? SO NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE LA English DT Editorial Material DE acute coronary syndrome; atherosclerotic plaque; cholesterol; chronic stable angina; erythrocyte ID INTRAPLAQUE HEMORRHAGE; PROGRESSION C1 Massachusetts Gen Hosp, Harvard Med Sch, Dept Cardiol, Boston, MA USA. RP Finn, AV (reprint author), Emory Univ Sch Med, Emory Crawford Long Hosp, Dept Internal Med, 550 Peachtree St NE, Atlanta, GA 30308 USA. EM avfinn@emory.edu NR 6 TC 0 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1743-4297 J9 NAT CLIN PRACT CARD JI Nat. Clin. Pract. Cardiovasc. Med. PD DEC PY 2007 VL 4 IS 12 BP 646 EP 647 DI 10.1038/ncpcardio0986 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 233FM UT WOS:000251075800004 PM 17768403 ER PT J AU Page, KA Dejardin, S Kahn, CR Kulkarni, RN Herold, KC Inzucchi, SE AF Page, Kathleen A. Dejardin, Stephanie Kahn, C. Ronald Kulkarni, Rohit N. Herold, Kevan C. Inzucchi, Silvio E. TI A patient with type B insulin resistance syndrome, responsive to immune therapy SO NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM LA English DT Article DE anti-insulin-receptor antibodies; autoimmunity; diabetes mellitus; insulin resistance; type B insulin resistance syndrome ID ACANTHOSIS NIGRICANS; RECEPTOR; AUTOANTIBODIES; CYCLOPHOSPHAMIDE; ANTIBODIES AB Background A 55-year-old woman with vitiligo, hypothyroidism, interstitial lung disease and diabetes mellitus developed severe insulin resistance during a hospital admission for respiratory failure. Before hospitalization, her HbA(1c) level was 8.1% on similar to 100 U/day of insulin. Her interstitial lung disease had been treated with glucocorticoids, but after their withdrawal her insulin requirements had increased dramatically. She remained hyperglycemic (blood glucose levels 16.7-27.8 mmol/l), despite intravenous insulin at doses as high as 30,000 U/day. Investigations The patient's serum creatinine level was 301 mu mol/l and her liver function tests were normal. A mildly elevated white cell count was present. The patient was diagnosed with pneumonia due to Pseudomonas aeruginosa. When the patient's plasma glucose level was 22.5 mmol/l, her plasma C-peptide level was 0.9 nmol/l and her serum insulin level was 294 pmol/l. At that time the patient was on 2,600 U/day of intravenous insulin aspart. Anti-insulin and anti-islet-cell antibodies were not detected, but anti-insulin-receptor antibodies were found. Diagnosis Type B insulin resistance syndrome. Management The patient's insulin resistance responded to glucocorticoids and plasmapheresis. After the patient was treated with prednisone (60 mg/day), her insulin requirements decreased within 1 week to pre-admission doses. When steroids were subsequently discontinued, glycemic control deteriorated once again. Plasmapheresis was initiated, inducing a striking acute decline in insulin needs. On a maintenance dose of 10 mg prednisone/day, glucose control improved (HbA(1C) 5.8%) with an average of 60 U of isophane insulin twice daily. C1 Yale Univ, Sch Med, Dept Internal Med, Endocrinol Sect, New Haven, CT 06520 USA. Joslin Diabet Ctr, Boston, MA USA. Harvard Sch Med, Boston, MA USA. RP Page, KA (reprint author), Yale Univ, Sch Med, Dept Internal Med, Endocrinol Sect, 333 Cedar St,PO Box 208030, New Haven, CT 06520 USA. EM kathleen.page@yale.edu FU NIDDK NIH HHS [P30DK 36836, R01 DK67536] NR 18 TC 16 Z9 18 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1745-8366 J9 NAT CLIN PRACT ENDOC JI Nat. Clin. Pract. Endocrinol. Metab. PD DEC PY 2007 VL 3 IS 12 BP 835 EP 840 DI 10.1038/ncpendmet0693 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 230HT UT WOS:000250868300014 PM 18026162 ER PT J AU Plenge, RM Cotsapas, C Davies, L Price, AL Bakker, PIW Maller, J Pe'er, I Burtt, NP Blumenstiel, B DeFelice, M Parkin, M Barry, R Winslow, W Healy, C Graham, RR Neale, BM Izmailova, E Roubenoff, R Parker, AN Glass, R Karlson, EW Maher, N Hafler, DA Lee, DM Seldin, MF Remmers, EF Lee, AT Padyukov, L Alfredsson, L Coblyn, J Weinblatt, ME Gabriel, SB Purcell, S Klareskog, L Gregersen, PK Shadick, NA Daly, MJ Altshuler, D AF Plenge, Robert M. Cotsapas, Chris Davies, Leela Price, Alkes L. Bakker, Paul I. Wde Maller, Julian Pe'er, Itsik Burtt, Noel P. Blumenstiel, Brendan DeFelice, Matt Parkin, Melissa Barry, Rachel Winslow, Wendy Healy, Claire Graham, Robert R. Neale, Benjamin M. Izmailova, Elena Roubenoff, Ronenn Parker, Alexander N. Glass, Roberta Karlson, Elizabeth W. Maher, Nancy Hafler, David A. Lee, David M. Seldin, Michael F. Remmers, Elaine F. Lee, Annette T. Padyukov, Leonid Alfredsson, Lars Coblyn, Jonathan Weinblatt, Michael E. Gabriel, Stacey B. Purcell, Shaun Klareskog, Lars Gregersen, Peter K. Shadick, Nancy A. Daly, Mark J. Altshuler, David TI Two independent alleles at 6q23 associated with risk of rheumatoid arthritis SO NATURE GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; GENETIC ASSOCIATION; POPULATION-STRUCTURE; STRATIFICATION; PROTEIN; VARIANT AB To identify susceptibility alleles associated with rheumatoid arthritis, we genotyped 397 individuals with rheumatoid arthritis for 116,204 SNPs and carried out an association analysis in comparison to publicly available genotype data for 1,211 related individuals from the Framingham Heart Study(1). After evaluating and adjusting for technical and population biases, we identified a SNP at 6q23 ( rs10499194, similar to 150 kb from TNFAIP3 and OLIG3) that was reproducibly associated with rheumatoid arthritis both in the genome-wide association ( GWA) scan and in 5,541 additional case-control samples (P = 10(-3), GWA scan; P < 10(-6), replication; P = 10(-9), combined). In a concurrent study, the Wellcome Trust Case Control Consortium ( WTCCC) has reported strong association of rheumatoid arthritis susceptibility to a different SNP located 3.8 kb from rs10499194 ( rs6920220; P = 5 x 10(-6) in WTCCC)(2). We show that these two SNP associations are statistically independent, are each reproducible in the comparison of our data and WTCCC data, and define risk and protective haplotypes for rheumatoid arthritis at 6q23. C1 MIT, Broad Inst Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA. Brigham & Womens Hosp, Harvard Med Sch, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA. Massachusetts Gen Hosp, Harvard Med Sch, Dept Med, Ctr Human Genet Res, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02115 USA. Harvard Med Sch, Dept Genet, Boston, MA 02115 USA. Columbia Univ, Dept Comp Sci, New York, NY 10027 USA. Coll London, London SE5 8AF, England. Millennium Pharmaceut Inc, Cambridge, MA 02139 USA. Brigham & Womens Hosp, Harvard Med Sch, Ctr Neurol Dis, Boston, MA 02115 USA. Univ Calif Davis, Rowe Program Genet, Davis, CA 95616 USA. NIAMSD, NIH, Genet Genom Branch, Bethesda, MD 20892 USA. N Shore Long Island Hlth Syst, Feinstein Inst Med Res, Manhasset, NY 11030 USA. Karilinska Univ Hosp Solna, Karolinska Inst, Dept Med, Rheumatol Unit, Stockholm, Sweden. Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden. RP Plenge, RM (reprint author), MIT, Broad Inst Harvard, Program Med & Populat Genet, 77 Massachusetts Ave, Cambridge, MA 02142 USA. EM rplenge@partners.org RI Padyukov, Leonid/A-4890-2009; Altshuler, David/A-4476-2009; de Bakker, Paul/B-8730-2009; OI Cotsapas, Chris/0000-0002-7772-5910; Padyukov, Leonid/0000-0003-2950-5670; Altshuler, David/0000-0002-7250-4107; de Bakker, Paul/0000-0001-7735-7858; Maller, Julian/0000-0002-1565-9559; Alfredsson, Lars/0000-0003-1688-6697; Healy, Claire M/0000-0001-7940-4611; Klareskog, Lars/0000-0001-9601-6186 FU NIAID NIH HHS [AI55314-3, K08 AI055314-01A1, K08 AI055314-02, K08 AI055314-03, K08 AI055314-04, K08 AI055314-05, K08 AI055314]; NIAMS NIH HHS [N01-AR-2-2263, R01 AR044422, R01-AR44422] NR 28 TC 371 Z9 380 U1 2 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD DEC PY 2007 VL 39 IS 12 BP 1477 EP 1482 DI 10.1038/ng.2007.27 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA 235XK UT WOS:000251267400015 PM 17982456 ER PT J AU Peterfy, M Ben-Zeev, O Mao, HZ Weissglas-Volkov, D Aouizerat, BE Pullinger, CR Frost, PH Kane, JP Malloy, MJ Reue, K Pajukanta, P Doolittle, MH AF Peterfy, Miklos Ben-Zeev, Osnat Mao, Hui Z. Weissglas-Volkov, Daphna Aouizerat, Bradley E. Pullinger, Clive R. Frost, Philip H. Kane, John P. Malloy, Mary J. Reue, Karen Pajukanta, Paeivi Doolittle, Mark H. TI Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia SO NATURE GENETICS LA English DT Article ID LIPOPROTEIN-LIPASE; ENDOPLASMIC-RETICULUM; HEPATIC LIPASE; MATURATION; CLD/CLD; MOUSE; MICE; CLD; METABOLISM; SECRETION AB Hypertriglyceridemia is a hallmark of many disorders, including metabolic syndrome, diabetes, atherosclerosis and obesity(1-3). A well-known cause is the deficiency of lipoprotein lipase ( LPL), a key enzyme in plasma triglyceride hydrolysis(4-6). Mice carrying the combined lipase deficiency ( cld) mutation show severe hypertriglyceridemia owing to a decrease in the activity of LPL and a related enzyme, hepatic lipase ( HL)(7-9), caused by impaired maturation of nascent LPL and hepatic lipase polypeptides in the endoplasmic reticulum ( ER)(10). Here we identify the gene containing the cld mutation as Tmem112 and rename it Lmf1 ( Lipase maturation factor 1). Lmf1 encodes a transmembrane protein with an evolutionarily conserved domain of unknown function that localizes to the ER. A human subject homozygous for a deleterious mutation in LMF1 also shows combined lipase deficiency with concomitant hypertriglyceridemia and associated disorders. Thus, through its profound effect on lipase activity, LMF1 emerges as an important candidate gene in hypertriglyceridemia(4,11,12). C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA. Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Cardiovasc Res Inst, San Francisco, CA 94143 USA. RP Peterfy, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. EM mpeterfy@ucla.edu; markdool@ucla.edu FU NCRR NIH HHS [KL2-RR024130]; NHGRI NIH HHS [T32 HG002536, T32 HG02536]; NHLBI NIH HHS [HL082762, HL28481] NR 26 TC 95 Z9 101 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD DEC PY 2007 VL 39 IS 12 BP 1483 EP 1487 DI 10.1038/ng.2007.24 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA 235XK UT WOS:000251267400016 PM 17994020 ER PT J AU Dolan, MJ Kulkarni, H Camargo, JF He, W Smith, A Anaya, JM Miura, T Hecht, FM Mamtani, M Pereyra, F Marconi, V Mangano, A Sen, L Bologna, R Clark, RA Anderson, SA Delmar, J O'Connell, RJ Lloyd, A Martin, J Ahuja, SS Agan, BK Walker, BD Deeks, SG Ahuja, SK AF Dolan, Matthew J. Kulkarni, Hemant Camargo, Jose F. He, Weijing Smith, Alison Anaya, Juan-Manuel Miura, Toshiyuki Hecht, Frederick M. Mamtani, Manju Pereyra, Florencia Marconi, Vincent Mangano, Andrea Sen, Luisa Bologna, Rosa Clark, Robert A. Anderson, Stephanie A. Delmar, Judith O'Connell, Robert J. Lloyd, Andrew Martin, Jeffrey Ahuja, Seema S. Agan, Brian K. Walker, Bruce D. Deeks, Steven G. Ahuja, Sunil K. TI CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms SO NATURE IMMUNOLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; CD8(+) T-CELLS; TYPE-1 INFECTION; DISEASE PROGRESSION; IN-VITRO; HYPERSENSITIVITY; CHEMOKINES; PLASMA; RNA; SUSCEPTIBILITY AB Although host defense against human immunodeficiency virus 1 (HIV- 1) relies mainly on cell-mediated immunity (CMI), the determinants of CMI in humans are poorly understood. Here we demonstrate that variations in the genes encoding the chemokine CCL3L1 and HIV coreceptor CCR5 influence CMI in both healthy and HIV- infected individuals. CCL3L1-CCR5 genotypes associated with altered CMI in healthy subjects were similar to those that influence the risk of HIV transmission, viral burden and disease progression. However, CCL3L1-CCR5 genotypes also modify HIV clinical course independently of their effects on viral load and CMI. These results identify CCL3L1 and CCR5 as major determinants of CMI and demonstrate that these host factors influence HIV pathogenesis through their effects on both CMI and other viral entry-independent mechanisms. C1 Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. Wilford Hall USAF Med Ctr, Infect Dis Clin Res Program, Lackland AFB, TX 78236 USA. Wilford Hall USAF Med Ctr, Infect Dis Serv, Lackland AFB, TX 78236 USA. Wilford Hall USAF Med Ctr, Henry M Jackson Fdn, Lackland AFB, TX 78236 USA. Univ Western Sydney, Sch Psychol, Penrith, NSW 1797, Australia. Univ Rosario, Corporac Invest Biol, Cellular Biol & Immunogenet Unit, Medellin, Colombia. Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div AIDS, Boston, MA 02114 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 20815 USA. San Francisco Gen Hosp, San Francisco, CA 20815 USA. Hosp Pediat JP Garrahan, Lab Biol Celular & Retrovirus, RA-1245 Buenos Aires, DF, Argentina. Hosp Pediat JP Garrahan, Serv Infectol, RA-1245 Buenos Aires, DF, Argentina. Univ New S Wales, Sch Med Sci, Sydney, NSW 2052, Australia. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. RP Ahuja, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX 78229 USA. EM mdolan@hjf.org; ahujas@uthscsa.edu RI Marconi, Vincent/N-3210-2014; Anaya, Juan-Manuel/J-1960-2016; OI Marconi, Vincent/0000-0001-8409-4689; Anaya, Juan-Manuel/0000-0002-6444-1249; Universidad del Rosario, Biblioteca/0000-0003-3491-9392; Agan, Brian/0000-0002-5114-1669 NR 53 TC 118 Z9 119 U1 3 U2 12 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1529-2908 J9 NAT IMMUNOL JI Nat. Immunol. PD DEC PY 2007 VL 8 IS 12 BP 1324 EP 1336 DI 10.1038/ni1521 PG 13 WC Immunology SC Immunology GA 235XG UT WOS:000251267000013 PM 17952079 ER PT J AU Horng, T Bezbradica, JS Medzhitov, R AF Horng, Tiffany Bezbradica, Jelena S. Medzhitov, Ruslan TI NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway SO NATURE IMMUNOLOGY LA English DT Article ID NATURAL-KILLER-CELLS; NK CELLS; BONE HOMEOSTASIS; IN-VIVO; RECEPTOR; MICE; IMMUNORECEPTOR; ACTIVATION; PROTEINS; IL-15 AB The effector functions of natural killer cells are regulated by activating receptors, which recognize stress-inducible ligands expressed on target cells and signal through association with signaling adaptors. Here we developed a mouse model in which a fusion of the signaling adaptor DAP10 and ubiquitin efficiently downregulated expression of the activating receptor NKG2D on the surfaces of natural killer cells. With this system, we identified coupling of the signaling pathways triggered by NKG2D and DAP10 to those initiated by the interleukin 15 receptor. We suggest that this coupling of activating receptors to other receptor systems could function more generally to regulate cell type-specific signaling events in distinct physiological contexts. C1 Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA. Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA. RP Horng, T (reprint author), Harvard Univ, Sch Med, Dept Pathol, Immune Dis Inst, Boston, MA 02115 USA. EM horng@cbrinstitute.org; ruslan.medzhitov@yale.edu OI Bezbradica, Jelena/0000-0003-1441-1727 FU NIAID NIH HHS [AI-0466888, AI-055502] NR 43 TC 79 Z9 85 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1529-2908 J9 NAT IMMUNOL JI Nat. Immunol. PD DEC PY 2007 VL 8 IS 12 BP 1345 EP 1352 DI 10.1038/ni1524 PG 8 WC Immunology SC Immunology GA 235XG UT WOS:000251267000015 PM 17952078 ER PT J AU Peer, D Karp, JM Hong, S FaroKHzad, OC Margalit, R Langer, R AF Peer, Dan Karp, Jeffrey M. Hong, SeungPyo FaroKHzad, Omid C. Margalit, Rimona Langer, Robert TI Nanocarriers as an emerging platform for cancer therapy SO NATURE NANOTECHNOLOGY LA English DT Review ID PEGYLATED LIPOSOMAL DOXORUBICIN; STERICALLY STABILIZED LIPOSOMES; TARGETED DRUG-DELIVERY; HUMAN-TUMOR XENOGRAFT; IN-VIVO; MULTIDRUG-RESISTANCE; MONOCLONAL-ANTIBODY; POLYALKYLCYANOACRYLATE NANOPARTICLES; ANTITUMOR-ACTIVITY; BREAST-CANCER AB Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment. C1 Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,HST Ctr Biomed Engn, Cambridge, MA 02138 USA. Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. MIT, Dept Chem Engn, Cambridge, MA 02139 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Lab Nanomed & Biomat, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol, Boston, MA 02115 USA. Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel. Tel Aviv Univ, Ctr Nanosci & Nanotechnol, IL-69978 Tel Aviv, Israel. RP Peer, D (reprint author), Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. EM rlanger@mit.edu RI Peer, Dan/A-1785-2011 OI Peer, Dan/0000-0001-8238-0673 FU NCI NIH HHS [CA119349]; NIBIB NIH HHS [R01-EB000244, EB 003647] NR 106 TC 3310 Z9 3356 U1 419 U2 2691 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1748-3387 J9 NAT NANOTECHNOL JI Nat. Nanotechnol. PD DEC PY 2007 VL 2 IS 12 BP 751 EP 760 DI 10.1038/nnano.2007.387 PG 10 WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Science & Technology - Other Topics; Materials Science GA 238OG UT WOS:000251456500010 PM 18654426 ER PT J AU Schmucker, D AF Schmucker, Dietmar TI Molecular diversity of Dscam: recognition of molecular identity in neuronal wiring SO NATURE REVIEWS NEUROSCIENCE LA English DT Review ID CELL-ADHESION-MOLECULE; DROSOPHILA SENSORY NEURONS; MOUSE OLFACTORY SYSTEM; AXON GUIDANCE; NERVOUS-SYSTEM; SELF-AVOIDANCE; IMMUNE-SYSTEM; RECEPTOR; MORPHOGENESIS; ORGANIZATION AB Our understanding of how the enormously complex task of interconnecting millions of nerve cells is accomplished remains rudimentary. What molecular mechanisms control its exquisite specificity? Can we pinpoint single molecular interactions that might help to explain some of the specificity requirements that underlie neuronal wiring? A series of recent studies on the molecular diversity of the Drosophila melanogaster cell-surface receptor Down syndrome cell-adhesion molecule (Dscam) provide one exceptional example of a novel mechanistic model of neuronal-wiring specificity, progressing from structural studies of single protein -protein interactions to biochemical analysis in vitro and to an understanding of complex neuronal differentiation at the single-cell or tissue levels. C1 Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RP Schmucker, D (reprint author), Harvard Univ, Sch Med, Dept Neurobiol, 1 Jimmy Fund Way, Boston, MA 02115 USA. EM dietmar_schmucker@dfci.harvard.edu NR 35 TC 33 Z9 34 U1 2 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-0048 J9 NAT REV NEUROSCI JI Nat. Rev. Neurosci. PD DEC PY 2007 VL 8 IS 12 BP 915 EP 920 DI 10.1038/nrn2256 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 233FD UT WOS:000251074900013 PM 18026165 ER PT J AU Nelson, GM Padera, TP Garkavtsev, I Shioda, T Jain, RK AF Nelson, Gregory M. Padera, Timothy P. Garkavtsev, Igor Shioda, Toshi Jain, Rakesh K. TI Differential gene expression of primary cultured lymphatic and blood vascular endothelial cells SO NEOPLASIA LA English DT Article DE lymphangiogenesis; microarray; LEC; BEC; endothelial ID HEPATOCYTE GROWTH-FACTOR; TYROSINE-PHOSPHATASE-MU; SENTINEL-NODE BIOPSY; IN-VITRO; VEGF-C; METASTASIS; PROTEIN; LIGAND; LYMPHANGIOGENESIS; VIVO AB Blood vascular endothelial cells (BECs) and the developmentally related lymphatic endothelial cells (LECs) create complementary, yet distinct vascular networks. Each endothelial cell type interacts with flowing fluid and circulating cells, yet each vascular system has evolved specialized gene expression programs and thus both cell types display different phenotypes. BECs and LECs express distinct genes that are unique to their specific vascular microenvironment. Tumors also take advantage of the molecules that are expressed in these vascular systems to enhance their metastatic potential. We completed transcriptome analyses on primary cultured LECs and BECs, where each comparative set was isolated from the same individual. Differences were resolved in the expression of several major categories, such as cell adhesion molecules (CAMs), cytokines, and cytokine receptors. We have identified new molecules that are associated with BECs ( e. g., claudin-9, CXCL11, neurexin-1, neurexin-2, and the neuronal growth factor regulator-1) and LECs ( e. g., claudin-7, CD58, hyaluronan and proteoglycan link protein 1 (HAPLN1), and the poliovirus receptor-related 3 molecule) that may lead to novel therapeutic treatments for diseases of lymphatic or blood vessels, including metastasis of cancer to lymph nodes or distant organs. C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc Res, Mol Profilling Lab, Charlestown, MA 02129 USA. RP Jain, RK (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, 100 Blosson St Cox 7, Boston, MA 02114 USA. EM jain@steele.mgh.harvard.edu RI Nelson, Gregory/H-6315-2011; OI Nelson, Gregory/0000-0002-8382-910X; Padera, Timothy/0000-0002-3453-9384 FU NCI NIH HHS [T32 CA73479, P01 CA080124, R01 CA085140, R01 CA85140, T32 CA073479] NR 48 TC 26 Z9 26 U1 0 U2 2 PU NEOPLASIA PRESS PI ANN ARBOR PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648 USA SN 1522-8002 J9 NEOPLASIA JI Neoplasia PD DEC PY 2007 VL 9 IS 12 BP 1038 EP 1045 DI 10.1593/neo.07643 PG 8 WC Oncology SC Oncology GA 238KL UT WOS:000251446400006 PM 18084611 ER PT J AU Kawasaki, T Nosho, K Ohnishi, M Suemoto, Y Kirknery, GJ Fuchs, CS Ogino, S AF Kawasaki, Takako Nosho, Katsuhiko Ohnishi, Mutsuko Suemoto, Yuko Kirknery, Gregory J. Fuchs, Charles S. Ogino, Shuji TI IGFBP3 promoter methylation in colorectal cancer: Relationship with microsatellite instability, CpG island methylator phenotype, and p53 SO NEOPLASIA LA English DT Article DE colon cancer; IGFBP3; methylation; CIMP; MSI ID EPITHELIAL OVARIAN-CANCER; FACTOR-BINDING PROTEIN-3; POPULATION-BASED SAMPLE; COMBINATION CHEMOTHERAPY; MOLECULAR-FEATURES; COLON-CANCER; LUNG-CANCER; CARCINOMA; INSULIN; CELLS AB Insulin-like growth factor binding protein 3 (IGFBP3), which is induced by wild-type p53, regulates IGF and interacts with the TGF-beta pathway. IGFBP3 promoter methylation may occur in colorectal cancer with or without the CpG island methylator phenotype (CIMP), which is associated with microsatellite instability (MSI) and TGFBR2 mutation. We examined the relationship between IGFBP3 methylation, p53 expression, CIMP and MSI in 902 population-based colorectal cancers. Utilizing real-time PCR (MethyLight), we quantified promoter methylation in IGFBP3 and eight other CIMP-high-specific promoters (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1). IGFBP3 methylation was far more frequent in non-MSI-high CIMP-high tumors (85% = 35/41) than in MSI-high CIMP-high (49% = 44/90, P <.0001), MSI-high non - CIMP-high (17% = 6/36, P <.0001), and non - MSI-high non - CIMP-high tumors (22% = 152/680, P <.0001). Among CIMP-high tumors, the inverse relationship between MSI and IGFBP3 methylation persisted in p53-negative tumors (P <.0001), but not in p53-positive tumors. IGFBP3 methylation was associated inversely with TGFBR2 mutation in MSI-high non - CIMP-high tumors (P = .02). In conclusion, IGFBP3 methylation is inversely associated with MSI in CIMP-high colorectal cancers, and this relationship is limited to p53-negative tumors. Our data suggest complex relationship between global genomic/epigenomic phenomena ( such as MSI/CIMP), single molecular events ( e. g., IGFBP3 methylation, TP53 mutation, and TGFBR2 mutation), and the related pathways. C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA. Dana Farber Harvard Canc Ctr, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Ogino, S (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Pathol, 44 Binney St,Room JF215C, Boston, MA 02115 USA. EM shuji_ogino@dfci.harvard.edu FU NCI NIH HHS [K07 CA122826, K07CA122826, P01 CA055075, P01 CA087969, P01 CA55075K07, P01 CA87969] NR 49 TC 21 Z9 23 U1 1 U2 4 PU NEOPLASIA PRESS PI ANN ARBOR PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648 USA SN 1522-8002 J9 NEOPLASIA JI Neoplasia PD DEC PY 2007 VL 9 IS 12 BP 1091 EP 1098 DI 10.1593/neo.07760 PG 8 WC Oncology SC Oncology GA 238KL UT WOS:000251446400011 PM 18084616 ER PT J AU Harisinghani, M Ross, RW Guimaraes, AR Weissleder, R AF Harisinghani, Mukesh Ross, Robert W. Guimaraes, Alexander R. Weissleder, Ralph TI Utility of a new bolus-injectable nanoparticle for clinical cancer staging SO NEOPLASIA LA English DT Article DE nanoparticle; MRI; ferumoxytol; prostate cancer; lymph nodes ID SUPERPARAMAGNETIC IRON-OXIDE; LYMPH-NODE METASTASES; PROSTATE-CANCER; NANOTECHNOLOGY; FERUMOXYTOL; AGENT; THERAPY; SAFETY; TUMORS AB BACKGROUND: In this study, we report on the use of a new, bolus-injectable, carboxymethyl dextran - based magnetic nanoparticle (MNP), ferumoxytol, to improve detection in loco-regional lymph nodes by magnetic resonance imaging (MRI). METHODS: This preliminary study was performed as a prospective, single-center, open label pilot study to determine the magnitude of nodal MRI signal changes and to determine the optimal time points for imaging following intravenous (IV) bolus injection of the MNP. The study group consisted of 10 patients, all of whom were diagnosed with prostate cancer before any systemic therapy. RESULTS: All 10 patients had lymph nodes evaluated by histopathology. Of the evaluated 26 lymph nodes, 20 were benign and 6 were malignant. The mean short-axis diameter of benign lymph nodes was 6 mm and the mean short-axis diameter of malignant lymph nodes was 7 mm. Following IV administration, there was a significant change in mean signal-to-noise ratio (SNR) of benign lymph nodes ( P < .0001) whereas there was little change in the mean SNR of malignant nodes (P =.1624). No adverse events were encountered. CONCLUSION: Ferumoxytol is safe and, at the appropriate circulation interval, modulates nodal signal intensity, allowing for identification of malignant nodal involvement by MRI. C1 Massachusetts Gen Hosp, Ctr Mol Imaging Res, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. RP Harisinghani, M (reprint author), Ctr Mol Imaging Res, Bldg 149,13th St,Room 5406, Charlestown, MA 02129 USA. EM mharisinghani@partners.org FU NCI NIH HHS [N01-CO-12400, N01CO12400] NR 21 TC 45 Z9 46 U1 1 U2 7 PU NEOPLASIA PRESS PI ANN ARBOR PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648 USA SN 1522-8002 J9 NEOPLASIA JI Neoplasia PD DEC PY 2007 VL 9 IS 12 BP 1160 EP 1165 DI 10.1593/neo.07940 PG 6 WC Oncology SC Oncology GA 238KL UT WOS:000251446400018 PM 18084623 ER PT J AU Garcia-Alloza, M Ferrara, BJ Dodwell, SA Hickey, GA Hyman, BT Bacskai, BJ AF Garcia-Alloza, Monica Ferrara, Brian J. Dodwell, Sarah A. Hickey, Gregory A. Hyman, Bradley T. Bacskai, Brian J. TI A limited role for microglia in antibody mediated plaque clearance in APP mice SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Alzheimer; immunotherapy; multiphoton; imaging; neuritic dystrophy; senile plaque; microglia ID AMYLOID-BETA-PEPTIDE; ALZHEIMERS-DISEASE; A-BETA; MOUSE MODEL; IN-VIVO; TRANSGENIC MODEL; MEMORY LOSS; ACTIVATION; MINOCYCLINE; DEPOSITION AB Amyloid-beta (A beta) accumulation in senile plaques is a hallmark of Alzheimer's disease (AD). Immunotherapy is a leading approach for amyloid clearance, despite the early termination of the Elan clinical trial with active immunization due to a few cases of meningoencephalitis. The mechanisms of immunotherapy-mediated amyloid clearance and this deleterious side effect are largely unknown. While clearance of A beta probably results in part from microglia-mediated inflammation, it can be microglia independent. Therefore, establishing the role of microglia in A beta clearance is important for the treatment of AD. We analyzed the effects of direct microglia activation and inhibition on antibody-mediated A beta clearance. Robust microglia activation with interferon-gamma led to modest A beta clearance alone but did not potentiate antibody-mediated clearance. Microglia elimination/inactivation with immunotoxin or minocycline only partially limited antibody-induced A beta clearance suggesting that although there is a role for microglia in A beta clearance, it does not account for the majority of the effect observed after anti-A beta antibody treatment. (C) 2007 Elsevier Inc. All rights reserved. C1 [Garcia-Alloza, Monica; Ferrara, Brian J.; Dodwell, Sarah A.; Hickey, Gregory A.; Hyman, Bradley T.; Bacskai, Brian J.] Massachusetts Gen Hosp, Alzheimers Dis Res Lab, Dept Neurol, Charlestown, MA 02129 USA. RP Ferrara, BJ (reprint author), Massachusetts Gen Hosp, Alzheimers Dis Res Lab, Dept Neurol, 114 16th St,2010, Charlestown, MA 02129 USA. EM bbacskai@partners.org OI Garcia-Alloza, Monica/0000-0003-1610-4114 FU NIA NIH HHS [P50 AG005134, R01 AG008487, R01 AG020570-04, AG020570, AG08487, R01 AG020570, R01 AG008487-15]; NIBIB NIH HHS [R01 EB000768-05, R01 EB000768, EB000768] NR 41 TC 22 Z9 22 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PD DEC PY 2007 VL 28 IS 3 BP 286 EP 292 DI 10.1016/j.nbd.2007.07.019 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 242TT UT WOS:000251749800005 PM 17822910 ER PT J AU Lok, J Gupta, P Guo, S Kim, WJ Whalen, MJ van Leyen, K Lo, EH AF Lok, Josephine Gupta, Punkaj Guo, Shuzhen Kim, Woo Jean Whalen, Michael J. van Leyen, Klaus Lo, Eng H. TI Cell-cell signaling in the neurovascular unit SO NEUROCHEMICAL RESEARCH LA English DT Review DE neurodegeneration; stroke; blood-brain barrier; neurogenesis; angiogenesis; neuroprotection ID ENDOTHELIAL GROWTH-FACTOR; BLOOD-BRAIN-BARRIER; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; NEURAL STEM-CELLS; HUMAN GLIOBLASTOMA-MULTIFORME; METHYL-D-ASPARTATE; PROGENITOR CELLS; IN-VIVO; ALZHEIMERS-DISEASE AB Historically, the neuron has been the conceptual focus for almost all of neuroscience research. In recent years, however, the concept of the neurovascular unit has emerged as a new paradigm for investigating both physiology and pathology in the CNS. This concept proposes that a purely neurocentric focus is not sufficient, and emphasizes that all cell types in the brain including neuronal, glial and vascular components, must be examined in an integrated context. Cell-cell signaling and coupling between these different compartments form the basis for normal function. Disordered signaling and perturbed coupling form the basis for dysfunction and disease. In this mini-review, we will survey four examples of this phenomenon: hemodynamic neurovascular coupling linking blood flow to brain activity; cellular communications that evoke the blood-brain barrier phenotype; parallel systems that underlie both neurogenesis and angiogenesis in the CNS; and finally, the potential exchange of trophic factors that may link neuronal, glial and vascular homeostasis. C1 Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Neurol, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA. Massachusetts Gen Hosp, Div Pediat Crit Care Med, Boston, MA 02114 USA. RP Lo, EH (reprint author), Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, MGH E 149-2401, Charlestown, MA 02129 USA. EM Lo@helix.mgh.harvard.edu RI van Leyen, Klaus/C-9126-2013 FU NINDS NIH HHS [P01-NS55104, P50-NS10828, R01-NS37074, R01-NS40529, R01-NS47447, R01-NS48422, R01-NS53560, R01-NS56458] NR 129 TC 136 Z9 146 U1 3 U2 20 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-3190 J9 NEUROCHEM RES JI Neurochem. Res. PD DEC PY 2007 VL 32 IS 12 BP 2032 EP 2045 DI 10.1007/s11064-007-9342-9 PG 14 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 226ZK UT WOS:000250626800005 PM 17457674 ER PT J AU Fennema-Notestine, C Gamst, AC Quinn, BT Pacheco, J Jernigan, TL Thal, L Buckner, R Killiany, R Blacker, D Dale, AM Fischl, B Dickerson, B Gollub, RL AF Fennema-Notestine, Christine Gamst, Anthony C. Quinn, Brian T. Pacheco, Jenni Jernigan, Terry L. Thal, Leon Buckner, Randy Killiany, Ron Blacker, Deborah Dale, Anders M. Fischl, Bruce Dickerson, Brad Gollub, Randy L. TI Feasibility of multi-site clinical structural neuroimaging studies of aging using legacy data SO NEUROINFORMATICS LA English DT Article DE MRI; hippocampus; asymmetry; image processing; statistical modeling ID SKULL STRIPPING PROBLEM; SURFACE-BASED ANALYSIS; ALZHEIMERS-DISEASE; INTENSITY NONUNIFORMITY; QUANTITATIVE-EVALUATION; CEREBRAL-CORTEX; VOLUMETRIC MRI; WHITE-MATTER; AGE; ASYMMETRY AB The application of advances in biomedical computing to medical imaging research is enabling scientists to conduct quantitative clinical imaging studies using data collected across multiple sites to test new hypotheses on larger cohorts, increasing the power to detect subtle effects. Given that many research groups have valuable existing (legacy) data, one goal of the Morphometry Biomedical Informatics Research Network (BIRN) Testbed is to assess the feasibility of pooled analyses of legacy structural neuroimaging data in normal aging and Alzheimer's disease. The present study examined whether such data could be meaningfully reanalyzed as a larger combined data set by using rigorous data curation, image analysis, and statistical modeling methods; in this case, to test the hypothesis that hippocampal volume decreases with age and to investigate findings of hippocampal asymmetry. This report describes our work with legacy T1-weighted magnetic resonance (MR) and demographic data related to normal aging that have been shared through the BIRN by three research sites. Results suggest that, in the present application, legacy MR data from multiple sites can be pooled to investigate questions of scientific interest. In particular, statistical analyses suggested that a mixed-effects model employing site as a random effect best fits the data, accounting for site-specific effects while taking advantage of expected comparability of age-related effects. In the combined sample from three sites, significant age-related decline of hippocampal volume and right-dominant hippocampal asymmetry were detected in healthy elderly controls. These expected findings support the feasibility of combining legacy data to investigate novel scientific questions. C1 Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA. Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. Univ Calif San Diego, Dept Biostat, La Jolla, CA 92093 USA. Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. MGH NMR Ctr, Ctr Biomed Imaging, Charlestown, MA USA. Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. Harvard Med Sch, Dept Radiol, Boston, MA USA. Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA. Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA USA. Harvard Sch Publ Hlth, Dept Epidemiol, Cambridge, MA USA. MIT, Comp Sci Artificial Intelligence Lab, Cambridge, MA 02139 USA. Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. HArvard Med Sch, Boston, MA USA. RP Fennema-Notestine, C (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr 0841, La Jolla, CA 92093 USA. EM Fennema@UCSD.edu RI Dale, Anders/A-5180-2010; OI Gollub, Randy L./0000-0002-9434-4044; Fennema-Notestine, Christine/0000-0002-6527-6361 FU NCRR NIH HHS [M01 RR 00827, P41 RR 13642, P41 RR 14075, R01 RR 16594-01A1, U24 RR 021382]; NIA NIH HHS [P01 AG 03991, P01 AG 04953, P50 AG 05131, P50 AG 05681, R01 AG 06849, R01 AG 12674]; NIBIB NIH HHS [R01 EB 002010, U54 EB 005149]; NINDS NIH HHS [R01 NS 052585-01] NR 48 TC 53 Z9 53 U1 0 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1539-2791 J9 NEUROINFORMATICS JI Neuroinformatics PD DEC PY 2007 VL 5 IS 4 BP 235 EP 245 DI 10.1007/s12021-007-9003-9 PG 11 WC Computer Science, Interdisciplinary Applications; Neurosciences SC Computer Science; Neurosciences & Neurology GA 238OX UT WOS:000251458200004 PM 17999200 ER PT J AU Yehuda, R Harvey, PD Buchsbaum, M Tischler, L Schmeidler, J AF Yehuda, Rachel Harvey, Philip D. Buchsbaum, Monte Tischler, Lisa Schmeidler, James TI Enhanced effects of cortisol administration on episodic and working memory in aging veterans with PTSD SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE posttraumatic stress disorder; combat veterans; cortisol/glucocorticoids; memory performance; cognitive function; aging ID POSTTRAUMATIC-STRESS-DISORDER; GLUCOCORTICOID-INDUCED IMPAIRMENT; POSITRON-EMISSION-TOMOGRAPHY; MAJOR DEPRESSIVE DISORDER; HIPPOCAMPAL VOLUME; DECLARATIVE MEMORY; HOLOCAUST SURVIVORS; PREFRONTAL CORTEX; NUCLEUS-ACCUMBENS; DOPAMINE RELEASE AB Though both glucocorticoid alterations and memory impairments have been noted in posttraumatic stress disorder (PTSD), it is not clear if these phenomena are causally linked. As there is emerging evidence that these domains become further altered in PTSD with increasing age, it is of interest to examine these relationships in an older cohort. Aging ( mean age, 62.7 +/- 8.9; range, 52-81) combat veterans with (n = 13) and without (n = 17) PTSD received an intravenous bolus of 17.5 mg hydrocortisone (cortisol), a naturally occurring glucocorticoid, or placebo in a randomized, double-blind manner, on two mornings approximately 1-2 weeks apart. Neuropsychological testing to evaluate episodic and working memory performance was performed 75 min later. Cortisol enhanced episodic memory performance in both groups of subjects, but enhanced elements of working memory performance only in the PTSD + group. The preferential effect of cortisol administration on working memory in PTSD may be related to the superimposition of PTSD and age, as cortisol had impairing effects on this task in a previously studied, younger cohort. The findings suggest that there may be opportunities for developing therapeutic strategies using glucocorticoids in the treatment of aging combat veterans. C1 Mt Sinai Sch Med, Traumat Stress Studies Program, Dept Psychiat, New York, NY USA. James J Peters Bronx Vet Affairs Med Ctr, PTSD Program, Bronx, NY USA. Mt Sinai Sch Med, Neurosci PET Lab, New York, NY USA. Mt Sinai Sch Med, Ctr Biomath Sci, New York, NY USA. RP Yehuda, R (reprint author), 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Rachel.Yehuda@med.va.gov FU NCRR NIH HHS [5 M01 RR00071] NR 80 TC 30 Z9 30 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2007 VL 32 IS 12 BP 2581 EP 2591 DI 10.1038/sj.npp.1301380 PG 11 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 231NS UT WOS:000250956000014 PM 17392739 ER PT J AU Oral, E Muratoglu, OK AF Oral, Ebru Muratoglu, Orhun K. TI Radiation cross-linking in ultra-high molecular weight polyethylene for orthopaedic applications SO NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION B-BEAM INTERACTIONS WITH MATERIALS AND ATOMS LA English DT Article; Proceedings Paper CT 7th International Symposium on Ionizing Radiation and Polymers CY SEP 23-28, 2006 CL Antalya, TURKEY DE radiation; cross-linking; antioxidant; joint arthroplasty; wear resistance ID TOTAL HIP-ARTHROPLASTY; LINKED POLYETHYLENE; MECHANICAL-PROPERTIES; ALPHA-TOCOPHEROL; PROSTHETIC APPLICATIONS; ACETABULAR COMPONENTS; IRRADIATED UHMWPE; FREE-RADICALS; WEAR; OXIDATION AB The motivation for radiation cross-linking of ultra-high molecular weight polyethylene (UHMWPE) is to increase its wear resistance to be used as bearing surfaces for total joint arthroplasty. However, radiation also leaves behind long-lived residual free radicals in this polymer, the reactions of which can detrimentally affect mechanical properties. In this review, we focus on the radiation cross-linking and oxidative stability of first and second generation highly cross-linked UHMWPEs developed in our laboratory. (C) 2007 Elsevier B.V. All rights reserved. C1 [Oral, Ebru] Massachusetts Gen Hosp, Dept Orthopaed Surg, Harris Orthopaed Biomech & Biomat Lab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Muratoglu, OK (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Harris Orthopaed Biomech & Biomat Lab, 55 Fruit St,GRJ 1206, Boston, MA 02114 USA. EM omuratoglu@partners.org FU NIAMS NIH HHS [R01 AR051142-01, R01 AR051142, R01 AR051142-02, R01 AR051142-03] NR 50 TC 38 Z9 38 U1 2 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-583X J9 NUCL INSTRUM METH B JI Nucl. Instrum. Methods Phys. Res. Sect. B-Beam Interact. Mater. Atoms PD DEC PY 2007 VL 265 IS 1 BP 18 EP 22 DI 10.1016/j.nimb.2007.08.022 PG 5 WC Instruments & Instrumentation; Nuclear Science & Technology; Physics, Atomic, Molecular & Chemical; Physics, Nuclear SC Instruments & Instrumentation; Nuclear Science & Technology; Physics GA 246RP UT WOS:000252025000004 PM 19050735 ER PT J AU Oral, E Bodugoz-Senturk, H Macias, C Muratoglu, OK AF Oral, Ebru Bodugoz-Senturk, Hatice Macias, Celia Muratoglu, Orhun K. TI Vitamin C hinders radiation cross-linking in aqueous poly(vinyl alcohol) solutions SO NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION B-BEAM INTERACTIONS WITH MATERIALS AND ATOMS LA English DT Article; Proceedings Paper CT 7th International Symposium on Ionizing Radiation and Polymers CY SEP 23-28, 2006 CL Antalya, TURKEY DE radiation; cross-linking; viscosity; antioxidant; theta gel; injectable ID NUCLEUS PULPOSUS REPLACEMENT; H ARTIFICIAL MENISCUS; X-RAY-DIFFRACTION; HYDROGELS; CRYSTALLINITY AB Poly(vinyl alcohol) (PVA) is a promising semi-crystalline material for biomedical applications. It is soluble in water and can be formed into hydrogels by freezing and thawing or crystallizing from an aqueous theta solution such as that of polyethylene glycol (PEG). Radiation cross-linking caused by sterilization or high dose irradiation of concentrated PVA solutions could compromise some properties of these hydrogels. Therefore, we hypothesized that radiation cross-linking of PVA solutions and PVA-PEG theta gels could be prevented by using the antioxidant vitamin C as an anticross-linking agent. Our hypothesis tested positive. Vitamin C concentrations of 0.75 and 4.5 mol/mol of PVA repeating unit could prevent cross-linking in 17.5 wt/v% PVA solutions made with PVA molecular weight of 115,000 g/mol irradiated to 25 and 100 kGy, respectively. Vitamin C also prevented cross-linking in 25 kGy irradiated PVA-PEG theta gels containing up to 5 wt% PEG and decreased the viscosity of those up to 39 wt%. (C) 2007 Elsevier B.V. All rights reserved. C1 [Oral, Ebru; Bodugoz-Senturk, Hatice; Macias, Celia; Muratoglu, Orhun K.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Harris Orthopaed Biomech & Biomat Lab, Boston, MA 02114 USA. [Oral, Ebru; Bodugoz-Senturk, Hatice; Muratoglu, Orhun K.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Muratoglu, OK (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Harris Orthopaed Biomech & Biomat Lab, 55 Fruit St,GRJ 1206, Boston, MA 02114 USA. EM omuratoglu@partners.org NR 27 TC 6 Z9 6 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-583X EI 1872-9584 J9 NUCL INSTRUM METH B JI Nucl. Instrum. Methods Phys. Res. Sect. B-Beam Interact. Mater. Atoms PD DEC PY 2007 VL 265 IS 1 BP 92 EP 97 DI 10.1016/j.nimb.2007.08.031 PG 6 WC Instruments & Instrumentation; Nuclear Science & Technology; Physics, Atomic, Molecular & Chemical; Physics, Nuclear SC Instruments & Instrumentation; Nuclear Science & Technology; Physics GA 246RP UT WOS:000252025000017 ER PT J AU Barton-Burke, M Gustason, CJ AF Barton-Burke, Margaret Gustason, Carolyn J. TI Sexuality in women with cancer SO NURSING CLINICS OF NORTH AMERICA LA English DT Article ID QUALITY-OF-LIFE; BREAST-CANCER; OVARIAN-CANCER; RANDOMIZED-TRIAL; CERVICAL-CANCER; RECTAL-CANCER; YOUNGER WOMEN; SURVIVORS; ADJUSTMENT; HEALTH AB There are gaps in the research regarding sexuality in women with cancer, making the interventions that are used more expert opinion rather than scientific evidence. There is a need for research about effective interventions, and there is a need to educate nurses to help change practice through communication about a topic that makes both the patient and the nurse uncomfortable. C1 [Barton-Burke, Margaret] Univ Massachusetts, Amherst, MA 01003 USA. [Barton-Burke, Margaret] Dana Farber Canc Inst, Phyllis F Cantor Ctr, Boston, MA 02115 USA. [Barton-Burke, Margaret] Massachusetts Gen Hosp, Inst Patient Care, Yvonne L Munn Ctr Nursing Res, Boston, MA 02114 USA. [Gustason, Carolyn J.] Univ Massachusetts, Sch Med, Clin Res Off, Ctr Canc, Worcester, MA 01605 USA. RP Barton-Burke, M (reprint author), Univ Massachusetts, Amherst, MA 01003 USA. EM bartonburkem@prodigy.net NR 71 TC 17 Z9 23 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0029-6465 J9 NURS CLIN N AM JI Nurs. Clin. North Am. PD DEC PY 2007 VL 42 IS 4 BP 531 EP + DI 10.1016/j.cnur.2007.08.001 PG 25 WC Nursing SC Nursing GA 241TX UT WOS:000251679800004 PM 17996754 ER PT J AU Tracy, EE AF Tracy, Erin E. TI Are doctors prepared for direct-to-consumer advertising of genetics tests? SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID PRESCRIPTION DRUGS; PROMOTION; PHYSICIANS; CARE C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Tracy, EE (reprint author), Massachusetts Gen Hosp, 55 Fruit St,406 Founders House, Boston, MA 02114 USA. EM EETracy@partners.org NR 13 TC 5 Z9 5 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD DEC PY 2007 VL 110 IS 6 BP 1389 EP 1391 DI 10.1097/01.AOG.0000295601.75089.6f PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 236LH UT WOS:000251304000026 PM 18055736 ER PT J AU Michaelson, MD AF Michaelson, M. Dror TI Treating bladder cancer: Ncoadjuvant vs adjuvant therapy - The Sonpavde/Lerner article reviewed SO ONCOLOGY-NEW YORK LA English DT Editorial Material ID TRANSITIONAL-CELL CARCINOMA; PHASE-II TRIAL; NEOADJUVANT CHEMOTHERAPY; RADICAL CYSTECTOMY; PRESERVATION; GEMCITABINE; PACLITAXEL; CISPLATIN C1 Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. RP Michaelson, MD (reprint author), Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. NR 15 TC 0 Z9 0 U1 0 U2 0 PU P R R INC PI MELVILLE PA 48 SOUTH SERVICE RD, MELVILLE, NY 11747 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD DEC PY 2007 VL 21 IS 14 BP 1686 EP + PG 2 WC Oncology SC Oncology GA 270RX UT WOS:000253739000005 ER PT J AU Alt, C Veilleux, I Lee, H Pitsillides, CM Cote, D Lin, CP AF Alt, C. Veilleux, I. Lee, H. Pitsillides, C. M. Cote, D. Lin, C. P. TI Retinal flow cytometer SO OPTICS LETTERS LA English DT Article ID CELLS AB The in vivo flow cytometer is an instrument capable of continuous, real-time monitoring of fluorescently labeled cells in the circulation without the need to draw blood samples. However, the original system probes a single vessel in the mouse ear; the small sample volume limits the sensitivity of the technique. We describe an in vivo retinal flow cytometer that simultaneously probes five artery-vein pairs in the mouse eye by circularly scanning a small laser spot rapidly around the optic nerve head. We demonstrate that the retinal flow cytometer detects about five times more cells per minute than the original in vivo flow cytometer does in the ear. (c) 2007 Optical Society of America. C1 [Alt, C.; Veilleux, I.; Lee, H.; Pitsillides, C. M.; Cote, D.; Lin, C. P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Adv Microscopy Program,Ctr Syst Biol, Boston, MA 02114 USA. [Alt, C.; Veilleux, I.; Lee, H.; Pitsillides, C. M.; Cote, D.; Lin, C. P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. [Alt, C.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA. [Lee, H.] Kyungpook Natl Univ, Taegu 702701, South Korea. [Pitsillides, C. M.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA. RP Lin, CP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Adv Microscopy Program,Ctr Syst Biol, Boston, MA 02114 USA. EM lin@helix.mgli.harvard.edu RI Cote, Daniel/D-5185-2011 FU NEI NIH HHS [BRP EY 014106, R01 EY014106, R01 EY014106-03] NR 8 TC 16 Z9 16 U1 0 U2 1 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 0146-9592 J9 OPT LETT JI Opt. Lett. PD DEC 1 PY 2007 VL 32 IS 23 BP 3450 EP 3452 DI 10.1364/OL.32.003450 PG 3 WC Optics SC Optics GA 247GC UT WOS:000252065000027 PM 18059963 ER PT J AU Moore, MG Deschler, DG McKenna, MJ Varvares, MA Lin, DT AF Moore, Michael G. Deschler, Daniel G. McKenna, Michael J. Varvares, Mark A. Lin, Derrick T. TI Management outcomes following lateral temporal bone resection for ear and temporal bone malignancies SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article ID SQUAMOUS-CELL CARCINOMA; PERINEURAL INVASION; STAGING SYSTEM; MIDDLE-EAR AB OBJECTIVE: To evaluate clinical outcomes following lateral temporal bone resection (LTBR) for management of malignancies involving the ear or temporal bone. SUBJECTS AND METHODS: A retrospective medical record review was performed on patients receiving LTBR for management of malignancies involving the ear or temporal bone between 1990 and 2007. RESULTS: In this group of 35 patients, the mean age was 62.7 years, with tumor histopathologies including squamous cell carcinoma (SCC, 20), basal cell carcinoma (BCC, 7), adenoid cystic carcinoma (ACC, 7), and adenocarcinoma (1). The 5-year overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were 77%, 79%, and 52%, respectively. Complete resection resulted in improved OS, DSS, and DFS (P < 0.004 for each) and reduced local recurrence (P < 0.001). CONCLUSIONS: In patients with carcinomas of the ear and temporal bone, upfront excision including LTBR is an effective management when combined with postoperative radiation therapy. Complete removal of all disease may improve survival and decrease recurrence. (c) 2007 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved. C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA. St Louis Univ, Sch Med, St Louis, MO USA. RP Moore, MG (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA. EM mgmoore@gmail.com NR 18 TC 32 Z9 34 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD DEC PY 2007 VL 137 IS 6 BP 893 EP 898 DI 10.1016/j.otohns.2007.09.010 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 237OQ UT WOS:000251385100009 PM 18036417 ER PT J AU Fisher, LM Doherty, JK Lev, MH Slattery, WH AF Fisher, Laurel M. Doherty, Joni K. Lev, Michael H. Slattery, William H., III TI Distribution of nonvestibular cranial nerve schwannomas in neurofibrornatosis 2 SO OTOLOGY & NEUROTOLOGY LA English DT Article DE aspiration; lower cranial nerve schwannoma; neurofibromatosis 2; nonacoustic neuroma; pneumonia ID NEUROFIBROMATOSIS 2 NF2; TYPE-2 NEUROFIBROMATOSIS; GROWTH; MANAGEMENT AB Objective: To describe the prevalence and location of cranial nerve schwannomas, other than bilateral vestibular schwannoma, in patients with neurofibromatosis 2 (NF2). The NF2 Natural History Consortium prospectively gathered cranial magnetic resonance imaging for 83 patients across 3 annual evaluations. The time between the first and last evaluation was approximately 3 years. Results: Forty-two patients (51%) had nonvestibular cranial nerve schwannomas (NVSs). Of these, 25 (60%) also had cranial meningiomas. Twenty-one of those without NVS (25% of 83) had at least 1 meningioma. The average size of the NVS was 0.4 cm(3). Overall, there was no significant change in NVS size from Year 1 to Year 3 or from Year 1 to Year 2. The most common locations of the NVS were occulomotor and trigeminal. A family history of NF2 did not predict NVS location or growth. Conclusion: Nonvestibular cranial nerve schwannoma usually affect cranial nerves III and V, as was the case in our NF2 sample. Fortunately, neuropathies associated with these tumors are rare. In contrast, lower cranial nerve schwannomas, although also rare, are associated with swallowing difficulty, aspiration, and other sequelae. C1 House Ear Res Inst, House Clin, Los Angeles, CA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Slattery, WH (reprint author), House Ear Res Inst, House Clin, 2100 W 3rd St, Los Angeles, CA USA. EM wslattery@hei.org NR 22 TC 23 Z9 25 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1531-7129 J9 OTOL NEUROTOL JI Otol. Neurotol. PD DEC PY 2007 VL 28 IS 8 BP 1083 EP 1090 PG 8 WC Clinical Neurology; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 237FF UT WOS:000251358900019 PM 18043434 ER PT J AU Bahmad, F Merchant, SN AF Bahmad, Fayez, Jr. Merchant, Saumil N. TI Paget disease of the temporal bone SO OTOLOGY & NEUROTOLOGY LA English DT Editorial Material C1 Massachusetts Eye & Ear Infirm, Harvard Med Sch, Otopathol Lab, Boston, MA USA. RP Merchant, SN (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM saumil_Merchant@meei.harvard.edu FU NIDCD NIH HHS [U24 DC008559, U24 DC008559-01] NR 5 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1531-7129 J9 OTOL NEUROTOL JI Otol. Neurotol. PD DEC PY 2007 VL 28 IS 8 BP 1157 EP 1158 PG 2 WC Clinical Neurology; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 237FF UT WOS:000251358900031 PM 17195769 ER PT J AU Minkowitz, HS Rathmell, JP Vallow, S Gargiulo, K Damaraju, CV Hewitt, DJ AF Minkowitz, Harold S. Rathmell, James P. Vallow, Sue Gargiulo, Kathryn Damaraju, C. V. Hewitt, David J. TI Efficacy and safety of the fentanyl iontophoretic transdermal system (ITS) and intravenous patient-controlled analgesia (IV PCA) with morphine for pain management following abdominal or pelvic surgery SO PAIN MEDICINE LA English DT Article DE pain management; fentanyl ITS; postoperative; acute Pain ID PLACEBO-CONTROLLED TRIAL; ACUTE POSTOPERATIVE PAIN; MULTICENTER; DELIVERY; ERRORS AB Objective. The fentanyl HCl iontophoretic transdermal system (ITS) has effectively managed pain following several types of surgery. This study evaluated the efficacy, safety, and ease of care associated with fentanyl ITS and morphine intravenous patient-controlled analgesia (IV PCA) for pain management following abdominal or pelvic surgery. Design. This open-label, multicenter, randomized, active-controlled, parallel-group, phase IIIb study enrolled 506 postoperative patients at 39 U. S. sites. Patients received fentanyl ITS (40 mu g fentanyl/dose) or morphine IV PCA (1 mg morphine/dose). The primary efficacy measure was demonstrating equivalence on the patient global assessment (PGA) of the method of pain control in the first 24 hours of treatment between the groups. Results. Percentages of patients in the fentanyl ITS and morphine IV PCA groups reporting PGA ratings of "good" or "excellent" in the first 24 hours were statistically equivalent (84.9% vs 84.3%, respectively; difference = 0.7%, 95% CI: -5.6% to 7.0%). Equivalence was also demonstrated based on mean last pain intensity scores in the first 24 hours (3.0 vs 2.9, respectively; difference = 0.1, 95% CI: -0.28 to 0.43). Overall discontinuation rates were not significantly different between groups (16.7% vs 11.8%, respectively; P = 0.128). Patients and nurses reported better ease-of- care ratings for fentanyl ITS than for morphine IV PCA. Commonly occurring adverse events were similar between groups. Conclusions. Fentanyl ITS and morphine IV PCA were comparable methods of pain control following abdominal or pelvic surgery; however, fentanyl ITS was rated better than morphine IV PCA for ease of care by patients and nurses. C1 Mem Hermann Mem City Hosp, Dept Anesthesiol, Houston, TX 77024 USA. Massachusetts Gen Hosp, Harvard Med Sch, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. Ortho McNeil Janssen Sci Afairs, LLC, Titusville, NJ USA. Ortho McNeil Inc, Raritan, NJ USA. Ortho McNeil Janssen Sci Affairs, LLC, Raritan, NJ USA. RP Minkowitz, HS (reprint author), Mem Hermann Mem City Hosp, Dept Anesthesiol, 921 Gessner Rd, Houston, TX 77024 USA. EM research@houston.rr.com NR 26 TC 41 Z9 43 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD DEC PY 2007 VL 8 IS 8 BP 657 EP 668 DI 10.1111/j.1526-4637.2006.00257.x PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 232OJ UT WOS:000251028700008 PM 18028044 ER PT J AU Sudore, RL Landefeld, CS Barnes, DE Lindquist, K Williams, BA Brody, R Schillinger, D AF Sudore, Rebecca L. Landefeld, C. Seth Barnes, Deborah E. Lindquist, Karla Williams, Brie A. Brody, Robert Schillinger, Dean TI An advance directive redesigned to meet the literacy level of most adults: A randomized trial SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE advance directive; health literacy; communication; decision-making; ethics; health disparities ID FUNCTIONAL HEALTH LITERACY; SURROGATE DECISION-MAKERS; OF-LIFE CARE; LIVING WILLS; MEDICAL-CARE; TREATMENT PREFERENCES; DIABETES PATIENTS; END; COMMUNICATION; COMPREHENSION AB Objective: To determine whether an advance directive redesigned to meet most adults' literacy needs (fifth grade reading level with graphics) was more useful for advance care planning than a standard form (> 12th grade level). Methods: We enrolled 205 English and Spanish-speaking patients, aged >= 50 years from an urban, general medicine clinic. We randomized participants to review either form. Main outcomes included acceptability and usefulness in advance care planning. Participants then reviewed the alternate form; we assessed form preference and six-month completion rates. Results: Forty percent of enrolled participants had limited literacy. Compared to the standard form, the redesigned form was rated higher for acceptability and usefulness in care planning, P <= 0.03, particularly for limited literacy participants (P for interaction <= 0.07). The redesigned form was preferred by 73% of participants. More participants randomized to the redesigned form completed an advance directive at six months (19% vs. 8%, P = 0.03); of these, 95% completed the redesigned form. Conclusions: The redesigned advance directive was rated more acceptable and useful for advance care planning and was preferred over a standard form. It also resulted in higher six-month completion rates. Practice implications: An advance directive redesigned to meet most adults' literacy needs may better enable patients to engage in advance care planning. (c) 2007 Elsevier Ireland Ltd. All rights reserved. C1 [Sudore, Rebecca L.; Landefeld, C. Seth; Barnes, Deborah E.; Lindquist, Karla; Williams, Brie A.] Univ Calif San Francisco, VAMC, Div Geriatr, San Francisco, CA 94121 USA. [Sudore, Rebecca L.; Landefeld, C. Seth; Barnes, Deborah E.; Lindquist, Karla; Williams, Brie A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Brody, Robert; Schillinger, Dean] Univ Calif San Francisco, San Francisco Gen Hosp, Ctr Vulnerable Populat, Div Gen Internal Med, San Francisco, CA 94143 USA. RP Sudore, RL (reprint author), Univ Calif San Francisco, VAMC, Div Geriatr, Clement St 4150,Box 181G, San Francisco, CA 94121 USA. EM rsuesf@yahoo.com FU NCRR NIH HHS [K23 RR016539, K-23 RR16539]; NIA NIH HHS [5R01AG023626-02, AG000212, K07 AG000912, K23 AG030344, K23 AG030344-01, R01 AG023626, T32 AG000212] NR 42 TC 51 Z9 51 U1 8 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD DEC PY 2007 VL 69 IS 1-3 BP 165 EP 195 DI 10.1016/j.pec.2007.08.015 PG 31 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 244WP UT WOS:000251896300021 PM 17942272 ER PT J AU Miser, JS Goldsby, RE Chen, Z Krailo, MD Tarbell, NJ Link, MP Fryer, CJH Pritchard, DJ Gebhardt, MC Dickman, PS Perlman, EJ Meyers, PA Donaldson, SS Moore, SG Rausen, AR Vietti, TJ Grier, HE AF Miser, James S. Goldsby, Robert E. Chen, Zhengjia Krailo, Mark D. Tarbell, Nancy J. Link, Michael P. Fryer, Christopher J. H. Pritchard, Douglas J. Gebhardt, Mark C. Dickman, Paul S. Perlman, Elizabeth J. Meyers, Paul A. Donaldson, Sarah S. Moore, Sheila G. Rausen, Aaron R. Vietti, Teresa J. Grier, Holcombe E. TI Treatment of metastatuc Ewing Sarcoma/Primitive neuroectodermal tumor of bone: Evaluation of increasing the dose intensity of chemotherapy - A report from the children's oncology group SO PEDIATRIC BLOOD & CANCER LA English DT Article DE alkylating agents; bone tumors; dose intensity; metastatic ewing sarcoma; metastatic PNET; oxazaphosphorine chemotherapy ID PEDIATRIC-PATIENTS; 2ND MALIGNANCIES; YOUNG-ADULTS; CANCER GROUP; SARCOMA; INTERGROUP; SURVIVAL; THERAPY; MARROW; FAMILY AB Background. The outcome for patients with Ewing sarcoma family of tumors (ESFTs) of bone with metastases at diagnosis remains poor despite new approaches to treatment. We evaluated whether a dose-intensity chemotherapy regimen improved survival for patients with ESFTs of bone with metastases at diagnosis. Methods. We entered 60 patients with metastatic ESFTs of bone onto a single arm trial of a new intensive therapy. Treatment consisted of 51-weeks of chemotherapy and local control of the primary with radiation, surgery, or both. The chemotherapeutic protocol included two alternating blocks: one with vincristine (2 mg/m(2)), doxorubicin (90 mg/m2), and cyclophosphamide (2,200 mg/m(2)); and the second with ifosfamide (2,800 mg/m(2)/day x 5 days) and etoposide (100 mg/m(2)/day x 5 days). Results. Of the 60 patients with metastatic ESFTs of bone enrolled onto this single arm trial, 12 had metastasis to lung only, 7 to bone marrow or bone only, 38 to multiple sites, 2 in other sites and 3 not specified. There were three toxic deaths. Six patients (6-year cumulative incidence: 9%) developed second malignant neoplasms and died. The 6-year overall event-free survival (EFS) was 28% (standard error (SE) 6%) and survival (S) was 29% (SE 6%). Conclusion. An intensified treatment regimen using higher doses of cyclophosphainide, ifosfamide, and doxorubicin increased toxicity and risk of second malignancy without improving EFS and S. C1 City Hope Natl Med Ctr, Div Pediat, Dept Pediat Hematol Oncol, Duarte, CA 91010 USA. Univ Calif San Francisco, Div Pediat Hematol Oncol, San Francisco, CA 94143 USA. Childrens Oncol Grp, Arcadia, CA USA. Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA. Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA. King Khalid Natl Gen Hosp, Dept Paediat, Jeddah, Saudi Arabia. Mayo Clin, Rochester, MI USA. Harvard Univ, Sch Med, Childrens Hosp, Dept Orthoped Surg, Boston, MA USA. Childrens Hosp Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA. Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA. Childrens Hosp Los Angeles, Dept Imaging, Los Angeles, CA 90027 USA. NYU, Med Ctr, Dept Pediat, New York, NY USA. Washington Univ, Sch Med, Med Ctr, Div Pediat Hematol Oncol, St Louis, MO USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Childrens Hosp, Boston, MA USA. Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. RP Miser, JS (reprint author), City Hope Natl Med Ctr, Div Pediat, Dept Pediat Hematol Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA. EM jmiser@coh.org FU NCI NIH HHS [U10 CA 13539, U10 CA 98543, U10 CA 30969] NR 28 TC 45 Z9 48 U1 0 U2 7 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2007 VL 49 IS 7 BP 894 EP 900 DI 10.1002/pbc.21233 PG 7 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 224ZV UT WOS:000250487800004 PM 17584910 ER PT J AU Silverman, LB AF Silverman, Lewis B. TI Acute lymphoblastic leukemia in infancy SO PEDIATRIC BLOOD & CANCER LA English DT Review DE infant; leukemia; lymphoblastic ID PEDIATRIC-ONCOLOGY-GROUP; CHILDRENS CANCER GROUP; VITRO DRUG-RESISTANCE; PROGNOSTIC-SIGNIFICANCE; MLL GENE; CELL TRANSPLANTATION; STRONGEST PREDICTOR; CHILDHOOD; REARRANGEMENTS; CHEMOTHERAPY AB Infant ALL is uncommon, biologically distinctive from the disease in older children, and associated with a relatively poor prognosis. Adverse prognostic factors include the presence of an MILL gene rearrangement (observed in up to 80% of infants with ALL), younger age at diagnosis, high presenting leukocyte counts, and slow early response to therapy. The role of stem cell transplant in first remission remains controversial. Current research efforts to improve the outcome of MLL-rearranged ALL in infants include clinical trials testing cytarabine-intensive regimens and translational investigations of novel, targeted therapies, such as FLT3-inhibitors. C1 Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. Childrens Hosp, Boston, MA 02115 USA. RP Silverman, LB (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA. EM lewis_silverman@dfci.harvard.edu NR 35 TC 26 Z9 28 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2007 VL 49 IS 7 SU S BP 1070 EP 1073 DI 10.1002/pbc.21352 PG 4 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 228UZ UT WOS:000250759400004 PM 17943956 ER PT J AU Brink, S Laffel, L Likitmaskul, S Li, L Maguire, AM Olsen, B Silink, M Hanas, R AF Brink, Stu Laffel, Lori Likitmaskul, Supawadee Li, Li Maguire, Ann M. Olsen, Birthe Silink, Martin Hanas, Ragnar TI Sick day management in children and adolescents with diabetes SO PEDIATRIC DIABETES LA English DT Article ID RANDOMIZED CLINICAL-TRIAL; REDUCES HOSPITAL VISITS; DOSE GLUCAGON RESCUE; TYPE-1; KETOACIDOSIS; HYPOGLYCEMIA; MELLITUS; KETONES; METER; T1DM C1 [Hanas, Ragnar] Uddevalla Cent Hosp, Dept Pediat, S-45180 Uddevalla, Sweden. [Brink, Stu] Tufts Univ, Sch Med, Dept Pediat, Boston, MA 02111 USA. [Laffel, Lori] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. [Likitmaskul, Supawadee] Mahidol Univ, Dept Pediat, Fac Med, Siriraj Hosp, Bangkok 10700, Thailand. [Li, Li] Guangzhou Children Hosp, Dept Endocrinol & Metab, Guangzhou, Peoples R China. [Maguire, Ann M.; Silink, Martin] Univ Sydney, Sydney, NSW 2006, Australia. [Maguire, Ann M.; Silink, Martin] Childrens Hosp Westmead, Sydney, NSW, Australia. [Olsen, Birthe] Glostrup Univ Hosp, Dept Pediat, Copenhagen, Denmark. RP Hanas, R (reprint author), Uddevalla Cent Hosp, Dept Pediat, S-45180 Uddevalla, Sweden. EM ragnar.hanas@vgregion.se NR 24 TC 8 Z9 10 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1399-543X J9 PEDIATR DIABETES JI Pediatr. Diabetes PD DEC PY 2007 VL 8 IS 6 BP 401 EP 407 DI 10.1111/j.1399-5448.2007.00351.x PG 7 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA 254GI UT WOS:000252574000012 PM 18036069 ER PT J AU Shields, DC Sharma, N Gale, JT Eskandar, EN AF Shields, Donald C. Sharma, Nutan Gale, John T. Eskandar, Emad N. TI Pallidal stimulation for dystonia in pantothenate kinase-associated neurodegeneration SO PEDIATRIC NEUROLOGY LA English DT Article ID HALLERVORDEN-SPATZ-SYNDROME; DEEP BRAIN-STIMULATION; GENERALIZED DYSTONIA; GLOBUS-PALLIDUS; BASAL GANGLIA; SYNDROME/; CENTERS; SYSTEM; IRON AB Patients with generalized dystonia secondary to pantothenate kinase-associated neurodegeneration are traditionally treated palliatively with medical therapy. Therapeutic advances include stereotactic basal ganglia ablative techniques and, more recently, pallidal deep-brain stimulation. We report the course of dystonia in a teenage male. Bilateral microelectrode-guided pallidal deep-brain stimulators were placed while the patient was awake. Three parasagittal microelectrodes were inserted simultaneously. Two anterior microelectrodes were relatively quiet. The posterior electrode demonstrated a pattern of frequent bursts with high-frequency activity. The stimulator was therefore placed in the posterior location, which resulted in symptomatic improvement. Pallidal deep-brain stimulation appears to create a functional correction that may alter globus pallidus internus inhibitory output to the motor thalamus. The prominent, noisy bursting patterns observed in the globus pallidus internus suggests that high-frequency stimulation may improve signs of dystonia by normalizing thalamic discharge patterns. (c) 2007 by Elsevier Inc. All rights reserved. C1 Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Eskandar, EN (reprint author), Wang Ambulatory Care Ctr, Room 331,15 Parkman St, Boston, MA 02114 USA. EM eeskandar@partners.org NR 14 TC 16 Z9 17 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0887-8994 J9 PEDIATR NEUROL JI Pediatr. Neurol. PD DEC PY 2007 VL 37 IS 6 BP 442 EP 445 DI 10.1016/j.pediatrneurol.2007.08.006 PG 4 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 236GO UT WOS:000251291200012 PM 18021929 ER PT J AU Mortensen, EM Restrepo, MI Copeland, LA Pugh, JA Anzueto, A Cornell, JE Pugh, MJV AF Mortensen, Eric M. Restrepo, Marcos I. Copeland, Laurel A. Pugh, Jacqueline A. Anzueto, Antonio Cornell, John E. Pugh, Mary Jo V. TI Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis SO PHARMACOTHERAPY LA English DT Article DE sepsis; 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor; statin; angiotensin II receptor blocker; mortality ID CHRONIC HEART-FAILURE; C-REACTIVE PROTEIN; CYTOKINE PRODUCTION; THERAPY; INHIBITORS; EPIDEMIOLOGY; PNEUMONIA; RISK; HYPERCHOLESTEROLEMIA; INFLAMMATION AB Study Objective. To examine the effect of previous outpatient use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and/or angiotensin II receptor blockers (ARBs) on 30-day mortality in patients hospitalized with sepsis. Design. Retrospective national cohort study. Data Source. Department of Veterans Affairs (VA) national patient care and pharmacy databases. Patients. A total of 3018 patients who were hospitalized with sepsis in fiscal year 2000, had at least I year of previous VA outpatient care, and had at least one active and filled VA prescription within 90 days of admission. Measurements and Main Results. The primary outcome was 30-day mortality. The primary analysis was a multilevel model with hospital as a random effect and control variables that included comorbid conditions, demographics, and other drugs. Among the 3018 patients hospitalized with sepsis, mean age was 74.4 years, 2975 (98.6%) were male, and 811 (26.9%) died within 30 days of admission. Regarding prescription drug use, 480 patients (15.9%) were taking statins and 107 (3.5%) were taking ARBs. After adjusting for potential confounders, statin use (odds ratio [OR] 0.48, 95% confidence interval [CI] 0.36-0.64) and ARB use (OR 0.42, 95% CI 0.24-0.76) were significantly associated with decreased 30-day mortality. Conclusions. Use of statins and/or ARBs before admission was associated with decreased mortality in patients hospitalized with sepsis. Further research is needed to determine if these drugs might be started on admission for those with sepsis. C1 Univ Texas San Antonio, Res Ctr, VERDICT, S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas Hlth Sci Ctr San Antonio, Div Gen Internal Med, San Antonio, TX USA. Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, San Antonio, TX USA. Univ Texas Hlth Sci Ctr San Antonio, Div Psychiat, San Antonio, TX USA. RP Mortensen, EM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Hosp, VERDICT, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. EM mortensene@uthscs.edu RI Restrepo, Marcos/H-4442-2014; OI Pugh, Jacqueline/0000-0003-4933-141X; Mortensen, Eric/0000-0002-3880-5563; Copeland, Laurel/0000-0002-9478-0209 NR 42 TC 33 Z9 35 U1 0 U2 2 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD DEC PY 2007 VL 27 IS 12 BP 1619 EP 1626 DI 10.1592/phco.27.12.1619 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 240DL UT WOS:000251567300003 PM 18041882 ER PT J AU Schuna, AA AF Schuna, Arthur A. TI Rituximab for the treatment of rheumatoid arthritis SO PHARMACOTHERAPY LA English DT Review DE rituximab; rheumatoid arthritis; tumor necrosis factor-alpha; inhibitors; TNF-alpha ID ANTITUMOR NECROSIS FACTOR; B-LYMPHOCYTE DEPLETION; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; INADEQUATE RESPONSE; CLINICAL-RESPONSE; CELL DEPLETION; TRIAL; EFFICACY; METHOTREXATE AB Rituximab has been approved by the United States Food and Drug Administration in combination with methotrexate for the treatment of rheumatoid arthritis in patients who failed to achieve adequate benefit from tumor necrosis factor-alpha inhibitors. Rituximab is a biologic agent that depletes peripheral B cells-an action thought to reduce rheumatoid arthritis activity-and induces prolonged clinical improvement. Two 1000-mg infusions administered 2 weeks apart can result in a response that lasts for months. Most patients will require retreatment, but the effect of repeated dosing on patient outcomes has not yet been determined. Combination therapy with methotrexate is recommended as this appears to achieve the best outcomes. Rituximab also has been shown to be safe, although the lack of long-term efficacy and safety data limit its use. More studies are needed, but this agent has been demonstrated to be safe and effective in patients who fail to achieve adequate clinical response to methotrexate and tumor necrosis factor-alpha inhibitors. C1 Univ Wisconsin, William S Middleton Mem Vet Adm Med Ctr, Sch Pharm, Serv Pharm, Madison, WI USA. RP Schuna, AA (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM aaschuna@wisc.edu NR 34 TC 12 Z9 12 U1 0 U2 1 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD DEC PY 2007 VL 27 IS 12 BP 1702 EP 1710 DI 10.1592/phco.27.12.1702 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 240DL UT WOS:000251567300011 PM 18041890 ER PT J AU Gay, HA Niemierko, A AF Gay, Hiram A. Niemierko, Andrzej TI A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy SO PHYSICA MEDICA LA English DT Article DE normal tissue complication probability; tumor control probability; equivalent uniform dose; dose-volume histogram; EUD; NTCP; TCP; DVH; software; program; radiotherapy; radiation ID NORMAL TISSUE; RADIATION PNEUMONITIS; BREAST-CANCER; TUMOR-CONTROL; RANDOMIZED-TRIAL; DOSE-RESPONSE; VOLUME; OPTIMIZATION; PROBABILITY; IRRADIATION AB Purpose: Provide a simple research tool. that may be used to calculate the NCTP or TCP of a particular treatment plan. Illustrate the implementation of the EUD-based NTCP and TCP models as a research tool. Methods and materials: A high-level computing language was chosen to implement Niemierko's EUD-based NTCP and TCP mathematical models. The necessary treatment planning software requirements were clearly defined. Results: The computer code is presented and explained. Six simple examples were created to quickly troubleshoot the reader's code implementation. A table of model, parameters based on the Emami data was generated. (C) 2007 Published by Elsevier Ltd on behalf of Associazione Italiana di Fisica Medica. C1 [Gay, Hiram A.] E Carolina Univ, Dept Radiat Oncol, Brody Sch Med, Greenville, NC 27834 USA. [Niemierko, Andrzej] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Gay, HA (reprint author), E Carolina Univ, Dept Radiat Oncol, Brody Sch Med, 600 Moye Blvd, Greenville, NC 27834 USA. EM gayh@ecu.edu NR 33 TC 84 Z9 87 U1 0 U2 12 PU IST EDITORIALI POLGRAFICI INT PI PISA PA CASELLA POSTALE N 1, SUCCURSALE N 8, 56123 PISA, ITALY SN 1120-1797 J9 PHYS MEDICA JI Phys. Medica PD DEC PY 2007 VL 23 IS 3-4 BP 115 EP 125 DI 10.1016/j.ejmp.2007.07.001 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 253RZ UT WOS:000252536600005 PM 17825595 ER PT J AU Guiot, C Pugno, N Delsanto, PP Deisboeck, TS AF Guiot, Caterina Pugno, Nicola Delsanto, Pier Paolo Deisboeck, Thomas S. TI Physical aspects of cancer invasion SO PHYSICAL BIOLOGY LA English DT Article ID QUANTIZED FRACTURE-MECHANICS; MALIGNANT PHENOTYPE; TUMOR-GROWTH; DROP IMPACT; MICROENVIRONMENT; DYNAMICS; SURFACE; MODEL; EVOLUTION; MEMBRANE AB Invasiveness, one of the hallmarks of tumor progression, represents the tumor's ability to expand into the host tissue by means of several complex biochemical and biomechanical processes. Since certain aspects of the problem present a striking resemblance with well-known physical mechanisms, such as the mechanical insertion of a solid inclusion in an elastic material specimen (G Eaves 1973 The invasive growth of malignant tumours as a purely mechanical process J. Pathol. 109 233; C Guiot, N Pugno and P P Delsanto 2006 Elastomechanical model of tumor invasion Appl. Phys. Lett. 89 233901) or a water drop impinging on a surface (C Guiot, P P Delsanto and T S Deisboeck 2007 Morphological instability and cancer invasion: a 'splashing water drop' analogy Theor. Biol. Med. Model 4 4), we propose here an analogy between these physical processes and a cancer system's invasive branching into the surrounding tissue. Accounting for its solid and viscous properties, we then arrive, as a unifying model, to an analogy with a granular solid. While our model has been explicitly formulated for multicellular tumor spheroids in vitro, it should also contribute to a better understanding of tumor invasion in vivo. C1 [Guiot, Caterina] Univ Turin, Dept Neurosci, Turin, Italy. [Guiot, Caterina; Delsanto, Pier Paolo] CNISM, Turin, Italy. [Pugno, Nicola] Politecn Torino, Dept Struct Engn & Geotechn, Turin, Italy. [Delsanto, Pier Paolo] Politecn Torino, Dept Phys, Turin, Italy. [Delsanto, Pier Paolo] Bioinformat & High Performance Comp Labs, Colleretto Giacosa, Italy. [Deisboeck, Thomas S.] Massachusetts Gen Hosp, Harvard MIT HST Athinoula A Martinos Ctr Biomed I, Complex Biosyst Modeling Lab, Charlestown, MA 02129 USA. RP Guiot, C (reprint author), Univ Turin, Dept Neurosci, Turin, Italy. EM deisboec@helix.mgh.harvard.edu RI guiot, caterina/C-6708-2009; Pugno, Nicola/C-2289-2014; OI guiot, caterina/0000-0001-8529-1625 FU NCI NIH HHS [CA 113004] NR 57 TC 10 Z9 12 U1 0 U2 6 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 1478-3967 J9 PHYS BIOL JI Phys. Biol. PD DEC PY 2007 VL 4 IS 4 BP P1 EP P6 DI 10.1088/1478-3975/4/4/P01 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 386OA UT WOS:000261891300001 PM 18185003 ER PT J AU Lin, H Gupta, V VerMilyea, MD Falciani, F Lee, JT O'Neill, LP Turner, BM AF Lin, Hong Gupta, Vibhor VerMilyea, Matthew D. Falciani, Francesco Lee, Jeannie T. O'Neill, Laura P. Turner, Bryan M. TI Dosage compensation in the mouse balances up-regulation and silencing of X-linked genes SO PLOS BIOLOGY LA English DT Article ID EMBRYONIC STEM-CELLS; CDNA MICROARRAY DATA; CHROMOSOME INACTIVATION; MUS MUSCULUS; SMCX GENE; XIST RNA; EXPRESSION; MAMMALS; METHYLATION; EVOLUTION AB Dosage compensation in mammals involves silencing of one X chromosome in XX females and requires expression, in cis, of Xist RNA. The X to be inactivated is randomly chosen in cells of the inner cell mass (ICM) at the blastocyst stage of development. Embryonic stem (ES) cells derived from the ICM of female mice have two active X chromosomes, one of which is inactivated as the cells differentiate in culture, providing a powerful model system to study the dynamics of X inactivation. Using microarrays to assay expression of X-linked genes in undifferentiated female and male mouse ES cells, we detect global up-regulation of expression (1.4- to 1.6-fold) from the active X chromosomes, relative to autosomes. We show a similar up-regulation in ICM from male blastocysts grown in culture. In male ES cells, up-regulation reaches 2- fold after 2-3 weeks of differentiation, thereby balancing expression between the single X and the diploid autosomes. We show that silencing of X-linked genes in female ES cells occurs on a gene-by-gene basis throughout differentiation, with some genes inactivating early, others late, and some escaping altogether. Surprisingly, by allele-specific analysis in hybrid ES cells, we also identified a subgroup of genes that are silenced in undifferentiated cells. We propose that X-linked genes are silenced in female ES cells by spreading of Xist RNA through the X chromosome territory as the cells differentiate, with silencing times for individual genes dependent on their proximity to the Xist locus. C1 [Lin, Hong; Gupta, Vibhor; VerMilyea, Matthew D.; O'Neill, Laura P.; Turner, Bryan M.] Univ Birmingham, Sch Med, Inst Biomed Res, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England. [Gupta, Vibhor; Falciani, Francesco] Univ Birmingham, Sch Biosci, Bioinformat Syst Biol Grp, Birmingham B15 2TT, W Midlands, England. [Lee, Jeannie T.] Harvard Med Sch, Howard Hughes Med Inst, Boston, MA USA. [Lee, Jeannie T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA USA. [Lee, Jeannie T.] Harvard Med Sch, Dept Genet, Boston, MA USA. RP Turner, BM (reprint author), Univ Birmingham, Sch Med, Inst Biomed Res, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England. EM m.turner@bham.ac.uk FU Biotechnology and Biological Sciences Research Council [G18987]; Medical Research Council [G0300332]; NIGMS NIH HHS [R01 GM058839, R01-GM58839] NR 51 TC 99 Z9 99 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1544-9173 J9 PLOS BIOL JI PLoS. Biol. PD DEC PY 2007 VL 5 IS 12 BP 2809 EP 2820 AR e326 DI 10.1371/journal.pbio.0050326 PG 12 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA 244OJ UT WOS:000251874900012 PM 18076287 ER PT J AU Bowman, TS Kurth, T Sesso, HD Manson, JE Gaziano, JM AF Bowman, Thomas S. Kurth, Tobias Sesso, Howard D. Manson, JoAnn E. Gaziano, J. Michael TI Eight-year change in body mass index and subsequent risk of cardiovascular disease among healthy non-smoking men SO PREVENTIVE MEDICINE LA English DT Article; Proceedings Paper CT 14th International Symposium on Atherosclerosis CY JUN 18-22, 2006 CL Rome, ITALY DE cardiovascular disease; body mass index; prospective studies; risk factors ID WEIGHT CHANGE; UNITED-STATES; MORTALITY; OVERWEIGHT; OBESITY; ASSOCIATIONS; FLUCTUATION; PHYSICIANS; BURDEN; LIFE AB Objective. To determine how change in BMI over 8 years is associated with risk of subsequent cardiovascular disease (CVD) among middle aged men. Methods. Prospective cohort study among 13,230 healthy men (aged 51.6 +/- 8.7 years) in the Physicians' Health Study. BMI was collected at baseline in 1982 and after 8 years, at which time follow-up began. Subsequent CVD events were collected and confirmed through March 31, 2005. Cox proportional hazards models evaluated BMI at 8 years and risk of CVD, 8-year change in BMI and risk of CVD, and whether change in BMI added prognostic information after the consideration of BMI at 8 years. Results. 1308 major CVD events occurred over 13.5 years. A higher BMI at year 8 was associated with an increased risk of CVD. Compared to a stable BMI (+/- 0.5 kg/m(2)), a 0.5-2.0 kg/m(2) increase had a multivariable-adjusted RR of 1.00 (0.86-1.16). A >= 2.0 kg/m(2) increase had a multivariable-adjusted RR of 1.39 (1.16-1.68), however further adjustment for BMI reduced the RR to 1.00 (0.81-1.23). A decrease in BMI had a multivariable RR of 1.23 (1.07-1.42) which was unaffected by adjustment for BMI at 8 years. Conclusion. A higher BMI and a rising BMI were both associated with an increased risk of CVD, however an increasing BMI did not add prognostic information once current BMI was considered. In contrast, a declining BMI was associated with an increased risk of CVD independent of current BMI. (c) 2007 Elsevier Inc. All rights reserved. C1 [Bowman, Thomas S.; Kurth, Tobias; Sesso, Howard D.; Gaziano, J. Michael] Brigham & Womens Hosp, VA Boston Healthcare Syst, Div Aging, Dept Med, Boston, MA 02120 USA. [Bowman, Thomas S.; Gaziano, J. Michael] MAVERIC, VA Boston Healthcare Syst, Boston, MA USA. [Kurth, Tobias; Sesso, Howard D.; Manson, JoAnn E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Bowman, TS (reprint author), Brigham & Womens Hosp, VA Boston Healthcare Syst, Div Aging, Dept Med, 1620 Tremont St, Boston, MA 02120 USA. EM tsbowman@partners.org RI Kurth, Tobias/A-9243-2012 OI Kurth, Tobias/0000-0001-7169-2620 FU NCI NIH HHS [R01 CA040360, CA-34944, CA-40360, R01 CA034944, R01 CA034944-03, R01 CA040360-17, R01 CA097193, R01 CA097193-01, R01 CA097193-02, R01 CA097193-03, R01 CA097193-04, R01 CA097193-05, R01 CA097193-06A1]; NHLBI NIH HHS [HL-26490, HL-34595, R01 HL026490, R01 HL026490-03, R01 HL034595, R01 HL034595-07] NR 29 TC 11 Z9 12 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD DEC PY 2007 VL 45 IS 6 BP 436 EP 441 DI 10.1016/j.ypmed.2007.06.022 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 255GO UT WOS:000252646000006 PM 17727941 ER PT J AU Vacanti, JP AF Vacanti, Joseph P. TI Tissue engineering and regenerative medicine SO PROCEEDINGS OF THE AMERICAN PHILOSOPHICAL SOCIETY LA English DT Article ID TRANSPLANTATION C1 [Vacanti, Joseph P.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Vacanti, Joseph P.] Massachusetts Gen Hosp, Lab Tissue Engn & Organ Fabricat, Boston, MA 02114 USA. RP Vacanti, JP (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 6 TC 5 Z9 5 U1 0 U2 2 PU AMER PHILOSOPHICAL SOC PI PHILADELPHIA PA 104 SOUTH FIFTH ST, PHILADELPHIA, PA 19106-3387 USA SN 0003-049X J9 P AM PHILOS SOC JI Proc. Amer. Philos. Soc. PD DEC PY 2007 VL 151 IS 4 BP 395 EP 402 PG 8 WC Humanities, Multidisciplinary SC Arts & Humanities - Other Topics GA 285GJ UT WOS:000254765000001 PM 18831155 ER PT J AU Morelli, M Di Paolo, T Wardas, J Calon, F Xiao, D Schwarzschild, MA AF Morelli, Micaela Di Paolo, Therese Wardas, Jadwiga Calon, Frederic Xiao, Danqing Schwarzschild, Michael A. TI Role of adenosine A(2A) receptors in parkinsonian motor impairment and L-DOPA-induced motor complications SO PROGRESS IN NEUROBIOLOGY LA English DT Article; Proceedings Paper CT International Research Conference on Targeting Adenosine A2A Receptons in Parkinson's Disease and other CNS Disorders CY MAY 17-19, 2006 CL Boston, MA SP US Army Mil Res Mat Command DE Parkinson's disease; dyskinesia; basal ganglia; tremor; adenosine A2A receptor antagonist; mGlu5 receptor; dopamine receptor; muscle rigidity; neuroplasticity; L-DOPA; MPTP; 6-hydroxydopamine; post-mortem human brain ID LEVODOPA-INDUCED DYSKINESIAS; C-FOS EXPRESSION; METABOTROPIC GLUTAMATE RECEPTORS; TREATED COMMON MARMOSETS; RAT GLOBUS-PALLIDUS; MESSENGER-RNA; 6-HYDROXYDOPAMINE-LESIONED RATS; RESPONSE COMPLICATIONS; BASAL GANGLIA; DISEASE PATIENTS AB Adenosine A(2A) receptors have a unique cellular and regional distribution in the basal ganglia, being particularly concentrated in areas richly innervated by dopamine such as the caudate-putamen and the globus pallidus. Adenosine A(2A) receptors are selectively located on striatopallidal neurons and are capable of forming functional heteromeric complexes with dopamine D-2 and metabotropic glutamate mGlu5 receptors. Based on the unique cellular and regional distribution of this receptor and in line with data showing that A(2A) receptor antagonists improve motor symptoms in animal models of Parkinson's disease (PD) and in initial clinical trials, A(2A) receptor antagonists have emerged as an attractive non-dopaminergic target to improve the motor deficits that characterize PD. Experimental data have also shown that A(2A) receptor antagonists do not induce neuroplasticity phenomena that complicate long-term dopaminergic treatments. The present review provides an updated summary of results reported in the literature concerning the biochemical characteristics and basal ganglia distribution of A(2A) receptors. We subsequently aim to examine the effects of adenosine A(2A) antagonists in rodent and primate models of PD and Of L-DOPA-induced dyskinesia. Finally, concluding remarks are made on post-mortem human brains and on the translation of adenosine A(2A) receptor antagonists in the treatment of PD. (C) 2007 Elsevier Ltd. All rights reserved. C1 Univ Cagliari, Dept Toxicol, I-09124 Cagliari, Italy. [Di Paolo, Therese; Calon, Frederic] Univ Laval, CHUQ, CHUL Pavillion,Fac Pharm, Mol Endocrinol & Oncol Res Ctr, Quebec City, PQ, Canada. [Wardas, Jadwiga] Polish Acad Sci, Inst Pharmacol, Dept Neuropharmacol, Krakow, Poland. [Xiao, Danqing; Schwarzschild, Michael A.] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Boston, MA 02114 USA. RP Morelli, M (reprint author), Univ Cagliari, Dept Toxicol, Via Osped 72, I-09124 Cagliari, Italy. EM morelli@unica.it OI morelli, micaela/0000-0003-0394-5782 FU NINDS NIH HHS [NS054978] NR 139 TC 81 Z9 83 U1 1 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0301-0082 J9 PROG NEUROBIOL JI Prog. Neurobiol. PD DEC PY 2007 VL 83 IS 5 BP 293 EP 309 DI 10.1016/j.pneurobio.2007.07.001 PG 17 WC Neurosciences SC Neurosciences & Neurology GA 244RH UT WOS:000251882500004 PM 17826884 ER PT J AU Sancha, FG Bachmann, A Choi, B Tabatabaei, S Muir, G AF Sancha, F. Gomez Bachmann, A. Choi, B. B. Tabatabaei, S. Muir, G. H. TI Photoselective vaporization of the prostate (GreenLight PV): lessons learnt after 3500 procedures SO PROSTATE CANCER AND PROSTATIC DISEASES LA English DT Review DE photoselective vaporization; BPH; laser therapy; KTP; PVP; GreenLight PV ID PHOSPHATE LASER VAPORIZATION; TRANSURETHRAL RESECTION; EXPERIENCE; HOLMIUM; ENUCLEATION AB The technical recommendations of an international group of experts on photoselective vaporization of the prostate (PVP; GreenLight PV) for benign prostatic hyperplasia are described. Their experience stems from the treatment of over 3500 patients at five centres in Europe and the United States. The objectives of this physician-based initiative are to optimize the results achieved with PVP by standardizing the procedure, as well as to recommend training requirements. C1 Kings Coll Hosp London, Dept Urol, London SE5 9RS, England. Univ Basel Hosp, Dept Urol, CH-4031 Basel, Switzerland. Inst Adv Urol Surg, Madrid, Spain. Cornell Univ, Dept Urol, Weill Med Coll, New York, NY USA. Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. RP Muir, G (reprint author), Kings Coll Hosp London, Dept Urol, Denmark Hill, London SE5 9RS, England. EM gordon@london-urology.co.uk NR 15 TC 37 Z9 40 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1365-7852 EI 1476-5608 J9 PROSTATE CANCER P D JI Prostate Cancer Prostatic Dis. PD DEC PY 2007 VL 10 IS 4 BP 316 EP 322 DI 10.1038/sj.pcan.4500989 PG 7 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 235XI UT WOS:000251267200002 ER PT J AU Brendel, RW Schouten, R AF Brendel, Rebecca W. Schouten, Ronald TI Legal concerns in psychosomatic medicine SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article ID INFORMED-CONSENT; HEALTH; HIPAA; PSYCHIATRISTS; LITIGATION; RESPONSES; PRIVACY; VIOLENT AB In the practice of psychosomatic medicine, psychiatrists frequently encounter issues of legal concern. This article provides an overview of legal topics frequently encountered by the psychiatric consultant. One such area, discussed first in this article, is confidentiality and the management of private patient information. A second common interface between law and psychiatry is in the area of medical decision making. The psychiatric consultant is often asked to evaluate a patient's ability to accept or refuse treatment, and then make a determination of capacity. When the patient cannot give informed consent, an alternate decision maker must be found. Finally, malpractice liability is often a concern for the psychiatric consultant. Overall, psychiatrists should approach the care of patients foremost from a clinical perspective, while understanding the applicable laws and regulations of the jurisdictions in which they practice. In addition, clinicians should be aware of the legal and risk management resources available to them should a complex situation arise. C1 Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Psychiat Consultat Serv, Boston, MA 02114 USA. Massachusetts Gen Hosp, Law & Psychiat Serv, Boston, MA 02114 USA. RP Brendel, RW (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, 15 Parkman St,WAC 812, Boston, MA 02114 USA. EM rbrendel@partners.org NR 54 TC 5 Z9 5 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD DEC PY 2007 VL 30 IS 4 BP 663 EP + DI 10.1016/j.psc.2007.07.010 PG 15 WC Psychiatry SC Psychiatry GA 233BW UT WOS:000251066400005 PM 17938039 ER PT J AU Lyons-Ruth, K Holmesa, BM Sasvari-Szekely, M Ronai, Z Nemoda, Z Pauls, D AF Lyons-Ruth, Karlen Holmesa, Bjarne M. Sasvari-Szekely, Maria Ronai, Zsolt Nemoda, Zsofia Pauls, David TI Serotonin transporter polymorphism and borderline or antisocial traits among low-income young adults SO PSYCHIATRIC GENETICS LA English DT Article DE antisocial personality disorder; borderline personality disorder; maternal care; serotonin transporter linked polymorphic region; sucidality ID AGGRESSIVE-BEHAVIOR; ENVIRONMENTAL-INFLUENCES; PERSONALITY-DISORDER; MATERNAL-BEHAVIOR; REGULATORY REGION; SOCIAL RISK; ASSOCIATION; GENE; STRESS; TWIN AB Objectives The short allele of the serotonin transporter linked polymorphic region, 5HTTLPR has been associated with anxiety, major depressive disorder and suicidality. The impulsive self- and other-damaging behaviors seen in borderline personality disorder and antisocial personality disorder also have substantial comorbidity with depression but are associated with more severe environmental stressors. This study tested the hypothesis of an association between the short allele of the 5HTTLPR and borderline or antisocial traits in young adulthood. Methods The 5HTTLPR was genotyped among 96 young adults from low to moderate income families (62 adults without and 34 adults with borderline personality disorder or antisocial personality disorder traits). Traits of borderline and antisocial personality disorders were assessed with the Structured Clinical Interview for Diagnosis-Axis II. Results The number of short 5HTTLPR alleles were significantly related to incidence of borderline personality disorder or antisocial personality disorder traits and also to each set of traits independently. Male sex and quality of care in infancy were also associated with incidence of borderline personality disorder and antisocial personality disorder traits but did not account for the association with the short allele. Depressive disorders were not associated with the short allele in this sample. Conclusions Young adults of lower socioeconomic status who carry the short 5HTTLPR allele may be especially vulnerable to developing antisocial or borderline traits by young adulthood. C1 Harvard Univ, Sch Med, Cambridge Hosp, Cambridge, MA 02139 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Charlestown, MA USA. Semmelweis Univ, Dept Med Chem Mol Biol & Pathobiochem, Budapest, Hungary. RP Lyons-Ruth, K (reprint author), Harvard Univ, Sch Med, Cambridge Hosp, 1493 Cambridge St, Cambridge, MA 02139 USA. EM klruth@hms.harvard.edu OI Ronai, Zsolt/0000-0002-0909-7932 FU FIC NIH HHS [R03 TW006014-03, R03 TW006014]; NIMH NIH HHS [R01 MH062030-04, R01 MH062030] NR 31 TC 35 Z9 36 U1 4 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0955-8829 J9 PSYCHIAT GENET JI Psychiatr. Genet. PD DEC PY 2007 VL 17 IS 6 BP 339 EP 343 PG 5 WC Genetics & Heredity; Neurosciences SC Genetics & Heredity; Neurosciences & Neurology GA 227ZB UT WOS:000250695400004 PM 18075474 ER PT J AU Resick, PA AF Resick, Patricia A. TI Whose role is it any way? SO PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES LA English DT Editorial Material C1 VA Boston Hlthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div 116B 3, Boston, MA 02130 USA. RP Resick, PA (reprint author), VA Boston Hlthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div 116B 3, 150 S Huntington St, Boston, MA 02130 USA. EM Resick@va.gov NR 0 TC 1 Z9 1 U1 0 U2 0 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0033-2747 J9 PSYCHIATRY JI Psychiatry-Interpers. Biol. Process. PD WIN PY 2007 VL 70 IS 4 BP 350 EP 353 PG 4 WC Psychiatry SC Psychiatry GA 249NX UT WOS:000252236600007 ER PT J AU Siefert, CJ Kehl-Fie, K Blais, MA Chriki, L AF Siefert, Caleb J. Kehl-Fie, Kendra Blais, Mark A. Chriki, Lyvia TI Detecting back irrelevant responding on the Personality Assessment Inventory in a psychiatric inpatient setting SO PSYCHOLOGICAL ASSESSMENT LA English DT Article; Proceedings Paper CT Annual Meeting of the Society-of-Personality-Assessment CY 2006 CL San Diego, CA SP Soc Personal Assessment DE back irrelevant responding; Personality Assessment Inventory; random responding; response styles AB The present studies focus on strategies for detecting back irrelevant responding (BIR) on the Personality Assessment Inventory (PAI; L. C. Morey, 1991). Moderate BIR levels can greatly affect the clinical scales of the PAL Further, the PAI's Inconsistency and Infrequency validity scales are less than optimal for detecting BIR. L. C. Morey and C. J. Hopwood (2004) developed an alternative strategy for detecting BIR that involves comparison of 2 scales from the PAI short-form with the same 2 scales from the PAI full-instrument. The present study examines how different BIR levels affect the clinical, treatment, and interpersonal scales of the PAI in 2 psychiatric inpatient samples. The effectiveness of various strategies for detecting BIR in an inpatient setting is also discussed. Consistent with previous research, moderate rates of BIR impacted several PAI scales in a meaningful way. The Inconsistency and Infrequency validity scales of the PAI were relatively ineffective for detecting low-to-moderate BIR levels. Conversely, the short-form full-instrument comparison strategy was much more sensitive to BIR. Finally, a new BIR detection indicator is presented that improves sensitivity rates for detecting all BIR levels in an acute setting. The implications of these results for detecting BIR in inpatient settings are discussed. C1 [Siefert, Caleb J.; Kehl-Fie, Kendra; Blais, Mark A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Siefert, Caleb J.; Kehl-Fie, Kendra; Blais, Mark A.; Chriki, Lyvia] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. [Chriki, Lyvia] Cambridge Hlth Allliance, Dept Psychiat, Cambridge, MA USA. RP Siefert, CJ (reprint author), Wang Ambulatory Care Ctr, 15 Parkman St,8th Floor Room 812, Boston, MA 02114 USA. EM csiefert@partners.org NR 11 TC 6 Z9 6 U1 1 U2 1 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1040-3590 J9 PSYCHOL ASSESSMENT JI Psychol. Assess. PD DEC PY 2007 VL 19 IS 4 BP 469 EP 473 DI 10.1037/1040-3590.19.4.469 PG 5 WC Psychology, Clinical SC Psychology GA 241BM UT WOS:000251631900010 PM 18085939 ER PT J AU Monuteaux, MC Faraone, SV Gross, LM Biederman, J AF Monuteaux, Michael C. Faraone, Stephen V. Gross, Lara Michelle Biederman, Joseph TI Predictors, clinical characteristics, and outcome of conduct disorder in girls with attention-deficit/hyperactivity disorder: a longitudinal study SO PSYCHOLOGICAL MEDICINE LA English DT Article ID DEFICIT HYPERACTIVITY DISORDER; OPPOSITIONAL DEFIANT DISORDER; ONSET ANTISOCIAL-BEHAVIOR; PREADOLESCENT GIRLS; FAMILIAL SUBTYPE; FOLLOW-UP; ADHD; BOYS; GENDER; FEMALE AB Background. Research on the overlap between attention-deficit/hyperactivity disorder (ADHD) and conduct disorder (CD) in males has provided useful information on the etiology, correlates, course, and nosology of this co-morbid condition. However, it is unclear how these results extend to females. Our aim was to examine the predictors, clinical characteristics, and functional outcome of CD in a sample of female youth with and without ADHD. Method. We conducted a blind, 5-year prospective longitudinal study of girls with (n= 140) and without (n = 122) ADHD, aged 6-18 years at baseline. At the 5-year follow-up, 123 (88 %) and 112 (92 %) of the ADHD and control children respectively were reassessed at a mean age of 16.7 years. Psychiatric disorders were assessed using blind structured diagnostic interviews. Results. Baseline ADHD was a significant risk factor for lifetime CID throughout childhood and adolescence [hazard ratio (HR) 5.8, 95% confidence interval (CI) 2.9-11.5, p<0.001]. Among ADHD girls, childhood-onset (<12 years) CD was predicted by paternal antisocial personality disorder (ASPD), while adolescent-onset CD (>= 12 years) was predicted by family conflict. In addition, lifetime CD significantly predicted academic, psychiatric and sexual behavior problems in girls with ADHD at follow-up. Conclusions. ADHD is a significant risk factor for CD in girls. CD is associated with increased risk for academic, psychiatric and sexual behavior problems compared to ADHD girls without CD. Given that the therapeutic approaches indicated by ADHD and CD differ, these findings highlight the importance of improved efforts aimed at early identification and treatment of CD in girls with ADHD. C1 [Monuteaux, Michael C.; Gross, Lara Michelle; Biederman, Joseph] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA. [Monuteaux, Michael C.; Gross, Lara Michelle; Biederman, Joseph] Harvard Univ, Sch Med, Boston, MA USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA. RP Monuteaux, MC (reprint author), Pediat Psychopharmacol Program, 55 Fruit St,Warren 705, Boston, MA 02114 USA. EM mmonuteaux@partners.org OI Faraone, Stephen/0000-0002-9217-3982 FU NICHD NIH HHS [5R01 HD36317-07] NR 54 TC 34 Z9 34 U1 3 U2 13 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 J9 PSYCHOL MED JI Psychol. Med. PD DEC PY 2007 VL 37 IS 12 BP 1731 EP 1741 DI 10.1017/S0033291707000529 PG 11 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 244TG UT WOS:000251887600005 PM 17451627 ER PT J AU Faraone, SV Biederman, J Wilens, TE Adamson, J AF Faraone, Stephen V. Biederman, Joseph Wilens, Timothy E. Adamson, Joel TI A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults SO PSYCHOLOGICAL MEDICINE LA English DT Article ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; PSYCHIATRIC STATUS; COCAINE ABUSERS; HISTORY; METHYLPHENIDATE; PREVALENCE; RISK AB Background. Studies of adults with attention deficit hyperactivity disorder (ADHD) show an elevated prevalence of substance use disorders (SUDs) and the substance abuse literature shows that ADHD is elevated in substance users. Some researchers postulate that stimulant treatment of ADHD increases the risk for SUD in ADHD patients but follow-up studies suggest treatment protects patients from subsequent SUDS. This report uses retrospective data to assess the impact of prior ADHD pharmacotherapy on SUDS in 206 ADHD adults (n = 79 late-onset ADHD, n = 127 full ADHD) grouped by lifetime history of ADHD treatment (no treatment, past treatment, current and past treatment). Method. Structured Clinical Interview for DSM-IV (SCID) data were used to establish abuse and dependence, and Drug Use Screening Inventory (DUSI) responses were used to establish prevalence of use, preference for cigarettes, alcohol and drugs of abuse, complications from use, and motivation for use (get high, change mood, sleep better). Results. No differences were found in the prevalence of cigarette smoking, alcohol or drug abuse or dependence, as well as no significant differences in 1-month prevalence of any use or use more than 20 times. No differences were found in complications of drug or alcohol use across groups. Subjects with current treatment rated getting high as a motivating factor significantly more frequently than subjects in the past treatment group; this result lost significance when we included ADHD diagnostic category. Conclusions. Our results are consistent across substances and ADHD diagnoses, and support the hypothesis that pharmacotherapy does not cause subsequent SUDS. C1 [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA. [Biederman, Joseph; Wilens, Timothy E.; Adamson, Joel] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Yawkey Ctr Outpatient Care, Dept Psychiat,Pediat Psychopharmacol Unit, Boston, MA USA. RP Faraone, SV (reprint author), SUNY Upstate Med Univ, Dept Psychiat Neurosci & Physiol, 750 E Adams St, Syracuse, NY 13210 USA. EM faraones@upstate.edu OI Adamson, Joel/0000-0002-1399-5786; Faraone, Stephen/0000-0002-9217-3982 FU NIDA NIH HHS [R01 DA14419A2-05, K24 DA016264A2-03, R01DA018659]; NIMH NIH HHS [R01MH57934] NR 32 TC 17 Z9 17 U1 1 U2 7 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 J9 PSYCHOL MED JI Psychol. Med. PD DEC PY 2007 VL 37 IS 12 BP 1743 EP 1752 DI 10.1017/S0033291707000335 PG 10 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 244TG UT WOS:000251887600006 PM 17349106 ER PT J AU Bambery, M Porcerelli, JH Ablon, JS AF Bambery, Michael Porcerelli, John H. Ablon, J. Stuart TI Measuring psychotherapy process with the adolescent psychotherapy Q-SET (APQ): Development and applications for training SO PSYCHOTHERAPY LA English DT Article DE adolescent; psychotherapy; process; Q-methodology ID COGNITIVE-BEHAVIORAL THERAPY; COLLABORATIVE RESEARCH-PROGRAM; CONTROLLED CLINICAL-TRIALS; THOMPSON-BRENNER 2004; PLAY THERAPY; ANXIETY DISORDERS; FAMILY-THERAPY; DEPRESSION; CHILD; ALLIANCE AB This study presents the initial findings front the development of an adolescent version of-the Child Psychotherapy Q-set (CPQ, Schneider, 2003). The CPQ is a psychotherapy process measure that utilizes Q-methodology to define psychotherapy process in an empirical form suitable for quantitative analysis. This new instrument, the Adolescent Psychotherapy Process Q-set (APQ), was developed to be pantheoretical in assessing the process of psychotherapy with adolescents. Panels of "expert" psychodynamic (PD) and cognitive-behavioral (CB) theoreticians and practitioners (N = 22) rated the 100 APQ items, and these ratings were factor analyzed to develop general prototypes of ideally conducted therapy for each respective orientation. Agreement between and amongst the experts was examined; in order to determine the reliability of, and shared variance between, each prototype. Coefficient alpha reliabilities were high for both PD (.93) and CB (.94) orientations. A significant correlation between the factor scores of each prototype (r =.31; p <= 01) was found. In a second study, a case example is provided to demonstrate the applications of the APQ and the prototypes in psychotherapy training and supervision. C1 [Bambery, Michael] Univ Detroit Mercy, Detroit, MI 48221 USA. [Porcerelli, John H.] Wayne State Univ, Sch Med, Detroit, MI 48202 USA. [Ablon, J. Stuart] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ablon, J. Stuart] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Bambery, M (reprint author), Univ Detroit Mercy, Detroit, MI 48221 USA. EM mbambery@msn.com RI Espinosa, Daniel/B-7285-2012 NR 81 TC 4 Z9 4 U1 1 U2 3 PU AMER PSYCHOLOGICAL ASSOC, DIV PSYCHOTHERAPY PI CORAL GABLES PA 1390 SOUTH DIXIE HIGHWAY, STE 2222, CORAL GABLES, FL 33146-2946 USA SN 0033-3204 J9 PSYCHOTHERAPY JI Psychotherapy PD DEC PY 2007 VL 44 IS 4 BP 405 EP 422 DI 10.1037/0033-3204.44.4.405 PG 18 WC Psychology, Clinical SC Psychology GA 250GP UT WOS:000252288300008 PM 22122320 ER PT J AU Fukuoka, Y Lindgren, TG Rankin, SH Cooper, BA Carroll, DL AF Fukuoka, Yoshimi Lindgren, Teri G. Rankin, Sally H. Cooper, Bruce A. Carroll, Diane L. TI Cluster analysis: a useful technique to identify elderly cardiac patients at risk for poor quality of life SO QUALITY OF LIFE RESEARCH LA English DT Article DE cluster analysis; health related quality of life; acute myocardial infarction; coronary artery bypass graft; psychological distress; aging; depression; cardiac symptom; fatigue; recovery; elderly; women ID ARTERY-BYPASS GRAFT; MYOCARDIAL-INFARCTION; SYMPTOM CLUSTERS; HEART-FAILURE; DEPRESSION; WOMEN; PREVALENCE; SURVIVORS; CANCER; MEN AB The purposes of this study are (1) to examine the frequency of cardiac symptoms in elderly people one year after acute myocardial infarction (AMI) and/or coronary artery bypass surgery (CABG); (2) to identify patient subgroups (cluster solutions) based on cardiac symptoms after cardiac events and (3) to determine if these subgroups vary based on health related quality of life and psychological distress. A sample of 206 elderly, unpartnered, patients (age >= 65) were interviewed one year after AMI and/or CABG by telephone. Cardiac symptoms, SF-36, POMS, and QOL-I were measured. A hierarchical cluster analysis was used to identify patient subgroups based on cardiac symptoms, using a combination of dendrograms and stopping rules. Three subgroups were identified: (1) the Weary (19.4%), (2) the Diffuse symptom (68.4%), and (3) the Breathless groups (12.2%). The Weary group had significantly lower scores on all of SF-36 subscales (except for social functioning) and higher scores on all of POMS subscales (except for Anger/hostility and Confusion/Bewilderment) compared to the Diffuse symptom group. The cluster analysis was useful to identify the subgroup with poorer recovery. Patients in the Weary group need more attention and intervention strategies to improve their health. C1 Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res inst Patient Care, Boston, MA 02114 USA. RP Fukuoka, Y (reprint author), Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. EM Yoshimi.Fukuoka@nursing.ucsf.edu FU NICHD NIH HHS [9 K12 HD052163-06]; NINR NIH HHS [T32 NR07088, R01 NR005205] NR 31 TC 22 Z9 22 U1 1 U2 8 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 J9 QUAL LIFE RES JI Qual. Life Res. PD DEC PY 2007 VL 16 IS 10 BP 1655 EP 1663 DI 10.1007/s11136-007-9272-7 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 227BQ UT WOS:000250632600011 PM 17955345 ER PT J AU Thrall, JH AF Thrall, James H. TI Changing relationships between radiologists and hospitals - Part I. Background and major issues SO RADIOLOGY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Harvard Med Sch, Dept Radiol, Boston, MA 02114 USA. RP Thrall, JH (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Dept Radiol, 14 Fruit St,MZ-FND 216,Box 9657, Boston, MA 02114 USA. EM jthrall@partners.org NR 4 TC 11 Z9 11 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD DEC PY 2007 VL 245 IS 3 BP 633 EP 637 DI 10.1148/radiol.2453071461 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 233DN UT WOS:000251070700003 PM 18024444 ER PT J AU Bullitt, E Lin, NU Smith, JK Zeng, DL Winer, EP Carey, LA Lin, W Ewend, MG AF Bullitt, Elizabeth Lin, Nancy U. Smith, J. Keith Zeng, Donglin Winer, Eric P. Carey, Lisa A. Lin, Weili Ewend, Matthew G. TI Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: A feasibility study SO RADIOLOGY LA English DT Article ID TUMOR VASCULATURE; TORTUOSITY; CANCER; ANGIOGENESIS; MALIGNANCY; THERAPY AB Purpose: To prospectively determine if magnetic resonance (MR) angiography can depict intracranial vascular morphologic changes during treatment of brain metastases from breast cancer and if serial quantitative vessel tortuosity measurements can be used to predict tumor treatment response sooner than traditional methods. Materials and Methods: Institutional review board approval and informed consent were obtained for this HIPAA-compliant study. Twenty-two women aged 31-61 years underwent brain MR angiography prior to and 2 months after initiation of lapatinib therapy for brain metastases from breast cancer. Vessels were extracted from MR angiograms with a computer program. Changes in vessel number, radius, and tortuosity were calculated mathematically, normalized with values obtained in 34 healthy control subjects (19 women, 15 men; age range, 19-72 years), and compared with subsequent assessments of tumor volume and clinical course. Results: All patients exhibited abnormal vessel tortuosity at baseline. Nineteen (86%) patients did not exhibit improvement in vessel tortuosity at 2-month follow-up, and all patients demonstrated tumor growth at 4-month follow-up. Vessel tortuosity measurements enabled us to correctly predict treatment failure 1-2 months earlier than did traditional methods. Three (14%) patients had quantitative improvement in vessel tortuosity at 2-month follow-up, with drop out of small abnormal vessels and straightening of large vessels. Each of the two patients for whom further follow-up data were available responded to treatment for more than 6 months. Conclusion: Study results established the feasibility of using MR angiography to quantify vessel shape changes during therapy. Although further research is required, results suggest that changes in vessel tortuosity might enable early prediction of tumor treatment response. C1 Univ N Carolina, Comp Assist Surg & Imaging Lab, Chapel Hill, NC 27599 USA. Dana Farber Harvard Canc Ctr, Dept Radiol, Boston, MA USA. RP Bullitt, E (reprint author), Univ N Carolina, Comp Assist Surg & Imaging Lab, 247 Wing E,CB 7062, Chapel Hill, NC 27599 USA. EM bullitt@med.unc.edu OI Smith, J Keith/0000-0001-7588-3520 FU NCI NIH HHS [P50 CA058223, P50 CA089393, P50CA089393-05S1, P50 CA058185, P30CA58223, P30 CA016086, T32 CA009172, P50CA89393-AV-55P, P50CA58185-AV-55P2, P30CA16086-29S1]; NCRR NIH HHS [M01RR00046, M01 RR000046]; NIBIB NIH HHS [R01EB000219, R01 EB000219-10, R01 EB000219, R01 EB000219-08A1] NR 20 TC 20 Z9 21 U1 0 U2 2 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD DEC PY 2007 VL 245 IS 3 BP 824 EP 830 DI 10.1148/radiol.2453061889 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 233DN UT WOS:000251070700024 PM 17954616 ER PT J AU Stone, ME AF Stone, Martha E. TI Great events from history: Gay, lesbian, bisexual, transgender events, 1846-2006 SO REFERENCE & USER SERVICES QUARTERLY LA English DT Book Review C1 [Stone, Martha E.] Massachusetts Gen Hosp, Treadwell Lib, Ref Serv, Boston, MA 02114 USA. RP Stone, ME (reprint author), Massachusetts Gen Hosp, Treadwell Lib, Ref Serv, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER LIBRARY ASSOC PI CHICAGO PA 50 E HURON ST, CHICAGO, IL 60611 USA SN 1094-9054 J9 REF USER SERV Q JI Ref. User Serv. Q. PD WIN PY 2007 VL 47 IS 2 BP 182 EP 183 PG 2 WC Information Science & Library Science SC Information Science & Library Science GA 266GT UT WOS:000253423200026 ER PT J AU Gold, EB Lasley, B Crawford, SL McConnell, D Joffe, H Greendale, GA AF Gold, Ellen B. Lasley, Bill Crawford, Sybil L. McConnell, Dan Joffe, Hadine Greendale, Gail A. TI Relation of daily urinary hormone patterns to vasomotor symptoms in a racially/Ethnically diverse sample of midlife women: Study of women's health across the nation SO REPRODUCTIVE SCIENCES LA English DT Article DE menopause; endogenous hormones; hot flashes; smoking; body weight; race/ethnicity; socioeconomic status; ovarian function ID HABITUAL PHYSICAL-ACTIVITY; MENOPAUSAL HOT FLASHES; POSTMENOPAUSAL WOMEN; MENSTRUAL CYCLES; RISK-FACTORS; PREMENOPAUSAL WOMEN; ESTROGEN; POPULATION; TRANSITION; PERIMENOPAUSE AB The associations of urinary pregnanediol-glucuronide (PdG) levels and menstrual bleeding and their modification of associations of other risk factors with vasomotor symptoms (VMS) are examined. Daily urine samples were collected for 1 menstrual cycle or 50 days if no bleeding occurred. Participants (n = 742) were aged 43 to 54 years, not using exogenous hormones, not pregnant, had an intact uterus and >1 ovary, and menstruated in the prior 3 months. Multivariate analyses were performed of urinary hormone metabolites and within-woman proportion of days reporting VMS. VMS reporting was 4-fold greater (P = .0005) in women whose urine collections ended without bleeding. In collections with PdG levels suggestive of ovulatory activity according to the work of Kassam et al, VMS are significantly associated with obesity, early perimenopause, and increasing PdG levels. In collections with lower PdG concentrations, VMS are significantly increased with no bleeding, smoking, higher age, physical activity, follicle-stimulating hormone, and luteinizing hormone and are significantly reduced with increasing estrogen concentrations. C1 [Gold, Ellen B.] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Div Epidemiol, Davis, CA 95616 USA. [Lasley, Bill] Univ Calif Davis, Ctr Hlth & Environm, Davis, CA 95616 USA. [Crawford, Sybil L.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA. [McConnell, Dan] Univ Michigan, Reprod Sci Program, Ann Arbor, MI 48109 USA. [Joffe, Hadine] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat,Perinatal & Reprod Psychiat Program, Cambridge, MA 02138 USA. [Greendale, Gail A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA USA. RP Gold, EB (reprint author), Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Div Epidemiol, 1 Shields Ave,TB168, Davis, CA 95616 USA. EM ebgold@ucdavis.edu FU NIA NIH HHS [AG012531, AG012546, AG012553, AG012505, AG012535, AG012554, AG012539, AG012495]; NINR NIH HHS [NR004061] NR 42 TC 9 Z9 9 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1933-7191 J9 REPROD SCI JI Reprod. Sci. PD DEC PY 2007 VL 14 IS 8 BP 786 EP 797 DI 10.1177/1933719107308613 PG 12 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 246UM UT WOS:000252032900009 PM 18089597 ER PT J AU Kaynar, AM Mathew, JJ Hudlin, MM Gingras, DJ Ritz, RH Jackson, MR Kacmarek, RM Kollef, MH AF Kaynar, A. Murat Mathew, Jacob J. Hudlin, Margaret M. Gingras, Dan J. Ritz, Ray H. Jackson, Michael R. Kacmarek, Robert M. Kollef, Marin H. TI Attitudes of respiratory therapists and nurses about measures to prevent ventilator-associated pneumonia: A multicenter, cross-sectional survey study SO RESPIRATORY CARE LA English DT Article DE prophylaxis; ventilator-associated pneumonia; guideline; adherence; compliance; prevention; behavioral modification; implementation; intensive care unit ID INTENSIVE-CARE UNIT; EVIDENCE-BASED GUIDELINES; NOSOCOMIAL PNEUMONIA; INFECTION-RATES; HOSPITAL STAY; RISK-FACTORS; MORTALITY; PHYSICIANS; MORBIDITY; ADULT AB OBJECTIVE: To understand the reported practices of and adherence to evidence-based guidelines for the prevention of ventilator-associated pneumonia (VAP) among respiratory therapists (RTs) and registered nurses (RNs) in academic and nonacademic intensive care units. METHODS: We conducted a multicenter, cross-sectional survey. We first obtained demographic information about health care professionals in a nonidentifiable method. We next questioned the practice patterns of RTs and RNs for preventing VAP based on evidence-supported guidelines. The participants were RTs and RNs working in academic and nonacademic intensive care units; 278 respondents participated in this study (172 RTs and 106 RNs). There were no interventions. RESULTS: The 3 major findings were: (1) both the RTs and the RNs reported that they frequently practice VAP-prevention measures, (2) the rate of adherence to ineffective measures (eg, routine changes of the ventilator circuit, disposable catheters) is also relatively high, which suggests that the evidence is not translated into bedside practice, (3) a substantial proportion of participants did not know the VAP rate in their institution, which might make it difficult to convince bedside practitioners to apply evidence-based practice, and might reflect a lack of infection-control/surveillance programs at hospitals. CONCLUSION: Consumers, the Centers for Disease Control and Prevention, and other organizations are currently trying to implement mandatory reporting of hospital infections, including VAP rate. Without a definition of VAP suited to individual institutions, an organized data-collection and reporting method, and team-based approaches to preventing and treating VAP, hospitals may not be able to meet these requests and track improvement efforts. Prevention measures need to be translated to bedside practice to improve the outcomes of critically ill patients. C1 Beth Israel Deaconess Med Ctr, Dept Resp Care, Boston, MA USA. Univ Massachusetts, Dept Surg, Div Surg Crit Care, Worcester, MA USA. Women & Infants Hosp Rhode Isl, Dept Res Care, Providence, RI USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Respirat Care Serv, Boston, MA USA. Washington Univ, Sch Med, Dept Pulm & Crit Care Med, St Louis, MO 63130 USA. RP Kaynar, AM (reprint author), Univ Pittsburgh, Sch Med, Dept Anesthesiol & Crit Care Med, 3550 Terrace St,Rm 639 Scaife Hall, Pittsburgh, PA 15261 USA. EM kaynarm@upmc.edu OI Kaynar, Ata Murat/0000-0001-8847-0450 NR 38 TC 9 Z9 9 U1 0 U2 0 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD DEC PY 2007 VL 52 IS 12 BP 1687 EP 1694 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 238NP UT WOS:000251454800004 PM 18028558 ER PT J AU Taylor, WJ Schumacher, HR Singh, JA Grainger, R Dalbeth, N AF Taylor, W. J. Schumacher, H. R., Jr. Singh, J. A. Grainger, R. Dalbeth, N. TI Assessment of outcome in clinical trials of gouta review of current measures SO RHEUMATOLOGY LA English DT Review ID HEALTH-ASSESSMENT QUESTIONNAIRE; DOUBLE-BLIND TRIAL; RHEUMATOID-ARTHRITIS; INDOMETHACIN; HYPERURICEMIA; EFFICACY; FIBROMYALGIA; ETORICOXIB; REDUCTION; THERAPY AB There has been renewed interest in the treatment of gout with recent reported intervention studies of new agents such as etoricoxib, febuxostat and pegylated-uricase. However, these studies have highlighted the relative paucity of validated outcome measures with which to judge efficacy. This review outlines the published information regarding which endpoints have been measured in randomized clinical trials, what should be measured, what tools or instruments are available for this and the technical properties of such instruments. It highlights recent work that validates measures of tophi, radiographic damage and patient-reported outcomes. The absence of a valid definition of gout-flare or how flare reduction defines response is problematic; this forms the basis for a current ACR-EULAR sponsored project. C1 Univ Otago, Wellington Sch Med & Hlth Sci, Dept Med, Rehabil Teaching & Res Unit, Wellington 6242, New Zealand. Univ Penn, Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA. Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. VA Med Ctr, Rheumatol Sect, Med Serv, Minneapolis, MN USA. VA Med Ctr, Ctr Epidemiol & Clin Res, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. Univ Minnesota, Dept Med, Div Rheumatol, Minneapolis, MN 55455 USA. Univ Auckland, Dept Med, Fac Med & Hlth Sci, Auckland, New Zealand. Malaghan Inst Med Res, Wellington, New Zealand. RP Taylor, WJ (reprint author), Univ Otago, Wellington Sch Med & Hlth Sci, Dept Med, Rehabil Teaching & Res Unit, POB 7343, Wellington 6242, New Zealand. EM will.taylor@otago.ac.nz RI Grainger, Rebecca/I-1866-2012; OI singh, jasvinder/0000-0003-3485-0006 NR 44 TC 20 Z9 21 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD DEC PY 2007 VL 46 IS 12 BP 1751 EP 1756 DI 10.1093/rheumatology/kem178 PG 6 WC Rheumatology SC Rheumatology GA 234XN UT WOS:000251197900004 PM 17650521 ER PT J AU Tregellas, JR Shatti, S Tanabe, JL Martin, LF Gibson, L Wylie, K Rojas, DC AF Tregellas, Jason R. Shatti, Shireen Tanabe, Jody L. Martin, Laura F. Gibson, Linzi Wylie, Korey Rojas, Donald C. TI Gray matter volume differences and the effects of smoking on gray matter in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; voxel-based morphometry; VBM; smoking; superior temporal gyrus; orbitofrontal cortex ID VOXEL-BASED MORPHOMETRY; NICOTINIC RECEPTORS; WHITE-MATTER; HUMAN BRAIN; ABNORMALITIES; MRI; CORTEX; METAANALYSIS; REDUCTION; SYMPTOMS AB Objective: Many studies have evaluated differences in gray matter volume in schizophrenia, but have not considered the possible effects of smoking, which is extraordinarily common in people with the illness. The present study used voxel-based morphometry (VBM) to examine differences in gray matter in subjects with schizophrenia and evaluate the effects of smoking on this measure. Methods: Thirty-two subjects with schizophrenia (14 smokers, 18 non-smokers) and 32 healthy comparison subjects participated in the study. Whole brain, voxel-wise analyses of regional gray matter volume were conducted using voxel-based morphometry (VBM). Results: Reduced gray matter was observed in the schizophrenia group in the orbitofrontal cortex, bilateral insula and superior temporal gyri (STG), bilateral dorsolateral prefrontal cortices (DLPFC), medial frontal gyrus, and cingulate gyrus. Within this group, smoking subjects had greater lateral prefrontal and STG gray matter volumes relative to non-smoking subjects. Conclusions: The finding of reduced gray matter volume in prefrontal and temporal regions in schizophrenia is consistent with prior anatomical tracing and whole-brain voxel-based studies. Greater gray matter volumes in smoking relative to non-smoking subjects with schizophrenia highlight a potential experimental confound in volumetric studies and suggests that smoking may be associated with a relative preservation of lateral prefrontal and temporal gray matter in schizophrenia. Published by Elsevier B.V. C1 [Tregellas, Jason R.; Shatti, Shireen; Tanabe, Jody L.; Martin, Laura F.; Gibson, Linzi; Wylie, Korey; Rojas, Donald C.] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. [Tregellas, Jason R.; Martin, Laura F.] Denver VA Med Ctr, Res Serv, Denver, CO USA. RP Tregellas, JR (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Campus Box C268-71,4200 E 9th Ave, Denver, CO 80262 USA. EM Jason.Tregellas@UCHSC.edu RI Rojas, Don/F-4296-2012; Tregellas, Jason/J-3637-2015; OI Rojas, Don/0000-0001-6560-9616 FU NIMH NIH HHS [5 P50 MH068582] NR 52 TC 37 Z9 39 U1 2 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2007 VL 97 IS 1-3 BP 242 EP 249 DI 10.1016/j.schres.2007.08.019 PG 8 WC Psychiatry SC Psychiatry GA 242RA UT WOS:000251742000027 PM 17890058 ER PT J AU Crowson, AN Magro, C Miller, A Mihm, MC AF Crowson, A. Neil Magro, Cynthia Miller, Arlo Mihm, Martin C., Jr. TI The molecular basis of melanomagenesis and the metastatic phenotype SO SEMINARS IN ONCOLOGY LA English DT Review ID CUTANEOUS MALIGNANT-MELANOMA; FIBROBLAST-GROWTH-FACTOR; COMPARATIVE GENOMIC HYBRIDIZATION; MATRIX METALLOPROTEINASE-2 MMP-2; MIB-1 PROLIFERATIVE ACTIVITY; BETA-3 INTEGRIN EXPRESSION; SPORADIC DYSPLASTIC NEVUS; BCL-2 PROTEIN EXPRESSION; BENIGN MELANOCYTIC NEVI; KINASE-4 INHIBITOR GENE AB The last two decades have seen spectacular advances in our understanding of the biology of melanoma and, in particular, have elucidated the mechanisms operative in disease initiation and progression. With respect to the former, the genetics of melanoma and in particular the impact of genetic defects on dysregulation of the cell cycle are key issues in malignant transformation and are a major focus of this review. With respect to the latter, consideration also is given to the acquisition of growth factor autonomy and the capacity for invasion and metastasis from the standpoint of cell adhesion, motility, and matrix digestion. These events have specific morphologic correlates that will be briefly addressed. Where relevant, we will address certain of the modern pharmacogenetic strategies that flow from these novel observations concerning melanoma biology. C1 [Crowson, A. Neil] St Johns Med Ctr, Reg Med Lab, Tulsa, OK 74114 USA. [Crowson, A. Neil] Univ Oklahoma, Dept Dermatol, Tulsa, OK USA. [Crowson, A. Neil] Univ Oklahoma, Dept Surg, Tulsa, OK USA. [Crowson, A. Neil] Univ Oklahoma, Dept Pathol, Tulsa, OK USA. [Magro, Cynthia] Cornell Univ, Weill Med Coll, Dept Pathol, Div Dermatopathol, New York, NY USA. [Magro, Cynthia] Cornell Univ, Weill Med Coll, Lab Med, New York, NY USA. [Miller, Arlo] Mayo Clin, Dept Dermatol, Rochester, MN USA. [Mihm, Martin C., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA USA. [Mihm, Martin C., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA. RP Crowson, AN (reprint author), St Johns Med Ctr, Reg Med Lab, 1923 S Utica St, Tulsa, OK 74114 USA. EM ncrowson@sjmc.org NR 198 TC 18 Z9 18 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0093-7754 J9 SEMIN ONCOL JI Semin. Oncol. PD DEC PY 2007 VL 34 IS 6 BP 476 EP 490 DI 10.1053/j.seminoncol.2007.09.007 PG 15 WC Oncology SC Oncology GA 245YM UT WOS:000251974700006 PM 18083371 ER PT J AU Muder, RR AF Muder, Robert R. TI Optimizing therapy for Stenotrophomonas maltophilia SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE Stenotrophomonas (Xanthomonas) maltophilia; nosocomial infections; antimicrobial resistance ID GRAM-NEGATIVE BACILLI; IN-VITRO ACTIVITIES; XANTHOMONAS-MALTOPHILIA; PSEUDOMONAS-MALTOPHILIA; CYSTIC-FIBROSIS; BETA-LACTAMASE; ANTIMICROBIAL SUSCEPTIBILITY; CATARACT-EXTRACTION; PERITONEAL-DIALYSIS; CANCER-PATIENTS AB Stenotrophomonas (Xanthomonas) maltophilia is a nonfermentative, gram-negative bacillus that is widely distributed in natural and humanmade environments. In the nonhospital setting it is an uncommon pathogen, typically causing soft tissue infection of contaminated wounds. In the hospital setting, particularly among critical care and oncology patients, S. maltophilia may cause catheter-related bacteremia, pneumonia, soft tissue infection, meningitis, prosthetic valve endocarditis, and ocular infections. S. maltophilia is usually resistant to multiple antimicrobials, including expanded-spectrum penicillins, third-generation cephalosporins, carbapenems, aminoglycosides, and quinolones. Trimethoprim-sulfamethoxazole is the antimicrobial agent of choice for this pathogen but is bacteriostatic. Further, resistance to this agent is increasing. Certain combinations of antibiotics are synergistic and may be appropriate for patients harboring resistant organisms or with life-threatening infections. C1 [Muder, Robert R.] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA. [Muder, Robert R.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. RP Muder, RR (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect 111E U, Univ Dr C, Pittsburgh, PA 15240 USA. EM Robert.muder@va.gov NR 64 TC 15 Z9 17 U1 3 U2 4 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 EI 1098-9048 J9 SEMIN RESP CRIT CARE JI Semin. Respir. Crit. Care Med. PD DEC PY 2007 VL 28 IS 6 BP 672 EP 677 DI 10.1055/s-2007-996414 PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 248VV UT WOS:000252186100012 PM 18095231 ER PT J AU Hough, S AF Hough, Sigmund TI From the editor SO SEXUALITY AND DISABILITY LA English DT Editorial Material C1 VA Boston Healthcare Syst, Spinal Cord Injury Serv, W Roxbury, MA 02132 USA. RP Hough, S (reprint author), VA Boston Healthcare Syst, Spinal Cord Injury Serv, SCI 128,1400 VFW Pkwy, W Roxbury, MA 02132 USA. EM Sigmund_Hough@hms.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0146-1044 J9 SEX DISABIL JI Sex. Disabil. PD DEC PY 2007 VL 25 IS 4 BP 161 EP 161 DI 10.1007/s11195-007-9052-x PG 1 WC Rehabilitation SC Rehabilitation GA 232IQ UT WOS:000251012700001 ER PT J AU Hess, MJ Hough, S Tammaro, E AF Hess, Marika J. Hough, Sigmund Tammaro, Elizabeth TI The experience of four individuals with paraplegia enrolled in an outpatient interdisciplinary sexuality program SO SEXUALITY AND DISABILITY LA English DT Article DE spinal cord injury; paraplegia; sexuality program; interdisciplinary ID SPINAL-CORD-INJURY; SATISFACTION; MEN; ADJUSTMENT; HEALTH; QUALITY; WOMEN AB Spinal cord injury has a significant impact on an individual's physical, emotional, as well as sexual functioning. Four consecutive males with spinal cord injury were referred to the outpatient spinal cord injury sexuality program at an urban Veterans Affairs Medical Center and seen by an interdisciplinary team comprised of a nurse, physician and psychologist. They felt that their questions had been answered and their emotional well-being had been appropriately addressed in a respectful environment and effective process. Results suggest that availability of continued access to counseling regarding sexually related issues is very important and that patients can benefit from an interdisciplinary approach in addressing functional and emotional needs. C1 VA Boston Healthcare Syst, Spinal Cord Injury Serv, W Roxbury, MA 02132 USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. VA Boston Healthcare Syst, Psychol Serv, W Roxbury, MA USA. RP Hess, MJ (reprint author), VA Boston Healthcare Syst, Spinal Cord Injury Serv, SCI 128,1400 VFW Pkwy, W Roxbury, MA 02132 USA. EM Marika.Hess@va.gov NR 24 TC 2 Z9 3 U1 1 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0146-1044 J9 SEX DISABIL JI Sex. Disabil. PD DEC PY 2007 VL 25 IS 4 BP 189 EP 195 DI 10.1007/s11195-007-9055-7 PG 7 WC Rehabilitation SC Rehabilitation GA 232IQ UT WOS:000251012700004 ER PT J AU Hough, S AF Hough, Sigmund TI Sexual health SO SEXUALITY AND DISABILITY LA English DT Book Review C1 VA Boston Healthcare Syst, Spinal Cord Injury Serv SCI 128, Boston, MA 02132 USA. RP Hough, S (reprint author), VA Boston Healthcare Syst, Spinal Cord Injury Serv SCI 128, 1400 VFW Pkwy, Boston, MA 02132 USA. EM Sigmund_Hough@hms.harvard.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0146-1044 J9 SEX DISABIL JI Sex. Disabil. PD DEC PY 2007 VL 25 IS 4 BP 215 EP 216 DI 10.1007/s11195-007-9059-3 PG 2 WC Rehabilitation SC Rehabilitation GA 232IQ UT WOS:000251012700009 ER PT J AU Morgenthaler, TI Kapur, VK Brown, T Swick, TJ Alessi, C Aurora, N Boehlecke, B Chesson, AL Friedman, L Maganti, R Owens, J Pancer, J Zak, R AF Morgenthaler, Timothy I. Kapur, Vishesh K. Brown, Terry Swick, Todd J. Alessi, Cathy Aurora, Nisha Boehlecke, Brian Chesson, Andrew L., Jr. Friedman, Leah Maganti, Rama Owens, Judith Pancer, Jeffrey Zak, Rochelle CA Stand Practice Comm AASM TI Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin SO SLEEP LA English DT Article DE narcolepsy; idiopathic hypersomnia; recurrent hypersomnia; Parkinson's disease; myotonic dystrophy; multiple sclerosis; modafinil; sodium oxybate; amphetamine; methamphetamine; dextroamphetamine; methylphenidate; selegiline; tricyclic antidepressants; fluoxetine ID EXCESSIVE DAYTIME SLEEPINESS; ADMINISTERED SODIUM OXYBATE; DOUBLE-BLIND; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; OPEN-LABEL; MODAFINIL; PLACEBO; TRIAL; WAKEFULNESS AB These practice parameters pertain to the treatment of hypersomnias of central origin. They serve as both an update of previous practice parameters for the therapy of narcolepsy and as the first practice parameters to address treatment of other hypersomnias of central origin. They are based on evidence analyzed in the accompanying review paper. The specific disorders addressed by these parameters are narcolepsy (with cataplexy, without cataplexy, due to medical condition and unspecified), idiopathic hypersomnia (with long sleep time and without long sleep time), recurrent hypersomnia and hypersomnia due to medical condition. Successful treatment of hypersomnia of central origin requires an accurate diagnosis, individual tailoring of therapy to produce the fullest possible return of normal function, and regular follow-up to monitor response to treatment. Modafinil, sodium oxybate, amphetamine, methamphetamine, dextroamphetamine, methylphenidate, and selegiline are effective treatments for excessive sleepiness associated with narcolepsy, while tricyclic antidepressants and fluoxetine are effective treatments for cataplexy, sleep paralysis, and hypnagogic hallucinations; but the quality of published clinical evidence supporting them varies. Scheduled naps can be beneficial to combat sleepiness in narcolepsy patients. Based on available evidence, modafinil is an effective therapy for sleepiness due to idiopathic hypersomnia, Parkinson's disease, myotonic dystrophy, and multiple sclerosis. Based on evidence and/or long history of use in the therapy of narcolepsy committee consensus was that modafinil, amphetamine, methamphetamine, dextroamphetamine, and methylphenidate are reasonable options for the therapy of hypersomnias of central origin. C1 [Stand Practice Comm AASM] Amer Acad Sleep Med, Westbrook Corp Ctr 1, Westchester, IL 60154 USA. [Kapur, Vishesh K.] Univ Washington, Seattle, WA 98195 USA. [Brown, Terry] Murfreesboro Med Ctr, Murfreesboro, TN USA. [Swick, Todd J.] Houston Sleep Ctr, Houston, TX USA. [Alessi, Cathy] VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. [Alessi, Cathy] Univ Calif Los Angeles, Los Angeles, CA USA. [Aurora, Nisha; Zak, Rochelle] Mt Sinai Med Ctr, New York, NY 10029 USA. [Boehlecke, Brian] Univ N Carolina, Chapel Hill, NC USA. [Chesson, Andrew L., Jr.] Louisiana State Univ, Shreveport, LA 71105 USA. [Friedman, Leah] Stanford Univ, Stanford, CA 94305 USA. [Maganti, Rama] Barrow Neurol Inst, Phoenix, AZ 85013 USA. [Owens, Judith] Rhode Isl Hosp, Providence, RI USA. RP Morgenthaler, TI (reprint author), Mayo Clin, Rochester, MN 55905 USA. EM aasm@aasmnet.org RI Kapur, Vishesh/K-1054-2014; OI Kapur, Vishesh/0000-0002-5417-1097; Morgenthaler, Timothy/0000-0002-2614-3793 NR 35 TC 145 Z9 149 U1 0 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD DEC 1 PY 2007 VL 30 IS 12 BP 1705 EP 1711 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 243OM UT WOS:000251807200010 PM 18246980 ER PT J AU Thomas, RJ Mietus, JE Peng, CK Gilmartin, G Daly, RW Goldberger, AL Gottlieb, DJ AF Thomas, Robert Joseph Mietus, Joseph E. Peng, Chung-Kang Gilmartin, Geoffrey Daly, Robert W. Goldberger, Ary L. Gottlieb, Daniel J. TI Differentiating obstructive from central and complex sleep apnea using an automated electrocardiogram-based method SO SLEEP LA English DT Article DE complex sleep apnea; cardiopulmonary coupling; ECG; spectrogram; central ID POSITIVE AIRWAY PRESSURE; CHEYNE-STOKES RESPIRATION; CYCLIC ALTERNATING PATTERN; HEART-FAILURE; BLOOD-PRESSURE; OSCILLATIONS; HEALTH AB Study Objectives: Complex sleep apnea is defined as sleep disordered breathing secondary to simultaneous upper airway obstruction and respiratory control dysfunction. The objective of this study was to assess the utility of an electrocardiogram (ECG)-based cardiopulmonary coupling technique to distinguish obstructive from central or complex sleep apnea. Design: Analysis of archived polysomnographic datasets. Setting: A laboratory for computational signal analysis. Interventions: None. Measurements and Results: The PhysioNet Sleep Apnea Database, consisting of 70 polysomnograms including single-lead ECG signals of approximately 8 hours duration, was used to train an ECG-based measure of autonomic and respiratory interactions (cardiopulmonary coupling) to detect periods of apnea and hypopnea, based on the presence of elevated low-frequency coupling (e-LFC). In the PhysioNet BIDMC Congestive Heart Failure Database (ECGs of 15 subjects), a pattern of "narrow spectral band" e-LFC was especially common. The algorithm was then applied to the Sleep Heart Health Study-I dataset, to select the 15 records with the highest amounts of broad and narrow spectral band e-LFC. The latter spectral characteristic seemed to detect not only periods of central apnea, but also obstructive hypopneas with a periodic breathing pattern. Applying the algorithm to 77 sleep laboratory split-night studies showed that the presence of narrow band e-LFC predicted an increased sensitivity to induction of central apneas by positive airway pressure. Conclusions: ECG-based spectral analysis allows automated, operator-independent characterization of probable interactions between respiratory dyscontrol and upper airway anatomical obstruction. The clinical utility of spectrographic phenotyping, especially in predicting failure of positive airway pressure therapy, remains to be more thoroughly tested. C1 [Thomas, Robert Joseph; Gilmartin, Geoffrey] Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Pulm Off, Boston, MA 02215 USA. [Mietus, Joseph E.; Goldberger, Ary L.] Beth Israel Deaconess Med Ctr, Div Interdisciplinary Med & Biotechnol, Boston, MA 02215 USA. [Daly, Robert W.] Period Breathing Fdn, Wellesley Hills, MA USA. [Gottlieb, Daniel J.] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA. [Gottlieb, Daniel J.] VA Boston Healthcare Syst, W Roxbury, MA USA. RP Thomas, RJ (reprint author), Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Pulm Off, KB 023, Boston, MA 02215 USA. EM rthomas1@bidmc.harvard.edu RI Peng, Chung-Kang/E-1489-2011 OI Peng, Chung-Kang/0000-0003-3666-9833 FU NHLBI NIH HHS [R21 HL079248, R21HL079248]; NIBIB NIH HHS [U01 EB008577, U01EB008577] NR 34 TC 56 Z9 61 U1 1 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD DEC 1 PY 2007 VL 30 IS 12 BP 1756 EP 1769 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 243OM UT WOS:000251807200015 PM 18246985 ER PT J AU Talati, A Wickramaratne, PJ Pilowsky, DJ Alpert, JE Cerda, G Garber, J Hughes, CW King, CA Malloy, E Sood, AB Verdeli, H Trivedi, MH Rush, AJ Weissman, MM AF Talati, Ardesheer Wickramaratne, Priya J. Pilowsky, Daniel J. Alpert, Jonathan E. Cerda, Gabriele Garber, Judy Hughes, Carroll W. King, Cheryl A. Malloy, Erin Sood, A. Bela Verdeli, Helen Trivedi, Madhukar H. Rush, A. John Weissman, Myrna M. TI Remission of maternal depression and child symptoms among single mothers SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY LA English DT Article DE fathers; single mothers; depression; remission; social functioning; STAR*D ID STAR-ASTERISK-D; SEQUENCED TREATMENT ALTERNATIVES; RANDOMIZED CONTROLLED-TRIAL; ATTACHMENT STYLES; MAJOR DEPRESSION; QUICK INVENTORY; MARRIED MOTHERS; SOCIAL SUPPORT; RATING-SCALE; PRIMARY-CARE AB Offspring of depressed parents are at increased risk for depressive and other disorders. We recently found that when depressed mothers reached full remission over 3 months of treatment, a significant improvement in the children's disorders occurred. Since only a third of the mothers remitted, factors related to maternal remission rates, and thereby child outcomes, were important. This report examined the relationship of the presence of a father in the household to maternal depression remission and child outcomes. Maternal depression was measured using the 17-item Hamilton Rating Scale for Depression (HRSD17); social functioning was assessed using the Social Adjustment Scale-Self Report (SAS-SR). Children (age 7-17) were assessed independently, blind to maternal outcome, using the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS-PL) and the Child Global Assessment Scale (C-GAS). Single mothers (n = 50), as compared to those in two-parent households (n = 61), were more likely to discontinue treatment (31% vs. 16%, P = 0.04), and less likely to remit if they remained in treatment (20% vs. 43%, P = 0.013). These differences remained significant after adjusting for socioeconomic status and potential confounders, but were partially explained by the mother's pre-treatment social functioning. The reduction in child diagnoses following maternal remission was greater in two-parent than in single-parent households, although a formal test of interaction between the odds ratios was not significant. Single depressed mothers are more likely to drop out of treatment, and less likely to reach remission if they stay in treatment. This high-risk group requires vigorous treatment approaches. C1 Columbia Univ, Dept Psychiat, Unit 24, New York, NY 10032 USA. Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. Vanderbilt Univ, Dept Psychol & Human Dev, Nashville, TN USA. Univ Texas Dallas, SW Med Ctr, Dept Psychiat, Dallas, TX USA. Univ Michigan, Dept Psychol, Ann Arbor, MI USA. Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. Univ N Carolina, Med Ctr, Dept Psychiat, Chapel Hill, NC USA. Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA. Columbia Univ, Teachers Coll, Dept Counseling & Clin Psychol, New York, NY 10027 USA. Columbia Univ, Dept Epidemiol & Psychiat, New York, NY 10032 USA. RP Talati, A (reprint author), Columbia Univ, Dept Psychiat, Unit 24, 1051 Riverside Dr, New York, NY 10032 USA. EM at2071@columbia.edu OI Alpert, Jonathan/0000-0002-4332-908X; Rush, Augustus/0000-0003-2004-2382; Weissman, Myrna/0000-0003-3490-3075 FU NIMH NIH HHS [R01MH063852, K02 MH066249, K02 MH66249, N01 MH090003, R01 MH063852, R01 MH063852-01] NR 46 TC 21 Z9 24 U1 2 U2 8 PU DR DIETRICH STEINKOPFF VERLAG PI DARMSTADT PA PO BOX 10 04 62, D-64204 DARMSTADT, GERMANY SN 0933-7954 J9 SOC PSYCH PSYCH EPID JI Soc. Psychiatry Psychiatr. Epidemiol. PD DEC PY 2007 VL 42 IS 12 BP 962 EP U3 DI 10.1007/s00127-007-0262-4 PG 10 WC Psychiatry SC Psychiatry GA 237KX UT WOS:000251373700003 PM 17934684 ER PT J AU Basile, JN AF Basile, Jan N. TI Clinical considerations and practical recommendations for the primary care practitioner in the management of anemia of chronic kidney disease SO SOUTHERN MEDICAL JOURNAL LA English DT Article DE cardiovascular disease; chronic kidney disease; end-stage renal disease; erythropoiesis-stimulating agent; erythropoietin; hemoglobin; left ventricular hypertrophy ID CONGESTIVE-HEART-FAILURE; CHRONIC-RENAL-FAILURE; HUMAN-ERYTHROPOIETIN THERAPY; LEFT-VENTRICULAR MASS; RED-CELL APLASIA; EPOETIN-ALPHA; UNITED-STATES; PREDIALYSIS PATIENTS; CARDIOVASCULAR EVENTS; MEDICARE POPULATION AB Anemia is prevalent in patients with. chronic kidney disease (CKD) and is a risk factor for poor disease outcome. Anemia acts as a risk multiplier, significantly increasing the risk of death in anemic versus nonanemic CKD patients with similar comorbidities. Erythropoiesis-stimulating agents (ESA) are a mainstay for the treatment of anemia in renal patients on dialysis, but recent data suggests that earlier treatment of anemia in CKD may delay the onset of end-stage renal disease (ESRD) and decrease mortality. Nonetheless, anemia of CKD is under-recognized and undertreated during the period before initiation of dialysis, when anemia correction may have the greatest impact on disease outcome. This report describes anemia in CKD and its association with diabetes, cardiovascular disease, and poor disease outcome, and offers suggestions for the recognition and treatment of anemia of CKD in the primary care setting. C1 [Basile, Jan N.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Basile, Jan N.] Med Univ S Carolina, Charleston, SC USA. RP Basile, JN (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. EM Jan.Basile@med.va.gov NR 43 TC 7 Z9 9 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD DEC PY 2007 VL 100 IS 12 BP 1200 EP 1207 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 239ZQ UT WOS:000251557200008 PM 18090962 ER PT J AU Suit, H Delaney, T Bortfeld, T Trofimov, A Kooy, H Munzenrider, J Paganetti, H AF Suit, H. Delaney, T. Bortfeld, T. Trofimov, A. Kooy, H. Munzenrider, J. Paganetti, H. TI Protons vs photons SO STRAHLENTHERAPIE UND ONKOLOGIE LA English DT Meeting Abstract CT 8th International Meeting on Progress in Radio-Oncology (ICRO/OGRO 8) CY MAY 16-19, 2007 CL Salzburg, AUSTRIA DE radiotherapy; protons; photons; dose distribution ID THERAPY; BEAMS C1 [Suit, H.; Delaney, T.; Bortfeld, T.; Trofimov, A.; Kooy, H.; Munzenrider, J.; Paganetti, H.] Harvard Univ, Sch Med, Dept Radiat Oncol, Massachusetts Gen Hosp, Boston, MA 02115 USA. EM suit.herman@mgh.harvard.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU URBAN & VOGEL PI MUNICH PA NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY SN 0179-7158 J9 STRAHLENTHER ONKOL JI Strahlenther. Onkol. PD DEC PY 2007 VL 183 SU 2 MA E21 BP 80 EP 81 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 248IN UT WOS:000252146800038 ER PT J AU Wambersie, A Jones, DTL Suit, HD AF Wambersie, A. Jones, D. T. L. Suit, H. D. TI Presentation of the ICRU-IAEA joint report "Prescribing, Recording, and Reporting Proton-beam Therapy" SO STRAHLENTHERAPIE UND ONKOLOGIE LA English DT Meeting Abstract CT 8th International Meeting on Progress in Radio-Oncology (ICRO/OGRO 8) CY MAY 16-19, 2007 CL Salzburg, AUSTRIA DE protons; radiotherapy; RBE; LET; W value; dose- volume histograms; reporting C1 [Wambersie, A.] Univ Catholique Louvain, B-1200 Brussels, Belgium. [Jones, D. T. L.] iThemba LABS, Somerset W, South Africa. [Suit, H. D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. EM Andre.Wambersie@imre.ucl.ac.be NR 11 TC 0 Z9 0 U1 2 U2 5 PU URBAN & VOGEL PI MUNICH PA NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY SN 0179-7158 J9 STRAHLENTHER ONKOL JI Strahlenther. Onkol. PD DEC PY 2007 VL 183 SU 2 MA E25 BP 87 EP 89 PG 3 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 248IN UT WOS:000252146800042 ER PT J AU Moskowitz, MA Kurth, T AF Moskowitz, Michael A. Kurth, Tobias TI Blood vessels, migraine, and stroke SO STROKE LA English DT Editorial Material ID ISCHEMIC-STROKE; MTHFR; RISK; AURA; INFARCTS; WOMEN C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Stroke & Neurovasc Regulat Lab,Dept Radiol, Charlestown, MA USA. Brigham & Womens Hosp, Harvard Med Sch, Dept Med, Div Aging & Prevent Med, Boston, MA 02115 USA. Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. RP Moskowitz, MA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Stroke & Neurovasc Regulat Lab,Dept Radiol, Charlestown, MA USA. EM moskowitz@helix.mgh.harvard.edu RI Kurth, Tobias/A-9243-2012 OI Kurth, Tobias/0000-0001-7169-2620 NR 18 TC 8 Z9 8 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD DEC PY 2007 VL 38 IS 12 BP 3117 EP 3118 DI 10.1161/STROKEAHA.107.495770 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 235OG UT WOS:000251243600001 PM 17962586 ER PT J AU Toro, JJ Morales, M Loberiza, F Ochoa-Bayona, JL Freytes, CO AF Toro, Juan J. Morales, Manuel Loberiza, Fausto Ochoa-Bayona, Jose L. Freytes, Cesar O. TI Patterns of use of vascular access devices in patients undergoing hematopoietic stem cell transplantation: results of an international survey SO SUPPORTIVE CARE IN CANCER LA English DT Article; Proceedings Paper CT 46th Annual Meeting of the American-Society-of-Hematology CY DEC 04-07, 2004 CL San Diego, CA SP Amer Soc Hematol DE central venous catheter; catheter-related thrombosis; catheter-related infection; hematopoietic stem cell transplantation; health care surveys ID CENTRAL VENOUS CATHETER; CANCER-PATIENTS; PREVENTION; INFECTIONS; THROMBOSIS; HARVEST; VEIN AB Introduction There is limited information regarding of use of vascular access devices (VAD) in patients undergoing hematopoietic stem cell transplantation (HSCT). The frequent use of VAD in HSCT and its potential to cause morbidity requires understanding of the general use of VAD in HSCT. Materials and methods A World Wide Web-based 19-item questionnaire was designed to determine the patterns of use of VAD in patients undergoing HSCT. The questionnaire was sent via electronic mail to the directors of HSCT programs throughout the world. Results Of the 445 centers surveyed, 163 centers replied for a response rate of 37%. The most commonly used catheter for autologous peripheral blood stem cell (PBSC) harvest is the dual-lumen plasmapheresis/hemodialysis (62%). Of the institutions, 58% utilize the same catheter used for PBSC harvest to provide vascular access support during the transplant. Catheter-related blood stream infection (36%) and withdrawal occlusion (31%) were the most frequently encountered complications of VAD. Of the centers, 65% have established criteria for VAD removal when infection is suspected and 48% when occlusion is suspected. Discussion Our study demonstrated that there are similarities in the utilization of VAD but also wide differences in the standard procedures for the insertion and care of VAD in the transplant setting. More comprehensive studies are needed to assess the use of central venous catheters in transplant recipients. Important areas for future research include the impact of VAD utilization on the quality of life of transplant recipients and the final consequences of VAD complications. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Hematol, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Adm Med Ctr, Bone Marrow Transplant Unit, Dept Med, Div Hematol, San Antonio, TX 78229 USA. Hosp Univ N S de Candelaria, Dept Med, Med Oncol Serv, Santa Cruz de Tenerife 38010, Canary Isl, Spain. Univ Nebraska, Med Ctr, Dept Internal Med, Hematol Oncol Sect, Omaha, NE 68198 USA. RP Toro, JJ (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Hematol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM toro@uthscsa.edu NR 14 TC 4 Z9 4 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0941-4355 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD DEC PY 2007 VL 15 IS 12 BP 1375 EP 1383 DI 10.1007/s00520-007-0261-8 PG 9 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 229HR UT WOS:000250794400006 PM 17486374 ER PT J AU Stavrakis, AI Ituarte, PHG Ko, CY Yeh, MW AF Stavrakis, Alexandra I. Ituarte, Philip H. G. Ko, Clifford Y. Yeh, Michael W. TI Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery SO SURGERY LA English DT Article ID UNITED-STATES; PARATHYROID SURGERY; THYROID-SURGERY; COMPLICATIONS; PREVENTION; MANAGEMENT; MORTALITY; PATIENT; FUTURE AB Background. Surgeon experience correlates with improved outcomes for complex operations. Endocrine operations are increasingly performed in the outpatient setting, where outcomes have not been systematically studied. We examined the effect of surgeon volume on clinical and economic outcomes for thyroid, parathyroid, and adrenal surgery across inpatient and outpatient settings. Methods. New York and Florida state discharge data (2002) were studied. Surgeons were grouped by annual endocrine operative volume: Group A, I to 3 operations; B, 4 to 8;,C, 9 to 19; D, 20 to 50; E, 51 to 99; and F, >= 100. Multiple regression analyses were applied to analyze complications, length of stay (LOS), and total charges (TC), while controlling for comorbidity, economic factors, and hospital-centric variables. Results. We identified 13,997 discharges, with 28 % of operations performed on an outpatient basis (admission/discharge on same calendar day). For all cases, group A contributed disproportionately more complications (observed/expected [O/E] 1.65, P < .001) and Group F contributed disproportionately less (0.52; P < .001). High surgeon volume was associated with decreased LOS and reduced TC. Hospital volume had a negligible effect on outcomes. Conclusions. Surgeon volume correlates inversely with complication rates, LOS, and TC, in endocrine surgery. The lowest complication rates are achieved by surgeons performing >= 100 endocrine operations annually. C1 [Stavrakis, Alexandra I.; Ituarte, Philip H. G.; Ko, Clifford Y.; Yeh, Michael W.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Surg, Endocrine Surg Unit,Dept Surg, Los Angeles, CA 90095 USA. [Stavrakis, Alexandra I.; Ituarte, Philip H. G.; Ko, Clifford Y.; Yeh, Michael W.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Surg Outcomes & Qual, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. RP Yeh, MW (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Surg, Endocrine Surg Unit,Dept Surg, 10833 Le Conte Ave 72-228 CHS, Los Angeles, CA 90095 USA. EM myeh@mednet.ucla.edu NR 19 TC 132 Z9 134 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD DEC PY 2007 VL 142 IS 6 BP 887 EP 894 DI 10.1016/j.surg.2007.09.003 PG 8 WC Surgery SC Surgery GA 242QV UT WOS:000251741500019 PM 18063073 ER PT J AU Bilimoria, KY Bentrem, DJ Linn, JG Freel, A Yeh, JJ Stewart, AK Winchester, DP Ko, CY Talamonti, MS Sturgeon, C AF Bilimoria, Karl Y. Bentrem, David J. Linn, John G. Freel, Andrew Yeh, Jen Jen Stewart, Andrew K. Winchester, David P. Ko, Clifford Y. Talamonti, Mark S. Sturgeon, Cord TI Utilization of total thyroidectomy for papillary thyroid cancer in the United States SO SURGERY LA English DT Article; Proceedings Paper CT 28th Annual Meeting of the American-Association-of-Endocrine-Surgeons CY APR 28-MAY 01, 2007 CL Tucson, AZ SP Amer Assoc Endocrine Surg ID DATA-BASE; SURGERY; CARCINOMA; MANAGEMENT; SURVIVAL; OUTCOMES; QUALITY; VOLUME; TRENDS; EXTENT AB Background. Despite guidelines that recommend total thyroidectomy for Papillary thyroid cancer (PTC) greater than or equal to 1 cm, the extent Of surgery remains controversial. We examined surgical practice patterns for PTC greater than or equal to 1 cm and identified factors that predict the use of total thyroidectomy. Methods. Of 90,382 patients in the National Cancer Center Data Base (NCDB) with PTC from 1985 to 2003, 5 7,243 patients had tumors greater than or equal to 1 cm and underwent total thyroidectomy or lobectomy. Trends in extent Of surgery for PTC were examined over 2 decades. Logistic regression was used to identify factors that predict use of total thyroidectomy compared with lobectomy. Results. Use of total thyroidectomy increased from 70.8% in 1985 to 90.4% in 2003 (P < .0001). Patients were less likely to undergo total thyroidectomy if they were black, older than 45 years, had Medicare, had lower household incomes, or had Less education (P < .0001). Moreover, patients treated at high-volume or academic centers were more likely to undergo total thyroidectomy than were patients examined at low-volume or community hospitals (P < .0001). Conclusions. Use of total thyroidectomy for PTC greater than or equal to I cm increased over time. Differences in use of total thyroidectomy are related to Patient, tumor, and hospital factors and likely reflect disparities in access to care. C1 [Bilimoria, Karl Y.; Bentrem, David J.; Linn, John G.; Talamonti, Mark S.; Sturgeon, Cord] Northwestern Univ, NW Mem Hosp, Dept Surg, Div Surg Oncol, Chicago, IL 60611 USA. [Bilimoria, Karl Y.; Freel, Andrew; Stewart, Andrew K.; Winchester, David P.; Ko, Clifford Y.] Amer Coll Surgeons, Canc Program, Chicago, IL USA. [Yeh, Jen Jen] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Surg, Chapel Hill, NC USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Winchester, David P.] Evanston NW Healthcare, Dept Surg, Evanston, IL USA. RP Sturgeon, C (reprint author), Northwestern Univ, NW Mem Hosp, Dept Surg, Div Surg Oncol, 675 N St Clair St,Galter 10-105, Chicago, IL 60611 USA. EM csturgeo@nmh.org NR 27 TC 40 Z9 45 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD DEC PY 2007 VL 142 IS 6 BP 906 EP 913 DI 10.1016/j.surg.2007.09.002 PG 8 WC Surgery SC Surgery GA 242QV UT WOS:000251741500022 PM 18063075 ER PT J AU Curtis, CS Kudsk, KA AF Curtis, Caitlin S. Kudsk, Kenneth A. TI Nutrition support in pancreatitis SO SURGICAL CLINICS OF NORTH AMERICA LA English DT Article ID TOTAL PARENTERAL-NUTRITION; RANDOMIZED CONTROLLED-TRIAL; EARLY ENTERAL NUTRITION; DIABETES-MELLITUS; DIAGNOSIS; SAFETY AB Nutrition support is especially important in patients who have pancreatitis, as these patients have high metabolic needs and are usually unable to ingest sufficient calories from an oral diet because of pain or intestinal dysfunction. Clinicians must assess severity of the disease carefully, as initiation and timing of nutrition support are crucial. Depending on the severity, early nutrition support may be unnecessary, while late support ultimately may lead to worse outcomes. Route of nutrition support also plays an important role in treatment. The clinician has many alternatives from which to choose, including enteral nutrition given nasogastrically or nasojejunally, or parenteral nutrition given through a central line. This article explores the role of nutrition support in the outcome of pancreatitis and provides guidelines to aid the clinician in caring for patients who have acute and chronic pancreatitis. C1 [Kudsk, Kenneth A.] Univ Wisconsin Hosp & Clin, Dept Surg, Madison, WI 53792 USA. [Curtis, Caitlin S.] Univ Wisconsin Hosp & Clin, Dept Pharm, Madison, WI 53792 USA. [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Dept Surg, Vet Adm Surg Serv, Madison, WI USA. RP Kudsk, KA (reprint author), Univ Wisconsin Hosp & Clin, Dept Surg, 600 Highland Ave,CSC H4-734, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu NR 35 TC 7 Z9 9 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0039-6109 J9 SURG CLIN N AM JI Surg. Clin.-North Am. PD DEC PY 2007 VL 87 IS 6 BP 1403 EP + DI 10.1016/j.suc.2007.08.010 PG 14 WC Surgery SC Surgery GA 247CS UT WOS:000252055300008 PM 18053838 ER PT J AU Subramanian, A Dente, CJ Feliciano, DV AF Subramanian, Anuradha Dente, Christopher J. Feliciano, David V. TI The management of pancreatic trauma in the modern era SO SURGICAL CLINICS OF NORTH AMERICA LA English DT Article ID SEVERE DUODENAL INJURIES; DUCT INJURY; COMPUTED-TOMOGRAPHY; PYLORIC EXCLUSION; BLUNT INJURY; DIAGNOSIS; GASTROJEJUNOSTOMY; EXPERIENCE; WOUNDS AB Pancreatic trauma presents challenging diagnostic and therapeutic dilemmas to trauma surgeons. Injuries to the pancreas have been associated with reported morbidity rates approaching 45%. If treatment is delayed, these rates may increase to 60%. The integrity of the main pancreatic duct is the most important determinant of outcome after injury to the pancreas. Undiagnosed ductal disruptions produce secondary infections, fistulas, fluid collections, and prolonged stays in the intensive care unit and hospital. This article analyzes the epidemiology, diagnostic approaches, options for nonoperative and operative management, and outcome after blunt and penetrating pancreatic trauma. C1 [Subramanian, Anuradha] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, Houston, TX 77030 USA. [Dente, Christopher J.; Feliciano, David V.] Emory Univ, Sch Med, Grady Mem Hosp, Dept Surg, Atlanta, GA 30303 USA. RP Subramanian, A (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM anu.mouse@gmail.com NR 31 TC 44 Z9 53 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0039-6109 J9 SURG CLIN N AM JI Surg. Clin.-North Am. PD DEC PY 2007 VL 87 IS 6 BP 1515 EP + DI 10.1016/j.suc.2007.08.007 PG 19 WC Surgery SC Surgery GA 247CS UT WOS:000252055300015 PM 18053845 ER PT J AU Wang, JQ Tueckmantel, W Zhu, AJ Pellegrino, D Brownell, AL AF Wang, Ji-Quan Tueckmantel, Werner Zhu, Aijun Pellegrino, Daniela Brownell, Anna-Liisa TI Synthesis and preliminary biological evaluation of 3-[F-18]Fluoro-5-(2-pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5 SO SYNAPSE LA English DT Article DE metabotropic glutamate receptor; mGluR5; PET; [F-18]FPEB; radiotracer ID METABOTROPIC GLUTAMATE-RECEPTOR; IN-VIVO CHARACTERIZATION; MGLUR5 ANTAGONIST; ALLOSTERIC MODULATORS; SUBTYPE-5; POTENT; BRAIN; MPEP; DERIVATIVES; BINDING AB The metabotropic glutamate receptor subtype 5 (mGluR5) has been reported to be implicated in various neurological disorders in the central nervous system. To investigate physiological and pathological functions of mGluR5, noninvasive imaging in a living body with PET technology and an mGluR5-specific radiotracer is urgently needed. Here, we report the synthesis of 3-[F-18]fluoro-5-(2-pyridinylethynyl)benzonitrile ([F-18]FPEB) through a convenient thermal reaction as a highly specific PET radiotracer for mGluR5. The precursor and standard compounds were prepared by a coupling reaction catalyzed by palladium. Radiosynthesis of [F-18]]FPEB was performed using nitro as a leaving group replaced by [F-18]fluoride under conventional heating condition. Biodistribution, metabolite, and microPET studies were performed using Sprague-Dawley rats. Upto 30 mCi of [F-18]FPEB was obtained with a radiochemical yield of 5% and a specific activity of 1900 +/- 200 mCi/mu mol at the end of syntheses. Biodistribution showed rapid clearance from the blood pool and fast and steady accumulation of radioactivity into the brain. Metabolite studies indicated that only 22% of [F-18]FPEB remained in the blood system 10 min after administration, and that a metabolite existed which was much more polar than the parent tracer. MicroPET studies demonstrated that [F-18]FPEB accumulated specifically in mGluR5-rich regions of the brain such as striatum and hippocampus, and that blockade with 2-methyl-6-(2-phenylethynyl)pyridine (MPEP) and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) substantially reduced the activity uptake in these regions. Selectivity was investigated by blockage with 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-caroxamide (YM-298198), a specific antagonist for mGluR1. [F-18]FPEB was prepared conveniently and showed high specificity and selectivity toward mGluR5. It possesses the potential to be used in human studies to evaluate mGluR5 functions in various neurological disorders. C1 Massachusetts Gen Hosp, Dept Radiol, Expt PET Lab, Boston, MA 02114 USA. Acenta Discovery Inc, Tucson, AZ 85747 USA. RP Brownell, AL (reprint author), Massachusetts Gen Hosp, Bartlett hall 504R, Boston, MA 02114 USA. EM abrownell@partners.org FU NIBIB NIH HHS [EB001850] NR 35 TC 43 Z9 43 U1 0 U2 10 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0887-4476 J9 SYNAPSE JI Synapse PD DEC PY 2007 VL 61 IS 12 BP 951 EP 961 DI 10.1002/syn.20445 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 223FX UT WOS:000250356200002 PM 17787003 ER PT J AU Fonda, SJ Bursell, SE Lewis, DG Garren, J Hock, K Cavallerano, J AF Fonda, Stephanie J. Bursell, Sven-Erik Lewis, Drew G. Garren, Jeonifer Hock, Kristen Cavallerano, Jerry TI The relationship of a diabetes telehealth eye care program to standard eye care and change in diabetes health outcomes SO TELEMEDICINE JOURNAL AND E-HEALTH LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Telemedicine-Association CY MAY, 2006 CL San Diego, CA SP Amer Telemed Assoc ID PERCEIVED BARRIERS; RETINOPATHY; VISION; MANAGEMENT; COMPLICATIONS; ADHERENCE; DISEASE; STATES; LEVEL; MODEL AB Several studies suggest that telehealth eye care programs that combine retinal imaging, education, and some care management can improve patient adherence to annual, comprehensive eye examinations and follow-up treatments. Little is known, however, about whether such programs relate to other, more distal outcomes that affect diabetic eye disease, such as blood glucose control. This paper assesses the relationship of participation in a diabetes telehealth eye care program with standard, face-to-face eye care as well as improvements in other diabetes-related health outcomes. We conducted a retrospective study using data from electronic medical records of Joslin Diabetes Center (n = 13,752). The data span 2 years: baseline and follow-up. Subjects' eye care groups were no eye care, eye care outside of the clinic, standard eye care at the clinic, or participation in the Joslin Vision Network telehealth eye care program. We analyzed the relationship of participation in the telehealth eye care program at baseline to follow-up eye care groups and changes in hemoglobin A(1c), low density lipoprotein levels, and systolic blood pressure. The results show that participation in the telehealth eye care program was significantly correlated with whether subjects later obtained standard eye care, improvement in hemoglobin A1c, and improvement in low density lipoprotein. Thus, telehealth eye care programs that incorporate evaluation, education, and care planning are related to use of recommended eye care and improvements in certain diabetes-related health outcomes. Such programs can address the many aspects of care necessary to reduce risk of vision loss due to diabetic retinopathy and other diabetes- related complications. Future research might test hypotheses suggested by sociological and psychological theories regarding causation between participation in a telehealth eye care program and other diabetes care. C1 [Fonda, Stephanie J.; Bursell, Sven-Erik; Garren, Jeonifer; Hock, Kristen; Cavallerano, Jerry] Joslin Diabet Ctr, Boston, MA 02215 USA. [Fonda, Stephanie J.; Bursell, Sven-Erik] Harvard Univ, Sch Med, Boston, MA USA. [Lewis, Drew G.] Estenda Sol, Conshohocken, PA USA. RP Fonda, SJ (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM fondasj@gmail.com NR 32 TC 14 Z9 14 U1 0 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED J E-HEALTH JI Telemed. J. e-Health PD DEC PY 2007 VL 13 IS 6 BP 635 EP 644 DI 10.1089/tmj.2007.0025 PG 10 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 275JJ UT WOS:000254067400021 PM 18092923 ER PT J AU Huddle, TS AF Huddle, Thomas S. TI The limits of objective assessment of medical practice SO THEORETICAL MEDICINE AND BIOETHICS LA English DT Article DE clinical judgment; pay for performance; performance assessment; quality of care; rule-following; social practice ID QUALITY IMPROVEMENT; PERFORMANCE; PAY AB Medical work is increasingly being subjected to objective assessment as those who pay for it seek to grasp the quality of that work and how best to improve it. While objective measures have a role in the assessment of health care, I argue that this role is currently overestimated and that no human practice such as medicine can be fully comprehended by objective assessment. I suggest that the character of practices, in which formalizations are combined with judgment, requires that valid assessment involve the perspective of the skilled practitioner. Relying exclusively on objective measures in assessing health care will not only distort our assessments of it but lead to damage as the incentives of health care workers are directed away from the important aspects of their work that are not captured by objective measures. C1 [Huddle, Thomas S.] Univ Alabama, Div Gen Internal Med, Sch Med, Birmingham, AL 35294 USA. [Huddle, Thomas S.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Huddle, TS (reprint author), Univ Alabama, Div Gen Internal Med, Sch Med, 1530 3rd Ave S,FOT 720, Birmingham, AL 35294 USA. EM thuddle@uab.edu NR 22 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1386-7415 J9 THEOR MED BIOETH JI Theor. Med. Bioeth. PD DEC PY 2007 VL 28 IS 6 BP 487 EP 496 DI 10.1007/s11017-007-9054-9 PG 10 WC Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Social Issues; Biomedical Social Sciences GA 278DD UT WOS:000254262800002 PM 18322821 ER PT J AU Ameri, A Machiah, DK Tran, TT Channell, C Crenshaw, V Fernstrom, K Khachidze, M Duncan, A Fuchs, S Howard, TE AF Ameri, Afshin Machiah, Deepa K. Tran, Thuy T. Channell, Cynthia Crenshaw, Valerie Fernstrom, Karl Khachidze, Manana Duncan, Alexander Fuchs, Sebastien Howard, Tom E. TI A nonstop mutation in the factor (F)X gene of a severely haemorrhagic patient with complete absence of coagulation FX SO THROMBOSIS AND HAEMOSTASIS LA English DT Article DE autosomal recessive; congenital bleeding disorder; mRNA surveillance; F10-Augusta ID MESSENGER-RNA SURVEILLANCE; TERMINATION CODON; FACTOR-X; TRANSLATION; LACKING; TRANSCRIPTS; EUKARYOTES; DATABASE; 3'-END; YEAST AB We identified a previously unknown mutation by sequencing the factor (F)X gene in a severely haemorrhagic 14-year-old maleAfrican-American individual with undetectable plasma FX-activity and -antigen levels. This mutation, called F10-Augusta, was homozygote and is a combination of an 8bp insertion in flanking 3'-genomic-DNA and a 5bp terminal exon-8 deletion involving codons 437 and 438. Sequencing of RT-PCR and 3'-RACE products showed that the F10-Augusta transcript is normally processed but lacks an in-frame stop codon. An allele specific 3'-RACE-based RFLP assay demonstrated that the steady-state concentration of the mutant transcript was markedly lower than that of the wild-type message in total-RNA samples from the patient's unaffected heterozygous parents. The recently discovered nonstop decay mechanism, a component pathway of the mRNA surveillance system, is a possible explanation for the reduced concentration of the mutant FX transcript. This is the first report implying such a mechanism in the pathogenesis of inherited bleeding disorders. C1 [Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Lab Med, Los Angeles, CA 90073 USA. [Ameri, Afshin; Crenshaw, Valerie] Med Coll Georgia, Dept Pediat, Div Hematol & Oncol, Augusta, GA 30912 USA. [Machiah, Deepa K.; Tran, Thuy T.; Channell, Cynthia; Fernstrom, Karl; Khachidze, Manana; Duncan, Alexander; Fuchs, Sebastien; Howard, Tom E.] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA. [Machiah, Deepa K.; Tran, Thuy T.; Channell, Cynthia; Fernstrom, Karl; Khachidze, Manana; Duncan, Alexander; Fuchs, Sebastien; Howard, Tom E.] Emory Univ, Sch Med, Lab Med, Atlanta, GA 30322 USA. [Howard, Tom E.] SW Fdn Biomed Res, Dept Genet, San Antonio, TX 78284 USA. RP Howard, TE (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol, 11301 Wilshire Blvd,Bldg 500,Room 1254, Los Angeles, CA 90073 USA. EM tom.howard@va.gov FU NHLBI NIH HHS [K08-HL071130, R01-HL072533] NR 15 TC 10 Z9 13 U1 0 U2 3 PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN PI STUTTGART PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY SN 0340-6245 J9 THROMB HAEMOSTASIS JI Thromb. Haemost. PD DEC PY 2007 VL 98 IS 6 BP 1165 EP 1169 DI 10.1160/TH07-02-0125 PG 5 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 241WV UT WOS:000251687400004 PM 18064309 ER PT J AU Levy, DE Thorndike, AN Biener, L Rigotti, NA AF Levy, Douglas E. Thorndike, Anne N. Biener, Lois Rigotti, Nancy A. TI Use of nicotine replacement therapy to reduce or delay smoking but not to quit: prevalence and association with subsequent cessation efforts SO TOBACCO CONTROL LA English DT Article ID DOUBLE-BLIND; PERSISTENT USE; TRIAL; GUM; CIGARETTE; PATTERNS; SMOKERS; ABUSE AB Objective: To assess the prevalence of nicotine replacement therapy (NRT) use for purposes other than quitting smoking and examine the relation of this non-standard NRT use (NSNRT) with subsequent smoking cessation efforts. Design: A population based cohort study of adult smokers who were interviewed by telephone at baseline (2001-2) and at two year follow-up. The association between NSNRT use to cut down on smoking or to delay smoking before baseline and cessation attempts and smoking outcomes at two year follow-up was assessed using logistic regression to adjust for multiple potential confounding factors. Setting: Massachusetts, USA. Subjects: 1712 adult smokers in Massachusetts who were selected using a random digit dial telephone survey. Main outcome measures: Quit attempt in 12 months before follow-up, NRT use at quit attempt in 12 months before follow-up, smoking cessation by follow-up, or 50% reduction in cigarettes smoked per day between baseline and follow-up. Results: 18.7% of respondents reported ever having used NSNRT. In a multiple logistic regression analysis, there was no statistically significant association between past NSNRT use and quit attempts (ORcut down = 0.89, 95% CI 0.59 to 1.33; ORdelay = 1.29, 95% CI 0.73 to 2.29), smoking cessation (ORcut down = 0.74, 95% CI 0.43 to 1.24; ORdelay = 1.22, 95% CI 0.60 to 2.50) or 50% reduction in cigarettes smoked per day (ORcut down = 0.93, 95% CI 0.62 to 1.38; ORdelay = 0.80, 95% CI 0.43 to 1.49) at follow- up. Past use of NRT to cut down on cigarettes was associated with use of NRT at a follow-up quit attempt (ORcut down = 2.28, 95% CI 1.50 to 3.47) but past use of NRT to delay smoking was not (ORdelay = 1.25, 95% CI 0.67 to 2.34). Conclusions: Use of NRT for reasons other than quitting smoking may be more common than was previously estimated. This population based survey finds no strong evidence that NRT use for purposes other than quitting smoking is either harmful or helpful. C1 Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA. Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA. RP Levy, DE (reprint author), Massachusetts Gen Hosp, Inst Hlth Policy, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM douglas_levy@hms2.harvard.edu OI Biener, Lois/0000-0002-4130-8138 FU NCI NIH HHS [R01 CA086257, R01 CA086257-07, R01-CA86257]; NHLBI NIH HHS [K24-HL04440] NR 22 TC 17 Z9 17 U1 0 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0964-4563 J9 TOB CONTROL JI Tob. Control PD DEC PY 2007 VL 16 IS 6 BP 384 EP 389 DI 10.1136/tc.2007.021485 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 236DN UT WOS:000251283300015 PM 18048614 ER PT J AU Woods, SS Haskins, AE AF Woods, Susan Swartz Haskins, Amy E. TI Increasing reach of quitline services in a US state with comprehensive tobacco treatment SO TOBACCO CONTROL LA English DT Article ID MASS-MEDIA CAMPAIGN; TELEPHONE QUITLINE; THERAPY; SMOKERS AB Objective: The population reach of tobacco quitlines is an important measure of treatment seeking and penetration of services. Maine offers an opportunity to examine temporal changes in quitline reach and referral sources in the context of a comprehensive tobacco treatment programme. The impact of a $ 1.00 cigarette tax increase is also examined. Methods: This is a descriptive analysis of Maine Tobacco Helpline call volume September 2001 to December 2006. Annual reach was estimated using a cross sectional state surveillance survey. Weekly call volume was examined during 2005, a year of marked changes in tobacco taxes and quitline resources. Referral patterns were analysed yearly. Results: Maine's Tobacco Helpline observed more than a threefold increase in population reach during a four year interval, from 1.9% to over 6% per year. Calls increased substantially in 2005, concurrent with added hours of operation and a rise in the cigarette tax. Over time, callers increasingly reported hearing about the quitline from health professionals, from 10% in 2001 to 38% in 2006. Conclusions: Tobacco treatment programmes offering free nicotine therapy and professional medical education can drive quitline utilisation over time. Call volume can also be affected by quitline operational and policy changes that promote the reduction of tobacco use. C1 Maine Med Ctr, Ctr Tobacco Independence, Portland, ME 04102 USA. RP Woods, SS (reprint author), Portland VA Med Ctr, 3710 SW,US Vet Hosp Rd, Portland, OR 97239 USA. EM woodssus@ohsu.edu NR 13 TC 16 Z9 17 U1 1 U2 3 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0964-4563 J9 TOB CONTROL JI Tob. Control PD DEC PY 2007 VL 16 SU 1 BP I33 EP I36 DI 10.1136/tc.2007.019935 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 236DS UT WOS:000251283800008 PM 18048629 ER PT J AU Komers, R Schutzer, W Xue, H Oyama, TT Lindsley, JN Anderson, S AF Komers, Radko Schutzer, William Xue, Hong Oyama, Terry T. Lindsley, Jessie N. Anderson, Sharon TI Effects of p38 mitogen-activated protein kinase inhibition on blood pressure, renal hemodynamics, and renal vascular reactivity in normal and diabetic rats SO TRANSLATIONAL RESEARCH LA English DT Article ID ANGIOTENSIN-II; MAP-KINASE; CYCLOOXYGENASE-2 EXPRESSION; SMOOTH-MUSCLE; ORGAN DAMAGE; GLUCOSE; KIDNEY; HYPERTROPHY; CONTRACTION; PATHWAYS AB p38 mitogen-activated protein kinase (p38) has been implicated in mediating vascular smooth muscle and mesangial cell contraction in response to several vasoactive factors, including angiotensin II. Early stages of diabetic nephropathy are associated with renal hemodynamic changes that are, at least in part, attributable to the dysbalance of vasoactive factors that control afferent and efferent arteriolar tone resulting in increased glomerular capillary pressure. Vascular and renal p38 have been found to be activated in diabetes. Therefore, p38 may be involved in the control of systemic and renal hemodynamics in diabetes. To address this issue, mean arterial blood pressure (MAP), glomerular filtration rate (GFR, inulin clearance), renal plasma flow (RPF, PAH clearance), metabolic parameters, and plasma renin concentrations (PRC) were determined in streptozotocin-diabetic rats (DM), and in age-matched non-diabetic controls (C), administered with the p38 inhibitor SB 239063 (SB, 50 mg/bwt, p.o.) or with vehicle. Furthermore, renal vascular responses to p38 inhibition (SB 202190, 25 mu M) before and after stimulation with the endothelium-dependent vasodilator acetylcholine (ACh) were studied in vitro in tertiary branches of the renal artery from separate groups of DM and C rats, using a fixed support and a force transducer in a myograph system. SB treatment was associated with marked reductions in MAP and GFR in both C and DM rats, whereas RPF remained unchanged, as compared with vehicle-treated animals. Observed differences in MAP and renal hemodynamics were not associated with changes in urinary sodium excretion or PRC. Incubation of KCI-contracted renal arteries from both C and DM rats with the p38 inhibitor resulted in progressive and significant vasorelaxation. Also, vessels from control and diabetic rats treated with the p38 inhibitor exhibited enhancement of ACh-induced vasorelaxation. These data indicate the role of p38 in the control of systemic and renal hemodynamics both in normal and in diabetic rats. The observed effects of p38 inhibition could be mediated at least in part by enhancement of endothelium-dependent vasodilation. C1 Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. Portland VA Med Ctr, Res Serv, Portland, OR USA. Ctr Diabet, Inst Clin & Expt Med, Prague, Czech Republic. RP Komers, R (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, PP262,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM komersr@ohsu.edu FU NIDDK NIH HHS [DK 063231] NR 27 TC 17 Z9 17 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1931-5244 J9 TRANSL RES JI Transl. Res. PD DEC PY 2007 VL 150 IS 6 BP 343 EP 349 DI 10.1016/j.trsl.2007.07.001 PG 7 WC Medical Laboratory Technology; Medicine, General & Internal; Medicine, Research & Experimental SC Medical Laboratory Technology; General & Internal Medicine; Research & Experimental Medicine GA 236BZ UT WOS:000251279300003 PM 18022596 ER PT J AU Jaaskelainen, IP Ahveninen, J Belliveau, JW Raij, T Sams, M AF Jaaskelainen, Iiro P. Ahveninen, Jyrki Belliveau, John W. Raij, Tommi Sams, Mikko TI Short-term plasticity in auditory cognition SO TRENDS IN NEUROSCIENCES LA English DT Review ID SPECTROTEMPORAL RECEPTIVE-FIELDS; SUPERIOR TEMPORAL SULCUS; VISUAL SPEECH; MULTISENSORY INTEGRATION; ASSOCIATIVE MEMORY; RHESUS-MONKEY; HUMAN BRAIN; CORTEX; MODULATION; ATTENTION AB Converging lines of evidence suggest that auditory system short-term plasticity can enable several perceptual and cognitive functions that have been previously considered as relatively distinct phenomena. Here we review recent findings suggesting that auditory stimulation, auditory selective attention and cross-modal effects of visual stimulation each cause transient excitatory and (surround) inhibitory modulations in the auditory cortex. These modulations might adaptively tune hierarchically organized sound feature maps of the auditory cortex (e.g. tonotopy), thus filtering relevant sounds during rapidly changing environmental and task demands. This could support auditory sensory memory, pre-attentive detection of sound novelty, enhanced perception during selective attention, influence of visual processing on auditory perception and longer-term plastic changes associated with perceptual learning. C1 [Jaaskelainen, Iiro P.; Sams, Mikko] Helsinki Univ Technol, Lab Computat Engn, FIN-02015 Espoo, Finland. [Ahveninen, Jyrki; Belliveau, John W.; Raij, Tommi] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Jaaskelainen, IP (reprint author), Helsinki Univ Technol, Lab Computat Engn, POB 9203, FIN-02015 Espoo, Finland. EM iiro.jaaskelainen@tkk.fi RI Jaaskelainen, Iiro/C-7392-2012; Sams, Mikko/G-7060-2012 OI Jaaskelainen, Iiro/0000-0001-6001-6950; FU NCRR NIH HHS [P41 RR 14075]; NICHD NIH HHS [R01 HD 040712]; NINDS NIH HHS [R01 NS 037462, R01 NS 048279] NR 74 TC 69 Z9 70 U1 4 U2 17 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0166-2236 J9 TRENDS NEUROSCI JI Trends Neurosci. PD DEC PY 2007 VL 30 IS 12 BP 653 EP 661 DI 10.1016/j.tins.2007.09.003 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 242LV UT WOS:000251727500007 PM 17981345 ER PT J AU Corby, PM Bretz, WA Hart, TC Schork, NJ Wessel, J Lyons-Weiler, J Paster, BJ AF Corby, Patricia M. Bretz, Walter A. Hart, Thomas C. Schork, Nicholas J. Wessel, J. Lyons-Weiler, James Paster, Bruce J. TI Heritability of oral microbial species in caries-active and caries-free twins SO TWIN RESEARCH AND HUMAN GENETICS LA English DT Article ID MUTANS STREPTOCOCCI; MOLECULAR ANALYSIS; DENTAL-CARIES; CHILDHOOD CARIES; BACTERIAL-FLORA; ASSOCIATIONS; DECAY; MICE AB Oral microbes that colonize in the mouths of humans contribute to disease susceptibility, but it is unclear if host genetic factors mediate colonization. We therefore tested the hypothesis that the levels at which oral microbes colonize in the mouth are heritable. Dental plaque biofilms were sampled from intact tooth surfaces of 118 caries-free twins. An additional 86 caries-active twins were sampled for plaque from carious lesions and intact tooth surfaces. Using a reverse capture checkerboard assay the relative abundance of 82 bacterial species was determined. An integrative computational predictive model determined microbial abundance patterns of microbial species in caries-free twins as compared to caries-active twins. Heritability estimates were calculated for the relative microbial abundance levels of the microbial species in both groups. The levels of 10 species were significantly different in healthy individuals than in caries-active individuals, including, A. defectiva, S. parasanguinis, S. mitis/oralis, S. sanguinis, S. cristatus, S. salivarius, Streptococcus sp. clone CHO16, G. morbillorum and G. haemolysans. Moderate to high heritability estimates were found for these species (h(2) = 56%-80 %, p < .0001). Similarity of the overall oral microbial flora was also evident in caries-free twins from multivariate distance matrix regression analysis. It appears that genetic and/or familial factors significantly contribute to the colonization of oral beneficial species in twins. C1 [Corby, Patricia M.; Bretz, Walter A.] NYU, Coll Dent, New York, NY 10010 USA. [Schork, Nicholas J.; Wessel, J.] Univ Calif San Diego, Scripps Res Inst, San Diego, CA 92103 USA. [Schork, Nicholas J.; Wessel, J.] Univ Calif San Diego, Ctr Human Genet & Genom, San Diego, CA 92103 USA. [Hart, Thomas C.] NIDCR, NIH, Div Intramural Clin Res, Bethesda, MD USA. [Lyons-Weiler, James] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Paster, Bruce J.] Forsyth Inst, Boston, MA USA. RP Corby, PM (reprint author), NYU, Coll Dent, 345 E 24th St, New York, NY 10010 USA. EM patricia.corby@nyu.edu OI Wessel, Jennifer/0000-0002-7031-0085 FU NHLBI NIH HHS [U01 HL064777, HL/MH065571-02, HL070137-01, HL074730-02, R01 HL070137, R01 HL074730, U01 HL064777-06]; NIA NIH HHS [U19 AG023122, U19 AG023122-01]; NIDCR NIH HHS [DE14528, DE15351, K12 DE014528, R01 DE015351, R01 DE015351-03] NR 31 TC 21 Z9 22 U1 0 U2 6 PU AUSTRALIAN ACAD PRESS PI BOWEN HILLS PA 32 JEAYS ST, BOWEN HILLS, QLD 4006, AUSTRALIA SN 1832-4274 J9 TWIN RES HUM GENET JI Twin Res. Hum. Genet. PD DEC PY 2007 VL 10 IS 6 BP 821 EP 828 DI 10.1375/twin.10.6.821 PG 8 WC Genetics & Heredity; Obstetrics & Gynecology SC Genetics & Heredity; Obstetrics & Gynecology GA 242LW UT WOS:000251727600004 PM 18179393 ER PT J AU Roehrl, MHA Croft, WJ Liao, Q Wang, JY Kradin, RL AF Roehrl, Michael H. A. Croft, William J. Liao, Qing Wang, Julia Y. Kradin, Richard L. TI Hemorrhagic pulmonary oxalosis secondary to a noninvasive Aspergillus niger fungus ball SO VIRCHOWS ARCHIV LA English DT Article DE pulmonary oxalosis; Aspergillus niger; fungus ball; calcium oxalate monohydrate; metabolite; X-ray powder diffractometry; electron impact ionization mass spectrometry; crystal deposition; sarcoidosis ID OXALATE; SARCOIDOSIS; DEPOSITION; INFECTION AB We report a case of hemorrhagic pulmonary oxalosis secondary to a noninvasive Aspergillus niger fungus ball. A patient with cavitary lung disease and hemoptysis developed progressive lung infiltrates and intractable metabolic acidosis leading to death. At autopsy, aspergillomas were identified in both the right upper and middle lobes surrounded by a large rim of necrotic and hemorrhagic parenchyma. Microscopic examination showed extensive crystal deposition and vascular thrombosis. Fungal growth was limited to the intraluminal mycelia, and no tissue or blood vessel invasion was present. Remote crystal deposits were also localized in the absence of fungal organisms to the contralateral lung and to the tubules of both kidneys. The crystals were birefringent in polarized light and stained with colloidal iron. X-ray powder diffractometry and electron impact ionization mass spectrometry identified the crystals as calcium oxalate monohydrate. Furthermore, non-necrotizing granulomatous lesions were identified in the lungs, liver, and spleen, consistent with sarcoidosis, and may have predisposed this patient to developing pulmonary aspergillomas. C1 Massachusetts Gen Hosp, Dept Pathol & Lab Med, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Dept Pathol & Lab Med, Boston, MA 02115 USA. Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. RP Roehrl, MHA (reprint author), Massachusetts Gen Hosp, Dept Pathol & Lab Med, Warren 2,55 Fruit St, Boston, MA 02114 USA. EM michael_roehrl@hms.harvard.edu NR 12 TC 13 Z9 13 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0945-6317 J9 VIRCHOWS ARCH JI Virchows Arch. PD DEC PY 2007 VL 451 IS 6 BP 1067 EP 1073 DI 10.1007/s00428-007-0487-3 PG 7 WC Pathology SC Pathology GA 233PI UT WOS:000251102400009 PM 17786471 ER PT J AU Fagenholz, PJ Murray, AE Gutman, JA Findley, JK Harris, NS AF Fagenholz, Peter J. Murray, Alice E. Gutman, Jonathan A. Findley, John K. Harris, N. Stuart TI New-onset anxiety disorders at high altitude SO WILDERNESS & ENVIRONMENTAL MEDICINE LA English DT Article DE anxiety; anxiety disorder; altitude sickness; mountaineering; panic ID PANIC-ATTACKS; SLEEP AB Objective.-Studies on the neurologic effects of high-altitude travel have focused on psychometric and cognitive testing and the long-term effects of hypoxia on memory and cognition. Few authors have discussed overt clinical psychiatric illness during high-altitude travel, and those few have focused on patients with preexisting psychiatric diagnoses. We describe a series of patients with new-onset anxiety disorders at high altitude treated at the Himalayan Rescue Association (HRA) clinic in Pheriche, Nepal (4240 m) in the spring season of 2006. Methods.-We report on all 6 cases of anxiety-related illness diagnosed at the HRA Pheriche Clinic during the spring season, 2006. Three cases, representing the 3 discrete types of illness we encountered, are described in detail. Results.-Six of 76 foreign patients and none of the 224 Nepalis seen during the season had anxiety-related primary diagnoses. None of the 6 patients had a history of psychiatric disorders or anxiety-related problems at low altitude. Three of the 6 patients were seen after hours, and all 6 required multiple visits. We describe 3 types of anxiety-related disorders: limited-symptom panic attacks induced by nocturnal periodic breathing, excessive health-related anxiety, and excessive emotionality. Conclusions.-Anxiety-related illness requires significant use of medical resources by high-altitude travelers. Further research is needed to define the epidemiology of anxiety-related disorders at high altitude, to quantify the contributions of various etiologic factors, and to identify safe, effective treatments. C1 Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02140 USA. [Fagenholz, Peter J.] Massachusetts Gen Hosp, Harvard Med Sch, Dept Surg, Boston, MA 02114 USA. [Murray, Alice E.] New Royal Infirm Edinburgh, Dept Emergency, Edinburgh, Midlothian, Scotland. [Gutman, Jonathan A.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. RP Harris, NS (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Clin 115,55 Fruit St, Boston, MA 02140 USA. EM nsharris@partners.org NR 14 TC 13 Z9 13 U1 0 U2 2 PU ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS PI LAWRENCE PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA SN 1080-6032 J9 WILD ENVIRON MED JI Wildern. Environ. Med. PD WIN PY 2007 VL 18 IS 4 BP 312 EP 316 DI 10.1580/07-WEME-BR-102R1.1 PG 5 WC Public, Environmental & Occupational Health; Sport Sciences SC Public, Environmental & Occupational Health; Sport Sciences GA 244BB UT WOS:000251839900010 PM 18076297 ER PT J AU Merriam, LC Chess, A AF Merriam, Lillian C. Chess, Andrew TI cis-regulatory elements within the odorant receptor coding region SO CELL LA English DT Editorial Material ID MOUSE; EXPRESSION; CHOICE AB Complex regulatory mechanisms lead to the expression in each olfactory neuron of one allele of only one of the 1000 odorant receptor (OR) genes. In this issue, Nguyen et al. (2007) provide evidence that regulatory elements residing within the coding region of OR genes are involved in the singularity of OR gene expression. C1 [Merriam, Lillian C.; Chess, Andrew] Massachusetts Gen Hosp, Ctr Human Genet Res, Harvard Med Sch, Dept Med, Boston, MA 02114 USA. RP Chess, A (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Harvard Med Sch, Dept Med, Simchess Res Bldg,185 Cambridge St, Boston, MA 02114 USA. EM chess@chgr.mgh.harvard.edu NR 9 TC 5 Z9 5 U1 2 U2 2 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 J9 CELL JI Cell PD NOV 30 PY 2007 VL 131 IS 5 BP 844 EP 846 DI 10.1016/j.cell.2007.11.016 PG 4 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 243MG UT WOS:000251800900008 PM 18045531 ER PT J AU Massberg, S Schaerli, P Knezevic-Maramica, I Kollnberger, M Tubo, N Moseman, EA Huff, IV Junt, T Wagers, AJ Mazo, IB von Andrian, UH AF Massberg, Steffen Schaerli, Patrick Knezevic-Maramica, Irina Koellnberger, Maria Tubo, Noah Moseman, E. Ashley Huff, Ines V. Junt, Tobias Wagers, Amy J. Mazo, Irina B. von Andrian, Ulrich H. TI Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues SO CELL LA English DT Article ID STEM-CELLS; BONE-MARROW; SPHINGOSINE 1-PHOSPHATE; MICE DEFICIENT; T-CELLS; SPHINGOSINE-1-PHOSPHATE; MIGRATION; ORGANS; MOBILIZATION; AGONISTS AB Constitutive egress of bone marrow (BM)-resident hematopoietic stem and progenitor cells (HSPCs) into the blood is a well-established phenomenon, but the ultimate fate and functional relevance of circulating HSPCs is largely unknown. We show that mouse thoracic duct (TD) lymph contains HSPCs that possess short- and long-term multilineage reconstitution capacity. TD-derived HSPCs originate in the BM, enter the blood, and traffic to multiple peripheral organs, where they reside for at least 36 hr before entering draining lymphatics to return to the blood and, eventually, the BM. HSPC egress from extramedullary tissues into lymph depends on sphingosine-1-phosphate receptors. Migratory HSPCs proliferate within extramedullary tissues and give rise to tissue-resident myeloid cells, preferentially dendritic cells. HSPC differentiation is amplified upon exposure to Toll-like receptor agonists. Thus, HSPCs can survey peripheral organs and can foster the local production of tissue-resident innate immune cells under both steady-state conditions and in response to inflammatory signals. C1 [Massberg, Steffen; Schaerli, Patrick; Knezevic-Maramica, Irina; Koellnberger, Maria; Tubo, Noah; Moseman, E. Ashley; Huff, Ines V.; Junt, Tobias; Wagers, Amy J.; Mazo, Irina B.; von Andrian, Ulrich H.] Harvard Med Sch, Immune Dis Inst, Dept Pathol, Boston, MA 02115 USA. [Wagers, Amy J.] Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Boston, MA 02215 USA. [Wagers, Amy J.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA. RP von Andrian, UH (reprint author), Harvard Med Sch, Immune Dis Inst, Dept Pathol, Boston, MA 02115 USA. EM uva@hms.harvard.edu RI von Andrian, Ulrich/A-5775-2008 FU NCRR NIH HHS [S10 RR021190, S10 RR021190-010001]; NHLBI NIH HHS [P01 HL056949-11, HL56949, P01 HL056949, P01 HL056949-08, P01 HL056949-089001, P01 HL056949-09, P01 HL056949-099001, P01 HL056949-10, P01 HL056949-109001, P01 HL056949-119001, P01 HL056949-12, P01 HL056949-129001]; NIAID NIH HHS [AI061663, R01 AI061663, R01 AI061663-05, R01 AI069259, R01 AI069259-03, R01 AI072252, R01 AI072252-01]; NIAMS NIH HHS [AR42689, P30 AR042689] NR 40 TC 384 Z9 388 U1 2 U2 9 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 J9 CELL JI Cell PD NOV 30 PY 2007 VL 131 IS 5 BP 994 EP 1008 DI 10.1016/j.cell.2007.09.047 PG 15 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 243MG UT WOS:000251800900020 PM 18045540 ER PT J AU Mathew, LK Sengupta, S Kawakami, A Andreasen, EA Lohr, CV Loynes, CA Renshaw, SA Peterson, RT Tanguay, RL AF Mathew, Lijoy K. Sengupta, Sumitra Kawakami, Atsushi Andreasen, Eric A. Loehr, Christiane V. Loynes, Catherine A. Renshaw, Stephen A. Peterson, Randall T. Tanguay, Robert L. TI Unraveling tissue regeneration pathways using chemical genetics SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID GLUCOCORTICOID-RECEPTOR ISOFORMS; CAUDAL FIN REGENERATION; APPENDAGE REGENERATION; EXPRESSION ANALYSIS; ZEBRAFISH; MECHANISMS; DISCOVERY; GROWTH; INFLAMMATION; SPECIFICITY AB Identifying the molecular pathways that are required for regeneration remains one of the great challenges of regenerative medicine. Although genetic mutations have been useful for identifying some molecular pathways, small molecule probes of regenerative pathways might offer some advantages, including the ability to disrupt pathway function with precise temporal control. However, a vertebrate regeneration model amenable to rapid throughput small molecule screening is not currently available. We report here the development of a zebrafish early life stage fin regeneration model and its use in screening for small molecules that modulate tissue regeneration. By screening 2000 biologically active small molecules, we identified 17 that specifically inhibited regeneration. These compounds include a cluster of glucocorticoids, and we demonstrate that transient activation of the glucocorticoid receptor is sufficient to block regeneration, but only if activation occurs during wound healing/blastema formation. In addition, knockdown of the glucocorticoid receptor restores regenerative capability to nonregenerative, glucocorticoid-exposed zebrafish. To test whether the classical anti-inflammatory action of glucocorticoids is responsible for blocking regeneration, we prevented acute inflammation following amputation by antisense repression of the Pu.1 gene. Although loss of Pu.1 prevents the inflammatory response, regeneration is not affected. Collectively, these results indicate that signaling from exogenous glucocorticoids impairs blastema formation and limits regenerative capacity through an acute inflammation-independent mechanism. These studies also demonstrate the feasibility of exploiting chemical genetics to define the pathways that govern vertebrate regeneration. C1 Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA. Oregon State Univ, Environm Hlth Sci Ctr, Corvallis, OR 97331 USA. Oregon State Univ, Marine & Freshwater Biomed Sci Ctr, Corvallis, OR 97331 USA. Oregon State Univ, Dept Vet Med, Corvallis, OR 97331 USA. Tokyo Inst Technol, Dept Biol Informat, Yokohama, Kanagawa 2268501, Japan. Univ Sheffield, MRC, Ctr Dev & Biomed Genet, Sheffield S10 2TN, S Yorkshire, England. Massachusetts Gen Hosp, Dev Biol Lab, Cardiovasc Res Ctr, Charlestown, MA 02129 USA. RP Tanguay, RL (reprint author), Oregon State Univ, Dept Environm & Mol Toxicol, 1007 ALS, Corvallis, OR 97331 USA. EM robert.tanguay@oregonstate.edu RI Renshaw, Stephen/E-6192-2010 OI Renshaw, Stephen/0000-0003-1790-1641 FU Medical Research Council [G108/595]; NIEHS NIH HHS [ES00210, ES03850, ES10820, P30 ES000210, R01 ES010820] NR 46 TC 92 Z9 93 U1 0 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 30 PY 2007 VL 282 IS 48 BP 35202 EP 35210 DI 10.1074/jbc.M706640200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 234IR UT WOS:000251155200065 PM 17848559 ER PT J AU Shibolet, O Giallourakis, C Rosenberg, I Mueller, T Xavier, RJ Podolsky, DK AF Shibolet, Oren Giallourakis, Cosmas Rosenberg, Ian Mueller, Tobias Xavier, Ramnik J. Podolsky, Daniel K. TI AKAP13, a RhoA GTPase-specific guanine exchange factor, is a novel regulator of TLR2 signaling SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; VAV PROTEINS; RESPONSES; INVOLVEMENT; RECEPTOR-3; PATHOGENS; PATHWAY; BIOLOGY AB Members of the guanine exchange factor (GEF) family of scaffold proteins are involved in the integration of signal flow downstream of many receptors in adaptive immunity. However, the full complement of GEFs that function downstream of Toll-like receptors (TLRs) requires further identification and functional understanding. By systematically integrating expression profiles from immune and epithelial cells with functional studies, we demonstrate that protein kinase A anchoring protein 13 (AKAP13), a scaffold protein with GEF activity, is an activator of NF-kappa B downstream of TLR2 signaling. Stimulation of the human macrophage cell line THP-1 and epithelial cells with a TLR2 ligand caused a significant up-regulation in AKAP13 mRNA, corresponding to an increase in protein expression. Analysis of TLR2 reporter cell lines deficient in AKAP 13 expression revealed significantly reduced NF-kappa B activation and reduced secretion of interleukin-8 and MCP-1 in response to specific ligand stimulation. Furthermore, NF-kappa B activation was partially inhibited by a GEF-deficient AKAP13 mutant. AKAP13 was also involved in phosphorylation of JNK but not of extracellular signal-regulated kinase ERK1 and -2 following ligand stimulation. Together, our results suggest that AKAP13 plays a role in TLR2-mediated NF-kappa B activation and suggest that GEF-containing scaffold proteins may confer specificity to innate immune responses downstream of TLRs. C1 Massachusetts Gen Hosp, Gastroenterol Unit, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Podolsky, DK (reprint author), Massachusetts Gen Hosp, Gastroenterol Unit, Ctr Study Inflammatory Bowel Dis, Jackson Bldg,Rm 719,55 Fruit St, Boston, MA 02114 USA. EM dpodolsky@partners.org FU NIDDK NIH HHS [R01 DK060049, DK043351, DK060049, P30 DK040561, P30 DK040561-12] NR 36 TC 31 Z9 31 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 30 PY 2007 VL 282 IS 48 BP 35308 EP 35317 DI 10.1074/jbc.M704426200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 234IR UT WOS:000251155200074 PM 17878165 ER PT J AU Lee, SR Lok, J Rosell, A Kim, HY Murata, Y Atochin, D Huang, PL Wang, X Ayata, C Moskowitz, MA Lo, EH AF Lee, S. -R. Lok, J. Rosell, A. Kim, H. -Y. Murata, Y. Atochin, D. Huang, P. L. Wang, X. Ayata, C. Moskowitz, M. A. Lo, E. H. TI Reduction of hippocampal cell death and proteolytic responses in tissue plasminogen activator knockout mice after transient global cerebral ischemia SO NEUROSCIENCE LA English DT Article DE excitotoxicity; anolkis; neuron; caspase; matrix metalloproteinase ID DELAYED NEURONAL DEATH; MATRIX METALLOPROTEINASES; FOREBRAIN ISCHEMIA; GENE KNOCKOUT; BRAIN INJURY; MATRIX-METALLOPROTEINASE-9; DAMAGE; INDUCTION; CATHEPSIN; CALPAIN AB Knockout mice deficient in tissue plasminogen activator (tPA) are protected against hippocampal excitotoxicity. But it is unknown whether similar neuroprotection occurs after transient global cerebral ischemia, which is known to selectively affect the hippocampus. In this study, we tested the hypothesis that hippocampal cell death in tPA knockout mice would be reduced after transient global cerebral ischemia, and this neuroprotection would occur concomitantly with amelioration of both intra- and extracellular proteolytic cascades. Wild-type and tPA knockout mice were subjected to 20 min of transient bilateral occlusions of the common carotid arteries. Three days later, Nissl and terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling staining demonstrated that hippocampal cell death was significantly reduced in tPA knockout brains compared with wildtype brains. Caspase-3 and the two major brain gelatinases (matrix metalloproteinase (MMP)-9 and MMP-2) were assessed as representative measurements of intra- and extracellular proteolysis. Post-ischemic levels of caspase-3, MMP-9 and MMP-2 were similarly reduced in tPA knockouts compared with wild-type hippocampi. Taken together, these data suggest that endogenous tPA contributes to hippocampal injury after cerebral ischemia, and these pathophysiologic pathways may involve links to aberrant activation of caspases and MMPs. (c) 2007 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Lee, S. -R.; Lok, J.; Rosell, A.; Kim, H. -Y.; Murata, Y.; Wang, X.; Lo, E. H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Neuroprotect Res Lab, Boston, MA 02129 USA. [Lee, S. -R.; Lok, J.; Rosell, A.; Kim, H. -Y.; Murata, Y.; Wang, X.; Lo, E. H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Neuroprotect Res Lab, Boston, MA 02129 USA. [Lee, S. -R.] Keimyung Univ, Sch Med, Dept Pharmacol, Taegu, South Korea. [Rosell, A.] Massachusetts Gen Hosp, Div Pediat Critical Care Med, Boston, MA 02129 USA. [Atochin, D.; Huang, P. L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Boston, MA 02129 USA. [Ayata, C.; Moskowitz, M. A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Stroke & Neurovasc Regulat Ctr, Boston, MA 02129 USA. RP Lo, EH (reprint author), Neuroprotect Res Lab, MGH E 149-2401,13th St, Charlestown, MA 02129 USA. EM Lo@helix.mgh.harvard.edu RI Atochin, Dmitriy/Q-3150-2016 FU NINDS NIH HHS [P50-NS10828, R01 NS040529, R01-NS48422, R01 NS048422, P50 NS010828, P50 NS010828-320037, R01-NS40529, R01-NS37074, R01 NS056458, R01-NS56458, R01 NS037074, R01 NS048426-04, R01 NS033335, R01 NS033335-13, R01 NS048426] NR 36 TC 19 Z9 20 U1 0 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD NOV 30 PY 2007 VL 150 IS 1 BP 50 EP 57 DI 10.1016/j.neuroscience.2007.06.029 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 242AI UT WOS:000251696500007 PM 17936515 ER PT J AU Uschakov, A Gong, H McGinty, D Szymusiak, R AF Uschakov, A. Gong, H. McGinty, D. Szymusiak, R. TI Efferent projections from the median preoptic nucleus to sleep- and arousal-regulatory nuclei in the rat brain SO NEUROSCIENCE LA English DT Article DE locus coeruleus; hypothalamus; dorsal raphe; magnocellular preoptic area; basal forebrain ID BODY-FLUID HOMEOSTASIS; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; WAKING DISCHARGE PATTERNS; MONOAMINERGIC CELL GROUPS; SUBFORNICAL ORGAN; LAMINA-TERMINALIS; SUPRAOPTIC NUCLEUS; ANGIOTENSIN-II; C-FOS; AFFERENT CONNECTIONS AB The median preoptic nucleus (MnPO) has been implicated in the regulation of hydromineral balance and cardiovascular regulation. The MnPO also contains neurons that are active during sleep and in response to increasing homeostatic pressure for sleep. The potential role of these neurons in the regulation of arousal prompted an analysis of the efferent projections from the MnPO. Anterograde and retrograde neuroanatomical tracers were utilized to characterize the neural connectivity from the MnPO to several functionally important sleep- and arousal-regulatory neuronal systems in the rat brain. Anterograde terminal labeling from the MnPO was confirmed within the core and extended ventrolateral preoptic nucleus. Within the lateral hypothalamus, labeled axons were observed in close apposition to proximal and distal dendrites of hypocretin/orexin immunoreactive (IR) cells. Projections from the MnPO to the locus coeruleus were observed within and surrounding the tyrosine hydroxylase-IR cell cluster. Labeled axons from the MnPO were mostly observed within the lateral division of the dorsal raphe nucleus and heavily within the ventrolateral periaqueductal gray. Few anterogradely labeled appositions were present juxtaposed to choline acetyltransferase-IR somata within the magnocellular preoptic area. The use of retrogradely transported neuroanatomical tracers placed within the prospective efferent terminal fields supported and confirmed findings from the anterograde tracer experiments. These anatomical findings support the hypothesis that MnPO neurons function to promote sleep by inhibition of orexinergic and monoaminergic arousal systems and disinhibition of sleep regulatory neurons in the ventrolateral preoptic area. (c) 2007 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Uschakov, A.; Gong, H.; McGinty, D.; Szymusiak, R.] VA Greater Los Angeles Hlth Care Syst, Res Serv 151A3, North Hills, CA 91344 USA. [Gong, H.; McGinty, D.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Uschakov, A.; Szymusiak, R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90025 USA. [Szymusiak, R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90025 USA. RP Szymusiak, R (reprint author), VA Greater Los Angeles Hlth Care Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91344 USA. EM rszym@ucla.edu RI Sanguansri, Luz/B-6630-2011 OI Sanguansri, Luz/0000-0003-1908-7604 FU NHLBI NIH HHS [HL60296, P50 HL060296, P50 HL060296-100011]; NIMH NIH HHS [MH63323, R01 MH063323, R01 MH063323-06] NR 57 TC 51 Z9 53 U1 0 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD NOV 30 PY 2007 VL 150 IS 1 BP 104 EP 120 DI 10.1016/j.neuroscience.2007.05.055 PG 17 WC Neurosciences SC Neurosciences & Neurology GA 242AI UT WOS:000251696500013 PM 17928156 ER PT J AU Cunningham, JT Rodgers, JT Arlow, DH Vazquez, F Mootha, VK Puigserver, P AF Cunningham, John T. Rodgers, Joseph T. Arlow, Daniel H. Vazquez, Francisca Mootha, Vamsi K. Puigserver, Pere TI mTOR controls mitochondrial oxidative function through a YY1-PGC-1 alpha transcriptional complex SO NATURE LA English DT Article ID RENAL-TRANSPLANT PATIENTS; INSULIN-RESISTANCE; AMINO-ACID; ERR-ALPHA; IN-VIVO; METABOLISM; PATHWAY; CELL; IDENTIFICATION; COACTIVATORS AB Transcriptional complexes that contain peroxisome-proliferator-activated receptor coactivator (PGC)-1 alpha control mitochondrial oxidative function to maintain energy homeostasis in response to nutrient and hormonal signals(1,2). An important component in the energy and nutrient pathways is mammalian target of rapamycin (mTOR), a kinase that regulates cell growth, size and survival(3-5). However, it is unknown whether and how mTOR controls mitochondrial oxidative activities. Here we show that mTOR is necessary for the maintenance of mitochondrial oxidative function. In skeletal muscle tissues and cells, the mTOR inhibitor rapamycin decreased the gene expression of the mitochondrial transcriptional regulators PGC-1 alpha, oestrogen-related receptor a and nuclear respiratory factors, resulting in a decrease in mitochondrial gene expression and oxygen consumption. Using computational genomics, we identified the transcription factor yin-yang 1 (YY1) as a common target of mTOR and PGC-1 alpha. Knockdown of YY1 caused a significant decrease in mitochondrial gene expression and in respiration, and YY1 was required for rapamycin-dependent repression of those genes. Moreover, mTOR and raptor interacted with YY1, and inhibition of mTOR resulted in a failure of YY1 to interact with and be coactivated by PGC-1 alpha. We have therefore identified a mechanism by which a nutrient sensor (mTOR) balances energy metabolism by means of the transcriptional control of mitochondrial oxidative function. These results have important implications for our understanding of how these pathways might be altered in metabolic diseases and cancer. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Syst Biol, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA. MIT, Broad Inst, Cambridge, MA 02139 USA. Harvard Univ, Cambridge, MA 02139 USA. RP Puigserver, P (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM vamsi@hms.harvard.edu; pere_puigserver@dfci.harvard.edu NR 30 TC 545 Z9 565 U1 11 U2 55 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD NOV 29 PY 2007 VL 450 IS 7170 BP 736 EP U12 DI 10.1038/nature06322 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 235BY UT WOS:000251209700057 PM 18046414 ER PT J AU Semigran, MJ Stevenson, LW Passeri, JJ Stone, JR Madsen, JC AF Semigran, Marc J. Stevenson, Lynne Warner Passeri, Jonathan J. Stone, James R. Madsen, Joren C. TI A 47-year-old man with left ventricular dysfunction after heart transplantation - Moderate-to-severe atherosclerosis of the donor heart with thrombosis of the left anterior descending coronary artery and extensive anterior and septal myocardial infarction. Mild acute cellular rejection. Pericardial amyloid deposition. SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID CARDIAC TRANSPLANTATION; DISEASE; DEATH C1 Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA. Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA. RP Semigran, MJ (reprint author), Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. NR 16 TC 2 Z9 2 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 29 PY 2007 VL 357 IS 22 BP 2286 EP 2297 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 234PQ UT WOS:000251176400012 PM 18046033 ER PT J AU Bauer, S Duensing, A Demetri, GD Fletcher, JA AF Bauer, S. Duensing, A. Demetri, G. D. Fletcher, J. A. TI KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway SO ONCOGENE LA English DT Article DE KIT; oncogenic signaling; sarcoma; gastrointestinal; neoplasm; PI3-K ID C-KIT; ACQUIRED-RESISTANCE; MUTATIONS; MESYLATE; MUTANTS; INHIBITION; ACTIVATION; ABL AB Most gastrointestinal stromal tumor (GIST) patients respond to KIT inhibition with imatinib, yet will eventually exhibit resistance. Imatinib-resistance mechanisms are heterogeneous, and little is known about KIT functional roles in imatinib-resistant GIST. Biological consequences of biochemical inhibition of KIT, phospha-tidyl-inositol- 3-kinase (PI3-K), PLC gamma, MAPK/ERK kinase/mitogen-activated protein kinase (MEK/MAPK), mammalian target of rapamycin (mTOR) and JAK were determined by immunoblotting for protein activation, and by cell proliferation and apoptosis assays in GIST cell lines from imatinib-sensitive GIST (GIST882), imatinib-resistant GISTs (GIST430 and GIST48) and KIT-negative GIST (GIST62). KIT activation was 3- to 6-fold higher in GIST430 and GIST48 than in GIST882, whereas total KIT expression was comparable in these three GIST lines. In addition to the higher set point for KIT activation, GIST430 and GIST48 had intrinsic imatinib resistance. After treatment with 1 mu M imatinib, residual KIT activation was 6- and 2.8-fold higher in GIST430 and GIST48, respectively, compared to GIST882. In all GIST lines, cell growth arrest resulted from PI3-K inhibition, and - to a lesser extent - from MEK/MAPK and mTOR inhibition. Inhibition of JAK/STAT or PLC gamma did not affect cell proliferation. Similarly, only PI3-K inhibition resulted in substantial apoptosis in the imatinib-resistant GISTs. We conclude that GIST secondary KIT mutations can be associated with KIT hyperactivation and imatinib resistance. Targeting critical downstream signaling proteins, such as PI3-K, is a promising therapeutic strategy in imatinib-resistant GISTs. C1 Brigham & Womens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA USA. Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA. Harvard Med Sch, Ludwig Ctr, Dana Farber Canc Inst, Boston, MA USA. RP Bauer, S (reprint author), W German Canc Res Ctr, Dept Internal Med, Ctr Canc Res, Hufelandstr 55, D-45122 Essen, Germany. EM sebastian.bauer@uni-due.de; jflecher@partners.org RI Bauer, Sebastian/D-8120-2012; OI Bauer, Sebastian/0000-0001-5949-8120; Duensing, Anette/0000-0002-0168-4067 NR 29 TC 121 Z9 126 U1 0 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD NOV 29 PY 2007 VL 26 IS 54 BP 7560 EP 7568 DI 10.1038/sj.onc.1210558 PG 9 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 236DB UT WOS:000251282100008 PM 17546049 ER PT J AU McCarthy, D Lueras, P Bhide, PG AF McCarthy, Deirdre Lueras, Paula Bhide, Pradeep G. TI Elevated dopamine levels during gestation produce region-specific decreases in neurogenesis and subtle deficits in neuronal numbers SO BRAIN RESEARCH LA English DT Article DE ganglionic eminence; dopamine; neurogenesis; striatum; caudate-putamen; frontal cortex ID MOUSE CORPUS STRIATUM; PRECURSOR CELL-PROLIFERATION; LATERAL GANGLIONIC EMINENCE; DEVELOPING CEREBRAL-CORTEX; RECEPTOR MESSENGER-RNA; COCAINE BINDING-SITES; RAT BASAL GANGLIA; NEOCORTICAL NEURONOGENESIS; POSTNATAL-DEVELOPMENT; DEVELOPING BRAIN AB Dopamine levels in the fetal brain were increased by administering the dopamine precursor 3,4-dihydroxy-L-phenylalanine (L-DOPA) to pregnant mice in drinking water. The L-DOPA exposure decreased bromodeoxyuridine (BrdU) labeling in the lateral ganglionic eminence and frontal cortical neuroepithelium but not medial or caudal ganglionic eminences. The regional differences appear to reflect heterogeneity in precursor cells' responses to dopamine receptor activation. Relative numbers of E15-generated neurons were decreased at postnatal day 21 (P21) in the caudate-putamen, nucleus accumbens and frontal cortex but not globus pallidus in the L-DOPA group. TUNEL labeling did not show significant differences on PO, P7 or P14 in the caudate-putamen or frontal cortex, suggesting that cell death was not altered. Although virtually all cells in the P21 brains that were labeled with the E15 BrdU injection were NeuN-positive, stereological analyses showed no significant changes in total numbers of NeuN-positive or NeuN-negative cells in the P21 caudate-putamen or frontal cortex. Thus persisting deficits in neuronal numbers were evident in the L-DOPA group only by birth-dating analyses and not upon gross histological examination of brain sections or analysis of total numbers of neurons or glia. One explanation for this apparent discrepancy is that L-DOPA exposure decreased cell proliferation at ElS but not at E13. By E15, expansion of the neuroepithelial precursor pool is complete and any decrease in cell proliferation likely produces only marginal decreases in the total numbers of cells generated. Our L-DOPA exposure model may be pertinent to investigations of neurological dysfunction produced by developmental dopamine imbalance. (C) 2007 Elsevier B.V. All rights reserved. C1 [McCarthy, Deirdre; Lueras, Paula; Bhide, Pradeep G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02129 USA. RP Bhide, PG (reprint author), Massachusetts Gen Hosp, Dev Neurobiol, 149 13th St, Charlestown, MA 02129 USA. EM Bhide@helix.mgh.harvard.edu OI Bhide, Pradeep/0000-0003-4236-9415 FU NIDA NIH HHS [DA020796, R01 DA020796, R01 DA020796-02]; NINDS NIH HHS [P30 NS045776-05, NS043426, NS045776, P30 NS045776, R01 NS043426, R01 NS043426-05] NR 73 TC 20 Z9 20 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD NOV 28 PY 2007 VL 1182 BP 11 EP 25 DI 10.1016/j.brainres.2007.08.088 PG 15 WC Neurosciences SC Neurosciences & Neurology GA 242CS UT WOS:000251702700002 PM 17950709 ER PT J AU Jaffe, HW Valdiserri, RO De Cock, KM AF Jaffe, Harold W. Valdiserri, Ronald O. De Cock, Kevin M. TI The reemerging HIV/AIDS epidemic in men who have sex with men SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID UNITED-STATES; HIV-INFECTION; RISK BEHAVIORS; INTERVENTIONS; PREVENTION; RECOMMENDATIONS; TRENDS C1 Univ Oxford, Dept Publ Hlth, Oxford OX3 7LF, England. US Dept Vet Affairs, Off Publ Hlth & Environm Hazards, Washington, DC USA. WHO, Dept HIV AIDS, CH-1211 Geneva, Switzerland. RP Jaffe, HW (reprint author), Univ Oxford, Dept Publ Hlth, Old Rd Campus, Oxford OX3 7LF, England. EM harold.jaffe@dphpc.ox.ac.uk NR 23 TC 103 Z9 105 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 28 PY 2007 VL 298 IS 20 BP 2412 EP 2414 DI 10.1001/jama.298.20.2412 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 234KR UT WOS:000251163400023 PM 18042919 ER PT J AU Loewenstein, G Brennan, T Volpp, KG AF Loewenstein, George Brennan, Troyen Volpp, Kevin G. TI Asymmetric paternalism to improve health behaviors SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID SMOKING-CESSATION; ADHERENCE; ECONOMICS C1 Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA. Aetna Inc, Hartford, CT USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Wharton Sch, Dept Hlth Care Syst, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Loewenstein, G (reprint author), Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA. EM gl20@andrew.cmu.edu NR 18 TC 173 Z9 175 U1 6 U2 29 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 28 PY 2007 VL 298 IS 20 BP 2415 EP 2417 DI 10.1001/jama.298.20.2415 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 234KR UT WOS:000251163400024 PM 18042920 ER PT J AU Gutschalk, A Oxenham, AJ Micheyl, C Wilson, C Melcher, JR AF Gutschalk, Alexander Oxenham, Andrew J. Micheyl, Christophe Wilson, Courtenay Melcher, Jennifer R. TI Human cortical activity during streaming without spectral cues suggests a general neural substrate for auditory stream segregation SO JOURNAL OF NEUROSCIENCE LA English DT Article DE auditory cortex; scene analysis; stream segregation; fMRI; MEG; adaptation ID TONE SEQUENCES; FMRI ACTIVATION; COMPLEX TONES; PERCEPTUAL ORGANIZATION; FUNDAMENTAL-FREQUENCY; SONGBIRD FOREBRAIN; AWAKE MACAQUES; CORTEX; SOUNDS; PITCH AB The brain continuously disentangles competing sounds, such as two people speaking, and assigns them to distinct streams. Neural mechanisms have been proposed for streaming based on gross spectral differences between sounds, but not for streaming based on other nonspectral features. Here, human listeners were presented with sequences of harmonic complex tones that had identical spectral envelopes, and unresolved spectral fine structure, but one of two fundamental frequencies (f(0)) and pitches. As the f(0) difference between tones increased, listeners perceived the tones as being segregated into two streams ( one stream for each f(0)) and cortical activity measured with functional magnetic resonance imaging and magnetoencephalography increased. This trend was seen in primary cortex of Heschl's gyrus and in surrounding nonprimary areas. The results strongly resemble those for pure tones. Both the present and pure tone results may reflect neuronal forward suppression that diminishes as one or more features of successive sounds become increasingly different. We hypothesize that feature- specific forward suppression subserves streaming based on diverse perceptual cues and results in explicit neural representations for auditory streams within auditory cortex. C1 Univ Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany. Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. Harvard Med Sch, Dept Otol & Laryngol, Boston, MA 02115 USA. Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA. Harvard Univ, MIT, Div Hlth Sci & Technol, Program Speech & Hearing Biosci & Technol, Cambridge, MA 02139 USA. RP Gutschalk, A (reprint author), Univ Heidelberg, Dept Neurol, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany. EM Alexander_Gutschalk@med.uni-heidelberg.de OI Oxenham, Andrew/0000-0002-9365-1157 FU NCRR NIH HHS [P41RR14075]; NIDCD NIH HHS [P01DC00119, R01DC07657] NR 58 TC 48 Z9 48 U1 1 U2 15 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 28 PY 2007 VL 27 IS 48 BP 13074 EP 13081 DI 10.1523/JNEUROSCI.2299-07.2007 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 236IO UT WOS:000251296700004 PM 18045901 ER PT J AU Solt, K Ruesch, D Forman, SA Davies, PA Raines, DE AF Solt, Ken Ruesch, Dirk Forman, Stuart A. Davies, Paul A. Raines, Douglas E. TI Differential effects of serotonin and dopamine on human 5-HT3A receptor kinetics: Interpretation within an allosteric kinetic model SO JOURNAL OF NEUROSCIENCE LA English DT Article DE serotonin; dopamine; receptor; kinetic; gating; channel ID NICOTINIC ACETYLCHOLINE-RECEPTORS; CONSERVED M2 LEUCINE; GABA(A) RECEPTORS; DESENSITIZATION MECHANISM; ACTIVATION MECHANISM; RECOGNITION SITES; SUBUNIT; DEPENDS; BINDING; CELLS AB Serotonin type 3 (5-HT3) receptors are members of the pentameric Cys-loop superfamily of receptors that modulate synaptic neurotransmission. In response to agonist binding and unbinding, members of this superfamily undergo a series of conformational transitions that define their functional properties. In this study, we report the results of electrophysiological studies using rapid solution exchange designed to characterize and compare the actions of the high- efficacy agonist serotonin and the low-efficacy agonist dopamine on human 5-HT3A receptors expressed in human embryonic kidney HEK293 cells. In the case of serotonin, receptor activation rates varied with agonist concentration, and deactivation occurred as a single-exponential process with a rate that was similar to the maximal rate of desensitization. Receptors recovered slowly from long desensitizing pulses of serotonin with a sigmoidal time course. In the case of dopamine, receptor activation rates were independent of agonist concentration, receptor deactivation occurred as a complex process that was significantly faster than the maximal rate of desensitization, and recovery from desensitization occurred more quickly than with 5-HT and its time course was not sigmoidal. We developed an allosteric kinetic model for 5-HT3A receptor activation, deactivation, desensitization, and resensitization. Interpretation of our results within the context of this model indicated that the distinct modulatory actions of serotonin versus dopamine are largely attributable to the vastly different rates with which these two agonists induce channel opening and dissociate from open and desensitized states. C1 Univ Hosp Gissen Marburg, Dept Anesthesia & Crit Care, D-35033 Marburg, Germany. RP Raines, DE (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, 55 Fruit St, Boston, MA 02114 USA. EM draines@partners.org OI Davies, Paul/0000-0002-3973-3143; Solt, Ken/0000-0001-5328-2062 FU NIGMS NIH HHS [GM58448] NR 40 TC 28 Z9 28 U1 0 U2 4 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 28 PY 2007 VL 27 IS 48 BP 13151 EP 13160 DI 10.1523/JNEUROSCI.3772-07.2007 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 236IO UT WOS:000251296700012 PM 18045909 ER PT J AU Kveraga, K Boshyan, J Bar, M AF Kveraga, Kestutis Boshyan, Jasmine Bar, Moshe TI Magnocellular projections as the trigger of top-down facilitation in recognition SO JOURNAL OF NEUROSCIENCE LA English DT Article DE top-down facilitation; fMRI; inferotemporal cortex; object recognition; prefrontal cortex; effective connectivity; dynamic; causal models; vision ID VISUAL OBJECT RECOGNITION; EVENT-RELATED FMRI; MEDIAL PREFRONTAL CORTEX; SURFACE-BASED ANALYSIS; RHESUS-MONKEY; ORBITOFRONTAL CORTEX; FACIAL EXPRESSIONS; FRONTAL-LOBE; HUMAN BRAIN; CORTICOCORTICAL COMMUNICATION AB Object recognition is traditionally viewed as a hierarchical, bottom- up neural process. This view has been challenged recently by theoretical models and by findings indicating that top- down processes are involved in facilitating recognition. However, how such high- level information can be activated quickly enough to facilitate the bottom- up processing is yet unknown. We propose that such top- down facilitation is triggered by magnocellular information projected early and rapidly to the orbitofrontal cortex. Using human neuroimaging, we show that stimuli designed to bias processing toward the magnocellular pathway differentially activated the orbitofrontal cortex compared with parvocellular- biased stimuli. Although the magnocellular stimuli had a lower contrast than the parvocellular stimuli, they were recognized faster and just as accurately. Moreover, orbitofrontal activity predicted the performance advantage for the magnocellular, but not for the parvocellular- biased, stimuli, whereas the opposite was true in the fusiform gyrus. Last, analyses of effective connectivity using dynamic causal modeling showed that magnocellular- biased stimuli significantly activated pathways from occipital visual cortex to orbitofrontal cortex and from orbitofrontal cortex to fusiform gyrus. Conversely, parvocellular- biased stimuli significantly activated a pathway from the occipital visual cortex to fusiform gyrus. Our findings support the proposal that fast magnocellular projections linking early visual and inferotemporal object recognition regions with the orbitofrontal cortex facilitate object recognition by enabling the generation of early predictions. C1 Massachusetts Gen Hosp, Harvard Med Sch, Athinoula A Martinos Ctr Biomed imaging, Charlestown, MA 02129 USA. RP Bar, M (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Martinos Ctr, 149 13th St, Charlestown, MA 02129 USA. EM bar@nmr.mgh.harvard.edu FU NCRR NIH HHS [5P41RR014075]; NINDS NIH HHS [NS44319, NS50615] NR 81 TC 183 Z9 190 U1 8 U2 21 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 28 PY 2007 VL 27 IS 48 BP 13232 EP 13240 DI 10.1523/JNEUROSCI.3481-07.2007 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 236IO UT WOS:000251296700020 PM 18045917 ER PT J AU Jaff, MR Constant, J Campbell, LA Lipicky, R Potomic, N Creager, M Cadden, S Sternlicht, A Hiatt, WR AF Jaff, Michael R. Constant, John Campbell, Lee Anne Lipicky, Ray Potomic, North Creager, Mark Cadden, Suzanne Sternlicht, Andrew Hiatt, William R. TI Prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication (IC) and other endpoints in Chlamydia seropositive patients (the PROVIDENCE-1 trial) SO CIRCULATION LA English DT Meeting Abstract CT 80th Annual Scientific Session of the American-Heart-Association CY NOV 04-07, 2007 CL Orlando, FL SP Amer Heart Assoc C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. PRA Int, Victoria, BC, Canada. Univ Washington, Seattle, WA 98195 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. ActivBiotics Inc, Mississauga, ON, Canada. Univ Colorado, Denver, CO 80202 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 27 PY 2007 VL 116 IS 22 BP 2632 EP 2632 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 235HP UT WOS:000251224700039 ER PT J AU de Lemos, JA Morrow, DA Blazing, MA Jarolim, P Wiviott, SD Sabatine, MS Califf, RM Braunwald, E AF de Lemos, James A. Morrow, David A. Blazing, Michael A. Jarolim, Petr Wiviott, Stephen D. Sabatine, Marc S. Califf, Robert M. Braunwald, Eugene TI Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID C-REACTIVE PROTEIN; RANDOMIZED CONTROLLED-TRIAL; TO-Z TRIAL; CARDIOVASCULAR-DISEASE; RHEUMATOID-ARTHRITIS; NATRIURETIC PEPTIDE; PROGNOSTIC VALUE; ARTERY-DISEASE; HEART-DISEASE; PLASMA-LEVELS AB Objectives This study sought to determine whether the novel biomarker monocyte chemoattractant protein (MCP)-1 adds prognostic value to standard risk assessment tools and biomarkers after acute coronary syndromes (ACS). Background Monocyte chemoattractant protein-1 is a chemokine recruiting signal for monocytes that may function as both a mediator and biomarker of ACS. Methods Monocyte chemoattractant protein-1 was measured at baseline (n = 4,244), 4 months (n = 3,603), and 12 months (n = 2,950), and correlated with clinical events in the Z phase of the A to Z (Aggrastat to Zocor) trial, which compared early intensive versus delayed and less intensive statin therapy after ACS. Results Rates of death and the composite end points of death or myocardial infarction (MI); death, MI, or heart failure; and cardiovascular death, MI, readmission for ACS, or stroke increased across baseline quartiles of MCP-1 and among patients with MCP-1 greater than versus less than or equal to the pre-specified threshold of 238 pg/ml (p < 0.01 for each). After adjustment for standard risk predictors and levels of C-reactive protein and B-type natriuretic peptide, MCP-1 >238 pg/ml remained independently associated with mortality (hazard ratio 2.16; 95% confidence interval 1.54 to 3.02) and with each composite end point, and increased the C-statistic of the fully adjusted mortality model from 0.76 to 0.78 (p < 0.0001). A value of MCP-1 >238 pg/ml at the 4-month follow-up visit was also independently associated with mortality after 4 months (hazard ratio 1.76; 95% confidence interval 1.12 to 2.76). Elevated MCP-1 levels did not identify patients who derived incremental benefit from intensive statin therapy. Conclusions Monocyte chemoattractant protein-1 provides independent prognostic value in the acute and chronic phases after ACS and merits further evaluation as a prognostic marker and potential therapeutic target. C1 Univ Texas Southwestern Med Ctr, Dallas, TX 75390 USA. Univ Texas Southwestern Med Ctr, Cardiovasc Clin Res Ctr, Dallas, TX USA. Brigham & Womens Hosp, Dept Pathol, TIMI Study Grp, Boston, MA 02115 USA. Duke Clin Res Inst, Durham, NC USA. RP de Lemos, JA (reprint author), Univ Texas Southwestern Med Ctr, 5909 Harry Hines Blvd,HA 9-108, Dallas, TX 75390 USA. EM james.delemos@utsouthwestern.edu NR 28 TC 90 Z9 91 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 27 PY 2007 VL 50 IS 22 BP 2117 EP 2124 DI 10.1016/j.jacc.2007.06.057 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 236CZ UT WOS:000251281900003 PM 18036447 ER PT J AU Gunzler, SA Shakil, S Carlson, NE Nutt, JG Meshul, CK AF Gunzler, Steven A. Shakil, Saate Carlson, Nichole E. Nutt, John G. Meshul, Charles K. TI Low doses of apomorphine transiently reduce locomotor activity in MPTP-treated mice SO NEUROSCIENCE LETTERS LA English DT Article DE Parkinson disease; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; apomorphine; levodopa; locomotion ID RECEPTOR KNOCKOUT MICE; PARKINSONS-DISEASE; L-DOPA; C57BL/6 MICE; LEVODOPA; AGONISTS; MOTOR; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMPHETAMINE; SENSITIVITY AB Parkinson's disease patients sometimes experience deterioration of motor function to below their baseline "off" state, termed the "super-off" state. We used low subthreshold (0.05 mg/kg) to threshold (0.10 and 0.20 mg/kg) doses of apomorphine to demonstrate the "super-off" state in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-lesioned mice. Twenty-four mice were randomized to receive apomorphine or vehicle. Within 20 min of administration, 0.10 and 0.20 mg/kg apomorphine-treated mice had less locomotion than controls. At the 100 min time point, 0.10 mg/kg apomorphine-treated mice had greater locomotion than controls. One week of suprathreshold levodopa pretreatment did not alter the response to these low apomorphine doses. Our results Suggest that low doses of apomorphine can initially depress locomotion and subsequently stimulate locomotion, in a manner similar to what is seen in Parkinson's disease patients. (C) 2007 Elsevier Ireland Ltd. All rights reserved. C1 Univ Hosp, Case Med Ctr, Movemet Disorder Ctr, Neurol Inst, Cleveland, OH 44106 USA. Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA. Portland VA Med Ctr, Parkinson Disease Res Educ & Clin Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Parkinson Ctr Oregon, Portland, OR 97201 USA. Portland VA Med Ctr, Res Serv, Neurocytol Lab, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Div Biostat, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Behav Neurosci & Pathol, Portland, OR 97201 USA. RP Gunzler, SA (reprint author), Univ Hosp, Case Med Ctr, Movemet Disorder Ctr, Neurol Inst, 111000 Euclid Ave, Cleveland, OH 44106 USA. EM gunzlers@ohsu.edu FU NCRR NIH HHS [UL1 RR024140 01] NR 18 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD NOV 27 PY 2007 VL 428 IS 2-3 BP 64 EP 67 DI 10.1016/j.neulet.2007.09.049 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 237EA UT WOS:000251355100003 PM 17964074 ER PT J AU Di Carlo, D Irimia, D Tompkins, RG Toner, M AF Di Carlo, Dino Irimia, Daniel Tompkins, Ronald G. Toner, Mehmet TI Continuous inertial focusing, ordering, and separation of particles in microchannels SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE cell manipulation; dean flow; filtration; hydrodynamic lift; microfluidics ID FINITE-REYNOLDS-NUMBER; MICROFLUIDIC DEVICE; POISEUILLE FLOW; BLOOD-PLASMA; FRACTIONATION; CELLS; CHANNEL; FORCES; SPHERE; CHIP AB Under laminar flow conditions, when no external forces are applied, particles are generally thought to follow fluid streamlines. Contrary to this perspective, we observe that flowing particles migrate across streamlines in a continuous, predictable, and accurate manner in microchannels experiencing laminar flows. The migration is attributed to lift forces on particles that are observed when inertial aspects of the flow become significant. We identified symmetric and asymmetric channel geometries that provide additional inertial forces that bias particular equilibrium positions to create continuous streams of ordered particles precisely positioned in three spatial dimensions. We were able to order particles laterally, within the transverse plane of the channel, with > 80-nm accuracy, and longitudinally, in regular chains along the direction of flow. A fourth dimension of rotational alignment was observed for discoidal red blood cells. Unexpectedly, ordering appears to be independent of particle buoyant direction, suggesting only minor centrifugal contributions. Theoretical analysis indicates the physical principles are operational over a range of channel and particle length scales. The ability to differentially order particles of different sizes, continuously, at high rates, and without external forces in microchannels is expected to have a broad range of applications in continuous bioparticle separation, high-throughput cytometry, and large-scale filtration systems. C1 Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Toner, M (reprint author), Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Boston, MA 02114 USA. EM mtoner@hms.harvard.edu OI Irimia, Daniel/0000-0001-7347-2082 FU NIBIB NIH HHS [P41 EB002503] NR 27 TC 487 Z9 487 U1 36 U2 332 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 27 PY 2007 VL 104 IS 48 BP 18892 EP 18897 DI 10.1073/pnas.0704958104 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 239DK UT WOS:000251498700006 PM 18025477 ER PT J AU Ramon-Maiques, S Kuo, AJ Carney, D Matthews, AGW Oettinger, MA Gozani, O Yang, W AF Ramon-Maiques, Santiago Kuo, Alex J. Carney, Dylan Matthews, Adam G. W. Oettinger, Marjorie A. Gozani, Or Yang, Wei TI The plant homeodomain finger of RAG2 recognizes histone H3 methylated at both lysine-4 and arginine-2 SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE H3K4me; regulation; V(D)J recombination; H3R2me; SCID ID V(D)J RECOMBINATION; PHD FINGER; STRUCTURAL BASIS; C-TERMINUS; CHROMATIN MODIFICATIONS; MOLECULAR-BASIS; B-CELL; GENE; DOMAIN; CHROMODOMAIN AB Recombination activating gene (RAG) 1 and RAG2 together catalyze V(D)J gene rearrangement in lymphocytes as the first step in the assembly and maturation of antigen receptors. RAG2 contains a plant homeodomain (PHD) near its C terminus (RAG2-PHD) that recognizes histone H3 methylated at lysine 4 (H3K4me) and influences V(D)J recombination. We report here crystal structures of RAG2-PHD alone and complexed with five modified H3 peptides. Two aspects of RAG2-PHD are unique. First, in the absence of the modified peptide, a peptide N-terminal to RAG2-PHD occupies the substrate-binding site, which may reflect an autoregulatory mechanism. Second, in contrast to other H3K4me3-binding PHD domains, RAG2-PHD substitutes a carboxylate that interacts with arginine 2 (112) with a Tyr, resulting in binding to H3K4me3 that is enhanced rather than inhibited by dimethylation of R2. Five residues involved in histone H3 recognition were found mutated in severe combined immunodeficiency (SCID) patients. Disruption of the RAG2-PHD structure appears to lead to the absence of T and B lymphocytes, whereas failure to bind H3K4me3 is linked to Omenn Syndrome. This work provides a molecular basis for chromatin-dependent gene recombination and presents a single protein domain that simultaneously recognizes two distinct histone modifications, revealing added complexity in the read-out of combinatorial histone modifications. C1 NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA. Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA. Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. RP Yang, W (reprint author), NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA. EM wei.yang@nih.gov RI Yang, Wei/D-4926-2011 OI Yang, Wei/0000-0002-3591-2195 FU Intramural NIH HHS NR 50 TC 131 Z9 132 U1 0 U2 8 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 27 PY 2007 VL 104 IS 48 BP 18993 EP 18998 DI 10.1073/pnas.0709170104 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 239DK UT WOS:000251498700024 PM 18025461 ER PT J AU Andrabi, S Gjoerup, OV Kean, JA Roberts, TM Schaffhausen, B AF Andrabi, Shaida Gjoerup, Ole V. Kean, Jennifer A. Roberts, Thomas M. Schaffhausen, Brian TI Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE apoptosis; cancer; DNA tumor virus ID HUMAN CELL-TRANSFORMATION; SMALL-T-ANTIGEN; APOPTOSIS; SURVIVAL; IDENTIFICATION; NUCLEAR; KINASE; MTOR; PHOSPHORYLATION; INVOLVEMENT AB Here, we show how targeting protein phosphatase 2A (PP2A), a key regulator of cellular protein phosphorylation, can either induce or prevent apoptosis depending on what other signals the cell is receiving. The oncoprotein polyoma small T interacts with PP2A to regulate survival. in the presence of growth factors, small T induces apoptosis. Akt activity, which usually promotes survival, is required for this death response, because inhibitors of Akt or P13 kinase protect cells from death. The activation of Akt under these conditions is partial, characterized by T308 phosphorylation but not S473 phosphorylation. in the absence of growth factors, small T protects from cell death. Here, small T uses PP2A to promote phosphorylation of Akt on both T308 and S473. This effect results in a different pattern of phosphorylation of Akt substrates and shifts Akt from a proapoptotic (presence of growth factors) to an antiapoptotic mode (absence of growth factors). An intriguing possibility is that Akt phosphorylation could be therapeutically disregulated to decrease the survival of cancer cells. C1 Tufts Univ, Sackler Sch Grad Biomed Sci, Sch Med, Dept Biochem, Boston, MA 02111 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA. RP Schaffhausen, B (reprint author), 136 Harrison Ave, Boston, MA 02111 USA. EM brian.schaffhausen@tufts.edu FU NCI NIH HHS [CA30002, CA34722, P01 CA050661, P01-CA50661, R01 CA030002, R01 CA034722, R37 CA030002] NR 33 TC 58 Z9 61 U1 0 U2 2 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 27 PY 2007 VL 104 IS 48 BP 19011 EP 19016 DI 10.1073/pnas.0706696104 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 239DK UT WOS:000251498700027 PM 18006659 ER PT J AU Nelson, EJ Chowdhury, A Harris, JB Begum, YA Chowdhury, F Khan, AI LaRocque, RC Bishop, AL Ryan, ET Camilli, A Qadri, F Calderwood, SB AF Nelson, Eric J. Chowdhury, Ashrafuzzaman Harris, Jason B. Begum, Yasmin A. Chowdhury, Fahima Khan, Ashraful I. LaRocque, Regina C. Bishop, Anne L. Ryan, Edward T. Camilli, Andrew Qadri, Firdausi Calderwood, Stephen B. TI Complexity of rice-water stool from patients with Vibrio cholerae plays a role in the transmission of infectious diarrhea SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE bacteriophage; biofilm; darkfield; mucin ID RURAL EAST PAKISTAN; VACCINE FIELD-TRIAL; ANTIBODY TITRE; IMMUNE-RESPONSES; ENDEMIC CHOLERA; BANGLADESH; O139; POPULATION; CHEMOTAXIS; EPIDEMICS AB At the International Centre for Diarrhoeal Disease Research, Bangladesh, one-half of the rice-water stool samples that were culture-positive for Vibrio cholerae did not contain motile V. cholerae by standard darkfield microscopy and were defined as darkfield-negative (DF-). We evaluated the host and microbial factors associated with DF status, as well as the impact of DF status on transmission. Viable counts of V. cholerae in DF- stools were three logs lower than in DF+ stools, although DF- and DF+ stools had similar direct counts of V. cholerae by microscopy. In DF- samples, non-V cholerae bacteria outnumbered V. cholerae 10:1. Lytic V. cholerae bacteriophage were present in 90% of DF- samples compared with 35% of DF+ samples, suggesting that bacteriophage may limit culture-positive patients from producing DF+ stools. V. cholerae in DF- and DF+ samples were found both planktonically and in distinct nonplanktonic populations; the distribution of organisms between these compartments did not differ appreciably between DF- and DF+ stools. This biology may impact transmission because epidemiological data suggested that household contacts of a DF+ index case were at greater risk of infection with V. cholerae. We propose a model in which V. cholerae multiply in the small intestine to produce a fluid niche that is dominated by V. cholerae. If lytic phage are present, viable counts of V. cholerae drop, stools become DF-, other microorganisms bloom, and cholera transmission is reduced. C1 Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. Tufts Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02111 USA. Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA. Int Ctr Diarrhoeal Dis Res, Div Sci Lab, Dhaka 1212, Bangladesh. Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. RP Calderwood, SB (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Gray Jackson 504,55 Fruit St, Boston, MA 02114 USA. EM scalderwood@partners.org FU FIC NIH HHS [K01 TW007409, D43 TW005572, K01 TW007144]; NIAID NIH HHS [R01 AI 055058, R01 AI055058, R03 AI063079, T32 AI007061, U01 AI 058935, U01 AI058935] NR 34 TC 24 Z9 24 U1 0 U2 5 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 27 PY 2007 VL 104 IS 48 BP 19091 EP 19096 DI 10.1073/pnas.0706352104 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 239DK UT WOS:000251498700042 PM 18024592 ER PT J AU Diswall, M Angstrom, J Schuurman, HJ Dor, FJMF Rydberg, L Breimer, ME AF Diswall, Mette Angstrom, Jonas Schuurman, Henk-Jan Dor, Frank J. M. F. Rydberg, Lennart Breimer, Michael E. TI Studies on glycolipid antigens in small intestine and pancreas from alpha 1,3-galactosyltransferase knockout miniature swine SO TRANSPLANTATION LA English DT Article DE alpha 1,3-galactosyltransferase; gal antigens; glycosphingolipids; knockout; pig tissues; xenotransplantation ID HANGANUTZIU-DEICHER ANTIGENS; N-GLYCOLYLNEURAMINIC ACID; PERIODATE-RESORCINOL METHOD; MONOCLONAL-ANTIBODY; STRUCTURAL CHARACTERIZATION; SIALIC ACIDS; GLYCOSPHINGOLIPIDS; PIGS; GENE; EXPRESSION AB Background. To avoid hyperacute rejection of xeno-organs, alpha 1,3-galactosyltransferase knockout (GaIT-KO) pigs have been produced. Gal alpha 1,3Gal determinant elimination may expose cryptic carbohydrate antigens and/or generate new antigens. This is the first biochemical study of carbohydrate antigens in GaIT-KO pig organs. Methods. Neutral and acidic glycolipids were isolated from small intestine and pancreas of two GaIT-KO and one wild-type (WT) pig. Glycolipid immune reactivity was tested on thin-layer chromatograms. Small intestine neutral glycolipids were separated by high-performance liquid chromatography and selected fractions were analyzed by proton nuclear magnetic resonance spectroscopy. Total gangliosides were quantified on thin-layer chromatograms and in microtiter wells. Results. Using Gal alpha 1,3nLc4 glycolipid reference, total Gal alpha 1,3Gal glycolipid antigens in the WT animal was estimated at about 30 mu g (small intestine) and 3 mu g (pancreas) per gram of dry tissue. Gal alpha 1,3Gal determinants were not detected in GaIT-KO tissues at a detection limit of less than 0.25% (small intestine) and 0.5% (pancreas) of the WT tissues. lsoglobotriaosylceramide (iGb3) was absent but trace amounts of Fuc-iGb3 was found in both GalT-KO and WT pig small intestine. Blood group H type 2 core saccharide compounds were increased in GalT-KO pancreas. Total amount of gangliosides was decreased in GalT-KO tissues. The alpha 1,3-galactosyltransferase acceptor, N-acetyllactosamine determinant, was not increased in GaIT-KO tissues. Human serum antibodies reacted with WT organ Gal alpha 1,3Gal antigens and gangliosides, of which the ganglioside reactivity remained in GalT-KO tissues. Conclusions. Knockout of porcine alpha 1,3-galactosyltransferase gene results in elimination of Gal alpha 1,3Gal -terminated glycolipid compounds. GaIT-KO genetic modification did not produce new compensatory glycolipid compounds reactive with human serum antibodies. C1 Sahlgrens Univ Hosp, Dept Surg, S-41345 Gothenburg, Sweden. Sahlgrens Univ Hosp, Dept Clin Chem & Transfus Med, S-41345 Gothenburg, Sweden. Immerge Biotherapeut Inc, Cambridge, MA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA. Erasmus MC, Dept Surg, Rotterdam, Netherlands. RP Breimer, ME (reprint author), Sahlgrens Univ Hosp, Dept Surg, S-41345 Gothenburg, Sweden. EM michael.breimer@gu.se RI Dor, Frank/E-1032-2013 OI Dor, Frank/0000-0001-7845-3075 NR 46 TC 26 Z9 27 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2007 VL 84 IS 10 BP 1348 EP 1356 DI 10.1097/01.tp.0000287599.46165.15 PG 9 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 236OC UT WOS:000251311300018 PM 18049121 ER PT J AU Fan, VS Ramsey, SD Giardino, ND Make, BJ Emery, CF Diaz, PT Benditt, JO Mosenifar, Z McKenna, R Curtis, JL Fishman, AP Martinez, FJ AF Fan, Vincent S. Ramsey, Scott D. Giardino, Nicholas D. Make, Barry J. Emery, Charles F. Diaz, Phillip T. Benditt, Joshua O. Mosenifar, Zab McKenna, Robert, Jr. Curtis, Jeffrey L. Fishman, Alfred P. Martinez, Fernando J. CA NETT Res Grp TI Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID AIR-FLOW OBSTRUCTION; QUALITY-OF-LIFE; MYOCARDIAL-INFARCTION; SOCIAL SUPPORT; HEALTH-STATUS; LUNG-VOLUME; REDUCTION SURGERY; RANDOMIZED-TRIAL; SEVERE EMPHYSEMA; UNSTABLE ANGINA AB Background: We sought to determine whether depressive or anxiety symptoms are associated with chronic obstructive pulmonary disease (COPD) hospitalization or mortality. These data were collected as part of the National Emphysema Treatment Trial (NETT), a randomized controlled trial of lung volume reduction surgery vs continued medical treatment conducted at 17 clinics across the United States between January 29, 1998, and July 31, 2002. Methods: Prospective cohort study among participants in the NETT with emphysema and severe airflow limitation who were randomized to medical therapy. Primary outcomes were 1- and 3-year mortality, as well as COPD or respiratory-related hospitalization or emergency department visit during the 1-year follow-up period. Of 610 patients randomized to medical therapy, complete data on hospitalization and mortality were available for 3 years of follow-up for 603 patients (98.9%). Results: Depressive symptoms were assessed using the Beck Depression Inventory (BDI) questionnaire, and anxiety was assessed using the State-Trait Anxiety Inventory. Among 610 subjects, 40.8% had at least mild to moderate depressive symptoms. Patients in the highest quintile of BDI score (BDI score, >= 15) had an increased risk of respiratory hospitalization in unadjusted analysis compared with patients in the lowest quintile (BDI score, < 5) (odds ratio [OR], 2.26; 95% confidence interval [CI], 1.30-3.93). After adjustment for disease severity, this relationship was no longer statistically significant. The adjusted risk of 3-year mortality was increased among those in the highest quintile of BDI score (OR, 2.74; 95% CI, 1.42-5.29) compared with those in the lowest quintile. Anxiety was not associated with hospitalization or mortality in this population. Conclusions: Depressive symptoms are common in patients with severe COPD and are treated in few subjects. Depressive symptoms are associated with increased risk for 3-year mortality but not 1-year mortality or hospitalization. C1 Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. Univ Washington, Fred Hutchinson Canc Res Ctr, Canc Technol Assesment Grp, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA USA. Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Univ Colorado, Div Pulm & Crit Care Med, Denver, CO 80309 USA. Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA. Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA. Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Fan, VS (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, 1660 S Columbian Way, Seattle, WA 98108 USA. EM vfan@u.washington.edu OI Curtis, Jeffrey/0000-0001-5191-4847 FU NHLBI NIH HHS [N01HR76102, N01HR76101, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR76110, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, N01HR76119] NR 51 TC 82 Z9 85 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 26 PY 2007 VL 167 IS 21 BP 2345 EP 2353 DI 10.1001/archinte.167.21.2345 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 235EU UT WOS:000251217100012 PM 18039994 ER PT J AU Chan, A Fuchs, CS AF Chan, Andrew Fuchs, Charles S. TI A possible overestimation of the effect of aspirin- Reply SO ARCHIVES OF INTERNAL MEDICINE LA English DT Editorial Material ID MORTALITY C1 Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. RP Chan, A (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St, GRJ 722, Boston, MA 02114 USA. EM archan@partners.org NR 3 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 26 PY 2007 VL 167 IS 21 BP 2373 EP 2373 DI 10.1001/archinte.167.21.2373 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 235EU UT WOS:000251217100026 ER PT J AU Du, XJ Woodcock, EA Kiriazis, H Pretorius, L Ming, ZQ Sadoshima, J Shioi, T Izumo, S Dart, AM Jennings, GL McMullen, JR AF Du, Xiao-Jun Woodcock, Elizabeth A. Kiriazis, Helen Pretorius, Lynette Ming, Ziqiu Sadoshima, Junichi Shioi, Tetsuo Izumo, Seigo Dart, Anthony M. Jennings, Garry L. McMullen, Julie R. TI Atrial fibrillation and conduction blockade in a mouse model of dilated cardiomyopathy with reduced phosphoinositide 3-kinase activity SO CIRCULATION RESEARCH LA English DT Meeting Abstract CT 80th Annual Scientific Session of the American-Heart-Association CY NOV 04-07, 2007 CL Orlando, FL SP Amer Heart Assoc C1 Baker Heart Rsch Inst, Melbourne, Vic, Australia. Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA. Harvard Univ, Sch Med, BIDMC, Boston, MA USA. Novartis Inst BioMed Rsch, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7330 J9 CIRC RES JI Circ.Res. PD NOV 26 PY 2007 VL 101 IS 11 MA 4008 BP 1206 EP 1207 PG 2 WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Hematology GA 235HS UT WOS:000251225000028 ER PT J AU Kathiresan, S Melander, O Guiducci, C Surti, A Burtt, NP Rieder, MJ Cooper, GM Roos, C Voight, BF Havulinna, AS Hedner, T Berglund, G Vartiainen, E Jousilahti, P Hedblad, B Newton-Cheh, C Salomaa, V Peltonen, L Groop, L Altshuler, DM Orho-Melander, M AF Kathiresan, Sekar Melander, Olle Guiducci, Candace Surti, Aarti Burtt, Noel P. Rieder, Mark J. Cooper, Gregory M. Roos, Charlotta Voight, Benjamin F. Havulinna, Aki S. Hedner, Thomas Berglund, Goran Vartiainen, Erkki Jousilahti, Pekka Hedblad, Bo Newton-Cheh, Christopher Salomaa, Veikko Peltonen, Leena Groop, Leif Altshuler, David M. Orho-Melander, Marju TI Common DNA sequence variants at six new loci with varied effects on blood lipids in humans SO CIRCULATION RESEARCH LA English DT Meeting Abstract CT 80th Annual Scientific Session of the American-Heart-Association CY NOV 04-07, 2007 CL Orlando, FL SP Amer Heart Assoc C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Lund Univ, Malmo, Sweden. Harvard Univ, MIT, Broad Inst, Cambridge, MA 02138 USA. Univ Washington, Seattle, WA 98195 USA. Natl Publ Hlth Inst, KTL, Helsinki, Finland. Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden. Univ Helsinki, Helsinki, Finland. RI Altshuler, David/A-4476-2009 OI Altshuler, David/0000-0002-7250-4107 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7330 J9 CIRC RES JI Circ.Res. PD NOV 26 PY 2007 VL 101 IS 11 MA 4011 BP 1207 EP 1207 PG 1 WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Hematology GA 235HS UT WOS:000251225000031 ER PT J AU Lichterfeld, M Kavanagh, DG Williams, KL Moza, B Mui, SK Miura, T Sivamurthy, R Allgaier, R Pereyra, F Trocha, A Feeney, M Gandhi, RT Rosenberg, ES Altfeld, M Allen, TM Allen, R Walker, BD Sundberg, EJ Yu, XG AF Lichterfeld, Mathias Kavanagh, Daniel G. Williams, Katie L. Moza, Beenu Mui, Stanley K. Miura, Toshiyuki Sivamurthy, Rohini Allgaier, Rachel Pereyra, Florencia Trocha, Alicja Feeney, Margaret Gandhi, Rajesh T. Rosenberg, Eric S. Altfeld, Marcus Allen, Todd M. Allen, Rachel Walker, Bruce D. Sundberg, Eric J. Yu, Xu G. TI A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells SO JOURNAL OF EXPERIMENTAL MEDICINE LA English DT Article ID CLASS-I MOLECULES; T-LYMPHOCYTE RESPONSE; VIRUS TYPE-1 INFECTION; NATURAL-KILLER-CELLS; DENDRITIC CELLS; HIV-1 INFECTION; IMMUNODEFICIENCY VIRUSES; IMMUNE ESCAPE; HOMOLOG UL18; CUTTING EDGE AB Viral mutational escape can reduce or abrogate recognition by the T cell receptor (TCR) of virus-specific CD8(+) T cells. However, very little is known about the impact of cytotoxic T lymphocyte (CTL) epitope mutations on interactions between peptide - major histocompatibility complex (MHC) class I complexes and MHC class I receptors expressed on other cell types. Here, we analyzed a variant of the immunodominant human leukocyte antigen (HLA)-B2705-restricted HIV-1 Gag KK10 epitope (KRWIILGLNK) with an L to M amino acid substitution at position 6 (L6M), which arises as a CTL escape variant after primary infection but is sufficiently immunogenic to elicit a secondary, de novo HIV-1-specific CD8+ T cell response with an alternative TCR repertoire in chronic infection. In addition to altering recognition by HIV-1-specific CD8(+) T cells, the HLA-B2705-KK10 L6M complex also exhibits substantially increased binding to the immunoglobulin-like transcript (ILT) receptor 4, an inhibitory MHC class I-specifi c receptor expressed on myelomonocytic cells. Binding of the B2705 - KK10 L6M complex to ILT4 leads to a tolerogenic phenotype of myelomonocytic cells with lower surface expression of dendritic cell (DC) maturation markers and co-stimulatory molecules. These data suggest a link between CTL-driven mutational escape, altered recognition by innate MHC class I receptors on myelomonocytic cells, and functional impairment of DCs, and thus provide important new insight into biological consequences of viral sequence diversification. C1 Harvard Univ, Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02115 USA. Boston Biomed Res Inst, Watertown, MA 02472 USA. Univ Cambridge, Dept Pathol, Cambridge CB2 1TN, England. Howard Hughes Med Inst, Chevy Chase, MD 20915 USA. RP Yu, XG (reprint author), Harvard Univ, Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02115 USA. EM xyu@partners.org RI Allen, Todd/F-5473-2011; OI Allen, Rachel/0000-0001-9834-8475; MOZA JALALI, Beenu/0000-0003-0954-3485 FU NIAID NIH HHS [F32 AI058457] NR 55 TC 65 Z9 66 U1 0 U2 1 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA SN 0022-1007 J9 J EXP MED JI J. Exp. Med. PD NOV 26 PY 2007 VL 204 IS 12 BP 2813 EP 2824 DI 10.1084/jem.20061865 PG 12 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 236RE UT WOS:000251320300008 PM 18025130 ER PT J AU Nahrendorf, M Swirski, FK Aikawa, E Stangenberg, L Wurdinger, T Figueiredo, JL Libby, P Weissleder, R Pittet, MJ AF Nahrendorf, Matthias Swirski, Filip K. Aikawa, Elena Stangenberg, Lars Wurdinger, Thomas Figueiredo, Jose-Luiz Libby, Peter Weissleder, Ralph Pittet, Mikael J. TI The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions SO JOURNAL OF EXPERIMENTAL MEDICINE LA English DT Article ID BLOOD-CELL COUNT; CHEMOATTRACTANT PROTEIN-1; MATRIX METALLOPROTEINASES; MACROPHAGE HETEROGENEITY; VENTRICULAR ENLARGEMENT; INFLAMMATORY RESPONSE; TARGETED DELETION; APOLIPOPROTEIN-E; BONE-MARROW; INFARCTION AB Healing of myocardial infarction ( MI) requires monocytes/ macrophages. These mononuclear phagocytes likely degrade released macromolecules and aid in scavenging of dead cardiomyocytes, while mediating aspects of granulation tissue formation and remodeling. The mechanisms that orchestrate such divergent functions remain unknown. In view of the heightened appreciation of the heterogeneity of circulating monocytes, we investigated whether distinct monocyte subsets contribute in specific ways to myocardial ischemic injury in mouse MI. We identify two distinct phases of monocyte participation after MI and propose a model that reconciles the divergent properties of these cells in healing. Infarcted hearts modulate their chemokine expression profile over time, and they sequentially and actively recruit Ly- 6C(hi) and - 6C(10) monocytes via CCR2 and CX3 CR1, respectively. Ly- 6C(hi) monocytes dominate early ( phase I) and exhibit phagocytic, proteolytic, and inflammatory functions. Ly- 6C(10) monocytes dominate later ( phase II), have attenuated inflammatory properties, and express vascular - endothelial growth factor. Consequently, Ly- 6C(hi) monocytes digest damaged tissue, whereas Ly- 6C(10) monocytes promote healing via myofibroblast accumulation, angiogenesis, and deposition of collagen. MI in atherosclerotic mice with chronic Ly- 6C(hi) monocytosis results in impaired healing, underscoring the need for a balanced and coordinated response. These observations provide novel mechanistic insights into the cellular and molecular events that regulate the response to ischemic injury and identify new therapeutic targets that can influence healing and ventricular remodeling after MI. C1 Massachusetts Gen Hosp, Harvard Med Sch, Ctr Syst Biol, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Harvard Med Sch, Ctr Mol Imaging Res, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Harvard Med Sch, Dept Neurol, Mol Neurogenet Unit, Charlestown, MA 02129 USA. Brigham & Womens Hosp, Harvard Med Sch, Dept Med, Div Cardiovasc, Boston, MA 02115 USA. Brigham & Womens Hosp, Harvard Med Sch, Ctr Excellence Vasc Biol, Boston, MA 02115 USA. Brigham & Womens Hosp, Harvard Med Sch, Donald W Reynolds Cardiovasc Clin Res Ctr Atheros, Boston, MA 02115 USA. RP Swirski, FK (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Ctr Syst Biol, Charlestown, MA 02129 USA. EM fswirski@mgh.harvard.edu; mpittet@mgh.harvard.edu FU NCI NIH HHS [P01 CA069246, R24 CA69246]; NHLBI NIH HHS [R01HL34636, R01 HL034636, U01 HL080731]; PHS HHS [P01-A154904] NR 59 TC 822 Z9 836 U1 5 U2 40 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA SN 0022-1007 J9 J EXP MED JI J. Exp. Med. PD NOV 26 PY 2007 VL 204 IS 12 BP 3037 EP 3047 DI 10.1084/jem.20070885 PG 11 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 236RE UT WOS:000251320300026 PM 18025128 ER PT J AU Mendu, DR Katinger, H Sodroski, J Kim, KS AF Mendu, Damodara Rao Katinger, Hermann Sodroski, Joseph Kim, Kwang Sik TI HIV-1 envelope protein gp140 binding studies to human brain microvascular endothelial cells SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE brain microvascular endothelial cells; HIV-1 envelope protein; optimal binding conditions; homologous competition binding studies ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD4-INDEPENDENT INFECTION; ENTRY; RECEPTORS; MOLECULES; GP120; GLYCOPROTEINS; INHIBITION; FUSION; CXCR4 AB Human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein gp140 interacts with its specific receptors on the surface of the target cells leading to cellular activation through various signaling pathways. The effect of blocking the chemokine repertoire in human brain microvascular endothelial cells in HIV dementia (HAD) disease has not been reported. Characterizing the nature of HIV-1 envelope protein gp140 (T-tropic, HXBc2) receptor binding conditions to HBMEC is critical to gain insight into the HIV dementia, and eventually to rationally design the agents to block envelope protein receptor interactions. HIV-1 gp140 oligomers were purified and separated to monomers, dimers, and trimers. The binding conditions of gp140 to HBMEC chemokine receptor, CXCR4, were optimized with an aim of understanding the structural interactions in HAD. Analysis of the interaction between HIV-1 gp140 and CXCR4 of HBMEC by saturation binding, cross-competition analysis with radiolabeled SDF and gp 140, revealed a strong interaction, specificity between HIV-1 gp140 and CXCR4. Our binding data demonstrate that HIV-1 envelope protein gp]40 enters cells by protein receptor mediated interactions that are regulated by the conformational state of the gp140 at physiological environment (pH and temperature). The CXCR4 antibody 12G5 inhibited SDF-1 binding to HBMEC indicating the specificity of gp140 binding to HBMEC. Scatchard analysis revealed the presence of approximately 70250 gp140 binding sites per cell with a K-d of 4.5 nM. Cross-competition experiments using labeled SDF-1 and gp 140 revealed that both unlabeled SDF-1 and gp 140 are capable of displacing their radiolabeled counterparts. The binding assay conditions and radioligand binding assay are highly valuable to identify and design better HIV inhibitors for HAD. (C) 2007 Elsevier Inc. All rights reserved. C1 Johns Hopkins Univ, Sch Med, Div Pediat Infect Dis, Baltimore, MD 21287 USA. Univ Agr & Forestry, Inst Appl Microbiol, A-1190 Vienna, Austria. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS,Dept Pathol, Boston, MA 02115 USA. RP Mendu, DR (reprint author), Johns Hopkins Univ, Sch Med, Div Pediat Infect Dis, 600 N Wolfe St,Pk 256, Baltimore, MD 21287 USA. NR 23 TC 1 Z9 1 U1 1 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD NOV 23 PY 2007 VL 363 IS 3 BP 466 EP 471 DI 10.1016/j.bbrc.2007.08.121 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 223HA UT WOS:000250359400003 PM 17888880 ER PT J AU Grammatopoulos, TN Outeiro, TF Hyman, BT Standaert, DG AF Grammatopoulos, Tom N. Outeiro, Tiago F. Hyman, Bradley T. Standaert, David G. TI Angiotensin II protects against alpha-synuclein-toxicity and reduces protein aggregation in vitro SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Parkinson's disease; inclusion; renin-angiotensin-system; synuclein; synphilin-1; angiotensin; AT receptor; losartan; PD123319 ID CONVERTING ENZYME-INHIBITION; NUCLEUS-TRACTUS-SOLITARIUS; FOCAL CEREBRAL-ISCHEMIA; AMYLOID BETA-PROTEIN; PARKINSONS-DISEASE; NEURODEGENERATIVE DISORDERS; DOPAMINERGIC-NEURONS; RECEPTOR SUBTYPE; TYROSINE-HYDROXYLASE; CHEMICAL HYPOXIA AB In this study, we examined the effects of angiotensin If (AngII) in a genetic in vitro PD model produced by alpha-synuclein (ot-syn) overexpression in the human neuroglioma H4 cell line. We observed a maximal decrease in alpha-syn-induced toxicity of 85% and reduction in inclusion formation by 19% when cultures were treated with AngII in the presence of the angiotensin type I (AT]) receptor antagonist losartan and AT2 receptor antagonist PD123319. When compared to AngII, the AT4 receptor agonist AngIV was moderately effective in protecting H4 cells against alpha-syn toxicity and did not significantly reduce inclusion formation. Here we show that AngII is protective against genetic, as well as neurotoxic models of PD. These data support the view that agents acting on the renin-angiotensin-system (RAS) may be useful in the prevention and/or treatment of Parkinson's disease. Published by Elsevier Inc. C1 Massachusetts Gen Hosp, Harvard Med Sch, Mass Gen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA. Inst Med Mol, Unit Neurociencia Celular, Lisbon, Portugal. RP Grammatopoulos, TN (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Mass Gen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA. EM thangram@hotmail.com RI Outeiro, Tiago/C-1067-2008; OI Outeiro, Tiago/0000-0003-1679-1727; Grammatopoulos, Tom/0000-0001-7175-051X FU NINDS NIH HHS [2P50NS038372-06A1, P50 NS038372, P50 NS038372-06A1] NR 46 TC 14 Z9 14 U1 3 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD NOV 23 PY 2007 VL 363 IS 3 BP 846 EP 851 DI 10.1016/j.bbrc.2007.09.043 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 223HA UT WOS:000250359400066 PM 17900533 ER PT J AU Weng, Z Signore, AP Gao, Y Wang, S Zhang, F Hastings, T Yin, XM Chen, J AF Weng, Zhongfang Signore, Armando P. Gao, Yanqin Wang, Suping Zhang, Feng Hastings, Teresa Yin, Xiao-Ming Chen, Jun TI Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID RECEPTOR MESSENGER-RNA; JAK-STAT PATHWAY; NEUROTROPHIC FACTOR; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; RAT-BRAIN; CEREBRAL-ISCHEMIA; NEURONAL SURVIVAL; INDUCED APOPTOSIS; GENE DELIVERY AB The death of midbrain dopaminergic neurons in sporadic Parkinson disease is of unknown etiology but may involve altered growth factor signaling. The present study showed that leptin, a centrally acting hormone secreted by adipocytes, rescued dopaminergic neurons, reversed behavioral asymmetry, and restored striatal catecholamine levels in the unilateral 6-hydroxydopamine (6-OHDA) mouse model of dopaminergic cell death. In vitro studies using the murine dopaminergic cell line MN9D showed that leptin attenuated 6-OHDA-induced apoptotic markers, including caspase-9 and caspase-3 activation, internucleosomal DNA fragmentation, and cytochrome c release. ERK1/2 phosphorylation (pERK1/2) was found to be critical for mediating leptin-induced neuroprotection, because inhibition of the MEK pathway blocked both the pERK1/2 response and the pro-survival effect of leptin in cultures. Knockdown of the downstream messengers JAK2 or GRB2 precluded leptin-induced pERK1/2 activation and neuroprotection. Leptin/pERK1/2 signaling involved phosphorylation and nuclear localization of CREB (pCREB), a well known survival factor for dopaminergic neurons. Leptin induced a marked MEK-dependent increase in pCREB that was essential for neuroprotection following 6-OHDA toxicity. Transfection of a dominant negative MEK protein abolished leptin-enhanced pCREB formation, whereas a dominant negative CREB or decoy oligonucleotide diminished both pCREB binding to its target DNA sequence and MN9D survival against 6-OHDA toxicity. Moreover, in the substantia nigra of mice, leptin treatment increased the levels of pERK1/2, pCREB, and the downstream gene product BDNF, which were reversed by the MEK inhibitor PD98059. Collectively, these data provide evidence that leptin prevents the degeneration of dopaminergic neurons by 6-OHDA and may prove useful in the treatment of Parkinson disease. C1 Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Med, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA 15261 USA. Fudan Univ, Sch Med, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15261 USA. RP Chen, J (reprint author), Univ Pittsburgh, Dept Neurol, Sch Med, S-507,Biomed Sci tower, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU NINDS NIH HHS [NS 44178, NS 45048, NS 43802] NR 62 TC 76 Z9 78 U1 0 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 23 PY 2007 VL 282 IS 47 BP 34479 EP 34491 DI 10.1074/jbc.M705426200 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 234FI UT WOS:000251145700063 PM 17895242 ER PT J AU Lyamin, O Pryaslova, J Kosenko, P Siegel, J AF Lyamin, Oleg Pryaslova, Julia Kosenko, Peter Siegel, Jerome TI Behavioral aspects of sleep in bottlenose dolphin mothers and their calves SO PHYSIOLOGY & BEHAVIOR LA English DT Article DE bottlenose dolphin; postpartum behavior; calf; rest; sleep; EEG; cetaceans ID SLOW-WAVE SLEEP; TURSIOPS-TRUNCATUS; ANESTHESIA; ASYMMETRY; CETACEANS; WHALE; STATE AB Adult dolphins are capable of sleeping with one eye open and exhibiting slow wave activity in the electroencephalogram (EEG) of one hemisphere at a time. The aim of this study was to examine the postpartum sleep behavior of bottlenose dolphin calves and their mothers. The behavior of three dolphin mother-calf pairs was monitored from birth to 13 months postpartum. Dolphin mothers and their calves exhibited a complete disappearance of rest at the surface for a minimum of 2 months postpartum, swimming in echelon formation on average in 97-100% of the observation time. Calves surfaced to breathe more often than their mothers between the postpartum age of 2 and 8 weeks. During the first postpartum month two dolphin mothers surfaced with both eyes open on average in 93 and 98% of the time while in their calves both eyes were open in 90 and 60% of the cases. In calves, the eye directed toward the mother was open more often (on average in 95% of all observations in calf 1 and 99% in calf 2) than the eye directed to the opposite side (82% in calf 1 and 60% in calf 2). Our data indicate that dolphin mothers and calves are highly active and vigilant during the initial period of the calf's life, continuously monitoring their position relative to each other by sight during wakefulness and sleep. We hypothesize that episodes of EEG slow wave activity at this time are likely to be brief, fragmenting EEG defined sleep into short episodes. (C) 2007 Elsevier Inc. All rights reserved. C1 VA GLAHS Sepulveda, North Hills, CA 91343 USA. Univ Calif Los Angeles, North Hills, CA USA. Utrish Dolphinarium Ltd, Moscow, Russia. RP Lyamin, O (reprint author), VA GLAHS Sepulveda, Neurobiol Res 151A3,16111 Plummer St, North Hills, CA 91343 USA. EM olyamin@ucla.edu FU NIMH NIH HHS [R01 MH064109]; NINDS NIH HHS [NS42947, R01 NS042947, R01 NS069640] NR 36 TC 13 Z9 15 U1 2 U2 17 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0031-9384 J9 PHYSIOL BEHAV JI Physiol. Behav. PD NOV 23 PY 2007 VL 92 IS 4 BP 725 EP 733 DI 10.1016/j.physbeh.2007.05.064 PG 9 WC Psychology, Biological; Behavioral Sciences SC Psychology; Behavioral Sciences GA 237XI UT WOS:000251409300023 PM 17599365 ER PT J AU Illies, C Gromada, J Fiume, R Leibiger, B Yu, J Juhl, K Yang, SN Barma, DK Falck, JR Saiardi, A Barker, CJ Berggren, PO AF Illies, Christopher Gromada, Jesper Fiume, Roberta Leibiger, Barbara Yu, Jia Juhl, Kirstine Yang, Shao-Nian Barma, Deb K. Falck, John R. Saiardi, Adolfo Barker, Christopher J. Berggren, Per-Olof TI Requirement of inositol pyrophosphates for full exocytotic capacity in pancreatic beta cells SO SCIENCE LA English DT Article ID PROTEIN-KINASE-C; B-CELLS; HEXAKISPHOSPHATE; INSULIN; GRANULES; COMPLEX AB Inositol pyrophosphates are recognized components of cellular processes that regulate vesicle trafficking, telomere length, and apoptosis. We observed that pancreatic beta cells maintain high basal concentrations of the pyrophosphate diphosphoinositol pentakisphosphate (InsP(7) or IP(7)). Inositol hexakisphosphate kinases (IP6Ks) that can generate IP(7) were overexpressed. This overexpression stimulated exocytosis of insulin-containing granules from the readily releasable pool. Exogenously applied IP7 dose-dependently enhanced exocytosis at physiological concentrations. We determined that IP6K1 and IP6K2 were present in b cells. RNA silencing of IP6K1, but not IP6K2, inhibited exocytosis, which suggests that IP6K1 is the critical endogenous kinase. Maintenance of high concentrations of IP(7) in the pancreatic b cell may enhance the immediate exocytotic capacity and consequently allow rapid adjustment of insulin secretion in response to increased demand. C1 Karolinska Inst, Rolf Luft Res Ctr Diabet & Endocrinol, SE-17176 Stockholm, Sweden. Novartis Inst BioMed Res, Diabet & Metab Dis Area, Cambridge, MA 02139 USA. Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA. UCL, UK Med Res Council, Cell Biol Unit, London WC1E 6BT, England. UCL, Dept Biochem & Mol Biol, Mol Cell Biol Lab, London WC1E 6BT, England. RP Barker, CJ (reprint author), Karolinska Inst, Rolf Luft Res Ctr Diabet & Endocrinol, SE-17176 Stockholm, Sweden. EM chris.barker@ki.se OI FIUME, ROBERTA/0000-0001-7757-4000 FU Medical Research Council [MC_U122680443]; NIGMS NIH HHS [GM31278] NR 23 TC 91 Z9 91 U1 0 U2 6 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD NOV 23 PY 2007 VL 318 IS 5854 BP 1299 EP 1302 DI 10.1126/science.1146824 PG 4 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 233JG UT WOS:000251086600043 PM 18033884 ER PT J AU Rajapakse, M Schmidt, B Feng, L Brusic, V AF Rajapakse, Menaka Schmidt, Bertil Feng, Lin Brusic, Vladimir TI Predicting peptides binding to MHC class II molecules using multi-objective evolutionary algorithms SO BMC BIOINFORMATICS LA English DT Article ID NONOBESE DIABETIC MICE; T-CELL EPITOPES; GENETIC ALGORITHM; MOTIFS; I-A(G7); SEQUENCE; DATABASE; AMINO; PROTEIN; GENERATION AB Background: Peptides binding to Major Histocompatibility Complex (MHC) class II molecules are crucial for initiation and regulation of immune responses. Predicting peptides that bind to a specific MHC molecule plays an important role in determining potential candidates for vaccines. The binding groove in class II MHC is open at both ends, allowing peptides longer than 9-mer to bind. Finding the consensus motif facilitating the binding of peptides to a MHC class II molecule is difficult because of different lengths of binding peptides and varying location of 9-mer binding core. The level of difficulty increases when the molecule is promiscuous and binds to a large number of low affinity peptides. In this paper, we propose two approaches using multi-objective evolutionary algorithms (MOEA) for predicting peptides binding to MHC class II molecules. One uses the information from both binders and non-binders for self-discovery of motifs. The other, in addition, uses information from experimentally determined motifs for guided-discovery of motifs. Results: The proposed methods are intended for finding peptides binding to MHC class II I-Ag(7) molecule-a promiscuous binder to a large number of low affinity peptides. Cross-validation results across experiments on two motifs derived for I-Ag(7) datasets demonstrate better generalization abilities and accuracies of the present method over earlier approaches. Further, the proposed method was validated and compared on two publicly available benchmark datasets: (1) an ensemble of qualitative HLA- DRB1* 0401 peptide data obtained from five differentsources, and (2) quantitative peptide data obtained for sixteen different alleles comprising of three mouse alleles and thirteen HLA alleles. The proposed method outperformed earlier methods on most datasets, indicating that it is well suited for finding peptides binding to MHC class II molecules. C1 [Rajapakse, Menaka] Inst Infocomm Res, Singapore 119613, Singapore. [Schmidt, Bertil] Univ Melbourne, NICTA VRL, Parkville, Vic 3010, Australia. [Rajapakse, Menaka; Feng, Lin] Nanyang Technol Univ, Sch Comp Engn, Singapore 639798, Singapore. [Brusic, Vladimir] Harvard Univ, Dana Farber Canc Inst, Sch Med, Canc Vaccine Ctr, Boston, MA 02115 USA. RP Rajapakse, M (reprint author), Inst Infocomm Res, 21 Heng Mui Keng Terrace, Singapore 119613, Singapore. EM menaka@i2r.a-star.edu.sg; bertil.schmidt@computer.org; asflin@ntu.edu.sg; vladimir_brusic@dfci.harvard.edu NR 73 TC 19 Z9 19 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2105 J9 BMC BIOINFORMATICS JI BMC Bioinformatics PD NOV 22 PY 2007 VL 8 AR 459 DI 10.1186/1471-2105-8-459 PG 12 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Mathematical & Computational Biology GA 253YC UT WOS:000252552500001 PM 18031584 ER PT J AU Sabatine, MS Poh, K Mega, JL Shepard, JO Stone, JR Frosch, MP Greenberg, JO Baggish, A AF Sabatine, Marc S. Poh, Kian-Keong Mega, Jessica L. Shepard, Jo-Anne O. Stone, James R. Frosch, Matthew P. Greenberg, Jeffrey O. Baggish, Aaron TI A 31-year-old woman with rash, fever, and hypotension - Acute necrotizing eosinophilic myocarditis associated with a systemic necrotizing inflammatory process also involving skeletal muscle, the liver, and the spinal cord, most consistent with a severe drug-induced hypersensitivity reaction. SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID GIANT-CELL MYOCARDITIS; CARDIOGENIC-SHOCK; DIAGNOSIS; MANIFESTATION; THERAPY C1 Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA USA. Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Sabatine, MS (reprint author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA. NR 33 TC 19 Z9 19 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 22 PY 2007 VL 357 IS 21 BP 2167 EP 2178 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 233FT UT WOS:000251076500010 PM 18032767 ER PT J AU Banez, LL Hamilton, RJ Partin, AW Vollmer, RT Sun, L Rodriguez, C Wang, YT Terris, MK Aronson, WJ Presti, JC Kane, CJ Amling, CL Moul, JW Freedland, SJ AF Banez, Lionel L. Hamilton, Robert J. Partin, Alan W. Vollmer, Robin T. Sun, Leon Rodriguez, Carmen Wang, Yiting Terris, Martha K. Aronson, William J. Presti, Joseph C., Jr. Kane, Christopher J. Amling, Christopher L. Moul, Judd W. Freedland, Stephen J. TI Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID BODY-MASS INDEX; RADICAL PROSTATECTOMY; POSTMENOPAUSAL WOMEN; RACIAL-DIFFERENCES; AFRICAN-AMERICAN; UNITED-STATES; WEIGHT CHANGE; SERUM-LEVELS; ANTIGEN PSA; US ADULTS AB Context Recent studies have suggested that obese men have lower serum prostate-specific antigen (PSA) concentrations than nonobese men. Because men with higher body mass index (BMI) have greater circulating plasma volumes, lower PSA concentrations among obese men may be due to hemodilution. Objective To determine the association between hemodilution and PSA concentration in obese men with prostate cancer. Design, Setting, and Participants Retrospective study of men who underwent radical prostatectomy for prostate adenocarcinoma from 1988 to 2006, using data from the databases of the Shared Equal Access Regional Cancer Hospital (n=1373), Duke Prostate Center (n=1974), and Johns Hopkins Hospital (n=10 287). Multivariate linear regression models adjusting for clinicopathological characteristics were used to analyze the main outcome measures. Main Outcome Measures Associations between BMI and mean adjusted PSA concentrations, mean plasma volume, and mean adjusted PSA mass ( total circulating PSA protein, calculated as PSA concentration multiplied by plasma volume), assessed by determining P values for trend. Results After controlling for clinicopathological characteristics, higher BMI was significantly associated with higher plasma volume ( P < .001 for trend) and lower PSA concentrations ( P <= .02 for trend) in all cohorts. In 2 of the 3 cohorts, PSA mass did not change significantly with increasing BMI. In the third cohort, higher BMI was associated with increased PSA mass ( P <. 001 for trend), but only between BMI category less than 25 and the other categories. Conclusions In men undergoing radical prostatectomy, higher BMI was associated with higher plasma volume hemodilution may therefore be responsible for the lower serum PSA concentrations among obese men with prostate cancer. Prospective studies are needed to evaluate this association in screened populations. C1 Duke Univ, Med Ctr, Div Urol Surg, Durham, NC 27710 USA. Duke Univ, Med Ctr, Dept Surg, Duke Prostate Ctr, Durham, NC 27710 USA. Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA. Vet Affairs Med Ctr, Urol Sect, Durham, NC USA. Vet Affairs Med Ctr, Dept Pathol, Durham, NC USA. Univ Toronto, Dept Surg, Div Urol, Toronto, ON, Canada. Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD 21205 USA. Amer Canc Soc, Dept Epidemiol & Surveillance Res, Atlanta, GA 30329 USA. Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA. Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA. Vet Affairs Med Ctr, Urol Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. Univ Alabama, Dept Urol, Birmingham, AL USA. RP Freedland, SJ (reprint author), Duke Univ, Med Ctr, Div Urol Surg, Box 2626, Durham, NC 27710 USA. EM steve.freedland@duke.edu FU NCI NIH HHS [P50 CA58236, P50 CA92131-01A1, R01CA100938] NR 37 TC 186 Z9 192 U1 0 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 21 PY 2007 VL 298 IS 19 BP 2275 EP 2280 DI 10.1001/jama.298.19.2275 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 232XV UT WOS:000251055900027 PM 18029831 ER PT J AU Goodson, JD AF Goodson, John D. TI Unintended consequences of resource-based relative value scale reimbursement SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID INTERNAL-MEDICINE; PRIMARY-CARE; HEALTH-CARE; PHYSICIANS; PREVENTION; QUALITY; SYSTEMS; COSTS C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA. RP Goodson, JD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, 15 Parkman St, Boston, MA 02114 USA. EM jgoodson1@partners.org NR 25 TC 25 Z9 25 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 21 PY 2007 VL 298 IS 19 BP 2308 EP 2310 DI 10.1001/jama.298.19.2308 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 232XV UT WOS:000251055900032 PM 18029836 ER PT J AU Feng, D Marshburn, D Jen, D Weinberg, RJ Taylor, RM Burette, A AF Feng, David Marshburn, David Jen, Dennis Weinberg, Richard J. Taylor, Russell M., II Burette, Alain TI Stepping into the third dimension SO JOURNAL OF NEUROSCIENCE LA English DT Article DE 3D reconstruction; confocal microscopy; neurons; software; calcium pump; visualization ID MICROSCOPY; VISUALIZATION; SYSTEM AB Recent advances in optical-sectioning microscopy, along with novel fluorescent proteins and probes, give us the tools to image molecules and their interactions in space and time. Investigators using these tools routinely collect multichannel three-dimensional (3D) images and time series, but analyzing such complex datasets requires sophisticated visualization techniques. We here provide an overview of the principles and practices of 3D visualization of multichannel microscopic data. We also describe ImageSurfer, a new software package for volume visualization and data analysis. ImageSurfer is freely available (www.imagesurfer.org) and provides powerful interactive tools to explore and analyze complex multichannel 3D datasets. Although ImageSurfer is designed with fluorescent microscopy in mind, it is also effective for other types of data, including 3D datasets acquired by functional magnetic resonance imaging and EM tomography. C1 Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA. Univ N Carolina, Dept Comp Sci, Chapel Hill, NC 27599 USA. Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA. Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Burette, A (reprint author), Univ N Carolina, Dept Cell & Dev Biol, CB 7090, Chapel Hill, NC 27599 USA. EM alain_burette@med.unc.edu OI Weinberg, Richard/0000-0001-9689-7278 FU NCRR NIH HHS [5-P41-RR02170-21]; NIBIB NIH HHS [P41 EB002025]; NINDS NIH HHS [NS39444, P01 NS44306] NR 13 TC 29 Z9 29 U1 0 U2 0 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 21 PY 2007 VL 27 IS 47 BP 12757 EP 12760 DI 10.1523/JNEUROSCI.2846-07.2007 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 234JK UT WOS:000251157200001 PM 18032646 ER PT J AU Stack, EC Dedeoglu, A Smith, KM Cormier, K Kubilus, JK Bogdanov, M Matson, WR Yang, LC Jenkins, BG Luthi-Carter, R Kowall, NW Hersch, SM Beal, MF Ferrante, RJ AF Stack, Edward C. Dedeoglu, Alpaslan Smith, Karen M. Cormier, Kerry Kubilus, James K. Bogdanov, Mikhail Matson, Wayne R. Yang, Lichuan Jenkins, Bruce G. Luthi-Carter, Ruth Kowall, Neil W. Hersch, Steven M. Beal, M. Flint Ferrante, Robert J. TI Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice SO JOURNAL OF NEUROSCIENCE LA English DT Article DE glutamate; dopamine; deafferentation; 6-OHDA; excitotoxicity; Huntington's disease ID TRANSGENIC MOUSE MODEL; TOXIN 3-NITROPROPIONIC ACID; NEUROTROPHIC FACTOR; QUINOLINIC ACID; NIGROSTRIATAL PATHWAY; STRIATAL NEURONS; KAINIC ACID; INTRASTRIATAL INJECTIONS; ANTEROGRADE TRANSPORT; PROLONGS SURVIVAL AB Huntington's disease (HD) is an autosomal dominant inherited neurodegenerative disorder in which the neostriatum degenerates early and most severely, with involvement of other brain regions. There is significant evidence that excitotoxicity may play a role in striatal degeneration through altered afferent corticostriatal and nigrostriatal projections that may modulate synaptically released striatal glutamate. Glutamate is a central tenant in provoking excitotoxic cell death in striatal neurons already weakened by the collective molecular events occurring in HD. In addition, transcriptional suppression of trophic factors occurs in human and transgenic mouse models of HD, suggesting that a loss of trophic support might contribute to degeneration. Since anti-glutamate approaches have been effective in improving disease phenotype in HD mice, we examined whether deafferentation of the corticostriatal and nigrostriatal pathways may mitigate striatal stress and neurodegeneration. Both surgical and chemical lesions of the corticostriatal and nigrostriatal pathways, respectively, improved the behavioral, neuropathological, and biochemical phenotype in R6/2 transgenic mice and extended survival. Decortication ameliorated hindlimb clasping, striatal neuron atrophy, and huntingtin-positive aggregates, improved N-acetyl aspartate/creatine levels, reduced oxidative stress, and significantly lowered striatal glutamate levels. In addition, 6-hydroxydopamine lesioned mice showed extended survival along with a significant reduction in striatal glutamate. These results suggest that synaptic stress is likely to contribute to neurodegeneration in HD, whereas transsynaptic trophic influences may not be as salient. Thus, modulation of synaptic influences continues to have therapeutic potential in HD. C1 Bedford Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Unit 182B, Bedford, MA 01730 USA. Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. Boston Univ, Sch Med, Dept Pathol & Psychiat, Boston, MA 02118 USA. Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA. Massachusetts Gen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA. Ecole Polytech Fed Lausanne, CH-1015 Lausanne, Switzerland. Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Phys, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Ferrante, RJ (reprint author), Bedford Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Unit 182B, 200 Springs Rd, Bedford, MA 01730 USA. EM rjferr@bu.edu RI Kowall, Neil/G-6364-2012; OI Kowall, Neil/0000-0002-6624-0213; Dedeoglu, Alpaslan/0000-0003-1156-0874 FU NINDS NIH HHS [NS045806, NS045242] NR 72 TC 50 Z9 50 U1 0 U2 0 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 21 PY 2007 VL 27 IS 47 BP 12908 EP 12915 DI 10.1523/JNEUROSCI.4318-07.2007 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 234JK UT WOS:000251157200019 PM 18032664 ER PT J AU Ren, Q Nishioka, S Shirato, H Berbeco, RI AF Ren, Qing Nishioka, Seiko Shirato, Hiroki Berbeco, Ross I. TI Adaptive prediction of respiratory motion for motion compensation radiotherapy SO PHYSICS IN MEDICINE AND BIOLOGY LA English DT Article ID REAL-TIME TUMOR; INTENSITY-MODULATED RADIOTHERAPY; TRACKING RADIOTHERAPY; GATED RADIOTHERAPY; RADIATION-THERAPY; LUNG-TUMORS; FEASIBILITY; DELIVERY; SYSTEM; IMRT AB One potential application of image-guided radiotherapy is to track the target motion in real time, then deliver adaptive treatment to a dynamic target by dMLC tracking or respiratory gating. However, the existence of a finite time delay (or a system latency) between the image acquisition and the response of the treatment system to a change in tumour position implies that some kind of predictive ability should be included in the real-time dynamic target treatment. If diagnostic x-ray imaging is used for the tracking, the dose given over a whole image-guided radiotherapy course can be significant. Therefore, the x-ray beam used for motion tracking should be triggered at a relatively slow pulse frequency, and an interpolation between predictions can be used to provide a fast tracking rate. This study evaluates the performance of an autoregressive- moving average (ARMA) model based prediction algorithm for reducing tumour localization error due to system latency and slow imaging rate. For this study, we use 3D motion data from ten lung tumour cases where the peak-to-peak motion is greater than 8 mm. Some strongly irregular traces with variation in amplitude and phase were included. To evaluate the prediction accuracy, the standard deviations between predicted and actual motion position are computed for three system latencies (0.1, 0.2 and 0.4 s) at several imaging rates (1.25-10 Hz), and compared against the situation of no prediction. The simulation results indicate that the implementation of the prediction algorithm in real-time target tracking can improve the localization precision for all latencies and imaging rates evaluated. From a common initial setting of model parameters, the predictor can quickly provide an accurate prediction of the position after collecting 20 initial data points. In this retrospective analysis, we calculate the standard deviation of the predicted position from the twentieth position data to the end of the session at 0.1 s interval. For both regular and irregular lung tumour motions, with prediction the range of average errors is 0.4-2.5mm in the SI direction from shorter to longer latency, corresponding to a range of 0.8-4.3 mm without prediction; for the AP direction a range of 0.3-1.6 mm is obtained with prediction, corresponding to a range of 0.6-3.0 mm without prediction. For 0.2 s and 0.4 s system latency, with prediction the localization based on a relatively slowimaging rate (2.5 Hz) can achieve a better or similar precision compared with no prediction but on a fast imaging rate (10 Hz). This means that precise localization can be realized at a slow imaging rate. This is important for the application of kV x-ray imaging systems and EPID-based systems in image-guided radiotherapy. In conclusion, the adaptive predictor can successfully predict irregular respiratory motion, and the adaptive prediction of respiration motion can effectively improve the delivery precision of real-time motion compensation radiotherapy. C1 Varian Med Syst, Far E Applicat Support, Beijing, Peoples R China. NTT E Japan Sapporo Hosp, Dept Radiat Oncol, Sapporo, Hokkaido, Japan. Hokkaido Univ, Sch Med, Dept Radiat Med, Sapporo, Hokkaido 060, Japan. Dana Farber Brigham & Womens Canc Inst, Dept Radiat Oncol, Boston, MA USA. Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA. RP Ren, Q (reprint author), Varian Med Syst, Far E Applicat Support, Beijing, Peoples R China. EM qing.ren@varian.com RI Shirato, Hiroki/A-7068-2010 NR 18 TC 43 Z9 44 U1 0 U2 4 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 0031-9155 J9 PHYS MED BIOL JI Phys. Med. Biol. PD NOV 21 PY 2007 VL 52 IS 22 BP 6651 EP 6661 DI 10.1088/0031-9155/52/22/007 PG 11 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA 228JO UT WOS:000250726400007 PM 17975289 ER PT J AU Heiny, AT Miotto, O Srinivasan, KN Khan, AM Zhang, GL Brusic, V Tan, TW August, JT AF Heiny, A. T. Miotto, Olivo Srinivasan, Kellathur N. Khan, Asif M. Zhang, G. L. Brusic, Vladimir Tan, Tin Wee August, J. Thomas TI Evolutionarily Conserved Protein Sequences of Influenza A Viruses, Avian and Human, as Vaccine Targets SO PLOS ONE LA English DT Article AB Background. Influenza A viruses generate an extreme genetic diversity through point mutation and gene segment exchange, resulting in many new strains that emerge from the animal reservoirs, among which was the recent highly pathogenic H5N1 virus. This genetic diversity also endows these viruses with a dynamic adaptability to their habitats, one result being the rapid selection of genomic variants that resist the immune responses of infected hosts. With the possibility of an influenza A pandemic, a critical need is a vaccine that will recognize and protect against any influenza A pathogen. One feasible approach is a vaccine containing conserved immunogenic protein sequences that represent the genotypic diversity of all current and future avian and human influenza viruses as an alternative to current vaccines that address only the known circulating virus strains. Methodology/Principal Findings. Methodologies for large-scale analysis of the evolutionary variability of the influenza A virus proteins recorded in public databases were developed and used to elucidate the amino acid sequence diversity and conservation of 36,343 sequences of the 11 viral proteins of the recorded virus isolates of the past 30 years. Technologies were also applied to identify the conserved amino acid sequences from isolates of the past decade, and to evaluate the predicted human lymphocyte antigen (HLA) supertype-restricted class I and II T-cell epitopes of the conserved sequences. Fifty-five (55) sequences of 9 or more amino acids of the polymerases (PB2, PB1, and PA), nucleoprotein (NP), and matrix 1 (M1) proteins were completely conserved in at least 80%, many in 95 to 100%, of the avian and human influenza A virus isolates despite the marked evolutionary variability of the viruses. Almost all (50) of these conserved sequences contained putative supertype HLA class I or class II epitopes as predicted by 4 peptide-HLA binding algorithms. Additionally, data of the Immune Epitope Database (IEDB) include 29 experimentally identified HLA class I and II T-cell epitopes present in 14 of the conserved sequences. Conclusions/Significance. This study of all reported influenza A virus protein sequences, avian and human, has identified 55 highly conserved sequences, most of which are predicted to have immune relevance as T-cell epitopes. This is a necessary first step in the design and analysis of a polyepitope, pan-influenza A vaccine. In addition to the application described herein, these technologies can be applied to other pathogens and to other therapeutic modalities designed to attack DNA, RNA, or protein sequences critical to pathogen function. C1 [Srinivasan, Kellathur N.; August, J. Thomas] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA. [Heiny, A. T.; Miotto, Olivo; Khan, Asif M.; Tan, Tin Wee] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore. [Miotto, Olivo] Natl Univ Singapore, Inst Syst Sci, Singapore 117595, Singapore. [Srinivasan, Kellathur N.] Hlth Sci Author, Ctr Drug Adm, Prod Evaluat & Registrat Div, Singapore, Singapore. [Khan, Asif M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Singapore 117595, Singapore. [Zhang, G. L.] Inst Infocomm Res, Singapore, Singapore. [Brusic, Vladimir] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. RP August, JT (reprint author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA. EM taugust@bs.jhmi.edu RI Khan, Mohammad Asif/F-4663-2010; Tan, Tin Wee/B-8963-2009; OI Khan, Mohammad Asif/0000-0001-9202-279X; Tan, Tin Wee/0000-0002-4062-2854; Miotto, Olivo/0000-0001-8060-6771 FU National Institute of Allergy and Infectious Diseases; National Institutes of Health; Department of Health and Human Services, USA [5 U19 AI56541, HHSN2662-00400085C] FX The development of the computational tools reported herein was supported by in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, USA, under Grant No. 5 U19 AI56541 and Contract No. HHSN2662-00400085C. NR 91 TC 97 Z9 103 U1 2 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 21 PY 2007 VL 2 IS 11 AR e1190 DI 10.1371/journal.pone.0001190 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA V10JB UT WOS:000207459200005 PM 18030326 ER PT J AU Hoshida, Y Brunet, JP Tamayo, P Golub, TR Mesirov, JP AF Hoshida, Yujin Brunet, Jean-Philippe Tamayo, Pablo Golub, Todd R. Mesirov, Jill P. TI Subclass Mapping: Identifying Common Subtypes in Independent Disease Data Sets SO PLOS ONE LA English DT Article AB Whole genome expression profiles are widely used to discover molecular subtypes of diseases. A remaining challenge is to identify the correspondence or commonality of subtypes found in multiple, independent data sets generated on various platforms. While model-based supervised learning is often used to make these connections, the models can be biased to the training data set and thus miss inherent, relevant substructure in the test data. Here we describe an unsupervised subclass mapping method (SubMap), which reveals common subtypes between independent data sets. The subtypes within a data set can be determined by unsupervised clustering or given by predetermined phenotypes before applying SubMap. We define a measure of correspondence for subtypes and evaluate its significance building on our previous work on gene set enrichment analysis. The strength of the SubMap method is that it does not impose the structure of one data set upon another, but rather uses a bi-directional approach to highlight the common substructures in both. We show how this method can reveal the correspondence between several cancer-related data sets. Notably, it identifies common subtypes of breast cancer associated with estrogen receptor status, and a subgroup of lymphoma patients who share similar survival patterns, thus improving the accuracy of a clinical outcome predictor. C1 [Hoshida, Yujin; Brunet, Jean-Philippe; Tamayo, Pablo; Golub, Todd R.; Mesirov, Jill P.] MIT, Eli & Edythe L Broad Inst, Cambridge, MA 02139 USA. [Hoshida, Yujin; Brunet, Jean-Philippe; Tamayo, Pablo; Golub, Todd R.; Mesirov, Jill P.] Harvard Univ, Cambridge, MA 02138 USA. [Hoshida, Yujin; Golub, Todd R.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Hoshida, Y (reprint author), MIT, Eli & Edythe L Broad Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM hoshida@broad.mit.edu FU Charles A King Trust Fellowship FX Yujin Hoshida is supported by Charles A King Trust Fellowship. There was no contribution from the funder in any aspects of the current study including the design, analysis, interpretation, and preparation of the manuscript. NR 20 TC 60 Z9 61 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 21 PY 2007 VL 2 IS 11 AR e1195 DI 10.1371/journal.pone.0001195 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA V10JB UT WOS:000207459200009 PM 18030330 ER PT J AU Farber, J Siu, A Bloom, P AF Farber, Jeffrey Siu, Albert Bloom, Patricia TI How much time do physicians spend providing care outside of office visits? SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID TELEPHONE AB Background: People with chronic illness require care outside of office visits, much of which is not reimbursed under current Medicare guidelines. Objective: To describe the amount of time geriatricians spend and the nature of care they provide outside of office visits. Design: Cross-sectional study on the time spent by physicians in clinical interactions outside of patient visits during 3 randomly sampled, 1-week periods. Setting: An academic geriatric medicine ambulatory practice. Participants: 16 physicians. Measurements: Information on the method, content, outcome, and participants in clinical interactions outside of office visits was collected on a structured form. Results: There were 472 discrete interactions, representing 296 episodes of care for 226 patients. Fifty-four percent of interactions were linked as multistep episodes, whose mean duration (range; 25th, 75th percentiles) was 18.9 minutes (3 to 70 minutes; 9, 21 minutes). Thirty-six percent of episodes involving a new medical symptom resulted in medication use, 27% resulted in an office visit, and 9% resulted in a referral to another physician. Mean time spent per physician per week was 112.2 minutes (range, 36 to 260 minutes), which represents an additional 6.7 minutes (range, 1.7 to 13.8) of care provided outside of office visits for every 30 minutes of time spent scheduled to see ambulatory patients. For a full-time physician scheduled to see 14 patients per day in 30-minute visits over a 5-day workweek, this would represent an extra 7.8 hours of clinical work per week. Limitation: Data were self-reported and were limited to an academic geriatric medicine practice. Conclusion: Physicians spend a considerable amount of time providing care outside of office visits for patients with chronic illness. This study suggests that collecting empirical data on the amount and nature of nonreimbursed care activities is feasible and should be done in more generalizable settings to inform debates about reimbursement reform. C1 Mt Sinai Sch Med, New York, NY 10029 USA. Bronx Vet Affairs Med Ctr, Bronx, NY USA. RP Farber, J (reprint author), Mt Sinai Sch Med, Box 1070, New York, NY 10029 USA. EM jeffrey.farber@mssm.edu NR 9 TC 43 Z9 45 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 20 PY 2007 VL 147 IS 10 BP 693 EP U119 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 235UJ UT WOS:000251259500003 PM 18025445 ER PT J AU Gibbons, RJ Fihn, SD AF Gibbons, Raymond J. Fihn, Stephan D. TI Coronary revascularization: New evidence, new challenges SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID ACUTE MYOCARDIAL-INFARCTION; BYPASS-SURGERY; RANDOMIZED TRIALS; ANGIOPLASTY; DISEASE; THERAPY; MORTALITY; SURVIVAL C1 Mayo Clin, Rochester, MN 55905 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. RP Gibbons, RJ (reprint author), Mayo Clin, Gonda 5,200 1st St SW, Rochester, MN 55905 USA. EM gibbons.raymond@mayo.edu NR 19 TC 5 Z9 5 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 20 PY 2007 VL 147 IS 10 BP 732 EP U140 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 235UJ UT WOS:000251259500009 PM 17938384 ER PT J AU Cannistra, SA Matulonis, UA Penson, RT Hambleton, J Dupont, J Mackey, H Douglas, J Burger, RA Armstrong, D Wenham, R McGuire, W AF Cannistra, Stephen A. Matulonis, Ursula A. Penson, Richard T. Hambleton, Julie Dupont, Jakob Mackey, Howard Douglas, Jeffrey Burger, Robert A. Armstrong, Deborah Wenham, Robert McGuire, William TI Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; COLORECTAL-CANCER; CARCINOMA; RECURRENT; EXPRESSION; TRIAL; NEOPLASMS; SURVIVAL AB Purpose We evaluated the efficacy and safety of bevacizumab in patients with platinum-resistant epithelial ovarian carcinoma (EOC) or peritoneal serous carcinoma (PSC) who had experienced disease progression during, or within 3 months of discontinuing, topotecan or liposomal doxorubicin. Patients and Methods No more than three prior treatment regimens were allowed. Patients received single-agent bevacizumab 15 mg/kg intravenously every 3 weeks. Response was assessed by computed tomography (CT) scan every 6 weeks using Response Evaluation Criteria in Solid Tumors (RECIST). Results Of 44 patients treated, 83.7% were primarily platinum resistant, 59.1% had received liposomal doxorubicin, 25% topotecan, 15.9% both agents, and 47.7% had received three prior chemotherapy regimens. A median of five (range, two to 16) bevacizumab doses were administered. Partial responses were observed in seven patients (15.9%). Median progression-free survival was 4.4 months (95% Cl, 3.1 to 5.5 months), with a median survival duration of 10.7 months at study termination. Bevacizumab-associated grade 3 to 4 events included hypertension (9.1%), proteinuria (15.9%), bleeding (2.3%), and wound-healing complications (2.3%). The incidence of GI perforation (GIP; 11.4%) was higher than reported in bevacizumab trials of other tumor types. GIP occurred in 23.8% of patients receiving three prior chemotherapy regimens, compared with 0% of patients receiving two prior chemotherapy regimens (P < .01). A trend toward higher risk of GIP was observed for patients with bowel wall thickening or bowel obstruction on CT scan. Arterial thromboembolic events occurred in three patients (6.8%). Three deaths were related to bevacizumab treatment. Conclusion Bevacizumab has single-agent activity in patients with platinum-resistant EOC or PSC. A higher than expected incidence of GIP was noted in these heavily pretreated patients. C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Dana Farber Canc Inst, Boston, MA USA. Genentech Inc, San Francisco, CA 94080 USA. Univ Calif Irvine, Orange, CA 92668 USA. Franklin Sq Hosp, Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA. H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. RP Cannistra, SA (reprint author), Beth Israel Deaconess Med Ctr, E Campus KS158,330 Brookline Ave, Boston, MA 02215 USA. EM scannist@bidmc.harvard.edu NR 27 TC 430 Z9 445 U1 0 U2 18 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2007 VL 25 IS 33 BP 5180 EP 5186 DI 10.1200/JCO.2007.12.0782 PG 7 WC Oncology SC Oncology GA 233EY UT WOS:000251074400009 PM 18024865 ER PT J AU de Lemos, JA O'Donoghue, M AF de Lemos, James A. O'Donoghue, Michelle TI The skinny on fatty acid-binding protein SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material ID ACUTE MYOCARDIAL-INFARCTION; ACUTE CORONARY SYNDROME; PROGNOSTIC VALUE; TROPONIN-T; MYOGLOBIN; SERUM; ELEVATION; MARKER C1 Univ Texas SW Med Ctr Dallas, Dept Med, Div Cardiol, Dallas, TX 75390 USA. Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. RP de Lemos, JA (reprint author), Univ Texas SW Med Ctr Dallas, Dept Med, Div Cardiol, Dallas, TX 75390 USA. EM James.deLemos@UTSouthwestern.edu NR 16 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 20 PY 2007 VL 50 IS 21 BP 2068 EP 2070 DI 10.1016/j.jacc.2007.07.072 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 234PY UT WOS:000251177200009 PM 18021875 ER PT J AU DaSilva, AFM Granziera, C Snyder, J Hadjikhani, N AF DaSilva, Alexandre F. M. Granziera, Cristina Snyder, Josh Hadjikhani, Nouchine TI Thickening in the somatosensory cortex of patients with migraine SO NEUROLOGY LA English DT Article ID HUMAN CEREBRAL-CORTEX; GRAY-MATTER; ALZHEIMERS-DISEASE; CORTICAL SURFACE; BACK-PAIN; BRAIN; THICKNESS; AURA; MRI; NEUROPLASTICITY AB Objective: To examine morphologic changes in the somatosensory cortex (SSC) of patients with migraine. Methods: Cortical thickness of the SSC of patients with migraine was measured in vivo and compared with age-and sex-matched healthy subjects. The cohort was composed of 24 patients with migraine, subdivided into 12 patients who had migraine with aura, 12 patients who had migraine without aura, and 12 controls. Group and individual analyses were performed in the SSC and shown as average maps of significant changes in cortical thickness. Results: Migraineurs had on average thicker SSCs than the control group. The most significant thickness changes were noticed in the caudal SSC, where the trigeminal area, including head and face, is somatotopically represented. Conclusions: Our findings indicate the presence of interictal structural changes in the somatosensory cortex (SSC) of migraineurs. The SSC plays a crucial role in the noxious and nonnoxious somatosensory processing. Thickening in the SSC is in line with diffusional abnormalities observed in the subcortical trigeminal somatosensory pathway of the same migraine cohort in a previous study. Repetitive migraine attacks may lead to, or be the result of, neuroplastic changes in cortical and subcortical structures of the trigeminal somatosensory system. C1 Massachusetts Gen Hosp, Harvard Med Sch, Martinos Ctr Biomed, Charlestown, MA 02129 USA. MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. McLean Hosp, Harvard Med Sch, Brain Imaging Ctr, PAIN Grp, Belmont, MA 02178 USA. RP Hadjikhani, N (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Martinos Ctr Biomed, Bldg 36,First St, Rm 417, Charlestown, MA 02129 USA. EM nouchine@nmr.mgh.harvard.edu RI Hadjikhani, Nouchine/C-2018-2008; OI Hadjikhani, Nouchine/0000-0003-4075-3106; Granziera, Cristina/0000-0002-4917-8761 FU NINDS NIH HHS [5P01 NS 35611-09, P01 NS035611] NR 37 TC 107 Z9 110 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 20 PY 2007 VL 69 IS 21 BP 1990 EP 1995 DI 10.1212/01.wnl.0000291618.32247.2d PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 232XM UT WOS:000251054500006 PM 18025393 ER PT J AU Pugh, MJV Berlowitz, DR Montouris, G Bokhour, B Cramer, JA Bohm, V Bollinger, M Helmers, S Ettinger, A Meador, KJ Fountain, N Boggs, J Tatum, WO Knoefel, J Harden, C Mattson, RH Kazis, L AF Pugh, M. J. V. Berlowitz, D. R. Montouris, G. Bokhour, B. Cramer, J. A. Bohm, V. Bollinger, M. Helmers, S. Ettinger, A. Meador, K. J. Fountain, N. Boggs, J. Tatum, W. O., IV Knoefel, J. Harden, C. Mattson, R. H. Kazis, L. TI What constitutes high quality of care for adults with epilepsy? SO NEUROLOGY LA English DT Article ID TECHNOLOGY-ASSESSMENT SUBCOMMITTEE; ACADEMY-OF-NEUROLOGY; AMERICAN-ACADEMY; STANDARDS-SUBCOMMITTEE; ANTIEPILEPTIC DRUGS; PRACTICE PARAMETER; HEALTH-CARE; SOCIETY; THERAPEUTICS; EFFICACY AB Background: Providers are increasingly being held accountable for the quality of care provided. While quality indicators have been used to benchmark the quality of care for a number of other disease states, no such measures are available for evaluating the quality of care provided to adults with epilepsy. In order to assess and improve quality of care, it is critical to develop valid quality indicators. Our objective is to describe the development of quality indicators for evaluating care of adults with epilepsy. As most care is provided in primary and general neurology care, we focused our assessment of quality on care within primary care and general neurology clinics. Methods: We reviewed existing national clinical guidelines and systematic reviews of the literature to develop an initial list of quality indicators; supplemented the list with indicators derived from patient focus groups; and convened a 10-member expert panel to rate the appropriateness, reliability, and necessity of each quality indicator. Results: From the original 37 evidence-based and 10 patient-based quality indicators, the panel identified 24 evidence-based and 5 patient-based indicators as appropriate indicators of quality. Of these, the panel identified 9 that were not necessary for high quality care. Conclusion: There is, at best, a poor understanding of the quality of care provided for adults with epilepsy. These indicators, developed based on published evidence, expert opinion, and patient perceptions, provide a basis to assess and improve the quality of care for this population. C1 S Texas Vet Hlth Care Syst, Audie L Murphy Div 11C6, VERDICT HSR&D, Dept Vet Affairs, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr, San Antonio, TX USA. Bedford VA Hosp, Dept Internal Med, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. Boston Univ, Sch Med, Dept Neurol, Boston, MA USA. Yale Univ, Dept Psychiat, West Haven, CT USA. Boston Univ, Sch Publ Hlth, Ctr Assessment Pharmaceut Practices, Dept Hlth Policy & Management, Boston, MA 02215 USA. Emory Univ, Sch Med, Atlanta, GA USA. Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11042 USA. Univ Florida, Sch Med, Dept Neurol, Gainesville, FL USA. Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA. Orlando Reg Healthcare, Orlando, FL USA. Univ S Florida, Tampa Gen Healthcare Outpatient Epilepsy Clin, Tampa, FL 33620 USA. Univ New Mexico, Vet Adm Hosp, Sch Med, Albuquerque, NM 87131 USA. Cornell Univ, New York Hosp, Weill Med Coll, Comprehens Epilepsy Ctr, New York, NY USA. Yale Univ, Sch Med, New Haven, CT USA. RP Pugh, MJV (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Div 11C6, VERDICT HSR&D, Dept Vet Affairs, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM PughM@uthscsa.edu FU PHS HHS [S3492-23/23] NR 40 TC 32 Z9 33 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 20 PY 2007 VL 69 IS 21 BP 2020 EP 2027 DI 10.1212/01.WNL.0000291947.29643.9f PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 232XM UT WOS:000251054500009 PM 17928576 ER PT J AU Betensky, RA Louis, DN Caimcross, JG AF Betensky, Rebecca A. Louis, David N. Caimcross, J. Gregory TI Tests of association under misclassification: Application to histological sampling in oncology SO STATISTICS IN MEDICINE LA English DT Article DE nuisance parameters; confidence set p-value ID COMPARING 2 PROBABILITIES; LOG-LINEAR MODELS; BINOMIAL DATA; CATEGORICAL-DATA; DATA SUBJECT; SCHEME; DESIGN AB Subjects in tumour studies are often misclassified with respect to histologic features that are not routinely recorded in diagnostic reports and that display heterogeneity within tumours. Pathologic analysis of the tumours may miss the feature of interest if the pathologist was not alerted to detail the microscopic feature of interest or if it is not present in the selected specimens. In this setting, only the subjects for whom the outcome is not found are potentially misclassified. Analyses of associations between the observed, potentially misclassified, outcome and a second outcome are invalid if the probability of misclassification depends on the second outcome. Three natural tests of association based on the observed data depend on different numbers of nuisance parameters. Most promising is a test based on the ratio of proportions of the observed feature. We illustrate this test using a study of the association of imaging parameters with genetic features in subjects with oligodendroglioma, a common brain tumour. In this study, calcification, a feature related to the imaging parameters, was potentially misclassified as not present. Copyright (C) 2007 John Wiley & Sons, Ltd. C1 Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Calgary, Calgary, AB, Canada. RP Betensky, RA (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat, 655 Huntington Ave, Boston, MA 02115 USA. EM betensky@hsph.harvard.edu FU NCI NIH HHS [CA057683, CA075791, R01 CA075971] NR 13 TC 0 Z9 0 U1 0 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0277-6715 J9 STAT MED JI Stat. Med. PD NOV 20 PY 2007 VL 26 IS 26 BP 4808 EP 4816 DI 10.1002/sim.2895 PG 9 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 227AC UT WOS:000250628600007 PM 17476651 ER PT J AU Wu, YN Martella, G Johnson, SW AF Wu, Yan-Na Martella, Giuseppina Johnson, Steven W. TI Rotenone enhances N-methyl-D-aspartate currents by activating a tyrosine kinase in rat dopamine neurons SO NEUROREPORT LA English DT Article DE brain slice; excitotoxicity; hydrogen peroxide; N-methyl-D-aspartate; patch clamp; reactive oxygen species; rotenone; substantia nigra; tyrosine kinase ID NMDA RECEPTOR; PARKINSONS-DISEASE; MODULATION; SRC; PHOSPHORYLATION; PHOSPHATASES; REDUCTION; INHIBITOR; RESPONSES; INVITRO AB Our previous work showed that the pesticide rotenone increases the amplitude of inward currents evoked by N-methyl-D-aspartate (NMDA) in substantia nigra dopamine neurons. Using patch pipettes to record whole-cell currents in rat brain slices, we report that the rotenone-induced potentiation of NMDA current is blocked by the tyrosine kinase inhibitors genistein and PPI. This action of rotenone is mimicked by H2O2, which is also blocked by genistein. Our results suggest that the rotenone-dependent increase in NMDA current is mediated by release of reactive oxygen species that activates a protein tyrosine kinase. C1 Portland VA Med Ctr, Portland, OR 97207 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy. RP Johnson, SW (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM johnsost@ohsu.edu NR 24 TC 8 Z9 8 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-4965 J9 NEUROREPORT JI Neuroreport PD NOV 19 PY 2007 VL 18 IS 17 BP 1813 EP 1816 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 230UO UT WOS:000250901700012 PM 18090317 ER PT J AU Parekkadan, B van Poll, D Megeed, Z Kobayashi, N Tilles, AW Berthiaume, F Yarmush, ML AF Parekkadan, Biju van Poll, Daan Megeed, Zaki Kobayashi, Naoya Tilles, Arno W. Berthiaume, Francois Yarmush, Martin L. TI Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE stem cell; fibrosis; immunomodulation; liver injury; mesenchymal stem cell; liver fibrosis ID LIVER FIBROSIS; RAT; APOPTOSIS; MYOFIBROBLASTS; DIFFERENTIATION; INTERLEUKIN-10; PROLIFERATION; EXPRESSION; RESOLUTION; ALPHA AB Bone marrow-derived mesenchymal stem cells (MSCs) have been reported to prevent the development of liver fibrosis in a number of pre-clinical studies. Marked changes in liver histopathology and serological markers of liver function have been observed without a clear understanding of the therapeutic mechanism by which stem cells act. We sought to determine if MSCs could modulate the activity of resident liver cells, specifically hepatic stellate cells (SCs) by paracrine mechanisms using indirect cocultures. Indirect coculture of MSCs and activated SCs led to a significant decrease in collagen deposition and proliferation, while inducing apoptosis of activated SCs. The molecular mechanisms underlying the modulation of SC activity by MSCs were examined. IL-6 secretion from activated SCs induced IL10 secretion from MSCs, suggesting a dynamic response of MSCs to the SCs in the microenvironment. Blockade of MSC-derived IL-10 and TNF-alpha abolished the inhibitory effects of MSCs on SC proliferation and collagen synthesis. In addition, release of HGF by MSCs was responsible for the marked induction of apoptosis in SCs as determined by antibody-neutralization studies. These findings demonstrate that MSCs can modulate the function of activated SCs via paracrine mechanisms provide a plausible explanation for the protective role of MSCs in liver inflammation and fibrosis, which may also be relevant to other models of tissue fibrosis. (C) 2007 Elsevier Inc. All rights reserved. C1 Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med & Surg Serv, Harvard Med Sch, Boston, MA 02114 USA. Harvard MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. Okayama Univ, Grad Sch Med & Dent, Dept Surg, Okayama 7008558, Japan. RP Yarmush, ML (reprint author), Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med & Surg Serv, Harvard Med Sch, 51 Blossom St, Boston, MA 02114 USA. EM ireis@sbi.org FU NIDDK NIH HHS [K08 DK066040, F32 DK070496, K08 DK066040-05, K08 DK66040, K18 DK076819, K18 DK076819-01, P30 DK040561, P30 DK040561-12, R01 DK043371, R01 DK043371-13, R01 DK43371] NR 24 TC 108 Z9 133 U1 3 U2 14 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD NOV 16 PY 2007 VL 363 IS 2 BP 247 EP 252 DI 10.1016/j.bbre.2007.05.150 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 219XM UT WOS:000250121500002 PM 17869217 ER PT J AU Bradner, J AF Bradner, James TI Common gene deletions and graft-versus-host disease after hematopoietic stem cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Bradner, James] Dana Farber Canc Inst, Div Hematol Neoplasia, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 37 BP 19A EP 19A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800038 ER PT J AU Faber, J Krivstov, AV Stubbs, MC van den Heuvel-Eibrink, M Kung, AL Zwaan, CM Armstrong, SA AF Faber, Jorg Krivstov, Andrei V. Stubbs, Matthew C. van den Heuvel-Eibrink, Marry Kung, Andrew L. Zwaan, Christian M. Armstrong, Scott A. TI The myocyte enhancer factor 2C (MEF2C) is a direct transcriptional target of HOXA9 and mediates leukemia survival in human mixed-lineage leukemias SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Faber, Jorg; Krivstov, Andrei V.; Stubbs, Matthew C.; Kung, Andrew L.; Armstrong, Scott A.] Childrens Hosp Boston, Div Hematol Oncol, Boston, MA USA. [van den Heuvel-Eibrink, Marry; Kung, Andrew L.; Zwaan, Christian M.; Armstrong, Scott A.] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA. Sophia Childrens Univ Hosp, Dept Pediat Hematol, Rotterdam, Netherlands. RI Faber, Joerg/G-4549-2010 NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 58 BP 26A EP 26A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800059 ER PT J AU Stubbs, MC Faber, J Kung, AL Cameron, S Armstrong, SA AF Stubbs, Matthew C. Faber, Joerg Kung, Andrew L. Cameron, Scott Armstrong, Scott A. TI HOXA9 represses bim expression in MLL rearranged leukemia: Implications for drug therapy SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Stubbs, Matthew C.; Faber, Joerg; Kung, Andrew L.; Armstrong, Scott A.] Childrens Hosp Boston, Div Hematol Oncol, Boston, MA USA. [Kung, Andrew L.; Armstrong, Scott A.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Kung, Andrew L.; Armstrong, Scott A.] Harvard Med Sch, Boston, MA USA. [Cameron, Scott] Univ Texas Southwestern Med Ctr, Dept Pediat, Dept Mol Biol, Dallas, TX USA. RI Faber, Joerg/G-4549-2010 NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 57 BP 26A EP 26A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800058 ER PT J AU Lu, SX Willis, L Smith, M Suh, D King, C Bautista, J Chow, M Cabrera-Perez, J Hubbard, V Rotolo, J Liu, C Murphy, G Alpdogan, O Blumberg, R Holmes, K Turbide, C Beauchemin, N van den Brink, MRM AF Lu, Sydney X. Willis, Lucy Smith, Marsinay Suh, David King, Christopher Bautista, Johanne Chow, Melanie Cabrera-Perez, Javier Hubbard, Vanessa Rotolo, Jimmy Liu, Chen Murphy, George Alpdogan, Onder Blumberg, Richard Holmes, Kathryn Turbide, Claire Beauchemin, Nicole van den Brink, Marcel R. M. TI CEACAM-1 is involved in graft-versus-host-discase in murine allogeneic bone marrow transplantation models SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Lu, Sydney X.; Willis, Lucy; Smith, Marsinay; Suh, David; King, Christopher; Bautista, Johanne; Chow, Melanie; Cabrera-Perez, Javier; van den Brink, Marcel R. M.] Mem Sloan Kettering Canc Ctr, Dept Immunol, New York, NY 10021 USA. [Hubbard, Vanessa] Albert Einstein Coll Med, Dept Pathol, New York, NY USA. [Rotolo, Jimmy] Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol & Chem, New York, NY 10021 USA. [Liu, Chen] Univ Florida, Coll Med, Dept Pathol, Gainesville, FL USA. [Murphy, George] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Alpdogan, Onder] Yale Univ, Sch Med, Dept Med, New Haven, CT USA. [Blumberg, Richard] Massachusetts Gen Hosp, Dept Gastroenterol, Boston, MA 02114 USA. [Holmes, Kathryn] Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80202 USA. [Turbide, Claire] McGill Canc Ctr, Dept Biochem, Montreal, PQ, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 67 BP 28A EP 28A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800068 ER PT J AU Lowder, JN Freidberg, JW Kelly, J Freedman, AS Coffman, R Kanzler, H Sims, P Hwang, J Haining, N AF Lowder, James N. Freidberg, Jonathan W. Kelly, Jennifer Freedman, Arnold S. Coffman, Robert Kanzler, Holger Sims, Paul Hwang, Jimmy Haining, Nicholas TI Dose finding in human trials of TLR9 agonists: Induction of interferon-alpha inducible genes in blood mononuclear cells as a measure of biologic activity of 1018 ISS SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Lowder, James N.; Coffman, Robert; Kanzler, Holger; Sims, Paul] Dynavax Technol, Berkeley, CA USA. [Freidberg, Jonathan W.; Kelly, Jennifer] Univ Rochester, Wilmot Canc Ctr, Rochester, NY USA. [Freedman, Arnold S.; Haining, Nicholas] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA. [Hwang, Jimmy] Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 3844 BP 29B EP 29B PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101100100 ER PT J AU Marina, O Biemacki, M Cai, A Zhang, WD Duke-Cohan, JS Brusic, V Liu, FL Alyea, E Canning, CM Seiffer, R Ritz, J Wu, CJ AF Marina, Ovidiu Biemacki, Melinda Cai, Ann Zhang, Wandi Duke-Cohan, Jonathan S. Brusic, Vladimir Liu, Fenglong Alyea, Edwin Canning, Christine M. Seiffer, Robert Ritz, Jerome Wu, Catherine J. TI Immunoproteomic identification of graft-versus-leukemia targets in patients with chronic lymphocytic leukemia SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Marina, Ovidiu; Biemacki, Melinda; Cai, Ann; Zhang, Wandi; Duke-Cohan, Jonathan S.; Brusic, Vladimir; Canning, Christine M.; Ritz, Jerome; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Marina, Ovidiu; Biemacki, Melinda; Cai, Ann; Zhang, Wandi; Duke-Cohan, Jonathan S.; Brusic, Vladimir; Alyea, Edwin; Canning, Christine M.; Seiffer, Robert; Ritz, Jerome; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Marina, Ovidiu; Cai, Ann; Duke-Cohan, Jonathan S.; Alyea, Edwin; Canning, Christine M.; Seiffer, Robert; Ritz, Jerome; Wu, Catherine J.] Harvard Med Sch, Boston, MA USA. [Marina, Ovidiu] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA. [Liu, Fenglong] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 71 BP 30A EP 30A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800072 ER PT J AU Rajkumar, SV Jacobus, S Callander, N Fonseca, R Vesole, D Williams, M Abonour, R Siegel, D Greipp, P AF Rajkumar, S. Vincent Jacobus, Susanna Callander, Natalie Fonseca, Rafael Vesole, David Williams, Michael Abonour, Rafat Siegel, David Greipp, Philip TI A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the eastern cooperative oncology group SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Rajkumar, S. Vincent; Greipp, Philip] Mayo Clin, Rochester, MN USA. [Jacobus, Susanna] Dana Farber Canc Inst, Boston, MA 02115 USA. [Callander, Natalie] Univ Wisconsin, Madison, WI USA. [Fonseca, Rafael] Mayo Clin, Scottsdale, AZ USA. [Vesole, David] St Vincents Comprehens Canc Ctr, New York, NY USA. [Williams, Michael] Univ Virginia, Charlottesville, VA USA. [Abonour, Rafat] Indiana Univ, Med Ctr, Indianapolis, IN 46204 USA. [Siegel, David] Hackensack Univ, Med Ctr, Hackensack, NJ USA. NR 0 TC 46 Z9 48 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 74 BP 31A EP 31A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800075 ER PT J AU San Miguel, JF Schlag, R Khuageya, N Shpilberg, O Dimopoulos, M Kropff, M Spicka, L Petrucci, M Sarrioilova, O Dmoszynska, A Abdulkadyrov, K Schots, R Jiang, B Palumbo, A Mateos, M Liu, K Cakana, A Van de Velde, H Richardson, P AF San Miguel, J. F. Schlag, R. Khuageya, N. Shpilberg, O. Dimopoulos, M. Kropff, M. Spicka, L. Petrucci, M. Sarrioilova, O. Dmoszynska, A. Abdulkadyrov, K. Schots, R. Jiang, B. Palumbo, A. Mateos, M. Liu, K. Cakana, A. Van de Velde, H. Richardson, P. TI MMY-3002: A phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [San Miguel, J. F.; Mateos, M.] Hosp Univ Salamanca, Salamanca, Spain. [Schlag, R.] Praxisklin Dr Schlag, Wurzburg, Germany. [Khuageya, N.] SP Botkin Moscow City Clin Hosp, Moscow, Russia. [Shpilberg, O.] Rabin Med Ctr, Petah Tiqwa, Israel. [Dimopoulos, M.] Univ Athens, Sch Med, Athens, Greece. [Kropff, M.] Univ Munster, D-4400 Munster, Germany. [Spicka, L.] Univ Hosp Prague, Prague, Czech Republic. [Petrucci, M.] Univ Roma La Sapienza, Rome, Italy. [Sarrioilova, O.] Nizhnii Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia. [Dmoszynska, A.] Med Univ Lublin, Lublin, Poland. [Abdulkadyrov, K.] St Petersburg Clin Res Inst Hematol & Transfusiol, St Petersburg, Russia. [Jiang, B.] Peking Univ, Peoples Hosp, Beijing, Peoples R China. [Palumbo, A.] Univ Turin, Turin, Italy. [Liu, K.] Johnson & Johnson PRD, Raritan, NJ USA. [Cakana, A.; Van de Velde, H.] Johnson & Johnson PRD, Beerse, Belgium. [Richardson, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 28 Z9 29 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 76 BP 31A EP 31A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800077 ER PT J AU Cserti, CM Xu, S Sutherland, R Nayar, R Reis, M Dorn, ME Quagliaroli, RO Sullivan, JD Preffer, FI Dzik, WH AF Cserti, Christine M. Xu, Songyi Sutherland, Robert Nayar, Rakesh Reis, Marciano Dorn, Michelle E. Quagliaroli, Robert O. Sullivan, John D. Preffer, Frederic I. Dzik, Walter H. TI Quantitative flow cytometric assessment of CD36 (Platelet glycoprotein IV) expression on monocytes and platelets: Assay development, role in Plasmodium falciparum risk assessment, and relationship to sickle hemoglobin SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Cserti, Christine M.; Sutherland, Robert; Reis, Marciano] Univ Hlth Network, Toronto Gen Hosp, Dept Lab Hematol, Toronto, ON, Canada. [Cserti, Christine M.; Sutherland, Robert; Reis, Marciano] Univ Toronto, Lab Med & Pathobiol, Toronto, ON, Canada. [Nayar, Rakesh] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada. [Dorn, Michelle E.; Quagliaroli, Robert O.; Sullivan, John D.; Preffer, Frederic I.; Dzik, Walter H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Dzik, Walter H.] Harvard Univ, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 3857 BP 32B EP 32B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101100113 ER PT J AU Tai, YT Tonon, G Leiba, M Li, XF Burger, P Song, W Podar, K Munshi, N Anderson, KC AF Tai, Yu Tzu Tonon, Giovanni Leiba, Merav Li, Xian-Feng Burger, Peter Song, Weihua Podar, Klaus Munshi, Nihkil Anderson, Kenneth C. TI CS1, a new surface target on multiple myeloma (MM) cells, protects myeloma cells from apoptosis via-regulation of ERKI/2, AKT and STAT3 signaling cascades SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Tai, Yu Tzu; Tonon, Giovanni; Leiba, Merav; Li, Xian-Feng; Burger, Peter; Song, Weihua; Podar, Klaus; Munshi, Nihkil; Anderson, Kenneth C.] Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst, Dept Med Sch, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 109 BP 40A EP 41A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100800110 ER PT J AU Driscoll, JJ Pelluru, D Prabhala, R Lefkitymiatis, K Fulciniti, M Munshi, NC AF Driscoll, James J. Pelluru, Dheeraj Prabhala, Rao Lefkitymiatis, Konstantinos Fulciniti, Mariateresa Munshi, Nikhil C. TI DNA damage induced sumoylation of p53 in multiple myeloma: Implications for cell proliferation and apoptosis SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Driscoll, James J.; Pelluru, Dheeraj; Prabhala, Rao; Lefkitymiatis, Konstantinos; Munshi, Nikhil C.] Boston VA Healthcare, W Roxbury, MA USA. [Driscoll, James J.; Pelluru, Dheeraj; Prabhala, Rao; Fulciniti, Mariateresa; Munshi, Nikhil C.] Dana Farber Canc Inst, Boston, MA USA. [Lefkitymiatis, Konstantinos; Fulciniti, Mariateresa] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 112 BP 41A EP 41A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800113 ER PT J AU Heinrichs, S Kulkarni, RV Bueso-Ramos, CE Loh, M Levine, R Li, C Neuberg, DS Kornblau, SM Issa, JP Gilliland, DG Estey, EH Look, AT AF Heinrichs, Stefan Kulkarni, Rima V. Bueso-Ramos, Carlos E. Loh, Mignon Levine, Ross Li, Cheng Neuberg, Donna S. Kornblau, Sieve M. Issa, Jean-Pierre Gilliland, D. Gary Estey, Elihu H. Look, A. Thomas TI Large regions of uniparental disomy (UPD) establish clonal hematopoietic stem cell selection in a subset of Myelodysplastic syndrome (MDS) patients with normal bone marrow cell karyotypes SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Heinrichs, Stefan; Kulkarni, Rima V.; Li, Cheng; Neuberg, Donna S.; Look, A. Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. [Levine, Ross; Gilliland, D. Gary] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Bueso-Ramos, Carlos E.; Kornblau, Sieve M.; Issa, Jean-Pierre; Estey, Elihu H.] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA. [Loh, Mignon] Univ Calif San Francisco, Dept Hematol Oncol, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 120 BP 43A EP 44A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100800121 ER PT J AU Sarantopoulos, S Stevenson, KE Kim, HT Bhuiya, NS Cutler, CS Soiffer, RJ Antin, JH Ritz, J AF Sarantopoulos, Stefanie Stevenson, Kristen E. Kim, Haesook T. Bhuiya, Nazmim S. Cutler, Corey S. Soiffer, Robert J. Antin, Joseph H. Ritz, Jerome TI Chronic GVHD is associated with a BAFF driven BCR-activated B cell repertoire SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Sarantopoulos, Stefanie; Bhuiya, Nazmim S.; Cutler, Corey S.; Soiffer, Robert J.; Antin, Joseph H.; Ritz, Jerome] Dana Farber Canc Inst, Boston, MA 02115 USA. [Stevenson, Kristen E.; Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 166 BP 56A EP 57A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100800167 ER PT J AU Richardson, P Jagannath, S Raje, N Jakubowiak, A Lonial, S Avigan, D Ghobrial, I Schlossman, R Mazumder, A Munshi, N Joyce, R Doss, D Warren, D Hayes, S Giove, L Kaster, S Delaney, C Lauria, M Mitsiades, C Hideshima, T Knight, R Esseltine, DL Anderson, K AF Richardson, Paul Jagannath, Sundar Raje, Noopur Jakubowiak, Andrzej Lonial, Sagar Avigan, David Ghobrial, Irene Schlossman, Robert Mazumder, Amitabha Munshi, Nikhil Joyce, Robin Doss, Deborah Warren, Diane Hayes, Stephen Giove, Lawrence Kaster, S. Delaney, Carol Lauria, Marisa Mitsiades, Constantine Hideshima, Teru Knight, Robert Esseltine, Dixie-Lee Anderson, Kenneth TI Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): Preliminary results of a phase 1/2 study SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Richardson, Paul; Ghobrial, Irene; Schlossman, Robert; Munshi, Nikhil; Doss, Deborah; Warren, Diane; Hayes, Stephen; Mitsiades, Constantine; Hideshima, Teru; Anderson, Kenneth] Dana Farber Canc Inst, Boston, MA 02115 USA. [Jagannath, Sundar; Mazumder, Amitabha; Giove, Lawrence] St Vincents Comprehens Canc Ctr, New York, NY USA. [Raje, Noopur] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Jakubowiak, Andrzej] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Lonial, Sagar] Winship Canc Inst, Atlanta, GA USA. [Avigan, David; Joyce, Robin; Delaney, Carol; Lauria, Marisa] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Knight, Robert] Celgene Inc, Summit, NJ USA. [Esseltine, Dixie-Lee] Millennium Pharmaceut Inc, Boston, MA USA. NR 0 TC 10 Z9 10 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 187 BP 63A EP 63A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800188 ER PT J AU de Jong, JL Davidson, AJ Wang, Y Palis, J Daley, GQ Zon, LI AF de Jong, Jill L. Davidson, Alan J. Wang, Yuan Palis, James Daley, George Q. Zon, Leonard I. TI Retinoic acid blockade increases primitive blood cell formation in cdx4 mutant zebrafish embryos, murine yolk sac explants and differentiated embryonic stem cells SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [de Jong, Jill L.; Wang, Yuan; Daley, George Q.; Zon, Leonard I.] Childrens Hosp, Harvard Med Sch, Dana Farber Canc Inst, Div Hematol Oncol,Stem Cell Program, Boston, MA 02115 USA. [Davidson, Alan J.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Palis, James] Univ Rochester, Dept Pediat, Rochester, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 201 BP 67A EP 67A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800202 ER PT J AU Mercher, T Cornejo, M Sears, C Kindler, T Moore, S Aster, J Gilliland, DG AF Mercher, Thomas Cornejo, Melanie Sears, Christopher Kindler, Thomas Moore, Sandra Aster, Jon Gilliland, D. Gary TI Notch signaling induces megakaryocytic cell fate SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Mercher, Thomas; Cornejo, Melanie; Kindler, Thomas; Moore, Sandra; Gilliland, D. Gary] Brigham & Womens Hosp, Boston, MA 02115 USA. [Sears, Christopher] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. [Aster, Jon] Brigham & Womens Hosp, Boston, MA 02115 USA. RI Mercher, Thomas/J-2446-2014 OI Mercher, Thomas/0000-0003-1552-087X NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 200 BP 67A EP 67A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800201 ER PT J AU Frohling, S Scholl, C Levine, RL Loriaux, M Boggon, TJ Bernard, OA Berger, R Dohner, H Dohner, K Ebert, BL Teckie, S Golub, TR Schittenhelm, MM Lee, BH Griffin, JD Stone, RM Heinrich, MC Deininger, MWN Druker, BJ Gilliland, DG AF Frohling, Stefan Scholl, Claudia. Levine, Ross L. Loriaux, Marc Boggon, Titus J. Bernard, Olivier A. Berger, Roland Dohner, Hartmut Dohner, Konstanze Ebert, Benjamin L. Teckie, Sewit Golub, Todd R. Schittenhelm, Marcus M. Lee, Benjamin H. Griffin, James D. Stone, Richard M. Heinrich, Michael C. Deininger, Michael W. N. Druker, Brian J. Gilliland, D. Gary TI Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Frohling, Stefan; Scholl, Claudia.; Levine, Ross L.; Lee, Benjamin H.; Gilliland, D. Gary] Brigham & Womens Hosp, Boston, MA 02115 USA. [Loriaux, Marc; Heinrich, Michael C.; Deininger, Michael W. N.; Druker, Brian J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Boggon, Titus J.] Yale Univ, Sch Med, New Haven, CT USA. [Bernard, Olivier A.; Berger, Roland] Inst Natl Sante & Rech Med, E0210, Paris, France. [Dohner, Hartmut; Dohner, Konstanze] Univ Ulm, Ulm, Germany. [Ebert, Benjamin L.; Teckie, Sewit; Golub, Todd R.] MIT, Broad Inst Harvard, Cambridge, MA 02139 USA. [Schittenhelm, Marcus M.] Univ Tubingen Hosp, Tubingen, Germany. [Griffin, James D.; Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 206 BP 68A EP 68A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800207 ER PT J AU Hahn, CK Ross, KN Kakoza, RM Carr, SA Du, J Ong, SE Golub, TR Stegmaier, K AF Hahn, Cynthia K. Ross, Kenneth N. Kakoza, Rose M. Carr, Steven A. Du, Jinyan Ong, Shao-En Golub, Todd R. Stegmaier, Kimberly TI Syk is a new target for AML differentiation SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Hahn, Cynthia K.; Kakoza, Rose M.; Du, Jinyan; Golub, Todd R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Carr, Steven A.; Du, Jinyan; Ong, Shao-En; Golub, Todd R.; Stegmaier, Kimberly] Harvard Univ, MIT, Broad Inst, Canc Program, Cambridge, MA 02139 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 209 BP 69A EP 69A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800210 ER PT J AU Sackstein, R Merzaban, JS Cain, DW Dagia, NM Spencer, JA Lin, CP Wohlgemuth, R AF Sackstein, Robert Merzaban, Jasmeen S. Cain, Derek W. Dagia, Nilesh M. Spencer, Joela A. Lin, Charles P. Wohlgemuth, Roland TI Ex vivo glycan engineering of membrane CD44 to create HCELL programs human mesenchymal stem cell trafficking to bone SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Sackstein, Robert; Merzaban, Jasmeen S.; Cain, Derek W.; Dagia, Nilesh M.] Brigham & Womens Hosp, Harvard Med Sch, Boston, MA 02115 USA. [Spencer, Joela A.; Lin, Charles P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wohlgemuth, Roland] Sigma Aldrich Chem, Buchs, Switzerland. RI Spencer, Joel/A-4590-2013 NR 0 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 218 BP 72A EP 72A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800219 ER PT J AU Mi, SL Lu, J Sun, M Li, ZJ Zhang, H Neilly, MB Wang, YG Qian, ZJ Jin, J Zhang, YM Bohlander, SK Le Beau, MM Larson, R Golub, TR Rowley, JD Chen, JJ AF Mi, Shuangli Lu, Jun Sun, Miao Li, Zejuan Zhang, Hao Neilly, Mary Beth Wang, Yungui Qian, Zhijian Jin, Jie Zhang, Yanming Bohlander, Stefan K. Le Beau, Michelle M. Larson, Richard Golub, Todd R. Rowley, Janet D. Chen, Jianjun TI MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Mi, Shuangli; Sun, Miao; Li, Zejuan; Neilly, Mary Beth; Qian, Zhijian; Zhang, Yanming; Le Beau, Michelle M.; Larson, Richard; Rowley, Janet D.; Chen, Jianjun] Univ Chicago, Chicago, IL 60637 USA. [Lu, Jun; Zhang, Hao; Golub, Todd R.] Broad Inst MIT & Harvard, Cambridge, MA USA. [Lu, Jun; Golub, Todd R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Wang, Yungui] Zhejiang Univ, Inst Hematol, Hangzhou 310027, Peoples R China. [Bohlander, Stefan K.] Univ Munich, Hosp Grosshadern, Munich, Germany. [Golub, Todd R.] Harvard Med Sch, Howard Hughes Med Inst, Boston, MA USA. NR 0 TC 2 Z9 2 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 231 BP 75A EP 75A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800232 ER PT J AU Raje, N Hideshima, T Vallet, S Cirstea, D Kiziltepe, T Chhetri, S Mani, M Mukherjee, S Carrasco, DR Mitsiades, C Rooney, M Podar, K Okawa, Y Ikeda, H Richardson, PG Chauhan, D Munshi, NC Sharma, S Parikh, H Chabner, B Anderson, KC AF Raje, Noopur Hideshima, Teru Vallet, Sonia Cirstea, Diana Kiziltepe, Tanyel Chhetri, Shweta Mani, Mala Mukherjee, Siddhartha Carrasco, Daniel Ruben Mitsiades, Constantine Rooney, Melissa Podar, Klaus Okawa, Yutaka Ikeda, Hiroshi Richardson, Paul G. Chauhan, Dharminder Munshi, Nikhil C. Sharma, Somesh Parikh, Himanshu Chabner, Bruce Anderson, Kenneth C. TI Preclinical validation of a clinical grade novel specific small molecule cyclin D1 inhibitor, P276-00 for the treatment of multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Raje, Noopur; Hideshima, Teru; Vallet, Sonia; Cirstea, Diana; Kiziltepe, Tanyel; Chhetri, Shweta; Mani, Mala; Carrasco, Daniel Ruben; Mitsiades, Constantine; Rooney, Melissa; Podar, Klaus; Okawa, Yutaka; Ikeda, Hiroshi; Richardson, Paul G.; Chauhan, Dharminder; Munshi, Nikhil C.; Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Mukherjee, Siddhartha; Chabner, Bruce] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. [Sharma, Somesh; Parikh, Himanshu] Nicholas Piramal India Ltd, Bumbay, India. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 256 BP 82A EP 83A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100800257 ER PT J AU Raab, MS Podar, K Zhang, J Tonon, G Fruehauf, JH Breitkreutz, I Lin, BK Hideshima, T Chauhan, D Anderson, KC AF Raab, Marc S. Podar, Klaus Zhang, Jing Tonon, Giovanni Fruehauf, Johannes H. Breitkreutz, Iris Lin, Boris K. Hideshima, Teru Chauhan, Dharminder Anderson, Kenneth C. TI Targeting proteinkinase C alters ER-stress and b-catenin signaling in multiple myeloma: Therapeutic implications SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Raab, Marc S.; Podar, Klaus; Zhang, Jing; Tonon, Giovanni; Breitkreutz, Iris; Hideshima, Teru; Chauhan, Dharminder; Anderson, Kenneth C.] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA USA. [Raab, Marc S.] Univ Heidelberg, Dept Internal Med 5, Heidelberg, Germany. [Fruehauf, Johannes H.] Harvard Med Sch, Div Gastroenterol, BIDMC, Boston, MA USA. [Lin, Boris K.] Eli Lilly & Co, Indianapolis, IN 46285 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 258 BP 83A EP 83A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800259 ER PT J AU Saito, N Ishikawa, F Shimoda, K Yoshida, S Saito, Y Fukata, M Kawano, N Shulz, LD Akashi, K Harada, M AF Saito, Noriyuki Ishikawa, Fumihiko Shimoda, Kazuya Yoshida, Shuro Saito, Yoriko Fukata, Mitsuhiro Kawano, Noriaki Shulz, Leonard D. Akashi, Koichi Harada, Mine TI Transplantation of primary human CD34+CD38 - Hematopoietic stem cells recapitulates idiopathic myelofibrosis in the NOD/scid/IL2rgKO mice SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Saito, Noriyuki; Ishikawa, Fumihiko; Yoshida, Shuro; Fukata, Mitsuhiro; Kawano, Noriaki; Akashi, Koichi; Harada, Mine] Kyushu Univ, Grad Sch Med, Dept Med & Biosyst Sci, Fukuoka 812, Japan. [Ishikawa, Fumihiko; Saito, Yoriko] RIKEN, Res Ctr Allergy & Immunol, Yokohama, Kanagawa, Japan. [Saito, Yoriko] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Akashi, Koichi] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Harada, Mine] Jackson Lab, Bar Harbor, ME 04609 USA. [Shimoda, Kazuya] Miyazaki Univ, Dept Internal Med, Miyazaki, Japan. [Harada, Mine] Omuta Natl Hosp, Fukuoka, Japan. RI 石川, 文彦/L-4488-2014 NR 0 TC 1 Z9 1 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 260 BP 84A EP 84A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800261 ER PT J AU Flick, MJ Chauhan, AK Welch, S Shaw, MA Talmage, KE Mullins, ES Palumbo, JS Thornton, S Wagner, DD Degen, JL AF Flick, Matthew J. Chauhan, Anil K. Welch, Sara Shaw, Maureen A. Talmage, Kathryn E. Mullins, Eric S. Palumbo, Joseph S. Thornton, Sherry Wagner, Denisa D. Degen, Jay L. TI Mice engineered to express a form of thrombin favoring protein C are resistant to S-aureus-induced sepsis SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Flick, Matthew J.; Welch, Sara; Shaw, Maureen A.; Talmage, Kathryn E.; Mullins, Eric S.; Palumbo, Joseph S.; Thornton, Sherry; Degen, Jay L.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH USA. [Wagner, Denisa D.] Harvsrd Med Sch, CBR Inst Biomed Res, Dept Pathol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 267 BP 86A EP 86A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800268 ER PT J AU Avigan, D Rosenblatt, J Vasir, B Wu, Z Bissonnette, A MacNamara, C Uhl, L Lenahan, C Miller, K Joyce, R Levine, JD Lowe, K Dombagoda, D Richardson, P Anderson, K Munshi, N Kufe, D AF Avigan, David Rosenblatt, Jacalyn Vasir, Baldev Wu, Zekui Bissonnette, Adam MacNamara, Claire Uhl, Lynne Lenahan, Corrinne Miller, Kenneth Joyce, Robin Levine, James D. Lowe, Karen Dombagoda, Dilani Richardson, Paul Anderson, Kenneth Munshi, Nikhil Kufe, Donald TI Phase I study of vaccination with dendritic cell myeloma fusions SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Avigan, David; Rosenblatt, Jacalyn; MacNamara, Claire; Uhl, Lynne; Lenahan, Corrinne; Miller, Kenneth; Joyce, Robin; Levine, James D.; Lowe, Karen; Dombagoda, Dilani] Beth Israel Deaconess Med Ctr, Boston, MA USA. [Vasir, Baldev; Bissonnette, Adam; Lowe, Karen; Richardson, Paul; Anderson, Kenneth; Munshi, Nikhil; Kufe, Donald] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 284 BP 90A EP 91A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100800285 ER PT J AU Lu, W Metulonis, UA Doherty-Gilman, A Lee, H Dean-Clower, E Rosulek, A Gibson, C Goodman, A Davis, RB Buring, JE Wayne, PM Penson, RT Rosenthal, DS AF Lu, Weidong Metulonis, Ursula A. Doherty-Gilman, Anne Lee, Hang Dean-Clower, Elizabeth Rosulek, Andrew Gibson, Carolyn Goodman, Annekathryn Davis, Roger B. Buring, Julie E. Wayne, Peter M. Penson, Richard T. Rosenthal, David S. TI Granulocyte colony-stimulating factor (G-CSF) levels in a randomized, controlled acupuncture trial for chemotherapy-induced neutropenia SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Lu, Weidong; Doherty-Gilman, Anne; Dean-Clower, Elizabeth; Rosulek, Andrew; Rosenthal, David S.] Dana Farber Canc Inst, Zakim Ctr Integrat Therapies, Boston, MA 02115 USA. [Lee, Hang; Gibson, Carolyn; Goodman, Annekathryn; Penson, Richard T.] Massachusetts Gen Hosp, Dept Gynecol Med Oncol, Boston, MA 02114 USA. [Lee, Hang] MGH Biostat Ctr, Boston, MA USA. [Metulonis, Ursula A.; Rosenthal, David S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Lu, Weidong; Wayne, Peter M.] New England Sch Acupunct, Newton, MA USA. [Davis, Roger B.; Wayne, Peter M.] Harvard Med Sch, Osher Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4088 BP 91B EP 91B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101100344 ER PT J AU Chauhan, AK Kiucka, J Brill, A Walsh, MT Wagner, DD AF Chauhan, Anil K. Kiucka, Janka Brill, Alexander Walsh, Meghan T. Wagner, Denisa D. TI Deficiency of the VWF-cleaving protease ADAMTS13 results in increased leukocyte rolling and adhesion in mice SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Chauhan, Anil K.; Kiucka, Janka; Brill, Alexander; Walsh, Meghan T.; Wagner, Denisa D.] Harvard Univ, Sch Med, CBR Inst Biomed Res, Dept Pathol, Cambridge, MA 02138 USA. [Chauhan, Anil K.; Kiucka, Janka; Brill, Alexander; Wagner, Denisa D.] CBR Inst Biomed Res, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 290 BP 92A EP 92A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800291 ER PT J AU Li, L Wang, H Boussiotis, VA AF Li, Lequn Wang, Hui Boussiotis, Vassiliki A. TI Roscovitine prevents TCR-mediated T cell clonal expansion in-vitro and protects against GvHD in-vivo SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Li, Lequn; Wang, Hui; Boussiotis, Vassiliki A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 318 BP 100A EP 100A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800319 ER PT J AU Krivtsov, AV Feng, Z Lemieux, M Faber, J Xia, X Kung, AL Armstrong, SA AF Krivtsov, Andrei V. Feng, Zhaohui Lemieux, Madeleine Faber, Joerg Xia, Xiaobo Kung, Andrew L. Armstrong, Scott A. TI Global increase in H3K79 dimethylation in murine and human MLL-AF4 lymphoblastic leukemias SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Krivtsov, Andrei V.; Armstrong, Scott A.] Childrens Hosp, Boston, MA 02115 USA. [Feng, Zhaohui; Lemieux, Madeleine; Xia, Xiaobo; Kung, Andrew L.; Armstrong, Scott A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 344 BP 108A EP 108A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800345 ER PT J AU Friese, CR Abel, GA Magazu, LA Neville, BA Richardson, LC Earle, CC AF Friese, Christopher R. Abel, Gregory A. Magazu, Lysa A. Neville, Bridget A. Richardson, Lisa C. Earle, Craig C. TI Predictors of diagnosis delay and complications for newly-diagnosed myeloma patients. SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Friese, Christopher R.; Abel, Gregory A.; Magazu, Lysa A.; Neville, Bridget A.; Earle, Craig C.] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA. [Friese, Christopher R.; Earle, Craig C.] Harvard Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA USA. [Abel, Gregory A.; Earle, Craig C.] Harvard Med Sch, Dept Med, Boston, MA USA. [Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 368 BP 115A EP 116A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100800369 ER PT J AU Schittenhelm, MM Kampa, KM Yee, KWH Kanz, L Heinrich, MC AF Schittenhelm, Marcus M. Kampa, Kerstin M. Yee, Kevin W. H. Kanz, Lothar Heinrich, Michael C. TI In vitro modeling of the use of FLT3 inhibitors to reduce chemotherapy doses for elderly patients with AML SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Schittenhelm, Marcus M.; Kampa, Kerstin M.; Kanz, Lothar] Med Univ Klin, Dept Hematol Oncol Rheumatol Immunol & Pulmonol, Tubingen, Germany. Oregon Hlth & Sci Univ, Inst Canc, Dept Med, Div Hematol Oncol, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Inst Canc, Dept Cell & Dev Biol, Div Hematol Oncol, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4213 BP 120B EP 121B PN 2 PG 2 WC Hematology SC Hematology GA 233OV UT WOS:000251101100469 ER PT J AU Smith, MR Zhang, L Gordon, LI Foran, J Kahl, B Gascoyne, RD Advani, R Paietta, E Weller, E Horning, SJ AF Smith, Mitchell R. Zhang, Lijun Gordon, Leo I. Foran, James Kahl, Brad Gascoyne, Randy D. Advani, Ranjana Paietta, Elisabeth Weller, Edie Horning, Sandra J. TI Phase II study of R-CHOP followed by Y-90-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern cooperative oncology group study E1499 SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Smith, Mitchell R.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Zhang, Lijun; Weller, Edie] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gordon, Leo I.] Northwestern Univ, Chicago, IL 60611 USA. [Foran, James] Univ Alabama, Birmingham, AL USA. [Kahl, Brad] Univ Wisconsin, Madison, WI USA. [Gascoyne, Randy D.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. [Advani, Ranjana; Horning, Sandra J.] Stanford Univ, Stanford, CA 94305 USA. [Paietta, Elisabeth] Our Lady Mercy Canc Ctr, Bronx, NY USA. NR 0 TC 18 Z9 19 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 389 BP 121A EP 121A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800390 ER PT J AU Mulligan, G Bryant, B Roels, S Bolt, A Meng, Y Koenig, E Boral, A Esseltine, DL Anderson, KA Bergsagel, PL Sonneveld, P Broyl, A Mitsiades, C Chng, WJ Richardson, PG Trepicchio, W AF Mulligan, George Bryant, Barb Roels, Steven Bolt, Andrew Meng, Yan Koenig, Erik Boral, Anthony Esseltine, Dixie-Lee Anderson, Kenneth A. Bergsagel, Peter Leif Sonneveld, Pieter Broyl, Annemiek Mitsiades, Constantine Chng, Wee-Joo Richardson, Paul G. Trepicchio, William TI Pharmacogenomics study of biological pathways related to bortezomilb activity in myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Mulligan, George; Bryant, Barb; Koenig, Erik; Boral, Anthony; Esseltine, Dixie-Lee; Trepicchio, William] Millennium Pharmaceut Inc, Cambridge, MA USA. [Roels, Steven] Helicos BioSci Corp, Cambridge, MA USA. [Meng, Yan] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Anderson, Kenneth A.; Mitsiades, Constantine; Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sonneveld, Pieter; Broyl, Annemiek] Erasmus MC, Rotterdam, Netherlands. [Bergsagel, Peter Leif; Chng, Wee-Joo] Mayo Clin, Ctr Comprehens Canc, Scottsdale, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 392 BP 122A EP 122A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800393 ER PT J AU Braunstein, MJ Carrasco, DR Campagne, F Mukherjee, P Sukhdeo, K Protopopov, A Anderson, KC Batuman, OA AF Braunstein, Marc J. Carrasco, Daniel R. Campagne, Fabien Mukherjee, Piali Sukhdeo, Kumar Protopopov, Alexei Anderson, Kenneth C. Batuman, Olcay A. TI Genome-wide profiling of endothelial progenitor cells in multiple myeloma: Overlaps with myeloma tumor cells and common cancer genepathways SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Braunstein, Marc J.; Batuman, Olcay A.] Suny Downstate Med Ctr, Div Hematol Oncol, Brooklyn, NY 11203 USA. [Carrasco, Daniel R.; Sukhdeo, Kumar; Protopopov, Alexei; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Campagne, Fabien; Mukherjee, Piali] Cornell Univ, Weill Med Coll, Inst Computat Biomed, New York, NY USA. RI Campagne, Fabien/F-5158-2010 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 394 BP 123A EP 123A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800395 ER PT J AU Keats, J Chapman, M Carpten, J Chng, WJ Baker, A Ahmann, G Trudel, S Siegel, D Rajkumar, SV Alsina, M Richardson, P Anderson, K Auclair, D Perkins, LM Trent, J Golub, TR Fonseca, R AF Keats, Jonathan Chapman, Mike Carpten, John Chng, Wee-Joo Baker, Angela Ahmann, Gregory Trudel, Suzanne Siegel, David Rajkumar, S. Vincent Alsina, Melissa Richardson, Paul Anderson, Kenneth Auclair, Daniel Perkins, Louise M. Trent, Jeffrey Golub, Todd R. Fonseca, Rafael TI Genome-wide profiling of gene expression and DNA copy number alterations in multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Keats, Jonathan; Chng, Wee-Joo; Ahmann, Gregory; Fonseca, Rafael] Mayo Clin, Div Hematol Oncol, Scottsdale, AZ USA. [Chapman, Mike; Golub, Todd R.] MIT, Broad Inst Harvad, Cambridge, MA 02139 USA. [Carpten, John; Baker, Angela; Trent, Jeffrey] TGen, Phoenix, AZ USA. [Trudel, Suzanne] Med Oncol Univ Hlth Network, Toronto, ON, Canada. [Siegel, David] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Rajkumar, S. Vincent] Mayo Clin, Rochester, MN USA. [Alsina, Melissa] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Richardson, Paul; Anderson, Kenneth] Dana Farber Canc Inst, Boston, MA 02115 USA. [Auclair, Daniel; Perkins, Louise M.] Multiple Myeloma Res Consortium, Norwalk, CT USA. RI Keats, Jonathan/B-2047-2009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 396 BP 123A EP 123A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800397 ER PT J AU Josefsson, EC Rumjantseva, V Dahlgren, C Bergmier, W Wagner, DD Hartwig, JH Hoffmeister, KM AF Josefsson, Entrina C. Rumjantseva, Viktoria Dahlgren, Claes Bergmier, Wolfgang Wagner, Denisa D. Hartwig, John H. Hoffmeister, Karin M. TI Metalloproteinase inhibitors increase the survival of long-term refrigerated platelets in mice SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Josefsson, Entrina C.; Rumjantseva, Viktoria; Hartwig, John H.; Hoffmeister, Karin M.] Brigham & Womens Hosp, Harvard Med Sch, Dept Med, Boston, MA USA. [Dahlgren, Claes] Gothenburg Univ, Dept Rheumatol & Inflamat Res, Gothenburg, Sweden. [Bergmier, Wolfgang; Wagner, Denisa D.] Harvard Med Sch, CBR Inst Biomed Res, Boston, MA USA. RI TEST-GU, TEST-GU/B-5469-2010 NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 419 BP 130A EP 130A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800420 ER PT J AU Li, AH Westman, UB Golovleva, I Kutok, JL Silverman, LB Sallan, SE Roos, G AF Li, Aihong Westman, Ulla-Britt Golovleva, Irina Kutok, Jeffery L. Silverman, Lewis B. Sallan, Stephen E. Roos, Goran TI Wilms tumor 1 gene (WT1) isoforms in leukemia and lymphoma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Li, Aihong; Westman, Ulla-Britt; Golovleva, Irina; Roos, Goran] Inst Med Biosci, Umea, Sweden. [Kutok, Jeffery L.] Brigham & Womens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA. [Silverman, Lewis B.; Sallan, Stephen E.] Childrens Hosp, Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4265 BP 134B EP 134B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101101036 ER PT J AU Xu, HM Geiger, H Szczur, K Deira, D Zheng, Y Settleman, J Williams, D Filippi, MD AF Xu, Haiming Geiger, Harmut Szczur, Kathleen Deira, Deidra Zheng, Yi Settleman, Jeffrey Williams, David Filippi, Marie-Dominique TI Loss of the rho GTPase activating protein p190-B enhances hematopoietic stem cell engraftment potential SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Xu, Haiming; Geiger, Harmut; Szczur, Kathleen; Deira, Deidra; Zheng, Yi; Williams, David; Filippi, Marie-Dominique] Cincinnati Childrens Res Fdn, Div Expt Hematol, Cincinnati, OH USA. [Xu, Haiming] Univ Cincinnati, Coll Med, Cell & Mol Biol Grad Program, Cincinnati, OH 45221 USA. [Settleman, Jeffrey] Massachusetts Gen Hosp, Ctr Canc, Harvard Med Sch, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 508 BP 156A EP 156A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800509 ER PT J AU LaBelle, JL Fisher, JK Katz, SG Bird, GH Lawrence, CE Silverstein, AM Walensky, LD AF LaBelle, James L. Fisher, Jill K. Katz, Samuel G. Bird, Gregory H. Lawrence, Chelsea E. Silverstein, Amy M. Walensky, Loren D. TI Pharmacologic, replacement of BIM BH3 reactivates apoptosis in hematologic cancer and lymphoproliferative disease SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [LaBelle, James L.; Fisher, Jill K.; Katz, Samuel G.; Bird, Gregory H.; Lawrence, Chelsea E.; Silverstein, Amy M.; Walensky, Loren D.] Childrens Hosp Boston, Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol,Program Canc Chem Biol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 524 BP 161A EP 161A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800525 ER PT J AU Goh, KC Ong, WC Hu, C Hentze, H Liang, AL Stunkel, W Tan, YC Sangthongpitag, K Goh, SK Sieh, S Bonday, ZQ William, AD Lee, A Llanchard, S Liu, TC Sattler, M Griffin, JD Dymock, BW Kantharaj, E Wood, JM AF Goh, Kee C. Ong, Wai C. Hu, Changyong Hentze, Harries Liang, Ai L. Stunkel, Walter Tan, Yong C. Sangthongpitag, Kanda Goh, Siok K. Sieh, Shirly Bonday, Zahid Q. William, Anthony D. Lee, Angeline Llanchard, Stephanie Liu, Te C. Sattler, Martin Griffin, James D. Dymock, Brian W. Kantharaj, Ethirajulu Wood, Jeanette M. TI SB1518: A potent and orally active JAK2 inhibitor for the treatment of myeloproliferative disorders. SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Goh, Kee C.; Ong, Wai C.; Hu, Changyong; Hentze, Harries; Liang, Ai L.; Stunkel, Walter; Tan, Yong C.; Sangthongpitag, Kanda; Goh, Siok K.; Sieh, Shirly; Bonday, Zahid Q.; William, Anthony D.; Lee, Angeline; Llanchard, Stephanie; Dymock, Brian W.; Kantharaj, Ethirajulu; Wood, Jeanette M.] SBIO Pte Ltd, Res & Preclin Dev, Singapore, Singapore. [Liu, Te C.] Natl Univ Singapore Hosp, Div Clin Hematol, Singapore, Singapore. [Sattler, Martin; Griffin, James D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. NR 0 TC 7 Z9 7 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 538 BP 165A EP 166A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100800539 ER PT J AU McMillin, DW Negri, JM Hayden, P Weisberg, E Klippel, S Schlossman, R Munshi, NC Mitsiades, N Richardson, PG Anderson, KC Mitsiades, CS AF McMillin, Douglas W. Negri, Joseph M. Hayden, Patrick Weisberg, Ellen Klippel, Steffen Schlossman, Robert Munshi, Nikhil C. Mitsiades, Nicholas Richardson, Paul G. Anderson, Kenneth C. Mitsiades, Constantine S. TI Compartment-specific bioluminescence Imaging (CS-BLI): A high-throughput approach to identify novel anti-neoplastic therapies that overcome the protection of stromal cells. SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [McMillin, Douglas W.; Negri, Joseph M.; Hayden, Patrick; Weisberg, Ellen; Klippel, Steffen; Schlossman, Robert; Munshi, Nikhil C.; Mitsiades, Nicholas; Richardson, Paul G.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [McMillin, Douglas W.; Negri, Joseph M.; Hayden, Patrick; Weisberg, Ellen; Klippel, Steffen; Schlossman, Robert; Munshi, Nikhil C.; Mitsiades, Nicholas; Richardson, Paul G.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Harvard Med Sch, Dept Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 536 BP 165A EP 165A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800537 ER PT J AU Holalkere, N Hochberg, EP Takvorian, R Blake, M Toomey, C Michaelson, J Rahemtullah, A Abramson, JS AF Holalkere, Nagaraj Hochberg, Ephraim P. Takvorian, Ronald Blake, Michael Toomey, Christiana Michaelson, James Rahemtullah, Aliyah Abramson, Jeremy S. TI Intensity of FDG uptake on PET scan varies by histologic subtype of Hodgkin lymphoma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Hochberg, Ephraim P.; Takvorian, Ronald; Toomey, Christiana; Michaelson, James; Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Holalkere, Nagaraj; Blake, Michael] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Rahemtullah, Aliyah] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 BP 166B EP 167B PN 2 PG 2 WC Hematology SC Hematology GA 233OV UT WOS:000251101101164 ER PT J AU Klippel, S Jakubikova, J Jenkins, L Negri, JM Tesmenitsky, Y Rooney, M Delmore, J McMillin, DW Selliah, R Robbins, P Mitsiades, N Schlossman, R Sahasrabudhe, S Anderson, KC Richardson, PG Mitsiades, CS AF Klippel, Steffen Jakubikova, Jana Jenkins, Lauren Negri, Joseph M. Tesmenitsky, Yevgenia Rooney, Melissa Delmore, Jake McMillin, Douglas W. Selliah, R. Robbins, P. Mitsiades, Nicholas Schlossman, Robert Sahasrabudhe, Sudhir Anderson, Kenneth C. Richardson, Paul G. Mitsiades, Constantine S. TI In vitro and in vivo anti-myeloma activity of PRLX, an orally-bioavailable agent against cells with constitutive activation of RAS or its downstream pathway. SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Klippel, Steffen; Jakubikova, Jana; Jenkins, Lauren; Negri, Joseph M.; Tesmenitsky, Yevgenia; Rooney, Melissa; Delmore, Jake; McMillin, Douglas W.; Mitsiades, Nicholas; Schlossman, Robert; Sahasrabudhe, Sudhir; Anderson, Kenneth C.; Richardson, Paul G.; Mitsiades, Constantine S.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Selliah, R.; Robbins, P.] Prolexys Pharmaceut Inc, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 540 BP 166A EP 166A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800541 ER PT J AU Fulciniti, M Tassone, P Hideshima, T Vallet, S Ettenberg, S Stover, D Blotta, S Shen, Z Dimartino, MT Neri, P Prabhala, R Nopur, R Goldring, SR Anderson, KC Munshi, NC AF Fulciniti, Mariateresa Tassone, Pierfrancesco Hideshima, Teru Vallet, Sonia Ettenberg, Seth Stover, David Blotta, Simona Shen, Zhenxin Dimartino, Maria Teresa Neri, Paola Prabhala, Rao Nopur, Raje Goldring, Steven R. Anderson, Kenneth C. Munshi, Nikhil C. TI Anti-DKK1 mAb (BHQ880) as a potential therapeutic for multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Fulciniti, Mariateresa; Tassone, Pierfrancesco; Hideshima, Teru; Vallet, Sonia; Blotta, Simona; Dimartino, Maria Teresa; Neri, Paola; Nopur, Raje; Anderson, Kenneth C.; Munshi, Nikhil C.] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA 02115 USA. [Fulciniti, Mariateresa; Tassone, Pierfrancesco; Blotta, Simona; Dimartino, Maria Teresa; Neri, Paola; Prabhala, Rao; Munshi, Nikhil C.] Harvard Med Sch, VA Boston Healthcare Syst, Boston, MA USA. [Fulciniti, Mariateresa; Tassone, Pierfrancesco; Blotta, Simona; Dimartino, Maria Teresa; Neri, Paola] Magna Graecia Univ Catanzaro, Campus Salvatore Venuta, Catanzaro, Italy. [Ettenberg, Seth; Stover, David] Novartis Inst Biomed Res, Cambridge, MA USA. [Shen, Zhenxin; Goldring, Steven R.] Beth Israel Deaconess Med Ctr, Harvard Med Sch, Boston, MA 02215 USA. NR 0 TC 6 Z9 7 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 551 BP 169A EP 169A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800552 ER PT J AU Wernig, G Kharas, MG Okabe, R Moore, SA Leeman, DS Cullen, DE Gozo, M McDowell, EP Levine, RL Doukas, J Mak, CM Noronha, G Martin, M Ko, YD Lee, BH Soll, R Tefferi, A Hood, JD Gilliland, DG AF Wernig, Gerlinde Kharas, Michael G. Okabe, Rachel Moore, Sandra A. Leeman, Dena S. Cullen, Dana E. Gozo, Maricel McDowell, Elizabeth P. Levine, Ross L. Doukas, John Mak, Chi Ming Noronha, Glenn Martin, Michael Ko, Yon D. Lee, Benjamin H. Soll, Richard Tefferi, Ayalew Hood, John D. Gilliland, D. Gary TI Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a marine model of JAK2V617F-induced polycythemia vera SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Wernig, Gerlinde; Kharas, Michael G.; Okabe, Rachel; Moore, Sandra A.; Leeman, Dena S.; Cullen, Dana E.; Gozo, Maricel; McDowell, Elizabeth P.; Levine, Ross L.; Lee, Benjamin H.; Gilliland, D. Gary] Brigham & Womens Hosp, Harvard Med Sch, Div Hematol, Boston, MA 02115 USA. [Gilliland, D. Gary] Harvard Med Sch, Dept Genet, Boston, MA USA. [Gilliland, D. Gary] Howard Hughes Med Inst, Boston, MA 02115 USA. [Doukas, John; Mak, Chi Ming; Noronha, Glenn; Martin, Michael; Soll, Richard; Hood, John D.] TargeGen Inc, San Diego, CA USA. [Ko, Yon D.] JohanniterKH, Div Hematol, Bonn, Germany. Dana Farber Canc Inst, Harvard Med Sch, Boston, MA 02115 USA. [Levine, Ross L.; Tefferi, Ayalew] Mayo Clin, Rochester, MN USA. NR 0 TC 1 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 556 BP 171A EP 171A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800557 ER PT J AU Kuter, DJ Bussel, JB Senecal, FM Aledort, LM Kessler, CM Sanz, MA Liebman, HA Slovick, FT Kelly, R Guo, M Nichol, JL AF Kuter, David J. Bussel, James B. Senecal, Francis M. Aledort, Louis M. Kessler, Craig M. Sanz, Miguel A. Liebman, Howard A. Slovick, Frank T. Kelly, Reggie Guo, Matthew Nichol, Janet L. TI Evaluation of AMG 531 efficacy in nonsplenectomized patients-with chronic immune thrombocytopenic purpura (ITP) in a randomized placebo-controlled phase 3 study SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Kuter, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bussel, James B.] Weill Cornell Med Ctr, New York, NY USA. [Senecal, Francis M.] NW Med Specialties, Tacoma, WA USA. [Aledort, Louis M.] Mt Sinai Hosp, New York, NY 10029 USA. [Kessler, Craig M.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA. [Sanz, Miguel A.] Hosp Univ La Fe, Valencia, Spain. [Liebman, Howard A.] Univ So Calif, Keck Sch Med, Los Angeles, CA USA. [Slovick, Frank T.] Heartland Hem Onc Associates Inc, Kansas City, MO USA. [Kelly, Reggie; Guo, Matthew; Nichol, Janet L.] Amgen Inc, Thousand Oaks, CA 91320 USA. NR 0 TC 3 Z9 4 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 565 BP 173A EP 173A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800566 ER PT J AU Bussel, JB Kuter, DJ de Wolf, JTM Guthrie, TH Newland, A Wasser, JS Hamburg, SI Bjorkquist, L Guo, M Nichol, J AF Bussel, James B. Kuter, D. J. de Wolf, J. Th. M. Guthrie, T. H. Newland, A. Wasser, J. S. Hamburg, S. I. Bjorkquist, L. Guo, M. Nichol, J. TI Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 2-year update SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Bussel, James B.] Weill Cornell Med Ctr, New York, NY USA. [Kuter, D. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Guthrie, T. H.] Univ Groningen, Med Ctr, NL-9700 AB Groningen, Netherlands. [Guthrie, T. H.] Univ Florida, Baptist Canc Inst, Jacksonville, FL USA. [Newland, A.] Barts & London, Queen Mary Sch Med, London, England. [Wasser, J. S.] DeQuattro Community Canc Ctr, Manchester, Lancs, England. [Hamburg, S. I.] Tower Canc Res Fdn, Los Angeles, CA USA. [Bjorkquist, L.; Guo, M.] Amgen Inc, Thousand Oaks, CA 91320 USA. NR 0 TC 7 Z9 9 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 568 BP 174A EP 175A PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100800569 ER PT J AU Avigan, D Rosenblatt, J Vasir, B Wu, ZK Bissonnette, A MacNamara, C Uhl, L Lenahan, C Miller, K Levine, JD Joyce, R Lowe, K Dombagoda, D Richardson, P Anderson, K Munshi, N Kuffe, D AF Avigan, David Rosenblatt, Jacalyri Vasir, Baldev Wu, Zekui Bissonnette, Adam MacNamara, Claire Uhl, Lynne Lenahan, Corrine Miller, Kenneth Levine, James D. Joyce, Robin Lowe, Karen Dombagoda, Dilani Richardson, Paul Anderson, Kenneth Munshi, Nikhil Kuffe, Donald TI Vaccination with DC/multiple myeloma fusions in conjunction with stem cell transplantation SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Avigan, David; Rosenblatt, Jacalyri; MacNamara, Claire; Uhl, Lynne; Lenahan, Corrine; Miller, Kenneth; Levine, James D.; Joyce, Robin; Lowe, Karen; Dombagoda, Dilani] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Vasir, Baldev; Wu, Zekui; Bissonnette, Adam; Richardson, Paul; Anderson, Kenneth; Munshi, Nikhil; Kuffe, Donald] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 578 BP 178A EP 178A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800579 ER PT J AU DeAngelo, DJ Dahlberg, S Silverman, LB Couban, S Amrein, PC Seftel, MD Turner, AR Leber, B Howsan-Jan, K Wadleigh, M Sirulnik, LA Supko, J Galinsky, I Sallan, SE Stone, RM AF DeAngelo, Daniel J. Dahlberg, Suzanne Silverman, Lewis B. Couban, Stephen Amrein, Philip C. Seftel, Matthew D. Turner, A. Robert Leber, Brian Howsan-Jan, Kang Wadleigh, Martha Sirulnik, L. Andres Supko, Jeffrey Galinsky, Ilene Sallan, Stephen E. Stone, Richard M. TI A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [DeAngelo, Daniel J.; Wadleigh, Martha; Sirulnik, L. Andres; Galinsky, Ilene; Stone, Richard M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Dahlberg, Suzanne; Silverman, Lewis B.; Sallan, Stephen E.] Dana Farber Canc Inst, Boston, MA USA. [Couban, Stephen; Seftel, Matthew D.; Turner, A. Robert; Howsan-Jan, Kang] Natl Canc Inst Canada, Clin Trials Grp, Kingston, ON, Canada. [Couban, Stephen] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada. [Amrein, Philip C.; Supko, Jeffrey] Massachusetts Gen Hosp, Boston, MA USA. [Seftel, Matthew D.] Canc Ctr Manitoba, Winnipeg, MB, Canada. [Turner, A. Robert] Cross Canc Inst, Edmonton, AB, Canada. [Leber, Brian] Hamilton Hlth Sci Ctr, Hamilton, ON, Canada. [Howsan-Jan, Kang] London Hlth Sci Serv, London, ON, Canada. NR 0 TC 26 Z9 26 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 587 BP 181A EP 181A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800588 ER PT J AU Richardson, P Keman, N Tomblyn, M Martin, P Arai, S Brochstein, J Guinan, E Steinbach, G Nemecek, E D'Agostino, R Revta, C Hannah, A Lacobelli, M Soiffer, R AF Richardson, Paul Keman, Nancy Tomblyn, Marcie Martin, Paul Arai, Sally Brochstein, Joel Guinan, Eva Steinbach, Gideon Nemecek, Elizabeth D'Agostino, Ralph Revta, Carolyn Hannah, Alison Lacobelli, Massimo Soiffer, Robert TI A phase 3 randomized, historically-controlled clinical trial investigating the use of defibrotide in the treatment of severe veno occlusive disease Post-SCT: A novel approach to the validation of a promising new drug for the treatment of a life threatening disease SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Richardson, Paul; Guinan, Eva; Revta, Carolyn; Soiffer, Robert] Massachusetts Gen Childrens Hosp, Dana Farber Canc Inst, BIDMC, Boston, MA USA. [Keman, Nancy] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Tomblyn, Marcie] Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA. [Martin, Paul] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Arai, Sally] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Brochstein, Joel] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Steinbach, Gideon] Fred Hutchinson Canc Res Ctr, Seattle, WA USA. [Nemecek, Elizabeth] Oregon Hlth & Sci Univ, Portland, OR USA. [D'Agostino, Ralph] Boston Univ, Boston, MA 02215 USA. [Hannah, Alison; Lacobelli, Massimo] Gentium SpA, Como, Italy. NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 614 BP 189A EP 189A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800615 ER PT J AU Ghobrial, IM Leleu, X Rubin, N Nelson, M Leduc, R Warren, D Allen, J Lovecchio, S Soumerai, J Sportelli, P Birch, R Henderson, C Treon, SR Richardson, P Anderson, KC AF Ghobrial, Irene M. Leleu, Xavier Rubin, Nancy Nelson, Marybeth Leduc, Renee Warren, Diane Allen, Jana Lovecchio, Sue Soumerai, Jacob Sportelli, Peter Birch, Robert Henderson, Craig Treon, Steven R. Richardson, Paul Anderson, Kenneth C. TI Phase II trial of perifosine (KRX-0401) in relapsed and/or refractory Waldenstrom macroglobulinemia: Preliminary results SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Ghobrial, Irene M.; Leleu, Xavier; Nelson, Marybeth; Leduc, Renee; Warren, Diane; Soumerai, Jacob; Treon, Steven R.; Richardson, Paul; Anderson, Kenneth C.] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Allen, Jana; Lovecchio, Sue] Community Hosp Monterey Peninsula, Monterey, CA USA. [Birch, Robert; Henderson, Craig] Keryx Pharmaceut, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4493 BP 194B EP 195B PN 2 PG 2 WC Hematology SC Hematology GA 233OV UT WOS:000251101101264 ER PT J AU Ghobrial, IM Padmanabhan, S Badros, A Nelson, M Leduc, R Leleu, X Warren, D Soumerai, J Birner, A Schlossman, R Munshi, N Richardson, P Treon, SP Anderson, KC AF Ghobrial, Irene M. Padmanabhan, Swaminathan Badros, Ashraf Nelson, Marybeth Leduc, Renee Leleu, Xavier Warren, Diane Soumerai, Jacob Birner, Ann Schlossman, Robert Munshi, Nikhil Richardson, Paul Treon, Steven P. Anderson, Kenneth C. TI Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom Macroglobulinemia: Preliminary results SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Ghobrial, Irene M.; Nelson, Marybeth; Leduc, Renee; Leleu, Xavier; Warren, Diane; Soumerai, Jacob; Munshi, Nikhil; Richardson, Paul; Treon, Steven P.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Padmanabhan, Swaminathan] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Badros, Ashraf] Univ Maryland, Washington, DC USA. [Birner, Ann] Millennium Pharmaceut Inc, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4494 BP 195B EP 195B PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101101265 ER PT J AU Ghobrial, IM Leduc, R Nelson, M Leleu, X Jacobsen, E LaCasce, A DeAngelo, D Fisher, D Brown, JR Schlossman, R Warren, D Soumerai, J O'Connor, K Munshi, N Richardson, P Anderson, KC Witzig, TE Treon, SP AF Ghobrial, Irene M. Leduc, Renee Nelson, Marybeth Leleu, Xavier Jacobsen, Eric LaCasce, Ann DeAngelo, Daniel Fisher, David Brown, Jennifer R. Schlossman, Robert Warren, Diane Soumerai, Jacob O'Connor, Kelly Munshi, Nikhil Richardson, Paul Anderson, Kenneth C. Witzig, Thomas E. Treon, Steven P. TI Phase II trial of the oral mTOR inhibitor RAD001 (everolimus) in relapsed and/or refractory Waldenstrom Macroglobulinemia: Preliminary results SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Ghobrial, Irene M.; Leduc, Renee; Nelson, Marybeth; Leleu, Xavier; Jacobsen, Eric; LaCasce, Ann; DeAngelo, Daniel; Fisher, David; Brown, Jennifer R.; Schlossman, Robert; Warren, Diane; Soumerai, Jacob; O'Connor, Kelly; Munshi, Nikhil; Richardson, Paul; Anderson, Kenneth C.; Treon, Steven P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Witzig, Thomas E.] Mayo Clin, Coll Med, Rochester, MN USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4496 BP 195B EP 196B PG 2 WC Hematology SC Hematology GA 233OV UT WOS:000251101101267 ER PT J AU Baeumer, N Diederichs, S Koschmieder, S Skryabin, BV Zhang, F Stehling, M Koehler, G Berdel, WE Serve, H Mueller-Tidow, C AF Baeumer, Nicole Diederichs, Sven Koschmieder, Steffen Skryabin, Boris V. Zhang, Feng Stehling, Martin Koehler, Gabriele Berdel, Wolfgang E. Serve, Hubert Mueller-Tidow, Carsten TI The cyclin interactor p26(INCA1) regulates the hematopoietic stem cell pool via CDK inhibition SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Baeumer, Nicole; Koschmieder, Steffen; Zhang, Feng; Berdel, Wolfgang E.; Serve, Hubert; Mueller-Tidow, Carsten] Univ Munster, Dept Med, D-4400 Munster, Germany. Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. [Stehling, Martin] Max Planck Inst Mol Med, Munster, Germany. [Koehler, Gabriele] Univ Munster, Gerhard Domagk Inst Pathol, D-4400 Munster, Germany. RI Muller-Tidow, Carsten/B-5257-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 637 BP 196A EP 197A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100800638 ER PT J AU Sankaran, VG Walkley, CR Spiegelman, BM Orkin, SH AF Sankaran, Vijay G. Walkley, Carl R. Spiegelman, Bruce M. Orkin, Stuart H. TI Rb intrinsically promotes erythropoiesis by coupling cell cycle exit with mitochondrial biogenesis SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Spiegelman, Bruce M.] Dana Farber Canc Inst, Dept Cell Biol, Boston, MA 02115 USA. [Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 638 BP 197A EP 197A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800639 ER PT J AU McMillin, DW Negri, JM Delmore, J Ooi, M Hayden, P Mitsiades, N Richardson, PG Schlossman, R Anderson, KC Mitsiades, CS AF McMillin, Douglas W. Negri, Joseph M. Delmore, Jake Ooi, Melissa Hayden, Patrick Mitsiades, Nicholas Richardson, Paul G. Schlossman, Robert Anderson, Kenneth C. Mitsiades, Constantine S. TI Anti-myeloma activity of the dual Akt/p70(S6K) inhibitor EXEL-6075 SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [McMillin, Douglas W.; Negri, Joseph M.; Ooi, Melissa; Hayden, Patrick; Mitsiades, Nicholas; Richardson, Paul G.; Schlossman, Robert; Anderson, Kenneth C.; Mitsiades, Constantine S.] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [McMillin, Douglas W.; Negri, Joseph M.; Delmore, Jake; Ooi, Melissa; Hayden, Patrick; Mitsiades, Nicholas; Richardson, Paul G.; Schlossman, Robert; Anderson, Kenneth C.; Mitsiades, Constantine S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 650 BP 200A EP 200A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800650 ER PT J AU Letai, A Shipp, M dal Cin, P Takeyama, K Deng, J AF Letai, Anthony Shipp, Margaret dal Cin, Paola Takeyama, Kunihiko Deng, Jing TI Detecting apoptotic blocks and sensitvity to ABT-737 and conventional chemotherapy via BH3 profiling SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Letai, Anthony; Shipp, Margaret; Takeyama, Kunihiko; Deng, Jing] Dana Farber Canc Inst, Boston, MA 02115 USA. [dal Cin, Paola] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4523 BP 202B EP 203B PN 2 PG 2 WC Hematology SC Hematology GA 233OV UT WOS:000251101101294 ER PT J AU Loiseau, HA Munshi, NC Li, C Magrangeas, F Gouraud, W Charbonnel, C Harousseau, JL Attal, M Marit, G Mathiot, C Facon, T Moreau, P Anderson, KC Minvielle, S AF Loiseau, Herve Avet Munshi, Nikhil C. Li, Cheng Magrangeas, Florence Gouraud, Wilfried Charbonnel, Catherine Harousseau, Jean-Luc Attal, Michel Marit, Gerald Mathiot, Claire Facon, Thierry Moreau, Philippe Anderson, Kenneth C. Minvielle, Stephane TI High-resolution genomic profiles identify novel genes and/or chromosomal regions with prognostic and oncogenic significance in myeloma patients SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Loiseau, Herve Avet; Magrangeas, Florence; Gouraud, Wilfried; Charbonnel, Catherine; Minvielle, Stephane] Univ Hosp, INSERM 601, Hematol Lab, Nantes, France. [Munshi, Nikhil C.; Li, Cheng; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA USA. [Munshi, Nikhil C.; Li, Cheng; Anderson, Kenneth C.] Harvard Univ, Sch Med, Boston, MA USA. [Munshi, Nikhil C.] Boston VA Healthcare Syst, Boston, MA USA. [Harousseau, Jean-Luc; Moreau, Philippe] Univ Hosp, Dept Hematol, Nantes, France. [Attal, Michel] Univ Hosp, Dept Hematol, Toulouse, France. [Marit, Gerald] Univ Hosp, Dept Hematol, Bordeaux, France. [Mathiot, Claire] Inst Curie, Hematol Lab, Paris, France. [Facon, Thierry] Univ Hosp, Dept Hematol, Lille, France. RI FACON, THIERRY/M-9736-2014; Magrangeas, Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015; richard, chrystelle/K-8595-2015 OI FACON, THIERRY/0000-0001-7705-8460; NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 657 BP 202A EP 202A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800658 ER PT J AU Blotta, S Negri, J Nanjappa, P Moreau, AS Prabhala, R Shammas, M Pelluru, D McMillin, D Tai, YT Tassone, P Anderson, KC Mitsiades, C Munshi, NC AF Blotta, Simona Negri, Joeseph Nanjappa, Purushotharna Moreau, Anne-Sophie Prabhala, Rao Shammas, Masood Pelluru, Dheeraj McMillin, Douglas Tai, Yu-Tzu Tassone, Pierfrancesco Anderson, Kenneth C. Mitsiades, Constantine Munshi, Nilchil C. TI Hedgehog pathway as a potential therapeutic target in multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Blotta, Simona; Negri, Joeseph; Nanjappa, Purushotharna; Moreau, Anne-Sophie; Prabhala, Rao; Pelluru, Dheeraj; McMillin, Douglas; Tai, Yu-Tzu; Anderson, Kenneth C.; Mitsiades, Constantine; Munshi, Nilchil C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Blotta, Simona; Prabhala, Rao; Shammas, Masood; Pelluru, Dheeraj; Munshi, Nilchil C.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA USA. [Blotta, Simona; Tassone, Pierfrancesco] Magna Graecia Univ Catanzaro, Ctr Canc, Catanzaro, Italy. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 672 BP 206A EP 207A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100800673 ER PT J AU Hideshima, T Raje, N Carrasco, R Ikeda, H Okawa, Y Kiziltepe, T Valet, S Pozzi, S Chauhan, D Mitsiades, C Podar, K Tai, YT Munshi, NC Richardson, PG Anderson, KC AF Hideshima, Tern Raje, Noopur Carrasco, Ruben Ikeda, Hiroshi Okawa, Yutaka Kiziltepe, Tanyel Valet, Sonia Pozzi, Samantha Chauhan, Dhanninder Mitsiades, Constantine Podar, Klaus Tai, Yu-Tzu Munshi, Nikhil C. Richardson, Paul G. Anderson, Kenneth C. TI Delineation of canonical and non-canonical NF-kappa B pathways in multiple myeloma: Therapeutic implications SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Hideshima, Tern; Raje, Noopur; Carrasco, Ruben; Ikeda, Hiroshi; Okawa, Yutaka; Kiziltepe, Tanyel; Valet, Sonia; Pozzi, Samantha; Chauhan, Dhanninder; Mitsiades, Constantine; Podar, Klaus; Tai, Yu-Tzu; Munshi, Nikhil C.; Richardson, Paul G.; Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 670 BP 206A EP 206A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800671 ER PT J AU Hiruma, Y Kurihara, N Roodman, D AF Hiruma, Yuko Kurihara, Noriyoshi Roodman, David TI P62 signaling is increased in multiple myeloma microenvironment SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Hiruma, Yuko; Kurihara, Noriyoshi; Roodman, David] Univ Pittsburgh, Pittsburgh, PA USA. [Roodman, David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 669 BP 206A EP 206A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800670 ER PT J AU Elgawa, SF Novak, AJ Ziesmer, SC Wilzig, TE Treon, SP Ansell, SM AF Elgawa, Sherine F. Novak, Anne J. Ziesmer, Steven C. Wilzig, Thomas E. Treon, Steven P. Ansell, Steven M. TI Role of CCL5 and interleukin-6 in the biology of waldenstrom macroglobulinemia. SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Elgawa, Sherine F.; Novak, Anne J.; Ziesmer, Steven C.; Wilzig, Thomas E.; Ansell, Steven M.] Mayo Clin, Coll Med, Rochester, MN USA. [Treon, Steven P.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 688 BP 212A EP 212A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100800689 ER PT J AU Dey, BR Spitzer, TR MacGillivray, TE Chung, SS Dec, GW Seldin, DC McAfee, SL Ballen, K Attar, E Skinner, M Madsen, JC Semigran, MJ AF Dey, Bimalangshu R. Spitzer, Thomas R. MacGillivray, Thomas E. Chung, Stephen S. Dec, G. W. Seldin, David C. McAfee, Steven L. Ballen, Karen Attar, Eyal Skinner, Martha Madsen, Joren C. Semigran, Marc J. TI Cardiac transplant followed by high-dose melphalan and autologous stem cell transplantation (ASCT) for patients with AL amyloidosis and severe heart failure SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Dey, Bimalangshu R.; Spitzer, Thomas R.; Chung, Stephen S.; Dec, G. W.; McAfee, Steven L.; Ballen, Karen; Attar, Eyal; Madsen, Joren C.; Semigran, Marc J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Seldin, David C.; Skinner, Martha] Boston Univ, Sch Med, Amyloid Treatment & Res Program, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 732 BP 225A EP 225A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801001 ER PT J AU Stone, RM Kantarjian, HM Baccarani, M Lipton, JH Hughes, T Ezzeddine, R Bleickardt, E Hochhaus, A AF Stone, Richard M. Kantarjian, Hagop M. Baccarani, Michele Lipton, Jeffrey H. Hughes, Timothy Ezzeddine, Rana Bleickardt, Eric Hochhaus, Andreas TI Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013) SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kantarjian, Hagop M.] MD Anderson Canc Ctr, Houston, TX USA. [Baccarani, Michele] St Orsola Marcello Malpighi Hosp, Bologna, Italy. [Lipton, Jeffrey H.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Hughes, Timothy] Inst Med & Vet Sci, Adelaide, SA 5000, Australia. [Ezzeddine, Rana; Bleickardt, Eric] Bristol Myers Squibb Co, Wallingford, CT 06492 USA. [Hochhaus, Andreas] Univ Heidelberg, Med Fac Mannheim, D-6800 Mannheim, Germany. NR 0 TC 12 Z9 12 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 734 BP 225A EP 225A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801003 ER PT J AU Ghia, P Muzio, M Apollonio, B Scielzo, C Frenquelli, M Vandoni, I Boussiotis, V Caligaris-Cappio, F AF Ghia, Paolo Muzio, Marta Apollonio, Benedetta Scielzo, Cristina Frenquelli, Michela Vandoni, Irene Boussiotis, Vassiliki Caligaris-Cappio, Federico TI A molecular signature of anergy detected in a subset of CLL patients SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 Univ Vita Salute San Raffaele, Dept Oncol, Milan, Italy. Ist Sci San Raffaele, Milan, Italy. Harvard Univ, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 742 BP 228A EP 228A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801011 ER PT J AU Davies, J Yuk, D Nadler, L Guinan, E AF Davies, Jeff Yuk, Dongin Nadler, Lee Guinan, Eva TI Donor-derived T cells can be rendered hyporesporisive to alloantigen without loss of pathogen or tumor immune responses SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Davies, Jeff; Yuk, Dongin; Nadler, Lee; Guinan, Eva] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 771 BP 237A EP 237A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801040 ER PT J AU Saito, Y Yoshida, S Saito, N Fukata, M Ozawa, H Doi, T Miyamoto, T Ohshima, K Uchida, N Taniguchi, S Akashi, K Harada, M Shultz, LD Ishikawa, F AF Saito, Yoriko Yoshida, Shuro Saito, Noriyuki Fukata, Mitsuhiro Ozawa, Hidetoshi Doi, Takehiko Miyamoto, Toshihiro Ohshima, Koichi Uchida, Naoyuki Taniguchi, Shuichi Akashi, Koichi Harada, Mine Shultz, Leonard D. Ishikawa, Fumihiko TI Human AML stem cells remain quiescent and exhibit chemotherapy resistance within the bone marrow endosteal region SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Saito, Yoriko; Ozawa, Hidetoshi; Doi, Takehiko; Ishikawa, Fumihiko] RIKEN, Res Ctr Allergy & Immunol, Res Unit Human Dis Models, Yokohama, Kanagawa, Japan. [Yoshida, Shuro; Saito, Noriyuki; Fukata, Mitsuhiro; Harada, Mine; Ishikawa, Fumihiko] Kyushu Univ, Grad Sch Med, Dept Med & Biosyst Sci, Fukuoka 812, Japan. [Miyamoto, Toshihiro] Kyushu Univ, Grad Sch Med, Ctr Cellular & Mol Med, Fukuoka 812, Japan. [Doi, Takehiko; Akashi, Koichi] Chiba Univ, Grad Sch Med, Dept Immunol, Chiba, Japan. [Ohshima, Koichi] Kurume Univ, Sch Med, Dept Pathol 1, Kurume, Fukuoka, Japan. [Uchida, Naoyuki; Taniguchi, Shuichi] Toranomon Gen Hosp, Dept Hematol, Tokyo, Japan. [Akashi, Koichi] Dana Farber Canc Inst, Dept Canc Immunol, AIDS, Boston, MA USA. [Shultz, Leonard D.] Jackson Lab, Bar Harbor, ME USA. RI 石川, 文彦/L-4488-2014 NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 780 BP 240A EP 240A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801049 ER PT J AU Bradner, J Greenberg, E Ponduru, S Patel, V Schreiber, S Rich, B Mazitschek, R AF Bradner, James Greenberg, Edward Ponduru, Sridevi Patel, Vishal Schreiber, Stuart Rich, Benjamin Mazitschek, Ralph TI A soft-drug histone deacetylase inhibitor for cutaneous T-cell lymphoma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Bradner, James; Greenberg, Edward; Ponduru, Sridevi; Schreiber, Stuart; Mazitschek, Ralph] MIT, Broad Inst Harvard, Chem Biol Program, Cambridge, MA 02139 USA. [Bradner, James] Dana Farber Canc Inst, Div Hematol Neoplasia, Boston, MA 02115 USA. [Patel, Vishal] Harvard Med Sch, Dept Chem & Mol Pharmacol, Boston, MA USA. [Rich, Benjamin] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA. RI Mazitschek, Ralph/E-3741-2013 OI Mazitschek, Ralph/0000-0002-1105-689X NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 800 BP 246A EP 246A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801069 ER PT J AU Vrooman, LM Neuberg, D O'Brien, J Sallan, SE Silverman, LB AF Vrooman, Lynda M. Neuberg, Donna O'Brien, Jane Sallan, Stephen E. Silverman, Lewis B. TI Increased risk of skeletal toxicity and infection in children 10 years or older treated for Acute Lymphoblastic Leukemia (ALL) with dexamethasone: Results from the DFCI ALL consortium SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Vrooman, Lynda M.; Neuberg, Donna; O'Brien, Jane; Sallan, Stephen E.; Silverman, Lewis B.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 849 BP 260A EP 260A PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801118 ER PT J AU Danaee, H Bryant, B Roels, S Lichter, D Koening, E Trepicchio, WL Boral, A Richardson, P Meng, Y Bergsagel, PL Sonneveld, P Broyl, A Mitsiades, C Chng, WJ Anderson, K Mulligan, G AF Danaee, Hadi Bryant, Barb Roels, Steve Lichter, Dave Koening, Eric Trepicchio, William L. Boral, Anthony Richardson, Paul Meng, Yan Bergsagel, Peter Leif Sonneveld, Pieter Broyl, Annemiek Mitsiades, Constantine Chng, Wee-Joo Anderson, Kenneth Mulligan, George TI High-resolution assessment of gains and losses of chromosomes in patients with multiple myeloma treated with bortezomib SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Danaee, Hadi; Bryant, Barb; Lichter, Dave; Koening, Eric; Trepicchio, William L.; Boral, Anthony; Mulligan, George] Millennium Pharmaceut Inc, Boston, MA USA. [Roels, Steve] Helicos BioSci Corp, Cambridge, MA USA. [Richardson, Paul; Anderson, Kenneth] Dana Farber Canc Inst, Boston, MA 02115 USA. [Meng, Yan] MGH, Boston, MA USA. [Bergsagel, Peter Leif] Ctr Comprehens Canc, Mayo Clin, Scottsdale, AZ USA. [Sonneveld, Pieter; Broyl, Annemiek] Erasmus MC, Rotterdam, Netherlands. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4763 BP 264B EP 264B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101102055 ER PT J AU Vallet, S Hideshima, T Pozzi, S Vaghela, N Gharti-Chhetri, G Mukherjee, S Breitkreutz, I Kiziltepe, T Okawa, Y Ikeda, H Santo, L Cirstea, D Boccadoro, M Anderson, KC Raje, N AF Vallet, Sonia Hideshima, Teru Pozzi, Samantha Vaghela, Nileshwari Gharti-Chhetri, Gaurav Mukherjee, Siddhartha Breitkreutz, Iris Kiziltepe, Tanyel Okawa, Yutaka Ikeda, Hiroshi Santo, Loredana Cirstea, Diana Boccadoro, Mario Anderson, Kenneth C. Raje, Noopur TI Multiple myeloma cell-osteoblast interaction results in impaired bone formation SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Vallet, Sonia; Hideshima, Teru; Pozzi, Samantha; Vaghela, Nileshwari; Gharti-Chhetri, Gaurav; Breitkreutz, Iris; Kiziltepe, Tanyel; Okawa, Yutaka; Ikeda, Hiroshi; Santo, Loredana; Cirstea, Diana; Anderson, Kenneth C.; Raje, Noopur] Harvard Med Sch, Jerome Lipper Multiple Myeloma Dis Ctr, Dana Farber Canc Inst, Boston, MA USA. [Mukherjee, Siddhartha; Raje, Noopur] Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA. [Boccadoro, Mario] Univ Turin, Dipartimento Med & Oncol Sperimentale, Cattedra Ematol, Turin, Italy. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4764 BP 264B EP 264B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101102056 ER PT J AU Schinzel, AC Chapman, M Wittner, B Shrestha, Y Ramaswamy, S Golub, TR Hahn, WC AF Schinzel, Anna C. Chapman, Mike Wittner, Ben Shrestha, Yashaswi Ramaswamy, Sridhar Golub, Todd R. Hahn, William C. TI A high-throughput arrayed lentiviral RNAi screen to identify novel oncogenes in multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Schinzel, Anna C.; Chapman, Mike; Ramaswamy, Sridhar; Golub, Todd R.; Hahn, William C.] MIT, Broad Inst, Cambridge, MA 02139 USA. [Schinzel, Anna C.; Shrestha, Yashaswi; Hahn, William C.] Dana Farber Canc Inst, Ctr Canc Syst Biol, Dept Med Oncol, Boston, MA 02115 USA. [Wittner, Ben; Ramaswamy, Sridhar] Massachusetts Gen Hosp, Inst Canc, Boston, MA 02114 USA. [Golub, Todd R.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4770 BP 266B EP 266B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101102062 ER PT J AU Hijiya, N Gaynon, P Fernandez, M Rytting, M Chu, R Barry, E Thomson, B Cooper, T Kadota, R Chaleff, S Steinherz, P Abichandani, R Carroll, W AF Hijiya, Nobuko Gaynon, Paul Fernandez, Manuel Rytting, Michael Chu, Roland Barry, Elly Thomson, Blythe Cooper, Todd Kadota, Richard Chaleff, Stanley Steinherz, Peter Abichandani, Rekba Carroll, William TI A novel therapy of clofarabine in combination with etoposide and cyclophosphamide shows activity in pediatric patients with refractory or relapsed acute leukemia SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Hijiya, Nobuko] St Jude Childrens Hosp, Memphis, TN 38105 USA. [Gaynon, Paul] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Fernandez, Manuel; Abichandani, Rekba] Genzyme Corp, Cambridge, MA USA. [Rytting, Michael] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Chu, Roland] Childrens Hosp Michigan, Detroit, MI 48201 USA. [Barry, Elly] Dana Farber Canc Inst, Boston, MA 02115 USA. [Thomson, Blythe] Childrens Hosp, Reg Med Ctr, Seattle, WA USA. [Thomson, Blythe] Univ Alabama, Birmingham, AL USA. [Cooper, Todd] Rady Childrens Hosp, San Diego, CA USA. [Chaleff, Stanley] Childrens Mem Hosp, Chicago, IL 60614 USA. [Steinherz, Peter] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Carroll, William] NYU, Inst Canc, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 883 BP 270A EP 270A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801152 ER PT J AU Leiba, M Tai, YT Hideshima, T Jakubikova, J Hiroshi, I Li, XF Burger, P Richardson, P Munshi, NC Nagler, A Anderson, KC AF Leiba, Merav Tai, Yu-Tzu Hideshima, Teru Jakubikova, Jana Hiroshi, Ikeda Li, Xian-Feng Burger, Peter Richardson, Paul Munshi, Nikhil C. Nagler, Amon Anderson, Kenneth C. TI Halofuginone, an old anticoccidosis drug, induces apoptosisin multiple myeloma cells, associated with down regulation of MCL1 SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Leiba, Merav; Tai, Yu-Tzu; Hideshima, Teru; Jakubikova, Jana; Hiroshi, Ikeda; Li, Xian-Feng; Burger, Peter; Richardson, Paul; Munshi, Nikhil C.; Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Leiba, Merav; Tai, Yu-Tzu; Hideshima, Teru; Jakubikova, Jana; Richardson, Paul; Munshi, Nikhil C.; Anderson, Kenneth C.] Harvard Med Sch, Boston, MA USA. [Nagler, Amon] Chaim Sheba Med Ctr, Div Hematol & Bone Marrow Transplantat, Tel Hashomer, Israel. Tel Aviv Univ, Sackler Sch Med, Ramat Gan, Israel. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 BP 270B EP 270B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101102078 ER PT J AU Loriaux, M Levine, R Tyner, J Frohling, S Scholl, C Stoffregen, E Wernig, G Erickson, H Eide, C Berger, R Bernard, O Griffin, J Stone, R Meyerson, M Heinrich, M Deininger, M Gilliland, G Druker, B AF Loriaux, Marc Levine, Ross Tyner, Jeffrey Frohling, Stephan Scholl, Claudia Stoffregen, Eric Wernig, Gerlinde Erickson, Heidi Eide, Chris Berger, Roland Bernard, Oliver Griffin, James Stone, Richard Meyerson, Matthew Heinrich, Michael Deininger, Michael Gilliland, Gary Druker, Brian TI High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Loriaux, Marc; Tyner, Jeffrey; Stoffregen, Eric; Erickson, Heidi; Eide, Chris; Deininger, Michael] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Levine, Ross; Frohling, Stephan; Scholl, Claudia; Wernig, Gerlinde; Gilliland, Gary] Howard Hughes Med Inst, Harvard Med Sch, Boston, MA 02115 USA. [Berger, Roland; Bernard, Oliver] INSERM, IRNEM, Paris, France. [Griffin, James; Stone, Richard; Meyerson, Matthew] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA 02115 USA. [Heinrich, Michael] VA Med Ctr, Portland, OR USA. [Druker, Brian] Howard Hughes Med Inst, Portland, OR USA. RI Meyerson, Matthew/E-7123-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 886 BP 271A EP 271A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801155 ER PT J AU Neri, P Calimeri, T Di Martino, M Rossi, M Eramo, O Propato, M Perri, G Pietragalla, A Ventura, M Bulotta, A Blotta, S Tagliaferri, P Anderson, KC Munshi, NC Tassone, P AF Neri, Paola Calimeri, Teresa Di Martino, Mariateresa Rossi, Marco Eramo, Orietta Propato, Mariagrazia Perri, Gino Pietragalla, Antonella Ventura, Monica Bulotta, Alessandra Blotta, Simona Tagliaferri, Pierosandro Anderson, Kenneth C. Munshi, Nikhil C. Tassone, Pierfrancesco TI Modulation of gene expression profile and in vivo anti-myeloma activity induced by valproic acid, a histone deacytylase inhibitor SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Neri, Paola; Calimeri, Teresa; Di Martino, Mariateresa; Rossi, Marco; Eramo, Orietta; Propato, Mariagrazia; Perri, Gino; Pietragalla, Antonella; Ventura, Monica; Bulotta, Alessandra; Blotta, Simona; Tagliaferri, Pierosandro; Tassone, Pierfrancesco] Magna Graecia Univ Catanzaro, Catanzaro, Italy. [Neri, Paola; Bulotta, Alessandra; Anderson, Kenneth C.; Munshi, Nikhil C.; Tassone, Pierfrancesco] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Neri, Paola; Blotta, Simona; Munshi, Nikhil C.; Tassone, Pierfrancesco] Harvard Med Sch, Boston VA Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4790 BP 271B EP 271B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101102082 ER PT J AU Frost, PJ Shi, Y Bardalaban, C Hoang, B Lichtenstein, A AF Frost, Patrick J. Shi, YiJiang Bardalaban, Carolyne Hoang, Bao Lichtenstein, Alan TI The role of AKT and ERK in regulating D-cyclin translation inhibition and G1 arrest in multiple myeloma cells treated with mTOR inhibitors: rationale for combination thereapy SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Frost, Patrick J.; Shi, YiJiang; Bardalaban, Carolyne; Hoang, Bao; Lichtenstein, Alan] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4795 BP 272B EP 272B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101102087 ER PT J AU Fulciniti, M Tassone, P Hideshima, T Anderson, KC Munshi, NC AF Fulciniti, Mariateresa Tassone, Pierfrancesco Hideshima, Teru Anderson, Kenneth C. Munshi, Nikhil C. TI Biologic sequelae of CDC2 inhibition in MM SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Fulciniti, Mariateresa; Tassone, Pierfrancesco; Hideshima, Teru; Anderson, Kenneth C.; Munshi, Nikhil C.] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA 02115 USA. [Fulciniti, Mariateresa; Tassone, Pierfrancesco; Munshi, Nikhil C.] Harvard Med Sch, VA Boston Healthcare Syst, Boston, MA USA. [Fulciniti, Mariateresa; Tassone, Pierfrancesco] Magna Graecia Univ Catanzaro, Catanzaro, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4797 BP 273B EP 273B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101102089 ER PT J AU Song, W Hideshima, T Tai, YT Anderson, KC Munshi, NC AF Song, Weihua Hideshima, Teru Tai, Yu-Tzu Anderson, Kenneth C. Munshi, Nikhil C. TI Phenotypic and functional effects of perifosine on dendritic cells SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Song, Weihua; Hideshima, Teru; Tai, Yu-Tzu; Anderson, Kenneth C.; Munshi, Nikhil C.] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA 02115 USA. Harvard Med Sch, Vet Adm Boston Hlth Care Syst, W Roxbury, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 BP 274B EP 274B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101102095 ER PT J AU Spencer, A Prince, M DeAngelo, DJ Fischer, T Bhalla, KN Giles, FJ Liu, A Parker, K Laird, G Masson, E Rediske, J Scott, JW Ottmann, OG AF Spencer, Andrew Prince, Miles DeAngelo, Daniel J. Fischer, Thomas Bhalla, Kapil N. Giles, Francis J. Liu, Angela Parker, Kathryn Laird, Glen Masson, Eric Rediske, John Scott, Jeffrey W. Ottmann, Oliver G. TI Phase IA/II study of oral LBH589, a novel deacetylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignancies SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Spencer, Andrew] Alfred Hosp, BMT, Melbourne, Vic, Australia. [Prince, Miles] Peter MacCallum Canc Inst, Dept Haematol, Melbourne, Vic, Australia. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA USA. [Fischer, Thomas] Johannes Gutenberg Univ Mainz, Dept Med 3, D-6500 Mainz, Germany. [Bhalla, Kapil N.] Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA. [Giles, Francis J.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA. [Liu, Angela; Parker, Kathryn; Laird, Glen; Masson, Eric; Rediske, John; Scott, Jeffrey W.] Novartis Oncol, Florham Pk, NJ USA. [Ottmann, Oliver G.] Univ Frankfurt, Med Klin 3, D-6000 Frankfurt, Germany. RI Ottmann, Oliver/D-5007-2016 OI Ottmann, Oliver/0000-0001-9559-1330 NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 907 BP 276A EP 277A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100801176 ER PT J AU Schiller, GJ DeAngelo, DJ Pigneux, A Vey, N Kell, J Solomon, SR Stuart, RK Johnson, BL O'Brien, S Giles, FJ AF Schiller, Gary J. DeAngelo, Daniel J. Pigneux, Arnaud Vey, Norbert Kell, Jonathan Solomon, Scott R. Stuart, Robert K. Johnson, Bonny L. O'Brien, Susan Giles, Francis J. TI Phase II study of VNP40101M (Cloretazine (R)) in elderly patients with de novo poor risk acute myelogenous leukemia (AML). SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Schiller, Gary J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. [DeAngelo, Daniel J.] Dana Farber Med Sch, Boston, MA USA. [Pigneux, Arnaud] Hop Haut Leveque, Bordeaux, France. [Vey, Norbert] Inst J Paoli I Calmettes, F-13009 Marseille, France. [Kell, Jonathan] Univ Wales Hosp, Cardiff, Wales. [Solomon, Scott R.] Northside Hosp, BMT Grp, Atlanta, GA USA. [Stuart, Robert K.] Hollings Canc Ctr, Charleston, SC USA. [Johnson, Bonny L.] Vion Pharmaceut Inc, New Haven, CT USA. [O'Brien, Susan; Giles, Francis J.] Univ Texas MD Anderson Canc Ctr Houston, Houston, TX USA. Hlth Sci Ctr, CTRC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 917 BP 279A EP 279A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801186 ER PT J AU Gorgun, G Philpot, P Naxerova, K Kohane, I Nadler, L Guinan, E AF Gorgun, Gullu Philpot, Patrick Naxerova, Kantila Kohane, Isaac Nadler, Lee Guinan, Eva TI Costimulatory blockade (CSB) during mixed lymphocyte reaction (MLR) prevents IL27 upregulation and signalling SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Gorgun, Gullu; Philpot, Patrick; Nadler, Lee; Guinan, Eva] Dana Farber Canc Inst, Boston, MA 02115 USA. [Naxerova, Kantila; Kohane, Isaac; Guinan, Eva] Childrens Hosp, Boston, MA 02115 USA. RI Kohane, Isaac Kohane/K-3716-2012 OI Kohane, Isaac Kohane/0000-0003-2192-5160 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4878 BP 294B EP 294B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101102170 ER PT J AU Nardi, V Naveiras, O Azam, M Daley, GQ AF Nardi, Valentina Naveiras, Olaia Azam, Mohammad Daley, George Q. TI A critical role for CCL chemokines in the immuno-protection induced by type I Interferons and IRF8/ICSBP against Bcr/Abl-induced leukemia SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Nardi, Valentina; Naveiras, Olaia; Azam, Mohammad] Childrens Hosp, Boston, MA USA. [Daley, George Q.] Childrens Hosp, Dana Farber Canc Inst, Dept Biol Chem & Mol Pharmacol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1001 BP 304A EP 304A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801270 ER PT J AU Toro, JJ Arango, JI Westbrook, SD Jewell, PS Shuko, L Ochoa-Bayona, JL Freytes, CO AF Toro, Juan J. Arango, Jorge I. Westbrook, Steven D. Jewell, Pamela S. Shuko, Lee Ochoa-Bayona, Jose L. Freytes, Cesar O. TI Oral mucositis measured by the oral mucositis assessment scale (OMAS), but not by the world health organization (WHO) scoring system, correlates with nutritional changes after autologous peripheral blood stem cell transplantation. SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Toro, Juan J.; Arango, Jorge I.; Westbrook, Steven D.; Ochoa-Bayona, Jose L.; Freytes, Cesar O.] Univ Texas Hlth Sci Ctr, San Antonio, TX USA. [Toro, Juan J.; Westbrook, Steven D.; Jewell, Pamela S.; Shuko, Lee; Ochoa-Bayona, Jose L.; Freytes, Cesar O.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 4944 BP 312B EP 312B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101102236 ER PT J AU Brown, J Ballen, K McDonough, S Ge, X Stevenson, K Kim, H Reynolds, C Jey, BR McAfee, S Attar, E Spitzer, T Cutler, C Ho, V Alyea, E Soiffer, R Antin, JH Ritz, J Boussiotis, VA AF Brown, Julia Ballen, Karen McDonough, Sean Ge, Xupeng Stevenson, Kristen Kim, Haesook Reynolds, Carol Jey, Bimalangshu R. McAfee, Steve Attar, Eyal Spitzer, Thomas Cutler, Corey Ho, Vincent Alyea, Edwin Soiffer, Robert Antin, Joseph H. Ritz, Jerome Boussiotis, Vassiliki A. TI Impaired immune reconstitution after cord blood transplantation in adults is associated with delayed recovery but not functional impairment of CD8(+)T cells SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Brown, Julia; Ballen, Karen; Ge, Xupeng; Jey, Bimalangshu R.; McAfee, Steve; Attar, Eyal; Spitzer, Thomas; Boussiotis, Vassiliki A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [McDonough, Sean; Stevenson, Kristen; Kim, Haesook; Reynolds, Carol; Cutler, Corey; Ho, Vincent; Alyea, Edwin; Soiffer, Robert; Antin, Joseph H.; Ritz, Jerome] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1057 BP 320A EP 320A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801326 ER PT J AU Levy, O Suter, EE Kalish, LA Scannon, P Weiss, JP Teghanemt, A Russell, JD Gallington, LC Leung, HM Soiffer, RJ Viriyakosol, S Priebe, G Wessels, MR Guinan, EC AF Levy, Ofer Suter, Eugenie E. Kalish, Leslie A. Scannon, Patrick Weiss, Jerrold P. Teghanemt, Athmane Russell, Janice D. Gallington, Leighanne C. Leung, Hoi M. Soiffer, Robert J. Viriyakosol, Suganya Priebe, Gregory Wessels, Michael R. Guinan, Eva C. TI Early deficieny of endogenous proteins inhibiting LPS-Induced TNF-alpha production correlates with acute graft vs host disease (aGVHD) after myeloablative stem cell transplantation (SCT) SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Levy, Ofer; Suter, Eugenie E.; Kalish, Leslie A.; Gallington, Leighanne C.; Priebe, Gregory; Wessels, Michael R.; Guinan, Eva C.] Childrens Hosp, Boston, MA 02115 USA. [Scannon, Patrick; Leung, Hoi M.] XOMA, Berkeley, CA USA. [Weiss, Jerrold P.; Teghanemt, Athmane] Univ Iowa, Iowa City, IA USA. [Russell, Janice D.; Soiffer, Robert J.; Guinan, Eva C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Viriyakosol, Suganya] Univ Calif San Diego, San Diego, CA 92103 USA. RI Gallington, Leighanne/G-9341-2011 OI Gallington, Leighanne/0000-0002-0383-7522 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1058 BP 320A EP 320A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801327 ER PT J AU Dey, BR Yee, AJ McAfee, S Dube, C Ballen, K Attar, E Colby, C Saidiman, S Malikowski, K Preffer, F Sykes, M Spitzer, TR AF Dey, Bimalangshu R. Yee, Andrew J. McAfee, Steven Dube, Christine Ballen, Karen Attar, Eyal Colby, Christine Saidiman, Susan Malikowski, Karen Preffer, Frederic Sykes, Megan Spitzer, Thornas R. TI Non-myeloablative T-cell depleted (TCD) haploidentical hematopoietic cell transplantation (HCT) followed by donor leukocyte infusion(s) for hematologic malignancies: The MGH experience SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Dey, Bimalangshu R.; Yee, Andrew J.; McAfee, Steven; Dube, Christine; Ballen, Karen; Attar, Eyal; Colby, Christine; Saidiman, Susan; Malikowski, Karen; Preffer, Frederic; Spitzer, Thornas R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sykes, Megan] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 5088 BP 353B EP 353B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101102380 ER PT J AU Richardson, P Lonial, S Jakubowiak, A Krishnan, A Wolf, J Densmore, J Singhal, S Ghobrial, I Stephenson, J Mehta, J Colson, K Francis, D Kendall, T Obadike, N Sullivan, K Martin, J Hideshima, T Lai, L Sportelli, P Gardner, L Birch, R Henderson, IC Anderson, K AF Richardson, Paul Lonial, S. Jakubowiak, A. Krishnan, A. Wolf, J. Densmore, J. Singhal, S. Ghobrial, I. Stephenson, J. Mehta, J. Colson, K. Francis, D. Kendall, T. Obadike, N. Sullivan, K. Martin, J. Hideshima, T. Lai, L. Sportelli, P. Gardner, L. Birch, R. Henderson, I. C. Anderson, K. TI Multi-center phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or Relapsed/Refractory multiple myeloma (MM): Promising activity as combination therapy with manageable toxicity SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Richardson, Paul; Ghobrial, I.; Colson, K.; Hideshima, T.; Anderson, K.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lonial, S.; Francis, D.] Emory Winship Canc Inst, Atlanta, GA 30322 USA. [Jakubowiak, A.; Kendall, T.] Univ Michigan, Ann Arbor, MI 48109 USA. [Wolf, J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Densmore, J.; Sullivan, K.] Univ Virginia, Charlottesville, VA 22903 USA. NR 0 TC 7 Z9 7 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1164 BP 353A EP 353A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801433 ER PT J AU Richardson, PG Chanan-Khan, A Lonial, S Krishman, A Carroll, M Cropp, GF Kersey, K Abitar, M Johnson, RG Hannah, AL Anderson, KC AF Richardson, Paul G. Chanan-Khan, Asher Lonial, Sagar Krishman, Antrita Carroll, Michael Cropp, G. F. Kersey, K. Abitar, M. Johnson, R. G. Hannah, Alison L. Anderson, Kenneth C. TI Tanespimycin (T) plus bortezomib (BZ) in multiple myeloma (MM): Confirmation of the recommended dose using a novel formulation SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Richardson, Paul G.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chanan-Khan, Asher] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Lonial, Sagar] Winship Canc Inst, Atlanta, GA USA. [Krishman, Antrita] City Hope Natl Med Ctr, Duarte, CA USA. [Carroll, Michael] Arizona Canc Ctr, Tucson, AZ USA. [Cropp, G. F.; Kersey, K.; Johnson, R. G.; Hannah, Alison L.] Kosan Biosci, Hayward, CA USA. [Abitar, M.] Quest Hematopathol, San Juan Capistrano, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1165 BP 353A EP 353A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801434 ER PT J AU Jakubowiak, A Zimmerman, T Alsina, M Richardson, P Kaufman, J Kendall, T Brozo, C McAllister, A Leister, C Hideshima, T Sportelli, P Gardner, L Birch, R Henderson, IC Giusti, K Anderson, K AF Jakubowiak, Andrzej Zimmerman, Todd Alsina, Melissa Richardson, Paul Kaufman, Jonathan Kendall, T. Brozo, C. McAllister, A. Leister, C. Hideshima, T. Sportelli, P. Gardner, L. Birch, R. Henderson, I. C. Giusti, K. Anderson, Kenneth TI A multiple myeloma research consortium (MMRC) Multicenter phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with Relapsed/Refractory multiple myeloma (MM): Updated results SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Jakubowiak, Andrzej; Kendall, T.; Brozo, C.; McAllister, A.; Leister, C.] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA. [Zimmerman, Todd] Univ Chicago, Ctr Canc, Chicago, IL 60637 USA. [Alsina, Melissa] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Richardson, Paul; Hideshima, T.; Anderson, Kenneth] Dana Farber Canc Inst, Boston, MA USA. [Kaufman, Jonathan] Emory Winship Canc Inst, Atlanta, GA USA. NR 0 TC 3 Z9 4 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1169 BP 354A EP 354A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801438 ER PT J AU Richardson, P Jakubowiak, A Wolf, J Allerton, J Zonder, J Lonial, S Krishnan, A Densmore, J Ghobrial, I Colson, K Kendall, T Leister, C Martineau, B Hideshima, T Facon, T Sportelli, P Gardner, L Birch, R Henderson, IC Anderson, K AF Richardson, Paul Jakubowiak, A. Wolf, J. Allerton, J. Zonder, J. Lonial, S. Krishnan, A. Densmore, J. Ghobrial, I. Colson, K. Kendall, T. Leister, C. Martineau, B. Hideshima, T. Facon, T. Sportelli, P. Gardner, L. Birch, R. Henderson, I. C. Anderson, K. TI Phase I/II report from a Multicenter trial of perifosine (KRX-0401) plus bortezomib in patients with relapsed or Relapsed/Refractory multiple myeloma previously treated with bortezomib SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Richardson, Paul; Ghobrial, I.; Colson, K.; Hideshima, T.; Anderson, K.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Jakubowiak, A.; Kendall, T.; Leister, C.] Univ Michigan, Ann Arbor, MI 48109 USA. [Wolf, J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Zonder, J.] Karmanos Canc Ctr, Karmanos, MI USA. [Lonial, S.] Emory Winship Canc Ctr, Atlanta, GA USA. [Densmore, J.] Univ Virginia, Charlottesville, VA 22903 USA. [Facon, T.] Huriez Hosp, Lille, France. RI FACON, THIERRY/M-9736-2014 OI FACON, THIERRY/0000-0001-7705-8460 NR 0 TC 3 Z9 4 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1170 BP 354A EP 355A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100801439 ER PT J AU Lacy, MQ Alsina, M Roberts, L Fonseca, R Melvin, C Yin, D Sharma, A Pollak, M Jagannath, S Richardson, P Gualberto, A AF Lacy, Martha Q. Alsina, Melissa Roberts, Luisa Fonseca, Rafael Melvin, Carrie Yin, Donghua Sharma, Amamath Pollak, Michael Jagannath, Sundar Richardson, Paul Gualberto, Antonio TI Phase I dose escalation study of the monoclonal antibody against the insulin like growth factor I receptor CP-751,871 in patients with multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Lacy, Martha Q.] Mayo Clin, Rochester, MN USA. [Alsina, Melissa] Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33620 USA. [Roberts, Luisa; Melvin, Carrie; Yin, Donghua; Sharma, Amamath; Gualberto, Antonio] Pfizer Global Res & Dev, New London, CT USA. [Fonseca, Rafael] Mayo Clin, Scottsdale, AZ USA. [Pollak, Michael] McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3A 2T5, Canada. [Jagannath, Sundar] St Vincents Comprehens Canc Ctr, New York, NY USA. [Richardson, Paul] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1171 BP 355A EP 355A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801440 ER PT J AU Chanan-Khan, AA Jagannath, S Munshi, NC Schlossman, RL Anderson, KC Lee, K DePaolo, D Miller, KC Zildjian, S Fram, RJ Qin AF Chanan-Khan, Asher A. Jagannath, Sundar Munshi, Nikhil C. Schlossman, Robert L. Anderson, Kenneth C. Lee, Kelvin DePaolo, Dawn Miller, Kena C. Zildjian, Sybil Fram, Robert J. Qin TI Phase I study of huN901-DM1 (BB-10901) in patients with relapsed and relapsed/refractory CD56-Positive multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Chanan-Khan, Asher A.; Lee, Kelvin; DePaolo, Dawn; Miller, Kena C.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Jagannath, Sundar] St Vincents Comprehens Canc Ctr, New York, NY USA. [Munshi, Nikhil C.; Schlossman, Robert L.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Zildjian, Sybil; Fram, Robert J.; Qin] Immuno Gen Inc, Cambridge, MA USA. NR 0 TC 5 Z9 7 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1174 BP 356A EP 356A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801443 ER PT J AU Ocio, EM Mitsiades, C Mateos, MV Maiso, P Mollinedo, F Garayoa, M Gajate, C Blade, J Prosper, F Lahuerta, JJ Mitsiades, N McMullan, CJ Munshi, NC Hideshima, T Chauhan, D Cuevas, C Aviles, P Faircloth, G Richardson, PG Pandiella, A Anderson, KC Miguel, JFS AF Ocio, Enrique M. Mitsiades, Constantine Mateos, M. Victoria Maiso, Patricia Mollinedo, Faustino Garayoa, Mercedes Gajate, Consuelo Blade, Joan Prosper, Felipe Lahuerta, Juan Jose Mitsiades, Nicholas McMullan, Ciaran J. Munshi, Nikhil C. Hideshima, Teru Chauhan, Dharminder Cuevas, Carmen Aviles, Pablo Faircloth, Glynn Richardson, Paul G. Pandiella, Atanasio Anderson, Kenneth C. Miguel, J. F. San TI Antimyeloma efficacy of plitidepsin (Aplidin (R)): From bench to the bedside SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Ocio, Enrique M.; Mateos, M. Victoria; Miguel, J. F. San] Hosp Univ Salamanca, Salamanca, Spain. [Ocio, Enrique M.; Maiso, Patricia; Mollinedo, Faustino; Garayoa, Mercedes; Gajate, Consuelo] Hosp Univ Salamanca, Ctr Invest Canc, Salamanca, Spain. [Mitsiades, Constantine; Mitsiades, Nicholas; McMullan, Ciaran J.; Munshi, Nikhil C.; Hideshima, Teru; Chauhan, Dharminder] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Blade, Joan] Hosp & Clin, Barcelona, Spain. [Prosper, Felipe] Univ Navarra Clin, Navarra, Spain. [Lahuerta, Juan Jose] Hosp 12 Octubre, E-28041 Madrid, Spain. [Cuevas, Carmen; Aviles, Pablo; Faircloth, Glynn] Pharmamar SA, Madrid, Spain. [Cuevas, Carmen; Aviles, Pablo; Faircloth, Glynn] Spain & Pharma Inc, Cambridge, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1178 BP 357A EP 357A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801447 ER PT J AU Richardson, PG Mitsiades, CS Colson, K Reilly, EE McBride, L Chiao, J Sun, L Ricker, JL Rizvi, S Oerth, C Atkins, B Fearen, I Anderson, KC Siegel, DS AF Richardson, Paul G. Mitsiades, Constantine S. Colson, Kathleen Reilly, Eileen McBride, Laura Chiao, Judy Sun, Linda Ricker, Justin L. Rizvi, Syed Oerth, Carol Atkins, Barbara Fearen, Ivy Anderson, Kenneth C. Siegel, David S. TI Final results of a phase I trial of oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Richardson, Paul G.; Mitsiades, Constantine S.; Colson, Kathleen; Anderson, Kenneth C.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. [Reilly, Eileen; McBride, Laura; Siegel, David S.] Hackensack Univ, Med Ctr, Ctr Canc, Hackensack, NJ USA. [Ricker, Justin L.; Rizvi, Syed; Oerth, Carol; Atkins, Barbara] Merck Res Labs, Upper Gwynedd, PA USA. NR 0 TC 5 Z9 6 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1179 BP 357A EP 357A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801448 ER PT J AU Bensinger, W Zonder, J Singhal, S Mohrbacher, A Dean, RM Van Rhee, F Al-Homsi, AS Munshi, AHC Conner, ER Hussein, MA AF Bensinger, William Zonder, Jeffrey Singhal, Seema Mohrbacher, Arm Dean, Robert M. van Rhee, Frits Al-Homsi, Ahmad-Samer Munshi, Nikhil C. Conner, Edward R. Hussein, Mohamad A. TI Phase I trial of HuLuc63 in multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Bensinger, William] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Zonder, Jeffrey] Karmanos Canc Ctr, Detroit, MI USA. [Singhal, Seema] Northwestern Univ, Chicago, IL 60611 USA. [Mohrbacher, Arm] Keck Sch Med, Los Angeles, CA USA. [Dean, Robert M.] Taussig Canc Ctr, Cleveland Clin, Cleveland, OH USA. [van Rhee, Frits] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA. [Al-Homsi, Ahmad-Samer] Univ Massachusetts, Med Ctr, Worcester, MA 01605 USA. [Munshi, Nikhil C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Conner, Edward R.] PDL Biopharma, Fremont, CA USA. [Hussein, Mohamad A.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1180 BP 358A EP 358A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801449 ER PT J AU Breitkreutz, I Raab, MS Vallet, S Hideshima, T Raje, N Mitsiades, C Chauhan, D Munshi, NC Richardson, PG Anderson, KC AF Breitkreutz, Iris Raab, Marc S. Vallet, Sonia Hideshima, Tem Raje, Noopur Mitsiades, Constantine Chauhan, Dharminder Munshi, Nikhil C. Richardson, Paul G. Anderson, Kenneth C. TI Lenalidomide and bortezomib: Targeting osteoclastogenesis, osteoclast survival factors, and bone remodeling markers in multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Breitkreutz, Iris; Raab, Marc S.; Vallet, Sonia; Hideshima, Tem; Raje, Noopur; Mitsiades, Constantine; Chauhan, Dharminder; Munshi, Nikhil C.; Richardson, Paul G.; Anderson, Kenneth C.] Jerome Lipper Multiple Myeloma Ctr, Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 2 Z9 3 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1184 BP 359A EP 359A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801453 ER PT J AU McMillin, DW Negri, J Delmore, J Hayden, P Mitsiades, N Richardson, PG Munshi, NC Schlossman, R Maira, SM Garcia-Echeverria, C Anderson, KC Mitsiades, CS AF McMillin, Douglas W. Negri, Joseph Delmore, Jake Hayden, Patrick Mitsiades, Nicholas Richardson, Paul G. Munshi, Nikhil C. Schlossman, Robert Maira, Saveur-Michel Garcia-Echeverria, Carlos Anderson, Kenneth C. Mitsiades, Constantine S. TI Anti-myeloma activity of selective PI-3K/PDK/mTOR inhibitor BEZ235 SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [McMillin, Douglas W.; Negri, Joseph; Delmore, Jake; Hayden, Patrick; Mitsiades, Nicholas; Richardson, Paul G.; Munshi, Nikhil C.; Schlossman, Robert; Anderson, Kenneth C.; Mitsiades, Constantine S.] Jerome Lipper Multiple Myeloma Ctr, Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Maira, Saveur-Michel; Garcia-Echeverria, Carlos] Novartis Inst Biomed Res, Dept Oncol, Basel, Switzerland. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1185 BP 359A EP 359A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801454 ER PT J AU North, TE Goessling, W Armant, M Kao, GS Silberstein, LE Ritz, J Zon, LI AF North, Trista E. Goessling, Wolfram Armant, Myriam Kao, Grace S. Silberstein, Leslie E. Ritz, Jerome Zon, Leonard I. TI Ex vivo treatment of human cord blood with dmPGE2 can safely increase the potential for hematopoietic engraftment SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [North, Trista E.; Goessling, Wolfram; Zon, Leonard I.] Childrens Hosp, Stwm Cell Program, HHMI, Boston, MA USA. [North, Trista E.; Goessling, Wolfram; Armant, Myriam; Kao, Grace S.; Silberstein, Leslie E.; Ritz, Jerome; Zon, Leonard I.] Harvard Med Sch, Harvard Stem Cell Inst, Boston, MA USA. [Goessling, Wolfram; Kao, Grace S.; Ritz, Jerome; Zon, Leonard I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Armant, Myriam; Kao, Grace S.; Silberstein, Leslie E.; Ritz, Jerome] Ctr Human Cell Therapy, Boston, MA USA. [Armant, Myriam; Silberstein, Leslie E.] CBR Inst Biomed Res, Boston, MA USA. [Silberstein, Leslie E.] Childrens Hosp, Joint Program Transfus Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1190 BP 361A EP 361A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801459 ER PT J AU Chen, YB Hochberg, EP Feng, Y Motyckova, G Neuberg, D Spitzer, TR Fisher, DC LaCasce, AS AF Chen, Yi-Bin Hochberg, Ephraim P. Feng, Yang Motyckova, Gabriela Neuberg, Donna Spitzer, Thomas R. Fisher, David C. LaCasce, Ann S. TI Impact of the addition of rituximab to initial CHOP chemotherapy compared with CHOP alone in patients with relapsed diffuse large B-cell lymphoma who underwent autologous stem cell transplantation SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Chen, Yi-Bin; Hochberg, Ephraim P.; Motyckova, Gabriela; Spitzer, Thomas R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Feng, Yang; Fisher, David C.; LaCasce, Ann S.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 5124 BP 362B EP 363B PN 2 PG 2 WC Hematology SC Hematology GA 233OV UT WOS:000251101102416 ER PT J AU Chung, SS Spitzer, TR Ting, DT Dube, C Yee, AJ Ballen, K McAfee, SL Attar, E Dey, BR AF Chung, Stephen S. Spitzer, Thomas R. Ting, David T. Dube, Christine Yee, Andrew J. Ballen, Karen McAfee, Steven L. Attar, Eyal Dey, Bimalangshu R. TI The type of upfront induction therapy for newly diagnosed multiple myeloma patients has no significant impact on clinical outcomes after autologous hematopoietic stem cell transplantation SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Chung, Stephen S.; Spitzer, Thomas R.; Ting, David T.; Dube, Christine; Yee, Andrew J.; Ballen, Karen; McAfee, Steven L.; Attar, Eyal; Dey, Bimalangshu R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 5128 BP 364B EP 364B PN 2 PG 1 WC Hematology SC Hematology GA 233OV UT WOS:000251101102420 ER PT J AU Arinobu, Y Mizuno, SI Chong, Y Shigematsu, H Iino, T Iwasaki, H Graf, T Mayfield, R Chan, S Kastner, P Akashi, K AF Arinobu, Yojiro Mizuno, Shin-ichi Chong, Yong Shigematsu, Hirokazu Iino, Tadafumi Iwasaki, Hiromi Graf, Thomas Mayfield, Robin Chan, Susan Kastner, Philippe Akashi, Koichi TI Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myelo-erythroid and myelo-lymphoid lineages SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Arinobu, Yojiro; Mizuno, Shin-ichi; Chong, Yong; Shigematsu, Hirokazu; Iino, Tadafumi; Akashi, Koichi] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Iwasaki, Hiromi; Akashi, Koichi] Kyushu Univ Hosp, Ctr Cellular & Mol Med, Fukuoka 812, Japan. [Graf, Thomas] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10467 USA. [Mayfield, Robin] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Chan, Susan; Kastner, Philippe] Inst Genet Biol Mol Cellulaire, Dept Mol Pathol, Illkirch Graffenstaden, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1228 BP 372A EP 372A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801497 ER PT J AU Li, X Shelley, CS Amaout, MA AF Li, Xiangen Shelley, Carl Simon Amaout, M. Amin TI Differential role of the transcription factor ZBP-89 in hemangioblast fate determination: ZBP-89 is a direct regulator of SCL. SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Li, Xiangen; Shelley, Carl Simon; Amaout, M. Amin] Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1253 BP 378A EP 378A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801521 ER PT J AU Rhodes, KE Gekas, C Wang, Y Lux, CT Francis, CS Conway, S Orkin, SH Yoder, MC Mikkola, HKA AF Rhodes, Katrin E. Gekas, Christos Wang, Yanting Lux, Christopher T. Francis, Cameron S. Conway, Simon Orkin, Stuart H. Yoder, Mervin C. Mikkola, Hanna K. A. TI Hematopoietic stem cells emerge in the placental vasculature in the absence of circulation SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Rhodes, Katrin E.; Gekas, Christos; Wang, Yanting; Francis, Cameron S.; Mikkola, Hanna K. A.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Mikkola, Hanna K. A.] Univ Calif Los Angeles, Inst Stem Cell Biol & Med, Los Angeles, CA 90024 USA. [Lux, Christopher T.; Conway, Simon; Yoder, Mervin C.] Indiana Univ, Sch Med, Herman Wells Ctr Pediat Res, Indianapolis, IN USA. [Orkin, Stuart H.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA. [Mikkola, Hanna K. A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1258 BP 379A EP 379A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801526 ER PT J AU Kikushige, Y Yoshimoto, G Miyamoto, T Ishikawa, F Iwasaki, H Akashi, K AF Kikushige, Yoshikane Yoshimoto, Goichi Miyamoto, Toshihiro Ishikawa, Fumihiko Iwasaki, Hiromi Akashi, Koichi TI Human FLT3/FLK2 targets hematopoietic stem cells and granulocyte/macrophage progenitors SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Kikushige, Yoshikane; Yoshimoto, Goichi] Kyushu Univ, Fukuoka 812, Japan. [Kikushige, Yoshikane; Yoshimoto, Goichi; Miyamoto, Toshihiro; Iwasaki, Hiromi] Kyushu Univ, Ctr Cellular & Mol Med, Fukuoka 812, Japan. [Ishikawa, Fumihiko] RIKEN, Yokohama Inst, Res Unit Human Dis Model, Yokohama, Kanagawa, Japan. [Akashi, Koichi] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1263 BP 380A EP 380A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801531 ER PT J AU Sloan, JM Coburn, JP Bertino, AM Wood, V Kuter, DJ AF Sloan, John M. Coburn, John P. Bertino, Amy M. Wood, Valerie Kuter, David J. TI A comparative proteomic analysis of platelets from healthy human patients and chronic ITP patients receiving AMG 531, a thrombopoiesis-stimulating protein SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Sloan, John M.; Coburn, John P.; Bertino, Amy M.; Wood, Valerie; Kuter, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1313 BP 395A EP 396A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100801581 ER PT J AU Chong, Y Iino, T Mizuno, S Shigematsu, H Arinobu, Y Iwasaki, H Akashi, K AF Chong, Yong Iino, Tadafumi Mizuno, Shin-ichi Shigematsu, Hirokazu Arinobu, Yojiro Iwasaki, Hiromi Akashi, Koichi TI In vivo permanent marking of cells with RAG1 activation history demonstrates that lymphoid and myeloid derived dendritic cells operate an identical developmental program after their lineage commitment SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Chong, Yong; Iino, Tadafumi; Mizuno, Shin-ichi; Shigematsu, Hirokazu; Arinobu, Yojiro; Akashi, Koichi] Dana Farber Canc Inst, Dept Immunol, AIDS, Boston, MA USA. [Iwasaki, Hiromi; Akashi, Koichi] Kyushu Univ Hosp, Ctr Cellular & Mol Med, Fukuoka, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1328 BP 400A EP 400A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801596 ER PT J AU Brown, JR Friedberg, J Feng, Y Phillips, K Clark, J dal Cin, P Joyce, R Fisher, DC Fisher, RI Takvorian, RW Liesveld, J Marquis, D Neuberg, D Freedman, AS AF Brown, Jennifer R. Friedberg, Jonathan Feng, Yang Phillips, Kimberly Clark, JenniferC. dal Cin, Paola Joyce, Robin Fisher, David C. Fisher, Richard I. Takvorian, Ronald W. Liesveld, Jane Marquis, Diana Neuberg, Donna Freedman, Arnold S. TI A phase 2 study of fludarabine and rituximab for the treatment of marginal zone lymphomas SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Brown, Jennifer R.; Phillips, Kimberly; Clark, JenniferC.; Fisher, David C.; Freedman, Arnold S.] Dana Farber Canc Inst, Boston, MA USA. [Friedberg, Jonathan; Fisher, David C.; Liesveld, Jane; Marquis, Diana] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY 14627 USA. [Feng, Yang; Neuberg, Donna] DFCI, Biostat & Computat Biol, Boston, MA USA. [dal Cin, Paola] Brigham & Womens Hosp, Boston, MA USA. [Joyce, Robin] Beth Israel Deaconess Med Ctr, Boston, MA USA. [Takvorian, Ronald W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1358 BP 408A EP 408A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801626 ER PT J AU Roccaro, A Leleu, X Moreau, AS Sacco, A Xu, L Hatjiharissi, E Ciccarelli, B Patterson, C Adamia, S Russo, D Vacca, A Dammacco, F Anderson, K Ghobrial, I Treon, S AF Roccaro, Aldo Leleu, Xavier Moreau, Anne-Sophie Sacco, Antonio Xu, Lian Hatjiharissi, Evdoxia Ciccarelli, Bryan Patterson, Christopher Adamia, Sophia Russo, Domenico Vacca, Angelo Dammacco, Franco Anderson, Kenneth Ghobrial, Irene Treon, Steven TI Resveratrol exerts antiproliferative effect and induces apoptosis in Waldenstrom's Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Roccaro, Aldo; Leleu, Xavier; Moreau, Anne-Sophie; Sacco, Antonio; Xu, Lian; Hatjiharissi, Evdoxia; Ciccarelli, Bryan; Adamia, Sophia; Anderson, Kenneth; Ghobrial, Irene; Treon, Steven] Dana Farber Canc Inst, Boston, MA 02115 USA. [Russo, Domenico] Univ Brescia, Sch Med, Unit Blood Dis & Cell Therapies, Brescia, Italy. [Vacca, Angelo; Dammacco, Franco] Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, Bari, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1383 BP 415A EP 416A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100801651 ER PT J AU Raponi, M Lancet, JE Fan, H Dossey, L Lee, G Gojo, I Feldman, EJ Gotlib, J Morris, LE Greenberg, PL Wright, JJ Harousseau, JL Lowenberg, B Stone, RM De Porre, P Wang, Y Karp, JE AF Raponi, Mitch Lancet, Jeffrey E. Fan, Hongtao Dossey, Lesley Lee, Grace Gojo, Ivana Feldman, Eric J. Gotlib, Jason Morris, Lawrence E. Greenberg, Peter L. Wright, John J. Harousseau, Jean-Luc Lowenberg, Bob Stone, Richard M. De Porre, Peter Wang, Yixin Karp, Judith E. TI A two-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Raponi, Mitch; Dossey, Lesley; Wang, Yixin] Johnson & Johnson Co, Veriex LLC, San Diego, CA USA. [Lancet, Jeffrey E.] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Fan, Hongtao; Lee, Grace] Johnson & Johnson Co, Pharma Biomaker Support Grp, San Diego, CA USA. [Gojo, Ivana] Univ Maryland, Greenbaum Canc Ctr, College Pk, MD 20742 USA. [Feldman, Eric J.] Cornell Univ, Weill Med Coll, Ithaca, NY 14853 USA. [Gotlib, Jason; Greenberg, Peter L.] Stanford Univ, Stanford Canc Ctr, Stanford, CA USA. [Morris, Lawrence E.] Blood & Bone Marrow Transplant Grp Georgia, Atlanta, GA USA. [Wright, John J.] Natl Canc Inst, Canc Therapy Evaluat Program, Bethesda, MD USA. [Harousseau, Jean-Luc] CHRU Hotel Dieu, Serv Hematol Clin, Nantes, France. [Harousseau, Jean-Luc] Erasmus Univ, Med Ctr, Dept Hematol, Rotterdam, Netherlands. [Lowenberg, Bob] Dana Farber Canc Inst, Adult Leukemia Program, Boston, MA USA. [Stone, Richard M.] Johnson & Johnson Pharmaceut Res Inst, Beerse, Belgium. [De Porre, Peter; Karp, Judith E.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1445 BP 433A EP 433A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100801713 ER PT J AU Blotta, S Prabhala, R Pelluru, D Tetsuro, S Franco, B Tagliaferri, P Tassone, P Anderson, KC Munshi, NC AF Blotta, Simona Prabhala, Rao Pelluru, Dheeraj Tetsuro, Sasada Franco, Brunella Tagliaferri, Pierosandro Tassone, Pierfranceso Anderson, Kenneth C. Munshi, Nikhil C. TI OFDI-mediated T cell responses in MGUS patients: Implications for immunotherapy SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Blotta, Simona; Prabhala, Rao; Pelluru, Dheeraj; Tetsuro, Sasada; Anderson, Kenneth C.; Munshi, Nikhil C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA. [Blotta, Simona; Prabhala, Rao; Pelluru, Dheeraj; Munshi, Nikhil C.] Harvard Med Sch, VA Boston Healthcare Syst, Boston, MA USA. [Tagliaferri, Pierosandro; Tassone, Pierfranceso] Magna Graecia Univ Catanzaro, Ctr Canc, Catanzaro, Italy. [Franco, Brunella] Tigem Inst, Naples, Italy. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1488 BP 445A EP 445A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802010 ER PT J AU Leleu, X Hatjiharissi, E Roccaro, AM Moreau, AS Leduc, R Nelson, M Farag, M Treon, SP Ghobrial, IM AF Leleu, Xavier Hatjiharissi, Evdoxia Roccaro, Aldo M. Moreau, Anne-Sophie Leduc, Renee Nelson, Marybeth Farag, Mena Treon, Steven P. Ghobrial, Irene M. TI Serum immunoglobulin free light chain (sFLC) is a sensitive marker of response in Waldenstrom Macroglobulinemia (WM) SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Leleu, Xavier; Hatjiharissi, Evdoxia; Roccaro, Aldo M.; Moreau, Anne-Sophie; Leduc, Renee; Nelson, Marybeth; Farag, Mena; Treon, Steven P.; Ghobrial, Irene M.] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA USA. [Leleu, Xavier; Moreau, Anne-Sophie] CHRU, Serv Malad Sang, Lille, France. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1486 BP 445A EP 445A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802008 ER PT J AU Leiba, M Xu, J Song, W Li, XF Burger, P Kordich, J Cassiano, L Podar, K Chauhan, D Hideshima, T Munshi, NC Richardson, P Anderson, KC Tai, YT AF Leiba, Merav Xu, Jiangehun Song, Weihua Li, Xian-Feng Burger, Peter Kordich, Jennifer Cassiano, Linda Podar, Klaus Chauhan, Dharminder Hideshima, Teru Munshi, Nikhil C. Richardson, Paul Anderson, Kenneth C. Tai, Yu-Tzu TI Activation of B-cell maturation antigen (BCMA) on human multiple myeloma cells by a proliferation-inducing ligand (APRIL) promotes myeloma cell function in the bone marrow microenvironment SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Leiba, Merav; Song, Weihua; Li, Xian-Feng; Burger, Peter; Podar, Klaus; Chauhan, Dharminder; Hideshima, Teru; Munshi, Nikhil C.; Richardson, Paul; Anderson, Kenneth C.; Tai, Yu-Tzu] Dana Farber Canc Inst, Jerome Lippet Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA. [Kordich, Jennifer; Cassiano, Linda] Amgen Inc, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1503 BP 450A EP 450A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802025 ER PT J AU Growney, JD Atadja, P Shao, W Wang, Y Pu, M Firestone, B Cheng, J Kowal, C Miller, C Eckman, J Yao, YM Fawell, S Spencer, A Miguel, JFS Anderson, KC AF Growney, Joseph D. Atadja, Peter Shao, Wenlin Wang, Youzhen Pu, Minying Firestone, Brant Cheng, Jane Kowal, Colleen Miller, Christine Eckman, Joseph Yao, Yung-Mae Fawell, Stephen Spencer, Andrew Miguel, Jesus F. San Anderson, Kenneth C. TI Efficacy of panobinostat (LBH589) in multiple myeloma cell lines and in vivo mouse model: Tumor-specific cytotoxicity and protection of bone integrity in multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Growney, Joseph D.; Atadja, Peter; Shao, Wenlin; Wang, Youzhen; Pu, Minying; Firestone, Brant; Cheng, Jane; Kowal, Colleen; Miller, Christine; Eckman, Joseph; Yao, Yung-Mae; Fawell, Stephen] Novartis Inst Biomed Res, Cambridge, MA USA. [Spencer, Andrew] Alfred Hosp, Myeloma Res Grp, Melbourne, Vic, Australia. [Miguel, Jesus F. San] Canc Res Ctr, Salamanca, Spain. [Miguel, Jesus F. San] Univ Hosp, Salamanca, Spain. [Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1510 BP 452A EP 452A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802032 ER PT J AU Tai, YT Rice, AG Leiba, M Li, XF Burger, P Song, W Prabhala, R Dillon, M Tolan, E Xie, X Hideshima, T Raje, N Richardson, P Munshi, NC Nagler, A Loiseau, HA Afar, DEH Anderson, KC AF Tai, Yu-Tzu Rice, Audie G. Leiba, Marav Li, Xian-Feng Burger, Peter Song, Weihua Prabhala, Rao Dillon, Myles Tolan, Edie Xie, Xanling Hideshima, Teru Raje, Noopur Richardson, Paul Munshi, Nihkil C. Nagler, Arnon Loiseau, Herve Avet Afar, Daniel E. H. Anderson, Kenneth C. TI Low levels of circulating CS1, a newly identified multiple myeloma (MM) antigen for a novel humanized HuLuc63 monoclonal antibody, is detected in MM patient sera and correlates with active disease SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Tai, Yu-Tzu; Leiba, Marav; Li, Xian-Feng; Burger, Peter; Song, Weihua; Prabhala, Rao; Hideshima, Teru; Raje, Noopur; Richardson, Paul; Munshi, Nihkil C.; Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA USA. [Rice, Audie G.; Dillon, Myles; Afar, Daniel E. H.] PDL BioPharma Inc, Dept Res, Fremont, CA USA. [Tolan, Edie; Xie, Xanling] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA USA. [Leiba, Marav; Nagler, Arnon] Tel Aviv Univ, Sackler Sch Med, Chaim Sheba Med Ctr, Div Hematol Bone Marrow Transplantat, IL-69978 Tel Aviv, Israel. [Loiseau, Herve Avet] Inst Biol, Hematol Lab, Nantes, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1509 BP 452A EP 452A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802031 ER PT J AU McMillin, DW Delmore, J Negri, JM Hayden, P Mitsiades, N Richardson, PG Schlossman, R Munshi, NC Anderson, KC Mitsiades, CS AF McMillin, Douglas W. Delmore, Jake Negri, Joseph M. Hayden, Patrick Mitsiades, Nicholas Richardson, Paul G. Schlossman, Robert Munshi, Nikhil C. Anderson, Kenneth C. Mitsiades, Constantine S. TI Activity of CDK1/2 inhibitor LCQ195 against multiple myeloma cells SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [McMillin, Douglas W.; Delmore, Jake; Negri, Joseph M.; Hayden, Patrick; Mitsiades, Nicholas; Richardson, Paul G.; Schlossman, Robert; Munshi, Nikhil C.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Dana Farber Canc Inst, Jerome Lipper Multiple Meloma Ctr, Dept Med Oncol, Boston, MA USA. [McMillin, Douglas W.; Delmore, Jake; Negri, Joseph M.; Hayden, Patrick; Mitsiades, Nicholas; Richardson, Paul G.; Schlossman, Robert; Munshi, Nikhil C.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Harvard Med Sch, Dept Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1519 BP 454A EP 455A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100802041 ER PT J AU Roccaro, A Leleu, X Sacco, A Jia, X Moreau, AS Ngo, H Azab, A Azab, F Hatjiharissi, E Treon, S Hideshima, T Palladino, M Anderson, K Chuahan, D Ghobrial, I AF Roccaro, Aldo Leleu, Xavier Sacco, Antonio Jia, Xiaoying Moreau, Anne-Sophie Ngo, Hai Azab, Abdelkareem Azab, Feda Hatjiharissi, Evdoxia Treon, Steven Hideshima, Tern Palladino, Michael Anderson, Kenneth Chuahan, Dharminder Ghobrial, Irene TI The combination of bortezomib and NPI-0052 exerts anti-tumor activity in Waldenstrom Macroglobulinemia (WM) SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Roccaro, Aldo; Leleu, Xavier; Sacco, Antonio; Jia, Xiaoying; Moreau, Anne-Sophie; Ngo, Hai; Azab, Abdelkareem; Azab, Feda; Hatjiharissi, Evdoxia; Treon, Steven; Hideshima, Tern; Anderson, Kenneth; Chuahan, Dharminder; Ghobrial, Irene] Dana Farber Canc Inst, Boston, MA USA. [Palladino, Michael] Nereus Pharmaceut, San Diego, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1516 BP 454A EP 454A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802038 ER PT J AU McMillin, DW Negri, J Delmore, J Hayden, P Ooi, M Mitsiades, N Schlossman', R Richardson, PG Munshi, NC Jensen, MR Quadt, C Chene, P Schoepfer, J Garcia-Echeverria, C Anderson, KC Mitsiades, CS AF McMillin, Douglas W. Negri, Joseph Delmore, Jake Hayden, Patrick Ooi, Melissa Mitsiades, Nicholas Schlossman', Robert Richardson, Paul G. Munshi, Nikhil C. Jensen, Michael R. Quadt, Cornelia Chene, Patrick Schoepfer, Joseph Garcia-Echeverria, Carlos Anderson, Kenneth C. Mitsiades, Constantine S. TI Activity of new heat shock protein 90 (hsp90) inhibitor NVP-AUY922 against myeloma cells sensitive and resistant to conventional agents SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [McMillin, Douglas W.; Negri, Joseph; Delmore, Jake; Hayden, Patrick; Ooi, Melissa; Mitsiades, Nicholas; Schlossman', Robert; Richardson, Paul G.; Munshi, Nikhil C.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA. [McMillin, Douglas W.; Negri, Joseph; Delmore, Jake; Hayden, Patrick; Ooi, Melissa; Mitsiades, Nicholas; Schlossman', Robert; Richardson, Paul G.; Munshi, Nikhil C.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Harvard Med Sch, Dept Med, Boston, MA USA. [Jensen, Michael R.; Chene, Patrick; Schoepfer, Joseph; Garcia-Echeverria, Carlos] Novartis Inst Biomed Res, Dept Oncol, Basel, Switzerland. [Quadt, Cornelia] Novartis Pharma AG, Basel, Switzerland. RI Jensen, Michael/E-9677-2011 NR 0 TC 4 Z9 4 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1587 BP 474A EP 474A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802109 ER PT J AU Song, W Tai, YT Sasada, T Burger, P Fulciniti, M Li, X Anderson, KC Munshi, NC AF Song, Weihua Tai, Yu-Tzu Sasada, Tetsuro Burger, Peter Fulciniti, Mariateresa Li, Xianfeng Anderson, Kenneth C. Munshi, Nikhil C. TI Identification of CS1 peptides for induction of antigen-specific CTLs in multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Song, Weihua; Tai, Yu-Tzu; Sasada, Tetsuro; Burger, Peter; Fulciniti, Mariateresa; Li, Xianfeng; Anderson, Kenneth C.; Munshi, Nikhil C.] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA USA. [Munshi, Nikhil C.] Harvard Med Sch, Vet Adm Boston Hlth Care Syst, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1611 BP 481A EP 481A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802133 ER PT J AU Abel, GK DeAngelo, DJ Connors, JM Sholl, LM McCaffrey, RP Longtime, JA AF Abel, Gregory K. DeAngelo, Daniel J. Connors, Jean M. Sholl, Lynette M. McCaffrey, Ronald P. Longtime, Janina A. TI JAK2 V617F in patients with idiopathic thromboses in common locations SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Abel, Gregory K.; DeAngelo, Daniel J.; Connors, Jean M.; McCaffrey, Ronald P.] Dana Farber Canc Inst, Boston, MA USA. [Abel, Gregory K.; DeAngelo, Daniel J.; Connors, Jean M.; Sholl, Lynette M.; McCaffrey, Ronald P.; Longtime, Janina A.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1634 BP 487A EP 487A PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802156 ER PT J AU Bashey, A Medina, B Corringham, S Pasek, M Carrier, E Vrooman, L Streicher, H Lowy, I Solomon, SW Morris, LE Holland, K Mason, JR Soiffer, RJ Ball, ED AF Bashey, Asad Medina, Bridget Corringham, Sue Pasek, Mildred Carrier, Ewa Vrooman, Linda Streicher, Howard Lowy, Israel Solomon, Scott W. Morris, Lawrence E. Holland, Kent Mason, James R. Soiffer, Robert J. Ball, Edward D. TI Clinical trial of therapeutic blockade of CTLA4 with ipilimumab in patients with relapse of malignancy following allogeneic hematopoietic transplantation SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Bashey, Asad; Medina, Bridget; Corringham, Sue; Carrier, Ewa; Ball, Edward D.] Univ Calif San Diego, Moores Canc Ctr, Blood & Marrow Transplant Program, La Jolla, CA 92093 USA. [Pasek, Mildred; Vrooman, Linda; Soiffer, Robert J.] Dana Farber Canc Inst, Boston, MA USA. [Streicher, Howard] NCI, Pharmaceut Management Branch, Bethesda, MD 20892 USA. [Lowy, Israel] Medarex Inc, Bloomsburg, NJ USA. [Mason, James R.] Scripps Clin, La Jolla, CA USA. [Solomon, Scott W.; Morris, Lawrence E.; Holland, Kent] Georgia Northside Hosp, Blood Marrow Transplant Grp, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1646 BP 491A EP 491A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802168 ER PT J AU Zhou, A Cho, A Huang, SC Benz, EJ AF Zhou, Anyu Cho, Aeri Huang, Shu-Ching Benz, Edward J. TI A novel splicing factor RBM25 in erythroid differentiation. SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Zhou, Anyu; Cho, Aeri; Huang, Shu-Ching; Benz, Edward J.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1711 BP 510A EP 510A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802233 ER PT J AU Haining, WN Kanzler, H Davis, J Drury, L Kutok, J Brenn, T Angelosanto, J Evans, J Russell, K Rivoli, S George, S Morgan, T Li, XC Coffman, R Wen, P Demetri, G Enadler, L AF Haining, W. Nicholas Kanzler, Holger Davis, Jeffrey Drury, Linda Kutok, Jeffrey Brenn, Thomas Angelosanto, Jill Evans, John Russell, Kate Rivoli, Stephen George, Suzanne Morgan, Thomas Li, Xiaochun Coffman, Robert Wen, Patrick Demetri, George Enadler, Lee TI A novel role for CpG oligonucleotides in tumor immunotherapy: CpG-ODN induce targeted chemokine-induced lymphocyte migration to the peripheral tissues in humans SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Haining, W. Nicholas; Davis, Jeffrey; Drury, Linda; Brenn, Thomas; Angelosanto, Jill; Evans, John; Russell, Kate; Rivoli, Stephen; George, Suzanne; Morgan, Thomas; Li, Xiaochun; Wen, Patrick; Demetri, George; Enadler, Lee] Dana Farber Canc Inst, Boston, MA USA. [Kanzler, Holger] Dynavax Technol, Berkeley, CA USA. [Kutok, Jeffrey] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1791 BP 531A EP 531A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802313 ER PT J AU Rosenblatt, J Wu, ZK Lenahan, C Bissonnette, A Vasir, B Miller, K Joyce, R Levine, J Galinsky, I Stone, R Kufe, D Avigan, D AF Rosenblatt, Jacalyn Wu, Zekui Lenahan, Corrine Bissonnette, Adam Vasir, Baldev Miller, Kenneth Joyce, Robin Levine, James Galinsky, Ilene Stone, Richard Kufe, Donald Avigan, David TI Targeting MUC1 as a marker for myeloid leukemia stem cells by DC/AML fusions. SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Rosenblatt, Jacalyn; Lenahan, Corrine; Miller, Kenneth; Joyce, Robin; Levine, James; Avigan, David] Beth Israel Deaconess Med Ctr, Boston, MA USA. [Wu, Zekui; Bissonnette, Adam; Vasir, Baldev; Galinsky, Ilene; Stone, Richard; Kufe, Donald] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1794 BP 532A EP 532A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802316 ER PT J AU Biernacki, MA Marina, O Fenglong, L Bruns, I Zahrieh, D Zhang, W Canning, C Alyea, EP Soiffer, RJ Ritz, J Wu, CJ AF Biernacki, Melinda A. Marina, Ovidiu Fenglong, Liu Bruns, Ingmar Zahrieh, David Zhang, Wandi Canning, Christine Alyea, Edwin P. Soiffer, Robert J. Ritz, Jerome Wu, Catherine J. TI Proteomics to identify novel immune-targeted CML stem cell antigens SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Biernacki, Melinda A.; Marina, Ovidiu; Zhang, Wandi; Canning, Christine; Ritz, Jerome; Wu, Catherine J.] Canc Vaccine Ctr, Dana Farber Canc Inst, Boston, MA USA. [Biernacki, Melinda A.; Marina, Ovidiu; Canning, Christine; Alyea, Edwin P.; Soiffer, Robert J.; Ritz, Jerome; Wu, Catherine J.] Brigham & Womens Hosp, Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Fenglong, Liu; Zahrieh, David] Dana Farber Canc Inst, Dept Biostat & Comp Biol, Boston, MA USA. [Bruns, Ingmar] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, D-4000 Dusseldorf, Germany. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1799 BP 533A EP 533A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802321 ER PT J AU Echart, C Repice, C Ferro, L Anderson, K Richardson, P Falanga, A Fareed, J Iacobelli, M AF Echart, Cinara Repice, Cinzia Ferro, Laura Anderson, Kenneth Richardson, Paul Falanga, Anna Fareed, Jawed Iacobelli, Massimo TI Reduced fibrinolysis in the hepatic venous occlusive disease: Effect of defibrotide on plasmin activity SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Echart, Cinara; Repice, Cinzia; Ferro, Laura; Iacobelli, Massimo] Gentium SpA, Como, Italy. [Anderson, Kenneth; Richardson, Paul] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Falanga, Anna] Osped Riuniti Bergamo, I-24100 Bergamo, Italy. [Fareed, Jawed] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 1992 BP 593A EP 593A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802514 ER PT J AU Ballen, K Wang, B Rosenthal, J Nademanee, A Karanes, C Jaing, TH Graham, M Tan, P Gjertson, D Petz, L Forman, S Chow, R AF Ballen, Karen Wang, Brian Rosenthal, Joseph Nademanee, Auayporn Karanes, Chatchada Jaing, Tang-Her Graham, Michael Tan, Patrick Gjertson, David Petz, Lawrence Forman, Stephen Chow, Robert TI An international multi-institutional study of double cord blood transplantation in a racially diverse population SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Ballen, Karen] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Wang, Brian; Petz, Lawrence; Chow, Robert] Stem Cyte, Arcadia, CA USA. [Rosenthal, Joseph; Nademanee, Auayporn; Karanes, Chatchada; Forman, Stephen] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Jaing, Tang-Her] Chang Gung Children Hosp, Taipei, Taiwan. [Graham, Michael] Univ Arizona, Med Ctr, Tucson, AZ USA. [Tan, Patrick] Mt Elizabeth Hosp, Singapore, Singapore. [Gjertson, David; Petz, Lawrence] Univ Calif Los Angeles, Ctr Med, Los Angeles, CA 90024 USA. [Chow, Robert] Stem Cyte Taiwan, Linko, Sweden. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2017 BP 600A EP 601A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100802539 ER PT J AU Cutler, C Mitrovich, R Kao, G Ho, V Alyea, E Koreth, J Armand, P Dey, B Spitzer, T Soiffer, R Antin, JH Ballen, K AF Cutler, Corey Mitrovich, Rachel Kao, Grace Ho, Vincent Alyea, Edwin Koreth, John Armand, Philippe Dey, Bimalangshu Spitzer, Thomas Soiffer, Robert Antin, Joseph H. Ballen, Karen TI Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Cutler, Corey; Mitrovich, Rachel; Kao, Grace; Ho, Vincent; Alyea, Edwin; Koreth, John; Armand, Philippe; Soiffer, Robert; Antin, Joseph H.] Brigham & Womens Hosp, Dana Faber Canc Inst, Boston, MA 02115 USA. [Dey, Bimalangshu; Spitzer, Thomas; Ballen, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2016 BP 600A EP 600A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802538 ER PT J AU Delaney, M Yeap, B Haspel, RL Spitzer, TR McAfee, SL Dey, B Attar, E Kao, G Alyea, E Lee, S Cutler, C Ho, V Soiffer, RJ Antin, JH Karen, B AF Delaney, Meghan Yeap, Beow Haspel, Richard L. Spitzer, Thomas R. McAfee, Steven L. Dey, Bimalangshu Attar, Eyal Kao, Grace Alyea, Edwin Lee, Stephanie Cutler, Corey Ho, Vincent Soiffer, Robert J. Antin, Joseph H. Karen, Ballen TI HLA locus-specific outcomes in double umbilical cord blood reduced intensity transplantation (DCBT) in adults SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Delaney, Meghan; Haspel, Richard L.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Yeap, Beow; Spitzer, Thomas R.; McAfee, Steven L.; Dey, Bimalangshu; Attar, Eyal; Karen, Ballen] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kao, Grace; Alyea, Edwin; Cutler, Corey; Ho, Vincent; Soiffer, Robert J.; Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lee, Stephanie] Fred Hutchinson Canc Res Ctr, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2032 BP 605A EP 605A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802554 ER PT J AU Brown, JR Levine, R Raderschall, E Thompson, C Gilliland, DG Freedman, AS AF Brown, Jennifer R. Levine, Ross Raderschall, Elke Thompson, Christina Gilliland, D. Gary Freedman, Arnold S. TI Systematic genomic screen for tyrosine kinase mutations in CLL SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Brown, Jennifer R.; Levine, Ross; Raderschall, Elke; Thompson, Christina; Gilliland, D. Gary; Freedman, Arnold S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Levine, Ross; Gilliland, D. Gary] Brigham & Womens Hosp, Boston, MA 02115 USA. [Brown, Jennifer R.; Levine, Ross; Gilliland, D. Gary; Freedman, Arnold S.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2069 BP 616A EP 616A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802591 ER PT J AU Zhou, DC Cui, Q Kim, H Thompson, R Greally, J Bouhassira, EE Gallagher, RE AF Zhou, Da-Cheng Cui, Qingping Kim, Haesook Thompson, Reid Greally, John Bouhassira, Eric E. Gallagher, Robert E. TI Increased global gene promoter methylation after relapse (Rel) of acute promyelocytic leukemia (APL) from all-trans retinoic acid (ATRA)Containing treatment is dissociated from concurrent gene expression changes SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Zhou, Da-Cheng; Cui, Qingping; Thompson, Reid; Greally, John; Bouhassira, Eric E.; Gallagher, Robert E.] Albert Einstein Canc Ctr, Bronx, NY 02115 USA. [Kim, Haesook] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2121 BP 632A EP 632A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802643 ER PT J AU Ge, XP Sykes, M Brown, J Boussiotis, VA AF Ge, Xupeng Sykes, Megan Brown, Julia Boussiotis, Vassiliki A. TI Targeting CD134 results in selective depletion of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Ge, Xupeng; Sykes, Megan; Brown, Julia; Boussiotis, Vassiliki A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2174 BP 646A EP 646A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802696 ER PT J AU Li, JM Southerland, L Giver, C McMillion, D Harris, W Jaye, DL Waller, N AF Li, Jian-Ming Southerland, Lauren Giver, Cindy McMillion, Doug Harris, Wayn Jaye, David L. Waller, Ned TI CD11b-donor dendritic cells elevate donor T-Cell production of interferon-gamma and graft-versus-leukemia activity in allogeneic bone marrow transplantation SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Li, Jian-Ming; Giver, Cindy; Harris, Wayn; Waller, Ned] Emory Univ, Dept Hematol Oncol, Atlanta, GA 30322 USA. [Southerland, Lauren] Duke Univ, Sch Med, Dept Med, Durham, NC USA. [McMillion, Doug] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Jaye, David L.] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2181 BP 648A EP 649A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100802703 ER PT J AU Sachs, J Sykes, M AF Sachs, Jessica Sykes, Megan TI Lymphopenia promotes the development of graft-versus-host disease upon donor leukocyte infusion SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Sachs, Jessica; Sykes, Megan] Massachusetts Gen Hosp, Dept Surg, Transplantat Biol Res Ctr, Boston, MA 02114 USA. [Sachs, Jessica] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sachs, Jessica] Childrens Hosp, Boston, MA 02115 USA. [Sachs, Jessica; Sykes, Megan] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2185 BP 650A EP 650A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100802707 ER PT J AU Mueller, MR Sasaki, Y Shamna, S Ghosh, S Gelinas, C Lamperti, EL Rajewsky, K Rao, A AF Mueller, Martin R. Sasaki, Yoshiteru Shamna, Sonia Ghosh, Srimoyee Gelinas, Curtis Lamperti, Edward L. Rajewsky, Klaus Rao, Anjana TI Expression of hyperactivable NFAT1 from the ROSA26 locus leads to detrimental effects during embryonic development SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Mueller, Martin R.; Sasaki, Yoshiteru; Shamna, Sonia; Ghosh, Srimoyee; Gelinas, Curtis; Lamperti, Edward L.; Rajewsky, Klaus; Rao, Anjana] Harvard Med Sch, Immunu Dis Inst, Dept Pathol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2296 BP 680A EP 680A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803078 ER PT J AU Zuckerman, D Lacasce, A Jacobsen, E Takvorian, T Hochberg, E AF Zuckerman, Dan Lacasce, Ann Jacobsen, Eric Takvorian, Tak Hochberg, Ephraim TI High false positive rate with the use of CT and FDG-PET in post-remission surveillance for Hodgkin lymphoma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Zuckerman, Dan] Massachusetts Gen Hosp, Dana Farber Canc Inst, Boston, MA 02114 USA. [Lacasce, Ann; Jacobsen, Eric] Dana Farber Canc Inst, Boston, MA 02115 USA. [Takvorian, Tak; Hochberg, Ephraim] Massachusetts Gen Hosp, Ctr Lymphoma, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2327 BP 688A EP 689A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100803109 ER PT J AU Brown, JR Rastarhuyeva, I Jagannathan, J Slevenson, K Neuberg, D Melenevsky, Y Phillips, KS Clark, JC Takvoriah, RW Fisher, DC Freedman, AS Van den Abbeele, AD AF Brown, Jennifer R. Rastarhuyeva, Iryna Jagannathan, Jyothi Slevenson, Kristen Neuberg, Donna Melenevsky, Yulia Phillips, Kimberly S. Clark, Jennifer C. Takvoriah, Ronald W. Fisher, David C. Freedman, Arnold S. Van den Abbeele, Aniick D. TI Prospective evaluation of FDG-PET imaging of treatment response in relapsed follicular lymphoma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Brown, Jennifer R.; Phillips, Kimberly S.; Clark, Jennifer C.; Fisher, David C.; Freedman, Arnold S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rastarhuyeva, Iryna; Jagannathan, Jyothi; Slevenson, Kristen; Melenevsky, Yulia; Van den Abbeele, Aniick D.] DFCI, Boston, MA USA. [Takvoriah, Ronald W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2331 BP 689A EP 690A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100803113 ER PT J AU Chen, Q Esseltine, DL Neuwirth, RB Richardson, PG Orlowski, RZ AF Chen, Qing Esseltine, Dixie-Lee Neuwirth, Rachel B. Richardson, Paul G. Orlowski, Robert Z. TI Ciprofloxacin inhibits bortezomib-mediated apoptosis in multiple myeloma models in association with induction of heme oxygenase-1 SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Chen, Qing; Orlowski, Robert Z.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA. [Esseltine, Dixie-Lee; Neuwirth, Rachel B.] Millennium Pharmaceut Inc, Cambridge, MA USA. [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2365 BP 698A EP 699A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100803147 ER PT J AU Tai, YT Buon, L King, B Li, C Li, C Burger, P Burger, P Li, XF Song, WH Schlossrnan, R Richardson, P Anderson, KC Munshi, N AF Tai, Yu-Tzu Buon, Leutz King, Benjamin Li, Cheng Li, Cheng Burger, Peter Burger, Peter Li, Xian-Feng Song, Weihua Schlossrnan, Robert Richardson, Paul Anderson, Kenneth C. Munshi, Nikhil TI Acquisition of new in vivo genomic change over time in multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Tai, Yu-Tzu; King, Benjamin; Burger, Peter; Burger, Peter; Li, Xian-Feng; Song, Weihua; Schlossrnan, Robert; Richardson, Paul; Anderson, Kenneth C.; Munshi, Nikhil] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Buon, Leutz] Boston VA Healthcare Syst, Boston, MA USA. [Li, Cheng; Li, Cheng] Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2481 BP 732A EP 732A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803263 ER PT J AU Adamia, S Reichert, A Ghosh, A Hodges, J Pilarski, P Treon, S Mant, MJ Reiman, T Belch, AR Pilarski, LM AF Adamia, Sophia Reichert, Amanda Ghosh, Anirban Hodges, Jennifer Pilarski, Patrick Treon, Steven Mant, Michael J. Reiman, Tony Belch, Andrew R. Pilarski, Linda M. TI Gerraline and somatic mutations in the hyaluronan synthase-1 (HAS1) gene may contribute to oncogenesis in multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Adamia, Sophia; Reichert, Amanda; Ghosh, Anirban; Pilarski, Patrick; Treon, Steven; Mant, Michael J.; Reiman, Tony; Belch, Andrew R.; Pilarski, Linda M.] Univ Alberta, Edmonton, AB, Canada. [Adamia, Sophia; Hodges, Jennifer] DFCI, Boston, MA USA. RI Pilarski, Patrick/C-3485-2008 OI Pilarski, Patrick/0000-0003-1686-2978 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2488 BP 733A EP 734A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100803270 ER PT J AU Trent, J Carpten, J Reich, M Liefeld, T Keats, J Mousses, S Hahn, W Trudel, S Siegel, D Rajkumar, SV Alsina, M Richardson, P Anderson, K Auclair, D Perkins, LM Giusti, K Fonseca, R Golub, TR AF Trent, Jeffrey Carpten, John Reich, Michael Liefeld, Ted Keats, Jonathan Mousses, Spyro Hahn, William Trudel, Suzanne Siegel, David Rajkumar, S. Vincent Alsina, Melissa Richardson, Paul Anderson, Kenneth Auclair, Daniel Perkins, Louise M. Giusti, Kathy Fonseca, Rafael Golub, Todd R. TI The Multiple Myeloma Research Consortium Genomics Initiative SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Trent, Jeffrey; Carpten, John; Mousses, Spyro] TGen, Phoenix, AZ USA. [Reich, Michael; Liefeld, Ted; Hahn, William; Golub, Todd R.] MIT, Broad Inst Harvard, Cambridge, MA 02139 USA. [Keats, Jonathan] Mayo Clin, Div Hematol Oncol, Scottsdale, AZ USA. [Trudel, Suzanne] Univ Hlth Network, Dept Med Oncol, Toronto, ON, Canada. [Siegel, David] Hackensack Univ, Hackensack, NJ USA. [Rajkumar, S. Vincent] Mayo Clin, Rochester, MN USA. [Alsina, Melissa] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Richardson, Paul; Anderson, Kenneth] Dana Farber Canc Inst, Boston, MA USA. [Auclair, Daniel; Perkins, Louise M.; Giusti, Kathy] Multiple Myeloma Res Consortium, Norwalk, CT USA. RI Keats, Jonathan/B-2047-2009 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2498 BP 736A EP 736A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803280 ER PT J AU Runnels, JM Azab, A Pitsillides, C Moreau, AS Azab, F Spencer, JA Leleu, X Carlson, AL Ospina, BE Wright, R Jia, X Ngo, H Kung, AL Lin, CP Ghobrial, IM AF Runnels, Judith M. Azab, Abdelkareem Pitsillides, Costas Moreau, Anne-Sophie Azab, Feda Spencer, Joel A. Leleu, Xavier Carlson, Alicia L. Ospina, Beatriz E. Wright, Renee Jia, Xiaoying Ngo, Hai Kung, Andrew L. Lin, Charles P. Ghobrial, Irene M. TI In vivo mobilization of multiple myeloma cells out of the bone marrow using the CXCR4 inhibitor AMD3100 and bortezomib: Implications for sensitization of myeloma cells to apoptosis SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Runnels, Judith M.; Azab, Abdelkareem; Pitsillides, Costas; Moreau, Anne-Sophie; Azab, Feda; Spencer, Joel A.; Leleu, Xavier; Carlson, Alicia L.; Jia, Xiaoying; Ngo, Hai; Lin, Charles P.; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ospina, Beatriz E.; Wright, Renee; Kung, Andrew L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Spencer, Joel/A-4590-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2501 BP 737A EP 737A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803283 ER PT J AU Ueno, S Tatetsu, H Harada, N Hata, H Iino, T Niiro, H Akashi, K Tenen, DG Mitsuya, H Okuno, Y AF Ueno, Shikiko Tatetsu, Hiro Harada, Naoko Hata, Hiroyuki Iino, Tadafumi Niiro, Hiroaki Akashi, Koichi Tenen, Daniel G. Mitsuya, Hiroaki Okuno, Yutaka TI Microarray analysis of PU.1-induced growth arrest and apoptosis of myeloma cell lines SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Ueno, Shikiko; Tatetsu, Hiro; Harada, Naoko; Mitsuya, Hiroaki; Okuno, Yutaka] Kumamoto Univ, Sch Med, Dept Hematol, Kumamoto, Japan. [Iino, Tadafumi; Niiro, Hiroaki; Akashi, Koichi] Kyushu Univ Hosp, Ctr Cellular & Mol Med, Fukuoka 812, Japan. [Iino, Tadafumi; Akashi, Koichi] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Tenen, Daniel G.] Harvard Inst Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2499 BP 737A EP 737A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803281 ER PT J AU Echart, C Graziadio, B Repice, C Boccadoro, M Palumbo, A Mitsiades, C Anderson, K Richardson, P Iacobelli, M AF Echart, Cinara Graziadio, Barbara Repice, Cinzia Boccadoro, Mario Palumbo, Antonio Mitsiades, Constantine Anderson, Kenneth Richardson, Paul Iacobelli, Massimo TI Defibrolide counteracts the modifications of anti-thrombotic phenotype of endothelial cells induced by thalidomide SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Echart, Cinara; Graziadio, Barbara; Repice, Cinzia; Iacobelli, Massimo] Gentium SpA, Como, Italy. [Boccadoro, Mario; Palumbo, Antonio] Inst Tumori, Turin, Italy. [Mitsiades, Constantine; Anderson, Kenneth; Richardson, Paul] Dana Farber Canc Inst, Jerompe Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2502 BP 738A EP 738A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803284 ER PT J AU Vallet, S Raje, N Fulciniti, MT Ishitsuka, K Hideshima, T Podar, K Pozzi, S Breitkreutz, I Kiziltepe, T Okawa, Y Ikeda, H Santo, L Mukherjee, S Vaghela, N Cirstea, D Boccadoro, M Anderson, KC AF Vallet, Sonia Raje, Noopur Fulciniti, Maria Teresa Ishitsuka, Kenji Hideshima, Teru Podar, Klaus Pozzi, Samanatha Breitkreutz, Iris Kiziltepe, Tanyel Okawa, Yutaka Ikeda, Hiroshi Santo, Loredana Mukherjee, SIddhartha Vaghela, Nileshwari Cirstea, Diana Boccadoro, Mario Anderson, Kenneth C. TI Targeting CCR1 for the treatment of osteolytic bone disease in multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Vallet, Sonia; Raje, Noopur; Fulciniti, Maria Teresa; Ishitsuka, Kenji; Hideshima, Teru; Podar, Klaus; Pozzi, Samanatha; Breitkreutz, Iris; Kiziltepe, Tanyel; Okawa, Yutaka; Ikeda, Hiroshi; Santo, Loredana; Vaghela, Nileshwari; Cirstea, Diana; Anderson, Kenneth C.] Dana Farber Canc Inst, Harvard Med Sch, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA. [Raje, Noopur; Mukherjee, SIddhartha] Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA. [Boccadoro, Mario] Univ Turin, Cattedra Ematol, Dipartimento Med & Oncol Sperimentale, Turin, Italy. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 1 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2503 BP 738A EP 738A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803285 ER PT J AU Podar, K Zhang, J Raab, MS Vallet, S Fulciniti, M Sattler, M Ikeda, Y Chauhan, D Anderson, KC AF Podar, Klaus Zhang, Jing Raab, Marc S. Vallet, Sonia Fulciniti, Mariateresa Sattler, Martin Ikeda, Yutaka Chauhan, Dharminder Anderson, Kenneth C. TI The tyrophostin adaphostin (NSC680410) inhibits multiple myeloma bone marrow angiogenesis in vitro and in vivo SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Podar, Klaus; Zhang, Jing; Raab, Marc S.; Vallet, Sonia; Fulciniti, Mariateresa; Sattler, Martin; Ikeda, Yutaka; Chauhan, Dharminder; Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2507 BP 739A EP 739A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803289 ER PT J AU Shen, JP Divakaran, S Kuai, L Wang, X Ong, SE Amaravadi, R Wood, J Carr, S Schreiber, S Haggarty, S Bradner, J AF Shen, John P. Divakaran, Sanjay Kuai, Letian Wang, Xiang Ong, Shao-En Amaravadi, Ravi Wood, John Carr, Steven Schreiber, Stuart Haggarty, Stephen Bradner, James TI Autophagy as a target pathway in multiple myeloma: A forward chemical genetic approach SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Shen, John P.; Divakaran, Sanjay; Kuai, Letian; Wang, Xiang; Ong, Shao-En; Carr, Steven; Schreiber, Stuart; Haggarty, Stephen; Bradner, James] MIT, Broad Inst Harvard, Chem Biol Program, Cambridge, MA 02139 USA. [Shen, John P.] Washington Univ, Sch Med, Dept Med, St Louis, MO USA. [Amaravadi, Ravi] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA. [Wood, John] Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA. [Bradner, James] Dana Farber Canc Inst, Div Hematol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2510 BP 740A EP 740A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803292 ER PT J AU Echart, C Distaso, M Ferro, L Boccadoro, M Palumbo, A Mitsiades, C Anderson, K Richardson, P Iacobelli, M AF Echart, Cinara Distaso, Maria Ferro, Laura Boccadoro, Mario Palumbo, Antonio Mitsiades, Constantine Anderson, Kenneth Richardson, Paul Iacobelli, Massimo TI Co-culture of myeloma and endothelial cells: Defibrotide downregulates heparanase and pro-angiogenic growth factors SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Echart, Cinara; Distaso, Maria; Ferro, Laura; Iacobelli, Massimo] Gentium SpA, Como, Italy. [Boccadoro, Mario; Palumbo, Antonio] Inst Tumori, Turin, Italy. [Mitsiades, Constantine; Anderson, Kenneth; Richardson, Paul] Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2513 BP 741A EP 741A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803295 ER PT J AU Leleu, X Jerome, E Jia, X Moreau, AS Roccaro, AM Farag, M Sacco, A Hatjiharissi, E Ngo, HT Runnels, J Azab, A Azab, F Hunter, Z Sportelli, P Treon, SP Hideshima, T Anderson, KC Ghobrial, IM AF Leleu, Xavier Jerome, Eeckhoute Jia, Xiaoying Moreau, Anne-Sophie Roccaro, Aldo M. Farag, Mena Sacco, Antonio Hatjiharissi, Evdoxia Ngo, Hai T. Runnels, Judith Azab, Abdelkareem Azab, Feda Hunter, Zachary Sportelli, Peter Treon, Steven P. Hideshima, Teru Anderson, Kenneth C. Ghobrial, Irene M. TI Targeting NF-kB by perifosine, bortezomib and rituximab in Waldenstrom macroglobulinemia (WM) SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Leleu, Xavier; Jerome, Eeckhoute; Jia, Xiaoying; Moreau, Anne-Sophie; Roccaro, Aldo M.; Farag, Mena; Sacco, Antonio; Hatjiharissi, Evdoxia; Ngo, Hai T.; Runnels, Judith; Azab, Abdelkareem; Azab, Feda; Hunter, Zachary; Sportelli, Peter; Treon, Steven P.; Hideshima, Teru; Anderson, Kenneth C.; Ghobrial, Irene M.] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA 02115 USA. [Leleu, Xavier; Moreau, Anne-Sophie] CHRU, Serv Maladies Sang Lab Immunol, Lille, France. [Sportelli, Peter] Keryx Biopharmaceut, New York, NY USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2512 BP 741A EP 741A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803294 ER PT J AU Adamia, S Xu, L Sacco, A Treon, S AF Adamia, Sophia Xu, Lian Sacco, Antonio Treon, Steven TI Identification genetic variations (GVs) causing splicing of TNF family members and adaptor proteins that modulate NFkB pathways in Waldenstrom's maroglobulinemia (WM) SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Adamia, Sophia; Xu, Lian; Sacco, Antonio; Treon, Steven] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2516 BP 742A EP 742A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803298 ER PT J AU Okawa, Y Hideshima, T Ikeda, H Vallet, S Kiziltepe, T Raje, N Yasui, H Enatsu, S Pozzi, S Reitkreutz, I Podar, K Richardson, PG Anderson, KC AF Okawa, Yutaka Hideshima, Teru Ikeda, Hiroshi Vallet, Sonia Kiziltepe, Tanyel Raje, Noopur Yasui, Hiroshi Enatsu, Sotaro Pozzi, Samantha Reitkreutz, Iris Podar, Klaus Richardson, Paul G. Anderson, Kenneth C. TI Inhibition of hsp90 targets multiple myeloma cell growth, angiogenesis, and osteoclastogenesis in the BM microenvironment SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Okawa, Yutaka; Hideshima, Teru; Ikeda, Hiroshi; Vallet, Sonia; Kiziltepe, Tanyel; Raje, Noopur; Yasui, Hiroshi; Enatsu, Sotaro; Pozzi, Samantha; Reitkreutz, Iris; Podar, Klaus; Richardson, Paul G.; Anderson, Kenneth C.] Jerome Lipper Myeloma Ctr, Harvard Med Sch, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut,Dept Med Oncol, Boston, MA USA. [Okawa, Yutaka] Jikei Univ, Sch Med, Dept Internal Med, Div Hematol & Oncol, Tokyo, Japan. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2521 BP 743A EP 744A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100803304 ER PT J AU Chauhan, D Singh, A Brahmandam, M Podar, K Hideshima, T Schlossman, R Richardson, P Munshi, N Palladino, M Anderson, KC AF Chauhan, Dharminder Singh, Ajita Brahmandam, Mohan Podar, Klaus Hideshima, Teru Schlossman, Robert Richardson, Paul Munshi, Nikhil Palladino, Michael Anderson, Kenneth C. TI Combination of proteasome inhibitors bortezomib and NPI-0052 trigger-in vivo synergistic cytotoxicity in multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Chauhan, Dharminder; Singh, Ajita; Brahmandam, Mohan; Podar, Klaus; Hideshima, Teru; Schlossman, Robert; Richardson, Paul; Munshi, Nikhil; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Palladino, Michael] Nereus Pharmaceut Inc, San Diego, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2524 BP 744A EP 744A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803306 ER PT J AU Raab, MS Breitkreutz, I Klaus, P Zhang, J Blotta, S Christensen, O Hideshima, T Chauhan, D Wilhelm, S Anderson, KC AF Raab, Marc S. Breitkreutz, Iris Klaus, Podar Zhang, Jing Blotta, Simona Christensen, Olaf Hideshima, Teru Chauhan, Dharminder Wilhelm, Scott Anderson, Kenneth C. TI The novel, orally available multi-kinase inhibitor BAY 73-4506 targets myeloma cells and their bone marrow microenvironment SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Raab, Marc S.; Breitkreutz, Iris; Klaus, Podar; Zhang, Jing; Blotta, Simona; Hideshima, Teru; Chauhan, Dharminder; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Raab, Marc S.] Univ Heidelberg, Dept Internal Med 5, D-6900 Heidelberg, Germany. [Christensen, Olaf; Wilhelm, Scott] Bayer Healthcare Pharmaceut, Dept Canc Ctr Biol, West Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2525 BP 744A EP 744A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803307 ER PT J AU Soumerai, JD O'Connor, KE Ioakimidis, LM Patterson, CJ Ciccarelli, BT Leduc, R Hunter, ZR Nelson, M Roccaro, AM Leleu, X Hatjiharissi, E Adamia, S Xu, L Ghobrial, IM Treon, SP AF Soumerai, Jacob D. O'Connor, Kelly E. Ioakimidis, Leukothea M. Patterson, Christopher J. Ciccarelli, Bryan T. Leduc, Renee Hunter, Zachary R. Nelson, Marybeth Roccaro, Aldo M. Leleu, Xavier Hatjiharissi, Evdoxia Adamia, Sophia Xu, Lian Ghobrial, Irene M. Treon, Steven P. TI Imatinib mesylate (Gleevec(R)) produces responses in patients with relapsed/refractory Waldenstrom's macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Soumerai, Jacob D.; O'Connor, Kelly E.; Ioakimidis, Leukothea M.; Patterson, Christopher J.; Ciccarelli, Bryan T.; Leduc, Renee; Hunter, Zachary R.; Nelson, Marybeth; Roccaro, Aldo M.; Leleu, Xavier; Hatjiharissi, Evdoxia; Adamia, Sophia; Xu, Lian; Ghobrial, Irene M.; Treon, Steven P.] Harvard Med Sch, Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2575 BP 759A EP 759A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803357 ER PT J AU Ngo, HT Farag, M Leleu, X Jia, X Runnels, J Moreau, AS Azab, A Azab, F Hatjiharissi, E Roccaro, A Sacco, A Ghobrial, IM AF Ngo, Hai T. Farag, Mena Leleu, Xavier Jia, Xiaoying Runnels, Judith Moreau, Anne-Sophie Azab, Abdelkareem Azab, Feda Hatjiharissi, Evdoxia Roccaro, Aldo Sacco, Antonio Ghobrial, Irene M. TI The interaction of CXCR4/SDF-1 and VLA-4 regulates adhesion and transendothelial migration in Waldenstrom macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Ngo, Hai T.; Farag, Mena; Leleu, Xavier; Jia, Xiaoying; Runnels, Judith; Moreau, Anne-Sophie; Azab, Abdelkareem; Azab, Feda; Hatjiharissi, Evdoxia; Roccaro, Aldo; Sacco, Antonio; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2617 BP 770A EP 771A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100803399 ER PT J AU Yang, J Chai, L Fowles, T Alipio, Z Gao, C Fink, L Ma, YP AF Yang, Jianchang Chai, Li Fowles, Taylor Alipio, Zaida Gao, Chong Fink, Louis Ma, Yupo TI SALL4-dependent signaling networks are required for survival of leukemia cells SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Yang, Jianchang; Fowles, Taylor; Alipio, Zaida; Fink, Louis; Ma, Yupo] Nevada Canc Inst, Div Lab Med, Las Vegas, NV USA. [Chai, Li; Gao, Chong] Brigham & Womens Hosp, Dana Farber Canc Inst, Joint Program Transfus Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2635 BP 775A EP 776A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100803417 ER PT J AU Payne, EM Grabher, C Bolli, N Kanki, J Falini, B Look, AT AF Payne, Elspeth M. Grabher, Clemens Bolli, Niccolo Kanki, John Falini, Brunangelo Look, A. Thomas TI Function of nucleophosmin in zebratish hematopoiesis SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Payne, Elspeth M.; Grabher, Clemens; Bolli, Niccolo; Kanki, John; Look, A. Thomas] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Falini, Brunangelo] Univ Perugia, Dept Hematol, I-06100 Perugia, Italy. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2644 BP 778A EP 778A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803426 ER PT J AU Palumbo, A Larocca, A Rus, C Gay, F Rossi, D Pregno, P Falco, P Avonto, I Magarotto, V Cavallo, F Iacobelli, M Gaidano, G Mitsiades, C Richardson, PG Anderson, KC Boccadoro, M AF Palumbo, Antonio Larocca, Alessandra Rus, Cecilia Gay, Francesca Rossi, Davide Pregno, Patrizia Falco, Patrizia Avonto, Ilaria Magarotto, Valeria Cavallo, Federica Iacobelli, Massimo Gaidano, Gianluca Mitsiades, Constantine Richardson, Paul G. Anderson, Kenneth C. Boccadoro, Mario TI A phase I/II trial on melphalan, prednisone, thalidomide and defribotide combination in relapsed/refractory multiple myeloma patients SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Palumbo, Antonio; Larocca, Alessandra; Rus, Cecilia; Gay, Francesca; Falco, Patrizia; Avonto, Ilaria; Magarotto, Valeria; Cavallo, Federica; Boccadoro, Mario] Univ Turin, Az Osp San Giovanni Battista, Div Ematol, Turin, Italy. [Rossi, Davide; Gaidano, Gianluca] Univ Piemonte Orientale Amedeo Avogadro, IRCAD Dipartimento Oncol, Dipartimento Sci Med, Div Ematol, Novara, Italy. [Pregno, Patrizia] Az Osp Giovanni Battista, Turin, Italy. [Mitsiades, Constantine; Richardson, Paul G.; Anderson, Kenneth C.] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2715 BP 797A EP 797A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803497 ER PT J AU Richardson, P Jagannath, S Raje, N Jakubowiak, A Lonial, S Ghobrial, I Schlossman, R Mazumder, A Munshi, N Colson, K McKenney, M Farrell, M Lunde, L Giove, L Kaster, S Mitsiades, C Hideshima, T Knight, R Esseltine, DL Anderson, K AF Richardson, Paul Jagannath, Sundaf Raje, Noopur Jakubowiak, Andrzej Lonial, Sagar Ghobrial, Irene Schlossman, Robert Mazumder, Amitabha Munshi, Nikhil Colson, Kathleen McKenney, Mary Farrell, Melissa Lunde, Laura Giove, Lawrence Kaster, Sarah Mitsiades, Constantine Hideshima, Teru Knight, Robert Esseltine, Dixie-Lee Anderson, Kenneth TI Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Richardson, Paul; Schlossman, Robert; Munshi, Nikhil; Colson, Kathleen; McKenney, Mary; Farrell, Melissa; Lunde, Laura; Mitsiades, Constantine; Hideshima, Teru; Anderson, Kenneth] Dana Farber Canc Inst, Boston, MA 02115 USA. [Jagannath, Sundaf; Mazumder, Amitabha; Giove, Lawrence] St Vincents Comprehens Canc Ctr, New York, NY USA. [Raje, Noopur] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Jakubowiak, Andrzej] Univ Michigan, Ann Arbor, MI 48109 USA. [Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Ghobrial, Irene; Knight, Robert] Celgene Corp, Summit, NJ USA. [Esseltine, Dixie-Lee] Millennium Pharmaceut Inc, Cambridge, MA USA. NR 0 TC 11 Z9 12 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2714 BP 797A EP 797A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803496 ER PT J AU Jagannath, S Barlogie, B Berenson, JR Siegel, D Irwin, D Richardson, P Niesvizky, R Alexanian, R Limentani, S Alsina, M Esseltine, DL Anderson, KC AF Jagannath, Sundar Barlogie, Bart Berenson, James R. Siegel, David Irwin, D. Richardson, Paul Niesvizky, Ruben Alexanian, Raymond Limentani, Steven Alsina, Melissa Esseltine, Dixie-Lee Anderson, Kenneth C. TI Updated survival analyses after prolonged follow-up of the phase 2 multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Jagannath, Sundar] St Vincents Comprehens Canc Ctr, New York, NY USA. [Barlogie, Bart] Myeloma Inst Res & Therapy, Little Rock, AR USA. [Berenson, James R.] Myeloma & Bone Canc Res, W Hollywood, CA USA. [Siegel, David] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Irwin, D.] Alta Bates Canc Ctr, Berkeley, CA USA. [Richardson, Paul] Dana Farber Canc Inst, Boston, MA 02115 USA. [Niesvizky, Ruben] Cornell Univ, Weill Med Coll, New York, NY USA. [Alexanian, Raymond] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Limentani, Steven] Carolinas Hematol Oncol Associates, Charlotte, NC USA. [Alsina, Melissa] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Esseltine, Dixie-Lee] Millennium Pharmaceut Inc, Cambridge, MA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2717 BP 798A EP 798A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803499 ER PT J AU Kumar, S Zhang, L Greipp, PR Rajkumar, SV AF Kumar, Shaji Zhang, Lijun Greipp, Philip R. Rajkumar, S. Vincent TI Effect of thrombotic events on overall survival in patients with newly diagnosed myeloma: Analysis from a randomized phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00) SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Kumar, Shaji; Greipp, Philip R.; Rajkumar, S. Vincent] Mayo Clin, Rochester, MN USA. [Zhang, Lijun] Dana Farber Canc Inst, Boston, MA 02115 USA. RI Kumar, Shaji/A-9853-2008 OI Kumar, Shaji/0000-0001-5392-9284 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2734 BP 803A EP 803A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803516 ER PT J AU Zhang, X Inukai, T Akahane, K Hirose, K Kuroda, I Honna, H Goi, K Kagami, K Inaba, T Kurosawa, H Goto, H Endo, M Yagita, H Look, AT Sugita, K AF Zhang, Xiaochun Inukai, Takeshi Akahane, Koshi Hirose, Kinuko Kuroda, Itaru Honna, Hiroko Goi, Kumiko Kagami, Keiko Inaba, Toshiya Kurosawa, Hidemitsu Goto, Hiroaki Endo, Mikiya Yagita, Hideo Look, A. Thomas Sugita, Kanji TI Induction of death receptors for TRAIL, a cytotoxic factor for GVL effect, by oncogenic fusion E2A-HLF derived from t(17;19)-positive acute lymphoblastic leukemia SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Zhang, Xiaochun; Inukai, Takeshi; Akahane, Koshi; Hirose, Kinuko; Kuroda, Itaru; Honna, Hiroko; Goi, Kumiko; Kagami, Keiko; Sugita, Kanji] Univ Yamanashi, Sch Med, Yamanashi, Japan. [Inaba, Toshiya] Hiroshima Univ, Res Inst Radiat Biol & Med, Hiroshima, Japan. [Kurosawa, Hidemitsu] Dokkyo Med Sch, Tochigi, Japan. [Goto, Hiroaki] Yokohama City Univ, Sch Med, Yokohama, Kanagawa 232, Japan. [Endo, Mikiya] Iwate Med Univ, Sch Med, Morioka, Iwate 020, Japan. [Yagita, Hideo] Juntendo Univ, Sch Med, Tokyo 113, Japan. [Look, A. Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2785 BP 820A EP 820A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803567 ER PT J AU Lipshultz, SE Walker, VE Torres, SM Walker, DM Barry, E Miller, TL Scully, RE Sallan, SE AF Lipshultz, Steven E. Walker, Vernon E. Torres, Salina M. Walker, Dale M. Barry, Elly Miller, Tracie L. Scully, Rebecca E. Sallan, Stephen E. TI Frequent mitochondrial DNA mutations and polymorphisms in long-term survivors of childhood acute lymphoblastic leukemia SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Lipshultz, Steven E.; Miller, Tracie L.; Scully, Rebecca E.] Univ Miami, Miller Sch Med, Miami, FL 33152 USA. [Walker, Vernon E.; Torres, Salina M.] Lovelace Resp Res Inst, Albuquerque, NM USA. [Walker, Dale M.] Expt Pathol Labs, Sterling, VA USA. [Barry, Elly; Sallan, Stephen E.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2800 BP 824A EP 824A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803582 ER PT J AU Gutierrez, A Feng, H Edward, P Kanki, J Look, AT AF Gutierrez, Alejandro Feng, Hui Edward, Prochownik Kanki, John Look, A. Thomas TI A tamoxifen-dependent conditional model of MYC-induced T cell acute lymphoblastic leukemia in the zebrafish SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Gutierrez, Alejandro; Feng, Hui; Kanki, John; Look, A. Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gutierrez, Alejandro; Look, A. Thomas] Childrens Hosp, Boston, MA 02115 USA. [Edward, Prochownik] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2808 BP 826A EP 826A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803590 ER PT J AU Moellering, R Cornejo, M Rocknik, J Hancock, M DelBianco, C Blacklow, S Gilliland, G Verdine, G Bradner, J AF Moellering, Raymond Cornejo, Melanie Rocknik, Jennifer Hancock, Michael DelBianco, Christina Blacklow, Stephen Gilliland, Gary Verdine, Gregory Bradner, James TI Direct inhibition of the Notch transactivation complex, with synthetic constrained peptides in T-Cell acute lymphoblastic leukemia SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Moellering, Raymond; Bradner, James] MIT, Broad Inst Harvard, Chem Biol Program, Cambridge, MA 02139 USA. [Moellering, Raymond; Verdine, Gregory] Harvard Univ, Dept Chem, Cambridge, MA 02138 USA. [Cornejo, Melanie; Rocknik, Jennifer; Gilliland, Gary] Brigham & Womens Hosp, Dept Hematol, Boston, MA 02115 USA. [Hancock, Michael] Invitrogen Corp, Carlsbad, CA USA. [DelBianco, Christina; Blacklow, Stephen] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Bradner, James] Dana Farber Canc Inst, Div Hematol Neoplasia, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2819 BP 829A EP 829A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803601 ER PT J AU Rodrigues, MS Gonneville, JR Podar, K Weinstock, DM Griffin, JD Sattler, M AF Rodrigues, Margret S. Gonneville, Jeffrey R. Podar, Klaus Weinstock, David M. Griffin, James D. Sattler, Martin TI BCR-ABL induces error-prone single strand annealing in transformed cells SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Rodrigues, Margret S.; Gonneville, Jeffrey R.; Podar, Klaus; Griffin, James D.; Sattler, Martin] Dana Farber Canc Inst, Boston, MA 02115 USA. [Weinstock, David M.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 BP 863A EP 863A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803719 ER PT J AU Nelson, EA Walker, SR Kepich, A Terrell, S Gashin, L Frank, DA AF Nelson, Erik A. Walker, Sarah R. Kepich, Alicia Terrell, Shariya Gashin, Laurie Frank, David A. TI Pimozide inhibits STAT5 signaling in chronic myelogenous leukemia and reduces the viability of both imatinib sensitive and imatinib resistant cells SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Nelson, Erik A.; Walker, Sarah R.; Kepich, Alicia; Terrell, Shariya; Gashin, Laurie; Frank, David A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2953 BP 868A EP 868A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100803735 ER PT J AU Davies, J Yuk, D Brennan, L Nadler, L Guinan, E AF Davies, Jeff Yuk, Dongin Brennan, Lisa Nadler, Lee Guinan, Eva TI In vivo expansion of CD4+ FOXP3+ regulatory T cells may contribute to control of acute GvHD after HLA-mismatched alloanergized HSCT SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Davies, Jeff; Yuk, Dongin; Brennan, Lisa; Nadler, Lee; Guinan, Eva] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2978 BP 874A EP 875A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100804015 ER PT J AU Armistead, PM Mohseni, M Gerwin, R Iravani, M Chardouli, B Khostami, S Ghavamzadeh, A Ritz, J Antin, JH Wu, C AF Armistead, Paul M. Mohseni, Mehrdad Gerwin, Roslyn Iravani, Masood Chardouli, Bahrain Khostami, Sharbano Ghavamzadeh, Ardeshir Ritz, Jerome Antin, Joseph H. Wu, Catherine TI Erythroid-lineage specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Armistead, Paul M.] MD Anderson Canc Ctr, Houston, TX USA. [Armistead, Paul M.; Ritz, Jerome; Antin, Joseph H.; Wu, Catherine] Brigham & Womens Hosp, Harvard Med Sch, Boston, MA 02115 USA. [Mohseni, Mehrdad; Gerwin, Roslyn; Ritz, Jerome; Antin, Joseph H.; Wu, Catherine] Dana Farber Canc Inst, Boston, MA USA. [Iravani, Masood; Chardouli, Bahrain; Khostami, Sharbano; Ghavamzadeh, Ardeshir] Bone Marrow Transplant Res Ctr, Tehran, Iran. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 2996 BP 880A EP 880A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100804033 ER PT J AU Pasquini, MC Ewell, M Stadtmauer, EA Bredeson, CN Alyea, EP Stockerl-Goldstein, K Krishnan, A Sahebi, F Rowley, SD Maloney, DG Vesole, DH Horowitz, MM Carter, S Geller, N Giralt, S AF Pasquini, Marcelo C. Ewell, Marian Stadtmauer, Edward A. Bredeson, Christopher N. Alyea, Edwin P. Stockerl-Goldstein, Keith Krishnan, Amrita Sahebi, Firoozeh Rowley, Scott D. Maloney, David G. Vesole, David H. Horowitz, Mary M. Carter, Shelly Geller, Nancy Giralt, Sergio TI Biologic assignment clinical trials in hematopoietic stem cell transplantation (HSCT) for multiple myeloma: Baseline characteristics by treatment allocation from BMT CTN 0102 according to availability of an HLA-matched sibling donor SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Pasquini, Marcelo C.; Horowitz, Mary M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Stadtmauer, Edward A.] Univ Penn, Philadelphia, PA 19104 USA. [Alyea, Edwin P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Stockerl-Goldstein, Keith] Stanford Univ, Stanford, CA 94305 USA. [Rowley, Scott D.] Hackensack Univ, Hackensack, NJ USA. [Maloney, David G.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Geller, Nancy] NHLBI, Bethesda, MD 20892 USA. [Giralt, Sergio] MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 3028 BP 889A EP 889A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100804065 ER PT J AU Vesole, DH Zhang, L Flomenberg, N Greipp, PR Lazarus, HM AF Vesole, David H. Zhang, Lijun Flomenberg, Neal Greipp, Philip R. Lazarus, Hillard M. TI A phase II trial of autologous stem cell transplant (AHSCT) followed by mini-allogeneic stem cell transplant (AlloTx) for the treatment of multiple myeloma: Analysis of ECOG E4A98 SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Vesole, David H.] St Vincents Canc Ctr, New York, NY USA. [Zhang, Lijun] Dana Farber Canc Inst, Boston, MA 02115 USA. [Flomenberg, Neal] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Greipp, Philip R.] Mayo Clin, Rochester, MN USA. [Lazarus, Hillard M.] Univ Hosp Cleveland, Cleveland, OH 44106 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 3027 BP 889A EP 889A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100804064 ER PT J AU Armand, P Kim, HT LaCasce, AS Cutler, CS Ho, VT Koreth, J Jacobsen, ED Fisher, DC Brown, JR Canellos, GP Antin, JH Freedman, AS Brown, RJ Canellos, GP Antin, JH Freedman, AS Soiffer, RJ Alyea, EP AF Armand, Philippe Kim, Haesook T. LaCasce, Ann S. Cutler, Corey S. Ho, Vincent T. Koreth, John Jacobsen, Eric D. Fisher, David C. Brown, Jennifer R. Canellos, George P. Antin, Joseph H. Freedman, Arnold S. Brown, Robert J. Canellos, George P. Antin, Joseph H. Freedman, Arnold S. Soiffer, Robert J. Alyea, Edwin P. TI Non-myeloablative allogeneic transplantation for Hodgkin's and non-Hodgkin's lymphoma: Evidence for a graft-versus-lymphoma effect and relevance of chimerism SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Armand, Philippe; Kim, Haesook T.; LaCasce, Ann S.; Cutler, Corey S.; Ho, Vincent T.; Koreth, John; Jacobsen, Eric D.; Fisher, David C.; Brown, Jennifer R.; Canellos, George P.; Antin, Joseph H.; Freedman, Arnold S.; Brown, Robert J.; Canellos, George P.; Antin, Joseph H.; Freedman, Arnold S.; Soiffer, Robert J.; Alyea, Edwin P.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 3041 BP 893A EP 894A PN 1 PG 2 WC Hematology SC Hematology GA 233OS UT WOS:000251100804078 ER PT J AU Ho, VT Kim, H Li, S Cutler, C Koreth, J Armand, P Soiffer, RJ Antin, JH Alyea, EP AF Ho, Vincent T. Kim, Haesook Li, Shuli Cutler, Corey Koreth, John Armand, Phillipe Soiffer, Robert J. Antin, Joseph. H. Alyea, Edwin P. TI Tacrolimus and sirolimus without methotrexate as acute GVHD prophylaxis after matched related donor reduced intensity conditioning (RIC) stem cell transplantation (SCT) SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Ho, Vincent T.; Kim, Haesook; Li, Shuli; Cutler, Corey; Koreth, John; Armand, Phillipe; Soiffer, Robert J.; Antin, Joseph. H.; Alyea, Edwin P.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 3046 BP 895A EP 895A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100804083 ER PT J AU Nakamae, H Storer, B Chauncey, T Pulsipher, M Petersen, F Wade, JC Maris, M Bruno, B Petersdorf, E Maloney, D Storb, R Sandmaier, BM AF Nakamae, Hirohisa Storer, Barry Chauncey, Thomas Pulsipher, Michael Petersen, Finn Wade, James C. Maris, Michael Bruno, Ben Petersdorf, Effie Maloney, David Storb, Rainer Sandmaier, Brenda M. TI Low-dose total body irradiation (TBI) and fludarabine conditioning for hematopoietic cell transplantation (HCT) in patients with HLA-class I mismatched donors SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Nakamae, Hirohisa; Storer, Barry; Chauncey, Thomas; Petersdorf, Effie; Maloney, David; Storb, Rainer; Sandmaier, Brenda M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Storer, Barry; Chauncey, Thomas; Petersdorf, Effie; Maloney, David; Storb, Rainer; Sandmaier, Brenda M.] Univ Washington, Seattle, WA 98195 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Pulsipher, Michael] Univ Utah, Salt Lake City, UT USA. [Petersen, Finn] Intermountain Blood & Marrow Transplant Program, Salt Lake City, UT USA. [Wade, James C.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Maris, Michael] Rocky Mountain Blood & Marrow Transplantat, Denver, CO USA. [Bruno, Ben] Univ Turin, Turin, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 BP 902A EP 902A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100804104 ER PT J AU Flowers, C Rosenthal, H Brown, J Stock, W Katzen, H Lakhanpal, S Jaye, D AF Flowers, Christopher Rosenthal, Hilary Brown, Jennifer Stock, Wendy Katzen, Harvey Lakhanpal, Shailendra Jaye, David TI Analysis of minimal residual disease (MRD) from the phase 2 multicenter study of subcutaneous (SC) alemtuzumab combined with fludarabine for treatment of relapsed/refractory B-cell chronic lymphocytic leukemia (CLL). SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Flowers, Christopher; Rosenthal, Hilary; Jaye, David] Emory Univ Hosp, Atlanta, GA 30322 USA. [Brown, Jennifer] Dana Farber Canc Inst, Boston, MA USA. [Stock, Wendy] Univ Chicago, Med Ctr & Hosp, Chicago, IL 60637 USA. [Katzen, Harvey] Oncol Hematol Assoc, Clinton, MD USA. [Lakhanpal, Shailendra] Birmingham Hematol & Oncol Assoc, LLC, Birmingham, AL USA. Oregon Hlth & Sci Univ, Portland, OR USA. RI Flowers, Christopher/F-1953-2010 OI Flowers, Christopher/0000-0002-9524-3990 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 3111 BP 915A EP 915A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100804148 ER PT J AU Amrein, PC Attar, EC Takvorian, T Hochberg, EP Ballen, K Zabrieh, D Brown, JR AF Amrein, Philip C. Attar, Eyal C. Takvorian, Tak Hochberg, Ephraim P. Ballen, Karen Zabrieh, David Brown, Jennifer R. TI A phase II study of dasatinib in relapsed and-refractory chronic lymphocytic leukemia (CLL/SLL) SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Amrein, Philip C.; Attar, Eyal C.; Takvorian, Tak; Hochberg, Ephraim P.; Ballen, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Zabrieh, David; Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 3126 BP 920A EP 920A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100804163 ER PT J AU Cui, QP Kim, H Zhou, DC Wiernik, PH Tallman, MS Gallagher, RE AF Cui, Qingping Kim, Haesook Zhou, Da-Cheng Wiernik, Peter H. Tallman, Martin S. Gallagher, Robert E. TI Treatment type determines gene expression changes from pretreatment (PTx) to relapse (Rel) in acute promyelocytic leukemia (APL) SO BLOOD LA English DT Meeting Abstract CT 49th Annual Meeting of the American-Society-of-Hematology CY DEC 08-11, 2007 CL Atlanta, GA SP Amer Soc Hematol C1 [Cui, Qingping; Zhou, Da-Cheng; Gallagher, Robert E.] Albert Einstein Canc Ctr, Bronx, NY 02115 USA. [Kim, Haesook] Dana Farber Canc Inst, Boston, MA USA. [Wiernik, Peter H.] New York Med Coll, Feinberg Sch Med, Bronx, NY 60611 USA. [Tallman, Martin S.] Northwestern Univ, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2007 VL 110 IS 11 MA 3167 BP 931A EP 931A PN 1 PG 1 WC Hematology SC Hematology GA 233OS UT WOS:000251100804204 ER EF